Clustering O 0 1.276382590731373e-05
of O 0 1.2097855517367861e-07
missense O 0 1.4390365322469734e-05
mutations O 0 3.369286332599586e-06
in O 0 1.9035443301618216e-06
the O 0 0.00017993582878261805
ataxia B-Disease 1 0.999984622001648
- I-Disease 1 0.9999644756317139
telangiectasia I-Disease 1 0.9999688863754272
gene O 0 2.496468596291379e-06
in O 0 8.762041403542753e-08
a O 0 3.303411517663335e-07
sporadic B-Disease 0 0.00021025283786002547
T I-Disease 1 0.9875461459159851
- I-Disease 0 0.4322362244129181
cell I-Disease 0 0.4813964366912842
leukaemia I-Disease 1 0.5523436665534973
. O 0 4.08411460739444e-06

Ataxia B-Disease 1 0.999338686466217
- I-Disease 1 0.9995571970939636
telangiectasia I-Disease 1 0.9998611211776733
( O 0 0.0029186264146119356
A B-Disease 1 0.9999209642410278
- I-Disease 1 0.9999798536300659
T I-Disease 1 0.9999939203262329
) O 0 1.1660436030069832e-06
is O 0 8.483375779633207e-09
a O 0 1.9612308221894637e-08
recessive B-Disease 0 7.238592661451548e-05
multi I-Disease 0 0.10372676700353622
- I-Disease 1 0.9961990714073181
system I-Disease 0 0.16682268679141998
disorder I-Disease 0 0.37786105275154114
caused O 0 4.305077709432226e-06
by O 0 9.524534938520901e-09
mutations O 0 1.9559447395067764e-08
in O 0 9.121139954437751e-10
the O 0 2.942762478141958e-09
ATM O 0 1.6520643839612603e-05
gene O 0 8.88706352952795e-08
at O 0 7.030706910882145e-06
11q22 O 0 2.546789801272098e-06
- O 0 0.0002123375452356413
q23 O 0 3.935341283067828e-06
( O 0 3.3624520945352288e-09
ref O 0 4.223622909194091e-06
. O 0 6.470636471078706e-09
3 O 0 4.4377280516982864e-08
) O 0 2.3063856602334454e-08
. O 0 8.508415305641392e-08

The O 0 6.053061497368617e-06
risk O 0 3.3369349694112316e-05
of O 0 1.560930513733183e-07
cancer B-Disease 0 0.00023441370285581797
, O 0 8.296667175500261e-08
especially O 0 2.113408825721308e-08
lymphoid B-Disease 0 2.977341409859946e-06
neoplasias I-Disease 0 0.00022270683257374913
, O 0 3.4310488672417705e-08
is O 0 1.4045768992332341e-09
substantially O 0 3.828998984545251e-08
elevated O 0 7.97152324594208e-07
in O 0 2.1203916276135715e-06
A B-Disease 1 0.9999240636825562
- I-Disease 1 0.9999920129776001
T I-Disease 1 0.9999972581863403
patients O 0 5.210304721003922e-07
and O 0 5.306546881911345e-07
has O 0 2.189507540606428e-06
long O 0 4.756861926580314e-06
been O 0 5.288601414576988e-07
associated O 0 1.3807729715153982e-07
with O 0 7.636553164047655e-06
chromosomal O 1 0.9999581575393677
instability O 1 0.9996744394302368
. O 0 2.798135938064661e-05

By O 0 5.804482157145685e-07
analysing O 0 0.00019196960784029216
tumour B-Disease 1 0.9998468160629272
DNA O 0 0.001144546433351934
from O 0 2.520077657663933e-07
patients O 0 1.0465405431148156e-08
with O 0 1.6325987672871634e-08
sporadic B-Disease 0 1.9238503227825277e-05
T I-Disease 1 0.6705938577651978
- I-Disease 0 0.053387757390737534
cell I-Disease 0 0.10267040878534317
prolymphocytic I-Disease 0 0.17152772843837738
leukaemia I-Disease 1 0.623649537563324
( O 0 2.909829106556572e-07
T B-Disease 0 0.1228049099445343
- I-Disease 0 0.02157893218100071
PLL I-Disease 0 0.000808769604191184
) O 0 2.7985198158830826e-08
, O 0 2.8661293338672067e-09
a O 0 3.6949390214147115e-09
rare O 0 8.413748986413339e-08
clonal B-Disease 0 1.6632252481940668e-06
malignancy I-Disease 0 0.0012772133341059089
with O 0 1.7286916786929396e-08
similarities O 0 5.1905658438045066e-08
to O 0 2.160865708589199e-09
a O 0 6.578995481731909e-08
mature B-Disease 0 1.0166893389396137e-06
T I-Disease 0 0.033113978803157806
- I-Disease 0 0.0017938464879989624
cell I-Disease 0 0.0029932642355561256
leukaemia I-Disease 0 0.00542137585580349
seen O 0 1.447453200853488e-06
in O 0 4.755442262194265e-07
A B-Disease 1 0.9972341656684875
- I-Disease 1 0.9999438524246216
T I-Disease 1 0.9999912977218628
, O 0 1.2702068374892406e-07
we O 0 1.9860814381988945e-10
demonstrate O 0 9.794979410893134e-11
a O 0 3.457394925909796e-10
high O 0 5.558166815688992e-09
frequency O 0 5.020551974155296e-09
of O 0 4.3323777898507387e-10
ATM O 0 4.5141518057789654e-05
mutations O 0 1.0445307907502865e-07
in O 0 2.3690152772815054e-07
T B-Disease 0 0.3287741243839264
- I-Disease 0 0.01132811140269041
PLL I-Disease 0 0.0009973769774660468
. O 0 5.036139896219538e-07

In O 0 4.739233929740294e-07
marked O 0 1.6499120647495147e-06
contrast O 0 4.35057501135816e-08
to O 0 2.442120394796632e-10
the O 0 8.155702224676986e-10
ATM O 0 2.786765071505215e-05
mutation O 0 4.998272729039854e-08
pattern O 0 7.158634161896771e-06
in O 0 4.2979809222742915e-06
A B-Disease 1 0.9999438524246216
- I-Disease 1 0.9999884366989136
T I-Disease 1 0.9999967813491821
, O 0 1.1609899530640178e-07
the O 0 3.6439856687664474e-10
most O 0 3.2366092445057504e-11
frequent O 0 8.552773073100539e-11
nucleotide O 0 2.8906740889844684e-10
changes O 0 3.086575994792895e-10
in O 0 7.623807363188462e-09
this O 0 3.8378388467208424e-08
leukaemia B-Disease 0 0.012060328386723995
were O 0 9.851818276729318e-07
missense O 0 4.896457539871335e-06
mutations O 0 1.0749732837211923e-06
. O 0 9.046729019246413e-07

These O 0 3.561736150459183e-08
clustered O 0 1.4040936093806522e-06
in O 0 2.2097740526305643e-08
the O 0 9.94929560960145e-09
region O 0 2.277376065507042e-09
corresponding O 0 1.663667120732626e-10
to O 0 9.510837950532647e-11
the O 0 4.401979891710539e-10
kinase O 0 6.494848747706783e-08
domain O 0 1.916375502730716e-09
, O 0 3.414289295733397e-09
which O 0 4.739050929458699e-09
is O 0 1.7207159308529896e-10
highly O 0 6.264257168542287e-11
conserved O 0 3.281634963769875e-10
in O 0 1.6203965946814947e-09
ATM O 0 0.0001365421194350347
- O 0 1.807392072805669e-05
related O 0 1.498174029279653e-08
proteins O 0 5.060795116307304e-10
in O 0 3.517594659996348e-09
mouse O 0 3.104641291429289e-05
, O 0 2.3907942292566986e-08
yeast O 0 1.8655023836799955e-07
and O 0 8.936800099945685e-08
Drosophila O 0 1.6237271438512835e-07
. O 0 2.479479519479355e-07

The O 0 1.0571437059070377e-07
resulting O 0 1.0447778464595103e-07
amino O 0 8.900546077938998e-09
- O 0 8.58699877426261e-06
acid O 0 5.730840246798152e-09
substitutions O 0 1.031081664493172e-09
are O 0 2.312065122689333e-10
predicted O 0 1.4526249003665725e-07
to O 0 3.5398303732669945e-10
interfere O 0 5.020035054315031e-09
with O 0 1.1530888244237758e-08
ATP O 0 5.6405340728815645e-05
binding O 0 1.02147873803915e-06
or O 0 1.1238287100923117e-07
substrate O 0 1.4360136901814258e-06
recognition O 0 4.724135038713939e-08
. O 0 8.622774885225226e-07

Two O 0 3.104184997937409e-08
of O 0 2.833148604608482e-09
seventeen O 0 7.63583187790573e-08
mutated O 0 3.276930783613352e-06
T B-Disease 0 0.035453811287879944
- I-Disease 0 0.0015928213251754642
PLL I-Disease 0 3.7771533243358135e-05
samples O 0 7.117512978993545e-08
had O 0 7.679420832573669e-07
a O 0 3.6398841274376537e-08
previously O 0 1.1766966053983197e-05
reported O 0 0.005133609287440777
A B-Disease 1 0.9574396014213562
- I-Disease 1 0.9996151924133301
T I-Disease 1 0.9999161958694458
allele O 0 1.4888177247485146e-05
. O 0 7.268199624377303e-07

In O 0 8.037278576011886e-07
contrast O 0 1.2780163842762704e-06
, O 0 5.698568728007558e-08
no O 0 7.756074893450204e-09
mutations O 0 1.0347149803635602e-08
were O 0 2.277698740726919e-08
detected O 0 5.2516504922550666e-08
in O 0 6.890436554662926e-10
the O 0 5.871520492028992e-10
p53 O 0 2.257279918538302e-09
gene O 0 1.3254465969225748e-08
, O 0 1.2537305416060462e-08
suggesting O 0 1.264019857671883e-07
that O 0 3.254883296222033e-08
this O 0 1.2566458451601648e-07
tumour B-Disease 1 0.9999839067459106
suppressor O 0 0.000161352741997689
is O 0 2.5043267015689707e-08
not O 0 1.0386334015066723e-09
frequently O 0 9.986959703667253e-09
altered O 0 1.1152233270195211e-07
in O 0 6.35076489174935e-08
this O 0 3.7583899370474683e-07
leukaemia B-Disease 0 0.1901615858078003
. O 0 2.151504304492846e-06

Occasional O 0 5.8929826991516165e-06
missense O 0 3.1391613447340205e-05
mutations O 0 2.281234856127412e-06
in O 0 4.471646164461163e-08
ATM O 0 0.0001226368040079251
were O 0 3.060392373299692e-06
also O 0 6.287979772423569e-07
found O 0 3.478105554677313e-06
in O 0 1.473179167987837e-06
tumour B-Disease 1 0.9999923706054688
DNA O 0 0.0003969910612795502
from O 0 8.524838079893016e-08
patients O 0 7.759922482364345e-09
with O 0 3.4660608605463494e-08
B B-Disease 0 5.213747044763295e-06
- I-Disease 0 0.0004935560864396393
cell I-Disease 0 0.0004906646790914237
non I-Disease 0 7.323737918341067e-07
- I-Disease 1 0.9254907369613647
Hodgkins I-Disease 1 0.9919410943984985
lymphomas I-Disease 0 0.21710258722305298
( O 0 1.2779461933121183e-08
B B-Disease 0 4.867740699410206e-07
- I-Disease 0 1.2726571185339708e-05
NHL I-Disease 0 2.313514926299831e-07
) O 0 3.4107745516820387e-09
and O 0 1.6541661373992156e-09
a O 0 3.638114165482875e-08
B B-Disease 0 6.887761401230819e-07
- I-Disease 0 6.131449481472373e-06
NHL I-Disease 0 1.9082506241829833e-07
cell O 0 7.310951332328841e-06
line O 0 1.536310082883574e-05
. O 0 4.6259455643848924e-07

The O 0 1.4752598076483991e-07
evidence O 0 1.2210136901558144e-07
of O 0 6.710387245867366e-10
a O 0 4.742667591983718e-09
significant O 0 3.468874909540176e-10
proportion O 0 1.8625729847343564e-09
of O 0 3.925884328737084e-08
loss O 0 0.0004349430091679096
- O 0 0.00011170995276188478
of O 0 2.428494561002026e-08
- O 0 0.00014472335169557482
function O 0 9.550803703461952e-09
mutations O 0 1.682364825228433e-08
and O 0 5.695653726434102e-09
a O 0 1.722944453774744e-08
complete O 0 8.498781767229957e-08
absence O 0 1.6384602119501324e-08
of O 0 1.8344652186197408e-10
the O 0 1.6573337147107736e-09
normal O 0 5.228656951850041e-10
copy O 0 2.5796126124078e-08
of O 0 2.963675416189915e-10
ATM O 0 1.3931128705735318e-05
in O 0 4.234709471973019e-09
the O 0 1.252638170967657e-08
majority O 0 5.70528690957417e-09
of O 0 5.967104144133373e-09
mutated O 0 2.4184553694794886e-05
tumours B-Disease 1 0.9991402626037598
establishes O 0 2.044218234686923e-07
somatic O 0 8.391920403028053e-08
inactivation O 0 1.7144631783594377e-05
of O 0 2.609909399708954e-09
this O 0 1.0476224332478523e-09
gene O 0 2.7344519981653548e-09
in O 0 8.448460264709468e-10
the O 0 4.513270202011199e-09
pathogenesis O 0 5.468971266964218e-07
of O 0 1.5461548708017858e-09
sporadic B-Disease 0 1.8730728697846644e-05
T I-Disease 1 0.7028371095657349
- I-Disease 0 0.002790001919493079
PLL I-Disease 0 0.00023203880118671805
and O 0 1.5423067623032694e-07
suggests O 0 2.170420998481859e-08
that O 0 1.901563795314587e-09
ATM O 0 3.3629557947278954e-06
acts O 0 7.970473170360037e-09
as O 0 9.406177170490082e-09
a O 0 2.1281973658915376e-06
tumour B-Disease 1 0.9999561309814453
suppressor O 0 0.002275015227496624
. O 0 3.2433399610454217e-06

As O 0 3.407329884907995e-08
constitutional O 0 4.677128018215626e-08
DNA O 0 1.1081261618528515e-05
was O 0 3.2744349027780117e-06
not O 0 7.185380068719383e-10
available O 0 2.5988899921003394e-10
, O 0 1.256252990522455e-09
a O 0 1.2220488621039749e-08
putative O 0 2.6855041141971014e-05
hereditary O 0 0.12278962880373001
predisposition O 0 0.001096178195439279
to O 0 4.66593792225467e-06
T B-Disease 1 0.6961894035339355
- I-Disease 0 0.004616830963641405
PLL I-Disease 0 5.865896673640236e-05
will O 0 9.146068902232685e-10
require O 0 4.93180279600991e-12
further O 0 6.103665489698429e-11
investigation O 0 4.2906400210540596e-08
. O 0 9.018920721359791e-09
. O 0 1.4302308670721686e-07

Myotonic B-Disease 1 0.9991962313652039
dystrophy I-Disease 1 0.9994994401931763
protein O 0 5.1810267905239016e-05
kinase O 0 0.00030631577828899026
is O 0 4.852510215869188e-08
involved O 0 9.924405741656983e-10
in O 0 2.004539173539044e-10
the O 0 1.7238728500235112e-10
modulation O 0 3.926219349636995e-09
of O 0 1.3900618156537092e-10
the O 0 1.1953600775882478e-08
Ca2 O 0 5.1897413868573494e-06
+ O 0 3.1239214877132326e-06
homeostasis O 0 0.00011581835133256391
in O 0 8.394322037474922e-08
skeletal O 0 0.006013831123709679
muscle O 0 6.44516694592312e-05
cells O 0 9.029188845488534e-07
. O 0 5.571850465457828e-07

Myotonic B-Disease 1 0.9991550445556641
dystrophy I-Disease 1 0.9997757077217102
( O 0 0.0015322384424507618
DM B-Disease 1 0.9999090433120728
) O 0 7.899968295532744e-06
, O 0 2.9211555840902292e-08
the O 0 5.9062306156931754e-09
most O 0 1.636414559413879e-08
prevalent O 0 2.8529555493150838e-05
muscular B-Disease 1 0.9400579333305359
disorder I-Disease 0 0.10250158607959747
in O 0 1.7983355746764573e-06
adults O 0 1.3720501556235831e-05
, O 0 1.4687701650473173e-06
is O 0 4.1009417373061297e-07
caused O 0 5.341173618944595e-07
by O 0 1.3153626632345095e-08
( O 0 2.015650979458883e-09
CTG O 0 5.3625144573743455e-06
) O 0 6.1184279864789914e-09
n O 0 4.917526439385256e-07
- O 0 7.0080673140182626e-06
repeat O 0 1.2952753536410455e-07
expansion O 0 2.1845156794597642e-09
in O 0 1.468926230652201e-10
a O 0 1.484213169034021e-10
gene O 0 1.0800073335648364e-10
encoding O 0 1.920132108867989e-10
a O 0 4.011866394648678e-09
protein O 0 3.8693855231031193e-08
kinase O 0 1.0791600288939662e-06
( O 0 2.5755895194379264e-09
DM B-Disease 1 0.9865191578865051
protein O 0 2.5397014269401552e-08
kinase O 0 7.544136337855889e-07
; O 0 9.963594393980202e-09
DMPK O 0 4.84675638290355e-06
) O 0 3.092575084906457e-10
and O 0 1.1863755811081234e-10
involves O 0 8.1952118702322e-11
changes O 0 1.010762168407453e-10
in O 0 6.512598460517438e-09
cytoarchitecture O 0 1.0402445695945062e-05
and O 0 1.3365945505938726e-07
ion O 0 4.637964957510121e-05
homeostasis O 0 0.0067563848569989204
. O 0 1.7088277672883123e-06

To O 0 3.4132099813177774e-08
obtain O 0 3.3700346957488136e-09
clues O 0 1.9481619517591753e-07
to O 0 3.8117761724798527e-10
the O 0 3.6201619479925284e-10
normal O 0 9.098777287164239e-10
biological O 0 1.2246271552385224e-08
role O 0 2.352868733179747e-10
of O 0 2.5447177698367796e-10
DMPK O 0 8.42298504721839e-06
in O 0 6.046600997677842e-10
cellular O 0 5.561556690736325e-07
ion O 0 5.738439995184308e-06
homeostasis O 0 0.0005557371187023818
, O 0 4.5830173434069366e-08
we O 0 1.0412913864499274e-09
have O 0 6.34396701837403e-10
compared O 0 3.7095140292819906e-09
the O 0 1.024561213647246e-09
resting O 0 3.1142155876295874e-06
[ O 0 2.6538171660206444e-09
Ca2 O 0 1.640481173126318e-07
+ O 0 2.9770842502330197e-07
] O 0 1.5143918119520094e-08
i O 0 6.173241029472365e-09
, O 0 4.804676448366685e-11
the O 0 3.513607807481556e-11
amplitude O 0 2.5158493066612664e-09
and O 0 5.853755258300453e-09
shape O 0 4.359238303663915e-08
of O 0 5.129442981477439e-10
depolarization O 0 2.1321638143945165e-07
- O 0 2.7966767447651364e-05
induced O 0 1.5794718137840391e-06
Ca2 O 0 1.7637397320413584e-07
+ O 0 2.4469028403473203e-07
transients O 0 7.904164363026212e-07
, O 0 1.3495220496650973e-09
and O 0 1.9515233873335092e-10
the O 0 2.7715095843316995e-11
content O 0 1.1052984916215536e-10
of O 0 7.27770621544721e-11
ATP O 0 1.5283719676517649e-06
- O 0 2.7395806228014408e-06
driven O 0 2.2038986458028376e-07
ion O 0 4.791917262991774e-07
pumps O 0 5.410201993072405e-07
in O 0 2.1218249379728604e-09
cultured O 0 1.144564862443076e-06
skeletal O 0 0.003907671198248863
muscle O 0 2.975056531795417e-06
cells O 0 1.50891086292404e-08
of O 0 9.819677293521067e-10
wild O 0 5.294940024214156e-07
- O 0 0.0013609156012535095
type O 0 1.2487066669564229e-06
and O 0 1.048087597155245e-06
DMPK O 0 0.00024418579414486885
[ O 0 2.550784827803909e-08
- O 0 7.280523277586326e-05
/ O 0 4.2409010347910225e-06
- O 0 7.780422311043367e-05
] O 0 6.818295901211968e-07
knockout O 0 0.00017821027722675353
mice O 0 4.123162216274068e-05
. O 0 2.4432023337794817e-07

In O 0 3.405037318771065e-07
vitro O 0 1.365963453281438e-05
- O 0 0.00011919167445739731
differentiated O 0 3.1543434033665108e-06
DMPK O 0 0.000952111033257097
[ O 0 3.6518386536954495e-07
- O 0 0.0002839908411260694
/ O 0 1.5518287909799255e-05
- O 0 0.0004411156114656478
] O 0 5.004297349842091e-07
myotubes O 0 1.1105032626801403e-06
exhibit O 0 4.111888607383207e-09
a O 0 2.2576371883076263e-09
higher O 0 4.052009838773074e-09
resting O 0 4.839412781620922e-07
[ O 0 1.8557008152342291e-09
Ca2 O 0 4.6172889511808535e-08
+ O 0 1.3457524516979902e-07
] O 0 1.5491075089357764e-08
i O 0 2.524126019309847e-09
than O 0 3.6235379280435964e-11
do O 0 9.24946438884966e-11
wild O 0 1.2064577781245589e-08
- O 0 0.00011933975474676117
type O 0 6.003352268635354e-07
myotubes O 0 2.9445429390762e-05
because O 0 4.184032675880189e-09
of O 0 5.708796976811037e-11
an O 0 2.1381609816018e-09
altered O 0 8.16459717611906e-08
open O 0 8.529571005055914e-08
probability O 0 1.8259903589168403e-09
of O 0 2.1786225601339027e-10
voltage O 0 2.0173871462247916e-07
- O 0 2.556409890530631e-05
dependent O 0 6.418569853394729e-08
l O 0 2.0777837562491186e-05
- O 0 2.133645466528833e-06
type O 0 2.3759200828976645e-08
Ca2 O 0 1.3440825341604068e-07
+ O 0 7.841923377327475e-08
and O 0 1.160644114150955e-08
Na O 0 2.271761871952549e-07
+ O 0 4.163408462432017e-08
channels O 0 8.218076885668779e-08
. O 0 1.0201901545769942e-07

The O 0 6.999592017109535e-08
mutant O 0 2.975893721668399e-06
myotubes O 0 1.4492886293737683e-05
exhibit O 0 9.272298484575003e-08
smaller O 0 2.0876038675510245e-08
and O 0 1.0534658478889014e-08
slower O 0 1.524069404013062e-07
Ca2 O 0 2.2072156014019129e-07
+ O 0 4.815840526362081e-08
responses O 0 1.8594166484309227e-10
upon O 0 3.1688190960110774e-10
triggering O 0 3.228309708447341e-08
by O 0 1.4332827147356397e-09
acetylcholine O 0 2.087983739329502e-05
or O 0 3.8427907611549017e-07
high O 0 2.985219907714054e-06
external O 0 1.369240408166661e-06
K O 0 2.7425815005699405e-06
+ O 0 8.88952797595266e-07
. O 0 1.6684280979006871e-07

In O 0 1.0141294382037813e-07
addition O 0 7.531022028217649e-09
, O 0 4.806872233587001e-09
we O 0 1.5241936879295537e-10
observed O 0 3.5788935703884306e-10
that O 0 1.8996738904153432e-10
these O 0 8.54163892394233e-11
Ca2 O 0 4.2573884684316e-07
+ O 0 2.940760623459937e-06
transients O 0 1.3436993867799174e-05
partially O 0 4.1490152398182545e-06
result O 0 8.655365313359198e-09
from O 0 1.977964875221616e-10
an O 0 8.038864018899972e-11
influx O 0 2.4139485549357076e-11
of O 0 6.149023564633316e-12
extracellular O 0 2.2384623044047203e-09
Ca2 O 0 4.35747615767923e-08
+ O 0 5.90523940857679e-09
through O 0 1.4888403010449025e-10
the O 0 1.8428240267098772e-08
l O 0 7.200973777798936e-05
- O 0 6.041538654244505e-06
type O 0 2.1982094366990168e-08
Ca2 O 0 1.9843157872401207e-07
+ O 0 1.0991255550152346e-07
channel O 0 2.1864775590074714e-06
. O 0 8.001244822253284e-08

Neither O 0 8.408388794123312e-07
the O 0 6.2087606167438025e-09
content O 0 7.967219772808676e-09
nor O 0 2.4069490844880193e-09
the O 0 6.847734879134038e-11
activity O 0 7.240796850993547e-10
of O 0 6.694216292402189e-10
Na O 0 1.2102649407097488e-06
+ O 0 1.9308197352074785e-07
/ O 0 3.6232393085811054e-08
K O 0 1.990649600713823e-08
+ O 0 1.4420939997705773e-08
ATPase O 0 3.2638794777994917e-07
and O 0 9.77582104155772e-09
sarcoplasmic O 0 9.61057821768918e-07
reticulum O 0 1.8344726413488388e-06
Ca2 O 0 1.7934594325197395e-06
+ O 0 2.7778598905570107e-06
- O 0 2.7180765755474567e-05
ATPase O 0 5.890926331630908e-06
are O 0 6.077136571747133e-10
affected O 0 4.2906189712255127e-10
by O 0 2.647189578652842e-09
DMPK O 0 4.8291134589817375e-05
absence O 0 1.7849062317054631e-07
. O 0 2.280142297195198e-07

In O 0 1.1206543604203034e-07
conclusion O 0 3.258852743215357e-08
, O 0 8.176624710642955e-09
our O 0 3.897089873028392e-10
data O 0 1.2642507485338683e-08
suggest O 0 1.9959646380129925e-08
that O 0 4.115413432259629e-08
DMPK O 0 8.645701018394902e-05
is O 0 1.4517747004560988e-09
involved O 0 4.6191339642120965e-10
in O 0 7.422948367086235e-10
modulating O 0 1.140343641736763e-07
the O 0 2.8930970952245616e-09
initial O 0 1.0646276082937334e-09
events O 0 3.0043467713625205e-10
of O 0 1.2513617919651665e-10
excitation O 0 8.181214639080281e-08
- O 0 0.0004366402281448245
contraction O 0 1.2221302085890784e-06
coupling O 0 6.731364692313946e-07
in O 0 1.2323177145390218e-07
skeletal O 0 0.039747558534145355
muscle O 0 6.523064075736329e-05
. O 0 6.924882711700775e-08
. O 0 2.0030245195812313e-07

Constitutional O 0 1.5877247278694995e-05
RB1 O 0 0.14973485469818115
- O 0 0.003988480195403099
gene O 0 1.255913775821682e-05
mutations O 0 9.385717021359596e-06
in O 0 3.317017558401858e-07
patients O 0 1.7480859071383748e-07
with O 0 4.7448600071220426e-07
isolated O 0 0.0004110608424525708
unilateral B-Disease 0 0.0006737135699950159
retinoblastoma I-Disease 0 0.007201638072729111
. O 0 1.8362370610702783e-06

In O 0 5.168840857550094e-07
most O 0 3.7279573206205896e-08
patients O 0 2.6139160169691422e-08
with O 0 1.0094592539644509e-07
isolated O 0 1.7004775145323947e-05
unilateral B-Disease 0 2.7368923838366754e-05
retinoblastoma I-Disease 0 0.005406576674431562
, O 0 2.4169482912839158e-06
tumor B-Disease 0 3.301115066278726e-05
development O 0 3.5629099670586584e-09
is O 0 6.770593530269764e-10
initiated O 0 6.724942269720202e-10
by O 0 1.13934521539516e-10
somatic O 0 5.134133562734178e-09
inactivation O 0 2.613946890051011e-06
of O 0 3.321964647806652e-10
both O 0 9.076728813006696e-10
alleles O 0 4.79360551253194e-09
of O 0 1.397228999167055e-09
the O 0 3.910996895228891e-07
RB1 O 0 0.0020752304699271917
gene O 0 3.5504845641298743e-07
. O 0 4.82670088786108e-07

However O 0 1.6314490949298488e-06
, O 0 1.4122390368243032e-08
some O 0 1.373468179466375e-11
of O 0 1.1045439562984427e-10
these O 0 2.646982633081052e-09
patients O 0 3.656108304994632e-09
can O 0 1.2129846016506463e-09
transmit O 0 1.07265723272576e-05
retinoblastoma B-Disease 0 0.0006904061883687973
predisposition O 0 9.482260793447495e-06
to O 0 5.165811778340412e-09
their O 0 4.1303309217255446e-08
offspring O 0 2.606217776701669e-06
. O 0 7.932376888675208e-07

To O 0 1.6112164047399347e-08
determine O 0 5.486783472008483e-09
the O 0 1.317727482685882e-09
frequency O 0 6.843070110562621e-08
and O 0 3.0155042907153984e-08
nature O 0 6.124511120475518e-09
of O 0 7.024957837664658e-10
constitutional O 0 2.7179552830602915e-07
RB1 O 0 0.005653449799865484
- O 0 0.00028275023214519024
gene O 0 2.6258845764459693e-07
mutations O 0 1.9015288899026928e-07
in O 0 3.6601079500542255e-08
patients O 0 1.3825273370571267e-08
with O 0 5.938177949360579e-08
isolated O 0 3.03475226246519e-05
unilateral B-Disease 0 6.270568974287016e-06
retinoblastoma I-Disease 0 6.182055949466303e-05
, O 0 2.0142993051308622e-08
we O 0 9.05191921418691e-10
analyzed O 0 4.620000382260514e-09
DNA O 0 8.944385285758472e-07
from O 0 1.6786467327278842e-08
peripheral O 0 0.00020231357484590262
blood O 0 0.00016841397155076265
and O 0 2.2340332179737743e-06
from O 0 1.0038467053163913e-06
tumor B-Disease 0 0.018616313114762306
tissue O 0 0.004145580343902111
. O 0 6.1847504184697755e-06

The O 0 3.665878978154069e-08
analysis O 0 7.531728840604046e-08
of O 0 4.1632188185758423e-07
tumors B-Disease 1 0.9999173879623413
from O 0 1.666381592713151e-07
54 O 0 2.3629056613572175e-06
( O 0 9.834113967599478e-09
71 O 0 1.500969119661022e-06
% O 0 5.686437543062084e-09
) O 0 1.862587306611374e-09
of O 0 1.1611395178690032e-09
76 O 0 9.479833238401625e-07
informative O 0 6.422500860026048e-07
patients O 0 3.6587337604032655e-07
showed O 0 0.00025201801327057183
loss O 0 4.6086282964097336e-05
of O 0 8.663392669916448e-09
constitutional O 0 6.298383596003987e-06
heterozygosity O 0 0.011388670653104782
( O 0 1.0655086271071923e-06
LOH O 0 0.2261822521686554
) O 0 1.3274191701384552e-07
at O 0 2.103328824887285e-06
intragenic O 0 0.00010783082689158618
loci O 0 3.880261658650852e-07
. O 0 3.90161261520916e-07

Three O 0 1.9614876123341674e-07
of O 0 3.306449514184351e-08
13 O 0 1.740129960126069e-06
uninformative O 0 0.0013008428504690528
patients O 0 4.882339226242038e-07
had O 0 2.0642253275582334e-06
constitutional O 0 3.4248839142492216e-07
deletions O 0 1.8997116058017127e-05
. O 0 3.934024334739661e-06

For O 0 1.0540246009327348e-08
39 O 0 3.802848169698336e-08
randomly O 0 1.7431109000654033e-08
selected O 0 2.422176237359963e-07
tumors B-Disease 1 0.999704897403717
, O 0 5.720642661799502e-07
SSCP O 0 0.00040563507354818285
, O 0 8.757229608136186e-08
hetero O 0 2.745006167970132e-05
- O 0 6.672097515547648e-05
duplex O 0 0.0014665296766906977
analysis O 0 9.480944918038858e-09
, O 0 7.278723179737767e-10
sequencing O 0 6.296894561330646e-09
, O 0 8.908409121488603e-09
and O 0 1.267894766954214e-08
Southern O 0 1.2329850029857425e-08
blot O 0 1.7679578377283178e-05
analysis O 0 8.695824504911798e-09
were O 0 1.93143989690725e-08
used O 0 5.023061522280159e-09
to O 0 1.5050268808991518e-09
identify O 0 1.0097288338783983e-07
mutations O 0 3.9305299992520304e-07
. O 0 4.481260589273006e-07

Mutations O 0 2.976898258566507e-06
were O 0 5.775734734925209e-07
detected O 0 1.1078989246016135e-06
in O 0 3.743505061493124e-08
21 O 0 3.794921781263838e-07
( O 0 2.8574613786247482e-09
91 O 0 3.91656556075759e-07
% O 0 3.399071690779465e-09
) O 0 3.25132010203788e-09
of O 0 3.1797995347915275e-08
23 O 0 0.0036672749556601048
tumors B-Disease 1 0.9999734163284302
with O 0 0.00020924967247992754
LOH O 1 0.6875316500663757
. O 0 3.4481372495065443e-06

In O 0 7.294260058188229e-07
6 O 0 2.442585582684842e-06
( O 0 7.58163842817794e-09
38 O 0 4.8030162957957145e-08
% O 0 1.2417805672626514e-09
) O 0 1.2637462187825577e-09
of O 0 4.383632568050189e-09
16 O 0 0.0016970832366496325
tumors B-Disease 1 0.9999853372573853
without O 0 1.0966374475174234e-06
LOH O 0 0.003990232478827238
, O 0 1.6341624942128874e-08
one O 0 1.976012686810691e-09
mutation O 0 4.761348204596061e-09
was O 0 4.498217094806023e-06
detected O 0 1.997172489609511e-07
, O 0 4.319804958186069e-09
and O 0 9.073202633658184e-09
in O 0 7.15720682720189e-09
9 O 0 9.374010119245213e-07
( O 0 1.0714070741713044e-09
56 O 0 8.19702137278e-08
% O 0 9.167271941556976e-10
) O 0 4.550705645645081e-10
of O 0 4.829909805437183e-10
the O 0 5.8265668485546485e-06
tumors B-Disease 1 0.9999890327453613
without O 0 1.6666627971062553e-06
LOH O 0 0.006451650056988001
, O 0 9.954989721450147e-09
both O 0 1.6659478241365377e-09
mutations O 0 2.855708380877786e-08
were O 0 1.991983253901708e-07
found O 0 2.425015281914966e-06
. O 0 3.296424893051153e-07

Thus O 0 1.025563733492163e-06
, O 0 1.7726728529510183e-08
a O 0 7.443477501034579e-10
total O 0 4.0143982582563353e-10
of O 0 3.8818298575549193e-10
45 O 0 4.424490551713234e-09
mutations O 0 6.373113592417212e-09
were O 0 5.014888770915604e-08
identified O 0 1.4320449963634019e-06
in O 0 3.094956127824844e-06
tumors B-Disease 1 0.9999632835388184
of O 0 1.3058864567483397e-07
36 O 0 3.769995828406536e-06
patients O 0 1.55232925180826e-07
. O 0 4.1452202026448504e-07

Thirty O 0 3.186440380886779e-06
- O 0 2.7079551728093065e-05
nine O 0 7.942916369074737e-08
of O 0 4.0177536297925087e-10
the O 0 9.384313770510744e-09
mutations O 0 9.324261185383875e-08
- O 0 2.927533205365762e-05
including O 0 5.714631434727835e-09
34 O 0 9.253461108471583e-09
small O 0 3.6677374470883706e-09
mutations O 0 1.091289636434567e-08
, O 0 9.584600668688381e-09
2 O 0 1.5125587893294323e-08
large O 0 4.453089452738368e-09
structural O 0 1.0748727845566464e-06
alterations O 0 2.1496857982583606e-07
, O 0 1.1184010162423874e-08
and O 0 1.69927965032457e-08
hypermethylation O 0 4.071374860359356e-06
in O 0 1.8467231654994976e-07
3 O 0 0.00036179606104269624
tumors O 1 0.9999897480010986
- O 0 0.006516933441162109
were O 0 6.018129852236598e-07
not O 0 4.258790653466349e-09
detected O 0 5.240863387712125e-08
in O 0 3.383455460248541e-10
the O 0 1.3563449252629312e-09
corresponding O 0 1.395807203152799e-08
peripheral O 0 7.516508776461706e-05
blood O 0 1.472324765927624e-05
DNA O 0 5.972014696453698e-05
. O 0 3.0056278319534613e-06

In O 0 1.3086257695249515e-06
6 O 0 7.287520020327065e-06
( O 0 1.9838042319975102e-08
17 O 0 1.69304314567853e-07
% O 0 1.9851773558343666e-09
) O 0 2.657569164732365e-10
of O 0 3.1419339352467546e-11
the O 0 2.5420229476935674e-08
36 O 0 3.647313917554129e-07
patients O 0 7.055859896354377e-09
, O 0 1.711349284505559e-09
a O 0 9.314056192977205e-09
mutation O 0 1.958259154832831e-08
was O 0 1.941288610396441e-05
detected O 0 1.6730250251839607e-07
in O 0 8.709298282560951e-10
constitutional O 0 3.3435092472444694e-09
DNA O 0 3.891519099852303e-06
, O 0 2.71415725450197e-08
and O 0 1.0546440165626336e-08
1 O 0 8.189918743184421e-10
of O 0 1.5433697375666355e-10
these O 0 9.304552128774901e-10
mutations O 0 1.5775082573554755e-08
is O 0 6.281204445457433e-09
known O 0 3.1088998042605454e-09
to O 0 3.2531934923696326e-09
be O 0 9.438309689357993e-09
associated O 0 7.059023587885349e-09
with O 0 1.0489306312422286e-08
reduced O 0 2.0895743091386976e-07
expressivity O 0 0.0003409818164072931
. O 0 7.357543267971778e-07

The O 0 3.2065241128975686e-08
presence O 0 1.0856902044054095e-08
of O 0 3.409003634935459e-10
a O 0 5.478585141105441e-09
constitutional O 0 2.9247010147059882e-08
mutation O 0 1.1595558646604331e-07
was O 0 6.16149918641895e-05
not O 0 3.3548435141028676e-08
associated O 0 5.533414615399579e-09
with O 0 1.2812110261606335e-09
an O 0 1.2962327211596403e-08
early O 0 1.0273423640683177e-06
age O 0 4.601157286288071e-07
at O 0 6.541722541442141e-06
treatment O 0 3.8243794620029803e-07
. O 0 2.4020343403208244e-07

In O 0 4.1927745542125194e-07
1 O 0 9.416267943151979e-08
patient O 0 6.956933873425442e-08
, O 0 1.220034295812411e-08
somatic O 0 1.851057334079087e-07
mosaicism O 0 0.00032365822698920965
was O 0 6.804610893595964e-05
demonstrated O 0 3.085602884311811e-07
by O 0 1.2119600878435222e-09
molecular O 0 1.28676902022562e-07
analysis O 0 3.81889542211411e-09
of O 0 9.813349022280704e-10
DNA O 0 8.060390427999664e-06
and O 0 1.0361413416148935e-07
RNA O 0 4.1864217337206355e-07
from O 0 2.868865500715856e-08
peripheral O 0 2.7170141038368456e-05
blood O 0 6.551028491230682e-05
. O 0 1.6568847058806568e-06

In O 0 1.0101966836373322e-06
2 O 0 3.494976681395201e-06
patients O 0 1.571354957263793e-08
without O 0 2.7298543980869283e-10
a O 0 4.5735841780469855e-09
detectable O 0 8.59532178765221e-08
mutation O 0 1.816577110957951e-08
in O 0 2.8564656417984224e-08
peripheral O 0 0.0002502836287021637
blood O 0 0.0013053884031251073
, O 0 1.5490492160097347e-06
mosaicism O 0 9.177606261800975e-05
was O 0 4.575486673275009e-05
suggested O 0 2.151634390656909e-07
because O 0 2.2219026618586213e-09
1 O 0 3.14055143002534e-10
of O 0 4.925369001540503e-10
the O 0 2.320782925835374e-07
patients O 0 2.786193533665937e-07
showed O 0 0.007335104513913393
multifocal O 1 0.9992750287055969
tumors B-Disease 1 0.9999953508377075
and O 0 1.9208910373436083e-07
the O 0 3.368042733598031e-09
other O 0 1.9790642458161756e-09
later O 0 2.70709307415018e-07
developed O 0 2.551914519699494e-07
bilateral B-Disease 0 2.5070662559301127e-06
retinoblastoma I-Disease 0 0.0003052214451599866
. O 0 5.868044468115841e-07

In O 0 1.2600371235294006e-07
conclusion O 0 2.013799793587623e-08
, O 0 3.1523936794286556e-09
our O 0 5.108733436287594e-10
results O 0 3.6706280237552846e-09
emphasize O 0 6.180589373627754e-10
that O 0 1.0598462107935802e-09
the O 0 8.941496987269204e-10
manifestation O 0 5.974383299189867e-08
and O 0 4.898457106605747e-08
transmissibility O 0 5.446984800983046e-07
of O 0 8.800085105065136e-10
retinoblastoma B-Disease 0 3.931819776425982e-07
depend O 0 6.829525139862014e-11
on O 0 1.0257466875884802e-08
the O 0 4.1365808556292905e-09
nature O 0 6.408511943334361e-09
of O 0 1.2280410022214028e-10
the O 0 1.3012257937816685e-09
first O 0 1.6342116548884178e-09
mutation O 0 2.283574440653524e-09
, O 0 9.23473131297925e-10
its O 0 4.873978998176653e-10
time O 0 1.3330061499061685e-09
in O 0 1.7179884181928173e-09
development O 0 2.3752981803681905e-09
, O 0 2.9483355756809715e-09
and O 0 1.9735795220299224e-09
the O 0 2.0799351130307286e-10
number O 0 4.1003013484530726e-11
and O 0 7.753397923693228e-09
types O 0 1.3191381320609707e-09
of O 0 7.727071205110292e-10
cells O 0 8.591945288571878e-08
that O 0 4.891265614759277e-09
are O 0 2.3929361270269567e-10
affected O 0 4.716009804894838e-10
. O 0 2.955305777874173e-09
. O 0 9.140008927488452e-08

Hereditary B-Disease 1 0.9986841082572937
deficiency I-Disease 1 0.9893207550048828
of I-Disease 0 1.4153455296650463e-08
the I-Disease 0 2.4705801848767805e-08
fifth I-Disease 0 6.868424407002749e-07
component I-Disease 0 2.802467236051598e-08
of I-Disease 0 4.992531943415202e-10
complement I-Disease 0 9.839273396039516e-09
in O 0 4.607427328551239e-08
man O 0 3.3765936677809805e-05
. O 0 6.371177505570813e-07

I O 0 0.0006354609504342079
. O 0 8.913016245060135e-06

Clinical O 0 4.885479938820936e-05
, O 0 5.519783826457569e-06
immunochemical O 0 0.0005280892364680767
, O 0 1.121313289331738e-06
and O 0 1.3310425401868997e-06
family O 0 1.593920387676917e-05
studies O 0 1.2855069542183628e-07
. O 0 3.016885727902263e-07

The O 0 6.393399587523163e-08
first O 0 7.18130337418188e-08
recognized O 0 6.586981271539116e-08
human O 0 2.4233452222688356e-07
kindred O 0 0.00013572342868428677
with O 0 0.00022730501950718462
hereditary B-Disease 1 0.9997729659080505
deficiency I-Disease 1 0.6228299736976624
of I-Disease 0 1.0398782945841845e-09
the I-Disease 0 1.530668569671434e-08
fifth I-Disease 0 4.0767574205347046e-07
component I-Disease 0 7.442090499409915e-09
of I-Disease 0 2.474039029198849e-10
complement I-Disease 0 1.1865056492865733e-08
( O 0 3.1798945698824355e-09
C5 O 0 0.0009683577809482813
) O 0 2.524122599822931e-08
is O 0 1.4675413773090895e-08
described O 0 1.012168559100246e-05
. O 0 1.0090624300573836e-06

The O 0 3.3624738193793746e-07
proband O 0 0.00011699071183102205
, O 0 3.208365484397291e-08
a O 0 8.745773882878893e-09
20 O 0 2.2274326383353582e-08
- O 0 2.3524064090452157e-05
year O 0 4.797660153599281e-07
- O 0 0.00022259942488744855
old O 0 0.0011687942314893007
black O 0 3.658004789031111e-05
female O 0 4.05027276428882e-06
with O 0 0.014244449324905872
systemic B-Disease 1 0.999991774559021
lupus I-Disease 1 0.9999696016311646
erythematosus I-Disease 1 0.9999768733978271
since O 0 7.473139703506604e-05
age O 0 1.540647076581081e-06
11 O 0 4.2243533471264527e-07
, O 0 7.492540987641405e-08
lacked O 0 1.23582663036359e-06
serum O 0 8.037505904212594e-05
hemolytic O 0 4.202007403364405e-05
complement O 0 4.3811063110688053e-10
activity O 0 1.132115468038819e-08
, O 0 2.8230613402513427e-09
even O 0 5.184052742635004e-09
during O 0 2.718670657486655e-07
remission O 0 3.955260126531357e-06
. O 0 3.1363347829937993e-07

C5 O 0 0.02828853391110897
was O 0 0.0003089442616328597
undetectable O 0 0.00010729174391599372
in O 0 1.9480337698496442e-07
her O 0 1.8415421436657198e-05
serum O 0 1.742788867886702e-06
by O 0 5.3571067581970055e-09
both O 0 3.001480308739701e-08
immunodiffusion O 0 0.0007878536125645041
and O 0 1.8107788491761312e-05
hemolytic O 0 0.059203892946243286
assays O 0 1.439098377886694e-05
. O 0 1.2458032188078505e-06

Other O 0 3.399992509756089e-09
complement O 0 1.6706477312666834e-09
components O 0 1.279573069723483e-08
were O 0 3.2330651489331785e-09
normal O 0 2.4456164871011765e-10
during O 0 7.971597604239378e-09
remission O 0 9.019716173952474e-08
of O 0 1.9070274248633723e-08
lupus O 0 0.01277128979563713
, O 0 6.014320064195999e-08
but O 0 3.145212446042933e-08
C1 O 0 5.7423723774263635e-05
, O 0 1.9769974102246124e-08
C4 O 0 0.004060717299580574
, O 0 3.864116422391817e-07
C2 O 0 0.0004030492855235934
, O 0 2.6748317338842753e-08
and O 0 7.872120733054544e-08
C3 O 0 0.003465276909992099
levels O 0 7.032444671040139e-08
fell O 0 0.0006707195425406098
during O 0 5.78092056002788e-07
exacerbations O 0 0.00023303585476242006
. O 0 4.2819985424102924e-07

A O 0 2.4798155209282413e-06
younger O 0 2.0892982774967095e-06
half O 0 4.890802074442036e-07
- O 0 0.0024704141542315483
sister O 0 0.0005792557494714856
, O 0 4.902270802631392e-07
who O 0 1.1160717576785828e-06
had O 0 2.41092548094457e-05
no O 0 2.3147472347773146e-06
underlying O 0 0.03564036265015602
disease O 0 0.00047283031744882464
, O 0 6.027561312293983e-07
was O 0 0.0003192790609318763
also O 0 6.662783107458381e-07
found O 0 2.077756988683177e-07
to O 0 1.608587929524674e-08
lack O 0 1.8317579986160126e-07
immunochemically O 0 0.00012492205132730305
detectable O 0 2.8070842290617293e-06
C5 O 0 0.0006239931099116802
. O 0 9.895754828903591e-07

By O 0 2.8052509151166305e-06
hemolytic O 0 0.06530243903398514
assay O 0 0.0001431687705917284
, O 0 1.3119572486175457e-06
she O 0 1.2080923852408887e-06
exhibited O 0 5.233910371771344e-08
1 O 0 5.622923460180118e-09
- O 0 2.1285472030285746e-05
2 O 0 8.356812486454146e-08
% O 0 8.223662723017e-11
of O 0 8.97691209561513e-12
the O 0 9.96389415419685e-10
normal O 0 7.834699111697319e-09
serum O 0 3.593871156226669e-07
C5 O 0 1.3299270904099103e-05
level O 0 3.1107860731793835e-09
and O 0 3.424169614518746e-09
normal O 0 6.073579417176234e-10
concentrations O 0 1.0328057298281124e-09
of O 0 1.5540058823093617e-11
other O 0 1.0694505003794319e-10
complement O 0 2.11810902150944e-09
components O 0 3.8471102925541345e-07
. O 0 1.7202427216034266e-07

C5 O 0 0.009916745126247406
levels O 0 5.40054600151052e-07
of O 0 2.5168525041863177e-09
other O 0 4.866531622127468e-09
family O 0 1.2354796297131543e-07
members O 0 1.802651916626985e-10
were O 0 1.3274167320886932e-09
either O 0 1.2541430394197306e-10
normal O 0 4.873021430817914e-10
or O 0 1.836755858519723e-09
approximately O 0 1.5421898480472152e-10
half O 0 1.6892553134084665e-08
- O 0 2.3260165107785724e-05
normal O 0 3.4584665797865455e-08
, O 0 2.3272784588357354e-08
consistent O 0 7.092157972010682e-08
with O 0 1.7002674894683878e-06
autosomal O 0 0.021809518337249756
codominant O 0 0.01705002970993519
inheritance O 0 1.9255548977525905e-06
of O 0 1.5820181831216473e-09
the O 0 9.264290667942987e-08
gene O 0 8.955174962466117e-06
determining O 0 0.00010267318430123851
C5 B-Disease 1 0.9999740123748779
deficiency I-Disease 1 0.9998717308044434
. O 0 4.592661753122229e-06

Normal O 0 9.044203034136444e-05
hemolytic O 1 0.8742015957832336
titers O 0 0.00023808340483810753
were O 0 4.283436112473282e-07
restored O 0 2.3788273040281638e-07
to O 0 1.9568953124604604e-09
both O 0 1.7692274312253176e-08
homozygous O 0 0.0003132100682705641
C5 B-Disease 1 0.9999717473983765
- I-Disease 1 0.9999552965164185
deficient I-Disease 1 0.999984860420227
( O 0 7.265355634444859e-06
C5D B-Disease 1 0.999968409538269
) O 0 6.254356321733212e-07
sera O 0 5.679899459209992e-06
by O 0 2.5603261177842285e-10
addition O 0 1.2830762841087306e-10
of O 0 2.7504254429544517e-10
highly O 0 2.6163352373487214e-08
purified O 0 2.2370129215687484e-07
human O 0 7.963394921262079e-08
C5 O 0 0.001023006858304143
. O 0 7.571698574793118e-07

In O 0 5.348441334263043e-08
specific O 0 6.95390633964621e-09
C5 O 0 0.0005683621857315302
titrations O 0 6.085052154958248e-05
, O 0 1.7216524383911747e-07
however O 0 3.5389426500387344e-08
, O 0 1.0999514188370085e-08
it O 0 1.0179002529753234e-08
was O 0 4.390506546769757e-06
noted O 0 1.454735709671695e-08
that O 0 4.5215828303746264e-10
when O 0 5.971905747692574e-10
limited O 0 1.2676944563527748e-11
amounts O 0 3.745354287126856e-12
of O 0 1.0421533080950951e-10
C5 O 0 2.9336650186451152e-05
were O 0 2.0422884716708722e-08
assayed O 0 1.9203287138225278e-07
in O 0 5.052240292791055e-10
the O 0 2.57511179047043e-10
presence O 0 2.197620280197654e-10
of O 0 5.768078237267105e-10
low O 0 2.0316204540904437e-07
dilutions O 0 8.034465963646653e-07
of O 0 4.949488818795089e-09
either O 0 3.380482382908667e-07
C5D B-Disease 1 0.9998953342437744
serum O 0 1.9334733224241063e-05
, O 0 7.40499306317588e-09
curving O 0 4.287858246243559e-08
rather O 0 8.543626917045799e-11
than O 0 2.8134473917251768e-11
linear O 0 2.066389059862672e-09
dose O 0 5.914662981609808e-09
- O 0 1.0968884680551128e-06
response O 0 3.748719112905974e-09
plots O 0 2.939858632089454e-07
were O 0 4.767266048588681e-08
consistently O 0 2.0724216653889016e-07
obtained O 0 1.2465675602868487e-08
, O 0 8.383677752021867e-09
suggesting O 0 1.5846131518060247e-08
some O 0 2.6701330382850053e-11
inhibitory O 0 7.192447526449541e-08
effect O 0 3.7149252563040136e-08
. O 0 7.159667347877985e-08

Further O 0 2.7883385200766497e-07
studies O 0 9.327889927135402e-08
suggested O 0 7.31088505290245e-08
that O 0 9.774907994142268e-09
low O 0 1.3959888178760593e-07
dilutions O 0 1.2967569091415498e-05
of O 0 3.880616930018732e-07
C5D B-Disease 1 0.9999531507492065
serum O 0 8.239573799073696e-05
contain O 0 1.4906973433426174e-08
a O 0 5.763685351212189e-08
factor O 0 7.738006502222561e-08
( O 0 1.389654280536945e-09
or O 0 1.3610154780963057e-08
factors O 0 2.9870297346690222e-09
) O 0 7.27135462952333e-10
interfering O 0 2.5267093306524657e-08
at O 0 5.264426761186769e-08
some O 0 8.6840760277207e-12
step O 0 1.946817596021333e-09
in O 0 1.2907648283544404e-09
the O 0 1.1118081033600902e-07
hemolytic O 0 0.0023934447672218084
assay O 0 4.1587188093217264e-07
of O 0 3.301840578728843e-09
C5 O 0 0.00045665205107070506
, O 0 1.6997198093449128e-09
rather O 0 4.8044200562369355e-11
than O 0 5.93042628893592e-11
a O 0 4.983230272870287e-09
true O 0 3.0201326239875925e-07
C5 O 0 0.0013698654947802424
inhibitor O 0 2.0099469111301005e-06
or O 0 3.705344227000751e-07
inactivator O 0 0.00013425720680970699
. O 0 4.433599656294973e-07

Of O 0 5.707215677830391e-07
clinical O 0 1.9465794593998e-06
interest O 0 1.870479735543995e-07
are O 0 1.3076107308052087e-08
( O 0 8.890616021162145e-10
a O 0 7.0276153785187034e-09
) O 0 2.3030524154421528e-09
the O 0 9.358445129947768e-10
documentation O 0 4.080023785490994e-08
of O 0 9.563403580159502e-08
membranous O 1 0.8875404596328735
glomerulonephritis B-Disease 1 0.9999822378158569
, O 0 0.038644175976514816
vasculitis B-Disease 1 0.9999843835830688
, O 0 0.001647798577323556
and O 0 0.27367427945137024
arthritis B-Disease 1 0.9999982118606567
in O 0 3.330634967824153e-07
an O 0 5.672369240983244e-08
individual O 0 1.9688844332677036e-08
lacking O 0 7.7050668778611e-07
C5 O 0 0.06338554620742798
( O 0 2.0919754817327885e-09
and O 0 1.3754462013793045e-09
its O 0 1.4422583127782218e-09
biologic O 0 6.46355886146921e-07
functions O 0 1.475035371623079e-10
) O 0 5.107031242346238e-09
, O 0 8.84272566281652e-09
and O 0 1.1786005416070111e-07
( O 0 1.0975639286314731e-09
b O 0 2.726173242706409e-08
) O 0 4.2615755369013186e-10
a O 0 7.250042233231113e-10
remarkable O 0 1.4343800813776397e-08
propensity O 0 5.013682766730199e-06
to O 0 1.0989050451826188e-06
bacterial B-Disease 1 0.9998394250869751
infections I-Disease 1 0.998557984828949
in O 0 1.3854893232689847e-08
the O 0 3.13476746782726e-08
proband O 0 0.00020482127729337662
, O 0 9.335861861359263e-09
even O 0 6.188551893160366e-10
during O 0 1.2158104523152247e-09
periods O 0 2.665875020735342e-10
of O 0 5.149656256975277e-10
low O 0 6.958306926208024e-07
- O 0 5.945044449617853e-06
dose O 0 4.971050682200939e-09
or O 0 6.790924489408212e-10
alternate O 0 5.557199145300729e-10
- O 0 2.2653959604213014e-05
day O 0 1.840474510572676e-06
corticosteroid O 0 1.920469912874978e-05
therapy O 0 7.714331218267034e-07
. O 0 6.019656240141558e-08

Other O 0 2.2991912373981904e-08
observations O 0 7.990843187144492e-08
indicate O 0 1.819594643848177e-07
that O 0 3.649943991490545e-08
the O 0 2.761252062555286e-07
C5D B-Disease 1 0.9998641014099121
state O 0 9.522174160281338e-09
is O 0 6.561733933985181e-10
compatible O 0 1.2289934403497682e-08
with O 0 1.0693374186132587e-08
normal O 0 1.120685944044908e-08
coagulation O 0 6.441332516260445e-07
function O 0 3.407105431119106e-10
and O 0 2.008551103216405e-09
the O 0 6.213092818008192e-10
capacity O 0 1.6746036779480278e-09
to O 0 1.2284914197024932e-09
mount O 0 1.128594703914132e-06
a O 0 6.145061774986971e-07
neutrophilic O 0 0.007289836183190346
leukocytosis O 0 0.007338583469390869
during O 0 6.516851954074809e-06
pyogenic B-Disease 0 0.004918812308460474
infection I-Disease 0 6.301749090198427e-05
. O 0 7.314734062902062e-08
. O 0 3.338378746775561e-07

Susceptibility O 0 0.00553527195006609
to O 0 0.0010810549138113856
ankylosing B-Disease 1 0.9998993873596191
spondylitis I-Disease 1 0.9999837875366211
in O 0 0.0009845382301136851
twins O 0 0.0027067759074270725
: O 0 4.694150845807599e-09
the O 0 3.8175099192905293e-10
role O 0 1.1302249136591058e-09
of O 0 3.4288147321426266e-10
genes O 0 5.284424009488475e-09
, O 0 5.014984338913564e-08
HLA O 0 6.753935394954169e-06
, O 0 2.6782316808748874e-08
and O 0 1.6623301846152572e-08
the O 0 2.1962522467333656e-08
environment O 0 2.2599833755521104e-06
. O 0 8.132034849950287e-07

OBJECTIVE O 0 4.32569436270569e-07
To O 0 1.0864318333858591e-08
determine O 0 1.8508766075342464e-08
the O 0 1.4980312101897653e-08
relative O 0 2.4541148491152853e-07
effects O 0 5.8637816380269214e-08
of O 0 2.1829245078208714e-09
genetic O 0 1.8248896367367706e-06
and O 0 2.948903272681491e-07
environmental O 0 3.7748883130461763e-08
factors O 0 1.8327350748137405e-09
in O 0 1.9327774936073183e-08
susceptibility O 0 5.8841607824433595e-05
to O 0 0.0020912950858473778
ankylosing B-Disease 1 0.9999897480010986
spondylitis I-Disease 1 0.999998927116394
( O 0 0.00010618344822432846
AS B-Disease 1 0.5422499775886536
) O 0 9.098140481000883e-07
. O 0 4.6676595388817077e-07

METHODS O 0 7.641142474312801e-06
Twins O 0 0.00012613338185474277
with O 0 1.8779327319862205e-06
AS B-Disease 0 0.040530022233724594
were O 0 1.3524143582799297e-07
identified O 0 8.735275969229406e-08
from O 0 1.64191316098794e-09
the O 0 1.0524998650396356e-08
Royal O 0 1.2494865586631931e-05
National O 0 6.839402431069175e-07
Hospital O 0 1.9928886104025878e-05
for O 0 2.0067177501914557e-06
Rheumatic B-Disease 1 0.9991316199302673
Diseases I-Disease 0 0.0008803775417618454
database O 0 1.1499128049763385e-06
. O 0 3.2200987334363163e-06

Clinical O 0 1.2868472367699724e-05
and O 0 1.419272848579567e-06
radiographic O 0 2.435401620459743e-05
examinations O 0 2.812770958371402e-07
were O 0 7.076376107306714e-08
performed O 0 5.153628190868176e-09
to O 0 4.4008549582308376e-10
establish O 0 1.5625920113393477e-08
diagnoses O 0 6.13450538367033e-05
, O 0 8.282173439511098e-06
and O 0 0.0007384425844065845
disease O 0 0.0003229040594305843
severity O 0 1.419882096342917e-06
was O 0 8.313850230479147e-06
assessed O 0 2.557146849824221e-08
using O 0 1.4701994066612656e-09
a O 0 2.1677442063605667e-08
combination O 0 1.740692212592876e-08
of O 0 1.1532687027582256e-09
validated O 0 3.467020519565267e-07
scoring O 0 5.7572030698338494e-08
systems O 0 1.8799428289639764e-05
. O 0 7.080736281750433e-07

HLA O 0 0.00012903453898616135
typing O 0 8.418101970164571e-06
for O 0 2.2947398647943373e-08
HLA O 0 8.554499800084159e-06
- O 0 2.804499672492966e-05
B27 O 0 6.622240675824287e-07
, O 0 1.7859967726963077e-08
HLA O 0 7.522109513047326e-07
- O 0 2.8364534955471754e-05
B60 O 0 1.0268937558066682e-06
, O 0 7.731379980668862e-09
and O 0 4.900747185843102e-08
HLA O 0 1.948946010088548e-05
- O 0 0.0062691387720406055
DR1 O 0 0.11159778386354446
was O 0 8.951554264058359e-06
performed O 0 2.5420312521617916e-09
by O 0 3.179601859581993e-10
polymerase O 0 3.4526541980994807e-07
chain O 0 6.879594707243086e-07
reaction O 0 3.5447689228362833e-10
with O 0 2.64237576264037e-10
sequence O 0 5.19602805226782e-10
- O 0 8.43402645500646e-08
specific O 0 1.7270783414513602e-10
primers O 0 1.3383270243139123e-06
, O 0 1.806408533866488e-08
and O 0 4.559772293077913e-08
zygosity O 0 1.568332481838297e-05
was O 0 1.7153687394966255e-06
assessed O 0 4.5587896124743565e-08
using O 0 4.9009994285142966e-08
microsatellite O 0 0.0023236358538269997
markers O 0 0.0006597289466299117
. O 0 4.001684374088654e-06

Genetic O 0 0.00010827275400515646
and O 0 1.0541140227360302e-06
environmental O 0 2.510098973118602e-08
variance O 0 1.630677815001036e-09
components O 0 6.815156439188286e-08
were O 0 1.836886553974182e-08
assessed O 0 1.0441239872704955e-08
with O 0 2.2604123017799793e-09
the O 0 3.1952522849820753e-09
program O 0 5.3530850863126034e-08
Mx O 0 1.8856981114367954e-06
, O 0 1.6224616095072975e-10
using O 0 8.574350257584129e-11
data O 0 8.980881816000874e-09
from O 0 7.648301436624649e-10
this O 0 3.888588340217325e-10
and O 0 2.3569134199874497e-08
previous O 0 1.6164901239790197e-07
studies O 0 1.9836821074648014e-09
of O 0 8.938461637519879e-10
twins O 0 4.329393959778827e-06
with O 0 1.1030655144850243e-07
AS B-Disease 0 0.0828804150223732
. O 0 3.9008937164908275e-06

RESULTS O 0 9.324978236691095e-06
Six O 0 6.480259884256157e-08
of O 0 3.6955736248955873e-09
8 O 0 2.046819872703054e-06
monozygotic O 0 3.374945299583487e-05
( O 0 9.304222459149969e-08
MZ O 1 0.7784937024116516
) O 0 3.294024395472661e-07
twin O 0 0.008128663524985313
pairs O 0 6.547156954184175e-05
were O 0 7.663870928809047e-05
disease O 0 1.5678839190513827e-05
concordant O 0 2.622668716867338e-06
, O 0 1.2008770511329203e-07
compared O 0 7.770678678298282e-08
with O 0 9.666537792440977e-09
4 O 0 5.212680420640936e-08
of O 0 1.5885431858819743e-09
15 O 0 9.224810781915949e-08
B27 O 0 1.245718863174261e-06
- O 0 1.7606520486879162e-05
positive O 0 8.631592329777504e-09
dizygotic O 0 7.11238271833281e-07
( O 0 2.999624326704975e-09
DZ O 0 0.008441533893346786
) O 0 1.036020762512635e-07
twin O 0 0.0006416606483981013
pairs O 0 1.4521818911816808e-06
( O 0 4.604025161114578e-09
27 O 0 1.3984700331093336e-07
% O 0 8.680259289128855e-10
) O 0 4.802782060941979e-10
and O 0 1.8537128498863353e-09
4 O 0 3.7103702332785815e-09
of O 0 6.125419060865056e-10
32 O 0 3.368173793205642e-07
DZ O 0 0.17539258301258087
twin O 0 0.013918915763497353
pairs O 0 1.708985905679583e-06
overall O 0 4.364455037375592e-07
( O 0 8.547086371990531e-10
12 O 0 7.929577883203365e-09
. O 0 2.3939277227214006e-09
5 O 0 2.9284857205880144e-08
% O 0 5.110363687776953e-09
) O 0 1.3879067672917245e-08
. O 0 1.5600970471041364e-07

Nonsignificant O 0 0.0026562106795608997
increases O 0 4.2760569840538665e-07
in O 0 3.2614566602973127e-09
similarity O 0 4.853479396160765e-09
with O 0 4.366375705444625e-09
regard O 0 5.324326757261133e-09
to O 0 3.146604399262287e-08
age O 0 1.035872060128895e-06
at O 0 0.0007532247109338641
disease O 0 9.463048627367243e-05
onset O 0 8.182000215128937e-07
and O 0 1.56240727022805e-08
all O 0 1.47977519127096e-10
of O 0 4.975385436978286e-09
the O 0 3.5865209611074533e-06
disease O 0 0.00012659572530537844
severity O 0 5.845924988534534e-07
scores O 0 3.117160574106492e-08
assessed O 0 2.3285535633021937e-07
were O 0 4.5502716261580645e-07
noted O 0 1.8937953427666798e-06
in O 0 2.017684664679109e-06
disease O 0 0.0002340278006158769
- O 0 0.00748081412166357
concordant O 0 0.024330105632543564
MZ O 1 0.9958794116973877
twins O 0 0.000166912010172382
compared O 0 2.2447670744440984e-06
with O 0 1.1569505886654952e-06
concordant O 0 0.011338207870721817
DZ O 1 0.990806519985199
twins O 0 0.0018743202090263367
. O 0 3.0295650503830984e-06

HLA O 0 0.001804431900382042
- O 0 0.0013287072069942951
B27 O 0 1.64296889124671e-05
and O 0 7.985523780007497e-07
B60 O 0 1.8116727460437687e-06
were O 0 6.318420275874814e-08
associated O 0 1.4540615822511427e-08
with O 0 1.6468444385964176e-08
the O 0 1.4243331634133938e-06
disease O 0 4.1338666051160544e-05
in O 0 6.399975660542623e-08
probands O 0 0.00047967612044885755
, O 0 3.200243270384817e-08
and O 0 8.973707110726536e-09
the O 0 1.1812737454874878e-08
rate O 0 8.36673052617698e-07
of O 0 1.745576305722807e-08
disease O 0 1.9197643723600777e-06
concordance O 0 1.5074977000040235e-07
was O 0 5.604205853160238e-06
significantly O 0 4.1773504655395755e-09
increased O 0 3.724044683739436e-10
among O 0 5.498265398529156e-09
DZ O 1 0.6992601156234741
twin O 0 0.1220618337392807
pairs O 0 1.5505108876823215e-06
in O 0 2.4706602985702375e-08
which O 0 6.707628585900238e-08
the O 0 1.9249492311246286e-07
co O 0 0.022785549983382225
- O 0 0.008577096275985241
twin O 0 0.027840860188007355
was O 0 3.6468654798227362e-06
positive O 0 6.806923774638207e-11
for O 0 5.639113828670439e-11
both O 0 1.2343537303394214e-09
B27 O 0 6.952131457182986e-07
and O 0 5.059738441559603e-07
DR1 O 0 0.028431452810764313
. O 0 3.155331285142893e-07

Additive O 0 7.0380392571678385e-06
genetic O 0 4.591322795022279e-05
effects O 0 4.19746993429726e-06
were O 0 1.8528837131270848e-07
estimated O 0 1.7279335295938836e-08
to O 0 5.686803805637908e-10
contribute O 0 1.6327217355893708e-10
97 O 0 3.2855464127123923e-08
% O 0 3.7301156607938424e-10
of O 0 3.668419387703459e-11
the O 0 8.12036304864705e-09
population O 0 8.009742313852541e-10
variance O 0 6.581001077421433e-09
. O 0 2.973338837364281e-07

CONCLUSION O 0 2.802424660330871e-06
Susceptibility O 0 2.535430212446954e-05
to O 0 2.581454054961796e-07
AS B-Disease 0 0.0007993340841494501
is O 0 1.5021742072462985e-08
largely O 0 5.346021847429938e-09
genetically O 0 2.625197836891857e-08
determined O 0 1.1819007283975225e-07
, O 0 3.599386033670271e-08
and O 0 4.637695383280516e-08
the O 0 4.0106524323846315e-08
environmental O 0 5.642285216822529e-08
trigger O 0 1.6333686403413594e-07
for O 0 2.8306801347355304e-09
the O 0 3.3364322007400915e-06
disease O 0 0.00018773334159050137
is O 0 2.5550212612301948e-08
probably O 0 1.2103325275347743e-07
ubiquitous O 0 2.644501591930748e-06
. O 0 1.0398588301541167e-06

HLA O 0 0.0017713658744469285
- O 0 0.0008260024478659034
B27 O 0 4.057266323798103e-06
accounts O 0 1.1960603174543394e-08
for O 0 1.1784691000826797e-09
a O 0 7.128052370575233e-09
minority O 0 2.5565649597325546e-09
of O 0 1.6261265944894632e-10
the O 0 1.5632835470569262e-08
overall O 0 8.234738402279618e-07
genetic O 0 1.2649666132347193e-06
susceptibility O 0 2.4778653369139647e-06
to O 0 1.4714716201069677e-07
AS B-Disease 0 0.040960393846035004
. O 0 3.4985284855792997e-06

Cell O 0 0.0004851285193581134
cycle O 0 0.00017973556532524526
- O 0 0.00018716372142080218
dependent O 0 3.99342098944544e-07
colocalization O 0 1.6823185433167964e-05
of O 0 1.9580536303465124e-08
BARD1 O 0 0.0010145790874958038
and O 0 2.2754370831989945e-07
BRCA1 O 0 1.0744423661890323e-06
proteins O 0 9.447940207962802e-10
in O 0 7.893222186972082e-10
discrete O 0 7.320679884514902e-08
nuclear O 0 3.233497773180716e-05
domains O 0 1.7752722669683862e-07
. O 0 2.955494551315496e-07

Germ O 0 0.08894450962543488
- O 0 0.01092110201716423
line O 0 4.6730423491680995e-05
mutations O 0 2.311635967089387e-07
of O 0 1.8111653288244156e-09
the O 0 9.714820237149979e-08
BRCA1 O 0 4.314464604249224e-05
gene O 0 2.5592504471205757e-07
predispose O 0 5.688283977178799e-07
women O 0 4.201169634399093e-09
to O 0 2.486652661559674e-09
early O 0 4.7052867557795253e-07
- O 0 0.47709399461746216
onset O 0 0.15308308601379395
breast B-Disease 1 0.998506486415863
and I-Disease 1 0.9994457364082336
ovarian I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999567270278931
by O 0 1.240938729551999e-07
compromising O 0 5.295170012686867e-06
the O 0 3.4789501057730376e-08
genes O 0 1.5610972070589924e-07
presumptive O 0 0.018962347880005836
function O 0 5.825486315558237e-09
as O 0 9.976183434901031e-09
a O 0 8.197848160307331e-07
tumor B-Disease 0 0.0015703300014138222
suppressor O 0 0.00024881106219254434
. O 0 3.3682872526696883e-06

Although O 0 1.3646030083691585e-07
the O 0 1.3348514293909375e-08
biochemical O 0 3.1145809771260247e-06
properties O 0 4.868139740210609e-07
of O 0 9.258722677429887e-09
BRCA1 O 0 1.5391682609333657e-05
polypeptides O 0 1.9138290952014358e-07
are O 0 3.879564725028928e-10
not O 0 1.061136623015102e-09
understood O 0 8.964452291593261e-09
, O 0 1.0199383559950093e-09
their O 0 1.8359598563666424e-10
expression O 0 1.2494186796274676e-09
pattern O 0 5.347890805751376e-07
and O 0 1.997690013411102e-08
subcellular O 0 1.8635142851053388e-07
localization O 0 1.0027466146311781e-07
suggest O 0 1.8478211183392546e-09
a O 0 5.087399390646397e-10
role O 0 3.0506586146117343e-09
in O 0 8.582867749851175e-09
cell O 0 9.154959116131067e-05
- O 0 0.0006406431784853339
cycle O 0 8.314381375384983e-06
regulation O 0 3.114308810836519e-07
. O 0 1.744796520597447e-07

When O 0 2.9623445243487367e-06
resting O 0 5.409489676821977e-05
cells O 0 9.210269240611524e-07
are O 0 1.940348770546052e-09
induced O 0 4.183611963526346e-07
to O 0 1.4679522042371218e-09
proliferate O 0 3.7370205063780304e-07
, O 0 1.6331772600963745e-09
the O 0 1.259561455135838e-09
steady O 0 9.847160526987864e-07
- O 0 5.601609245786676e-06
state O 0 1.5570961187094667e-09
levels O 0 1.402739591149782e-10
of O 0 2.7768485427737133e-11
BRCA1 O 0 5.982399642334713e-08
increase O 0 1.476237326825114e-10
in O 0 2.9053162653447373e-10
late O 0 1.0671536188056052e-07
G1 O 0 0.0005236736033111811
and O 0 5.650564016690396e-09
reach O 0 5.336971975467009e-10
a O 0 3.074402121772124e-10
maximum O 0 1.3765222295347712e-09
during O 0 4.139037201866813e-08
S O 0 0.0004012351855635643
phase O 0 5.994793355057482e-07
. O 0 1.2779345581748203e-07

Moreover O 0 2.951020405816962e-06
, O 0 9.573459891498715e-08
in O 0 1.0198395905547386e-08
S O 0 8.08636104920879e-06
phase O 0 3.015464145050828e-08
cells O 0 1.592277243389617e-07
, O 0 4.0591672245682275e-08
BRCA1 O 0 1.3981034499011002e-06
polypeptides O 0 1.1084139828199113e-07
are O 0 7.284292058429287e-10
hyperphosphorylated O 0 7.627775175933493e-06
and O 0 2.7643020317213995e-08
accumulate O 0 2.9567168269295507e-08
into O 0 8.016665664634104e-10
discrete O 0 4.137783378155291e-07
subnuclear O 0 0.0003332260239403695
foci O 0 6.613067671423778e-05
termed O 0 8.428673027083278e-06
" O 0 8.900505008568871e-07
BRCA1 O 0 2.0492772819125094e-05
nuclear O 0 7.81547641963698e-05
dots O 0 3.6991044908063486e-05
. O 0 1.4365507468028227e-06

" O 0 0.00015662785153836012
BRCA1 O 0 0.005920263472944498
associates O 0 0.10464078933000565
in O 0 2.1133529060080036e-07
vivo O 0 1.8260861907037906e-05
with O 0 1.5587407631301176e-07
a O 0 3.8207011243684974e-07
structurally O 0 0.001447047688998282
related O 0 6.918241979292361e-07
protein O 0 2.2147662548377411e-07
termed O 0 3.257596108596772e-05
BARD1 O 0 0.0015315864002332091
. O 0 1.1549320788617479e-06

Here O 0 5.381903633860929e-07
we O 0 7.53990381241465e-09
show O 0 8.980727272955846e-09
that O 0 5.503896782776962e-10
the O 0 6.567054677830697e-10
steady O 0 8.761804792811745e-07
- O 0 2.167181719414657e-06
state O 0 7.468706764157673e-10
levels O 0 1.606228761108497e-10
of O 0 2.501894247330938e-10
BARD1 O 0 1.842887832026463e-05
, O 0 1.6007183356592236e-09
unlike O 0 4.334146652684723e-10
those O 0 7.173134308757767e-11
of O 0 1.3961473088741627e-09
BRCA1 O 0 1.1513829122122843e-05
, O 0 6.064774993319588e-08
remain O 0 5.42056488583853e-09
relatively O 0 8.194825373841752e-10
constant O 0 1.7076940972415855e-09
during O 0 1.755074308107396e-08
cell O 0 6.931035022716969e-05
cycle O 0 1.4629584256908856e-05
progression O 0 4.951208666170714e-06
. O 0 1.0715709777286975e-06

However O 0 1.6435831184935523e-06
, O 0 1.0411915809527272e-06
immunostaining O 0 0.00025433750124648213
revealed O 0 3.695441046147607e-05
that O 0 1.0730317256957278e-07
BARD1 O 0 8.456248178845271e-05
resides O 0 1.761816434964203e-07
within O 0 2.573074253664487e-10
BRCA1 O 0 1.5832767985557439e-06
nuclear O 0 1.675671592238359e-05
dots O 0 2.1947212189843412e-06
during O 0 1.6021462556636834e-07
S O 0 5.3301806474337354e-05
phase O 0 2.2772936869586147e-09
of O 0 2.2226760362786813e-11
the O 0 1.2471781385414715e-09
cell O 0 3.11697949655354e-05
cycle O 0 1.849826844591007e-06
, O 0 5.0457416023164114e-09
but O 0 5.160226135281221e-10
not O 0 3.684337210319022e-11
during O 0 6.681931674634711e-10
the O 0 2.5332222985952058e-09
G1 O 0 0.0010677851969376206
phase O 0 5.891437808713818e-07
. O 0 5.395187372414512e-07

Nevertheless O 0 2.7083839086117223e-05
, O 0 8.854811994751799e-07
BARD1 O 0 5.0501475925557315e-05
polypeptides O 0 1.745721931456501e-07
are O 0 6.111263717301085e-10
found O 0 4.543223575126376e-09
exclusively O 0 1.2233698776231705e-10
in O 0 4.2370745800823784e-10
the O 0 4.1793965510628084e-10
nuclear O 0 5.798053592798169e-08
fractions O 0 1.6067763439209237e-11
of O 0 1.8158988202010562e-11
both O 0 7.922604239318787e-10
G1 O 0 0.003039094852283597
- O 0 0.00013045060040894896
and O 0 3.0504631354233425e-07
S O 0 9.232343290932477e-05
- O 0 2.0160844087513397e-06
phase O 0 5.958122883953365e-08
cells O 0 1.489640624185995e-07
. O 0 6.215018544253326e-08

Therefore O 0 6.235881642169261e-07
, O 0 4.909007600417681e-08
progression O 0 3.1862262517279305e-07
to O 0 3.194888265056761e-08
S O 0 0.0001374894636683166
phase O 0 2.9896563091824646e-07
is O 0 7.38366834340809e-09
accompanied O 0 6.81310030614668e-09
by O 0 1.6731087348897944e-10
the O 0 1.2960360562530582e-10
aggregation O 0 1.4191245512051864e-08
of O 0 6.860291446031397e-09
nuclear O 0 7.395230932161212e-05
BARD1 O 0 5.741056611441309e-06
polypeptides O 0 1.0039978626252832e-08
into O 0 7.99087018776845e-09
BRCA1 O 0 1.166958645626437e-05
nuclear O 0 3.4276530641363934e-05
dots O 0 2.473009953973815e-05
. O 0 1.035834543472447e-06

This O 0 3.021947492243271e-08
cell O 0 1.4760924386791885e-05
cycle O 0 2.048581518465653e-05
- O 0 0.00012582034105435014
dependent O 0 1.4194026221048262e-07
colocalization O 0 6.6766197051038034e-06
of O 0 3.6270473291466487e-09
BARD1 O 0 0.0002924721920862794
and O 0 4.5941766302348697e-07
BRCA1 O 0 1.0978494174196385e-05
indicates O 0 3.223461320089882e-08
a O 0 9.31364207978902e-10
role O 0 8.505016135806898e-10
for O 0 5.091877586238525e-09
BARD1 O 0 0.00029211491346359253
in O 0 9.447714433008514e-08
BRCA1 O 0 0.0002524484589230269
- O 0 0.010550469160079956
mediated O 0 0.017358843237161636
tumor B-Disease 0 0.02842548117041588
suppression O 0 1.2732033610518556e-05
. O 0 1.3136736924934667e-06

Ethnic O 0 3.1899261898615805e-07
differences O 0 1.5271625670720823e-06
in O 0 1.6846028572103933e-08
the O 0 2.805745680234395e-08
HFE O 0 6.150262925075367e-05
codon O 0 1.5782282503096212e-07
282 O 0 1.744400469760876e-05
( O 0 6.659352891347226e-08
Cys O 0 0.0008895734208635986
/ O 0 3.1681771361036226e-05
Tyr O 0 7.866020314395428e-05
) O 0 3.958146876925639e-08
polymorphism O 0 8.159644835359359e-07
. O 0 6.239605454538832e-07

Recent O 0 3.2380089578509796e-06
studies O 0 1.7879848712709645e-07
have O 0 1.813063832400985e-08
shown O 0 1.4291116485765087e-06
that O 0 0.00011735898442566395
hereditary B-Disease 1 0.9999947547912598
hemochromatosis I-Disease 1 0.9999991655349731
( O 0 0.0006955737480893731
HH B-Disease 1 0.9997020363807678
) O 0 9.199927717418177e-07
is O 0 2.661285058991325e-08
likely O 0 3.9116528682825447e-08
to O 0 2.7510458355806122e-09
be O 0 3.102734780213723e-08
caused O 0 1.3730516457144404e-07
by O 0 3.8380636446788685e-09
homozygosity O 0 8.628190698800609e-06
for O 0 7.701982940311325e-10
a O 0 6.064150426254855e-08
Cys282Tyr O 0 2.3419355784426443e-05
mutation O 0 1.0209276091188713e-08
in O 0 1.1225058660357945e-09
the O 0 1.7021992704258082e-08
HFE O 0 4.031672506243922e-05
gene O 0 1.0028346508761388e-07
located O 0 5.4390227433032123e-08
4 O 0 4.7200549602166575e-07
. O 0 5.483751692736405e-07

5 O 0 5.0816574912460055e-06
Mb O 0 0.0005371171282604337
telomeric O 0 0.00034055038122460246
to O 0 1.8133565049538447e-07
HLA O 0 4.86182798340451e-05
- O 0 0.0003179455816280097
A O 0 4.977028766006697e-06
. O 0 1.3714318356505828e-06

Population O 0 2.523839270907047e-07
studies O 0 3.143131266369892e-08
of O 0 5.967647487281624e-10
this O 0 4.6193984748477135e-10
polymorphism O 0 6.808880925746053e-08
are O 0 2.5636540113005424e-10
facilitated O 0 7.287964898239352e-09
by O 0 2.149323385935986e-09
the O 0 2.181143266000163e-09
fact O 0 1.912442870732889e-09
that O 0 3.2641698233248917e-09
the O 0 2.8036701849032397e-08
Cys282Tyr O 0 4.439984695636667e-05
mutation O 0 3.270602988436622e-08
creates O 0 1.9789970551187253e-08
a O 0 6.12529618138069e-08
Rsal O 0 2.8000500606140122e-05
restriction O 0 3.900878908780214e-08
site O 0 5.149406661075773e-07
. O 0 2.0962188784778846e-07

We O 0 1.8653867073226138e-07
have O 0 3.1251543575194773e-09
studied O 0 9.205328166395077e-10
the O 0 5.31990784757852e-10
codon O 0 2.6287352739018388e-08
282 O 0 6.610041054955218e-06
( O 0 3.8555796777473006e-08
Cys O 0 0.0005270506953820586
/ O 0 4.0071226976579055e-06
Tyr O 0 2.1337350517569575e-06
) O 0 3.7147249720703712e-09
polymorphism O 0 1.2448212238780343e-08
in O 0 3.532896197810942e-10
different O 0 2.1405212671798957e-11
ethnic O 0 8.341469182049366e-10
groups O 0 6.435152855033266e-09
. O 0 2.047374891844811e-07

In O 0 1.992621747604062e-07
agreement O 0 6.843618649554628e-08
with O 0 3.437551798768368e-09
previous O 0 1.78081300816757e-08
observations O 0 7.234960630597698e-09
the O 0 4.378234663704461e-09
Tyr O 0 9.010720987134846e-07
allele O 0 8.085992675432863e-08
appeared O 0 3.8945344726926123e-07
to O 0 1.6706573902069977e-09
be O 0 4.587379365261768e-09
rare O 0 2.5241563506028797e-08
or O 0 1.4774527379302071e-08
absent O 0 4.233330841429961e-08
in O 0 3.186368147112262e-08
Asiatic O 0 0.0001564324920764193
( O 0 4.699095779159279e-09
Indian O 0 8.19758039227736e-09
, O 0 2.0674848499879772e-09
Chinese O 0 2.1537503724911033e-10
) O 0 1.3211096661081e-09
populations O 0 1.1916102549136554e-09
. O 0 3.060457132164629e-08

The O 0 2.0429274272260045e-08
highest O 0 3.584512242582605e-08
allele O 0 1.8142745972227203e-08
frequency O 0 1.0066943190167876e-07
( O 0 1.0325693633461697e-09
7 O 0 2.6520728724221954e-08
. O 0 5.175141204460942e-09
5 O 0 4.4775440244393394e-08
% O 0 2.3721378195062925e-09
) O 0 4.2237147113155515e-09
was O 0 5.964745014352957e-06
found O 0 8.049552207012312e-07
in O 0 4.784729412676825e-08
Swedes O 0 0.00011713672574842349
. O 0 1.0680367950044456e-06

Saamis O 0 0.0014807638945057988
( O 0 2.5619291932343913e-07
2 O 0 4.6474713144561974e-07
% O 0 1.2272647786915059e-08
) O 0 8.4489801821519e-09
and O 0 3.288630878728327e-08
Mordvinians O 0 1.6295550722134067e-06
( O 0 5.445699793882319e-11
1 O 0 1.2523335146674697e-10
. O 0 5.477610587334425e-10
8 O 0 5.346167242237243e-08
% O 0 1.5953325327444645e-09
) O 0 8.896009484615774e-10
had O 0 3.893520172937315e-08
significantly O 0 1.7697733278865257e-09
lower O 0 1.0703959940627783e-09
frequencies O 0 5.056250418356001e-10
of O 0 5.512414483210826e-11
the O 0 1.0296101748963338e-08
Tyr O 0 1.3746748663834296e-05
allele O 0 5.729104941565311e-07
. O 0 1.6830620097607607e-07

Comparisons O 0 1.3692329048353713e-08
with O 0 1.4915584323205167e-09
allele O 0 6.154665221913547e-09
frequencies O 0 7.1826020686671654e-09
based O 0 4.708069667458403e-08
on O 0 4.022836492367787e-06
prevalence O 0 1.982852518267464e-05
estimates O 0 2.1146350093204092e-07
of O 0 2.3640044588546516e-08
HH B-Disease 1 0.9894635677337646
showed O 0 1.533376780571416e-05
some O 0 2.504179849593946e-11
disagreements O 0 2.7732058427432094e-08
with O 0 3.877665744056458e-09
the O 0 6.576396316404498e-09
RFLP O 0 5.567411790252663e-06
data O 0 1.7550281938838452e-07
, O 0 2.0637823894276153e-08
particularly O 0 7.014999692245283e-09
in O 0 2.8845470012583974e-08
Finns O 0 8.506964150001295e-06
. O 0 5.087958356853051e-07

The O 0 4.929527790409338e-07
newly O 0 3.1842532735026907e-06
described O 0 4.411975896800868e-05
HFE O 0 0.00017298870079685003
marker O 0 3.0860314836900216e-06
provides O 0 6.931364926465733e-10
a O 0 1.9546197993491887e-09
new O 0 1.4824313998573757e-09
approach O 0 7.268016410932887e-09
to O 0 1.2126231963005552e-10
the O 0 8.330192091676736e-11
screening O 0 9.207330453619988e-10
of O 0 1.7906996996330804e-09
HH B-Disease 0 0.04171968623995781
as O 0 1.9150856456207066e-09
well O 0 3.8321440465338696e-10
as O 0 5.876505948521071e-10
studies O 0 4.5904580137090534e-10
of O 0 3.416813360024307e-11
the O 0 2.033196500050849e-09
relationship O 0 9.382313237438211e-08
between O 0 2.489187878040866e-08
the O 0 3.329491349290947e-08
HFE O 0 0.00011334672308294103
Tyr O 0 9.386817509948742e-06
allele O 0 2.526507500988373e-07
and O 0 1.4348786692153226e-07
different O 0 8.854763677845767e-08
disorders O 0 0.14937563240528107
including O 0 1.642567804083228e-05
cancer B-Disease 0 0.25475555658340454

Autosomal B-Disease 1 0.987281858921051
dominant I-Disease 1 0.9804766178131104
neurohypophyseal I-Disease 1 0.999086856842041
diabetes I-Disease 1 0.9998077750205994
insipidus I-Disease 1 0.9958968162536621
associated O 0 1.0315726285625715e-05
with O 0 9.71535811800095e-08
a O 0 1.6346028530733747e-07
missense O 0 7.859148354327772e-07
mutation O 0 1.1303160185605066e-08
encoding O 0 3.977134355181988e-08
Gly23 O 0 0.0003435684775467962
- O 0 0.004310889635235071
- O 0 0.0052564251236617565
> O 0 5.173822046344867e-07
Val O 0 4.217121750116348e-05
in O 0 3.1078673146112124e-07
neurophysin O 0 0.0007959259673953056
II O 0 0.008560827001929283
. O 0 2.2228928173717577e-06

Autosomal B-Disease 1 0.9871472120285034
dominant I-Disease 1 0.9757423400878906
neurohypophyseal I-Disease 1 0.999078631401062
diabetes I-Disease 1 0.9997950196266174
insipidus I-Disease 1 0.9984040856361389
( O 0 2.1844622096978128e-05
ADNDI B-Disease 0 0.43052950501441956
) O 0 5.001891167921713e-06
is O 0 2.0148004296061117e-06
an O 0 0.005889055319130421
inherited B-Disease 1 0.999998927116394
disease I-Disease 1 0.9999961853027344
caused O 0 0.002452754881232977
by O 0 6.211712388903834e-07
progressive O 0 0.0012079650769010186
degeneration O 0 0.16118435561656952
of O 0 5.584317452900223e-09
the O 0 7.995218709311303e-08
magnocellular O 0 1.7729384126141667e-05
neurons O 0 1.5937099817620037e-07
of O 0 5.840112837773859e-10
the O 0 1.9770087789083846e-08
hypothalamus O 0 2.2327925819354277e-07
leading O 0 3.456963781900413e-07
to O 0 6.7898660027765345e-09
decreased O 0 3.475037146927207e-08
ability O 0 6.146016473529414e-10
to O 0 2.739770355031368e-10
produce O 0 3.711741469736296e-10
the O 0 1.3233146134439266e-08
hormone O 0 1.4085433974742045e-07
arginine O 0 5.203412456467049e-07
vasopressin O 0 2.8939521712345595e-07
( O 0 3.440273621535539e-09
AVP O 0 1.4048467164684553e-05
) O 0 2.008012067733489e-08
. O 0 6.006719388551574e-08

Affected O 0 2.6668599275581073e-06
individuals O 0 1.298982343911348e-08
are O 0 1.2615497535506393e-09
not O 0 5.952269788167541e-09
symptomatic O 0 3.88955726293716e-07
at O 0 1.2735081327264197e-05
birth O 0 1.432563976777601e-06
, O 0 1.987819757687248e-07
but O 0 1.7597913881672866e-07
usually O 0 1.9144589202824136e-07
develop O 0 2.4915307221817784e-06
diabetes B-Disease 0 0.08700727671384811
insipidus I-Disease 0 0.00030519498977810144
at O 0 1.382141931571823e-06
1 O 0 1.2397605075875617e-07
- O 0 0.0025295333471149206
6 O 0 1.2107671864214353e-05
yr O 0 0.014444987289607525
of O 0 2.2610988636984075e-08
age O 0 5.70932741084107e-07
. O 0 2.1679183248579648e-07

The O 0 3.6721078799928364e-07
genetic O 0 3.281955969214323e-06
locus O 0 1.4668282346974593e-05
of O 0 6.862231316517864e-08
the O 0 8.118311598082073e-06
disease O 0 0.00012350875476840883
is O 0 9.026821068403024e-09
the O 0 6.138898811514082e-08
AVP O 0 0.02722308039665222
- O 0 0.058183226734399796
neurophysin O 0 0.010672302916646004
II O 0 0.008801826275885105
( O 0 8.950545193897597e-09
NPII O 0 2.358462370466441e-05
) O 0 1.4506951195869533e-09
gene O 0 2.2083277428919246e-09
, O 0 1.4642366430450693e-08
and O 0 4.513238494041616e-08
mutations O 0 5.798761293362986e-08
that O 0 1.6700663252322556e-07
cause O 0 4.0165551240534114e-07
ADNDI B-Disease 0 0.000819460314232856
have O 0 1.309857680098503e-07
been O 0 2.287857370220081e-07
found O 0 7.67136327795015e-08
in O 0 5.972988215141584e-10
both O 0 1.0194691618670149e-10
the O 0 4.937982800434781e-10
signal O 0 5.0600856837945685e-08
peptide O 0 1.1920148201838288e-09
of O 0 6.32457280991261e-11
the O 0 1.4584697005659564e-08
prepro O 0 0.00019732287910301238
- O 0 0.0007143894326873124
AVP O 0 0.002047422342002392
- O 0 0.00041965628042817116
NPII O 0 3.534461939125322e-05
precursor O 0 1.0838530073442598e-08
and O 0 3.059597908361411e-09
within O 0 3.748860111230101e-10
NPII O 0 3.922944233636372e-05
itself O 0 9.393143045599572e-07
. O 0 4.006378730991855e-07

An O 0 2.324373440387717e-07
affected O 0 2.8159487897028157e-07
girl O 0 5.930093175265938e-05
who O 0 1.9546271801118564e-07
presented O 0 2.7159646975860596e-08
at O 0 1.2023730278087896e-06
9 O 0 2.8939436447217304e-07
months O 0 9.58902930392469e-08
of O 0 1.1816810863152227e-09
age O 0 8.035166132458471e-08
and O 0 4.896999783454703e-08
her O 0 4.479663402889855e-06
similarly O 0 4.4297030399320647e-07
affected O 0 1.515370717797282e-09
younger O 0 6.437635136080644e-08
brother O 0 3.5503051094565308e-06
and O 0 1.6644311529034894e-07
father O 0 2.1779158032586565e-06
were O 0 1.712424513300448e-08
all O 0 2.4490240391195073e-10
found O 0 1.067477271021744e-07
to O 0 2.4365851558627583e-09
have O 0 3.4618308220046856e-09
a O 0 6.0136291502033146e-09
novel O 0 3.362742262424945e-08
missense O 0 1.737419239589144e-07
mutation O 0 1.4068245235421273e-08
( O 0 5.098765298860997e-10
G1758 O 0 4.513841247444361e-07
- O 0 0.00286940042860806
- O 0 0.013133774511516094
> O 0 1.7744800118180137e-07
T O 0 6.369000402628444e-06
) O 0 1.2102841298600175e-11
encoding O 0 5.617790520967558e-12
the O 0 4.187549612622021e-11
amino O 0 4.678816362124749e-11
acid O 0 5.502393332634803e-11
substitution O 0 6.971668381483553e-11
Gly23 O 0 6.463441764026356e-07
- O 0 4.382638508104719e-05
- O 0 0.00012504623737186193
> O 0 7.825890691037785e-08
Val O 0 1.0824149967447738e-06
within O 0 1.3174886737132852e-09
NPII O 0 0.00010869730613194406
. O 0 3.4590743780427147e-07

The O 0 2.611280649489345e-07
mutation O 0 5.157228770258371e-06
was O 0 2.3734419301035814e-05
confirmed O 0 5.638573270516645e-07
by O 0 7.070410035225905e-09
restriction O 0 9.404601541973534e-08
endonuclease O 0 4.6684228436788544e-05
analysis O 0 1.077252591130673e-06
. O 0 1.4901877420925302e-06

A O 0 9.166619747702498e-06
T1 O 0 0.07653705775737762
- O 0 7.131434540497139e-05
weighted O 0 1.6545983783089468e-07
magnetic O 0 4.910801294499834e-07
resonance O 0 6.249371722333308e-07
imaging O 0 4.70560189569369e-06
of O 0 2.3714501473648397e-09
the O 0 1.5526282481914677e-07
fathers O 0 1.0114660653925966e-05
pituitary O 0 5.746152237406932e-05
gland O 0 1.1595394425967243e-05
demonstrates O 0 1.4186122143655666e-07
an O 0 6.444712141728814e-08
attenuated O 0 0.00043507531518116593
posterior O 0 0.0023433698806911707
pituitary O 0 0.00044424502993933856
bright O 0 1.2360951586742885e-05
spot O 0 7.791782263666391e-05
. O 0 3.0550036171916872e-06

This O 0 9.340637774357674e-08
mutation O 0 8.70892961302161e-07
may O 0 7.994166395519642e-08
be O 0 8.903949105798503e-11
valuable O 0 9.282796753495859e-11
for O 0 4.78579884055641e-11
developing O 0 8.228311365598984e-10
models O 0 5.855768137053019e-08
of O 0 1.9477694124248046e-08
dominantly B-Disease 0 0.004709139000624418
inherited I-Disease 1 0.9849034547805786
neurodegeneration I-Disease 1 0.9999840259552002
, O 0 9.661620481438149e-08
as O 0 1.0388038207409522e-09
the O 0 1.573435715052085e-09
early O 0 3.391315317458066e-08
age O 0 4.834015854271456e-08
of O 0 3.0116749094588613e-09
onset O 0 1.7597388932699687e-06
of O 0 1.1369502317393199e-07
symptoms O 0 9.748999900693889e-07
suggests O 0 4.510501483423468e-08
that O 0 6.3454463905543435e-09
this O 0 1.2522625159050449e-09
mutation O 0 4.014762211568268e-08
may O 0 9.421297875178425e-08
be O 0 1.6229236843301464e-09
particularly O 0 6.394381690810746e-10
deleterious O 0 5.646481060495034e-09
to O 0 2.4603122317223836e-10
the O 0 9.04332964068999e-09
magnocellular O 0 6.782374839531258e-06
neuron O 0 2.6776071536005475e-05
. O 0 5.3360004415026197e-08
. O 0 2.5069226694540703e-07

Frequent O 0 6.1390555856633e-06
inactivation O 0 0.0012358042877167463
of O 0 7.880155408201972e-07
PTEN O 0 0.004608014598488808
/ O 0 0.0001761888706823811
MMAC1 O 0 0.005172802601009607
in O 0 7.508666385547258e-06
primary O 0 0.031704165041446686
prostate B-Disease 1 0.9999359846115112
cancer I-Disease 1 0.9998441934585571
. O 0 0.00018191142589785159

Sporadic B-Disease 0 0.08531714975833893
prostate I-Disease 1 0.9998077750205994
carcinoma I-Disease 1 0.9999784231185913
is O 0 7.1261365519603714e-06
the O 0 1.1875476246814287e-07
most O 0 9.882739071542801e-09
common O 0 5.422386948339408e-07
male B-Disease 0 2.1679237761418335e-05
cancer I-Disease 0 3.315062349429354e-05
in O 0 2.541410859535631e-09
the O 0 5.659819279912881e-09
Western O 0 2.2460423565462406e-07
world O 0 8.675878575559182e-07
, O 0 9.776287335228062e-09
yet O 0 7.390484335623171e-10
many O 0 5.036600043278883e-12
of O 0 4.4992905234853e-11
the O 0 3.300178352816374e-09
major O 0 7.134336232894611e-09
genetic O 0 4.587950286349951e-08
events O 0 4.376063955646714e-09
involved O 0 1.795385173863906e-09
in O 0 1.203889432588312e-09
the O 0 1.7403202434707055e-08
progression O 0 1.4150506331134238e-06
of O 0 3.787536062560548e-09
this O 0 7.968454696083427e-08
often O 0 3.739420571946539e-05
fatal O 1 0.9260312914848328
cancer B-Disease 0 0.005669104401022196
remain O 0 9.019613145255789e-08
to O 0 5.2164468300475164e-09
be O 0 6.913862904411872e-08
elucidated O 0 4.412000998854637e-05
. O 0 6.073375971027417e-07

Numerous O 0 7.521284715039656e-07
cytogenetic O 0 0.0012147451052442193
and O 0 8.12233156466391e-06
allelotype O 0 0.001491056988015771
studies O 0 3.0531580819115334e-07
have O 0 5.3865562676946865e-08
reported O 0 9.242329724656884e-06
frequent O 0 1.7018105324950739e-07
loss O 0 2.186479832744226e-05
of O 0 1.3705968804345048e-08
heterozygosity O 0 1.2166563465143554e-05
on O 0 3.096595173701644e-05
chromosomal O 0 0.26415514945983887
arm O 1 0.5861966013908386
10q O 0 1.3666463019035291e-05
in O 0 4.889347451353387e-07
sporadic B-Disease 0 0.0752919465303421
prostate I-Disease 1 0.9999852180480957
cancer I-Disease 1 0.9998928308486938
. O 0 4.710944995167665e-05

Deletion O 0 9.32719703996554e-05
mapping O 0 2.2069234546506777e-05
studies O 0 5.269058078738453e-07
have O 0 5.502810651591972e-08
unambiguously O 0 1.0275080057908781e-05
identified O 0 2.7499936550157145e-07
a O 0 3.315568619655096e-08
region O 0 1.5810929454573852e-08
of O 0 4.723808455509015e-09
chromosome O 0 2.4610770196886733e-05
10q23 O 0 2.770737523860589e-07
to O 0 1.532797666570218e-09
be O 0 4.890685079139701e-10
the O 0 7.935428425476232e-10
minimal O 0 2.277914967763195e-09
area O 0 8.426593645083358e-09
of O 0 2.293348622117719e-08
loss O 0 0.0005372138693928719
. O 0 1.587637484590232e-06

A O 0 1.5410585092467954e-06
new O 0 3.8152793990775535e-07
tumor B-Disease 0 8.806468395050615e-05
suppressor O 0 1.2486074410844594e-05
gene O 0 4.755065674544312e-07
, O 0 4.335317100867542e-07
PTEN O 0 0.00015845903544686735
/ O 0 2.518840119591914e-05
MMAC1 O 0 0.00470284279435873
, O 0 3.8775425537096453e-07
was O 0 2.4234655938926153e-05
isolated O 0 4.5234523895487655e-06
recently O 0 2.939941850854666e-06
at O 0 3.185032255714759e-07
this O 0 2.4776328211295606e-10
region O 0 1.698559515261877e-09
of O 0 1.5945538223149924e-09
chromosome O 0 6.457804556703195e-05
10q23 O 0 1.8949569948745193e-06
and O 0 1.0012960416361238e-07
found O 0 2.134360421734982e-08
to O 0 1.1608509986604787e-10
be O 0 1.2945092220384424e-10
inactivated O 0 6.431606802692613e-09
by O 0 2.7595159490800825e-10
mutation O 0 2.1996260368695175e-09
in O 0 7.183522399145659e-08
three O 0 0.0060656145215034485
prostate B-Disease 1 0.999993085861206
cancer I-Disease 1 0.9999399185180664
cell O 0 0.009346066042780876
lines O 0 0.00015469461504835635
. O 0 6.278156433836557e-06

We O 0 3.0142686568979116e-07
screened O 0 3.6227945656719385e-06
80 O 0 6.946597295609536e-06
prostate B-Disease 1 0.9925601482391357
tumors I-Disease 1 0.9999468326568604
by O 0 1.4772436998100602e-06
microsatellite O 0 0.002647135639563203
analysis O 0 5.144655119693198e-07
and O 0 4.3643387925840216e-07
found O 0 1.8985766701007378e-06
chromosome O 0 1.9701823475770652e-05
10q23 O 0 1.065906076291867e-06
to O 0 5.3499897845199484e-09
be O 0 2.6563644617283444e-09
deleted O 0 3.623391364726558e-08
in O 0 1.4424735184093151e-08
23 O 0 2.5109997636718617e-07
cases O 0 9.178739901472e-08
. O 0 8.320532174366235e-07

We O 0 2.9034247006620717e-08
then O 0 9.05594799149867e-09
proceeded O 0 4.180419121979639e-09
with O 0 1.0160040864182207e-10
sequence O 0 2.7614219244576077e-10
analysis O 0 2.7871863150785714e-10
of O 0 3.379377333523337e-11
the O 0 3.226073630457904e-09
entire O 0 3.9712215738063605e-08
PTEN O 0 2.2144369722809643e-05
/ O 0 7.501163281631307e-07
MMAC1 O 0 9.984683856600896e-06
coding O 0 9.599817531125154e-06
region O 0 4.838213030211591e-08
and O 0 3.221605027192709e-08
tested O 0 3.7785547135626985e-08
for O 0 1.3385495489792731e-10
homozygous O 0 2.3540470905913935e-08
deletion O 0 3.2072030364815873e-08
with O 0 1.2913565328176446e-08
new O 0 3.388985021501867e-07
intragenic O 0 0.00047517981147393584
markers O 0 5.6314115681743715e-06
in O 0 5.284363169266726e-09
these O 0 3.7748051906483227e-10
23 O 0 3.2158034457552276e-08
cases O 0 2.9496856068789157e-09
with O 0 1.946638974459347e-07
10q23 O 0 4.5073818910168484e-05
loss O 0 4.157211151323281e-05
of O 0 2.5444581552847012e-08
heterozygosity O 0 7.398713933071122e-05
. O 0 6.328479571493517e-07

The O 0 1.073498090420344e-08
identification O 0 2.4033433021486417e-09
of O 0 2.720176583981271e-10
the O 0 3.3054261550091724e-09
second O 0 1.1563930968350178e-07
mutational O 0 1.872792608992313e-06
event O 0 7.204901066870661e-07
in O 0 5.50109735542037e-09
10 O 0 2.4939401654933135e-08
( O 0 1.099701218976179e-09
43 O 0 1.2059543053055677e-07
% O 0 1.770932378519774e-08
) O 0 9.546160981699359e-07
tumors B-Disease 1 0.9994433522224426
establishes O 0 6.373708856699523e-06
PTEN O 0 0.0006777904345653951
/ O 0 2.731414951995248e-06
MMAC1 O 0 1.1621963494690135e-05
as O 0 3.1077954099067995e-10
a O 0 8.42816538781932e-10
main O 0 3.419165395257551e-08
inactivation O 0 5.036398306401679e-06
target O 0 1.2880963140560198e-07
of O 0 2.2322714787748055e-09
10q O 0 2.2072649699111935e-06
loss O 0 1.2618433174793608e-05
in O 0 2.1024293062055222e-07
sporadic B-Disease 0 0.03506084904074669
prostate I-Disease 1 0.999990701675415
cancer I-Disease 1 0.9999295473098755
. O 0 1.490021645622619e-06
. O 0 1.7551329847265151e-06

Risk O 0 5.5034452088875696e-05
reversals O 0 3.5973236663267016e-05
in O 0 4.277631049376396e-08
predictive O 0 1.8242910755361663e-06
testing O 0 1.2066693670931272e-05
for O 0 3.725616988958791e-05
Huntington B-Disease 1 0.9999507665634155
disease I-Disease 1 0.999702513217926
. O 0 1.874252120614983e-05

The O 0 1.0043234688339453e-08
first O 0 3.223275202302034e-09
predictive O 0 3.1150216273090336e-07
testing O 0 5.631937710859347e-06
for O 0 6.115908036008477e-05
Huntington B-Disease 1 0.9999911785125732
disease I-Disease 1 0.999752938747406
( O 0 2.5841874418119914e-08
HD B-Disease 0 0.0007983099203556776
) O 0 5.925833690412219e-08
was O 0 1.6171914012375055e-06
based O 0 1.7194414780874467e-08
on O 0 1.6557110882331472e-07
analysis O 0 6.568523946981486e-09
of O 0 1.2303204011132607e-09
linked O 0 2.257605501654325e-06
polymorphic O 0 5.830079885527084e-08
DNA O 0 4.259851266397163e-06
markers O 0 8.49565549287945e-06
to O 0 1.1025393042984888e-08
estimate O 0 4.977457379595762e-08
the O 0 1.6471798369721569e-09
likelihood O 0 7.402535917577779e-09
of O 0 4.3294701157492455e-10
inheriting O 0 4.1062290279114677e-07
the O 0 4.619717941523049e-09
mutation O 0 7.656069556105649e-09
for O 0 2.4018951272353206e-09
HD B-Disease 0 0.0008454633643850684
. O 0 1.1051341743950616e-06

Limits O 0 9.247784049648544e-08
to O 0 4.506053752351136e-09
accuracy O 0 5.316282170042541e-08
included O 0 2.2367284413515875e-10
recombination O 0 5.013320603097782e-08
between O 0 1.5066618175296753e-08
the O 0 1.842300534349306e-08
DNA O 0 3.5881410440197214e-05
markers O 0 6.470687367254868e-05
and O 0 5.5897558581818885e-08
the O 0 7.68260566275103e-09
mutation O 0 4.586445712106979e-08
, O 0 2.687632729703182e-07
pedigree O 0 2.0218345525790937e-05
structure O 0 1.1159085033796146e-07
, O 0 1.6217114762184792e-08
and O 0 5.497279964572499e-09
whether O 0 1.8999248840856353e-09
DNA O 0 1.8911373445007484e-07
samples O 0 3.212472954317036e-09
were O 0 3.0762337122069994e-09
available O 0 6.800775498305711e-10
from O 0 2.5682116433500823e-09
family O 0 2.6167302280555305e-07
members O 0 1.1973126934350375e-09
. O 0 1.065548858036891e-07

With O 0 2.1542824413245398e-08
direct O 0 1.2326739629031636e-09
tests O 0 3.0888276381091373e-09
for O 0 1.5064356012617353e-11
the O 0 5.668480129727982e-10
HD B-Disease 0 2.3557196982437745e-05
mutation O 0 1.8589998873608238e-08
, O 0 8.101921800118816e-09
we O 0 4.5937598169842886e-10
have O 0 1.3454888592168146e-10
assessed O 0 8.909593618433576e-10
the O 0 3.255538061353036e-10
accuracy O 0 2.3785278813193145e-07
of O 0 1.0652654314213805e-09
results O 0 6.416978948209362e-08
obtained O 0 3.2839846397791916e-09
by O 0 2.5981961027099487e-10
linkage O 0 7.341360941381936e-08
approaches O 0 6.300810984072314e-09
when O 0 3.5729612601897998e-09
requested O 0 2.7976521099759566e-10
to O 0 3.5272268439356935e-10
do O 0 2.2309157993172235e-11
so O 0 3.459425107488201e-11
by O 0 6.907025645874754e-11
the O 0 4.680597243122975e-09
test O 0 1.8391727962807636e-07
individuals O 0 9.528073885434196e-10
. O 0 6.021643628173479e-08

For O 0 2.8277513663965692e-08
six O 0 9.830385749864945e-08
such O 0 7.021341286161942e-10
individuals O 0 7.907899335357627e-10
, O 0 3.343362697805219e-09
there O 0 4.843507817042791e-10
was O 0 9.674562306827283e-07
significant O 0 1.7869875579279437e-09
disparity O 0 7.534904966632894e-08
between O 0 1.9234953185787163e-08
the O 0 9.837719261440725e-08
tests O 0 4.5112071234143514e-07
. O 0 3.4265468684679945e-07

Three O 0 3.850039433928032e-07
went O 0 3.5640207443066174e-06
from O 0 1.3905193441132724e-08
a O 0 1.3130946285855316e-07
decreased O 0 1.3396002032095566e-06
risk O 0 2.344038030344109e-08
to O 0 3.9242781246784375e-10
an O 0 1.126390447581116e-08
increased O 0 9.258673117074068e-08
risk O 0 2.4700813128220034e-07
, O 0 1.1401072086414388e-08
while O 0 1.1838066527047886e-08
in O 0 6.054044487946442e-10
another O 0 2.482349659160832e-09
three O 0 1.1829083490511039e-08
the O 0 2.3520684067079856e-07
risk O 0 1.2174119774499559e-06
was O 0 1.3587607099907473e-05
decreased O 0 2.7577304990700213e-06
. O 0 3.449560495027981e-07

Knowledge O 0 5.340826447763902e-08
of O 0 5.590254037457498e-09
the O 0 1.0397280370000317e-08
potential O 0 5.625089727345767e-09
reasons O 0 2.4871921189273394e-10
for O 0 2.7081751771684814e-11
these O 0 1.7612081931739354e-11
changes O 0 6.117931855564862e-11
in O 0 6.424789145142995e-09
results O 0 1.9534213890892715e-07
and O 0 7.04004108342815e-08
impact O 0 2.799105613959796e-09
of O 0 4.027466971034954e-10
these O 0 2.5699267158785233e-09
risk O 0 4.9212886210625584e-08
reversals O 0 1.6404887901444454e-06
on O 0 2.1737866973126074e-06
both O 0 7.736339568964468e-08
patients O 0 4.339641535011651e-09
and O 0 5.6861990671563944e-09
the O 0 5.050903251202499e-09
counseling O 0 8.330804490697119e-09
team O 0 2.9898570286235326e-09
can O 0 4.247704618598469e-11
assist O 0 5.464918101383276e-11
in O 0 2.536953980225576e-10
the O 0 7.525202683211774e-10
development O 0 2.7386209966451247e-10
of O 0 5.887553639061238e-11
strategies O 0 1.0665916150287558e-08
for O 0 1.808002914049922e-10
the O 0 1.0604209066400472e-08
prevention O 0 1.2804402160782047e-07
and O 0 1.3980720581230344e-08
, O 0 1.8569684678837461e-09
where O 0 5.712786910194723e-10
necessary O 0 2.1722326715156726e-10
, O 0 2.411208566144296e-09
management O 0 2.4011486132735627e-09
of O 0 1.0558928731363437e-10
a O 0 3.1161684432845504e-07
risk O 0 2.2274161892710254e-07
reversal O 0 2.1136389705134206e-07
in O 0 2.3150038830355157e-10
any O 0 3.5832902617327633e-11
predictive O 0 7.224136400196812e-09
testing O 0 1.4127643943595558e-08
program O 0 1.7058296108984905e-08
. O 0 1.2874674659713037e-09
. O 0 3.66150487707273e-08

A O 0 1.3152947758499067e-05
novel O 0 6.212630410118436e-07
common O 0 4.6887578264431795e-08
missense O 0 8.411821568188316e-07
mutation O 0 5.689087601012943e-08
G301C O 0 2.224726358690532e-07
in O 0 3.5119900321234354e-09
the O 0 3.410015025906432e-08
N O 0 2.9807093596900813e-05
- O 0 0.0013156853383406997
acetylgalactosamine O 0 0.0002918346144724637
- O 0 0.0002712544228415936
6 O 0 2.128779897248023e-06
- O 0 0.0005652358522638679
sulfate O 0 1.2043552487739362e-05
sulfatase O 0 4.253721272107214e-06
gene O 0 3.20882485027596e-08
in O 0 1.746123103885111e-07
mucopolysaccharidosis B-Disease 0 0.0006150724366307259
IVA I-Disease 0 0.12590228021144867
. O 0 4.9643058446235955e-06

Mucopolysaccharidosis B-Disease 1 0.5529913902282715
IVA I-Disease 1 0.9949319958686829
( O 0 0.0003817523247562349
MPS B-Disease 1 0.999434769153595
IVA I-Disease 1 0.999950647354126
) O 0 0.0001128054573200643
is O 0 1.845098267949652e-06
an O 0 5.287075964588439e-06
autosomal B-Disease 1 0.9909143447875977
recessive I-Disease 1 0.9996582269668579
lysosomal I-Disease 1 0.9998565912246704
storage I-Disease 1 0.999885082244873
disorder I-Disease 1 0.9963877201080322
caused O 0 4.5129643694963306e-05
by O 0 1.3197080761528923e-07
a O 0 4.0611379517940804e-05
genetic B-Disease 1 0.9998859167098999
defect I-Disease 1 0.9999136924743652
in O 0 1.544386577734258e-06
N O 0 0.002287206007167697
- O 0 0.02781413123011589
acetylgalactosamine O 0 0.0026660719886422157
- O 0 0.0024917996488511562
6 O 0 2.4607155864941888e-05
- O 0 0.17934976518154144
sulfate O 0 0.0013450256083160639
sulfatase O 0 0.00032953484333120286
( O 0 1.3363620432471635e-08
GALNS O 0 3.289735468570143e-05
) O 0 1.1481771977628341e-08
. O 0 4.55762432238771e-08

In O 0 4.2210112383145315e-07
previous O 0 5.778070999440388e-07
studies O 0 5.88593493944245e-08
, O 0 1.862055398760276e-08
we O 0 4.604429282295541e-09
have O 0 6.202649505127056e-10
found O 0 5.447554407567168e-09
two O 0 3.3754383732542692e-09
common O 0 1.2660726689261992e-08
mutations O 0 2.0008092960210888e-08
in O 0 1.7023161547058407e-08
Caucasians O 0 3.3148418765449605e-07
and O 0 1.2761429957208748e-07
Japanese O 0 9.44657642776292e-07
, O 0 4.0493308262057326e-08
respectively O 0 9.288866920087457e-08
. O 0 1.6830428251068952e-07

To O 0 2.2741868832554246e-08
characterize O 0 1.1118123666165047e-07
the O 0 4.833690780969846e-09
mutational O 0 1.7084743149098358e-06
spectrum O 0 1.0267689276588499e-07
in O 0 5.221830190471621e-10
various O 0 1.425005512895039e-11
ethnic O 0 3.958120498026574e-10
groups O 0 5.127642754843009e-10
, O 0 7.997609685617135e-09
mutations O 0 4.4684895783575485e-09
in O 0 1.2541508942476298e-09
the O 0 1.2178441366472725e-08
GALNS O 0 2.002734618145041e-05
gene O 0 6.0534008916590665e-09
in O 0 2.4137452925288017e-08
Colombian O 0 2.57472311204765e-05
MPS B-Disease 1 0.9984719157218933
IVA I-Disease 1 0.9999889135360718
patients O 0 4.3961949813819956e-07
were O 0 1.5315951884531387e-07
investigated O 0 9.05777960724663e-06
, O 0 1.1422973500430089e-07
and O 0 1.1708937819321363e-07
genetic O 0 4.717418278232799e-07
backgrounds O 0 6.063919499865733e-08
were O 0 4.266833997235153e-08
extensively O 0 4.089287131137098e-08
analyzed O 0 6.478183678382265e-08
to O 0 1.3292486000793247e-09
identify O 0 5.985147932818791e-09
racial O 0 2.509151109109098e-08
origin O 0 3.261962078227043e-08
, O 0 1.5472560122020695e-08
based O 0 1.0083773815949826e-08
on O 0 1.1220868145755958e-06
mitochondrial O 0 2.6693111067288555e-05
DNA O 0 0.000145866593811661
( O 0 3.950226368232279e-09
mtDNA O 0 3.106773505123783e-08
) O 0 7.81935227678332e-09
lineages O 0 1.2647095104512118e-07
. O 0 1.6064485919287108e-07

Three O 0 7.385431217699079e-07
novel O 0 1.8164579387303093e-06
missense O 0 4.696204996434972e-06
mutations O 0 2.68851454165997e-06
never O 0 1.5893067484284984e-06
identified O 0 1.4945442217140226e-07
previously O 0 1.6257584434242744e-07
in O 0 5.212448694891236e-09
other O 0 2.881938909737869e-09
populations O 0 5.2629385294267195e-09
and O 0 1.2694317774730735e-07
found O 0 2.4363546913264145e-07
in O 0 1.9364740921901102e-09
16 O 0 1.0641369563302305e-08
out O 0 9.047729676581184e-09
of O 0 1.3484723337953142e-09
19 O 0 6.321898240457813e-07
Colombian O 0 5.296745712257689e-06
MPS B-Disease 1 0.9549655318260193
IVA I-Disease 1 0.9999312162399292
unrelated O 0 2.131726432708092e-05
alleles O 0 7.073083452269202e-08
account O 0 1.0566575170400938e-08
for O 0 7.731570939029098e-09
84 O 0 2.0178983959340258e-06
. O 0 4.3544980599108385e-07

2 O 0 5.053891982242931e-06
% O 0 1.611096678288959e-08
of O 0 2.6981228362643606e-10
the O 0 3.4056844011587373e-09
alleles O 0 8.263009831921408e-09
in O 0 3.9595726697427835e-09
this O 0 2.0487600504992542e-09
study O 0 1.1266354960071112e-08
. O 0 2.1009900308399665e-07

The O 0 3.4391675285405654e-07
G301C O 0 9.297928954765666e-06
and O 0 2.1114632886565232e-07
S162F O 0 1.6714125194994267e-06
mutations O 0 7.007326274788284e-08
account O 0 3.543135118633245e-09
for O 0 6.20559958974809e-09
68 O 0 1.5208637705654837e-05
. O 0 9.820975037655444e-07

4 O 0 1.7602540538064204e-05
% O 0 2.136393248974855e-07
and O 0 1.8037599147646688e-07
10 O 0 2.2393479071070033e-07
. O 0 2.439316517666157e-07

5 O 0 1.980803745027515e-06
% O 0 2.4540860010802135e-08
of O 0 1.7014973874296402e-09
mutations O 0 1.2573291030548717e-07
, O 0 5.987811135810261e-08
respectively O 0 5.479695275312224e-08
, O 0 5.463141494743695e-09
whereas O 0 5.341167508277067e-10
the O 0 1.7743395641645066e-09
remaining O 0 1.4234896639209182e-07
F69V O 0 0.00013463797222357243
is O 0 2.6064070901554715e-09
limited O 0 7.519259520583077e-11
to O 0 6.655826584323066e-11
a O 0 2.0279911083775914e-09
single O 0 4.018493271473744e-08
allele O 0 2.4032221972447587e-06
. O 0 4.996118718736398e-07

The O 0 1.1382304165863388e-07
skewed O 0 3.0031808364583412e-06
prevalence O 0 9.60346278588986e-06
of O 0 6.367123273065545e-09
G301C O 0 8.473480761495011e-07
in O 0 4.379696161294078e-09
only O 0 2.0983924320372438e-10
Colombian O 0 9.749030738248621e-08
patients O 0 9.307537851555026e-09
and O 0 6.149926434773079e-08
haplotype O 0 5.496597623277921e-06
analysis O 0 2.799724674318327e-09
by O 0 9.904247422198864e-10
restriction O 0 7.653849998234818e-09
fragment O 0 2.972817014779139e-07
length O 0 2.376083898525394e-07
polymorphisms O 0 2.3933705506351544e-07
in O 0 1.0584123799617373e-08
the O 0 3.235213341667986e-08
GALNS O 0 0.0001726712944218889
gene O 0 2.714488545052518e-08
suggest O 0 8.382126104322651e-09
that O 0 4.156265553945104e-09
G301C O 0 1.4216229260455293e-07
originated O 0 1.9071148216198708e-08
from O 0 2.891915040770243e-10
a O 0 1.1323185056255625e-08
common O 0 7.584910832747482e-08
ancestor O 0 2.250000989079126e-06
. O 0 3.1160336675384315e-06

Investigation O 0 2.2889930733072106e-06
of O 0 9.986750093560204e-09
the O 0 1.1678076283772043e-08
genetic O 0 7.194616102879081e-08
background O 0 6.8226060356835205e-09
by O 0 3.231918066504136e-09
means O 0 1.2854163289333087e-09
of O 0 3.392579828176423e-10
mtDNA O 0 2.7578456851529154e-08
lineages O 0 4.677779585904318e-08
indicate O 0 1.7303378285760118e-08
that O 0 2.9006168578149527e-09
all O 0 1.1818809819708065e-10
our O 0 1.898252577348103e-08
patients O 0 3.3803866372750235e-09
are O 0 2.486907346721523e-10
probably O 0 7.78620901087379e-09
of O 0 5.458368201871622e-10
native O 0 1.555408601916497e-07
American O 0 1.0338535503251478e-05
descent O 0 0.0032894329633563757

Low O 0 1.2551633972179843e-06
frequency O 0 1.9028240672014363e-07
of O 0 1.9356773961476392e-08
BRCA1 O 0 3.110683974227868e-05
germline O 0 4.351888037490426e-06
mutations O 0 4.047949175856047e-07
in O 0 2.2260486787217815e-07
45 O 0 3.530761887304834e-06
German O 1 0.979233980178833
breast B-Disease 1 0.9999351501464844
/ I-Disease 1 0.999958872795105
ovarian I-Disease 1 0.9999970197677612
cancer I-Disease 1 0.9999639987945557
families O 0 2.151225635316223e-05
. O 0 3.6768703921552515e-06

In O 0 1.2963567996848724e-07
this O 0 1.3675879317887052e-09
study O 0 3.900428868774952e-10
we O 0 6.587766998578104e-10
investigated O 0 1.056541023558566e-07
45 O 0 2.876312237276579e-07
German O 1 0.5655614137649536
breast B-Disease 1 0.9998378753662109
/ I-Disease 1 0.9999042749404907
ovarian I-Disease 1 0.9999974966049194
cancer I-Disease 1 0.9999678134918213
families O 0 3.59900212743014e-07
for O 0 3.669193171518259e-09
germline O 0 1.6021416513467557e-06
mutations O 0 7.702945481469214e-08
in O 0 1.2981601571482315e-08
the O 0 7.087114539672257e-08
BRCA1 O 0 9.425817552255467e-05
gene O 0 2.6169348075200105e-06
. O 0 1.5894675016170368e-06

We O 0 1.1807583177869674e-07
identified O 0 1.0625674917719152e-07
four O 0 1.0377230630354006e-08
germline O 0 2.6697074417825206e-07
mutations O 0 1.0045728515706287e-07
in O 0 7.694751502640429e-08
three O 0 8.760126365814358e-05
breast B-Disease 1 0.9549593329429626
cancer I-Disease 0 0.003134341211989522
families O 0 1.0806125771978259e-07
and O 0 1.5991390966973995e-07
in O 0 1.9428722453085356e-07
one O 0 0.0012744577834382653
breast B-Disease 1 0.9999651908874512
- I-Disease 1 0.9999986886978149
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999960660934448
family O 0 0.0006710043526254594
. O 0 1.7691263565211557e-08
among O 0 2.056067677225215e-10
these O 0 2.864958270620832e-10
were O 0 1.3114195951402507e-08
one O 0 1.825625695062172e-08
frameshift O 0 8.83568100107368e-06
mutation O 0 3.06909093694685e-08
, O 0 1.8598653284129796e-08
one O 0 6.34924779419066e-09
nonsense O 0 2.0565776139847003e-06
mutation O 0 2.2260396193019005e-08
, O 0 8.90823859123202e-09
one O 0 3.987683072637083e-09
novel O 0 3.095033207500819e-08
splice O 0 2.8970638595637865e-05
site O 0 5.801532552140998e-06
mutation O 0 7.782663402622347e-08
, O 0 1.7031638321896025e-08
and O 0 1.805478611061062e-08
one O 0 2.9522311706386972e-08
missense O 0 3.870814452966442e-06
mutation O 0 5.182889140087354e-07
. O 0 1.0118087629962247e-06

The O 0 2.0572767311932694e-07
missense O 0 1.0134493095392827e-05
mutation O 0 3.0147796223900514e-06
was O 0 6.968970410525799e-05
also O 0 1.1781952480305335e-06
found O 0 5.963295279798331e-07
in O 0 4.2150251289285734e-08
2 O 0 8.370489581466245e-07
. O 0 8.56904648571799e-07

8 O 0 5.8642567637434695e-06
% O 0 2.5386023949636183e-08
of O 0 3.8538330859871905e-10
the O 0 2.1743229439152856e-09
general O 0 9.65321267365482e-10
population O 0 1.595390264341745e-09
, O 0 1.5761697724769874e-08
suggesting O 0 1.6446918493784324e-07
that O 0 9.433216874299433e-09
it O 0 4.480012805174738e-08
is O 0 7.817953928679344e-08
not O 0 7.665927910238679e-07
disease O 0 3.1652776669943705e-05
associated O 0 1.7685619013718679e-07
. O 0 4.2760447627188114e-07

The O 0 1.9626720870746794e-07
average O 0 8.545350283384323e-06
age O 0 1.7951142581296153e-06
of O 0 3.050602686016646e-07
disease O 0 0.0008855669293552637
onset O 0 9.243096428690478e-06
in O 0 5.4290108408849846e-08
those O 0 5.274698722246285e-08
families O 0 2.9774645327051985e-07
harbouring O 0 0.004311833065003157
causative O 0 1.533645786366833e-06
mutations O 0 7.113386573109892e-07
was O 0 1.2252285159775056e-05
between O 0 2.2769914664877433e-07
32 O 0 4.866682047577342e-06
. O 0 2.4877649593690876e-06

3 O 0 3.527053422658355e-06
and O 0 3.192866415702156e-07
37 O 0 6.903135840730101e-07
. O 0 2.345192342545488e-07

4 O 0 1.2590736332640518e-05
years O 0 1.1827221442217706e-06
, O 0 1.613895506125118e-08
whereas O 0 2.651489916516425e-09
the O 0 1.1535419730535068e-08
family O 0 4.468540737434523e-06
harbouring O 0 0.0001496428158134222
the O 0 3.469824605417671e-08
missense O 0 6.348790293486672e-07
mutation O 0 5.5198718484916753e-08
had O 0 6.13020517903351e-07
an O 0 2.440353519261862e-08
average O 0 6.732507813467237e-07
age O 0 5.5032202794791374e-08
of O 0 6.742001179560475e-09
onset O 0 2.1097773696965305e-06
of O 0 2.3355140044145628e-08
51 O 0 8.936985068430658e-06
. O 0 1.5245665281327092e-06

2 O 0 1.7382428268319927e-05
years O 0 3.561173343769042e-06
. O 0 1.771806068973092e-06

These O 0 2.8980579713788757e-08
findings O 0 2.2361426488259895e-07
show O 0 1.4945128441468114e-06
that O 0 1.5915288997803145e-07
BRCA1 O 0 1.5968020306900144e-05
is O 0 8.405088181007159e-08
implicated O 0 1.1825562751255347e-06
in O 0 3.072609944254623e-09
a O 0 1.0105838832430436e-08
small O 0 1.6536148450541077e-08
fraction O 0 1.5348843973583826e-08
of O 0 2.5900849323079456e-06
breast B-Disease 1 0.9996891021728516
/ I-Disease 1 0.9999212026596069
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999839067459106
families O 0 5.201398494136811e-07
suggesting O 0 4.688408807851374e-07
the O 0 9.297299818911142e-09
involvement O 0 8.498262360490116e-08
of O 0 9.281969637342513e-10
another O 0 1.5173561962456006e-07
susceptibility O 0 6.727335858158767e-06
gene O 0 2.5419101348234108e-06
( O 0 1.4193767583492445e-07
s O 0 0.0012403569417074323
) O 0 2.3804643660696456e-06

Paternal O 0 0.0034519138280302286
transmission O 1 0.8011683821678162
of O 0 0.15513238310813904
congenital B-Disease 1 0.9998323917388916
myotonic I-Disease 1 0.9998494386672974
dystrophy I-Disease 1 0.9998140931129456
. O 0 0.025860846042633057

We O 0 1.0671165000530891e-06
report O 0 2.7383322276364197e-07
a O 0 1.795529769310633e-08
rare O 0 8.771907289428782e-08
case O 0 2.428481309380004e-07
of O 0 1.80867431254228e-07
paternally O 1 0.9548798203468323
transmitted O 1 0.9996040463447571
congenital B-Disease 1 0.9999897480010986
myotonic I-Disease 1 0.9999885559082031
dystrophy I-Disease 1 0.9999920129776001
( O 0 0.008867532014846802
DM B-Disease 1 0.9999501705169678
) O 0 3.368932084413245e-05
. O 0 3.6562123568728566e-06

The O 0 7.223766260722186e-07
proband O 0 0.00014581209688913077
is O 0 1.8534766610400766e-08
a O 0 3.6183013918389406e-08
23 O 0 3.477902339454886e-07
year O 0 2.1335549149625876e-07
old O 0 0.0004507613484747708
, O 0 6.412270886357874e-05
mentally B-Disease 1 0.9999758005142212
retarded I-Disease 1 0.9999663829803467
male O 0 0.0009977382142096758
who O 0 0.03216482698917389
suffers O 1 0.9957275390625
severe O 0 0.15912917256355286
muscular B-Disease 1 0.9970876574516296
weakness I-Disease 1 0.8948783278465271
. O 0 2.4562068574596196e-05

He O 0 2.800175570882857e-05
presented O 0 4.816502041649073e-06
with O 0 3.431878940318711e-05
respiratory O 0 0.0700279027223587
and O 0 6.44033980279346e-06
feeding O 0 7.42153060855344e-05
difficulties O 0 8.341478860529605e-06
at O 0 9.523569133307319e-06
birth O 0 2.9593797989946324e-06
. O 0 8.256804449047195e-07

His O 0 1.383256858389359e-05
two O 0 4.4992735638516024e-05
sibs O 1 0.8526113629341125
suffer O 0 0.0009783285204321146
from O 0 1.3136949519321206e-06
childhood O 0 0.0008451986941508949
onset O 0 0.015429014340043068
DM B-Disease 1 0.9996609687805176
. O 0 4.7982237447286025e-05

Their O 0 1.0863846000574995e-07
late O 0 2.433591816952685e-06
father O 0 3.7149295621929923e-06
had O 0 2.9933681844340754e-07
the O 0 6.683358866332867e-10
adult O 0 1.3794693387580992e-08
type O 0 6.801819552038069e-08
of O 0 2.502668223769433e-07
DM B-Disease 1 0.9999895095825195
, O 0 3.843307752049441e-07
with O 0 1.5958254095949087e-07
onset O 0 2.400990751993959e-06
around O 0 4.2248931464428097e-08
30 O 0 1.0664048488706612e-07
years O 0 2.9942646051495103e-07
. O 0 2.465548334384948e-07

Only O 0 2.1703133512573913e-08
six O 0 2.9155057035268328e-08
other O 0 5.731417007659445e-10
cases O 0 1.591323961491753e-09
of O 0 2.076364635783534e-09
paternal O 0 1.1089295185229275e-05
transmission O 0 0.053688909858465195
of O 0 0.0009381946292705834
congenital B-Disease 1 0.9999896287918091
DM I-Disease 1 0.9999957084655762
have O 0 1.5944799088174477e-05
been O 0 9.585712177795358e-06
reported O 0 0.0001256113755516708
recently O 0 2.2699958208249882e-05
. O 0 8.448644166492159e-07

We O 0 5.972287198119375e-08
review O 0 2.768088869231633e-09
the O 0 3.99627930747215e-09
sex O 0 1.0997673172141731e-07
related O 0 2.4353462890758237e-07
effects O 0 3.858397334965957e-08
on O 0 5.895524282095721e-07
transmission O 0 0.007413754239678383
of O 0 0.00010405007924418896
congenital B-Disease 1 0.9998999834060669
DM I-Disease 1 0.9999136924743652
. O 0 0.0001802341139409691

Decreased O 0 0.00018712034216150641
fertility O 0 1.9139901269227266e-05
of O 0 4.438081013802275e-09
males O 0 5.3667946531277266e-08
with O 0 5.5945658772316165e-08
adult O 0 1.2308922123338562e-05
onset O 0 0.0024102837778627872
DM B-Disease 1 0.9999827146530151
and O 0 1.3086808394291438e-05
contraction O 0 5.617040415017982e-07
of O 0 4.98588004216316e-10
the O 0 1.4389013536231232e-08
repeat O 0 2.4199320591833384e-07
upon O 0 1.9726724698188036e-09
male O 0 2.8237845839385045e-08
transmission O 0 2.3054985831549857e-06
contribute O 0 1.631081242292609e-10
to O 0 8.71146974001924e-11
the O 0 6.747890024527692e-10
almost O 0 2.8567312959637547e-09
absent O 0 7.656434597436146e-09
occurrence O 0 6.3501319758074715e-09
of O 0 1.6625830712158063e-09
paternal O 0 2.5626364731579088e-05
transmission O 0 0.03651727735996246
of O 0 0.0003339781833346933
congenital B-Disease 1 0.9999462366104126
DM I-Disease 1 0.9999183416366577
. O 0 0.00018992646073456854

Also O 0 4.855333486375457e-07
the O 0 8.185175204289408e-09
fathers O 0 2.5196730035759174e-08
of O 0 8.674135298925023e-10
the O 0 1.522275567822362e-07
reported O 0 0.00035037696943618357
congenitally O 0 0.003525560488924384
affected O 0 3.039444962382731e-08
children O 0 5.7250638008099486e-08
showed O 0 4.172919943812303e-06
, O 0 8.321513256248636e-09
on O 0 1.1787781062366776e-07
average O 0 8.209320156993272e-08
, O 0 1.0645408998755101e-08
shorter O 0 1.2469497789879824e-07
CTG O 0 8.806860023469198e-06
repeat O 0 9.882137419481296e-07
lengths O 0 4.371310205897316e-05
and O 0 1.355020913251792e-07
hence O 0 2.266958709640221e-08
less O 0 5.2737938460722944e-08
severe O 0 1.1000123777193949e-05
clinical O 0 3.4679967484407825e-06
symptoms O 0 3.631338074683299e-07
than O 0 1.6619522424932143e-09
the O 0 2.5992355290327396e-07
mothers O 0 9.586567557562375e-07
of O 0 2.2666821308803264e-08
children O 0 1.0320508408767637e-05
with O 0 0.016640396788716316
congenital B-Disease 1 0.9999582767486572
DM I-Disease 1 0.9999595880508423
. O 0 0.00010711416689446196

We O 0 1.9677361251524417e-07
conclude O 0 6.515247150673531e-07
that O 0 2.7666548163551852e-08
paternal O 0 1.8561390788818244e-06
transmission O 0 0.002673558657988906
of O 0 0.0001678502740105614
congenital B-Disease 1 0.9999904632568359
DM I-Disease 1 0.9999959468841553
is O 0 4.0666142012923956e-05
rare O 0 5.682601909029472e-07
and O 0 4.193118385842354e-08
preferentially O 0 8.323930700271376e-08
occurs O 0 2.658640418928826e-09
with O 0 1.09879190191009e-08
onset O 0 4.2043648136314005e-06
of O 0 1.4076999832468573e-07
DM B-Disease 1 0.999974250793457
past O 0 2.608403519843705e-07
30 O 0 2.3916744140706214e-08
years O 0 7.3913901665889625e-09
in O 0 1.0678001816089022e-09
the O 0 9.401584399881813e-09
father O 0 2.4993578335852362e-06
. O 0 9.78106307059079e-09
. O 0 9.053343319465057e-08

The O 0 1.0549397302384023e-06
RB1 O 0 0.0007067052647471428
gene O 0 8.974735123956634e-07
mutation O 0 8.844178296385508e-07
in O 0 5.302438665921727e-08
a O 0 1.3077723224341753e-06
child O 0 0.00018591119442135096
with O 0 0.000173625405295752
ectopic B-Disease 1 0.9997697472572327
intracranial I-Disease 1 0.9996960163116455
retinoblastoma I-Disease 0 0.2027643918991089
. O 0 1.3284049600770231e-05

The O 0 1.108494984691788e-06
RB1 O 0 0.0016039953334257007
gene O 0 1.012561710922455e-06
mutation O 0 2.29948864216567e-06
was O 0 1.722309571050573e-05
investigated O 0 3.991420726379147e-06
in O 0 4.4345465965989206e-08
a O 0 5.198363055569644e-07
child O 0 4.468124461709522e-05
with O 0 1.9934208467020653e-05
ectopic B-Disease 1 0.9992478489875793
intracranial I-Disease 1 0.9890566468238831
retinoblastoma I-Disease 0 3.792974166572094e-05
using O 0 1.1117462506149423e-08
DNA O 0 5.215189048612956e-06
obtained O 0 3.8361115173302096e-08
from O 0 7.578136451691364e-10
both O 0 4.963004451852271e-10
the O 0 5.284587700771226e-08
pineal B-Disease 0 0.00013301643775776029
and I-Disease 0 4.069132046424784e-05
retinal I-Disease 0 0.16816185414791107
tumours I-Disease 1 0.999962568283081
of O 0 5.2450634058232026e-08
the O 0 4.515192983944871e-07
patient O 0 8.751518180361018e-06
. O 0 6.836678039690014e-06

A O 0 3.772653599298792e-06
nonsense O 0 6.9067450567672495e-06
mutation O 0 1.496317025839744e-07
in O 0 4.6751924998034156e-08
exon O 0 1.545323357277084e-05
17 O 0 3.0202759262465406e-06
( O 0 1.110133096560162e-09
codon O 0 2.4127588815758827e-09
556 O 0 2.3441056384854164e-07
) O 0 1.9736359213595733e-09
of O 0 1.108122829607261e-10
the O 0 2.4578239887773634e-08
RB1 O 0 7.234810618683696e-05
gene O 0 3.262895376110464e-08
was O 0 4.992993126506917e-06
found O 0 1.0015997276013877e-07
to O 0 1.6095416111028271e-09
be O 0 4.199599334953064e-09
present O 0 2.7960374016089418e-09
homozygously O 0 4.441921646503033e-06
in O 0 3.160087302944703e-09
both O 0 5.5750559724288e-10
the O 0 2.1000520433744896e-08
retinal B-Disease 0 1.1668862498481758e-05
and I-Disease 0 8.854307509409409e-08
the I-Disease 0 4.5563123762804025e-07
pineal I-Disease 0 0.01490811351686716
tumours I-Disease 1 0.9998692274093628
. O 0 8.740425073483493e-06

The O 0 2.7200341534694417e-08
same O 0 3.1779926246144896e-08
mutation O 0 1.4970277106840513e-07
was O 0 5.894028618058655e-06
present O 0 2.3401648618914805e-08
heterozygously O 0 7.631253538420424e-06
in O 0 2.1374064740342646e-09
the O 0 4.885130966414408e-09
DNA O 0 2.90542470793298e-06
from O 0 1.7006537289532275e-09
the O 0 1.2935867932384326e-09
constitutional O 0 4.888523807977663e-09
cells O 0 1.041607777807485e-08
of O 0 3.072907206469466e-10
the O 0 8.536243711887437e-08
patient O 0 2.7170895577910414e-07
, O 0 6.6587304559107e-08
proving O 0 8.666129929224553e-07
it O 0 2.570715862404427e-09
to O 0 4.0957776059613593e-10
be O 0 5.274371495112007e-10
of O 0 6.831483156943818e-10
germline O 0 9.211876772496908e-07
origin O 0 5.013865234104742e-08
. O 0 3.8281160641417955e-07

The O 0 8.905524850888469e-08
initial O 0 1.3643246177252877e-07
mutation O 0 1.657256092357784e-07
was O 0 8.527880709152669e-06
shown O 0 4.988310919884498e-08
to O 0 1.4659237157488292e-09
have O 0 2.7290540938196273e-09
occurred O 0 1.7480450864582053e-08
in O 0 8.838842435743288e-10
the O 0 3.5789923913398525e-08
paternally O 0 5.1003811677219346e-05
derived O 0 7.593016704277034e-08
RB1 O 0 0.00014485008432529867
allele O 0 2.2700257886754116e-06
. O 0 8.126608008751646e-07

The O 0 3.843054514618416e-07
mutation O 0 2.0928080175508512e-06
is O 0 7.912795041420395e-08
in O 0 4.1823171592625386e-09
an O 0 4.926470342780931e-09
area O 0 5.081884246749269e-09
of O 0 5.701411565084413e-10
the O 0 5.20612930543507e-09
gene O 0 5.224960908378762e-09
that O 0 1.2251779590854994e-09
encodes O 0 8.535421813782307e-10
the O 0 1.4245394863721117e-09
protein O 0 1.0578876441513785e-08
- O 0 8.80090510690934e-07
binding O 0 1.894718515416116e-08
region O 0 2.3618804689817807e-09
known O 0 5.507992950626317e-10
as O 0 4.614220672216618e-10
the O 0 2.3610079225022673e-08
pocket O 0 0.013442146591842175
region O 0 3.2505159452966836e-08
and O 0 3.5300036671515045e-08
has O 0 4.550189203200716e-08
been O 0 8.607593571241523e-08
detected O 0 1.3577465551861678e-07
in O 0 1.1391850796016456e-09
other O 0 5.496490484979688e-10
cases O 0 1.6301957561637437e-09
of O 0 5.9790439266294015e-09
retinoblastoma B-Disease 0 2.5572899176040664e-05
. O 0 2.1187526400012757e-08
. O 0 1.6684823833656992e-07

Low O 0 8.883214832167141e-06
levels O 0 2.6319963097876098e-08
of O 0 1.1820213696722703e-09
beta O 0 2.5186738028537548e-08
hexosaminidase O 0 6.094709533499554e-06
A O 0 2.986561753459682e-07
in O 0 5.9598956880790865e-08
healthy O 0 2.4149244381987955e-07
individuals O 0 3.869103260001339e-09
with O 0 1.990465307244449e-06
apparent O 1 0.8137469291687012
deficiency O 0 0.013495191000401974
of O 0 3.8244915567808846e-10
this O 0 1.8877805985084706e-09
enzyme O 0 8.663495520977449e-08
. O 0 2.281680195892477e-07

Appreciable O 0 5.675324246112723e-06
beta O 0 3.6947337775927735e-06
hexosaminidase O 0 0.0002527613251004368
A O 0 1.6049509667936945e-06
( O 0 4.929656682861605e-09
hex O 0 4.277421339793364e-06
A O 0 5.791863486592774e-07
) O 0 1.3682122101954519e-08
activity O 0 7.616932862219983e-09
has O 0 9.733420291979655e-09
been O 0 6.7232783784731964e-09
detected O 0 2.7934694557529838e-08
in O 0 3.626154931879455e-09
cultured O 0 3.6553894460666925e-05
skin O 0 0.0022563214879482985
fibroblasts O 0 3.3371416066074744e-05
and O 0 0.0028883859049528837
melanoma B-Disease 1 0.9989539384841919
tissue O 0 0.003549326676875353
from O 0 1.784290049045012e-07
healthy O 0 1.2376554536785989e-07
individuals O 0 2.8147331132544195e-09
previously O 0 1.2808766314265085e-06
reported O 0 9.614842565497383e-05
as O 0 2.9510724175452197e-07
having O 0 6.481995660578832e-05
deficiency B-Disease 0 0.0003115750150755048
of I-Disease 0 4.646713291922566e-10
hex I-Disease 0 3.0273957236204296e-05
A I-Disease 0 2.4106396878664782e-08
activity O 0 1.1869108362816405e-08
indistinguishable O 0 4.134532005650726e-08
from O 0 5.327127627907657e-10
that O 0 2.0728510019552004e-09
of O 0 6.215229664263688e-09
patients O 0 8.96928497695626e-07
with O 0 0.07474279403686523
Tay B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999939203262329
Sachs I-Disease 1 0.9999933242797852
disease I-Disease 0 0.14196519553661346
( O 0 1.757798742119121e-07
TSD B-Disease 0 0.00026069176965393126
) O 0 2.3966845219547395e-07
. O 0 7.881681085564196e-07

Identification O 0 1.1481902220111806e-06
and O 0 5.084883127892681e-07
quantitation O 0 1.21978282550117e-05
of O 0 7.736365326138639e-09
hex O 0 9.476476407144219e-06
A O 0 2.494002728781197e-07
, O 0 2.8914712402183795e-08
amounting O 0 1.5606262948608673e-08
to O 0 8.622176306261053e-10
3 O 0 1.1212165418328368e-07
. O 0 1.5385107587917446e-07

5 O 0 1.3435354048851877e-05
% O 0 9.803466127777938e-07
- O 0 0.000366730586392805
6 O 0 2.0303576093283482e-05
. O 0 1.1232174301767373e-06

9 O 0 3.2429659768240526e-05
% O 0 3.087921740529964e-08
of O 0 2.716998015461769e-10
total O 0 1.5712583456561902e-09
beta O 0 2.8125917150845225e-09
hexosaminidase O 0 1.7854982843346079e-06
activity O 0 1.426867957121658e-08
, O 0 5.409802383837814e-09
has O 0 8.240943039083959e-09
been O 0 6.488680703853333e-09
obtained O 0 1.2588577957828306e-09
by O 0 2.7129911650547456e-09
cellulose O 0 1.578274168423377e-05
acetate O 0 8.75536716193892e-06
gel O 0 4.4292468373896554e-05
electrophoresis O 0 6.566251977346838e-05
, O 0 1.0426080621073197e-07
DEAE O 0 3.1083705835044384e-05
- O 0 8.69673203851562e-06
cellulose O 0 9.650055289966986e-06
ion O 0 1.4815016129432479e-06
- O 0 4.576135324896313e-06
exchange O 0 8.656657257688494e-08
chromatography O 0 3.1979248888092116e-05
, O 0 3.459495800939294e-08
radial O 0 1.8995775462826714e-05
immunodiffusion O 0 0.0001070163634722121
, O 0 3.9575883903353315e-08
and O 0 3.782182318445848e-07
radioimmunoassay O 0 0.00020239675359334797
. O 0 4.974671696800215e-07

Previous O 0 4.779126538778655e-05
family O 0 0.0002294397709192708
studies O 0 1.3776660523490136e-07
suggested O 0 1.249967880312397e-07
that O 0 5.6355280442232925e-09
these O 0 6.197056756640507e-10
individuals O 0 1.4828612782125106e-09
may O 0 2.8584766553763075e-08
be O 0 1.633083779317701e-09
compound O 0 1.6512390743628202e-07
heterozygotes O 0 1.944143157572853e-08
for O 0 1.6616152898052405e-10
the O 0 1.75789094392087e-09
common O 0 1.4948914994761253e-08
mutant O 0 1.9183862605132163e-06
TSD B-Disease 0 1.760608392942231e-05
gene O 0 8.29135160529404e-08
and O 0 1.610295470300116e-07
a O 0 2.2287761680672702e-07
rare O 0 1.847662019827112e-06
( O 0 6.843289046543077e-09
allelic O 0 1.4338215805764776e-06
) O 0 5.994301233158694e-08
mutant O 0 7.390179916910711e-07
gene O 0 1.5134195336941048e-06
. O 0 9.822398396863719e-07

Thus O 0 6.668834657830303e-07
, O 0 2.0225030539222644e-08
the O 0 6.128750285050444e-10
postulated O 0 4.306570389189801e-08
rate O 0 5.4802388405050806e-08
mutant O 0 1.2806111726604286e-07
gene O 0 5.239763822828536e-08
appears O 0 1.521753034694484e-07
to O 0 2.1670019945130292e-10
code O 0 2.202832638520391e-10
for O 0 1.8268811463606482e-10
the O 0 1.5284273846560836e-09
expression O 0 1.0395887484193622e-09
of O 0 7.284708947175034e-10
low O 0 1.38828852414008e-07
amounts O 0 1.6374433753352235e-10
of O 0 4.1603484546293146e-10
hex O 0 1.7234233382623643e-05
A O 0 1.547338001728349e-06
. O 0 7.509945589845302e-07

Heterozygotes O 0 1.0337944331695326e-05
for O 0 1.9061836553646572e-08
the O 0 1.500845314694743e-08
rare O 0 1.7267448981783673e-07
mutant O 0 2.3514546683145454e-06
may O 0 2.213263030625967e-07
be O 0 4.611715453961551e-09
indistinguishable O 0 1.8466846540832194e-07
from O 0 5.3944702038677406e-09
heterozygotes O 0 3.6477096898579475e-08
for O 0 1.233042556947339e-10
the O 0 1.1934032428939645e-08
common O 0 4.394832444631902e-07
TSD B-Disease 0 0.00036671783891506493
mutant O 0 1.0934399142570328e-05
. O 0 5.354647782951361e-07

However O 0 4.6528995767403103e-07
, O 0 1.7874239865989239e-09
direct O 0 6.064026364382968e-11
visualization O 0 3.2363803370571986e-07
and O 0 6.855873380118283e-08
quantitation O 0 3.0054729904804844e-06
of O 0 1.3106713492305744e-09
hex O 0 3.5376310734136496e-06
A O 0 1.178633812770613e-08
by O 0 3.6737146658083475e-10
the O 0 1.6149138692966858e-09
methods O 0 4.5385661451291526e-08
described O 0 1.6172924006241374e-05
may O 0 1.1967223656483839e-07
prevent O 0 3.1272424649841923e-08
false O 0 1.7914953787112609e-06
- O 0 3.376619497430511e-05
positive O 0 1.825011919365238e-09
prenatal O 0 4.094914629604318e-08
diagnosis O 0 3.0789652782914345e-07
of O 0 4.052983726410275e-09
TSD B-Disease 0 0.00010576176282484084
in O 0 9.836368519700045e-08
fetuses O 0 9.405124728800729e-06
having O 0 1.6373855160622952e-08
the O 0 9.612392659619218e-09
incomplete O 0 1.106865965994075e-05
hex B-Disease 0 0.0782170444726944
A I-Disease 0 0.014125647023320198
deficiency I-Disease 0 0.009560699574649334
of O 0 3.4423527917049057e-10
the O 0 2.5953559301683526e-08
type O 0 6.920359396644926e-07
described O 0 1.2268044883967377e-05
in O 0 1.2873700327986626e-08
the O 0 2.3452139785717918e-08
four O 0 1.196147877635667e-06
healthy O 0 3.177882490490447e-06
individuals O 0 1.1242509856401739e-07

The O 0 4.078445101640682e-07
tumor B-Disease 0 0.00032421352807432413
suppressor O 0 2.4686813048901968e-05
gene O 0 2.3445263650501147e-06
Smad4 O 0 0.0002916195953730494
/ O 0 1.5336516298702918e-05
Dpc4 O 0 1.1641663149930537e-05
is O 0 1.1559201373856354e-09
required O 0 2.822929390244866e-11
for O 0 1.638708613249662e-10
gastrulation O 0 6.772510232622153e-07
and O 0 4.381988460977482e-08
later O 0 3.998935369509127e-07
for O 0 6.636590388353625e-09
anterior O 0 2.4083246898953803e-06
development O 0 1.021717932481181e-09
of O 0 1.715417252690088e-10
the O 0 3.565903128333048e-08
mouse O 0 0.00010150566231459379
embryo O 0 1.9348144633113407e-05
. O 0 1.7198373143401113e-06

Mutations O 0 7.3765449997154064e-06
in O 0 9.941008727309963e-08
the O 0 1.9945248652675218e-07
SMAD4 O 0 0.017913561314344406
/ O 0 9.52175905695185e-05
DPC4 O 0 0.004772834479808807
tumor B-Disease 0 0.00019227847224101424
suppressor O 0 5.886754024686525e-06
gene O 0 6.432075139173321e-08
, O 0 6.312792510954068e-09
a O 0 1.557369344595827e-09
key O 0 9.595905403614324e-09
signal O 0 1.0008282202988994e-07
transducer O 0 8.179262067642412e-07
in O 0 5.854949858274949e-09
most O 0 5.185912144156646e-09
TGFbeta O 0 5.514929580385797e-05
- O 0 0.0001767670619301498
related O 0 1.239377525052987e-07
pathways O 0 7.136163304721777e-08
, O 0 4.077532533841577e-09
are O 0 3.6457777768950095e-11
involved O 0 3.1562846780630593e-10
in O 0 1.0309675335662405e-09
50 O 0 1.3818577393465148e-08
% O 0 2.197898085753991e-09
of O 0 2.6800208274835313e-07
pancreatic B-Disease 1 0.9982001781463623
cancers I-Disease 0 0.2197703868150711
. O 0 4.106360393052455e-06

Homozygous O 0 9.852163202594966e-05
Smad4 O 0 0.0005634247791022062
mutant O 0 0.0007252250798046589
mice O 0 0.008109425194561481
die O 0 0.00012865394819527864
before O 0 1.198668826418725e-07
day O 0 5.497711299540242e-07
7 O 0 9.173084549729538e-07
. O 0 4.4386001718521584e-07

5 O 0 3.389558287381078e-06
of O 0 9.714097615187711e-08
embryogenesis O 0 7.44745775591582e-05
. O 0 1.2975622666999698e-05

Mutant O 0 1.0393341653980315e-05
embryos O 0 7.612090939801419e-07
have O 0 6.679859865243998e-08
reduced O 0 1.671263660796285e-08
size O 0 6.462930173256609e-07
, O 0 2.255564481856709e-07
fail O 0 1.9079921287357138e-07
to O 0 6.26936724756888e-09
gastrulate O 0 2.6175135644734837e-05
or O 0 6.671252350543e-08
express O 0 6.314405887053454e-09
a O 0 6.57905596668229e-09
mesodermal O 0 3.912439751729835e-06
marker O 0 0.00020220867008902133
, O 0 8.821200481179403e-08
and O 0 2.590909353727966e-08
show O 0 6.37709206330328e-07
abnormal O 0 7.336068961194542e-07
visceral O 0 1.8764777109936404e-07
endoderm O 0 1.0299116183887236e-05
development O 0 5.834952432337559e-08
. O 0 2.438274577798438e-07

Growth B-Disease 1 0.9992204904556274
retardation I-Disease 1 0.9992924928665161
of O 0 8.841886511845587e-08
the O 0 1.8680442508411943e-06
Smad4 O 0 0.010205142199993134
- O 0 0.07943964749574661
deficient O 0 0.0012974623823538423
embryos O 0 3.7542059772022185e-07
results O 0 1.5710351419784274e-07
from O 0 2.9631570530597173e-09
reduced O 0 7.083259756512916e-09
cell O 0 4.961957984050969e-06
proliferation O 0 8.925980523599719e-07
rather O 0 8.540986667915362e-11
than O 0 4.9725723538784905e-11
increased O 0 1.1132840205263506e-09
apoptosis O 0 4.2099551933461044e-07
. O 0 1.9231730163937755e-07

Aggregation O 0 1.4502470548904967e-06
of O 0 1.591303444570258e-08
mutant O 0 7.257945981109515e-06
Smad4 O 0 9.550293907523155e-05
ES O 0 7.841212209314108e-06
cells O 0 3.25698863434809e-08
with O 0 4.4750592564923863e-08
wild O 0 1.016892952065973e-06
- O 0 0.0005222389590926468
type O 0 9.060509569280839e-07
tetraploid O 0 1.917724875966087e-05
morulae O 0 0.0005623421166092157
rescues O 0 4.017793617094867e-05
the O 0 2.8992420197937463e-07
gastrulation B-Disease 0 0.0008128919871523976
defect I-Disease 0 0.0005342703079804778
. O 0 1.3364127653403557e-06

These O 0 1.2628871104425343e-07
results O 0 6.161845362839813e-07
indicate O 0 9.198701889090444e-08
that O 0 7.177469285579718e-08
Smad4 O 0 1.012291158986045e-05
is O 0 3.904062850779155e-09
initially O 0 3.3639211416414128e-09
required O 0 6.228796558399585e-12
for O 0 1.4316173246875508e-11
the O 0 9.311524468147425e-11
differentiation O 0 6.6622696248686e-10
of O 0 1.3253290132020368e-10
the O 0 2.5607864717613893e-09
visceral O 0 3.0087480951124235e-08
endoderm O 0 1.4359397937369067e-06
and O 0 1.8260330136854463e-08
that O 0 3.371680934449728e-09
the O 0 1.4839174333758365e-08
gastrulation B-Disease 0 1.9636470824480057e-05
defect I-Disease 0 8.802745469438378e-06
in O 0 3.5503397999292474e-09
the O 0 5.135193958949458e-08
epiblast O 0 0.001392951002344489
is O 0 1.4116788626949983e-08
secondary O 0 1.565475971077035e-09
and O 0 2.925951037013874e-08
non O 0 1.669626037426042e-08
- O 0 3.256862692069262e-05
cell O 0 2.9585124138975516e-05
autonomous O 0 6.545388941958663e-08
. O 0 3.851735925763933e-07

Rescued O 0 0.002311976160854101
embryos O 0 9.712049359222874e-05
show O 0 0.0006069511873647571
severe O 0 0.00022871287364978343
anterior O 0 8.258278830908239e-05
truncations O 0 1.2219004929647781e-05
, O 0 7.810752435943868e-07
indicating O 0 5.801980478281621e-07
a O 0 2.2465860283205075e-08
second O 0 2.2031709789871456e-08
important O 0 1.467285321021805e-10
role O 0 1.9977539622573204e-09
for O 0 4.728306191026377e-09
Smad4 O 0 2.177882743126247e-05
in O 0 4.128055053342905e-08
anterior O 0 3.112048943876289e-05
patterning O 0 0.0004951468436047435
during O 0 1.342831183137605e-06
embryogenesis O 0 3.572643254301511e-05
. O 0 1.0012555549110402e-06

Prevalence O 0 0.0003097351873293519
of O 0 3.3011936295679334e-08
p16 O 0 1.7360920310238726e-06
and O 0 2.3921543856886274e-07
CDK4 O 0 6.151647539809346e-05
germline O 0 1.7977869219976128e-06
mutations O 0 2.3574762053613085e-07
in O 0 1.7420680364921282e-07
48 O 0 6.901263259351254e-05
melanoma B-Disease 1 0.999738872051239
- O 1 0.9734825491905212
prone O 1 0.5818986296653748
families O 0 7.914875936876342e-07
in O 0 1.9591489319736866e-07
France O 0 2.144382415281143e-05
. O 0 1.4875454326102044e-06

The O 0 1.8658258795767324e-06
French O 0 0.0001999646337935701
Familial B-Disease 0 0.4509466290473938
Melanoma I-Disease 1 0.9984598159790039
Study O 0 1.927055564010516e-06
Group O 0 1.0444075087434612e-05
. O 0 9.158399052466848e-07

Germline O 0 0.00015188305405899882
mutations O 0 2.7384965051169274e-06
in O 0 3.391160063870302e-08
the O 0 1.241276770258537e-08
p16 O 0 7.706912015237322e-07
and O 0 3.0008280305082735e-07
CDK4 O 0 3.410534918657504e-05
genes O 0 1.4758220423516377e-08
have O 0 1.5668240038735348e-08
been O 0 2.1553432816290297e-07
reported O 0 2.93821517516335e-06
in O 0 3.673532589232309e-10
a O 0 1.185274545179027e-09
subset O 0 3.6802603187169325e-09
of O 0 2.1776905612114206e-07
melanoma B-Disease 1 0.9062325954437256
pedigrees O 0 1.785007589205634e-05
, O 0 5.6384983793122956e-08
but O 0 6.1910694348910056e-09
their O 0 8.540018470171162e-09
prevalence O 0 2.807432338158833e-06
is O 0 3.8067069496605654e-09
not O 0 7.606533736215226e-10
well O 0 1.8818131497511104e-09
known O 0 8.591519673473158e-08
. O 0 2.739967328579951e-07

We O 0 5.1497405451073064e-08
searched O 0 2.641295679950417e-07
for O 0 2.568474877229221e-10
such O 0 1.2328120468918513e-10
germline O 0 6.41827639924486e-08
mutations O 0 6.83143452917534e-09
in O 0 6.346330128081945e-09
48 O 0 8.964265134636662e-07
French O 0 0.03529009968042374
melanoma B-Disease 1 0.9998842477798462
- O 1 0.7673346400260925
prone O 0 0.018807029351592064
families O 0 9.877387796564108e-09
selected O 0 8.919621985459258e-11
according O 0 4.2777736908305997e-10
to O 0 2.1983204145925583e-10
two O 0 5.9362723625611125e-09
major O 0 4.933089936542956e-09
criteria O 0 5.041086215129553e-09
families O 0 8.359805292457168e-09
with O 0 1.695204154827934e-08
at O 0 9.882381846182398e-07
least O 0 8.98224342127385e-11
three O 0 3.1215559026520623e-09
affected O 0 1.2606309329754595e-09
members O 0 6.902824145615938e-11
( O 0 1.2372666780002817e-10
n O 0 6.645636858593207e-07
= O 0 6.386532049873495e-07
20 O 0 1.2514346003911214e-08
) O 0 7.21681991944223e-10
or O 0 2.9624958042262506e-09
families O 0 8.662000006154358e-10
with O 0 7.629767373451557e-10
two O 0 1.198670673829838e-08
affected O 0 8.387096017692386e-10
members O 0 8.345777541274302e-11
, O 0 6.195862711777522e-10
one O 0 1.576354602406127e-10
of O 0 5.947066450406879e-11
them O 0 3.658757463664841e-10
affected O 0 5.965584276568237e-11
before O 0 9.194466299433657e-10
the O 0 9.633898123695417e-10
age O 0 2.2853479109130603e-09
of O 0 1.7370983818043584e-10
50 O 0 3.6387091117973114e-09
( O 0 3.063327369545732e-10
n O 0 5.022930054110475e-07
= O 0 6.969710284465691e-07
28 O 0 9.433345837805973e-08
) O 0 2.4819000188358586e-09
, O 0 9.66666191537513e-10
and O 0 1.7945087638082668e-09
one O 0 3.685168281641893e-10
additional O 0 2.4332724724018817e-10
minor O 0 3.7751977544076e-08
criterion O 0 1.3708631740882993e-06
. O 0 4.1058999045162636e-07

Sixteen O 0 1.4393218350505776e-07
different O 0 4.429827171748002e-09
p16 O 0 1.025774054141948e-06
germline O 0 3.1106033020478208e-06
mutations O 0 7.586920673929853e-07
were O 0 3.8201363850021153e-07
found O 0 6.297137247202045e-07
in O 0 1.1635099106399593e-08
21 O 0 3.7658853102584544e-07
families O 0 2.8132584262152704e-08
, O 0 3.9395717799095564e-09
while O 0 2.134192378377975e-09
one O 0 2.3394095549633676e-09
germline O 0 1.5440727452187275e-07
mutation O 0 3.157365568995374e-08
, O 0 7.35583967070852e-08
Arg24His O 0 1.1198599167983048e-05
, O 0 3.283948757371036e-08
was O 0 4.803186584467767e-06
detected O 0 1.6142317349476798e-07
in O 0 1.7204937474701865e-09
the O 0 3.7763069116181214e-08
CDK4 O 0 0.00038746686186641455
gene O 0 3.1577997106069233e-07
. O 0 5.855577569491288e-07

The O 0 9.106663867441966e-09
frequency O 0 6.151733344950117e-08
of O 0 2.3983290908802246e-09
p16 O 0 1.2503971902333433e-07
gene O 0 2.1111768333526015e-08
mutation O 0 5.810294911867686e-09
in O 0 9.161189029605055e-10
our O 0 1.0471630229602624e-09
sample O 0 2.406131960341895e-09
( O 0 1.8328574213910542e-09
44 O 0 5.037388106643448e-08
% O 0 2.5967754613276384e-09
) O 0 1.7494985460331236e-09
is O 0 2.659364117807428e-10
among O 0 1.7591268719474584e-11
the O 0 3.2854130527226744e-09
highest O 0 4.606882555435732e-07
rates O 0 6.269752361731662e-07
yet O 0 2.4896626982240377e-08
reported O 0 1.6279738019875367e-06
and O 0 8.364112069614293e-09
the O 0 1.0812368778090331e-08
CDK4 O 0 0.0003326638543512672
mutation O 0 8.150045971433428e-09
is O 0 5.005690861814571e-10
the O 0 1.4371041023863995e-09
second O 0 6.34641779129197e-08
mutation O 0 8.827222508500654e-09
detected O 0 6.603826108175781e-08
in O 0 8.321255906551528e-10
this O 0 5.436196492958345e-10
gene O 0 4.759443683610698e-08
worldwide O 0 1.1891206241898544e-07
. O 0 1.64177393457976e-07

In O 0 6.505300689241267e-07
summary O 0 8.137984877976123e-06
, O 0 3.16016155466059e-08
our O 0 2.9730811146322367e-09
results O 0 4.998940283940101e-08
show O 0 3.810529847214639e-08
frequent O 0 9.52120715602689e-10
involvement O 0 6.9265575497468035e-09
of O 0 1.2498375945302342e-10
the O 0 3.3437452806595047e-09
p16 O 0 1.060607459635321e-07
gene O 0 3.47689343982438e-08
in O 0 1.1905662944400319e-07
familial B-Disease 0 0.018166067078709602
melanoma I-Disease 1 0.9941800832748413
and O 0 4.713820374036004e-07
confirm O 0 4.249567453484815e-08
the O 0 1.7329527812748324e-09
role O 0 1.3472588600293989e-09
of O 0 4.459904667797332e-10
the O 0 2.4868294090651943e-08
CDK4 O 0 0.00016843788034748286
gene O 0 1.0179739717841585e-08
as O 0 4.9251740463773785e-09
a O 0 2.201754796260502e-06
melanoma B-Disease 1 0.9735991358757019
- O 0 0.0023806069511920214
predisposing O 0 2.8715537609969033e-06
gene O 0 1.0385551263425441e-07
. O 0 2.4430361733607242e-08
. O 0 1.7246121331027098e-07

Progression O 0 1.7008163922582753e-05
of O 0 1.5356809157651696e-08
somatic O 0 1.0801392136272625e-06
CTG O 0 0.0005912767956033349
repeat O 0 1.8024453311227262e-05
length O 0 1.9530168628989486e-06
heterogeneity O 0 1.9380472622287925e-06
in O 0 3.895154065958195e-08
the O 0 1.5245099405092333e-07
blood O 0 7.976302003953606e-05
cells O 0 1.0704397936933674e-05
of O 0 5.980385685688816e-05
myotonic B-Disease 1 0.9999815225601196
dystrophy I-Disease 1 0.9999842643737793
patients O 0 0.00013910900452174246
. O 0 1.1316683412587736e-05

The O 0 4.3541778182998314e-08
genetic O 0 1.6375907989640837e-06
basis O 0 3.2492394552718906e-07
of O 0 0.00059263821458444
myotonic B-Disease 1 0.9999881982803345
dystrophy I-Disease 1 0.9999924898147583
( O 0 0.0005018552765250206
DM B-Disease 1 0.9999866485595703
) O 0 4.910637017019326e-07
is O 0 1.6489023479948628e-09
the O 0 7.400597912265994e-10
expansion O 0 4.111935680839451e-09
of O 0 1.1650860276546382e-09
an O 0 5.4102180513382336e-08
unstable O 0 0.0013571984600275755
CTG O 0 2.614784170873463e-05
repeat O 0 2.266678365003827e-07
in O 0 2.2099193308644516e-10
the O 0 9.522986843535364e-10
34 O 0 9.065884931658275e-09
UTR O 0 6.067644164886588e-08
of O 0 2.2402979471536355e-10
the O 0 1.1427114543494099e-07
DM B-Disease 1 0.9998000264167786
protein O 0 5.2160289421010475e-09
kinase O 0 1.733284271665525e-08
gene O 0 2.4315616187209343e-09
on O 0 3.3714195524225943e-07
chromosome O 0 0.0001681469293544069
19 O 0 2.7142561975779245e-06
. O 0 7.792672818141e-07

One O 0 8.645238835924829e-08
of O 0 1.3718672864371229e-09
the O 0 3.1273721390334686e-09
principal O 0 3.450841390417736e-09
features O 0 3.6909522105332826e-09
of O 0 1.3579679603026307e-09
the O 0 8.525348107468744e-07
DM B-Disease 1 0.9999819993972778
mutation O 0 2.3006722926766088e-07
is O 0 2.6199842295682174e-09
an O 0 3.485962407623333e-09
extraordinarily O 0 3.4343077004450606e-06
high O 0 4.954322889716423e-07
level O 0 1.9910397774935973e-09
of O 0 1.8708358473507047e-10
somatic O 0 7.996241180308061e-08
mosaicism O 0 7.830396498320624e-05
, O 0 1.0140733053276563e-07
due O 0 1.481502209799146e-08
to O 0 1.6998236151977153e-09
an O 0 4.8001198571512305e-09
extremely O 0 1.719771915986712e-07
high O 0 1.547563783788064e-06
degree O 0 8.328388645395535e-09
of O 0 1.0238111469718092e-09
somatic O 0 3.166798876463872e-07
instability O 0 1.891701458589523e-06
both O 0 1.164732865710505e-09
within O 0 1.9604547152329843e-10
and O 0 1.3523081321409336e-08
between O 0 8.798630268813667e-09
different O 0 2.828391743037173e-09
tissues O 0 9.904168109642342e-06
. O 0 1.3974928378956974e-06

This O 0 3.584458454497508e-07
instability O 0 5.66641710975091e-06
appears O 0 3.1135306244323147e-07
to O 0 8.363182368853472e-10
be O 0 1.605049704256345e-10
biased O 0 3.6596194519233904e-08
towards O 0 1.1787141263042145e-09
further O 0 6.068122393454445e-11
expansion O 0 3.8039904559639126e-10
and O 0 5.540287117966614e-10
continuous O 0 2.599594151053708e-10
throughout O 0 9.211980483980753e-11
the O 0 1.787219483517788e-09
life O 0 6.6837571033318e-09
of O 0 2.755970729406698e-10
an O 0 4.689855170880719e-09
individual O 0 1.9734101019963646e-09
, O 0 2.000038534788473e-08
features O 0 1.3757223804589103e-08
that O 0 1.989532307788977e-07
could O 0 2.6405248831906647e-07
be O 0 1.720806430682842e-08
associated O 0 6.870295887750899e-09
with O 0 3.951559968129459e-09
the O 0 4.288103738758764e-08
progressive O 0 1.1869265108543914e-06
nature O 0 6.196813728820416e-08
of O 0 7.814625391233676e-09
the O 0 9.090438652492594e-06
disease O 0 0.0002668760425876826
. O 0 9.301753038926108e-07

Although O 0 4.909045259182676e-08
increasing O 0 4.671482312090802e-09
measured O 0 9.064591921514875e-08
allele O 0 1.4296935546553868e-07
size O 0 3.2192297112487722e-06
between O 0 9.246369359061646e-07
patients O 0 2.2662842269483008e-08
clearly O 0 7.748329977630419e-08
correlates O 0 5.62412729721018e-08
with O 0 6.783135386712047e-09
an O 0 3.732596454142367e-08
increased O 0 1.1096408769617483e-07
severity O 0 3.523866325849667e-06
of O 0 4.125182329062227e-08
symptoms O 0 1.9130828832203406e-07
and O 0 2.4158639533311543e-08
an O 0 1.4295512329454141e-08
earlier O 0 2.2754878955311142e-05
age O 0 2.6426100419030263e-08
of O 0 2.5540745074437154e-09
onset O 0 4.96761288104608e-07
, O 0 2.7574129646268375e-09
this O 0 7.207942576137327e-11
correlation O 0 6.064772684055697e-09
is O 0 8.727540357078567e-10
not O 0 7.012451036514378e-11
precise O 0 2.5207005371896685e-09
and O 0 3.9316990552151765e-08
measured O 0 7.737873630730974e-08
allele O 0 3.788947111615926e-08
length O 0 2.650799331149756e-07
cannot O 0 1.964105855734033e-08
be O 0 5.026988825207468e-10
used O 0 1.834305263237468e-09
as O 0 4.2811690303956595e-10
an O 0 1.013695349882937e-09
accurate O 0 7.703062721020615e-08
predictor O 0 9.90772946352081e-07
of O 0 4.269673059553725e-09
age O 0 1.8529649992160557e-07
of O 0 1.4257390823502192e-08
onset O 0 1.3802181456412654e-05
. O 0 1.2777775282302173e-06

In O 0 4.7074678377612145e-08
order O 0 3.5289178246245e-09
to O 0 1.6762902177447359e-10
further O 0 5.6486725019677664e-11
characterize O 0 8.468179046872137e-09
the O 0 9.302196346538949e-09
dynamics O 0 8.337312465300784e-06
of O 0 2.905436531364103e-07
DM B-Disease 1 0.9999194145202637
CTG O 0 0.00018071680096909404
repeat O 0 4.424906876465684e-07
somatic O 0 1.1908524299997225e-07
instability O 0 2.5809101771301357e-06
, O 0 1.4457513408672185e-08
we O 0 1.2734927556934394e-09
have O 0 7.623047193483501e-10
studied O 0 1.4791720071016812e-09
repeat O 0 3.732069231432433e-08
length O 0 1.142615069227304e-08
changes O 0 4.3992916948232264e-11
over O 0 2.2178887615353915e-09
time O 0 8.23001045091587e-09
in O 0 2.4940598564171523e-07
111 O 1 0.7062415480613708
myotonic B-Disease 1 0.9999970197677612
dystrophy I-Disease 1 0.9999973773956299
patients O 0 5.439603114609781e-07
with O 0 1.9522175875863468e-08
varying O 0 4.256210672792804e-08
clinical O 0 8.475517461192794e-07
severity O 0 5.9381145547376946e-06
and O 0 2.338634885745705e-07
CTG O 0 3.0409057217184454e-05
repeat O 0 1.9415126928379323e-07
size O 0 3.8259472034951614e-08
over O 0 4.92937468621335e-09
time O 0 7.558301762244923e-10
intervals O 0 3.0316158472487587e-09
of O 0 4.166876010902598e-10
1 O 0 1.7890004144760496e-08
- O 0 3.1830106308916584e-05
7 O 0 1.6150984265550505e-06
years O 0 3.0671370154777833e-07
. O 0 4.277566034716074e-08

We O 0 5.52757285277039e-07
have O 0 3.568672113374305e-08
found O 0 2.7974470739877688e-08
a O 0 4.3021408657750726e-10
direct O 0 7.069931445835564e-11
progression O 0 4.5147711347226505e-08
of O 0 1.853506792492965e-10
the O 0 7.300388737974117e-09
size O 0 4.1888259261213534e-07
heterogeneity O 0 7.894644227235403e-08
over O 0 2.8736796053863145e-08
time O 0 5.227801747054173e-09
related O 0 4.700799305368264e-09
to O 0 4.349633153655219e-10
initial O 0 5.482515774701824e-09
CTG O 0 3.2563850709266262e-06
repeat O 0 1.7242503247416607e-07
size O 0 1.077578772878951e-07
and O 0 3.4048401875708123e-09
the O 0 4.112380436183116e-10
time O 0 2.6728974589218524e-09
interval O 0 2.9185267536036008e-08
and O 0 4.343160497910503e-09
always O 0 4.5155415517861286e-10
biased O 0 7.174482785643477e-09
towards O 0 2.813835275894405e-10
further O 0 4.1496256431017287e-10
expansion O 0 4.330804515007003e-08
. O 0 7.310745075983505e-08

Attempts O 0 6.010077413520776e-07
to O 0 5.778090894636989e-09
mathematically O 0 4.640615358653122e-08
model O 0 6.057930335146011e-08
the O 0 2.1967091257124594e-08
dynamics O 0 4.3001986341550946e-05
have O 0 1.610541318086689e-07
proved O 0 1.0267311836287263e-06
only O 0 5.761063293086011e-10
partially O 0 1.7544084585097153e-06
successful O 0 8.757263003644766e-08
suggesting O 0 4.2619706164259696e-07
that O 0 3.276564131127202e-09
individual O 0 5.6083079152946524e-11
specific O 0 1.3888082350810294e-10
genetic O 0 1.018203874991741e-06
and O 0 2.635481223478564e-06
/ O 0 9.77341096586315e-06
or O 0 7.663742280783481e-07
environmental O 0 1.8273262014645297e-07
factors O 0 4.023223088012173e-09
also O 0 1.8133775592232837e-09
play O 0 2.4883878291248607e-10
a O 0 2.0044943482844246e-09
role O 0 2.472370308481686e-09
in O 0 2.437142709865725e-09
somatic O 0 1.6341259367891325e-07
mosaicism O 0 2.4016042516450398e-05
. O 0 2.6377406925348623e-08
. O 0 1.8071639829031483e-07

Aspartylglucosaminuria B-Disease 1 0.9872596263885498
among O 0 4.177376808911504e-07
Palestinian O 0 1.6053463696152903e-05
Arabs O 0 1.7354781448375434e-05
. O 0 1.5620370277247275e-06

Aspartylglucosaminuria B-Disease 1 0.998954176902771
( O 0 0.000765112170483917
AGU B-Disease 1 0.999671220779419
) O 0 6.1429668676282745e-06
is O 0 1.2035646079766593e-07
a O 0 9.879630624709534e-07
rare O 0 5.6431272241752595e-05
disorder B-Disease 0 0.0015893165254965425
of I-Disease 0 6.74538682687853e-08
glycoprotein I-Disease 0 0.0026983721181750298
metabolism I-Disease 0 0.00018044750322587788
caused O 0 1.063905415321642e-06
by O 0 2.1778769010438737e-08
the O 0 3.1402210879605263e-05
deficiency B-Disease 0 0.0010153992334380746
of I-Disease 0 3.803439230232186e-10
the I-Disease 0 1.0630215996343395e-07
lysosomal I-Disease 0 0.0005620709271170199
enzyme I-Disease 0 2.010382104344899e-06
aspartylglucosaminidase I-Disease 0 0.00013596579083241522
( O 0 5.524787738409032e-09
AGA O 0 2.304990448465105e-05
) O 0 3.224420552783158e-08
. O 0 7.808549895571559e-08

AGU B-Disease 1 0.9989346861839294
is O 0 0.000343998777680099
inherited O 0 0.02846294641494751
as O 0 1.4869284541418892e-06
an O 0 9.062358913070057e-06
autosomal O 1 0.7551899552345276
recessive O 1 0.6716195344924927
trait O 0 0.024852951988577843
and O 0 3.5792043490801007e-05
occurs O 0 1.327000234141451e-07
with O 0 5.6078852672669655e-09
a O 0 2.0801870448394766e-08
high O 0 3.460783659647859e-07
frequency O 0 2.2854237613501027e-07
in O 0 3.5913490847860885e-08
Finland O 0 1.8060662796415272e-06
because O 0 5.076700837491899e-09
of O 0 1.943659261316455e-10
a O 0 1.0581100440276714e-07
founder O 0 1.97392455447698e-05
effect O 0 5.3657199572398895e-08
. O 0 1.741154562751035e-07

While O 0 1.3986448266223306e-06
very O 0 3.039166784901681e-08
few O 0 4.5567812634317306e-08
patients O 0 6.52815828061648e-08
with O 0 3.39401208293566e-06
AGU B-Disease 1 0.9999573230743408
have O 0 1.4413592452910962e-06
been O 0 1.0253886557620717e-06
reported O 0 6.869865956105059e-06
from O 0 1.4620730182102193e-09
non O 0 2.7123394641392906e-09
- O 0 6.4580653997836635e-06
Finnish O 0 2.6264558528055204e-06
origin O 0 2.995595238530768e-08
, O 0 1.12367011695369e-07
we O 0 3.44921176065327e-07
diagnosed O 0 0.00018286755948793143
the O 0 7.990993253770284e-07
disorder O 0 0.0015258502680808306
in O 0 4.823764854222645e-08
8 O 0 3.031345386261819e-06
patients O 0 3.6878278208973825e-09
originating O 0 6.32792984678332e-10
from O 0 1.3789319686097201e-09
3 O 0 2.2689617296123288e-08
unrelated O 0 7.391787448796094e-07
families O 0 1.7554759423887845e-08
, O 0 7.937259738355351e-10
all O 0 1.6615511050366294e-11
Palestinian O 0 1.2331524601449928e-07
Arabs O 0 1.215920519825886e-07
from O 0 1.3278903532309982e-09
the O 0 8.543000085126096e-09
region O 0 1.5158686750282868e-08
of O 0 4.685456467257154e-09
Jerusalem O 0 3.0730901926290244e-05
. O 0 6.570041932718595e-07

The O 0 1.0257035683025606e-06
clinical O 0 1.6113219317048788e-05
diagnosis O 0 0.0006325216963887215
of O 0 1.319959028478479e-05
AGU B-Disease 1 0.9999595880508423
is O 0 3.886860213242471e-06
often O 0 1.5049894841467903e-07
difficult O 0 2.2299562374428206e-07
, O 0 5.411525894061242e-09
in O 0 3.162527739686283e-10
particular O 0 8.475070645275196e-11
early O 0 7.057596285164891e-09
in O 0 2.7048017159359006e-09
the O 0 1.1040102165793542e-08
course O 0 1.809728360058216e-06
of O 0 9.417252755383743e-09
the O 0 1.2738166333292611e-05
disease O 0 0.0004901487845927477
, O 0 2.2599907723019896e-08
and O 0 1.0102138681133965e-08
most O 0 2.0536729261610986e-10
of O 0 2.464954240721795e-09
the O 0 2.387764368450007e-07
patients O 0 4.2194248095484e-08
are O 0 1.4894894206918252e-08
diagnosed O 0 2.94177280011354e-05
after O 0 1.1442440381870256e-06
the O 0 4.359512928431286e-08
age O 0 6.834826393742333e-08
of O 0 1.3979779556194671e-09
5 O 0 1.0752074786068988e-07
years O 0 4.334420111717918e-07
. O 0 1.8573136628674547e-07

However O 0 1.8880715515479096e-06
, O 0 4.9170854055091695e-08
since O 0 9.095034059214413e-09
these O 0 1.6161887106402872e-10
patients O 0 2.619303385298366e-10
excrete O 0 8.088731351385547e-10
early O 0 6.155460585688388e-10
large O 0 2.7095148347200393e-10
amounts O 0 1.1550996964482252e-10
of O 0 6.583119604997023e-10
aspartylglucosamine O 0 2.8399070288287476e-05
in O 0 1.769386059891076e-08
urine O 0 1.600959507186417e-07
, O 0 4.344229420638612e-09
biochemical O 0 3.8775272770408264e-08
screening O 0 3.6108469547713185e-09
is O 0 1.8271957280546758e-09
easy O 0 1.626398216103553e-08
by O 0 1.5550520870988294e-08
urine O 0 1.7846350601757877e-06
chromatography O 0 0.0013312712544575334
. O 0 1.168795336070616e-07
. O 0 2.2197481541752495e-07

Detection O 0 2.9172551876399666e-06
of O 0 3.195851405735084e-08
heterozygous O 0 5.033158458900289e-07
carriers O 0 3.820868812454137e-07
of O 0 7.370431376330089e-08
the O 0 0.0003009630599990487
ataxia B-Disease 1 0.99998939037323
- I-Disease 1 0.9999822378158569
telangiectasia I-Disease 1 0.9999828338623047
( O 0 1.127355986341172e-07
ATM O 0 0.0005360318464227021
) O 0 8.644443383332145e-09
gene O 0 1.0020650975661738e-09
by O 0 5.079606513191948e-09
G2 O 0 0.0026059772353619337
phase O 0 6.9754281639689e-07
chromosomal O 0 0.0006112604751251638
radiosensitivity O 0 8.70294970809482e-05
of O 0 3.341254029010088e-08
peripheral O 0 0.0009356344235129654
blood O 0 0.0003011329681612551
lymphocytes O 0 0.00011150901264045388
. O 0 2.307130671397317e-06

In O 0 0.003202012972906232
ataxia B-Disease 1 0.9997827410697937
- I-Disease 1 0.9998652935028076
telangiectasia I-Disease 1 0.9999508857727051
( O 0 0.0005393932806327939
A B-Disease 1 0.9999105930328369
- I-Disease 1 0.9999903440475464
T I-Disease 1 0.9999966621398926
) O 0 3.5737512007472105e-06
patients O 0 1.299666330112359e-08
, O 0 7.990519357292669e-09
mutations O 0 4.363021055553418e-09
in O 0 1.3107888108265797e-09
a O 0 6.764736326658749e-09
single O 0 1.1321543702536019e-08
gene O 0 2.045239355652484e-08
, O 0 2.1793729487740165e-08
ATM O 0 0.00011063459533033893
, O 0 2.317275402674568e-07
result O 0 3.4870089393734816e-07
in O 0 3.1011368264444172e-06
an O 0 0.3922102749347687
autosomal B-Disease 1 0.9999990463256836
recessive I-Disease 1 0.9999974966049194
syndrome I-Disease 1 0.9999994039535522
that O 0 3.610708745327429e-06
embraces O 0 4.164497227066022e-07
a O 0 7.096988952071115e-08
variety O 0 6.106384731197068e-09
of O 0 8.665325346157715e-09
clinical O 0 7.507046007049212e-08
features O 0 5.725532901124097e-07
and O 0 3.5969819691672456e-06
manifests O 0 2.6280995371052995e-06
extreme O 0 3.494103566481499e-06
radiosensitivity O 0 0.0001734857214614749
and O 0 2.3727862341615946e-08
a O 0 1.0597172916959607e-08
strong O 0 4.327526070824206e-08
pre O 0 9.4013139460003e-06
- O 0 0.0003897623100783676
disposition O 0 2.707152134462376e-06
to O 0 2.5777688961170497e-07
malignancy B-Disease 0 0.0034480139147490263
. O 0 4.161650792866567e-07

Heterozygotes O 0 1.438089839211898e-05
for O 0 1.2967494633642218e-08
the O 0 1.6650719913968715e-08
ATM O 0 4.309579526307061e-05
gene O 0 1.8743565988188493e-07
have O 0 4.236141748492628e-08
no O 0 1.4261089198441823e-08
clinical O 0 1.6203356878463637e-08
expression O 0 3.988679608823986e-09
of O 0 9.685921043001144e-08
A B-Disease 1 0.9998801946640015
- I-Disease 1 0.9999805688858032
T I-Disease 1 0.9999967813491821
but O 0 5.090395643492229e-05
may O 0 3.1177430628304137e-06
be O 0 2.5754836769920075e-06
cancer B-Disease 0 0.0016270066844299436
prone O 0 0.00011462777911219746
with O 0 4.222838967393727e-08
a O 0 1.2951754513323976e-07
moderate O 0 9.565306982040056e-07
increase O 0 3.5755041150054012e-09
in O 0 6.989316680972024e-09
in O 0 6.923496442823307e-08
vitro O 0 0.00012820889241993427
radiosensitivity O 0 0.0009262285893782973
. O 0 5.817965984533657e-07

We O 0 3.570729347757151e-07
performed O 0 9.096025621602166e-08
a O 0 4.764457628425589e-08
blind O 0 4.105726020497968e-06
chromosomal O 0 4.376193373900605e-06
analysis O 0 4.0911727339221216e-09
on O 0 5.316637157193327e-07
G2 O 0 0.009286358952522278
- O 0 2.0449821022339165e-05
phase O 0 7.143012936694504e-08
lymphocytes O 0 2.998722266056575e-07
from O 0 2.1141857153850196e-09
7 O 0 1.6285517290270946e-07
unrelated O 0 9.200046042678878e-05
A B-Disease 1 0.9995087385177612
- I-Disease 1 0.9999734163284302
T I-Disease 1 0.9999938011169434
patients O 0 1.6872469643658405e-07
, O 0 6.996639712042452e-09
13 O 0 1.0782362558359182e-08
obligate O 0 3.7173708733462263e-07
A B-Disease 1 0.9985289573669434
- I-Disease 1 0.9999821186065674
T I-Disease 1 0.9999963045120239
heterozygotes O 0 2.901136213040445e-05
( O 0 1.9598798139952578e-09
parents O 0 5.654087198436741e-10
of O 0 3.476744170338719e-10
the O 0 8.450821553651622e-08
patients O 0 1.727277876284461e-08
) O 0 8.115171312716996e-10
, O 0 1.0016982798788376e-09
and O 0 2.4845192569955543e-09
14 O 0 2.8111168948186105e-09
normal O 0 3.151700567194382e-10
controls O 0 4.649224560893117e-09
following O 0 2.5660082947354113e-09
X O 0 6.671833489235723e-06
- O 0 5.74746991333086e-07
irradiation O 0 2.412896771275541e-09
with O 0 4.291275779166881e-09
1 O 0 5.226785226852826e-09
Gy O 0 1.6519251744284702e-08
in O 0 5.170489730810246e-11
order O 0 2.441080844406418e-11
to O 0 3.3085891665285416e-11
evaluate O 0 4.703108388848243e-11
this O 0 1.2616327253744952e-11
cytogenetic O 0 2.448344815775272e-08
method O 0 4.902808159457095e-10
as O 0 1.4612136500780082e-10
a O 0 2.8537467944289574e-09
tool O 0 1.266343616634913e-07
for O 0 6.604067986915041e-11
detection O 0 9.661855315812318e-09
of O 0 8.703203713267271e-10
ATM O 0 0.00010059267515316606
carriers O 0 4.921288905279653e-07
. O 0 1.7568301302617328e-07

Both O 0 1.552422509121243e-05
A B-Disease 1 0.9158160090446472
- I-Disease 1 0.999263346195221
T I-Disease 1 0.9998713731765747
homozygotes O 0 4.1394330764887854e-05
and O 0 1.4972619055697578e-07
heterozygotes O 0 2.105593495116409e-07
showed O 0 1.052929405886971e-06
significantly O 0 1.6095823340833704e-08
increased O 0 2.2603161009548955e-10
levels O 0 2.054628966963179e-10
of O 0 2.2560013857031436e-09
radiation O 0 0.00014064068091101944
- O 0 0.17123281955718994
induced O 0 0.00250956485979259
chromatid O 0 0.06903278827667236
damage O 0 0.00045143841998651624
relative O 0 7.190788409161541e-08
to O 0 1.3212407834473083e-09
that O 0 2.336778326395006e-09
of O 0 7.302208837600688e-10
normal O 0 1.6108293365846293e-08
controls O 0 1.2554794466268504e-06
. O 0 5.397868676482176e-07

These O 0 1.0924520665867021e-07
results O 0 9.719806115526808e-08
show O 0 5.105300360241927e-08
that O 0 1.6530874447084898e-09
the O 0 3.421042560347587e-09
G2 O 0 0.001187725574709475
- O 0 2.3794815206201747e-05
phase O 0 2.2896844598108146e-07
chromosomal O 0 2.7559151931200176e-05
radiosensitivity O 0 2.7333922844263725e-05
assay O 0 1.1805144595200545e-06
can O 0 7.536621882131556e-10
be O 0 7.302665416819565e-11
used O 0 1.6839972472038056e-10
for O 0 1.198373865418656e-11
the O 0 9.875423812033546e-10
detection O 0 3.306008409253991e-07
of O 0 5.924918156097192e-08
A B-Disease 1 0.9993674159049988
- I-Disease 1 0.9999256134033203
T I-Disease 1 0.9999641180038452
heterozygotes O 0 6.247550481930375e-05
. O 0 8.105045026240987e-07

In O 0 4.51940593393374e-07
combination O 0 3.386209641575988e-07
with O 0 3.810522741787281e-08
molecular O 0 2.54563406087982e-06
genetic O 0 2.6344632715336047e-06
analyses O 0 9.974348813557299e-07
, O 0 4.3609514221998325e-08
this O 0 2.0184749427443194e-09
test O 0 2.8509606408988475e-07
may O 0 3.333710552055891e-08
be O 0 3.44858280820759e-10
of O 0 2.0205540018913837e-10
value O 0 2.3851225439130985e-09
in O 0 4.694831190477089e-09
studies O 0 2.001552479313773e-09
of O 0 1.9696860809048644e-10
familial B-Disease 0 6.527482128149131e-06
and I-Disease 0 1.6144053915922996e-06
sporadic I-Disease 0 2.6780820917338133e-05
cancers I-Disease 0 0.000820056302472949
aimed O 0 1.2045995845255675e-06
at O 0 2.1503144580492517e-06
determination O 0 1.9851100319101533e-08
of O 0 1.4410862780867006e-10
the O 0 2.2550810108157293e-09
potential O 0 1.656774273328665e-09
involvement O 0 3.120496527841965e-09
of O 0 7.099758558837266e-10
ATM O 0 0.00037071932456456125
mutations O 0 7.343075481003325e-07
in O 0 8.226857630688755e-07
tumor B-Disease 0 0.057120274752378464
risk O 0 6.929050755388744e-07
or O 0 1.8065499318709044e-08
development O 0 4.654983065677243e-09
. O 0 1.2342815658428208e-08
. O 0 1.7855411726941384e-07

Ataxia B-Disease 1 0.9996728897094727
- I-Disease 1 0.9997269511222839
telangiectasia I-Disease 1 0.9998438358306885
: O 0 2.600197603896959e-07
identification O 0 3.767961231915251e-08
and O 0 3.208163690260335e-08
detection O 0 8.536179052498483e-08
of O 0 3.263715520063215e-09
founder O 0 2.2230107788345776e-05
- O 0 7.776090933475643e-05
effect O 0 2.176656010988154e-08
mutations O 0 2.9679931845549845e-09
in O 0 3.227419720364111e-10
the O 0 2.684428901389424e-09
ATM O 0 4.2541854782029986e-05
gene O 0 3.2302807539963396e-08
in O 0 4.874911141428129e-09
ethnic O 0 2.2229974305787437e-08
populations O 0 6.809516861494558e-08
. O 0 3.9886896274765604e-07

To O 0 3.114235314072289e-09
facilitate O 0 1.5910296413679248e-09
the O 0 4.785235541149291e-10
evaluation O 0 2.160666784378762e-10
of O 0 1.3409975907485716e-10
ATM O 0 1.450111267331522e-05
heterozygotes O 0 2.2691915546602104e-07
for O 0 2.044282743085546e-09
susceptibility O 0 1.780399401241084e-07
to O 0 1.1178379999421395e-08
other O 0 2.956768412332167e-07
diseases O 0 7.11443935870193e-05
, O 0 1.030346830077633e-08
such O 0 1.066100874247411e-09
as O 0 9.705736374598928e-06
breast B-Disease 1 0.7046672105789185
cancer I-Disease 0 0.0013975858455523849
, O 0 2.8523659878487706e-08
we O 0 2.249993968916897e-09
have O 0 7.007213143062074e-10
attempted O 0 4.006975018455705e-07
to O 0 1.2890646328145294e-09
define O 0 1.3292587031088487e-09
the O 0 9.480415341656112e-10
most O 0 3.2087968393490485e-10
common O 0 2.740117022170807e-09
mutations O 0 2.7728448426245222e-09
and O 0 8.367858073121681e-10
their O 0 4.297663058761003e-10
frequencies O 0 4.1168433995153464e-07
in O 0 6.548030796693638e-05
ataxia B-Disease 1 0.9999943971633911
- I-Disease 1 0.9999854564666748
telangiectasia I-Disease 1 0.9999932050704956
( O 0 1.5300158338504843e-05
A B-Disease 1 0.9997933506965637
- I-Disease 1 0.9999783039093018
T I-Disease 1 0.999991774559021
) O 0 1.9146561669458606e-07
homozygotes O 0 9.572035253313516e-08
from O 0 2.809448507168355e-10
10 O 0 1.4820836780060631e-09
ethnic O 0 3.1298068581264715e-09
populations O 0 1.634829693841766e-08
. O 0 1.839462129282765e-07

Both O 0 1.7317501033176086e-07
genomic O 0 4.494743734539952e-06
mutations O 0 1.672838038757618e-06
and O 0 1.850252573376565e-07
their O 0 1.4147732763092336e-08
effects O 0 2.0041094117573266e-08
on O 0 5.909388534064419e-08
cDNA O 0 9.500151350039232e-07
were O 0 3.1191328275781416e-07
characterized O 0 8.220660674851388e-06
. O 0 4.5433296236296883e-07

Protein O 0 2.046201188932173e-06
- O 0 2.3418393539031968e-05
truncation O 0 3.686012632897473e-06
testing O 0 7.30305202978343e-08
of O 0 1.6378055855970075e-10
the O 0 5.084324627979697e-10
entire O 0 1.9481660729070427e-09
ATM O 0 1.4115894373389892e-06
cDNA O 0 1.3896237760491204e-07
detected O 0 8.897016527953383e-07
92 O 0 2.251657207352764e-07
( O 0 1.1872430816239898e-09
66 O 0 6.250945148167375e-07
% O 0 1.5214728366075292e-09
) O 0 9.314334858956386e-10
truncating O 0 5.8008634340467324e-08
mutations O 0 8.975761467411303e-09
in O 0 1.276530103844209e-09
140 O 0 1.067236610197142e-08
mutant O 0 6.419353439923725e-07
alleles O 0 6.354993331569858e-08
screened O 0 1.3629270370074664e-06
. O 0 5.949826231699262e-07

The O 0 9.344359455099038e-07
haplotyping O 0 0.0005129475612193346
of O 0 1.8126475254121033e-07
patients O 0 1.7279079145282594e-07
with O 0 9.273607304294273e-08
identical O 0 0.00012948740913998336
mutations O 0 2.1838059183210135e-06
indicates O 0 1.7675181140930363e-07
that O 0 1.6514148271085105e-08
almost O 0 3.3784447461826517e-10
all O 0 5.792937657345121e-11
of O 0 2.0599380534669365e-10
these O 0 3.9717024113983257e-10
represent O 0 1.5386258933602903e-10
common O 0 7.312083738497677e-08
ancestry O 0 2.923393367382232e-06
and O 0 3.243715980261186e-07
that O 0 5.28077954697892e-08
very O 0 5.835261163156247e-09
few O 0 9.264392808461253e-09
spontaneously O 0 1.0610425249524269e-07
recurring O 0 3.2704321029086714e-07
ATM O 0 0.00029497119248844683
mutations O 0 6.656368896074127e-07
exist O 0 4.532700259574085e-08
. O 0 5.23210928804474e-07

Assays O 0 2.864343969122274e-06
requiring O 0 7.625876463634995e-08
minimal O 0 2.4394228859137e-08
amounts O 0 7.987057126790376e-10
of O 0 3.637236345443995e-10
genomic O 0 7.472161200894334e-08
DNA O 0 5.485757810674841e-06
were O 0 1.6370209721117135e-07
designed O 0 2.856572791642975e-07
to O 0 1.2342685207222814e-10
allow O 0 2.8249652617162724e-11
rapid O 0 1.9649430693657877e-10
screening O 0 4.6205880788185993e-10
for O 0 1.9744406110078216e-10
common O 0 3.269210457901295e-09
ethnic O 0 8.19014189801237e-09
mutations O 0 3.730240791810502e-07
. O 0 3.529738137331151e-07

These O 0 3.2139191308289128e-09
rapid O 0 1.1212482498024201e-08
assays O 0 1.9036916398817993e-07
detected O 0 5.1767244713119e-07
mutations O 0 3.732396791633619e-08
in O 0 5.838935113189336e-09
76 O 0 5.226398798185983e-07
% O 0 1.1044203329646507e-09
of O 0 1.7959880249662774e-09
Costa O 0 2.4768044113443466e-06
Rican O 0 1.3522045492209145e-06
patients O 0 3.431539852272181e-08
( O 0 1.9897290759463004e-10
3 O 0 9.51055678655166e-09
) O 0 9.687519675338763e-10
, O 0 9.167114289887479e-10
50 O 0 4.134362574514938e-10
% O 0 6.178464684314378e-11
of O 0 6.392503748564593e-10
Norwegian O 0 0.002405177801847458
patients O 0 2.018102485124018e-08
( O 0 6.934362806187977e-11
1 O 0 8.698788911409849e-10
) O 0 1.4567146378041684e-09
, O 0 4.494303151858503e-09
25 O 0 5.833146854428151e-09
% O 0 2.4921401053923375e-10
of O 0 1.2283742911733952e-09
Polish O 0 4.729671127279289e-05
patients O 0 2.9447909000168693e-08
( O 0 1.8750549724000365e-10
4 O 0 4.9375639576965114e-08
) O 0 2.3627546585913706e-09
, O 0 1.7572640009788643e-09
and O 0 7.618328190517332e-09
14 O 0 2.5379533141745014e-08
% O 0 3.642560975070097e-10
of O 0 9.614276041958192e-10
Italian O 0 3.0019098630873486e-05
patients O 0 1.1128940435867207e-08
( O 0 7.026830506351445e-11
1 O 0 2.105465357615799e-09
) O 0 2.3408199822938514e-09
, O 0 1.3320707870079218e-09
as O 0 2.997952719407948e-10
well O 0 6.026785737134333e-10
as O 0 2.057539916222595e-09
in O 0 1.1490535634095522e-08
patients O 0 1.558742357410381e-09
of O 0 9.476799345264908e-10
Amish O 0 0.00012649811105802655
/ O 0 6.8040644691791385e-06
Mennonite O 0 2.6190864446107298e-05
and O 0 7.873709364503156e-07
Irish O 0 5.915500764785975e-07
English O 0 4.583122503731829e-08
backgrounds O 0 2.4055924541244167e-07
. O 0 4.367819599337963e-07

Additional O 0 2.089400474858394e-08
mutations O 0 1.5985565937626234e-07
were O 0 4.3651127157318115e-08
observed O 0 1.6911059219637536e-08
in O 0 1.9300763209884053e-09
Japanese O 0 2.532634937324474e-07
, O 0 1.4099566847391998e-08
Utah O 0 1.5046035173327255e-07
Mormon O 0 1.0952289386523262e-07
, O 0 9.639951059625673e-09
and O 0 1.0542658301915253e-08
African O 0 2.7421467763133478e-08
American O 0 2.492773489848332e-07
patients O 0 5.0764999315333625e-08
. O 0 8.989076860643763e-08

These O 0 3.819172089691847e-09
assays O 0 2.3754399336439747e-08
should O 0 5.6979296281234326e-11
facilitate O 0 1.1918089778961694e-11
screening O 0 1.4339580634015192e-09
for O 0 1.205675648208171e-08
A B-Disease 1 0.9591692090034485
- I-Disease 1 0.9999428987503052
T I-Disease 1 0.9999876022338867
heterozygotes O 0 1.1611874697337043e-06
in O 0 1.6306155314893545e-09
the O 0 5.305632821972495e-09
populations O 0 1.7400605401007851e-09
studied O 0 6.030709709392568e-09
. O 0 1.1823376944164465e-08
. O 0 2.101262595033404e-07

The O 0 1.2710257578874007e-05
von B-Disease 1 0.970603883266449
Hippel I-Disease 1 0.9929699301719666
- I-Disease 1 0.9989861845970154
Lindau I-Disease 1 0.9976586103439331
tumor I-Disease 0 0.10803012549877167
suppressor O 0 6.885512266308069e-05
gene O 0 4.0614909835312574e-07
is O 0 8.61670645946333e-09
required O 0 1.307442210052301e-10
for O 0 4.671711351100782e-10
cell O 0 1.2706645065918565e-05
cycle O 0 1.7338813904643757e-06
exit O 0 3.553394094524265e-07
upon O 0 4.8810075981009504e-08
serum O 0 4.815675765712513e-06
withdrawal O 0 1.138132006417436e-06
. O 0 8.18344460640219e-07

The O 0 1.4671950054889749e-07
inactivation O 0 3.30107104673516e-05
of O 0 1.8069323814984273e-08
the O 0 1.5591674582537962e-06
von B-Disease 1 0.9830470681190491
Hippel I-Disease 1 0.9924446940422058
- I-Disease 1 0.9992751479148865
Lindau I-Disease 1 0.998009979724884
( I-Disease 0 1.4894120567987557e-06
VHL I-Disease 0 0.0010437036398798227
) I-Disease 0 3.984112311172794e-07
tumor I-Disease 0 0.00011344793165335432
suppressor O 0 5.667558070854284e-05
gene O 0 1.6387077721446985e-06
predisposes O 0 2.1051764633739367e-05
affected O 0 1.5954976007037658e-08
individuals O 0 1.4454329400059862e-10
to O 0 1.9544035279039917e-09
the O 0 5.325984488990798e-07
human O 0 0.0015093251131474972
VHL B-Disease 1 0.9999126195907593
cancer I-Disease 1 0.9999815225601196
syndrome I-Disease 1 0.9998809099197388
and O 0 3.3436213016102556e-06
is O 0 9.804638523291942e-08
associated O 0 4.82245852140295e-08
with O 0 4.417443619786354e-07
sporadic B-Disease 0 0.0432952418923378
renal I-Disease 1 0.9998947381973267
cell I-Disease 1 0.9993019104003906
carcinomas I-Disease 1 0.9999891519546509
( O 0 2.9606726457132027e-06
RCC B-Disease 0 0.23711302876472473
) O 0 4.867016514253919e-07
and O 0 3.818005552602699e-06
brain B-Disease 0 0.001464451546780765
hemangioblastomas I-Disease 0 0.003797798650339246
. O 0 2.0639006379497005e-06

VHL O 0 0.008442896418273449
- O 0 0.00034312004572711885
negative O 0 3.9675995822108234e-07
786 O 0 3.6271379940444604e-05
- O 0 0.0013173228362575173
0 O 0 2.5665929115348263e-07
RCC B-Disease 0 8.029231685213745e-05
cells O 0 1.1386777032384998e-07
are O 0 3.894602862430929e-09
tumorigenic O 0 4.948943023919128e-05
in O 0 2.787982396057487e-07
nude O 0 0.018270185217261314
mice O 0 0.0012575369328260422
which O 0 1.7860197942809464e-07
is O 0 4.0850598459485354e-09
suppressed O 0 6.623754433832119e-09
by O 0 3.0490923674797443e-10
the O 0 1.343194555580851e-09
reintroduction O 0 5.933399620516866e-07
of O 0 7.780689514902406e-08
VHL B-Disease 0 0.00045503408182412386
. O 0 1.325451307820913e-06

Remarkably O 0 7.320966687984765e-05
, O 0 1.659236090745253e-07
this O 0 1.087544609923441e-09
occurs O 0 2.292358969313568e-09
without O 0 1.5362711103250604e-10
affecting O 0 1.3333870119147662e-10
the O 0 7.322827677569421e-09
growth O 0 4.3525423620849324e-07
rate O 0 1.0496975022533661e-07
and O 0 3.176253571268717e-08
cell O 0 2.8301012207521126e-05
cycle O 0 1.6625527905489434e-06
profile O 0 3.471453169368033e-08
of O 0 2.021802864016209e-10
these O 0 4.30921187621891e-10
cells O 0 3.380065649594144e-08
in O 0 2.7746858144439557e-09
culture O 0 1.2316856157212897e-07
. O 0 2.1330443189526704e-07

The O 0 7.564077719734996e-08
786 O 0 1.685904680925887e-05
- O 0 0.0008480132091790438
0 O 0 9.399150258104783e-08
cell O 0 7.4715226219268516e-06
line O 0 1.641006747377105e-05
, O 0 2.88878645449131e-08
like O 0 9.26928933608906e-09
many O 0 5.199222830043482e-09
cancer B-Disease 0 2.7546511773834936e-05
cells O 0 1.851279876063927e-07
, O 0 7.829384429669517e-08
fails O 0 1.7978298672005621e-07
to O 0 4.68709016043789e-10
exit O 0 4.82247699551408e-08
the O 0 8.093581804757832e-09
cell O 0 1.4040096175449435e-05
cycle O 0 1.038289269672532e-06
upon O 0 4.657602747926148e-09
serum O 0 1.5587540929118404e-06
withdrawal O 0 9.404400884704955e-07
. O 0 7.113549145287834e-07

Here O 0 2.1015280253777746e-06
, O 0 5.608957920344437e-08
it O 0 6.13107964397841e-09
is O 0 8.972608211976763e-10
shown O 0 1.8687933422967262e-09
that O 0 2.7695820636886026e-10
reintroduction O 0 7.006735636139183e-09
of O 0 1.5574547207464207e-10
the O 0 4.499002947966346e-09
wild O 0 5.65667050977936e-07
- O 0 0.0005397085333243012
type O 0 3.4715864671852614e-07
VHL B-Disease 0 1.1195961633347906e-06
gene O 0 1.0749625634076665e-09
restores O 0 2.727603565233494e-08
the O 0 1.031099206016961e-09
ability O 0 3.1027982405618104e-09
of O 0 9.504862674702963e-09
VHL O 0 0.0036709653213620186
- O 0 0.024594618007540703
negative O 0 2.6118509595107753e-06
RCC B-Disease 0 0.12059295922517776
cancer I-Disease 0 3.0206938390620053e-05
cells O 0 9.301734493760705e-09
to O 0 6.358613080514885e-10
exit O 0 4.672268616445763e-08
the O 0 5.107712919283358e-09
cell O 0 3.2460971851833165e-05
cycle O 0 1.2033090115437517e-06
and O 0 7.425699610763559e-09
enter O 0 3.408069160215632e-09
G0 O 0 1.8528446162235923e-05
/ O 0 1.4942747839086223e-06
quiescence O 0 1.299098767049145e-05
in O 0 5.212909215401851e-08
low O 0 2.727531182245002e-06
serum O 0 6.440235210902756e-06
. O 0 1.7139512920039124e-07

Both O 0 6.759012194379466e-07
VHL O 0 0.0005372336017899215
- O 0 0.00034702359698712826
positive O 0 2.677833066400126e-08
and O 0 5.430221676760993e-07
VHL O 0 0.00018584614736028016
- O 0 0.0009330546599812806
negative O 0 2.026202565730273e-07
RCC B-Disease 0 8.39737695059739e-05
cells O 0 3.692798955512444e-08
exit O 0 3.904362699813646e-08
the O 0 2.2432931956473112e-08
cell O 0 0.00013636829680763185
cycle O 0 1.965029696293641e-06
by O 0 3.1999607408295105e-09
contact O 0 5.942301939398931e-08
inhibition O 0 2.611691343190614e-07
. O 0 3.732283460067265e-07

The O 0 5.112618737257435e-07
cyclin O 0 0.00011422516399761662
- O 0 1.276029615837615e-05
dependent O 0 2.3689514350166974e-08
kinase O 0 2.0515028609224828e-07
inhibitor O 0 6.143385178347671e-08
, O 0 1.3356276085119134e-09
p27 O 0 4.47295755989785e-09
, O 0 8.027559728063238e-10
accumulates O 0 2.877742266704786e-09
upon O 0 3.001122406143253e-10
serum O 0 9.454727489810466e-08
withdrawal O 0 3.15738972744839e-08
, O 0 4.258035701809604e-09
only O 0 3.85990024664995e-11
in O 0 2.985945934952383e-10
the O 0 3.179699281652404e-10
presence O 0 7.248521227687377e-10
of O 0 5.346878495515739e-09
VHL B-Disease 0 3.1452382245333865e-05
, O 0 2.037914903496585e-08
as O 0 8.145986107876979e-10
a O 0 8.903992210207434e-09
result O 0 8.015110353198907e-09
of O 0 1.8663987022549122e-10
the O 0 6.059754475984391e-09
stabilization O 0 1.2571260477045598e-08
of O 0 1.3937759280047146e-10
the O 0 7.754787922920059e-09
protein O 0 4.6313218149407476e-08
. O 0 4.441131906673945e-08

We O 0 6.326029478032069e-08
propose O 0 1.6479223319265657e-08
that O 0 7.003114532722066e-09
the O 0 1.1081239925658792e-08
loss O 0 1.6764616930231568e-06
of O 0 7.313569194700165e-10
wild O 0 8.776020763434644e-07
- O 0 0.015661943703889847
type O 0 1.04534944966872e-06
VHL B-Disease 0 4.414733211888233e-06
gene O 0 9.275938239738934e-09
results O 0 4.711672119128707e-08
in O 0 1.4420162841588535e-09
a O 0 1.3799712483830717e-09
specific O 0 7.621535069723961e-10
cellular O 0 0.0005762068904004991
defect O 0 7.018175529083237e-05
in O 0 1.2552050066005904e-07
serum O 0 2.0396963009261526e-05
- O 0 2.4442340873065405e-05
dependent O 0 2.4495966144399972e-08
growth O 0 2.6847168044241698e-08
control O 0 3.88405574369699e-08
, O 0 1.8513356181415475e-08
which O 0 2.9015978952884325e-08
may O 0 1.7796347506759957e-08
initiate O 0 3.247460611532915e-08
tumor B-Disease 0 4.6864395699230954e-05
formation O 0 6.001926635690324e-07
. O 0 9.624959602660965e-07

This O 0 1.808194838304189e-07
is O 0 5.94187135050106e-08
corrected O 0 2.1920281767506822e-07
by O 0 7.421330910917234e-11
the O 0 3.2066493904636673e-10
reintroduction O 0 1.8290622350036756e-08
of O 0 7.396830370431928e-10
wild O 0 6.370393634824723e-07
- O 0 0.029164046049118042
type O 0 6.078277237975271e-06
VHL B-Disease 0 0.00020353989384602755
, O 0 1.6104475264455687e-07
implicating O 0 4.682110738940537e-05
VHL B-Disease 0 7.86451801104704e-06
as O 0 9.89152204589061e-10
the O 0 1.9848553911572253e-09
first O 0 9.543123269395437e-08
tumor B-Disease 0 6.903013854753226e-05
suppressor O 0 7.862221877985576e-07
involved O 0 3.529813108471558e-09
in O 0 4.3245515501944e-10
the O 0 8.286158981185565e-10
regulation O 0 3.867671516388782e-09
of O 0 5.341239117662155e-10
cell O 0 6.10377755947411e-05
cycle O 0 2.5431297672184883e-06
exit O 0 1.5613043160556117e-06
, O 0 1.0483529422344873e-07
which O 0 5.1355172558942286e-08
is O 0 4.837727995976593e-10
consistent O 0 1.838915242302619e-09
with O 0 9.38849886722437e-10
its O 0 8.032710496763684e-09
gatekeeper O 0 2.2214010186871747e-06
function O 0 2.2456765336187345e-09
in O 0 1.4679137017026278e-08
the O 0 2.534735131121124e-06
kidney O 0 0.02827497385442257
. O 0 2.1854634724149946e-07
. O 0 4.5547221816377714e-07

Piebaldism B-Disease 1 0.9987898468971252
with O 0 0.06560054421424866
deafness B-Disease 1 0.9999521970748901
: O 0 1.0312472795703798e-06
molecular O 0 2.088065230054781e-06
evidence O 0 2.158823946274424e-07
for O 0 1.2790825287822827e-08
an O 0 1.4512418147205608e-06
expanded O 0 0.0005691283731721342
syndrome O 1 0.9949871301651001
. O 0 9.857835721049923e-06

In O 0 1.6819836901049712e-07
a O 0 8.768595449737404e-08
South O 0 4.303056471144373e-07
African O 0 3.823620176035547e-08
girl O 0 1.3422269375951146e-06
of O 0 3.0488962465824443e-09
Xhosa O 0 0.00015237205661833286
stock O 0 2.752769660219201e-06
with O 0 1.5033743920866982e-06
severe O 0 0.0002001363318413496
piebaldism B-Disease 0 0.036172762513160706
and O 0 0.00040728627936914563
profound O 0 0.0016149221919476986
congenital O 1 0.9999852180480957
sensorineural B-Disease 1 0.9999666213989258
deafness I-Disease 1 0.9999967813491821
we O 0 3.7370457448560046e-06
identified O 0 6.142881829873659e-07
a O 0 8.683943519827153e-08
novel O 0 1.1864654680948661e-07
missense O 0 1.0789671023303526e-07
substitution O 0 3.292181638414604e-09
at O 0 4.595123073158902e-07
a O 0 2.3282940020408205e-09
highly O 0 1.5281184095883305e-09
conserved O 0 2.4743891380296645e-09
residue O 0 6.392412643663192e-08
in O 0 1.6887158338363406e-10
the O 0 3.4023517336834175e-10
intracellular O 0 4.83395155015387e-08
kinase O 0 5.215514775613883e-08
domain O 0 1.1618876694097224e-10
of O 0 1.6696172222552264e-11
the O 0 7.508146104839852e-09
KIT O 0 0.00013952986046206206
proto O 0 8.283802890218794e-05
- O 0 0.00040188501589000225
oncogene O 0 5.644864359055646e-06
, O 0 3.417111926751204e-08
R796G O 0 1.3453485507852747e-06
. O 0 1.694962321607818e-07

Though O 0 6.965883130760631e-06
auditory B-Disease 0 8.584521856391802e-05
anomalies I-Disease 0 0.015142321586608887
have O 0 1.9016594876575255e-07
been O 0 1.708085051177477e-07
observed O 0 7.043479399726493e-08
in O 0 5.140397618674797e-08
mice O 0 2.6979944323102245e-06
with O 0 2.0989467941490147e-08
dominant O 0 1.2471436093619559e-05
white O 0 0.018932325765490532
spotting O 0 0.08680948615074158
( O 0 4.2194895399916277e-07
W O 1 0.5922189354896545
) O 0 1.3027587897340709e-08
due O 0 4.848529133738566e-09
to O 0 9.701114578319903e-09
KIT O 0 0.00055255729239434
mutations O 0 1.3947873185315984e-06
, O 0 3.350126280565746e-05
deafness B-Disease 1 0.9999960660934448
is O 0 5.612767495222215e-07
not O 0 1.2477022970358576e-08
typical O 0 1.1470547889302907e-07
in O 0 7.408075930470659e-08
human O 0 6.591964734070643e-07
piebaldism B-Disease 0 0.0006854456150904298
. O 0 9.483893563810852e-07

Thus O 0 7.015791538833582e-07
, O 0 2.2749807371269526e-08
the O 0 2.962331935307816e-09
occurrence O 0 3.64014852038963e-07
of O 0 4.836478524339327e-07
sensorineural B-Disease 1 0.9997805953025818
deafness I-Disease 1 0.9999974966049194
in O 0 3.693807457239018e-06
this O 0 2.79979559536514e-08
patient O 0 2.9005354562627872e-08
extends O 0 4.350282356568869e-09
considerably O 0 6.5017626837970965e-09
the O 0 2.6546612130751157e-10
phenotypic O 0 2.392931408579102e-10
range O 0 3.943009119211638e-08
of O 0 3.151732430595189e-09
piebaldism B-Disease 0 2.291078635607846e-05
due O 0 1.1881452266493397e-08
to O 0 2.160729817290985e-09
KIT O 0 3.3248479667236097e-06
gene O 0 3.072609944254623e-09
mutation O 0 3.2330156329862803e-09
in O 0 4.218038807124458e-09
humans O 0 2.2829778068000905e-09
and O 0 3.154981698116899e-08
tightens O 0 4.236065433360636e-05
the O 0 9.344109486164598e-09
clinical O 0 2.563778878084122e-08
similarity O 0 2.7727931950494167e-08
between O 0 1.9967953335253696e-07
piebaldism B-Disease 0 0.0005290377885103226
and O 0 1.5693602861688305e-08
the O 0 2.834422696551542e-10
various O 0 1.5987462742561576e-10
forms O 0 4.218765070618247e-08
of O 0 9.404162119608372e-05
Waardenburg B-Disease 1 0.9998897314071655
syndrome I-Disease 1 0.9967711567878723
. O 0 2.1477247003076627e-07
. O 0 6.870213269394299e-07

Cycloheximide O 0 3.254497278248891e-05
facilitates O 0 9.290993574495587e-08
the O 0 9.952578317040661e-09
identification O 0 3.443623697307885e-08
of O 0 8.772389037403627e-09
aberrant O 0 1.9716897440957837e-05
transcripts O 0 1.2259846698725596e-05
resulting O 0 3.5776415074906254e-07
from O 0 2.856911152093744e-09
a O 0 2.0597633820784722e-08
novel O 0 1.627779937507512e-07
splice O 0 0.00026725317002274096
- O 0 0.0006450590444728732
site O 0 1.5627402945028734e-06
mutation O 0 4.213240600847712e-08
in O 0 6.646840944313226e-08
COL17A1 O 0 0.00039704632945358753
in O 0 1.0877942102638372e-08
a O 0 9.99496663212085e-08
patient O 0 5.804625970995403e-07
with O 0 3.5406822007644223e-06
generalized O 0 0.00013299169950187206
atrophic B-Disease 1 0.9146593809127808
benign I-Disease 1 0.9678922295570374
epidermolysis I-Disease 1 0.9617087244987488
bullosa I-Disease 1 0.7254149317741394
. O 0 2.212465369666461e-05

Patients O 0 1.5876928955549374e-05
with O 0 1.5893674571998417e-06
generalized O 0 7.460380584234372e-05
atrophic B-Disease 1 0.7512727379798889
benign I-Disease 1 0.8651332259178162
epidermolysis I-Disease 1 0.9048289656639099
bullosa I-Disease 1 0.5816556811332703
often O 0 9.564144420437515e-06
show O 0 5.671433882525889e-06
decreased O 0 2.3052031394854566e-07
expression O 0 1.9234576154048e-09
of O 0 4.78649742063908e-09
type O 0 6.401748578355182e-06
XVII O 0 0.009041407145559788
collagen O 0 3.987619129475206e-05
, O 0 7.034336846345468e-08
a O 0 6.009526742900562e-08
transmembrane O 0 4.3935250459981035e-07
hemidesmosomal O 0 2.0148695512034465e-06
protein O 0 7.649847977297952e-10
encoded O 0 9.856249150175245e-10
by O 0 4.1550627827291464e-08
COL17A1 O 0 0.000499591464176774
. O 0 4.308024870169902e-07

This O 0 1.0230663605170776e-07
report O 0 8.569523402002233e-08
documents O 0 2.154397549247733e-08
a O 0 5.919470691395645e-09
novel O 0 1.8468918838721038e-08
splice O 0 3.926320277969353e-05
- O 0 0.001685979194007814
site O 0 6.425235824281117e-06
mutation O 0 5.8560807758567535e-08
in O 0 3.157353845040234e-08
COL17A1 O 0 0.0003252305032219738
in O 0 3.56636533638266e-08
a O 0 1.213756348761308e-07
patient O 0 3.667117312033952e-07
with O 0 4.971313956048107e-07
generalized O 0 2.1177209418965504e-05
atrophic B-Disease 0 0.3215750753879547
benign I-Disease 0 0.15135160088539124
epidermolysis I-Disease 0 0.12434934079647064
bullosa I-Disease 0 0.049927741289138794
, O 0 2.357157029564405e-07
and O 0 5.657930124414179e-09
applies O 0 5.448019257947578e-10
a O 0 1.1715148851010326e-09
new O 0 3.164870587823998e-09
methodology O 0 2.6943611786123256e-08
to O 0 1.1270625543957635e-09
define O 0 4.445969370436842e-09
and O 0 2.994275760670462e-08
characterize O 0 6.312890832305129e-08
the O 0 8.268192241978056e-10
resulting O 0 1.320812459404408e-09
mRNA O 0 1.806941929416439e-09
splice O 0 1.1184148206666578e-05
variants O 0 5.171622206034954e-07
. O 0 7.022136969681014e-07

Mutational O 0 0.00011136641842313111
analysis O 0 8.047647952480474e-07
of O 0 2.528488352027125e-08
COL17A1 O 0 0.00022412215184886009
identified O 0 9.598139740774059e-07
a O 0 2.0991855365082301e-07
maternally O 0 0.0005533042130991817
inherited O 0 0.013180957175791264
G O 0 0.010540995746850967
- O 0 0.0010528534185141325
to O 0 4.5978671892044076e-07
- O 0 0.018795408308506012
T O 0 0.005911612417548895
transversion O 0 2.9724133128183894e-06
at O 0 4.203905135113928e-08
the O 0 1.1586483994463492e-09
- O 0 1.2034605560984346e-06
1 O 0 6.884984249388992e-10
position O 0 9.60111878889336e-10
of O 0 5.034664907199726e-10
exon O 0 9.588020475348458e-07
32 O 0 4.927154009237711e-07
. O 0 2.8051471190337907e-07

This O 0 4.836808287222993e-09
acceptor O 0 2.126274445402032e-08
splice O 0 5.0517613999545574e-05
- O 0 0.0006583695649169385
site O 0 2.0950405996700283e-06
mutation O 0 6.622342851869689e-08
led O 0 5.500701760752236e-08
to O 0 8.924101457807865e-10
the O 0 8.401553897030567e-10
formation O 0 1.8527133605061863e-08
of O 0 1.1190747217781905e-09
aberrant O 0 9.30611804506043e-07
transcripts O 0 5.019022637497983e-07
present O 0 9.142603119016712e-09
at O 0 8.812033911453909e-07
extremely O 0 5.522188075701706e-07
low O 0 2.138279796781717e-06
levels O 0 5.7196611891185967e-08
. O 0 9.035712622562642e-08

Based O 0 5.716356099583209e-07
on O 0 1.89539306916231e-07
our O 0 3.611108745360525e-09
recent O 0 5.7541371667468866e-09
finding O 0 2.7671809288420945e-09
that O 0 1.083061551554465e-08
cycloheximide O 0 5.723006324842572e-06
stabilized O 0 2.6779923700814834e-06
mutant O 0 1.2203071264593746e-07
COL17A1 O 0 1.805656324904703e-06
transcripts O 0 5.453691187540244e-08
in O 0 4.727684022043377e-09
keratinocytes O 0 2.7410754910306423e-07
homozygous O 0 3.593767772258616e-08
for O 0 2.484916161726858e-10
a O 0 4.562390643059189e-08
frameshift O 0 2.0781939383596182e-05
mutation O 0 9.003473877555734e-08
, O 0 1.6549906334262232e-08
the O 0 8.475272927910282e-09
effects O 0 1.5213663218105467e-08
of O 0 5.4900233664723075e-11
the O 0 2.678751664930701e-09
splice O 0 8.895614155335352e-05
- O 0 0.00017228581418748945
site O 0 2.70352984443889e-07
mutation O 0 7.389666656365534e-10
on O 0 5.511179512751596e-09
splicing O 0 4.772661554852675e-08
of O 0 2.1018864426736172e-09
COL17A1 O 0 1.0872219718294218e-05
transcripts O 0 6.65515074160794e-08
were O 0 2.3087525224951833e-09
determined O 0 3.838976914138925e-10
using O 0 1.9612589330364472e-10
reverse O 0 6.420829095077352e-07
transcriptase O 0 1.809697323551518e-06
polymerase O 0 2.823081786118564e-06
chain O 0 2.4836024294927483e-06
reaction O 0 6.30999641426655e-10
of O 0 2.7575258049195028e-11
total O 0 2.304817725562458e-10
RNA O 0 5.190988527914442e-09
from O 0 1.7474499625080853e-10
keratinocytes O 0 2.4154491740091544e-08
incubated O 0 1.2498820467499172e-07
for O 0 9.70769908903435e-10
2 O 0 7.80656890242426e-08
. O 0 1.1275538014388076e-07

5 O 0 4.774277840624563e-06
h O 0 2.1412781279650517e-05
in O 0 1.3300176959774035e-08
the O 0 3.054717145900554e-09
presence O 0 6.253805473477314e-09
or O 0 3.084442923295683e-08
absence O 0 5.7181419599317e-09
of O 0 5.875396280607958e-10
10 O 0 5.87026072196295e-08
microg O 0 4.9551290430827066e-05
cycloheximide O 0 1.1994950000371318e-05
per O 0 2.244594199396488e-08
ml O 0 7.220870884339092e-06
. O 0 1.3655014186042536e-07

Using O 0 7.069644425428123e-08
this O 0 3.511259949462442e-09
approach O 0 4.884704907226478e-08
, O 0 1.034706986757783e-08
an O 0 5.595971686034318e-09
abnormally O 0 8.345633432327304e-06
spliced O 0 0.0003590998239815235
transcript O 0 0.0012952411780133843
was O 0 0.0005506950546987355
identified O 0 1.266459577209389e-07
that O 0 1.6473556962992575e-09
contains O 0 2.669740817307087e-11
an O 0 5.2470167100082676e-11
extra O 0 4.475582057739125e-11
264 O 0 2.7604227792465963e-09
bases O 0 1.0152142460029268e-09
upstream O 0 3.4058469378095424e-09
from O 0 1.3160815492962996e-10
exon O 0 1.817838679585293e-08
32 O 0 3.819159744011813e-08
, O 0 1.923605452702759e-08
resulting O 0 1.0600165190055577e-08
in O 0 2.9497249087739874e-09
a O 0 1.0927896454404618e-07
premature O 0 2.5993024337367387e-06
termination O 0 2.252270725477956e-08
codon O 0 1.8206137708531855e-09
27 O 0 8.045348209861913e-08
bp O 0 1.493280478825909e-06
downstream O 0 2.5322576036046485e-08
from O 0 1.8018646297246477e-10
the O 0 5.308575801166171e-10
cryptic O 0 1.1676627309498144e-06
splice O 0 4.645950684789568e-05
site O 0 2.486804260115605e-05
. O 0 1.7069254454327165e-06

Three O 0 2.170607338314312e-08
other O 0 6.404036190232887e-10
splice O 0 4.438009000296006e-06
variants O 0 8.195752911888121e-07
, O 0 4.3873324528931334e-08
including O 0 5.120410762060601e-10
one O 0 7.395419832079142e-10
derived O 0 1.3653925212686602e-10
from O 0 6.278957909167104e-11
the O 0 2.059486192695914e-10
skipping O 0 2.704205037673546e-08
of O 0 6.059358015342298e-10
exon O 0 4.3430637219898927e-07
32 O 0 7.289108339136874e-08
, O 0 1.3522797104315032e-08
were O 0 1.9643531246060775e-08
also O 0 2.4723338043486365e-08
identified O 0 2.1000606409415923e-07
. O 0 2.2410635835967696e-07

These O 0 7.437751037286944e-08
results O 0 1.578526251932999e-07
indicate O 0 1.6752212061987848e-08
the O 0 1.324384490963837e-09
usefulness O 0 5.994415630539152e-08
of O 0 4.226567540399628e-09
cycloheximide O 0 9.623484220355749e-05
treatment O 0 3.0805097139818827e-08
in O 0 7.433177962035131e-10
evaluating O 0 6.716879275003862e-10
the O 0 2.577417612670274e-09
abnormal O 0 9.092366326513002e-08
processing O 0 1.6761086962802096e-09
of O 0 1.2539725334492768e-11
mRNA O 0 2.5611465725994265e-10
due O 0 1.0990344190275891e-09
to O 0 1.6359137655630462e-10
splice O 0 1.985102062462829e-05
- O 0 0.001076200744137168
site O 0 1.800989957700949e-05
mutations O 0 2.3598740028774046e-07
, O 0 7.868668205901486e-08
because O 0 1.0183316589973401e-07
( O 0 1.6137929881310242e-09
i O 0 1.3336253346096782e-07
) O 0 8.414495766828622e-10
aberrant O 0 3.047682639589766e-08
splicing O 0 1.567086904685766e-08
often O 0 1.952663586379799e-09
generates O 0 4.470362968689301e-10
a O 0 1.3417460031917017e-08
premature O 0 1.0381347692600684e-06
termination O 0 2.1745893974411956e-08
codon O 0 1.0922724946738072e-08
, O 0 6.164795252061595e-08
( O 0 1.9254324801210032e-09
ii O 0 1.1419937436585315e-05
) O 0 2.946379140666977e-09
transcripts O 0 1.3136282461800874e-07
with O 0 1.3008374821765756e-07
premature O 0 1.8238735037812148e-06
termination O 0 1.4631199363179803e-08
codons O 0 3.248865176885829e-09
can O 0 3.546750670935239e-10
occur O 0 3.8790173850777876e-10
at O 0 2.5274812287534587e-07
low O 0 3.7844552025489975e-07
or O 0 7.606004004401257e-08
undetectable O 0 8.21039805032342e-07
levels O 0 5.359352961420427e-10
due O 0 1.0382213977422339e-09
to O 0 1.0875488287709345e-09
nonsense O 0 1.7186226841658936e-07
- O 0 2.869566628760367e-07
mediated O 0 8.217136837629369e-08
mRNA O 0 2.504645602030564e-09
decay O 0 7.745227748046091e-08
, O 0 9.479244944543552e-09
and O 0 9.319212068703564e-08
( O 0 1.361308177294518e-09
iii O 0 5.132078877068125e-05
) O 0 2.002476628959471e-09
the O 0 6.579918276905516e-10
levels O 0 1.5930633201488575e-10
of O 0 2.1559563162520945e-11
these O 0 5.0003154394850924e-11
transcripts O 0 5.193100705014331e-08
can O 0 2.40592434863629e-10
be O 0 2.6036331424172943e-10
increased O 0 4.2750331052943125e-10
by O 0 6.8156604804414656e-09
cycloheximide O 0 0.0001061933726305142
. O 0 3.5337160397830303e-07

A O 0 3.471362106211018e-06
deletion O 0 1.3582332940131892e-05
mutation O 0 1.1141916047563427e-06
in O 0 2.5329731556666957e-07
COL17A1 O 0 0.0008238840382546186
in O 0 3.5206234372253675e-08
five O 0 6.941929342474396e-08
Austrian O 0 0.00013423006748780608
families O 0 1.6910647104850796e-07
with O 0 3.443322214025102e-07
generalized O 0 1.9093360606348142e-05
atrophic B-Disease 1 0.8172975778579712
benign I-Disease 1 0.9190909266471863
epidermolysis I-Disease 1 0.6065165400505066
bullosa I-Disease 0 0.05477474257349968
represents O 0 1.5353799653894384e-07
propagation O 0 1.3317112745880877e-07
of O 0 1.6880854492029584e-09
an O 0 3.567304318607967e-08
ancestral O 0 2.1980264136800542e-05
allele O 0 1.6358006178052165e-05
. O 0 2.1497342004295206e-06

Patients O 0 4.02121695515234e-05
with O 0 2.1894616111239884e-06
generalized O 0 5.306505772750825e-05
atrophic B-Disease 1 0.8348654508590698
benign I-Disease 1 0.9592784643173218
epidermolysis I-Disease 1 0.9269675016403198
bullosa I-Disease 1 0.6483582258224487
, O 0 1.1313404684187844e-06
a O 0 2.7325814500045453e-08
usually O 0 3.3643574592900904e-09
nonlethal O 0 6.448597389407951e-08
form O 0 2.0179360404881663e-09
of O 0 2.1102104952319678e-08
junctional B-Disease 0 0.326612651348114
epidermolysis I-Disease 0 0.1316424161195755
bullosa I-Disease 0 0.008726611733436584
, O 0 1.4467396169948188e-07
have O 0 5.270331726592303e-09
generalized O 0 3.744190379961765e-08
blistering B-Disease 0 0.003437597304582596
, O 0 0.0006996921147219837
nail B-Disease 1 0.999982476234436
dystrophy I-Disease 1 0.9997960925102234
, O 0 0.00045021818368695676
patchy B-Disease 1 0.8752346634864807
alopecia I-Disease 1 0.9999110698699951
, O 0 1.728964525682386e-05
and O 0 2.0399686036398634e-05
dental B-Disease 0 0.04061631113290787
abnormalities I-Disease 1 0.8917320370674133
. O 0 1.3622664482682012e-05

Skin B-Disease 1 0.9375138878822327
fragility I-Disease 0 0.3594736158847809
in O 0 3.7866718116674747e-07
most O 0 2.4222403638418655e-08
cases O 0 1.4822121841007174e-07
is O 0 2.2529754062361462e-08
due O 0 8.878892288066709e-09
to O 0 2.219826988891782e-09
mutations O 0 4.013343879449849e-09
in O 0 4.0009828783382773e-10
the O 0 5.185117890604829e-10
gene O 0 3.728780395562126e-09
encoding O 0 1.6973492833471937e-08
type O 0 2.5961983283195877e-06
XVII O 0 0.00484040891751647
collagen O 0 0.0003636153996922076
( O 0 1.026420335392686e-07
COL17A1 O 0 0.0005217095604166389
) O 0 4.7003712921878105e-08
. O 0 1.4986619589762995e-07

Recently O 0 3.067375291720964e-05
, O 0 4.389885361888446e-07
we O 0 2.8808685215153673e-08
reported O 0 1.2107774409741978e-06
five O 0 1.1647378173051948e-08
Austrian O 0 1.2486932064348366e-05
families O 0 4.071262793559072e-08
with O 0 1.8848642469038168e-07
generalized O 0 1.7050469978130423e-05
atrophic B-Disease 1 0.6002933979034424
benign I-Disease 1 0.896423876285553
epidermolysis I-Disease 1 0.5794492363929749
bullosa I-Disease 0 0.07479745894670486
who O 0 1.680199147813255e-06
share O 0 7.82007134603191e-08
the O 0 1.2248187353236517e-08
same O 0 8.932028805475056e-08
COL17A1 O 0 0.000871366064529866
mutation O 0 2.9854737704226864e-07
. O 0 3.497563341170462e-07

Affected O 0 4.466814971237909e-06
individuals O 0 1.926013659669934e-08
in O 0 2.178690117204951e-09
three O 0 8.415254271199046e-09
families O 0 4.695269950616421e-09
are O 0 1.347160577536144e-10
homozygous O 0 7.78588216121534e-09
for O 0 2.234998186523285e-09
4003delTC O 0 1.725083961900964e-06
, O 0 1.0540286865534654e-08
whereas O 0 1.4550596283413597e-09
those O 0 8.200454204576602e-10
in O 0 1.0132042982391454e-09
two O 0 2.2268208610398688e-08
others O 0 3.2100611946361823e-08
are O 0 5.018022108949083e-10
compound O 0 1.5378329862869577e-06
heterozygotes O 0 1.1029535471607232e-06
. O 0 1.8660040268514422e-07

To O 0 6.800237173365531e-08
determine O 0 4.426400224133431e-08
if O 0 1.1573231262218542e-09
the O 0 5.172395289854137e-10
occurrence O 0 1.0588000698419364e-08
of O 0 2.2724817583252843e-09
4003delTC O 0 1.1454842024249956e-05
in O 0 6.325062251733016e-09
these O 0 7.515749689268603e-10
unrelated O 0 5.799054179078666e-07
families O 0 1.8733409490323538e-08
signifies O 0 1.868373722402339e-08
propagation O 0 1.1604272209808641e-08
of O 0 2.562260681404638e-10
an O 0 5.475116804376512e-09
ancestral O 0 2.1486519017344108e-06
allele O 0 2.70043017280841e-07
or O 0 1.596243315304946e-08
a O 0 1.4193194175504686e-08
mutational O 0 9.799456393011496e-07
hot O 0 1.7052560679076123e-06
spot O 0 4.892536708211992e-06
, O 0 4.2563485180835414e-08
haplotypes O 0 4.2729831761789683e-07
were O 0 1.6252229784186056e-08
determined O 0 1.1398767263415266e-08
for O 0 5.932918600848325e-10
polymorphisms O 0 9.552046265071112e-08
both O 0 1.4738635867317385e-09
within O 0 3.494241840318324e-10
and O 0 2.332024848783476e-07
flanking O 0 0.00046025586198084056
COL17A1 O 0 0.13443179428577423
. O 0 1.2590741107487702e-06

Five O 0 3.789171387325041e-06
intragenic O 0 0.00016381921886932105
polymorphisms O 0 6.523269348690519e-06
were O 0 6.581367983926611e-08
chosen O 0 1.3225240902414725e-09
based O 0 3.5907514739363933e-09
on O 0 1.7154459897028573e-07
their O 0 1.2961589845872368e-07
informativeness O 0 0.00022107527183834463
. O 0 3.885797639213706e-07

One O 0 6.324943768731828e-08
of O 0 2.864724901741056e-09
these O 0 1.3339674920231914e-09
, O 0 4.512995310790302e-09
not O 0 1.3272142274090015e-09
previously O 0 3.991041239714832e-07
reported O 0 1.5836778402444907e-05
, O 0 8.144436236534602e-09
was O 0 1.8904210037362645e-06
2988 O 0 4.855555744143203e-07
A O 0 1.1600724292293307e-07
or O 0 1.6562039206746704e-07
C O 0 9.001101375361031e-07
that O 0 8.849943000655003e-10
introduces O 0 1.2139635963137607e-09
a O 0 1.000386551375243e-09
new O 0 1.7437351562676895e-09
restriction O 0 2.8564042242607e-09
site O 0 1.624265344446485e-08
for O 0 8.84159134795226e-10
Eco0109 O 0 1.1090173757111188e-06
I O 0 2.911416004280909e-06
. O 0 1.0951976037176792e-07

All O 0 8.468776790948596e-09
the O 0 1.1691448698059048e-08
4003delTC O 0 2.0048144051543204e-06
alleles O 0 8.299927856114664e-08
showed O 0 2.210422735515749e-06
the O 0 1.9928785288669815e-09
same O 0 6.306341671091786e-09
haplotype O 0 5.379243248171406e-06
for O 0 3.5145347743181787e-10
these O 0 3.6305686235138523e-10
five O 0 4.8311033395975755e-08
polymorphic O 0 1.4479999208560912e-06
markers O 0 0.00023924256674945354
. O 0 6.060848136257846e-06

Fourteen O 0 2.980485987791326e-06
microsatellite O 0 0.00031305482843890786
polymorphisms O 0 1.1376262591511477e-05
were O 0 7.049177952467289e-08
selected O 0 7.667917967246751e-10
based O 0 3.4380893687568914e-09
on O 0 2.3472126997603482e-07
their O 0 5.360339372373346e-08
high O 0 4.249448011250934e-06
heterozygosity O 0 2.4073556232906412e-06
and O 0 5.138258263315265e-09
their O 0 1.718584025089953e-10
location O 0 3.6981120388190902e-09
within O 0 4.0835468340105763e-10
10q23 O 0 1.0265010814691777e-06
- O 0 0.00023273099213838577
q25 O 0 7.068422746669967e-06
near O 0 2.2521438950207084e-05
COL17A1 O 0 0.0012258616043254733
. O 0 5.450975777421263e-07

Three O 0 5.19300670021039e-07
families O 0 5.201914063945878e-07
shared O 0 4.335474272920692e-07
microsatellite O 0 0.00031242662225849926
polymorphisms O 0 1.0438239769428037e-05
covering O 0 1.3089003232380492e-06
at O 0 4.211451596347615e-06
most O 0 1.0492026802921828e-08
19 O 0 6.551547357958043e-07
cM O 0 2.6761827029986307e-05
, O 0 2.3866618903412018e-08
whereas O 0 9.67260049833385e-10
the O 0 1.8924817268839433e-09
others O 0 2.839154689127099e-08
shared O 0 6.345410419328346e-09
smaller O 0 1.0202910516454722e-08
regions O 0 2.9231256304385056e-10
consistent O 0 6.662400409140901e-09
with O 0 2.684568300992396e-08
cross O 0 1.7865014569906634e-06
- O 0 0.00010406318324385211
over O 0 1.8708043114656903e-07
events O 0 7.560497117253817e-09
during O 0 4.750136728404186e-09
passage O 0 1.0164484809394025e-09
of O 0 1.0687816603960343e-10
this O 0 2.694168221850646e-10
mutation O 0 5.83868731141024e-10
through O 0 5.398842484183319e-10
several O 0 7.979965133131373e-09
generations O 0 2.3539242022252438e-07
. O 0 2.918692132425349e-07

These O 0 3.4054849606945936e-08
results O 0 6.244076189432235e-07
indicate O 0 2.573598010258138e-07
that O 0 4.619852589371476e-08
4003delTC O 0 3.6774981708731502e-06
occurs O 0 2.8119588879604862e-09
on O 0 1.908526670035826e-08
a O 0 1.0388598425947748e-08
single O 0 1.523035741968215e-08
ancestral O 0 5.379828508011997e-06
allele O 0 1.122332946579263e-06
. O 0 6.803636409813407e-08
. O 0 2.626826471896493e-07

The O 0 9.59453359428153e-07
haptoglobin O 0 0.00022558876662515104
- O 0 0.0003875174734275788
gene O 0 4.951568826072617e-07
deletion O 0 1.7242286958207842e-06
responsible O 0 1.6970327010312758e-07
for O 0 4.998101132969168e-08
anhaptoglobinemia B-Disease 0 0.000703245576005429
. O 0 1.4571594419976464e-06

We O 0 6.087061592552345e-07
have O 0 1.4284772476003127e-08
found O 0 1.2796755655131165e-08
an O 0 5.404601766123562e-10
allelic O 0 1.101895918509399e-06
deletion O 0 8.848969628161285e-07
of O 0 3.162637929321477e-09
the O 0 9.5454353754576e-08
haptoglobin O 0 8.590048673795536e-05
( O 0 2.332258608461757e-09
Hp O 0 2.1455662135849707e-06
) O 0 4.958389698828114e-09
gene O 0 4.178656975994954e-09
from O 0 6.787764794680129e-10
an O 0 1.0992651233721062e-09
individual O 0 2.4898703099296426e-09
with O 0 1.6001321228031884e-06
anhaptoglobinemia B-Disease 0 0.013659058138728142
. O 0 1.8329373006054084e-06

The O 0 1.9138857965117495e-07
Hp O 0 4.642342901206575e-06
gene O 0 1.109276936972492e-07
cluster O 0 1.1502088455017656e-06
consists O 0 3.9044798505472045e-09
of O 0 1.5225092298010168e-09
coding O 0 1.011608856060775e-05
regions O 0 7.265407164780413e-10
of O 0 1.4156409378074386e-10
the O 0 3.9025218612209756e-09
alpha O 0 4.491372163073493e-09
chain O 0 8.627512784187275e-07
and O 0 4.813303533524049e-09
beta O 0 7.947530966667671e-10
chain O 0 5.1419473123814896e-08
of O 0 3.196401476834865e-11
the O 0 2.857145187107335e-09
haptoglobin O 0 8.688522257216391e-07
gene O 0 2.2426856816082363e-08
( O 0 8.38384917045687e-10
Hp O 0 4.275950971077691e-07
) O 0 7.326819706499066e-10
and O 0 4.1816608509215314e-10
of O 0 1.6306605371552152e-11
the O 0 1.0436058683893634e-09
alpha O 0 2.135299936867341e-09
chain O 0 1.011227141134441e-06
and O 0 4.82956208358587e-09
beta O 0 5.730280139282229e-10
chain O 0 2.5495250355334065e-08
of O 0 6.960468312833257e-11
the O 0 1.671346616660685e-08
haptoglobin O 0 1.7495382053311914e-05
- O 0 9.966879588318989e-05
related O 0 9.842148784855453e-08
gene O 0 2.2883149597419106e-08
( O 0 1.2613381450421457e-09
Hpr O 0 2.4164313572327956e-07
) O 0 2.5770734435326403e-09
, O 0 1.3226880701822097e-09
in O 0 9.745954043793859e-10
tandem O 0 3.8069451875344384e-06
from O 0 1.9973918075066877e-09
the O 0 1.0847215570208846e-08
5 O 0 1.9584091148772131e-07
side O 0 1.994090553125716e-06
. O 0 2.495372939392837e-07

Southern O 0 2.6984114356309874e-06
blot O 0 0.00023644964676350355
and O 0 1.768406860946925e-07
PCR O 0 5.18544811711763e-06
analyses O 0 6.204110718499578e-07
have O 0 3.023359695930594e-08
indicated O 0 5.978749584301113e-08
that O 0 1.3505004892166994e-09
the O 0 5.020827087420798e-10
individual O 0 4.5302067652741584e-10
with O 0 5.435849459445308e-08
anhaptoglobinemia B-Disease 0 5.452383265946992e-05
was O 0 6.6800716922443826e-06
homozygous O 0 2.9096005604856146e-08
for O 0 1.6964508964267822e-10
the O 0 1.7338851465709126e-09
gene O 0 2.004181887116374e-08
deletion O 0 3.6861496255369275e-07
and O 0 4.0985714377939075e-08
that O 0 2.3641386626138683e-09
the O 0 5.879656206353445e-10
gene O 0 9.392962851961784e-09
deletion O 0 3.558317871465988e-07
was O 0 2.612827529446804e-06
included O 0 9.718538196423765e-10
at O 0 1.0862768817787583e-07
least O 0 7.189667611262607e-11
from O 0 1.1853464043642958e-10
the O 0 9.901867104034068e-10
promoter O 0 2.5750020995474188e-06
region O 0 4.173479783986522e-09
of O 0 2.501264195764463e-10
Hp O 0 4.2968480329363956e-07
to O 0 1.5950070153536444e-09
Hpr O 0 2.215893957213666e-08
alpha O 0 2.444660585076974e-10
but O 0 3.8640643462706237e-10
not O 0 1.0670055811123902e-10
to O 0 3.616250410232169e-09
Hpr O 0 7.742804086774413e-07
beta O 0 1.2759246992288809e-08
( O 0 1.580606645568139e-09
Hpdel O 0 4.3199820538575295e-06
) O 0 1.584997022519019e-08
. O 0 5.1590699712278365e-08

In O 0 9.438996784183473e-08
addition O 0 1.2590696485403896e-08
, O 0 1.2883771383087605e-08
we O 0 3.462629960537811e-09
found O 0 2.710949509321381e-08
seven O 0 9.982826121301969e-09
individuals O 0 4.877780124257214e-11
with O 0 4.508856843443709e-09
hypohaptoglobinemia B-Disease 0 7.80690425017383e-06
in O 0 3.199924103469698e-09
three O 0 2.9236135290489074e-08
families O 0 5.0905594406458476e-08
, O 0 4.511600870671373e-09
and O 0 2.489661365956408e-09
the O 0 2.3182749053773932e-09
genotypes O 0 5.341274800230167e-08
of O 0 2.792246711624813e-10
six O 0 1.2465343424139519e-08
of O 0 3.553013716572906e-10
the O 0 8.332234457952836e-09
seven O 0 4.162399847018605e-08
individuals O 0 1.6897436228013873e-10
were O 0 1.2258143833321355e-08
found O 0 5.529302882223419e-08
to O 0 3.129239756205493e-09
be O 0 5.455896356920675e-08
Hp2 O 0 5.449211676022969e-05
/ O 0 2.485962568243849e-06
Hpdel O 0 2.4014485461520962e-05
. O 0 1.5303336908800702e-07

The O 0 2.618664893816458e-07
phenotypes O 0 1.0773814210551791e-05
and O 0 2.710319222387625e-07
genotypes O 0 9.923408015310997e-07
in O 0 8.536859219532289e-09
one O 0 1.0026425245612813e-09
of O 0 2.2003801558589942e-10
these O 0 2.47853043644497e-10
three O 0 2.8477344926614023e-08
families O 0 7.253824918507235e-08
showed O 0 9.16930366656743e-06
the O 0 1.6720033357842112e-08
father O 0 1.089114448404871e-06
to O 0 5.3199005201065575e-09
be O 0 2.0805281053526414e-08
hypohaptoglobinemic B-Disease 0 1.9390608940739185e-05
( O 0 1.7061378976279684e-09
Hp2 O 0 1.9752201296796557e-06
) O 0 2.7999920160226566e-09
and O 0 2.246821750873096e-08
Hp2 O 0 1.0313394341210369e-05
/ O 0 3.774118511046254e-07
Hpdel O 0 1.5384622429337469e-06
, O 0 3.0041475973519027e-09
the O 0 1.2928220716190708e-09
mother O 0 2.236820932921546e-07
to O 0 4.1158881858294194e-10
be O 0 2.0442867398884346e-09
Hp2 O 0 1.167359869214124e-06
- O 0 2.4015953385969624e-06
1 O 0 3.423601402374743e-09
and O 0 3.401005699288362e-08
Hp1 O 0 6.9398770392581355e-06
/ O 0 3.4156724382228276e-07
Hp2 O 0 9.542892485114862e-07
, O 0 6.764604432163424e-10
one O 0 7.601148876990038e-11
of O 0 2.037484070349649e-11
the O 0 8.510614990520082e-10
two O 0 2.570084944863993e-08
children O 0 1.0069493683317887e-08
to O 0 1.885398503986835e-09
be O 0 1.8151398606391922e-08
hypohaptoglobinemic B-Disease 0 2.8533935619634576e-05
( O 0 8.887970914805976e-10
Hp2 O 0 1.1723290072040982e-06
) O 0 2.27610819081292e-09
and O 0 2.0882968243540745e-08
Hp2 O 0 1.111551137000788e-05
/ O 0 6.151217917249596e-07
Hpdel O 0 2.776506335067097e-06
, O 0 1.9985924026855173e-09
and O 0 3.7878739034269415e-10
the O 0 5.102997469030868e-10
other O 0 5.423230198253748e-10
child O 0 1.714444231026846e-08
to O 0 4.5685077942891894e-10
be O 0 1.427027829237204e-09
Hp1 O 0 9.111060421673756e-07
and O 0 1.1388015508373428e-07
Hp1 O 0 3.6733723391080275e-05
/ O 0 1.2222444638609886e-06
Hpdel O 0 4.004410129709868e-06
, O 0 3.555245875475066e-09
showing O 0 3.0233021419689976e-08
an O 0 3.2694724705351064e-09
anomalous O 0 5.813146231048449e-07
inheritance O 0 1.7102364608945209e-06
of O 0 1.2709648444797494e-08
Hp O 0 5.941187555436045e-05
phenotypes O 0 4.853745849686675e-07
in O 0 6.442705924314396e-09
the O 0 6.448105693834805e-08
child O 0 9.575918738846667e-06
with O 0 2.141586037396337e-06
Hp1 O 0 0.0009508703951723874
. O 0 8.228583396885369e-07

The O 0 1.4781680874875747e-06
Hp2 O 0 0.0016665180446580052
/ O 0 0.00020867923740297556
Hpdel O 0 0.00031193523318506777
individuals O 0 1.379819281055461e-08
had O 0 2.1032253982866678e-07
an O 0 5.1855755245355795e-09
extremely O 0 1.3184501312935026e-07
low O 0 1.3075663218842237e-07
level O 0 3.5463330050333752e-09
of O 0 1.3842972323985236e-09
Hp O 0 5.3740136536362115e-06
( O 0 7.488505371355814e-10
mean O 0 3.74292463689585e-09
+ O 0 7.036309312979938e-08
/ O 0 8.206892943007915e-08
- O 0 3.936242137569934e-06
SD O 0 1.2576696462929249e-05
= O 0 1.4395085656815354e-07
0 O 0 2.2968964230596356e-10
. O 0 8.412035651383931e-11
049 O 0 5.8089902665869886e-08
+ O 0 4.540297382504832e-08
/ O 0 2.114892616589259e-08
- O 0 2.6921321705231094e-07
0 O 0 3.0842808862452387e-10
. O 0 1.160224624707773e-10
043 O 0 2.087297268360544e-08
mg O 0 1.5205270642582036e-07
/ O 0 2.6598032221158974e-08
ml O 0 2.647911117037438e-07
; O 0 9.978957660194965e-10
n O 0 4.3553736617241157e-08
= O 0 8.761406178336983e-08
6 O 0 4.112306584147518e-08
) O 0 2.9645306209857836e-09
, O 0 3.535810311205978e-09
compared O 0 9.182868687673817e-09
with O 0 3.9442835109149144e-10
the O 0 2.8996156586913457e-09
level O 0 7.2106178805597665e-09
( O 0 5.4079192512990204e-11
1 O 0 8.567942189063871e-11
. O 0 1.2031428631154029e-10
64 O 0 1.2502082924470415e-08
+ O 0 2.997498427248502e-08
/ O 0 9.789983934638258e-09
- O 0 8.188271038989114e-08
1 O 0 1.6711250439005454e-10
. O 0 1.476127553523554e-10
07 O 0 4.368950090594126e-09
mg O 0 4.41669385509158e-07
/ O 0 7.410746860614381e-08
ml O 0 3.848365395242581e-07
) O 0 3.546615501281991e-10
obtained O 0 1.6470595720630143e-10
from O 0 8.608303653234728e-11
52 O 0 1.1100744323755407e-08
healthy O 0 1.9504451387319932e-09
volunteers O 0 1.447789110819997e-10
having O 0 3.3960130263466226e-09
phenotype O 0 6.216192360852801e-08
Hp2 O 0 8.212731472667656e-07
, O 0 1.875020139152639e-09
whereas O 0 1.9812762541704387e-10
the O 0 1.2792136239170304e-09
serum O 0 5.005275625080685e-07
Hp O 0 4.245152069870528e-07
level O 0 6.289113674284863e-10
of O 0 1.0304323366794321e-10
an O 0 2.834110501837017e-09
individual O 0 8.802536477503509e-10
with O 0 7.033235647213587e-07
Hp1 O 0 0.0014826304977759719
/ O 0 7.16942213330185e-06
Hpdel O 0 1.245436942554079e-05
was O 0 5.871665962331463e-06
0 O 0 2.8659231432470733e-08
. O 0 8.505283943804898e-08

50 O 0 2.730268988671014e-06
mg O 0 0.00015015434473752975
/ O 0 2.8564754757098854e-05
ml O 0 8.400388469453901e-05
, O 0 2.2322561221699289e-07
which O 0 2.4489706262897926e-08
was O 0 1.6167227556707076e-07
approximately O 0 9.774860781908146e-11
half O 0 1.4298742745388893e-10
the O 0 1.5730927671597783e-10
level O 0 9.004341161578111e-10
of O 0 3.436278206425669e-10
Hp O 0 3.7541593655987526e-07
in O 0 7.939974899784374e-09
control O 0 2.5424068894608354e-07
sera O 0 4.356937552074669e-06
from O 0 2.9264057843647606e-10
the O 0 2.685053512863078e-09
Hp1 O 0 4.541485395748168e-06
phenotype O 0 4.238226480879348e-08
( O 0 6.07029843058271e-11
1 O 0 6.930303553254191e-11
. O 0 1.7589800449524517e-10
26 O 0 1.1480940642627502e-08
+ O 0 5.23051753020809e-08
/ O 0 2.4819250654672942e-08
- O 0 3.0452542887360323e-07
0 O 0 2.634052698180511e-10
. O 0 6.783800604592827e-11
33 O 0 1.6384157364157659e-09
mg O 0 1.419535209379319e-07
/ O 0 1.5714210377382187e-08
ml O 0 1.9362539660505718e-07
; O 0 1.8748664842860308e-09
n O 0 2.4739853188293637e-07
= O 0 3.092968086093606e-07
9 O 0 4.287662136448489e-08
) O 0 1.3899299489139594e-09
, O 0 8.38162650396157e-10
showing O 0 1.2258914772189655e-08
a O 0 3.6798037950092066e-09
gene O 0 1.1184463488689289e-07
- O 0 0.00011479273962322623
dosage O 0 1.458700012335612e-06
effect O 0 3.896908040701419e-08
. O 0 5.8723326645804264e-08

The O 0 3.9745334134977384e-08
other O 0 1.0918975945628517e-08
allele O 0 1.5253547189786332e-06
( O 0 1.3267618115264668e-08
Hp2 O 0 1.0651891898305621e-05
) O 0 3.050978802932036e-09
of O 0 1.82939177695296e-10
individuals O 0 1.9664278538833457e-10
with O 0 6.942723729252975e-08
Hp2 O 0 0.00046291478793136775
/ O 0 3.710347982632811e-06
Hpdel O 0 1.607390004210174e-05
was O 0 4.9959558054979425e-06
found O 0 6.371767113932947e-08
to O 0 9.14694153753004e-10
have O 0 2.4288178135378757e-09
, O 0 2.21964069346825e-09
in O 0 1.4125930980490864e-10
all O 0 5.0417354319209906e-11
exons O 0 1.1030529378786014e-07
, O 0 2.1065792665808658e-08
no O 0 4.606906411908085e-09
mutation O 0 1.2523103665174062e-09
, O 0 4.1873757239407894e-10
by O 0 3.5488487148960246e-10
DNA O 0 5.753228720095649e-07
sequencing O 0 2.5232859570678556e-06
. O 0 4.347091362433275e-07

On O 0 5.769238669017795e-07
the O 0 5.134456859678949e-09
basis O 0 1.3490331074450523e-09
of O 0 1.0816736395469206e-09
the O 0 1.4572017370539925e-08
present O 0 4.9130988166723455e-09
study O 0 5.087574250772775e-10
, O 0 4.81215345349284e-10
the O 0 4.95202712169629e-10
mechanism O 0 1.326192666795123e-08
of O 0 3.906059031777431e-09
anhaptoglobinemia B-Disease 0 2.3436019546352327e-05
and O 0 3.1349689511017687e-09
the O 0 3.6447780904502736e-10
mechanism O 0 5.188266261058061e-09
of O 0 2.1123387761168289e-10
anomalous O 0 2.2973638635903626e-07
inheritance O 0 2.524585624996689e-07
of O 0 1.078518074848489e-08
Hp O 0 3.4778589906636626e-05
phenotypes O 0 4.065742302827857e-07
were O 0 1.122402011333179e-07
well O 0 1.7241015726199294e-08
explained O 0 4.2404869304846216e-07
. O 0 1.963638140978219e-07

However O 0 1.0547727242737892e-06
, O 0 6.959970377806712e-09
the O 0 1.3003103038755626e-09
mechanism O 0 8.023312858540521e-08
of O 0 2.4905222772986235e-08
hypohaptoglobinemia B-Disease 0 0.0005195692647248507
remains O 0 3.128659227513708e-05
unknown O 0 1.0348538125981577e-05

ATM O 0 0.0006576054147444665
mutations O 0 3.220252983737737e-05
and O 0 8.990155947685707e-06
phenotypes O 0 0.00034062250051647425
in O 0 0.0006709576700814068
ataxia B-Disease 1 0.9999839067459106
- I-Disease 1 0.9999804496765137
telangiectasia I-Disease 1 0.9999879598617554
families O 0 2.357819175813347e-05
in O 0 4.236949635583187e-08
the O 0 1.0989704435360181e-07
British O 0 5.2220140787540004e-05
Isles O 0 1.069617246685084e-05
: O 0 1.4000427206450894e-10
expression O 0 1.2605575437640848e-11
of O 0 3.807531026578381e-11
mutant O 0 1.0679660533696733e-07
ATM O 0 2.2709311451762915e-05
and O 0 1.1175080771863577e-07
the O 0 3.051352948091335e-08
risk O 0 6.152403102532844e-07
of O 0 7.259360472744447e-07
leukemia B-Disease 1 0.9988186955451965
, O 0 0.03602733090519905
lymphoma B-Disease 1 0.9999979734420776
, O 0 0.0003096997388638556
and O 0 0.0028471832629293203
breast B-Disease 1 0.9888533353805542
cancer I-Disease 0 0.07194535434246063
. O 0 5.186021098779747e-06

We O 0 1.679569834323047e-07
report O 0 1.9412974339161337e-08
the O 0 3.2260286109142555e-10
spectrum O 0 7.566758775112703e-09
of O 0 6.188374812587938e-10
59 O 0 2.2085295370288804e-07
ATM O 0 2.9415847166092135e-05
mutations O 0 1.713863042596131e-07
observed O 0 5.742873554481775e-07
in O 0 6.412014045054093e-05
ataxia B-Disease 1 0.9999947547912598
- I-Disease 1 0.9999938011169434
telangiectasia I-Disease 1 0.9999942779541016
( O 0 4.7289762733271345e-05
A B-Disease 1 0.9999630451202393
- I-Disease 1 0.9999951124191284
T I-Disease 1 0.9999973773956299
) O 0 1.6351717704310431e-06
patients O 0 7.71832464607769e-09
in O 0 1.4779594215141856e-09
the O 0 7.26714688426e-08
British O 0 0.00011902334517799318
Isles O 0 7.480276690330356e-05
. O 0 4.868632572652132e-07

Of O 0 5.709971162559668e-08
51 O 0 1.6949718428804772e-06
ATM O 0 0.00012846171739511192
mutations O 0 6.776729151170002e-07
identified O 0 4.651195979477052e-07
in O 0 3.6405715775345016e-08
families O 0 1.8666069578898714e-08
native O 0 5.292440374837781e-10
to O 0 5.338601227755646e-10
the O 0 5.34859223577655e-09
British O 0 9.391330422658939e-06
Isles O 0 1.582580262038391e-05
, O 0 1.1481618322761733e-08
11 O 0 2.43920421638677e-08
were O 0 2.862296000216702e-08
founder O 0 4.855718316321145e-07
mutations O 0 5.309085171489869e-09
, O 0 4.819679322309867e-09
and O 0 1.2383657654879698e-08
2 O 0 1.1466977589691396e-08
of O 0 1.0668427946614045e-10
these O 0 2.068083343464977e-10
11 O 0 1.4954418148249715e-08
conferred O 0 1.0091103952447611e-08
a O 0 9.374599763134484e-09
milder O 0 1.1313366599097208e-07
clinical O 0 5.9501957139218575e-08
phenotype O 0 1.3459128922477248e-07
with O 0 6.112549133518996e-09
respect O 0 2.724444558843686e-10
to O 0 1.0061718569431832e-08
both O 0 2.9517593702621525e-07
cerebellar B-Disease 0 0.15548010170459747
degeneration I-Disease 0 0.08379175513982773
and O 0 1.7263563734104537e-07
cellular O 0 3.960352478316054e-05
features O 0 6.163847046991577e-06
. O 0 4.309596079110634e-06

We O 0 3.015867378053372e-07
report O 0 2.314578608775264e-07
, O 0 3.590340691417282e-09
in O 0 1.8973176363346056e-09
two O 0 8.531960702384822e-07
A B-Disease 1 0.9991087317466736
- I-Disease 1 0.9999706745147705
T I-Disease 1 0.9999929666519165
families O 0 3.591109987155505e-07
, O 0 4.8163801835698905e-09
an O 0 8.521319205812006e-10
ATM O 0 3.767286034417339e-05
mutation O 0 4.440335743538526e-08
( O 0 5.824894455663809e-10
7271T O 0 8.469668699717658e-08
- O 0 0.00022521331266034395
- O 0 0.007280525751411915
> O 0 3.486742912173213e-07
G O 0 0.00025049824034795165
) O 0 1.2210073840890345e-08
that O 0 6.556972209637024e-08
may O 0 4.782101825639984e-08
be O 0 1.5558641042190402e-09
associated O 0 1.957776607497408e-09
with O 0 2.0438344350282023e-09
an O 0 9.879403961576827e-09
increased O 0 2.9318391270294342e-08
risk O 0 2.177337563580295e-07
of O 0 1.544196521763297e-07
breast B-Disease 0 0.17572759091854095
cancer I-Disease 0 8.238867303589359e-05
in O 0 7.47267137057861e-09
both O 0 1.0800248695375103e-08
homozygotes O 0 9.290653224525158e-07
and O 0 1.8308148241885647e-07
heterozygotes O 0 3.2432518537461874e-07
( O 0 1.2751892874973692e-09
relative O 0 3.61617651378765e-08
risk O 0 1.5187424651230685e-08
12 O 0 2.5030457706520792e-09
. O 0 2.165445378565778e-09
7 O 0 2.5723073804329033e-07
; O 0 4.48537349484468e-08
P O 0 0.00019812562095467
= O 0 4.927699706058775e-07
. O 0 4.668275543906475e-09
0025 O 0 7.862529400881613e-07
) O 0 2.17783435729757e-09
, O 0 1.8290960968059267e-09
although O 0 6.282304121363325e-10
there O 0 2.4254739883211585e-10
is O 0 8.443772347987988e-10
a O 0 1.8198162976545973e-08
less O 0 3.21444559858719e-07
severe O 0 0.00018562053446657956
A B-Disease 1 0.9989226460456848
- I-Disease 1 0.999985933303833
T I-Disease 1 0.9999957084655762
phenotype O 0 9.960802344721742e-06
in O 0 2.698340217932582e-09
terms O 0 2.7688534798286923e-10
of O 0 1.4521726876548513e-10
the O 0 1.168569596643465e-08
degree O 0 1.5071425707446906e-07
of O 0 3.705181654822809e-07
cerebellar B-Disease 1 0.7923587560653687
degeneration I-Disease 1 0.8140103816986084
. O 0 1.130328655563062e-05

This O 0 7.537534685297942e-08
mutation O 0 3.484080650650867e-07
( O 0 1.095590018707071e-08
7271T O 0 1.2376735867292155e-06
- O 0 0.0011389993596822023
- O 0 0.00926240161061287
> O 0 6.29734756785183e-07
G O 0 0.000703451398294419
) O 0 3.253292968352639e-09
also O 0 4.2921988185895543e-10
allows O 0 4.8962153775811146e-12
expression O 0 9.24663731000086e-12
of O 0 1.5865763564049118e-11
full O 0 2.5887196830609582e-09
- O 0 5.30430770595558e-06
length O 0 4.834412692389378e-08
ATM O 0 4.302184152038535e-06
protein O 0 1.5441655731862625e-09
at O 0 1.815122452342166e-08
a O 0 1.6335230945685453e-09
level O 0 4.473623249623415e-09
comparable O 0 1.4345743259980281e-08
with O 0 1.303300578570088e-08
that O 0 1.5168092204476125e-07
in O 0 2.0671296852015075e-07
unaffected O 0 5.793007403553929e-06
individuals O 0 2.0910579934252382e-09
. O 0 2.1953356110770983e-07

In O 0 1.647371448143531e-07
addition O 0 6.219237569382585e-09
, O 0 5.370089262157762e-09
we O 0 3.5939834441833796e-10
have O 0 9.316925009272836e-11
studied O 0 2.890344852346516e-09
18 O 0 4.717917647667491e-07
A B-Disease 1 0.9978722333908081
- I-Disease 1 0.9999881982803345
T I-Disease 1 0.9999979734420776
patients O 0 2.8933698104083305e-07
, O 0 6.5022840445294605e-09
in O 0 1.1699473612125644e-09
15 O 0 2.841592561253492e-08
families O 0 3.8926291523466716e-08
, O 0 6.394375162699362e-08
who O 0 1.4921074580342975e-06
developed O 0 5.755074380431324e-05
leukemia B-Disease 1 0.9948219060897827
, O 0 0.0016697699902579188
lymphoma B-Disease 1 0.9999966621398926
, O 0 2.800565562210977e-05
preleukemic O 0 0.01616569235920906
T O 0 0.09892469644546509
- O 0 0.00022255869407672435
cell O 0 0.0004183429991826415
proliferation O 0 0.0005639746086671948
, O 0 2.067795549010043e-06
or O 0 0.002459906740114093
Hodgkin B-Disease 1 0.9999681711196899
lymphoma I-Disease 1 0.9999974966049194
, O 0 1.1050507964682765e-05
mostly O 0 2.825492551039588e-08
in O 0 3.040007925392274e-07
childhood O 0 6.372100324369967e-05
. O 0 2.404927954557934e-06

A O 0 1.3345672869036207e-06
wide O 0 6.371851668518502e-08
variety O 0 3.422354399873484e-09
of O 0 1.2436435214979724e-09
ATM O 0 0.00023841505753807724
mutation O 0 1.350656333443112e-07
types O 0 9.990964144890313e-08
, O 0 7.568205262487027e-08
including O 0 1.026570739526278e-08
missense O 0 7.294294732673734e-07
mutations O 0 6.468146551696918e-08
and O 0 1.1240494046660388e-07
in O 0 6.088929893621753e-08
- O 0 0.0010945153189823031
frame O 0 0.005649794824421406
deletions O 0 1.2461798633012222e-06
, O 0 5.296071137195213e-08
were O 0 1.0590549948119587e-07
seen O 0 2.9210784191491257e-07
in O 0 3.3025586709811705e-09
these O 0 5.518921764036122e-09
patients O 0 5.431548188994384e-08
. O 0 2.2460724835582369e-07

We O 0 1.9363389469617687e-07
also O 0 2.2042469183247704e-08
show O 0 2.490802586407881e-08
that O 0 3.826222894076636e-09
25 O 0 1.9374124526905234e-09
% O 0 4.324392233190366e-11
of O 0 7.181800293354357e-11
all O 0 1.539058835930973e-08
A B-Disease 1 0.9991814494132996
- I-Disease 1 0.9999521970748901
T I-Disease 1 0.9999935626983643
patients O 0 2.3869350940231016e-08
carried O 0 1.7932750040472456e-07
in O 0 1.2644846947296173e-08
- O 0 0.0004250109486747533
frame O 0 0.0022400333546102047
deletions O 0 1.1699276001309045e-06
or O 0 1.1554207901554037e-07
missense O 0 9.001033163258398e-07
mutations O 0 1.6527201296412386e-07
, O 0 8.280490959577946e-09
many O 0 3.2744557065811364e-11
of O 0 2.1097468216879633e-09
which O 0 4.2137713762713247e-07
were O 0 4.7170806283247657e-07
also O 0 1.550039172570905e-07
associated O 0 1.103652191858373e-08
with O 0 3.3294136336792235e-09
expression O 0 4.1196110411867437e-10
of O 0 1.9570771392363184e-10
mutant O 0 5.131366265231918e-07
ATM O 0 7.844192441552877e-05
protein O 0 1.281341752701337e-07
. O 0 1.0194919042305628e-07

The O 0 4.624869234248763e-07
DMPK O 0 0.00040419044671580195
gene O 0 2.475444262017845e-06
of O 0 1.1171238156748586e-06
severely O 1 0.970027506351471
affected O 0 0.010551773011684418
myotonic B-Disease 1 0.999980092048645
dystrophy I-Disease 1 0.9999909400939941
patients O 0 5.817042983835563e-05
is O 0 1.0131470844498836e-06
hypermethylated O 0 0.0004508262500166893
proximal O 0 3.3936510590137914e-05
to O 0 1.071303401545265e-08
the O 0 8.336065171477003e-09
largely O 0 6.477825564843442e-08
expanded O 0 5.8427374938219145e-08
CTG O 0 6.726886931573972e-05
repeat O 0 4.091467417310923e-06
. O 0 2.397647165253147e-07

Using O 0 5.9291693332852446e-08
methylation O 0 2.041340167124872e-06
- O 0 3.90458844776731e-05
sensitive O 0 4.5019416461400397e-07
restriction O 0 1.7333899648974693e-08
enzymes O 0 1.8680459845654696e-08
, O 0 1.1189429827140884e-08
we O 0 8.528733830281965e-10
characterized O 0 8.853813682208056e-09
the O 0 5.50610224081538e-10
methylation O 0 5.0366104176191584e-08
pattern O 0 2.7746565933739475e-07
on O 0 1.2813100624953222e-07
the O 0 1.3590828906728802e-08
5 O 0 4.040458279064296e-08
side O 0 1.8192817918816218e-08
of O 0 7.663440715344194e-11
the O 0 5.642809330907994e-09
CTG O 0 1.1020925740012899e-05
repeat O 0 1.1251734832740112e-07
in O 0 9.255116117934392e-10
the O 0 8.191984868233249e-09
DMPK O 0 2.694544309633784e-05
gene O 0 2.187125591746053e-09
of O 0 5.018174764614969e-10
normal O 0 7.916022504161901e-09
individuals O 0 1.7835066756788365e-10
and O 0 1.6872267138978714e-08
of O 0 1.9173306498032616e-08
patients O 0 1.1976814562331128e-07
affected O 0 6.896977566839269e-08
with O 0 0.002389700850471854
myotonic B-Disease 1 0.9999977350234985
dystrophy I-Disease 1 0.9999969005584717
, O 0 8.835597327561118e-06
showing O 0 4.6598456719948445e-06
expansions O 0 2.168387709389208e-07
of O 0 6.721108114504659e-10
the O 0 5.868981745038582e-09
repetitive O 0 1.937633442139486e-06
sequence O 0 2.1536789063247852e-07
. O 0 2.2183353394211736e-06

The O 0 2.6670678110463086e-08
gene O 0 2.9035909676622396e-08
segment O 0 2.442291417992237e-07
analyzed O 0 4.0252515987049264e-08
corresponds O 0 2.8863067491613492e-09
to O 0 1.4416470794920144e-10
the O 0 1.6368445487913164e-09
genomic O 0 7.512044248869643e-07
SacI O 0 1.2615533705684356e-05
- O 0 1.707782575977035e-05
HindIII O 0 3.5256946375739062e-06
fragment O 0 5.967356742075935e-08
carrying O 0 1.889251421971494e-08
exons O 0 1.4440487916544953e-07
11 O 0 3.8962173221079865e-07
- O 0 5.43450987606775e-05
15 O 0 3.447074448104104e-07
. O 0 1.5484287985145784e-07

There O 0 1.60371172341911e-07
is O 0 4.6857246971399036e-09
constitutive O 0 1.194995391529119e-08
methylation O 0 9.917847165752391e-08
in O 0 8.387004868382064e-09
intron O 0 3.542101330822334e-05
12 O 0 1.2066975330071728e-07
at O 0 6.868254587288902e-08
restriction O 0 7.262317414102881e-10
sites O 0 4.5364581535700665e-10
of O 0 4.745208115330968e-10
SacII O 0 5.161253284313716e-06
and O 0 4.1249617055427734e-08
HhaI O 0 1.4371837551152566e-06
, O 0 5.7579113699191e-10
localized O 0 7.867639317815645e-10
1 O 0 8.741684043300779e-10
, O 0 3.656226654769057e-09
159 O 0 2.814203696743789e-07
- O 0 6.4789410316734575e-06
1 O 0 2.9852071925517976e-09
, O 0 1.4255316926892192e-09
232 O 0 2.0120182853133883e-08
bp O 0 1.4250436208840256e-07
upstream O 0 5.726663032668e-10
of O 0 1.4389568529782348e-11
the O 0 1.0490380786265519e-09
CTG O 0 2.7575463263929123e-06
repeat O 0 9.260279654199621e-08
, O 0 6.765210058823357e-10
whereas O 0 2.706931900853249e-10
most O 0 2.8964303178113937e-10
, O 0 8.753517910520259e-09
if O 0 1.3746750404663999e-09
not O 0 1.7233205140687602e-10
all O 0 2.365006801507974e-11
, O 0 4.1760578328720044e-10
of O 0 1.2866757138907392e-11
the O 0 2.1930812721393522e-10
other O 0 5.5606106524885845e-11
sites O 0 3.0321825050805273e-09
of O 0 1.4277192761369406e-09
SacII O 0 1.2568149031721987e-05
, O 0 2.703266233083923e-08
HhaI O 0 9.6272731298086e-07
, O 0 1.6616193976304316e-09
and O 0 9.353810170864563e-09
HpaII O 0 9.740989526108024e-07
in O 0 1.032045671145454e-09
this O 0 9.654366889266797e-11
region O 0 3.647900870262788e-10
are O 0 6.10278078072568e-11
unmethylated O 0 2.8968736387469107e-07
, O 0 7.140272373362677e-09
in O 0 1.217513867501907e-09
normal O 0 4.825142507769442e-09
individuals O 0 2.808221710726144e-10
and O 0 3.4304123985862134e-09
most O 0 6.636811239468798e-11
of O 0 1.035926899817241e-09
the O 0 1.432770204701228e-07
patients O 0 7.87383243050499e-08
. O 0 1.9504280146520614e-07

In O 0 1.0500559710635571e-07
a O 0 2.510279539791327e-09
number O 0 1.931272225474956e-10
of O 0 2.479084937334619e-09
young O 0 2.0831299707424478e-07
and O 0 6.50899949050654e-07
severely O 0 0.003832561429589987
affected O 0 4.446369672450601e-08
patients O 0 6.913095429439409e-09
, O 0 1.6475073749688818e-08
however O 0 6.209471159479563e-09
, O 0 1.4958946303877951e-09
complete O 0 2.0956656410220376e-09
methylation O 0 1.5705310829616792e-08
of O 0 3.830088676770593e-11
these O 0 2.8621056913369358e-11
restriction O 0 1.492013623760613e-09
sites O 0 9.098469533341813e-09
was O 0 6.082440449972637e-06
found O 0 1.1886331208188494e-07
in O 0 5.055604268555669e-10
the O 0 2.0459991478816164e-09
mutated O 0 1.453169460319259e-07
allele O 0 1.2902875141662662e-06
. O 0 4.5551215066552686e-07

In O 0 8.533818629530288e-08
most O 0 9.198237727048308e-10
of O 0 7.947303370947623e-10
these O 0 3.0506994708190405e-09
patients O 0 7.058970297180167e-09
, O 0 6.491156057109038e-09
the O 0 1.0606960643144703e-08
onset O 0 1.9201397662982345e-06
of O 0 2.3100660939689988e-08
the O 0 0.00020035360648762435
disease O 0 0.07873094826936722
was O 1 0.718798816204071
congenital O 1 0.9998729228973389
. O 0 6.297940126387402e-05

Preliminary O 0 1.3388083743848256e-06
in O 0 4.1958668361985474e-07
vivo O 0 1.673159931669943e-05
footprinting O 0 5.0704737077467144e-05
data O 0 1.2506274060797296e-07
gave O 0 2.427309198083094e-08
evidence O 0 9.779010490262863e-09
for O 0 4.901368200194156e-10
protein O 0 2.6533934160966055e-08
- O 0 1.4060624380363151e-05
DNA O 0 3.0280398277682252e-06
contact O 0 9.050839366864238e-08
in O 0 1.6040313521870075e-09
normal O 0 1.494309120886328e-09
genes O 0 3.5199032577537537e-09
at O 0 2.850148064226232e-07
an O 0 1.366532575985957e-08
Sp1 O 0 1.7981777773456997e-06
consensus O 0 3.4118852187958737e-10
binding O 0 8.196716638764201e-10
site O 0 1.2616996336589636e-08
upstream O 0 2.360259321321223e-09
of O 0 6.694889087555111e-11
the O 0 3.598773501423125e-09
CTG O 0 6.539320565934759e-06
repeat O 0 2.8590991973942437e-07
and O 0 2.84449774845541e-09
for O 0 5.405938890978845e-11
a O 0 3.5665610464974407e-09
significant O 0 2.0421112023605303e-10
reduction O 0 1.556908935107515e-09
of O 0 1.1754239075123518e-11
this O 0 1.0394965270499323e-11
interaction O 0 2.0111098550379403e-11
in O 0 7.627512510488543e-10
cells O 0 5.095802890764389e-09
with O 0 6.429790921913536e-09
a O 0 5.937962441748823e-07
hypermethylated O 0 0.003443789202719927
DMPK O 0 0.00016786596097517759
gene O 0 9.847819626429555e-08
. O 0 2.0423936319957647e-08
. O 0 1.262923348122058e-07

The O 0 1.1054049537051469e-05
hemochromatosis B-Disease 1 0.9990780353546143
gene O 0 3.030001380466274e-06
product O 0 5.123728215039591e-07
complexes O 0 1.6390423240864038e-07
with O 0 5.761121801839408e-09
the O 0 6.752360892647857e-09
transferrin O 0 1.9019691990251886e-06
receptor O 0 6.688590570291808e-09
and O 0 1.7081999814649862e-08
lowers O 0 1.89772080716466e-07
its O 0 2.0431591141178984e-10
affinity O 0 2.8885867031647194e-09
for O 0 1.3874157378523932e-10
ligand O 0 2.018937905745588e-08
binding O 0 2.7299310545458866e-07
. O 0 4.2454274762349087e-07

We O 0 7.430632535943005e-07
recently O 0 2.3566360596305458e-06
reported O 0 4.0228883335657883e-07
the O 0 1.4834347639158807e-10
positional O 0 1.708825614343823e-08
cloning O 0 7.887041988396959e-07
of O 0 9.749803187020234e-10
a O 0 2.4392832642661233e-08
candidate O 0 8.452771993461283e-08
gene O 0 1.3799884754917002e-06
for O 0 2.0116967789363116e-05
hereditary B-Disease 1 0.99998939037323
hemochromatosis I-Disease 1 0.9999949932098389
called O 0 0.04400647059082985
HFE O 0 0.3577587902545929
. O 0 1.8890563296736218e-05

The O 0 6.194757418143126e-08
gene O 0 1.8541545898642653e-07
product O 0 2.2899749296811933e-07
, O 0 8.913337623539519e-09
a O 0 9.154970115332617e-10
member O 0 3.920505586840761e-11
of O 0 7.32664831581964e-11
the O 0 3.3574791835633278e-09
major O 0 3.824712102584726e-09
histocompatibility O 0 1.356310235678393e-06
complex O 0 1.552489123923806e-07
class O 0 3.76015698577703e-08
I O 0 2.0643237803597003e-06
- O 0 0.0001282609737245366
like O 0 9.193544769914297e-08
family O 0 2.615607400002773e-06
, O 0 3.884122534714152e-08
was O 0 1.9129820429952815e-06
found O 0 4.149360322003304e-08
to O 0 3.225874845025345e-10
have O 0 5.266229119449406e-10
a O 0 1.0269834982423731e-09
mutation O 0 4.106433415529409e-09
, O 0 1.2447143760141444e-08
Cys O 0 7.04556032360415e-06
- O 0 4.316135800763732e-06
282 O 0 2.423907744741882e-06
- O 0 0.000425593345426023
- O 0 0.00036304505192674696
> O 0 3.3466690751993156e-08
Tyr O 0 4.971778935214388e-07
( O 0 3.13039649757485e-10
C282Y O 0 2.4905936868435674e-08
) O 0 1.0341817402448328e-09
, O 0 8.913537685728556e-10
in O 0 1.737987531669205e-09
85 O 0 1.4171553708308693e-08
% O 0 2.7252658463261525e-10
of O 0 8.597724199255197e-10
patient O 0 3.720130337114824e-07
chromosomes O 0 1.343083113169996e-05
. O 0 1.5901603092061123e-06

This O 0 3.6296722072393095e-08
mutation O 0 6.071048375133614e-08
eliminates O 0 7.897760383457353e-07
the O 0 1.0003660122492875e-08
ability O 0 9.003143119912238e-09
of O 0 2.2569399682481617e-09
HFE O 0 2.145136932085734e-05
to O 0 1.036474905902196e-08
associate O 0 2.7642599320643058e-08
with O 0 1.7282638964388752e-07
beta2 O 0 0.011088566854596138
- O 0 0.3574219346046448
microglobulin O 0 0.02648988366127014
( O 0 1.636467672483377e-08
beta2m O 0 1.2558060916489922e-05
) O 0 3.0201423584230724e-09
and O 0 5.516332279853486e-09
prevents O 0 2.051874048447644e-08
cell O 0 5.5660690122749656e-05
- O 0 0.00013203115668147802
surface O 0 9.460368346481118e-06
expression O 0 1.2222055545407784e-07
. O 0 6.002974259899929e-07

A O 0 3.5900800412491662e-06
second O 0 7.587094046357379e-07
mutation O 0 3.6749105447597685e-07
that O 0 6.744357250454414e-08
has O 0 1.1153338874692054e-07
no O 0 6.633957827517634e-09
effect O 0 1.3191741032869686e-08
on O 0 1.7666162648311001e-06
beta2m O 0 0.0010391942923888564
association O 0 1.0232221292483246e-08
, O 0 1.4118242575023032e-08
H63D O 0 8.69400828378275e-05
, O 0 1.6644559508449674e-08
was O 0 8.554121109227708e-07
found O 0 8.092241898793873e-08
in O 0 1.0976958231267986e-09
eight O 0 5.000082126116467e-09
out O 0 1.2537473281781786e-08
of O 0 1.1082481599089533e-09
nine O 0 1.20714176432557e-07
patients O 0 8.218900005019236e-10
heterozygous O 0 9.512294285585199e-10
for O 0 2.1973185770907122e-10
the O 0 1.1780718622844688e-08
C282Y O 0 4.257219643477583e-06
mutant O 0 5.21077436133055e-06
. O 0 5.314168447512202e-07

In O 0 3.67852209137709e-07
this O 0 1.2121526005159922e-08
report O 0 7.609588692503166e-08
, O 0 9.38989552778935e-10
we O 0 2.3014440353463783e-10
demonstrate O 0 4.085821680988033e-10
in O 0 2.2400158117275026e-10
cultured O 0 1.484390708128558e-07
293 O 0 3.699871058415738e-07
cells O 0 9.49406739891856e-08
overexpressing O 0 1.3497141253537848e-06
wild O 0 1.3042422608577908e-07
- O 0 6.979491445235908e-05
type O 0 1.5165402089678537e-07
or O 0 6.547736575157614e-08
mutant O 0 5.936207116974401e-07
HFE O 0 2.0997993033233797e-06
proteins O 0 1.920755776652072e-09
that O 0 7.140718016884762e-10
both O 0 2.380331209916875e-10
the O 0 8.10206035595229e-09
wild O 0 7.489668405469274e-07
- O 0 0.001633225823752582
type O 0 4.2073145323229255e-07
and O 0 7.039738534331264e-07
H63D O 0 0.00018373584316577762
HFE O 0 6.251534159673611e-06
proteins O 0 3.6031690964222207e-09
form O 0 4.621407978522285e-10
stable O 0 1.484501126469695e-07
complexes O 0 5.930616708837988e-08
with O 0 7.1281069935480446e-09
the O 0 8.277935847900153e-08
transferrin O 0 5.028992745792493e-05
receptor O 0 2.277447350707007e-07
( O 0 1.0598183664001226e-08
TfR O 0 6.440597644541413e-06
) O 0 2.7952388848007104e-08
. O 0 6.387232076576765e-08

The O 0 8.989231048417423e-08
C282Y O 0 2.548077418396133e-06
mutation O 0 4.1264496530857286e-07
nearly O 0 8.724419586769727e-08
completely O 0 1.6799250488475082e-06
prevents O 0 9.641296827567203e-08
the O 0 2.4106533658141416e-08
association O 0 2.9763549402872513e-09
of O 0 3.904498599438533e-11
the O 0 5.90372994935251e-09
mutant O 0 3.330620756969438e-06
HFE O 0 1.372665155940922e-05
protein O 0 7.716500327603626e-09
with O 0 2.1998955546109755e-08
the O 0 2.823774423177383e-07
TfR O 0 0.00017361663049086928
. O 0 4.0374087006966874e-07

Studies O 0 2.1726455656789767e-07
on O 0 9.384887675878417e-07
cell O 0 0.0006947217043489218
- O 0 0.004964934661984444
associated O 0 8.871158456713601e-07
transferrin O 0 4.051203632116085e-06
at O 0 1.455108247228054e-07
37 O 0 8.652345506732217e-09
degrees O 0 2.9293907743976888e-08
C O 0 9.629541182221146e-07
suggest O 0 3.4463356612945972e-09
that O 0 1.212311473430816e-09
the O 0 2.497928308642372e-09
overexpressed O 0 1.126982397181564e-06
wild O 0 4.5386437363958976e-07
- O 0 0.0010593886254355311
type O 0 8.610579698142828e-07
HFE O 0 4.012376848550048e-06
protein O 0 3.556602123921948e-09
decreases O 0 6.439704325345019e-10
the O 0 6.72195077378035e-11
affinity O 0 4.039085066409598e-09
of O 0 3.674051063384809e-10
the O 0 3.210526600128105e-08
TfR O 0 8.39126732898876e-06
for O 0 9.432119085772683e-09
transferrin O 0 4.4843240175396204e-05
. O 0 1.9625149150215293e-07

The O 0 4.2281138235011895e-07
overexpressed O 0 0.0001392664125887677
H63D O 0 0.0009054379188455641
protein O 0 2.173269422200974e-07
does O 0 4.571665712660433e-09
not O 0 3.7434441657602235e-10
have O 0 3.207401844118607e-10
this O 0 1.1001895228179848e-10
effect O 0 8.654667538188221e-10
, O 0 1.2215278788474393e-10
providing O 0 3.695426777083899e-12
the O 0 5.207534750639731e-11
first O 0 1.5546293419266277e-10
direct O 0 5.6427286454496794e-11
evidence O 0 4.524570051955834e-09
for O 0 1.7613267788707532e-10
a O 0 1.3738238990868012e-08
functional O 0 5.0697144260425375e-09
consequence O 0 5.984759798849382e-09
of O 0 2.0209856010922067e-10
the O 0 1.1293898438680117e-07
H63D O 0 0.0029164168518036604
mutation O 0 9.528842497275036e-07
. O 0 3.2443531949866156e-07

Addition O 0 7.404204893646238e-08
of O 0 1.0333343070101364e-08
soluble O 0 9.046884770214092e-07
wild O 0 1.6906694781937404e-06
- O 0 0.0044008358381688595
type O 0 1.2589955986186396e-05
HFE O 0 0.0018205425003543496
/ O 0 2.80690765066538e-05
beta2m O 0 1.5339544916059822e-05
heterodimers O 0 3.35099400672334e-07
to O 0 3.5097802442152215e-09
cultured O 0 9.01390876606456e-07
cells O 0 3.04707867826437e-07
also O 0 9.168871173415027e-08
decreased O 0 2.6967516220111065e-08
the O 0 9.443004156395318e-10
apparent O 0 7.447857797160395e-07
affinity O 0 2.6594380031497167e-08
of O 0 9.69776148274093e-10
the O 0 1.1642625530328132e-08
TfR O 0 3.688118681566266e-07
for O 0 1.557647066885437e-11
its O 0 6.51789802685876e-11
ligand O 0 5.776236711163563e-10
under O 0 2.521604702820923e-09
steady O 0 8.747545052756323e-07
- O 0 2.108362787112128e-05
state O 0 1.0483565127117345e-08
conditions O 0 1.2460832010674494e-07
, O 0 9.273847245694355e-10
both O 0 4.3067199112512e-11
in O 0 1.3254257691386329e-09
293 O 0 1.7964552512239607e-07
cells O 0 1.953845618629657e-08
and O 0 1.3670513610009039e-08
in O 0 4.0101550524695995e-08
HeLa O 0 0.0002934990043286234
cells O 0 5.703787451238895e-07
. O 0 8.688019903502209e-08

Furthermore O 0 9.037778454512591e-07
, O 0 6.996909007739305e-08
at O 0 1.5304182454656257e-07
4 O 0 3.860583674963891e-08
degrees O 0 8.812271090619106e-08
C O 0 3.58667830369086e-06
, O 0 4.005145992636017e-09
the O 0 3.3128297882711877e-09
added O 0 1.8885511110511288e-07
soluble O 0 1.0814843243167616e-08
complex O 0 1.2052985276511663e-08
of O 0 7.222055842248665e-09
HFE O 0 0.0005052732303738594
/ O 0 5.511683411896229e-06
beta2m O 0 2.901725110859843e-06
inhibited O 0 1.0253398130544156e-08
binding O 0 8.713800792037318e-10
of O 0 1.3342518756509492e-10
transferrin O 0 2.9469777018675813e-07
to O 0 2.1269872529927625e-09
HeLa O 0 8.440771125606261e-06
cell O 0 2.6989058824256063e-05
TfR O 0 3.6367448501550825e-06
in O 0 9.767952002803781e-10
a O 0 1.98539797935382e-08
concentration O 0 3.0396536203625146e-06
- O 0 0.0002073003852274269
dependent O 0 7.03596043649668e-08
manner O 0 2.9527615197366686e-07
. O 0 5.704821433027973e-07

Scatchard O 0 7.633921632077545e-05
plots O 0 1.6284757293760777e-05
of O 0 6.8868009073241865e-09
these O 0 9.31586252583827e-10
data O 0 1.8057816575378638e-08
indicate O 0 2.7733749519143203e-08
that O 0 1.6903635158271868e-09
the O 0 3.926975633561369e-09
added O 0 4.560485677984616e-08
heterodimer O 0 3.6994823204850036e-08
substantially O 0 1.2570708918246964e-08
reduced O 0 2.8668825646782636e-10
the O 0 1.284597012096711e-10
affinity O 0 2.145621813554044e-08
of O 0 6.91095936034003e-09
TfR O 0 7.658155482204165e-06
for O 0 7.656376865838865e-09
transferrin O 0 3.170117633999325e-05
. O 0 1.3966919709673675e-07

These O 0 2.241706376082675e-08
results O 0 2.4619858152163943e-08
establish O 0 2.0706023562411247e-09
a O 0 1.915327629831154e-08
molecular O 0 1.1793914609370404e-06
link O 0 7.637354428879917e-06
between O 0 5.994610887682938e-07
HFE O 0 0.0003869457286782563
and O 0 1.0938719441355715e-07
a O 0 4.396209174473142e-09
key O 0 2.221399597601703e-08
protein O 0 9.240440079771872e-10
involved O 0 1.1152648804468868e-09
in O 0 8.067887691254327e-09
iron O 0 0.00012070533557562158
transport O 0 6.934200769137533e-08
, O 0 2.414167310504922e-09
the O 0 8.449834609791651e-09
TfR O 0 6.861615474917926e-06
, O 0 1.0231752334277644e-08
and O 0 4.411159881811955e-09
raise O 0 7.38189065430106e-10
the O 0 5.226742372244075e-10
possibility O 0 1.9290238295610607e-09
that O 0 2.9424591652116305e-09
alterations O 0 1.2811407934520957e-08
in O 0 8.677991658601059e-10
this O 0 2.0028192992960214e-10
regulatory O 0 2.060211379273369e-08
mechanism O 0 7.307803429057458e-08
may O 0 1.8514946020786738e-08
play O 0 6.80772868633106e-11
a O 0 5.044757944716594e-10
role O 0 5.391587731828906e-10
in O 0 1.4383957358532484e-09
the O 0 2.1138683692356608e-08
pathogenesis O 0 9.660721843829378e-05
of O 0 7.511380772484699e-06
hereditary B-Disease 1 0.9999909400939941
hemochromatosis I-Disease 1 0.9999967813491821
. O 0 4.8933223297353834e-05
. O 0 5.3603876040142495e-06

Genomic O 0 4.972227543476038e-06
organization O 0 3.410756477251198e-08
of O 0 2.209448402012981e-09
the O 0 4.876596548797352e-08
UBE3A O 0 0.0003823412407655269
/ O 0 2.283304820593912e-05
E6 O 0 0.012101656757295132
- O 0 0.04380716010928154
AP O 0 2.161747033824213e-05
gene O 0 3.044481289293799e-08
and O 0 8.053363131921287e-08
related O 0 3.583907925985841e-07
pseudogenes O 0 2.9577686291304417e-06
. O 0 1.5853801187404315e-06

The O 0 1.3322727454578853e-07
UBE3A O 0 8.771939974394627e-06
gene O 0 2.874057614121739e-08
encodes O 0 4.7665114522033036e-08
the O 0 4.1251034588185576e-08
E6 O 0 0.011052979156374931
- O 0 0.061638906598091125
AP O 0 2.3442009478458203e-05
ubiquitin O 0 2.2996925963525428e-06
- O 0 3.5210778150940314e-06
protein O 0 3.81048437247955e-09
ligase O 0 1.2382334269034345e-08
and O 0 1.2001804883254863e-08
has O 0 2.284581945843911e-08
recently O 0 1.2862659559687017e-07
been O 0 5.91335425070838e-09
shown O 0 1.1501932739577114e-09
to O 0 1.0947513034986756e-10
be O 0 4.716083967792883e-09
mutated O 0 2.456241963955108e-05
in O 0 0.3912948668003082
Angelman B-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999983310699463
patients O 0 2.3306338334805332e-06
who O 0 7.937522923384677e-07
lack O 0 4.785039564580984e-08
15q11 O 0 3.2037662549555534e-06
- O 0 0.00031625383417122066
q13 O 0 2.5465130875090836e-06
deletions O 0 1.017360546029522e-06
or O 0 1.3100517435304937e-06
chromosome O 0 0.00020230085647199303
15 O 0 1.7364795894536655e-06
paternal O 0 0.00019982265075668693
uniparental B-Disease 0 0.0681731179356575
disomy I-Disease 0 0.018730735406279564
. O 0 3.0593303108616965e-06

Previous O 0 9.020453717312193e-07
UBE3A O 0 2.283849062223453e-05
cDNA O 0 6.477949341388012e-07
analysis O 0 5.188031693137418e-08
has O 0 6.263334029199541e-08
shown O 0 9.546706536411875e-09
a O 0 3.9844669785793485e-09
coding O 0 6.949427188374102e-06
region O 0 8.077896573865928e-09
of O 0 5.444497630513467e-10
approximately O 0 7.3837811420673916e-09
2 O 0 3.560670620572637e-07
. O 0 5.164515073374787e-07

6 O 0 2.190083614550531e-05
kb O 0 0.00022565483232028782
and O 0 6.796683749143995e-08
a O 0 3.945235604874142e-08
3 O 0 3.6507591971712827e-07
- O 0 0.0018081176094710827
untranslated O 0 0.0001612889172974974
region O 0 1.2087915024494578e-07
( O 0 1.095572743636808e-09
UTR O 0 2.301021169159867e-07
) O 0 1.6335502395214974e-10
of O 0 1.1036468960945456e-10
< O 0 7.117917366628035e-09
50 O 0 1.1278453726504267e-09
bp O 0 8.843064733810024e-07
, O 0 1.0326994814846557e-09
whereas O 0 9.883446144831609e-11
Northern O 0 1.0383714721395876e-10
analysis O 0 7.864593976059098e-10
has O 0 1.272568272980834e-08
indicated O 0 2.4776289908601257e-09
mRNA O 0 2.8878510693886028e-11
sizes O 0 6.420694531605875e-10
of O 0 9.159786817924953e-11
5 O 0 7.614974606440228e-08
- O 0 6.26405089860782e-05
8 O 0 1.0313711982234963e-06
kb O 0 0.0001676078245509416
. O 0 2.2952966105549422e-07

We O 0 4.914506845921096e-08
have O 0 5.366307953558191e-10
analyzed O 0 4.09496520026309e-10
additional O 0 2.795666649568762e-11
cDNA O 0 5.257643564959835e-08
clones O 0 1.3314844409251236e-06
and O 0 7.768274024044786e-09
provide O 0 3.7078194681239296e-11
evidence O 0 1.849905229001081e-09
for O 0 4.279624224445833e-11
an O 0 3.1482699780482903e-10
additional O 0 5.934276403607441e-10
0 O 0 2.017794464848066e-08
. O 0 9.458045724386466e-08

5 O 0 1.5936415138639859e-06
kb O 0 2.296201273566112e-05
of O 0 3.6738008191150584e-09
5 O 0 8.013616081825603e-08
- O 0 3.943122646887787e-05
UTR O 0 3.398002036192338e-06
and O 0 1.4936828662825974e-08
> O 0 1.591557774460739e-09
2 O 0 7.531883561284758e-09
kb O 0 4.442226781975478e-06
of O 0 1.667130322680066e-09
3 O 0 1.2980012797925156e-06
- O 0 0.00260821171104908
UTR O 0 6.382519495673478e-05
. O 0 1.36664127126096e-07

We O 0 1.3829446743329754e-07
have O 0 1.199836563436918e-09
established O 0 6.469247360030295e-11
the O 0 2.2259609433472605e-10
genomic O 0 7.751371988717892e-09
organization O 0 4.3164918861471335e-10
of O 0 9.79917147425624e-10
UBE3A O 0 4.591006472765002e-06
and O 0 1.832591633998959e-09
the O 0 1.1744048789008588e-10
sequence O 0 6.026567023198481e-10
of O 0 3.0314655230512244e-09
intron O 0 0.0019256181549280882
- O 0 0.003796850098297
exon O 0 5.3113457397557795e-05
borders O 0 4.114937382837525e-06
. O 0 8.19875481283816e-07

We O 0 2.865197075152537e-07
have O 0 9.934675304634766e-09
also O 0 1.7997943135839023e-09
mapped O 0 2.0973420333803006e-08
two O 0 4.3011888495314565e-10
highly O 0 3.539945003794287e-10
homologous O 0 7.070990015733969e-09
processed O 0 6.898408955180457e-09
pseudogenes O 0 2.307930202505304e-08
, O 0 1.801347515595353e-08
UBE3AP1 O 0 3.689817094709724e-05
and O 0 1.7967876431157492e-07
UBE3AP2 O 0 3.352810745127499e-05
, O 0 9.74257230446085e-10
to O 0 8.254180672295774e-11
chromosomes O 0 6.081362613485908e-08
2 O 0 1.521412684724055e-08
and O 0 3.04649709903515e-08
21 O 0 4.752494930926332e-08
, O 0 2.1398061988975314e-08
respectively O 0 2.0008132040061355e-08
, O 0 6.077487402222914e-09
and O 0 2.445995628264086e-09
determined O 0 4.1480370249757925e-09
their O 0 8.957543040644111e-10
genomic O 0 6.788263107182502e-08
organization O 0 1.2432527896066858e-08
. O 0 1.127205493389738e-07

These O 0 1.022627387214925e-07
results O 0 3.0776033099755296e-07
will O 0 2.1322392740330542e-09
form O 0 3.61449550845272e-11
the O 0 2.2590145032364006e-10
basis O 0 1.2279712802154563e-09
for O 0 8.045924482225075e-10
studies O 0 5.895602339656136e-10
of O 0 1.0624261886915676e-10
mutation O 0 8.909496251874316e-09
and O 0 1.7770771520986273e-08
imprinting O 0 2.0840268916799687e-05
of O 0 1.2696787621280237e-07
UBE3A O 0 0.0008878548396751285
. O 0 1.0384893585069221e-06

Mutation O 0 3.939291673304979e-06
spectrum O 0 3.7571639950328972e-06
and O 0 1.2062607765983557e-06
genotype O 0 2.024931563937571e-05
- O 0 0.0006305664428509772
phenotype O 0 8.479159077978693e-06
analyses O 0 6.385493179550394e-06
in O 0 9.769152711669449e-06
Cowden B-Disease 1 0.994436502456665
disease I-Disease 0 0.00314572942443192
and O 0 1.2763168342644349e-05
Bannayan B-Disease 1 0.8711619973182678
- I-Disease 1 0.9998829364776611
Zonana I-Disease 1 0.9998680353164673
syndrome I-Disease 1 0.9997676014900208
, O 0 7.756061677355319e-07
two O 0 1.001995951810386e-05
hamartoma B-Disease 1 0.9844799637794495
syndromes I-Disease 0 0.37395980954170227
with O 0 4.826912572752917e-06
germline O 0 0.0009158973698504269
PTEN O 0 0.018606988713145256
mutation O 0 7.450808880093973e-06
. O 0 3.291394023108296e-06

The O 0 3.905109770130366e-05
tumour B-Disease 1 0.9994645714759827
suppressor O 0 0.0011328693944960833
gene O 0 1.3441415831039194e-05
PTEN O 0 0.0009546233923174441
, O 0 1.0249139847928745e-07
which O 0 8.941791307393032e-09
maps O 0 7.685628133913269e-08
to O 0 4.282120968923664e-08
10q23 O 0 7.794347766321152e-06
. O 0 5.611134952232533e-07

3 O 0 1.2051407338731224e-06
and O 0 1.960441764481402e-08
encodes O 0 1.2961608675254865e-08
a O 0 2.3872934740154506e-09
403 O 0 6.374937466802066e-09
amino O 0 9.335963113699108e-10
acid O 0 9.454628191463144e-10
dual O 0 4.984361368087775e-09
specificity O 0 7.524262457536679e-08
phosphatase O 0 0.0001322927710134536
( O 0 5.864312924153126e-10
protein O 0 1.0372872560893143e-09
tyrosine O 0 3.300413098372701e-08
phosphatase O 0 4.1098617657553405e-05
; O 0 1.8555390113306203e-08
PTPase O 0 6.23895539320074e-06
) O 0 8.019224395638958e-09
, O 0 5.753434617616904e-09
was O 0 2.0107770524191437e-06
shown O 0 4.183787538636352e-08
recently O 0 1.7845061961452302e-07
to O 0 1.6398937763284493e-10
play O 0 2.1591795018593984e-10
a O 0 8.386247807301572e-10
broad O 0 9.993742722258503e-09
role O 0 2.2753452455503975e-08
in O 0 1.460398095787241e-07
human O 0 1.468369646318024e-06
malignancy B-Disease 0 0.022797122597694397
. O 0 2.017276756305364e-06

Somatic O 0 2.871168908313848e-05
PTEN O 0 0.0015305511187762022
deletions O 0 4.498797352425754e-05
and O 0 2.16394118979224e-06
mutations O 0 4.651267033750628e-07
were O 0 7.356723585871805e-08
observed O 0 8.13093592455516e-08
in O 0 2.5963659666672356e-08
sporadic B-Disease 0 6.67424246785231e-05
breast I-Disease 1 0.7007954716682434
, I-Disease 0 0.00016829707601573318
brain I-Disease 0 0.21664133667945862
, I-Disease 0 0.0003361708368174732
prostate I-Disease 1 0.9820482730865479
and I-Disease 0 0.3574114441871643
kidney I-Disease 1 0.9849411845207214
cancer I-Disease 0 0.0010214702924713492
cell O 0 0.000637694844044745
lines O 0 1.9903243810404092e-05
and O 0 3.354338389272016e-07
in O 0 9.55685397485695e-09
several O 0 5.950377257590844e-08
primary O 0 9.342328849015757e-05
tumours B-Disease 1 0.9999576807022095
such O 0 1.4376642099023229e-08
as O 0 7.383090178336715e-06
endometrial B-Disease 1 0.9978027939796448
carcinomas I-Disease 1 0.9999958276748657
, O 1 0.999508261680603
malignant B-Disease 1 0.9999984502792358
melanoma I-Disease 1 0.9999970197677612
and O 1 0.9952996969223022
thyroid B-Disease 1 0.9998875856399536
tumours I-Disease 1 0.9999477863311768
. O 0 0.0005654108827002347

In O 0 1.0271097039549204e-07
addition O 0 1.9562731878863815e-08
, O 0 8.77076971050883e-08
PTEN O 0 2.7400421458878554e-05
was O 0 6.102113275119336e-06
identified O 0 2.0243863474433965e-08
as O 0 2.5914256851500284e-10
the O 0 2.939889887088043e-09
susceptibility O 0 2.414077187040675e-07
gene O 0 1.6188218765478268e-08
for O 0 6.0497074017007435e-09
two O 0 4.9957721785176545e-05
hamartoma B-Disease 1 0.9992183446884155
syndromes I-Disease 1 0.9990230798721313
Cowden B-Disease 1 0.9994879961013794
disease I-Disease 0 0.02442690171301365
( O 0 1.4997979747022328e-08
CD B-Disease 0 2.6916624847217463e-05
; O 0 2.8814986308134394e-07
MIM O 0 0.000574657809920609
158350 O 0 5.817621968162712e-06
) O 0 7.556085535043167e-09
and O 0 6.04078493893212e-08
Bannayan B-Disease 0 0.00020230164227541536
- I-Disease 0 0.05328455939888954
Zonana I-Disease 0 0.0028224701527506113
( I-Disease 0 3.921735824974348e-09
BZS I-Disease 0 2.818329107867612e-07
) I-Disease 0 1.058038434642583e-09
or I-Disease 0 2.7802126822962236e-08
Ruvalcaba I-Disease 0 3.819420817308128e-05
- I-Disease 0 0.008012213744223118
Riley I-Disease 0 0.014910501427948475
- I-Disease 1 0.9985778331756592
Smith I-Disease 1 0.9991534948348999
syndrome I-Disease 1 0.9986271858215332
( O 0 9.925587107773026e-08
MIM O 0 0.0005243804189376533
153480 O 0 1.3504078197001945e-05
) O 0 1.9169467790902672e-08
. O 0 8.711067067679323e-08

Constitutive O 0 5.554911695071496e-06
DNA O 0 6.151573415991152e-06
from O 0 4.132080277940986e-08
37 O 0 8.469007184430666e-08
CD B-Disease 0 1.7796977545003756e-06
families O 0 6.409052133449222e-08
and O 0 3.474632848110559e-08
seven O 0 1.464277659124491e-07
BZS B-Disease 0 4.152973815507721e-06
families O 0 1.7784232753115248e-08
was O 0 3.202887910447316e-07
screened O 0 4.4935084986263973e-08
for O 0 2.3444926000593114e-09
germline O 0 1.2615051673492417e-05
PTEN O 0 0.00026962667470797896
mutations O 0 1.8239778682982433e-06
. O 0 5.21614140325255e-07

PTEN O 0 0.001062589231878519
mutations O 0 1.3114758075971622e-05
were O 0 7.400576578220353e-07
identified O 0 1.27431746932416e-07
in O 0 3.7059992852306323e-09
30 O 0 1.0047219944908647e-08
of O 0 2.8777202842888983e-09
37 O 0 7.262088388415577e-07
( O 0 2.759801720486621e-09
81 O 0 6.686921949494717e-08
% O 0 1.955999806568798e-09
) O 0 1.762567647389801e-09
CD B-Disease 0 4.7105712042139203e-07
families O 0 2.8450852340711208e-08
, O 0 3.1103233322227197e-09
including O 0 6.711462496866716e-10
missense O 0 2.6443555611876945e-07
and O 0 1.2280777639261942e-07
nonsense O 0 9.675405635789502e-06
point O 0 1.3700698673346778e-06
mutations O 0 3.6179496731847394e-08
, O 0 9.274788936863843e-09
deletions O 0 6.692230414273581e-08
, O 0 3.0105102410971085e-08
insertions O 0 6.500984568447166e-07
, O 0 5.320867302316401e-08
a O 0 4.7295447558326487e-08
deletion O 0 4.625805104296887e-06
/ O 0 1.0115057875736966e-06
insertion O 0 1.1647872355524669e-07
and O 0 1.044118462800725e-07
splice O 0 8.643079490866512e-05
site O 0 1.9919385522371158e-05
mutations O 0 1.9682438505697064e-06
. O 0 7.782097100061947e-07

These O 0 2.018206401999123e-08
mutations O 0 5.329419536792557e-07
were O 0 6.214627745748658e-08
scattered O 0 1.21000240937974e-07
over O 0 3.060848285940665e-08
the O 0 7.56872164942024e-09
entire O 0 2.7581139150356648e-08
length O 0 5.216047043177241e-07
of O 0 1.4118834990028972e-08
PTEN O 0 0.00011100636038463563
, O 0 1.76508514471152e-08
with O 0 2.3207169519423587e-09
the O 0 3.383483049290703e-09
exception O 0 5.270198721873953e-10
of O 0 5.678714443124733e-11
the O 0 3.534569747998262e-09
first O 0 2.7070019115171817e-08
, O 0 3.190960384813479e-08
fourth O 0 1.2524707244665478e-06
and O 0 1.3817239619129396e-07
last O 0 1.8745402030617697e-06
exons O 0 3.7254665130603826e-06
. O 0 7.235839234454033e-07

A O 0 1.7629371313887532e-06
hot O 0 2.249162207590416e-06
spot O 0 9.864284038485494e-07
for O 0 6.2333227468514e-09
PTEN O 0 8.503371645929292e-06
mutation O 0 1.3227292150475023e-08
in O 0 4.705642986380099e-09
CD B-Disease 0 5.608627816400258e-06
was O 0 9.881300684355665e-06
identified O 0 2.9017527936048282e-08
in O 0 9.442752135768728e-10
exon O 0 2.496101387805538e-07
5 O 0 3.9936754347991155e-08
that O 0 1.6048882223174132e-09
contains O 0 8.413866131595782e-11
the O 0 1.938879945484473e-09
PTPase O 0 1.5794236105648451e-06
core O 0 6.459195844854548e-08
motif O 0 6.276704311858339e-08
, O 0 9.214304874660684e-10
with O 0 8.49622872056699e-10
13 O 0 9.872453077264254e-09
of O 0 7.179147276659137e-10
30 O 0 3.0647914428527656e-08
( O 0 3.112303748054046e-10
43 O 0 4.046504997745615e-08
% O 0 1.1667673494031305e-09
) O 0 9.688498892046482e-10
CD B-Disease 0 5.395820039666432e-07
mutations O 0 1.8239653343243845e-08
identified O 0 1.3085238670385024e-08
in O 0 1.7380041850145744e-09
this O 0 3.347446320134395e-09
exon O 0 9.65398703556275e-06
. O 0 1.3249027688289061e-06

Seven O 0 1.8804188073318073e-07
of O 0 8.41008773733165e-09
30 O 0 4.796827468567244e-08
( O 0 1.1035695690608804e-09
23 O 0 7.785217093214669e-08
% O 0 1.0133358596675635e-09
) O 0 5.478540399117549e-10
were O 0 2.5895877109327614e-10
within O 0 3.0153832989571194e-12
the O 0 5.705675376610486e-10
core O 0 2.257027631458186e-07
motif O 0 1.2042905837006401e-06
, O 0 7.426181003467036e-09
the O 0 3.999848452451715e-09
majority O 0 4.9046811056996376e-09
( O 0 1.1252898612923445e-10
five O 0 7.178202476865181e-10
of O 0 3.4764857659297377e-10
seven O 0 9.109933785111934e-08
) O 0 8.281055285941363e-10
of O 0 1.9180272647911778e-10
which O 0 4.427987931876487e-08
were O 0 3.2746104494663086e-08
missense O 0 3.072286460792384e-07
mutations O 0 5.000924119258343e-08
, O 0 3.026879369372182e-08
possibly O 0 6.307667632654557e-08
pointing O 0 8.378739266845514e-07
to O 0 5.07951736228307e-10
the O 0 7.728397366513207e-10
functional O 0 5.023039206797364e-10
significance O 0 4.576252154997462e-10
of O 0 3.1938612865545224e-10
this O 0 5.587087681391267e-09
region O 0 7.957109460221545e-08
. O 0 2.3838872209580586e-07

Germline O 0 0.0014343663351610303
PTEN O 0 0.0014139525592327118
mutations O 0 4.925392204313539e-06
were O 0 5.834908165525121e-07
identified O 0 3.2684522466297494e-07
in O 0 3.388966218764722e-09
four O 0 8.833352715953424e-09
of O 0 6.363651383622937e-09
seven O 0 5.725445362259052e-07
( O 0 6.4923946219153095e-09
57 O 0 8.640933515380311e-07
% O 0 9.009156087813608e-09
) O 0 1.1462955029628574e-08
BZS B-Disease 0 1.3045860214333516e-06
families O 0 1.1194169147188404e-08
studied O 0 3.2361636925770654e-08
. O 0 2.2895861206961854e-07

Interestingly O 0 3.2642878068145365e-05
, O 0 6.904294878040673e-07
none O 0 9.554594448957232e-09
of O 0 7.375244165386263e-11
these O 0 4.5259229697336423e-10
mutations O 0 3.369438772438116e-08
was O 0 1.136476839747047e-06
observed O 0 2.4342357463069675e-08
in O 0 3.535351567052203e-09
the O 0 1.9764545555744917e-08
PTPase O 0 4.606475340551697e-05
core O 0 1.7688702200757689e-06
motif O 0 2.6728230295702815e-06
. O 0 2.3103113733213831e-07

It O 0 4.839689609070774e-07
is O 0 6.051313761190613e-08
also O 0 1.5282152432405383e-08
worthy O 0 5.759166032959229e-09
of O 0 2.4507356144454207e-09
note O 0 1.039520256540527e-07
that O 0 1.3879853932863284e-09
a O 0 3.0775835213603386e-09
single O 0 1.775698166284201e-08
nonsense O 0 5.486851023306372e-06
point O 0 4.011196210740309e-07
mutation O 0 1.044522424109573e-08
, O 0 1.359806311995726e-08
R233X O 0 1.322568294881421e-07
, O 0 1.630669110852523e-08
was O 0 2.1388386812759563e-06
observed O 0 2.3170780849568473e-08
in O 0 1.6212684528227328e-09
the O 0 2.327588122241764e-09
germline O 0 1.6683645753801102e-07
DNA O 0 7.370740036094503e-07
from O 0 9.61592694359581e-10
two O 0 9.537842515783268e-09
unrelated O 0 2.5573233415343566e-06
CD B-Disease 0 2.296398270118516e-05
families O 0 9.6406907346136e-08
and O 0 6.684346942620323e-08
one O 0 1.4737524622887577e-07
BZS B-Disease 0 6.0189540818100795e-05
family O 0 6.8548920353350695e-06
. O 0 5.629589168165694e-07

Genotype O 0 0.0006055918638594449
- O 0 0.026002224534749985
phenotype O 0 7.046623068163171e-05
studies O 0 1.193813403688182e-07
were O 0 7.943795310438873e-08
not O 0 1.6334263941431004e-09
performed O 0 4.902557915187344e-09
on O 0 1.0731013588838323e-07
this O 0 1.1912307806838385e-09
small O 0 4.950961862704162e-09
group O 0 3.495991762747508e-08
of O 0 4.116023522016121e-09
BZS B-Disease 0 1.87727200682275e-05
families O 0 8.790532035618526e-08
. O 0 1.2110899660910945e-07

However O 0 2.969079844206135e-07
, O 0 7.787622280375217e-08
genotype O 0 2.1398036551545374e-06
- O 0 0.0001751336531015113
phenotype O 0 1.1524971341714263e-06
analysis O 0 8.04430211331919e-09
inthe O 0 8.539547593500174e-07
group O 0 1.3023021949720714e-07
of O 0 1.770465440920077e-09
CD B-Disease 0 2.3991913622012362e-05
families O 0 2.045640030701179e-07
revealed O 0 1.4936978232071851e-06
two O 0 1.6592314189267654e-09
possible O 0 1.3561224365687963e-09
associations O 0 2.3343570132450253e-11
worthy O 0 7.412789826410915e-10
of O 0 1.4594839226056422e-10
follow O 0 4.379821394451255e-09
- O 0 1.9153962057316676e-05
up O 0 2.2018943468538055e-07
in O 0 2.947154964516585e-09
independent O 0 4.526702568341534e-09
analyses O 0 3.172197295953083e-07
. O 0 3.144337199501024e-07

The O 0 7.071154328741613e-08
first O 0 3.9537337670481065e-07
was O 0 1.9271627024863847e-05
an O 0 8.216258606807969e-08
association O 0 4.0672116341511355e-08
noted O 0 1.2267826754452926e-08
in O 0 6.394979545909507e-10
the O 0 2.230062801089616e-09
group O 0 9.893210517475381e-08
of O 0 1.6856048778990385e-09
CD B-Disease 0 8.424856787314638e-05
families O 0 1.6572259937674971e-06
with O 0 6.640341598540545e-05
breast B-Disease 1 0.9445235133171082
disease I-Disease 0 0.0018961869645863771
. O 0 1.2858555464845267e-06

A O 0 1.9600774976424873e-06
correlation O 0 1.2306869621170335e-06
was O 0 2.6224361135973595e-06
observed O 0 1.6943021208248865e-08
between O 0 4.7763926147581515e-09
the O 0 5.412010839478398e-09
presence O 0 1.350150924395166e-08
/ O 0 3.850292671359057e-07
absence O 0 1.8393081502310338e-09
of O 0 1.164632279504474e-10
a O 0 1.4595501340863848e-07
PTEN O 0 0.0001050928040058352
mutation O 0 3.396435843683321e-08
and O 0 2.3348102118347924e-08
the O 0 7.750780461890372e-09
type O 0 1.1686437062508048e-07
of O 0 2.4929991582212097e-07
breast O 0 0.011818967759609222
involvement O 0 1.0287923942087218e-05
( O 0 2.1647940329216908e-08
unaffected O 0 6.130735982878832e-06
versus O 0 0.0004930165014229715
benign O 0 0.2021748572587967
versus O 0 0.13115642964839935
malignant O 1 0.9893229603767395
) O 0 7.965064128256927e-07
. O 0 7.254868705786066e-07

Specifically O 0 5.717053568332631e-07
and O 0 2.6774399586315667e-08
more O 0 7.107951727203243e-11
directly O 0 5.242970058105811e-09
, O 0 1.4199259545932819e-08
an O 0 2.6548413245564007e-08
association O 0 5.263884972350752e-08
was O 0 8.891249308362603e-06
also O 0 9.122609867517895e-08
observed O 0 9.173327875089399e-09
between O 0 2.4157149614012496e-09
the O 0 2.836127555028156e-09
presence O 0 6.729240498160038e-10
of O 0 2.38073089020574e-10
a O 0 2.507281351427082e-07
PTEN O 0 0.0032566010486334562
mutation O 0 1.138457446359098e-05
and O 0 0.008338971063494682
malignant B-Disease 1 0.9999186992645264
breast I-Disease 1 0.9987841248512268
disease I-Disease 0 0.020965689793229103
. O 0 4.931022886012215e-06

Secondly O 0 0.00029192279907874763
, O 0 6.715379754496098e-07
there O 0 1.4036243278781058e-08
appeared O 0 3.577675613541942e-07
to O 0 6.108035743856988e-10
be O 0 1.1251058973371642e-09
an O 0 1.1293333379569503e-08
interdependent O 0 0.002806809265166521
association O 0 8.037557108764304e-08
between O 0 5.03467951773473e-08
mutations O 0 6.348354730789652e-08
upstream O 0 3.546794857811619e-08
and O 0 2.371798535349967e-09
within O 0 1.7660454695866967e-11
the O 0 2.0040051840197748e-09
PTPase O 0 1.190792772831628e-06
core O 0 2.0014282142710726e-07
motif O 0 3.981893996751751e-07
, O 0 1.4649650381670654e-09
the O 0 1.8261250844808785e-10
core O 0 4.8782059280938483e-08
motif O 0 6.973314015112919e-08
containing O 0 6.240876704310949e-09
the O 0 2.7290125714785063e-09
majority O 0 1.6456818130450301e-09
of O 0 5.288636195643903e-10
missense O 0 4.7012139248181484e-07
mutations O 0 3.771261347651489e-08
, O 0 7.309096439200857e-09
and O 0 1.0251677728945197e-08
the O 0 3.1666760325066434e-09
involvement O 0 1.3142171439994854e-07
of O 0 1.2719293396301623e-09
all O 0 7.104757338005641e-10
major O 0 3.3598702486870025e-08
organ O 0 0.000124986152513884
systems O 0 8.24292073957622e-05
( O 0 1.6170035310736353e-09
central O 0 2.7079507525229474e-09
nervous O 0 9.013556905301812e-07
system O 0 9.839050107984804e-07
, O 0 1.6675003280397505e-05
thyroid O 0 0.2966630458831787
, O 0 1.3550881703849882e-05
breast O 0 0.06570778042078018
, O 0 0.00047600286779925227
skin O 1 0.950021505355835
and O 0 0.10121547430753708
gastrointestinal O 1 0.9456537365913391
tract O 0 0.1954079568386078
) O 0 1.5644044424334425e-06
. O 0 1.6402384517277824e-06

However O 0 1.0070070857182145e-06
, O 0 1.9126991546158933e-08
these O 0 7.740342394813027e-11
observations O 0 1.1555636447724282e-08
would O 0 5.653895573942691e-09
need O 0 9.420188934461393e-11
to O 0 2.1058900456782936e-10
be O 0 6.94333979200934e-10
confirmed O 0 1.3164494383488545e-08
by O 0 1.2556437833932677e-10
studying O 0 8.977310561597562e-11
a O 0 5.460242258337189e-10
larger O 0 3.809522974851376e-10
number O 0 3.6847167678155657e-11
of O 0 6.390955542556753e-10
CD B-Disease 0 2.12257364182733e-05
families O 0 3.3003414046106627e-07
. O 0 1.4634721878792334e-07

Molecular O 0 0.2924957871437073
defects O 1 0.994906485080719
leading O 0 9.801206942938734e-06
to O 0 5.5479878469100186e-09
human O 0 2.602457804812275e-09
complement B-Disease 0 3.324655750702732e-08
component I-Disease 0 0.0001892493019113317
C6 I-Disease 1 0.9999945163726807
deficiency I-Disease 1 0.9999816417694092
in O 0 2.5702075134859115e-08
an O 0 1.0088548663134134e-07
African O 0 9.269934366784582e-07
- O 0 0.0006685844273306429
American O 0 2.3886304916231893e-06
family O 0 3.0168132070684806e-05
. O 0 9.830514500208665e-07

Complement B-Disease 0 3.1447852961719036e-05
component I-Disease 0 0.02825622446835041
C6 I-Disease 1 0.9998331069946289
deficiency I-Disease 1 0.9999120235443115
( O 0 9.27769065128814e-07
C6D B-Disease 0 0.01791023090481758
) O 0 1.712585003588174e-06
was O 0 0.001370728830806911
diagnosed O 0 0.00019805498595815152
in O 0 3.8449585737510006e-09
a O 0 1.040889259229516e-07
16 O 0 7.176893745963753e-07
- O 0 0.0029003694653511047
year O 0 1.6102753761515487e-06
- O 0 9.143878560280427e-05
old O 0 0.0001247454056283459
African O 0 1.552809010263445e-07
- O 0 2.7138130462844856e-05
American O 0 6.011728146404494e-07
male O 0 1.3042351838521427e-06
with O 0 9.468880307395011e-05
meningococcal B-Disease 1 0.9998582601547241
meningitis I-Disease 1 0.9994376301765442
. O 0 2.892249085562071e-06

The O 0 1.1562623285499285e-06
patients O 0 7.021989745226165e-07
father O 0 2.8104111606808146e-06
and O 0 1.5595229285736423e-07
two O 0 3.683401814669196e-07
brothers O 0 0.0013363142497837543
also O 0 3.49398277421642e-07
had O 0 9.079124538402539e-06
C6D B-Disease 0 0.0001383552298648283
, O 0 1.2441708108212879e-08
but O 0 4.863107250230314e-09
gave O 0 7.690111658575915e-09
no O 0 3.2043703246387167e-09
history O 0 2.9381089561297813e-08
of O 0 2.3479962862893444e-07
meningitis B-Disease 1 0.9988864064216614
or O 0 2.977799624659383e-07
other O 0 7.225062148563666e-08
neisserial B-Disease 0 0.018266385421156883
infection I-Disease 0 6.868423224659637e-05
. O 0 1.1402961490603047e-06

By O 0 1.7515160877223934e-08
using O 0 7.042562977233047e-09
exon O 0 8.412928877987724e-07
- O 0 4.006064045825042e-06
specific O 0 2.1732449173583746e-09
polymerase O 0 2.0150495402049273e-05
chain O 0 5.222287654760294e-05
reaction O 0 3.007359694606748e-08
( O 0 4.889556537435169e-10
PCR O 0 8.045331014727708e-07
) O 0 2.3754702649370074e-09
/ O 0 9.806616851903982e-09
single O 0 1.74882797132625e-09
- O 0 1.9713945221155882e-05
strand O 0 3.0404737572098384e-06
conformation O 0 1.0573635478294818e-07
polymorphism O 0 3.792764857735165e-08
as O 0 1.6567133775957643e-10
a O 0 1.9406254381237886e-10
screening O 0 2.425760980973024e-10
step O 0 2.695705048072483e-10
and O 0 2.8526936021733285e-11
nucleotide O 0 1.1232714411391065e-11
sequencing O 0 3.027638417751888e-10
of O 0 2.4082414881720915e-11
target O 0 1.5880047499194916e-08
exons O 0 3.439744133970635e-08
, O 0 3.624813338376498e-09
we O 0 3.9732331313935276e-10
determined O 0 1.0372733783015065e-09
that O 0 6.556754028608225e-10
the O 0 8.816890328944282e-09
proband O 0 2.390425834164489e-05
was O 0 7.639938530701329e-07
a O 0 3.1888838236682204e-09
compound O 0 8.173509513653698e-08
heterozygote O 0 3.093433775802623e-08
for O 0 2.3466659171411663e-10
two O 0 3.0087594637961956e-08
C6 O 0 0.0004976184573024511
gene O 0 2.182397622618737e-07
mutations O 0 4.791871219822497e-07
. O 0 2.8666727303061634e-07

The O 0 4.97031358293043e-08
first O 0 2.237968033114157e-08
, O 0 1.6071405539719308e-08
1195delC O 0 9.324137550947853e-08
located O 0 1.887924483412462e-09
in O 0 1.7656566209112157e-09
exon O 0 6.229717541827995e-07
7 O 0 2.070664777420461e-06
, O 0 6.666788010534219e-08
is O 0 4.256671459756944e-09
a O 0 8.137122975426792e-09
novel O 0 2.9791111799681858e-08
mutation O 0 7.1662227263402656e-09
, O 0 4.768355044149075e-09
while O 0 1.7495587201210583e-09
the O 0 6.380091455149284e-10
second O 0 2.6950907283662673e-08
, O 0 1.2535679161373992e-08
1936delG O 0 7.349387942667818e-08
in O 0 7.301958482308635e-10
exon O 0 2.5144649384856166e-07
12 O 0 2.679392139270931e-07
, O 0 5.438825922965407e-08
has O 0 4.725036362174251e-08
been O 0 8.370132320578705e-08
described O 0 6.311446441031876e-07
before O 0 5.005676229075107e-08
to O 0 1.1190454785037218e-08
cause O 0 7.014347147560329e-08
C6D B-Disease 0 1.3685113117389847e-05
in O 0 1.7723609246900196e-09
an O 0 2.767979445650326e-08
unrelated O 0 9.473694262851495e-06
African O 0 1.53640229427765e-07
- O 0 5.46438641322311e-05
American O 0 1.198714585370908e-07
individual O 0 4.0581897842173476e-09
. O 0 1.1376291553233386e-07

Both O 0 9.302551688961103e-07
mutations O 0 6.8208787524781656e-06
result O 0 1.359953785140533e-06
in O 0 5.761722832176019e-07
premature O 0 3.8671318179694936e-05
termination O 0 1.3262326774565736e-06
codons O 0 2.8844488042523153e-07
and O 0 1.6272489347102237e-06
C6 O 0 0.0317685604095459
null O 0 0.0004209493927191943
alleles O 0 1.845304041125928e-06
. O 0 2.6183727186435135e-06

Allele O 0 5.594385584117845e-06
- O 0 4.1109606172540225e-06
specific O 0 3.4957770012056244e-09
PCR O 0 9.773140845936723e-06
indicated O 0 1.1767737078116625e-06
that O 0 2.6591628898842146e-09
the O 0 4.562336286539903e-09
probands O 0 2.8217036742717028e-05
two O 0 8.038919077080209e-07
brothers O 0 0.0008529078913852572
also O 0 4.898167844658019e-07
inherited O 0 7.7539998528664e-06
the O 0 9.779625997907715e-09
1195delC O 0 2.444822712277528e-06
mutation O 0 7.398710533124131e-09
from O 0 5.998127550199683e-10
their O 0 7.497927612121202e-09
heterozygous O 0 6.381168304869789e-07
mother O 0 7.0924274950812105e-06
and O 0 1.47986130016875e-08
the O 0 8.363601367022966e-09
1936delG O 0 3.1604586183675565e-06
mutation O 0 7.815549096790164e-09
from O 0 4.336189185494277e-10
their O 0 6.915653827377355e-09
homozygous O 0 1.3110903864799184e-06
father O 0 8.86065845406847e-06
. O 0 7.038080696020188e-08
. O 0 3.552065948042582e-07

PAX6 O 0 0.006283887661993504
mutations O 0 0.00010687726171454415
reviewed O 0 9.045410843100399e-05
. O 0 1.149441141023999e-05

Mutations O 0 3.614238084992394e-05
in O 0 5.245618694971199e-07
PAX6 O 0 6.559155735885724e-05
are O 0 5.2828110774783e-09
responsible O 0 1.6957764970015887e-08
for O 0 4.958437216373568e-09
human O 0 5.692185709449404e-07
aniridia B-Disease 1 0.99986732006073
and O 0 2.7836965728056384e-06
have O 0 3.777632429091682e-08
also O 0 1.0244429660133392e-07
been O 0 2.40035149090545e-07
found O 0 3.3809726573963417e-07
in O 0 3.3269646593225843e-08
patients O 0 3.518831093174413e-08
with O 0 1.5572859410895035e-05
Peters B-Disease 1 0.999984622001648
anomaly I-Disease 1 0.9999892711639404
, O 0 0.001677455729804933
with O 1 0.7335889935493469
congenital B-Disease 1 0.9999966621398926
cataracts I-Disease 1 0.9999393224716187
, O 0 4.602084663929418e-05
with O 0 1.9843564587063156e-05
autosomal B-Disease 1 0.6275756359100342
dominant I-Disease 0 0.053415946662425995
keratitis I-Disease 1 0.9928794503211975
, O 0 6.063507953513181e-06
and O 0 3.270546130806906e-06
with O 0 3.464746623649262e-05
isolated B-Disease 1 0.889551043510437
foveal I-Disease 1 0.9999110698699951
hypoplasia I-Disease 1 0.9998812675476074
. O 0 0.00012275426706764847

No O 0 4.3500196511558897e-07
locus O 0 2.3968086679815315e-06
other O 0 6.348690906321508e-09
than O 0 3.4710607721422093e-09
chromosome O 0 5.677462468156591e-06
11p13 O 0 1.6785303387223394e-06
has O 0 4.403227080729266e-07
been O 0 3.657348770502722e-07
implicated O 0 2.7710530048352666e-05
in O 0 9.98844598143478e-07
aniridia B-Disease 1 0.9998915195465088
, O 0 4.116348293337069e-07
and O 0 2.219606471953739e-07
PAX6 O 0 5.9506996876734775e-06
is O 0 4.724331148509009e-09
clearly O 0 1.720412612371547e-08
the O 0 1.6598740160134184e-09
major O 0 5.784000833841674e-09
, O 0 2.025726608678724e-08
if O 0 2.6231943284216186e-09
not O 0 1.069189528579706e-10
only O 0 4.01897751189928e-11
, O 0 2.5709807616181024e-09
gene O 0 1.5268925679379208e-08
responsible O 0 9.71130091897976e-08
. O 0 5.231764816926443e-07

Twenty O 0 2.1488301626959583e-06
- O 0 0.00011517298844410107
eight O 0 5.446444788503868e-07
percent O 0 5.995747756060155e-07
of O 0 2.285922007239094e-10
identified O 0 4.5108112800562594e-08
PAX6 O 0 9.380019605487178e-07
mutations O 0 2.581256453026981e-08
are O 0 1.3593829395475154e-09
C O 0 1.1731615813914686e-05
- O 0 0.004327653907239437
T O 0 0.00020093364582862705
changes O 0 2.4264920628347397e-10
at O 0 5.016984232497634e-07
CpG O 0 1.8093718608724885e-05
dinucleotides O 0 5.372445230023004e-06
, O 0 2.966317858010825e-09
20 O 0 7.214397412802498e-10
% O 0 2.1037132105772294e-11
are O 0 2.586312457600326e-12
splicing O 0 1.1681417610986955e-08
errors O 0 1.7291487210968626e-06
, O 0 1.2323032372307807e-08
and O 0 2.4307316159877246e-09
more O 0 6.972718930020605e-11
than O 0 5.731132235453629e-10
30 O 0 9.488778651700613e-09
% O 0 5.354550691727411e-10
are O 0 1.928905091208577e-10
deletion O 0 9.965499714326143e-08
or O 0 3.647222612812584e-08
insertion O 0 1.9248557237006025e-07
events O 0 1.393525366211179e-07
. O 0 8.888891898095608e-07

There O 0 3.7691907550652104e-07
is O 0 1.219187506507069e-08
a O 0 9.413696488991263e-09
noticeably O 0 1.0250934110445087e-06
elevated O 0 7.436587452502863e-07
level O 0 3.4398277559688495e-09
of O 0 2.322735059845371e-10
mutation O 0 2.890791162002415e-09
in O 0 2.001048660105198e-09
the O 0 5.9670131058453535e-09
paired O 0 4.2735459260256903e-07
domain O 0 1.4142552906548644e-08
compared O 0 6.996963008987223e-08
with O 0 3.700496797875985e-09
the O 0 2.3229768331134437e-08
rest O 0 5.667002422882206e-09
of O 0 1.5031643985086163e-10
the O 0 1.4865831232668825e-08
gene O 0 2.86429525431231e-07
. O 0 4.4375505581228936e-07

Increased O 0 3.564088331131643e-07
mutation O 0 1.53981432049477e-07
in O 0 4.6447659052262225e-09
the O 0 1.0484405343902381e-08
homeodomain O 0 6.308344836725155e-06
is O 0 1.968204799140949e-08
accounted O 0 8.486984448552448e-09
for O 0 5.192468677250872e-11
by O 0 5.188383056520252e-10
the O 0 2.5414800930434467e-08
hypermutable O 0 0.0002449459570925683
CpG O 0 3.5009030398214236e-05
dinucleotide O 0 1.5346873851740384e-06
in O 0 1.4403037651433692e-09
codon O 0 8.339324786277302e-09
240 O 0 6.245296901852271e-08
. O 0 1.1773153829608418e-07

Very O 0 1.2745654487389402e-07
nearly O 0 2.8545757757569845e-08
all O 0 8.324224642919376e-10
mutations O 0 6.79593199492956e-08
appear O 0 6.906745397827763e-08
to O 0 2.2304517699467397e-07
cause O 0 5.205980869504856e-06
loss O 0 4.518054538493743e-06
of O 0 3.10682340964874e-10
function O 0 1.3187928527003123e-10
of O 0 2.3300110105206606e-11
the O 0 8.779632021393979e-10
mutant O 0 2.1017835649672634e-07
allele O 0 5.087841614681565e-08
, O 0 3.907698609140198e-09
and O 0 6.870987112606031e-10
more O 0 2.3754406427989316e-11
than O 0 1.3708151280766856e-10
80 O 0 1.0409557660295832e-09
% O 0 7.811876145957797e-11
of O 0 1.6413487236022206e-10
exonic O 0 3.210164550182526e-06
substitutions O 0 8.739671208957134e-09
result O 0 8.048844257757537e-09
in O 0 5.165132321849342e-09
nonsense O 0 2.3133436570788035e-06
codons O 0 2.474801874541299e-07
. O 0 4.224200438329717e-07

In O 0 2.0820891677431064e-07
a O 0 2.2985686243259806e-08
gene O 0 1.527478055152187e-08
with O 0 9.671314415982124e-09
such O 0 3.0008817653026654e-10
extraordinarily O 0 2.2981789982168266e-07
high O 0 8.432031961547182e-08
sequence O 0 6.186309242650623e-10
conservation O 0 4.088979155270067e-10
throughout O 0 1.4197667347337628e-11
evolution O 0 5.883010190110838e-10
, O 0 1.7837252785923852e-09
there O 0 3.6405817249729466e-10
are O 0 6.933084106819365e-10
presumed O 0 8.885644638212398e-05
undiscovered O 0 9.240931831300259e-05
missense O 0 1.3678308050657506e-06
mutations O 0 1.7227233684025123e-07
, O 0 8.3909243997482e-09
these O 0 7.586953981730815e-11
are O 0 1.0752777834799332e-10
hypothesized O 0 1.5665401420505987e-08
to O 0 1.2803218485402112e-09
exist O 0 6.028348931153005e-10
in O 0 1.342559396988463e-09
as O 0 8.714104104967646e-09
- O 0 4.737887138617225e-05
yet O 0 5.728537288973712e-08
unidentified O 0 0.0001011691929306835
phenotypes O 0 1.0679024171622586e-06
. O 0 4.9313612748846936e-08
. O 0 4.165434859260131e-07

Genetic O 0 3.069133890676312e-05
heterogeneity O 0 4.736369373858906e-05
and O 0 1.2648749816435156e-06
penetrance O 0 1.7074340576073155e-05
analysis O 0 2.6956152865409422e-08
of O 0 1.6938296321100665e-09
the O 0 2.399978313860629e-07
BRCA1 O 0 0.00014125611050985754
and O 0 3.196149236828205e-06
BRCA2 O 0 6.404760642908514e-05
genes O 0 4.04112995511241e-07
in O 0 3.836182440863922e-05
breast B-Disease 1 0.9917388558387756
cancer I-Disease 0 0.17488275468349457
families O 0 1.5065045317896875e-06
. O 0 1.1233051964154583e-06

The O 0 0.007108496967703104
Breast B-Disease 1 0.9992029070854187
Cancer I-Disease 1 0.9989203214645386
Linkage O 0 0.023150552064180374
Consortium O 0 0.0005256865406408906
. O 0 1.096496453101281e-05

The O 0 2.006675714483208e-08
contribution O 0 2.3981963082064794e-09
of O 0 2.3204689281186575e-09
BRCA1 O 0 2.51409292104654e-05
and O 0 7.288854249054566e-06
BRCA2 O 0 0.06544267386198044
to O 0 0.09122781455516815
inherited B-Disease 1 0.9999970197677612
breast I-Disease 1 0.9999785423278809
cancer I-Disease 1 0.9999887943267822
was O 0 0.013566895388066769
assessed O 0 8.479511279801955e-07
by O 0 1.2498459156518038e-08
linkage O 0 9.325342944066506e-06
and O 0 1.5494126159865118e-07
mutation O 0 4.1117784732591645e-09
analysis O 0 6.131933183439742e-09
in O 0 3.8998062557027424e-09
237 O 0 1.5514516462644679e-06
families O 0 1.097455992749019e-07
, O 0 6.750738634764275e-09
each O 0 1.290894613426019e-10
with O 0 1.8277438229574727e-08
at O 0 1.4342455187943415e-06
least O 0 2.4059101932927263e-10
four O 0 1.2266657023474181e-08
cases O 0 3.522746183648451e-08
of O 0 1.1456602351245238e-06
breast B-Disease 1 0.9531320929527283
cancer I-Disease 0 0.01366374734789133
, O 0 4.093212524480805e-08
collected O 0 1.3473108850803328e-08
by O 0 3.412930880131171e-07
the O 0 0.0025567556731402874
Breast B-Disease 1 0.9999710321426392
Cancer I-Disease 1 0.9997276663780212
Linkage O 0 0.0009275700431317091
Consortium O 0 1.880192030512262e-05
. O 0 6.974723305575026e-07

Families O 0 2.680297029655776e-06
were O 0 6.313613454267397e-08
included O 0 9.813442281014773e-10
without O 0 4.779753259853692e-10
regard O 0 5.001641462110129e-11
to O 0 1.008291714010845e-10
the O 0 2.1083106371833082e-09
occurrence O 0 4.373813453639741e-07
of O 0 5.301801593304845e-07
ovarian B-Disease 1 0.9766300916671753
or I-Disease 0 9.912389941746369e-06
other I-Disease 0 9.86146346804162e-07
cancers I-Disease 0 0.02051507495343685
. O 0 3.8130528992041945e-06

Overall O 0 0.00020951559417881072
, O 0 0.00042790360748767853
disease O 0 0.002486785175278783
was O 0 0.00010734811803558841
linked O 0 1.9483624782878906e-05
to O 0 2.295851864175802e-08
BRCA1 O 0 3.7067336506879656e-06
in O 0 7.480957187055992e-09
an O 0 3.159968287036463e-08
estimated O 0 1.5893341753780987e-07
52 O 0 1.0723525178946147e-07
% O 0 3.712258278554259e-10
of O 0 5.572823869037791e-10
families O 0 2.369823626224843e-08
, O 0 3.5340235182701463e-09
to O 0 2.8606679247644706e-09
BRCA2 O 0 4.4408486132851976e-07
in O 0 3.1645810416591758e-09
32 O 0 6.166370525306775e-08
% O 0 1.0048211152025033e-09
of O 0 1.298684382255999e-09
families O 0 5.3556078682959196e-08
, O 0 7.671301816003506e-09
and O 0 3.460371988950328e-09
to O 0 7.199784657352382e-10
neither O 0 1.9759862635027048e-09
gene O 0 7.875416430103144e-10
in O 0 2.1248747206215057e-09
16 O 0 5.636756128524212e-08
% O 0 1.6966653637595641e-09
( O 0 8.90367779504686e-11
95 O 0 3.420266292408769e-09
% O 0 2.8565444454287103e-10
confidence O 0 1.1166403801610159e-08
interval O 0 1.776545133225227e-08
[ O 0 2.5906112810503146e-09
CI O 0 7.983354407770094e-06
] O 0 1.9833350961562246e-08
6 O 0 2.874578441947051e-08
% O 0 2.3918009794954287e-09
- O 0 2.3936447178130038e-05
28 O 0 6.341807079479622e-07
% O 0 2.5343049880888202e-09
) O 0 4.828806687839915e-09
, O 0 5.208473652373868e-09
suggesting O 0 6.164007260167637e-08
other O 0 2.517428709936098e-09
predisposition O 0 1.9752540083572967e-06
genes O 0 1.6339826913736033e-07
. O 0 1.0436838238092605e-06

The O 0 7.260122174557182e-07
majority O 0 3.4166109230682196e-07
( O 0 1.0812039263896622e-08
81 O 0 1.3976060131426493e-07
% O 0 1.5641745676475693e-09
) O 0 9.866198968921935e-10
of O 0 2.3998572018513187e-09
the O 0 9.373687498737127e-05
breast B-Disease 1 0.9999251365661621
- I-Disease 1 0.9999969005584717
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999808073043823
families O 0 5.56287773179065e-07
were O 0 1.6465263286136178e-07
due O 0 3.270571724556248e-08
to O 0 1.9654699201510084e-08
BRCA1 O 0 5.998344022373203e-06
, O 0 5.415968828970108e-08
with O 0 3.485126498503632e-08
most O 0 1.621105383264876e-08
others O 0 2.3336554022534983e-07
( O 0 7.999284568072085e-10
14 O 0 1.1169817071277066e-07
% O 0 4.231076378147236e-09
) O 0 4.86122475606976e-09
due O 0 1.3402266851869626e-08
to O 0 4.557615795874881e-08
BRCA2 O 0 3.915633715223521e-05
. O 0 6.567767627529975e-07

Conversely O 0 2.4906730686780065e-05
, O 0 1.9501007386679703e-07
the O 0 1.2698889051421247e-08
majority O 0 3.959194749825201e-09
of O 0 2.4013271371359224e-09
families O 0 2.2272244493137805e-08
with O 0 2.9371282295187484e-08
male B-Disease 0 5.437668164631759e-07
and I-Disease 0 5.2520836106850766e-06
female I-Disease 0 0.00015784241259098053
breast I-Disease 1 0.5510485172271729
cancer I-Disease 0 0.001323917182162404
were O 0 1.3327149872566224e-07
due O 0 5.867585883834181e-08
to O 0 1.3290798506204737e-07
BRCA2 O 0 0.00011688144149957225
( O 0 3.248780089393222e-08
76 O 0 3.7968907236063387e-06
% O 0 3.8424090575972514e-08
) O 0 4.118153640320088e-08
. O 0 1.2641645241728838e-07

The O 0 9.247659704669786e-08
largest O 0 2.8595056278390985e-07
proportion O 0 3.613632415522261e-08
( O 0 2.392914311144523e-09
67 O 0 5.009669052924437e-07
% O 0 4.443010848120821e-09
) O 0 1.1452109260901011e-09
of O 0 3.9902298132332703e-10
families O 0 1.4736702524942302e-08
due O 0 6.564678578513394e-09
to O 0 1.1535942201490457e-09
other O 0 5.075255771203047e-10
genes O 0 1.98725818023604e-08
was O 0 0.00022814357362221926
found O 0 1.7772181308828294e-06
in O 0 1.5800166508483926e-08
families O 0 5.1558504132742655e-09
with O 0 3.4885565547426722e-09
four O 0 7.642271526719924e-08
or O 0 7.195796314363179e-08
five O 0 5.62052413499714e-08
cases O 0 1.3972935697381672e-08
of O 0 4.48927650609221e-08
female O 0 0.0006529094534926116
breast B-Disease 1 0.6000442504882812
cancer I-Disease 0 0.0002510216145310551
only O 0 7.977681626414324e-09
. O 0 2.677606687484513e-07

These O 0 4.902747718915634e-08
estimates O 0 3.5762704442277027e-07
were O 0 2.1101582703408894e-08
not O 0 2.206445914865185e-09
substantially O 0 4.1833565944671136e-08
affected O 0 1.3431990242285252e-10
either O 0 3.035055193278957e-11
by O 0 1.9939003226276952e-10
changing O 0 2.5445734408435783e-09
the O 0 1.3078619298667604e-09
assumed O 0 7.943552304823243e-08
penetrance O 0 5.635734510178736e-07
model O 0 1.2950370376074716e-07
for O 0 1.1034796187914253e-08
BRCA1 O 0 8.01246005721623e-06
or O 0 5.583351736504483e-08
by O 0 5.718796547427019e-09
including O 0 8.366026982287167e-09
or O 0 1.960144970780675e-07
excluding O 0 7.849253620406671e-07
BRCA1 O 0 4.785144938068697e-06
mutation O 0 2.7957241854892345e-08
data O 0 2.2112713793376315e-07
. O 0 1.0279480875396985e-06

Among O 0 2.731595145633037e-07
those O 0 1.550887986923044e-07
families O 0 6.25582345037401e-07
with O 0 3.067823627134203e-06
disease O 0 7.467413524864241e-05
due O 0 7.0104540839111e-08
to O 0 2.144643929113954e-08
BRCA1 O 0 3.4674744711082894e-06
that O 0 1.1054729043280531e-07
were O 0 1.9181688060143642e-07
tested O 0 6.398499152737713e-08
by O 0 3.771415679754142e-10
one O 0 1.6424636650747004e-10
of O 0 6.477038350105602e-11
the O 0 4.859887492436599e-10
standard O 0 1.9017341035265645e-09
screening O 0 2.465465331891181e-10
methods O 0 3.897627109950008e-09
, O 0 7.592636741549086e-09
mutations O 0 3.0508682247187835e-09
were O 0 8.356298764056191e-09
detected O 0 1.231804969137329e-08
in O 0 1.9050187816116448e-10
the O 0 4.591289848310254e-10
coding O 0 2.072044367196213e-07
sequence O 0 1.8648480537564183e-09
or O 0 3.5715441715211682e-09
splice O 0 3.526262730702001e-07
sites O 0 6.301135613284714e-09
in O 0 1.594784859726417e-09
an O 0 1.3799771991784837e-08
estimated O 0 1.984798387866249e-07
63 O 0 4.1496224412185256e-07
% O 0 1.2967215079484617e-09
( O 0 8.593817324431541e-11
95 O 0 6.716857292587974e-09
% O 0 4.325881430844447e-09
CI O 0 0.0003183037624694407
51 O 0 1.027633402372885e-06
% O 0 8.752231828168533e-09
- O 0 0.00017173372907564044
77 O 0 7.207980274870351e-07
% O 0 5.24256016376512e-09
) O 0 1.0930102156692101e-08
. O 0 7.163436777091192e-08

The O 0 2.7512632527759706e-07
estimated O 0 5.400515306064335e-07
sensitivity O 0 1.437376795365708e-07
was O 0 7.258487926264934e-07
identical O 0 6.305574373755007e-08
for O 0 5.6025344086219064e-11
direct O 0 2.8751499445145434e-11
sequencing O 0 1.858886378158786e-08
and O 0 5.631047184095905e-09
other O 0 3.6574523964993944e-10
techniques O 0 1.3725673397857463e-07
. O 0 2.0541163792131556e-07

The O 0 4.912463964501512e-07
penetrance O 0 6.051355740055442e-05
of O 0 1.457666627402432e-07
BRCA2 O 0 0.0002747518301475793
was O 0 3.178023689542897e-05
estimated O 0 8.000066387126026e-09
by O 0 6.56059095938133e-11
maximizing O 0 1.0035531294860789e-09
the O 0 4.417938015421896e-09
LOD O 0 8.522970347257797e-06
score O 0 1.383474401706053e-08
in O 0 5.357559373919685e-08
BRCA2 O 0 3.1492661946685985e-05
- O 0 0.008667459711432457
mutation O 0 1.1209936019440647e-06
families O 0 7.067001916993831e-08
, O 0 6.245973516172398e-09
over O 0 3.351317889865868e-09
all O 0 1.2876068267164698e-10
possible O 0 1.5513903051100897e-08
penetrance O 0 3.4138595310651e-06
functions O 0 6.803400065535925e-09
. O 0 2.3161619822076318e-07

The O 0 2.898750040003506e-07
estimated O 0 5.463675165628956e-07
cumulative O 0 9.61380465014372e-07
risk O 0 8.452729503005685e-07
of O 0 1.0644194503584004e-07
breast B-Disease 0 0.2653448283672333
cancer I-Disease 0 0.004087928216904402
reached O 0 1.018409056996461e-05
28 O 0 1.190564489661483e-06
% O 0 2.081106620366313e-09
( O 0 8.100337067773467e-11
95 O 0 4.512013873636533e-09
% O 0 1.7855157352641982e-09
CI O 0 3.200988066964783e-05
9 O 0 7.304597602342255e-07
% O 0 6.557457687961232e-09
- O 0 1.725459333101753e-05
44 O 0 7.067325924481338e-08
% O 0 7.08697267537417e-10
) O 0 3.0429284092470255e-10
by O 0 4.6317147339713927e-10
age O 0 1.9801931205876144e-09
50 O 0 4.105836226564463e-10
years O 0 3.774418111390787e-09
and O 0 1.2054847786657774e-08
84 O 0 9.59719059778763e-08
% O 0 4.959295751838511e-10
( O 0 4.838648579030824e-11
95 O 0 3.3641520680305348e-09
% O 0 9.124880850919226e-10
CI O 0 3.934656342607923e-05
43 O 0 3.515752666771732e-07
% O 0 4.384351992570146e-09
- O 0 4.5703263822360896e-06
95 O 0 2.345836520589728e-07
% O 0 2.668816945217145e-09
) O 0 8.143313801056706e-10
by O 0 6.974491539857297e-10
age O 0 1.932829185591345e-08
70 O 0 1.665395821248694e-08
years O 0 1.5300066991130734e-07
. O 0 2.723840282214951e-07

The O 0 3.0510547730955295e-05
corresponding O 0 0.09429644048213959
ovarian B-Disease 1 0.9999842643737793
cancer I-Disease 1 0.9999568462371826
risks O 0 0.0015812634956091642
were O 0 1.9963033537351293e-06
0 O 0 2.6807416020346864e-07
. O 0 3.3566360002623696e-07

4 O 0 8.534095286449883e-06
% O 0 1.1586582360223474e-07
( O 0 1.69992075971237e-09
95 O 0 1.0792938986980971e-08
% O 0 2.051133485281298e-09
CI O 0 1.5862520740483887e-05
0 O 0 1.2101220470128737e-08
% O 0 1.2262463267020962e-09
- O 0 9.13719031814253e-06
1 O 0 4.957125199211987e-08
% O 0 8.357314840168328e-10
) O 0 1.4642685675081424e-10
by O 0 2.0571504222299808e-10
age O 0 2.118674791162789e-09
50 O 0 4.2765174734782363e-10
years O 0 5.807879510655312e-09
and O 0 1.5717567691808654e-08
27 O 0 1.1767159691089546e-07
% O 0 2.412914035243574e-10
( O 0 5.939414932099041e-11
95 O 0 2.316356662035446e-09
% O 0 6.518137141142688e-10
CI O 0 1.4503753845929168e-05
0 O 0 6.569801591638225e-09
% O 0 2.3412305427683577e-09
- O 0 1.5069405890244525e-05
47 O 0 7.006242981333344e-07
% O 0 1.9689283536905577e-09
) O 0 4.4391626485840163e-10
by O 0 1.8046962813045297e-09
age O 0 1.5326904190260393e-08
70 O 0 7.977195792818748e-09
years O 0 7.274052649108853e-08
. O 0 1.4020514527146588e-07

The O 0 3.8843995753268246e-06
lifetime O 0 8.779268682701513e-05
risk O 0 2.919620783359278e-05
of O 0 1.5970251752150944e-06
breast B-Disease 1 0.8097830414772034
cancer I-Disease 0 0.003445069072768092
appears O 0 4.932772412757913e-07
similar O 0 1.0021459218023665e-08
to O 0 9.639234299640975e-09
the O 0 5.964216143183876e-08
risk O 0 4.473097021673311e-07
in O 0 2.341946547801399e-08
BRCA1 O 0 1.426693324901862e-05
carriers O 0 9.119147392766536e-08
, O 0 1.2578310837341178e-08
but O 0 7.959124914691529e-09
there O 0 4.689245103328687e-10
was O 0 2.745355516253767e-07
some O 0 1.6331817842552e-11
suggestion O 0 1.6902570454391252e-09
of O 0 3.4209954313801916e-10
a O 0 1.5226122229705652e-07
lower O 0 1.701990913716145e-05
risk O 0 2.4439734147563286e-07
in O 0 9.315761495543029e-09
BRCA2 O 0 1.6033567362683243e-06
carriers O 0 4.0466979100983735e-08
< O 0 2.1184455079037434e-08
50 O 0 1.8906742837998536e-09
years O 0 3.770893997057101e-08
of O 0 5.335051067589802e-09
age O 0 6.063318096494186e-07
. O 0 4.2890854956567637e-07

Eye B-Disease 0 0.0035584080033004284
movement I-Disease 0 4.163956691627391e-05
abnormalities I-Disease 0 0.03266727179288864
correlate O 0 1.7922950519277947e-06
with O 0 1.9440672076598275e-06
genotype O 0 0.0005054823704995215
in O 0 4.588791853166185e-06
autosomal O 1 0.9297134280204773
dominant O 1 0.7844709157943726
cerebellar B-Disease 1 0.9990839958190918
ataxia I-Disease 1 0.9989525079727173
type I-Disease 0 0.005222983192652464
I I-Disease 0 0.03906017914414406
. O 0 2.9276561690494418e-05

We O 0 3.2149239359569037e-07
compared O 0 1.039371113620291e-06
horizontal O 0 3.6124460166320205e-05
eye O 0 4.184392673778348e-05
movements O 0 5.221825745138631e-07
( O 0 6.6747634086539165e-09
visually O 0 3.0767873226977827e-07
guided O 0 2.9022235139564145e-06
saccades O 0 5.473251803778112e-05
, O 0 3.090461859756033e-07
antisaccades O 0 1.7675160052021965e-05
, O 0 1.726658638290246e-08
and O 0 5.522744039865302e-09
smooth O 0 4.3773522406809207e-07
pursuit O 0 9.684175893198699e-06
) O 0 5.8972027261461335e-09
in O 0 7.838730775588942e-10
control O 0 2.020401623781254e-08
subjects O 0 5.962883076193748e-09
( O 0 3.6914152290457025e-10
n O 0 1.400036808263394e-06
= O 0 9.327460475105909e-07
14 O 0 4.3540531180497055e-08
) O 0 8.650991922820594e-09
and O 0 6.46923226099716e-08
patients O 0 8.835707721033259e-10
with O 0 1.7683865483064665e-09
three O 0 2.783581898313514e-08
forms O 0 5.723761464793142e-09
of O 0 3.603322085155014e-08
autosomal O 0 0.00509196612983942
dominant O 0 0.0005204195622354746
cerebellar B-Disease 0 0.21379587054252625
ataxias I-Disease 0 0.034017328172922134
type I-Disease 0 8.641118256491609e-06
I I-Disease 0 9.164575021713972e-05
spinocerebellar B-Disease 0 0.003404860617592931
ataxias I-Disease 0 0.00018215303134638816
1 I-Disease 0 1.731222631917717e-08
and I-Disease 0 5.687753201755186e-08
2 I-Disease 0 1.0761082336330219e-07
( O 0 1.718968412056654e-09
SCA1 B-Disease 0 1.4684909729112405e-05
, O 0 1.4977111106873053e-08
n O 0 5.114481496093504e-07
= O 0 1.6013642323287058e-07
11 O 0 3.7398223184936796e-08
; O 0 3.819776939195663e-09
SCA2 B-Disease 0 8.61815715325065e-06
, O 0 3.034428885939633e-08
n O 0 4.018785091375321e-07
= O 0 1.1741085614858093e-07
10 O 0 2.071827154281891e-09
) O 0 1.1238190378293211e-09
and O 0 4.423940254127956e-07
SCA3 B-Disease 1 0.9995909333229065
/ O 0 1.1319338227622211e-05
Machado B-Disease 0 0.00014759253826923668
- I-Disease 0 0.1099255159497261
Joseph I-Disease 0 0.0010718062985688448
disease I-Disease 0 0.0014270506799221039
( O 0 6.982643441233449e-08
MJD B-Disease 1 0.9998730421066284
) O 0 1.2384559511247062e-07
( O 0 3.153897365493208e-09
n O 0 3.7474526379810413e-06
= O 0 4.917910700896755e-06
16 O 0 1.8978474258801725e-07
) O 0 2.8451610845081632e-08
. O 0 5.393290081201485e-08

In O 0 1.378708702759468e-06
SCA1 B-Disease 0 0.00013348083302844316
, O 0 1.1806181809959071e-08
saccade O 0 9.556018909506747e-08
amplitude O 0 5.861143037577676e-08
was O 0 1.4165116226649843e-06
significantly O 0 1.2522106018764134e-08
increased O 0 1.913541103348848e-09
, O 0 8.62461480011234e-09
resulting O 0 2.9186827177341e-08
in O 0 1.4017199134741531e-07
hypermetria B-Disease 0 0.0009923044126480818
. O 0 2.063491137960227e-06

The O 0 6.971132648914136e-08
smooth O 0 3.578464884412824e-06
pursuit O 0 4.989558146917261e-05
gain O 0 3.007916120623122e-06
was O 0 3.161549102514982e-05
decreased O 0 2.8969916456844658e-06
. O 0 2.695271632546792e-07

In O 0 1.129374254560389e-06
SCA2 B-Disease 0 0.00011214562255190685
, O 0 3.152347360924068e-08
saccade O 0 4.2817535472750023e-07
velocity O 0 1.5980247098923428e-06
was O 0 9.461621630180161e-06
markedly O 0 2.908948545154999e-06
decreased O 0 1.3033425148023525e-06
. O 0 2.8122533990426746e-07

The O 0 3.9142656760304817e-07
percentage O 0 9.484363658884831e-07
of O 0 5.944226000309527e-09
errors O 0 3.0580088150600204e-06
in O 0 2.165257058095449e-07
antisaccades O 0 0.0004199031973257661
was O 0 1.4183624443830922e-05
greatly O 0 6.276545949646106e-09
increased O 0 8.826662178940126e-10
and O 0 6.20755269409301e-09
was O 0 8.118196319628623e-07
significantly O 0 1.0755988100186187e-08
correlated O 0 6.528831164587245e-08
with O 0 2.4767427930783015e-07
age O 0 1.4061160982237197e-05
at O 0 0.004325849935412407
disease O 0 0.00044823289499618113
onset O 0 1.7319087419309653e-05
. O 0 2.7012977170670638e-06

In O 0 1.9116802718599502e-07
addition O 0 1.1839105695798935e-08
, O 0 2.1869963617859867e-09
a O 0 8.642510596068576e-10
correlation O 0 8.728493483545208e-09
between O 0 1.2083715361654868e-08
smooth O 0 9.781231256056344e-07
pursuit O 0 4.4307129428489134e-05
gain O 0 2.2556247358807013e-07
and O 0 1.1012130762821926e-08
the O 0 5.821329529531738e-10
number O 0 2.1501095348597232e-10
of O 0 8.457670119810246e-09
trinucleotide O 0 4.093550887773745e-05
repeats O 0 5.296270956023363e-06
was O 0 4.448146864888258e-05
found O 0 3.304852725705132e-06
. O 0 7.624972795383655e-07

In O 0 2.7089263312518597e-05
SCA3 B-Disease 1 0.9981963038444519
, O 0 1.0609408036543755e-06
gaze B-Disease 0 1.286520819121506e-05
- I-Disease 0 0.0033310852013528347
evoked I-Disease 0 9.552734991302714e-05
nystagmus I-Disease 0 0.00010980973456753418
was O 0 2.7635869628284127e-05
often O 0 5.529184221586547e-09
present O 0 2.409731580943486e-10
as O 0 7.763604203958607e-10
was O 0 1.1582267234189203e-06
saccade O 0 9.697489531390602e-07
hypometria O 0 7.555896900157677e-06
and O 0 1.1293096235931444e-08
smooth O 0 3.313185743536451e-07
pursuit O 0 7.914281013654545e-06
gain O 0 5.120587047713343e-07
was O 0 1.2900283763883635e-05
markedly O 0 3.101645688730059e-06
decreased O 0 1.0112048585142475e-06
. O 0 2.0355962249141157e-07

Three O 0 2.6189894697381533e-07
major O 0 1.2266002435978862e-08
criteria O 0 3.5967904210565393e-09
, O 0 1.794375315000707e-09
saccade O 0 1.5249570495257103e-08
amplitude O 0 4.217837634712396e-09
, O 0 8.920510996546227e-10
saccade O 0 8.904111226115674e-09
velocity O 0 9.782334586816432e-08
, O 0 2.63946553502592e-09
and O 0 1.4595987751775397e-09
presence O 0 2.2615408157289352e-10
of O 0 1.0635439195993968e-09
gaze B-Disease 0 1.5621111742802896e-05
- I-Disease 0 0.00027198344469070435
evoked I-Disease 0 1.8922609115179512e-06
nystagmus I-Disease 0 8.440735541626054e-07
, O 0 9.233040443312746e-10
permitted O 0 2.842574786665608e-11
the O 0 2.1410122286180666e-10
correct O 0 2.65063171411839e-08
assignment O 0 1.5309044032463248e-09
of O 0 1.1666999311099602e-10
90 O 0 5.057108620754036e-10
% O 0 2.2844911726216388e-11
of O 0 2.4129268028083573e-11
the O 0 9.035312942273777e-09
SCA1 B-Disease 0 4.280751818441786e-05
, O 0 3.434536877122696e-09
90 O 0 2.097384071975128e-10
% O 0 2.1689899876164986e-11
of O 0 2.485682666641953e-11
the O 0 1.2122590042906722e-08
SCA2 B-Disease 0 0.000980942859314382
, O 0 2.3288947659239057e-08
and O 0 3.280517901771418e-08
93 O 0 6.163054422358982e-08
% O 0 1.0829075136609134e-10
of O 0 7.335414914377836e-11
the O 0 2.0370714892692376e-08
patients O 0 1.0500035507732264e-08
with O 0 3.5593393477029167e-07
SCA3 B-Disease 1 0.9998688697814941
to O 0 5.4394249104916526e-09
their O 0 1.1888519058089742e-09
genetically O 0 8.602833645454666e-08
confirmed O 0 7.743365131318569e-07
patient O 0 4.121320529293371e-08
group O 0 1.6011688330763718e-07
and O 0 9.716098503531612e-08
, O 0 3.67624224395513e-08
therefore O 0 2.605348381479189e-09
, O 0 1.2059239828943191e-08
may O 0 1.899762835932961e-08
help O 0 2.4575979029606287e-09
orient O 0 1.4170022950565908e-05
diagnoses O 0 7.341093919421837e-07
of O 0 3.725723729530728e-09
SCA1 B-Disease 0 0.0010688910260796547
, O 0 1.9320631849950587e-07
SCA2 B-Disease 0 0.0001547545107314363
, O 0 5.3756565421281266e-08
and O 0 1.192474542222044e-06
SCA3 B-Disease 1 0.9997701048851013
at O 0 9.743822602104046e-07
early O 0 1.7292160592319306e-08
clinical O 0 3.823167915584236e-08
stages O 0 1.6075965447726048e-07
of O 0 9.306703852018927e-09
the O 0 4.755968348035822e-06
diseases O 0 0.00035775863216258585
. O 0 4.545626453023033e-08
. O 0 7.618765494044055e-07

Genetic O 0 5.776677880930947e-06
basis O 0 8.843505838740384e-08
and O 0 5.071182727078849e-07
molecular O 0 4.999938028049655e-05
mechanism O 0 0.0003924953634850681
for O 0 0.011930324137210846
idiopathic B-Disease 1 0.99997878074646
ventricular I-Disease 1 0.9997169375419617
fibrillation I-Disease 1 0.9997836947441101
. O 0 0.00109160749707371

Ventricular B-Disease 1 0.9601170420646667
fibrillation I-Disease 1 0.6590057611465454
causes O 0 6.593808848265326e-06
more O 0 9.685597879283137e-10
than O 0 9.889918883843052e-10
300 O 0 3.2803413319015817e-09
, O 0 4.484353333111812e-09
000 O 0 8.349416269481935e-09
sudden O 0 2.1269158878567396e-07
deaths O 0 1.0666896343991539e-07
each O 0 2.5397040026575723e-10
year O 0 5.4008559402518586e-08
in O 0 7.931226342350328e-09
the O 0 1.5061253577641764e-07
USA O 0 0.00010539600043557584
alone O 0 2.4357836991839577e-06
. O 0 8.782788540884212e-08

In O 0 6.365292648524701e-08
approximately O 0 6.960089837804162e-09
5 O 0 4.589525559595131e-08
- O 0 4.665228334488347e-05
12 O 0 3.956894829570956e-07
% O 0 4.0075739948797207e-10
of O 0 9.420566410289766e-11
these O 0 2.7467400576242085e-10
cases O 0 4.154585120375032e-09
, O 0 6.033240573799503e-09
there O 0 6.831405441332095e-10
are O 0 8.110591642740417e-10
no O 0 5.08935578125147e-08
demonstrable O 0 4.221330164000392e-05
cardiac O 0 0.002624048152938485
or O 0 7.084194635353924e-07
non O 0 4.847954073738947e-07
- O 0 0.4084816575050354
cardiac O 0 0.04710415005683899
causes O 0 4.384103391430472e-08
to O 0 1.7234003113486551e-09
account O 0 6.614913061753214e-10
for O 0 2.556480860338439e-10
the O 0 4.744287185332041e-09
episode O 0 1.9957151380367577e-06
, O 0 1.4420120919567125e-07
which O 0 3.4239231894162e-08
is O 0 4.320810376157169e-09
therefore O 0 8.34709101837916e-09
classified O 0 2.843397123797331e-05
as O 0 0.007986189797520638
idiopathic B-Disease 1 0.9999958276748657
ventricular I-Disease 1 0.9999655485153198
fibrillation I-Disease 1 0.9999829530715942
( O 0 0.0003806922468356788
IVF B-Disease 1 0.999881386756897
) O 0 6.673722964478657e-06
. O 0 1.8747367676041904e-06

A O 0 4.3386054926486395e-07
distinct O 0 7.225034437396971e-08
group O 0 3.0724115731572965e-06
of O 0 2.3460697775590234e-06
IVF B-Disease 1 0.9999672174453735
patients O 0 5.072365638625342e-06
has O 0 7.240567470034875e-07
been O 0 6.835020940343384e-07
found O 0 2.957922049517947e-07
to O 0 1.8454824335378817e-09
present O 0 1.224724655024545e-09
with O 0 6.9049774786833495e-09
a O 0 1.7117362460794538e-07
characteristic O 0 2.3444549697160255e-06
electrocardiographic O 0 0.0003369948535691947
pattern O 0 7.238206308102235e-05
. O 0 3.361099516041577e-06

Because O 0 2.6549784593044023e-07
of O 0 1.2222579615084328e-09
the O 0 3.0351856583621384e-09
small O 0 4.613888382465348e-09
size O 0 1.2164424845195754e-07
of O 0 7.901265197673979e-10
most O 0 1.0105255521253298e-09
pedigrees O 0 8.164470273186453e-07
and O 0 3.562184502925447e-08
the O 0 3.550503890892287e-08
high O 0 3.7674726627301425e-05
incidence O 0 7.402372830256354e-06
of O 0 2.7721784867651422e-09
sudden B-Disease 0 8.948736649472266e-06
death I-Disease 0 4.746457307192031e-06
, O 0 3.212002752661647e-08
however O 0 5.527623692103134e-09
, O 0 3.0607243406421958e-09
molecular O 0 2.7878812147719145e-07
genetic O 0 9.668751772551332e-07
studies O 0 5.748896469981446e-08
of O 0 8.360733971812806e-08
IVF B-Disease 1 0.9999163150787354
have O 0 5.4399045268382906e-08
not O 0 1.2792136239170304e-09
yet O 0 3.506595014357572e-09
been O 0 3.089488842533683e-08
done O 0 6.734999402624453e-08
. O 0 1.1722200099484326e-07

Because O 0 0.000346270389854908
IVF B-Disease 1 0.998964786529541
causes O 0 0.0009319155942648649
cardiac O 0 0.023672878742218018
rhythm O 0 0.002255198545753956
disturbance O 0 0.00021942384773865342
, O 0 3.1503401487498195e-07
we O 0 3.96082633358219e-09
investigated O 0 8.47888230737226e-08
whether O 0 1.4409942572513046e-08
malfunction O 0 9.393211075803265e-05
of O 0 1.372471164495792e-10
ion O 0 5.703576334781246e-06
channels O 0 2.1127911168150604e-05
could O 0 3.384686806384707e-06
cause O 0 2.066847883952505e-07
the O 0 4.314438797337061e-07
disorder O 0 3.6374738556332886e-05
by O 0 3.1609854733716247e-09
studying O 0 2.3855424302610118e-08
mutations O 0 3.996487052404518e-08
in O 0 3.913591228865698e-09
the O 0 5.931725155505774e-08
cardiac O 0 5.662268813466653e-05
sodium O 0 2.6705800237891708e-08
channel O 0 5.438334483187646e-06
gene O 0 1.1011774176949984e-06
SCN5A O 0 0.0005582487210631371
. O 0 1.8329512840864481e-06

We O 0 7.044224616947758e-07
have O 0 7.99064565626395e-08
now O 0 4.820037702302216e-09
identified O 0 7.33497484972645e-09
a O 0 8.998662259784851e-09
missense O 0 5.710297159566835e-07
mutation O 0 3.001732196139528e-08
, O 0 5.2374131698229576e-09
a O 0 9.265064271346546e-09
splice O 0 0.001767622889019549
- O 0 0.025094231590628624
donor O 0 3.8284190395643236e-07
mutation O 0 2.7359821075378932e-08
, O 0 9.190631367061997e-09
and O 0 2.0167595593534315e-08
a O 0 4.763993644019138e-08
frameshift O 0 7.020723387540784e-06
mutation O 0 8.655629990528269e-09
in O 0 1.5413260667784812e-09
the O 0 1.4496253974982665e-08
coding O 0 3.0339824661496095e-05
region O 0 1.5970321953773237e-08
of O 0 7.976571403389698e-09
SCN5A O 0 0.000564435264095664
in O 0 5.6055036168345396e-08
three O 0 2.93260814032692e-06
IVF B-Disease 1 0.9998050332069397
families O 0 2.0460997802729253e-06
. O 0 5.095960773360275e-07

We O 0 1.2633472579182126e-07
show O 0 2.3772345869588207e-08
that O 0 1.8102906673700403e-10
sodium O 0 2.0568285963307176e-10
channels O 0 1.3372793983279507e-09
with O 0 8.064899859050456e-10
the O 0 5.916423351237654e-09
missense O 0 4.079693951553054e-07
mutation O 0 9.981821591509288e-08
recover O 0 7.287369498953922e-07
from O 0 1.0823897333978039e-09
inactivation O 0 7.738241833976645e-07
more O 0 2.095100135046657e-11
rapidly O 0 9.856191418577964e-10
than O 0 5.86116780110224e-11
normal O 0 1.171740593441939e-09
and O 0 1.7154647480310814e-08
that O 0 8.473979740131199e-09
the O 0 1.9576617660277407e-08
frameshift O 0 1.350633283436764e-05
mutation O 0 2.0297450831208153e-08
causes O 0 1.1978952274560584e-09
the O 0 8.360403341844957e-11
sodium O 0 2.081269379061723e-09
channel O 0 5.26734027062048e-07
to O 0 9.841502057739149e-10
be O 0 8.371481285962545e-10
non O 0 1.0308122133650954e-09
- O 0 3.474379127510474e-06
functional O 0 4.9157911519159825e-08
. O 0 3.9442960542146466e-07

Our O 0 2.8743707503053884e-07
results O 0 5.089831347504514e-07
indicate O 0 1.6512029787918436e-07
that O 0 1.2044458763682542e-08
mutations O 0 1.715006803237884e-08
in O 0 9.20993414865734e-09
cardiac O 0 3.9312883018283173e-05
ion O 0 2.5857169021037407e-05
- O 0 0.002151664812117815
channel O 0 8.583821909269318e-06
genes O 0 1.6889968312838732e-09
contribute O 0 3.539355614146089e-11
to O 0 2.2608938332613349e-10
the O 0 9.063551686949722e-09
risk O 0 4.879080961472937e-08
of O 0 1.3263006248820375e-09
developing O 0 3.5749269500229275e-07
IVF B-Disease 1 0.977893590927124
. O 0 2.6666512553674693e-07
. O 0 2.346120737684032e-07

Molecular O 0 1.164814875664888e-05
heterogeneity O 0 2.1203582946327515e-05
in O 0 1.24199402762315e-06
mucopolysaccharidosis B-Disease 0 0.002090500434860587
IVA I-Disease 0 0.10424179583787918
in O 0 1.9135316620122467e-07
Australia O 0 3.569815731907511e-08
and O 0 1.0061564914565224e-08
Northern O 0 6.546235553628321e-09
Ireland O 0 2.0642785258928598e-08
: O 0 4.203099257527043e-10
nine O 0 3.8586600581425046e-09
novel O 0 8.475288915121837e-09
mutations O 0 5.59916379927472e-09
including O 0 2.6186304236119895e-09
T312S O 0 3.2113968018165906e-07
, O 0 4.9344919261784526e-09
a O 0 3.3522189468726538e-09
common O 0 1.0549840112616948e-08
allele O 0 1.5020616217498173e-07
that O 0 3.30569882578402e-08
confers O 0 3.0029838171685697e-07
a O 0 4.628752208191145e-07
mild O 0 5.1684626669157296e-05
phenotype O 0 5.90280324104242e-05
. O 0 1.3284301303428947e-06

Mucopolysaccharidosis B-Disease 0 0.4095425605773926
IVA I-Disease 1 0.9946251511573792
( O 0 0.0002664247585926205
MPS B-Disease 1 0.9991342425346375
IVA I-Disease 1 0.9999401569366455
) O 0 0.00010189367458224297
is O 0 1.5138019762162003e-06
an O 0 8.164865903381724e-06
autosomal B-Disease 1 0.9787178039550781
recessive I-Disease 1 0.9990932941436768
lysosomal I-Disease 1 0.9998921155929565
storage I-Disease 1 0.9999195337295532
disorder I-Disease 1 0.9984052777290344
caused O 0 0.00011080118565587327
by O 0 1.2822364681142062e-07
a O 0 0.00011389190331101418
genetic B-Disease 1 0.9999226331710815
defect I-Disease 1 0.9998760223388672
in O 0 1.8659147826838307e-06
N O 0 0.0015211564023047686
- O 0 0.007446895353496075
acetylgalactosamine O 0 0.0007028986001387239
- O 0 0.001220485894009471
6 O 0 1.7319745893473737e-05
- O 0 0.029255829751491547
sulfate O 0 0.00027627378585748374
sulfatase O 0 0.0001743065076880157
( O 0 1.4508397150336805e-08
GALNS O 0 3.456803096923977e-05
) O 0 1.1940795019427242e-08
. O 0 5.202459618658395e-08

Previous O 0 7.678025212953798e-06
studies O 0 5.625435051115346e-07
of O 0 1.4534377257291453e-08
patients O 0 2.3433495144331573e-08
from O 0 2.0080874740813215e-09
a O 0 4.210268755855395e-08
British O 0 4.233965228195302e-05
- O 0 0.003510595764964819
Irish O 0 1.4843951703369385e-06
population O 0 6.011722231136218e-10
showed O 0 1.3096153850256087e-07
that O 0 9.882432649988004e-10
the O 0 1.5923077301138733e-09
I113F O 0 1.0550145645993325e-07
mutation O 0 3.50269147020299e-09
is O 0 1.066045918207692e-09
the O 0 4.383229335047645e-10
most O 0 1.1552847567486424e-10
common O 0 9.155232683077941e-10
single O 0 2.1293304897085363e-08
mutation O 0 3.079306054587505e-07
among O 0 6.923224304955511e-07
MPS B-Disease 1 0.9998264908790588
IVA I-Disease 1 0.9999954700469971
patients O 0 3.6242875012248987e-06
and O 0 3.3750418992894993e-07
produces O 0 4.3617754386104934e-07
a O 0 4.047411493957043e-06
severe O 0 0.00014590081991627812
clinical O 0 5.22349137099809e-06
phenotype O 0 8.763828373048455e-05
. O 0 3.7186266581556993e-06

We O 0 5.336204011996415e-08
studied O 0 4.109451978706602e-08
mutations O 0 5.8320154039392946e-08
in O 0 4.7877390940698206e-09
the O 0 1.107686475876335e-08
GALNS O 0 1.7046599168679677e-05
gene O 0 3.3166547286356263e-09
from O 0 1.9300245845954578e-09
23 O 0 1.9857047561799845e-08
additional O 0 1.4635553213793173e-08
MPS B-Disease 1 0.9970736503601074
IVA I-Disease 1 0.9999891519546509
patients O 0 1.4922212585588568e-06
( O 0 1.0516525428272416e-09
15 O 0 3.394471592699233e-09
from O 0 8.330021672442456e-10
Australia O 0 7.1598282858076345e-09
, O 0 9.692749936007772e-10
8 O 0 4.63378491133426e-09
from O 0 3.768431677819706e-10
Northern O 0 2.0632315411717173e-08
Ireland O 0 2.732582515818649e-07
) O 0 8.789153405075467e-09
, O 0 9.284926716368602e-10
with O 0 8.277865060080103e-10
various O 0 8.867481748886519e-10
clinical O 0 6.582283731404459e-07
phenotypes O 0 8.147839253069833e-06
( O 0 5.309310324719263e-08
severe O 0 2.4064283934421837e-06
, O 0 2.6924398710548303e-08
16 O 0 6.019966747317085e-08
cases O 0 6.755169756900159e-09
; O 0 1.563876361743155e-09
intermediate O 0 1.3461961323457672e-08
, O 0 7.616932862219983e-09
4 O 0 1.2439245722362102e-07
cases O 0 2.460849657381914e-08
; O 0 5.329785324192926e-08
mild O 0 7.427287869177235e-07
, O 0 5.093997401672823e-08
3 O 0 1.5693939303673687e-07
cases O 0 5.446403861242288e-08
) O 0 6.30252046107671e-08
. O 0 1.374831128941878e-07

We O 0 6.121757678556605e-07
found O 0 2.4239463414232887e-07
two O 0 1.1094266838540534e-08
common O 0 4.144069265521466e-08
mutations O 0 5.351564169586709e-08
that O 0 1.241854530320552e-08
together O 0 2.785557740025979e-08
accounted O 0 1.3274579657718277e-08
for O 0 2.980875823954676e-10
32 O 0 2.7362586862977878e-08
% O 0 4.5185483132925697e-10
of O 0 6.024598181442187e-11
the O 0 9.902248798709934e-09
44 O 0 5.816351844600831e-08
unrelated O 0 2.973525852212333e-07
alleles O 0 1.0918975945628517e-08
in O 0 5.564276595038109e-09
these O 0 9.639124165516932e-09
patients O 0 1.4948093962630082e-07
. O 0 8.000463935786684e-07

One O 0 8.394609807282905e-08
is O 0 1.3115972308241908e-08
the O 0 3.806598147804152e-09
T312S O 0 7.548706548732298e-07
mutation O 0 5.4008559402518586e-08
, O 0 1.995051235326173e-08
a O 0 1.0551309159723132e-08
novel O 0 9.369865949793166e-08
mutation O 0 1.95001081948476e-08
found O 0 4.1116631877002874e-08
exclusively O 0 4.4022838707746814e-09
in O 0 5.474305098118748e-08
milder O 0 5.54009329789551e-06
patients O 0 3.474295908745262e-07
. O 0 9.379429002365214e-07

The O 0 1.0845606368548033e-07
other O 0 6.509568439838631e-09
is O 0 2.1735226951591358e-09
the O 0 1.5403679443082297e-09
previously O 0 1.526622384062648e-07
described O 0 2.321764668522519e-06
I113F O 0 1.0264745924359886e-06
that O 0 2.2914466768497732e-08
produces O 0 5.1379668519757615e-08
a O 0 5.331646093509335e-07
severe O 0 1.602901829755865e-05
phenotype O 0 2.1251336875138804e-05
. O 0 1.3758242403127952e-06

The O 0 1.4035310869076056e-07
I113F O 0 3.064054681090056e-06
and O 0 1.2199905086163199e-07
T312S O 0 6.437352908506e-07
mutations O 0 3.617977029080066e-08
accounted O 0 1.966729890057195e-08
for O 0 6.841889832465142e-10
8 O 0 1.2142102434609114e-07
( O 0 5.622062260179916e-10
18 O 0 6.058855461787971e-08
% O 0 1.2850878139403221e-09
) O 0 1.0063171407281857e-09
and O 0 2.9643230092801787e-08
6 O 0 1.9318311217375594e-07
( O 0 1.5966445943149665e-09
14 O 0 5.517219392459083e-08
% O 0 1.1861520654576907e-09
) O 0 3.270194393056869e-10
of O 0 2.3978566354720954e-10
44 O 0 3.314879393201409e-08
unrelated O 0 5.507524747372372e-07
alleles O 0 3.51789140040637e-08
, O 0 4.0733603157150355e-08
respectively O 0 2.8261885631764017e-07
. O 0 4.420528227910836e-07

The O 0 8.607560175732942e-08
relatively O 0 8.550274088747756e-08
high O 0 2.3773288830852835e-06
residual O 0 1.2754766203215695e-06
GALNS O 0 2.5939734769053757e-05
activity O 0 2.0943479839274914e-08
seen O 0 7.523914824503208e-09
when O 0 3.2804459149105014e-10
the O 0 4.120324220702187e-11
T312S O 0 4.506457873532099e-09
mutant O 0 7.2460917266425895e-09
cDNA O 0 3.58572975756033e-08
is O 0 1.5683659926324367e-09
overexpressed O 0 3.150964644760279e-08
in O 0 9.84065717801741e-10
mutant O 0 8.263376116701693e-08
cells O 0 7.965973658485836e-09
provides O 0 1.0066142364095754e-10
an O 0 5.877604514203938e-10
explanation O 0 5.3894594342907e-10
for O 0 4.113674956229829e-10
the O 0 2.1022165697104356e-07
mild O 0 3.627947808126919e-05
phenotype O 0 2.334605778742116e-05
in O 0 2.8917256145177817e-07
patients O 0 1.629030954575228e-08
with O 0 5.170849526336951e-09
this O 0 1.0179526555020857e-08
mutation O 0 2.0512837295427744e-07
. O 0 3.55959116404847e-07

The O 0 2.2450224790304674e-08
distribution O 0 1.5425795751866644e-08
and O 0 1.3157483991221852e-09
relative O 0 3.240675783278135e-10
frequencies O 0 2.0170498604699105e-10
of O 0 5.0538274953826345e-11
the O 0 9.95832749595138e-10
I113F O 0 4.786043561466613e-08
and O 0 4.715625667728318e-09
T312S O 0 2.9713365989891827e-08
mutations O 0 4.564895572656269e-09
in O 0 1.5570188471869528e-09
Australia O 0 4.165392031296733e-09
corresponded O 0 1.5603575098666056e-09
to O 0 1.4023195105128394e-10
those O 0 1.4652716540108912e-10
observed O 0 6.049845957534217e-09
in O 0 9.278606216689411e-10
Northern O 0 4.4760986028791194e-09
Ireland O 0 5.505288669382935e-08
and O 0 6.565730181762319e-09
are O 0 7.588962444571301e-12
unique O 0 7.0919958274073824e-12
to O 0 3.820712843327634e-11
these O 0 1.043137104472791e-11
two O 0 1.6960214344052815e-09
populations O 0 2.8840283494702135e-09
, O 0 3.5114007257419644e-09
suggesting O 0 3.0185312027697364e-08
that O 0 2.1299670915908564e-09
both O 0 4.911925310935317e-10
mutations O 0 2.444964897208024e-09
were O 0 1.6335985009163778e-08
probably O 0 6.805139118881698e-09
introduced O 0 1.02899910814358e-09
to O 0 8.803308637617135e-10
Australia O 0 3.0757054680918827e-09
by O 0 5.15523790323158e-10
Irish O 0 2.223739414830561e-08
migrants O 0 1.6026979743344327e-09
during O 0 4.4253911646308097e-10
the O 0 8.669504558689312e-10
19th O 0 4.6572587564241985e-08
century O 0 1.5253694130024087e-07
. O 0 3.283460898728663e-07

Haplotype O 0 9.522520849714056e-05
analysis O 0 6.239022098952773e-08
using O 0 4.3182090792015515e-08
6 O 0 4.334994798682601e-07
RFLPs O 0 1.0218431043540477e-06
provides O 0 2.983200492190363e-11
additional O 0 1.468163611517692e-11
data O 0 4.247952212210748e-09
that O 0 1.6698035176787585e-09
the O 0 3.0778770643280495e-09
I113F O 0 1.4480579011433292e-06
mutation O 0 1.4544776050229302e-08
originated O 0 2.1572963859739502e-08
from O 0 6.271085872811e-10
a O 0 1.4565014971879009e-08
common O 0 6.789557716047057e-08
ancestor O 0 1.853805770224426e-06
. O 0 2.7935711841564626e-06

The O 0 5.8148103221355996e-08
other O 0 1.755047485119121e-08
9 O 0 5.464956984724267e-07
novel O 0 8.968440567969083e-08
mutations O 0 2.7078076669795337e-08
identified O 0 1.3536454446239077e-07
in O 0 1.5000038544599192e-08
these O 0 3.0299451836413027e-09
23 O 0 1.1704722737704287e-06
patients O 0 5.3635993424450135e-09
were O 0 5.850786077843395e-09
each O 0 9.955643948122983e-11
limited O 0 3.9105149673979156e-10
to O 0 5.853316720205726e-10
a O 0 2.1470709654636266e-08
single O 0 6.310025923994544e-07
family O 0 0.00021574606944341213
. O 0 2.29649276661803e-06

These O 0 4.7654364898619406e-09
data O 0 5.99915983556798e-09
provide O 0 9.06279912227248e-11
further O 0 1.0853226650731074e-10
evidence O 0 2.0008006362814967e-09
for O 0 2.6231716451774467e-11
extensive O 0 5.231988731146942e-10
allelic O 0 3.843003355541441e-07
heterogeneity O 0 3.0844544198771473e-06
in O 0 3.83079986931989e-06
MPS B-Disease 1 0.994489312171936
IVA I-Disease 1 0.999970555305481
in O 0 1.5106695627764566e-06
British O 0 0.00040846169576980174
- O 0 0.17637215554714203
Irish O 0 0.00015252336743287742
patients O 0 1.7536487817437774e-08
and O 0 1.4598633413243078e-09
provide O 0 1.2513347996678803e-11
evidence O 0 1.5823561350103432e-09
for O 0 5.7312172369039516e-11
their O 0 8.157382547224756e-10
transmission O 0 1.8652564222065848e-06
to O 0 2.929624098868544e-09
Australia O 0 4.939021192029713e-09
by O 0 1.7388960271702558e-09
British O 0 1.2711122963082744e-06
- O 0 0.00012136990699218586
Irish O 0 5.77483149299951e-07
migrants O 0 1.7757487924541238e-08
. O 0 2.569269907937155e-09
. O 0 4.18367562815547e-08

Identification O 0 5.051768425801129e-07
of O 0 2.3858607534066323e-08
constitutional O 0 6.367490072989312e-07
WT1 O 0 0.000485484953969717
mutations O 0 2.1281707631715108e-06
, O 0 1.2531607751498086e-07
in O 0 3.4937389870037805e-08
patients O 0 1.8017598080177777e-08
with O 0 1.147814217006271e-07
isolated O 0 0.0009803841821849346
diffuse B-Disease 0 0.16503487527370453
mesangial I-Disease 1 0.9999898672103882
sclerosis I-Disease 1 0.9999946355819702
, O 0 2.950496127596125e-05
and O 0 2.531869540689513e-07
analysis O 0 6.094261095768161e-09
of O 0 3.0368938475078266e-09
genotype O 0 7.216382527985843e-06
/ O 0 6.897924322402105e-06
phenotype O 0 1.329030737906578e-06
correlations O 0 5.310070037012338e-07
by O 0 1.0776723957661716e-09
use O 0 2.7458965656812495e-10
of O 0 5.863977081688176e-10
a O 0 4.742661019463412e-08
computerized O 0 4.0523550524085294e-06
mutation O 0 4.632439356555551e-07
database O 0 7.192365387709287e-07
. O 0 1.7423269582650391e-06

Constitutional O 0 8.871124919096474e-07
mutations O 0 6.052433718650718e-07
of O 0 2.877895921571394e-09
the O 0 1.6722074391850583e-08
WT1 O 0 1.1333013389958069e-05
gene O 0 9.696100811140695e-09
, O 0 1.4907165502009434e-09
encoding O 0 3.793920289041353e-09
a O 0 1.062921683114837e-06
zinc O 0 0.006211727857589722
- O 0 0.0027029302436858416
finger O 0 0.00026915359194390476
transcription O 0 2.1769299252127894e-08
factor O 0 3.5822007582453352e-09
involved O 0 2.3463313514326956e-09
in O 0 1.7027488752319186e-07
renal O 0 0.1393362134695053
and O 0 1.4520849163091043e-06
gonadal O 0 0.0004210885090287775
development O 0 2.278619959383832e-08
, O 0 4.048541057954935e-09
are O 0 1.738775790016689e-10
found O 0 6.081641146238326e-08
in O 0 2.4027106970692103e-09
most O 0 2.1313082410046036e-09
patients O 0 1.3343576021895842e-08
with O 0 6.162318641145248e-06
Denys B-Disease 1 0.9998301267623901
- I-Disease 1 0.9999721050262451
Drash I-Disease 1 0.9999498128890991
syndrome I-Disease 1 0.9999016523361206
( O 0 2.6133932351513067e-07
DDS B-Disease 1 0.9999338388442993
) O 0 3.0182553700797143e-07
, O 0 1.1912182174000918e-07
or O 0 3.7043516840640223e-06
diffuse B-Disease 0 0.04388454556465149
mesangial I-Disease 1 0.9999874830245972
sclerosis I-Disease 1 0.999994158744812
( O 0 1.7664089682511985e-05
DMS B-Disease 1 0.7031517624855042
) O 0 2.921730413163459e-07
associated O 0 2.576800568476756e-07
with O 0 4.4720400182995945e-06
pseudohermaphroditism B-Disease 1 0.9999655485153198
and O 0 0.00013198898523114622
/ O 0 0.00022048165556043386
or O 0 0.0001471709256293252
Wilms B-Disease 1 0.9720982313156128
tumor I-Disease 1 0.7213192582130432
( O 0 2.120970066243899e-06
WT B-Disease 1 0.9995070695877075
) O 0 8.21392234229279e-07
. O 0 5.694558353752655e-07

Most O 0 1.3140642352027498e-07
mutations O 0 1.0441764061397407e-05
in O 0 1.443009477952728e-05
DDS B-Disease 1 0.9999475479125977
patients O 0 4.311705197324045e-06
lie O 0 7.2946122600114904e-06
in O 0 6.558558141023241e-09
exon O 0 5.813800498799537e-07
8 O 0 2.4447987811981875e-07
or O 0 1.010873074136498e-08
exon O 0 1.2462055565265473e-07
9 O 0 7.229817811094108e-08
, O 0 2.1054813448273535e-09
encoding O 0 1.4314011309579655e-08
zinc O 0 8.883661939762533e-05
finger O 0 6.703417602693662e-05
2 O 0 1.5175848488979682e-07
or O 0 2.41811420664817e-07
zinc O 0 7.07935614627786e-05
finger O 0 5.940326445852406e-05
3 O 0 7.449889949384669e-08
, O 0 1.1691270174196688e-08
respectively O 0 8.454025923754216e-09
, O 0 9.537474143783697e-10
with O 0 1.5537940933896266e-09
a O 0 4.489421812081673e-08
hot O 0 6.842052698630141e-06
spot O 0 1.823430648073554e-05
( O 0 2.0574457693101067e-09
R394W O 0 4.33766587093487e-08
) O 0 4.40565028902995e-10
in O 0 8.064883760816599e-10
exon O 0 1.5699613413744373e-06
9 O 0 3.303164021417615e-06
. O 0 1.73505128486795e-07

We O 0 7.509567012675689e-08
analyzed O 0 5.7109510009922815e-08
a O 0 4.211776261087152e-09
series O 0 4.192534674984927e-08
of O 0 7.0851249311942865e-09
24 O 0 1.3505484730558237e-06
patients O 0 1.0546641782127608e-08
, O 0 5.5017794764467e-09
10 O 0 1.2622099809789233e-08
with O 0 3.106424344423431e-07
isolated B-Disease 0 0.0015670679276809096
DMS I-Disease 0 0.33657005429267883
( O 0 1.4989286256650303e-08
IDMS B-Disease 0 1.6378535292460583e-05
) O 0 1.0598547817153303e-08
, O 0 2.6389872509469114e-09
10 O 0 3.674936355224645e-09
with O 0 1.8785273141475045e-06
DDS B-Disease 1 0.9999858140945435
, O 0 6.521028126371675e-07
and O 0 1.335837680471741e-07
4 O 0 4.874663090959075e-07
with O 0 4.149569122091634e-06
urogenital B-Disease 1 0.8923817276954651
abnormalities I-Disease 1 0.9674246907234192
and O 0 2.1376748918555677e-05
/ O 0 0.0001221734273713082
or O 0 0.00011800918582594022
WT B-Disease 1 0.9996063113212585
. O 0 1.6909767509787343e-05

We O 0 8.907629194254696e-07
report O 0 5.190773890717537e-07
WT1 O 0 1.4100169209996238e-05
heterozygous O 0 2.220065624669587e-07
mutations O 0 7.708603533274072e-08
in O 0 4.5958152838920796e-08
16 O 0 3.4668519788283447e-07
patients O 0 7.380545952173634e-08
, O 0 1.726655263212251e-08
4 O 0 5.845156181294442e-08
of O 0 5.407522429834444e-09
whom O 0 2.3365170420674986e-07
presented O 0 2.24377103563711e-07
with O 0 1.8540196151661803e-06
IDMS B-Disease 0 0.006438565440475941
. O 0 1.151457922787813e-06

One O 0 8.237754514084372e-07
male O 0 5.957372195553035e-07
and O 0 2.2887520856329502e-07
two O 0 2.584982041753392e-07
female O 0 1.1920918041141704e-05
IDMS B-Disease 0 0.02355257049202919
patients O 0 9.662468158921911e-08
with O 0 2.471306572715548e-07
WT1 O 0 0.0024399003013968468
mutations O 0 2.0607319584087236e-06
underwent O 0 1.5106988030311186e-05
normal O 0 8.460125400233665e-07
puberty O 0 4.360086313681677e-05
. O 0 1.3021150380154722e-06

Two O 0 4.8862420953810215e-06
mutations O 0 2.281532943015918e-05
associated O 0 2.172145514123258e-06
with O 0 6.947505539756094e-07
IDMS B-Disease 0 0.0006574286380782723
are O 0 7.01432689709236e-10
different O 0 1.8769513721039743e-10
from O 0 5.212021036982151e-09
those O 0 3.361382994171436e-08
described O 0 0.00011463280679890886
in O 0 1.9618650185293518e-05
DDS B-Disease 1 0.9999322891235352
patients O 0 4.042967248096829e-06
. O 0 6.330694191092334e-07

No O 0 2.8078927698516054e-06
WT1 O 0 0.00016202185361180454
mutations O 0 1.1868586398122716e-06
were O 0 1.231599924267357e-07
detected O 0 7.861974040679343e-07
in O 0 4.588796898019609e-09
the O 0 1.3702047496622072e-08
six O 0 3.057263313621661e-07
other O 0 1.0139437733869272e-07
IDMS B-Disease 0 0.01905105821788311
patients O 0 5.250518242405633e-08
, O 0 1.8447900984597254e-08
suggesting O 0 3.835735356005898e-07
genetic O 0 2.6171741751568334e-07
heterogeneity O 0 1.2610737485374557e-06
of O 0 7.681846625473554e-08
this O 0 1.497941752859333e-06
disease O 0 0.00016616420180071145
. O 0 8.703674438947928e-07

We O 0 2.783619947877014e-07
analyzed O 0 1.0223558319921722e-06
genotype O 0 9.744875569595024e-06
/ O 0 1.3919616321800277e-05
phenotype O 0 3.6377437027113046e-06
correlations O 0 7.205009751487523e-06
, O 0 1.3611860083528882e-07
on O 0 8.888181923794036e-08
the O 0 1.4993195573964613e-09
basis O 0 5.51633017042974e-10
of O 0 1.4846441853677561e-09
the O 0 3.975822338020407e-08
constitution O 0 9.434080183723381e-09
of O 0 6.4785982134552e-10
a O 0 8.872836332329825e-08
WT1 O 0 1.0782058780023362e-05
mutation O 0 1.1913489084136586e-09
database O 0 1.5478722747985785e-09
of O 0 5.651264789463539e-09
84 O 0 2.20472384171444e-06
germ O 0 0.005642063450068235
- O 0 0.003372788894921541
line O 0 1.564710146340076e-05
mutations O 0 2.9202251283777514e-08
, O 0 3.4997729159158553e-09
to O 0 3.486266553220929e-10
compare O 0 8.925821193273009e-10
the O 0 2.8319532829890193e-10
distribution O 0 3.259014391687742e-08
and O 0 6.867730917292647e-08
type O 0 2.0056234006915474e-08
of O 0 2.120615238965229e-09
mutations O 0 5.719093820744092e-08
, O 0 8.565549158845442e-09
according O 0 5.345274778356668e-10
to O 0 2.443136248864164e-10
the O 0 2.3004795846048864e-09
different O 0 1.4663634750888832e-08
symptoms O 0 9.506577498541446e-07
. O 0 2.945437813650642e-07

This O 0 1.3623872519019642e-07
demonstrated O 0 2.1798857687826967e-06
( O 0 7.098082566159292e-09
1 O 0 1.892612644383007e-08
) O 0 2.2599120352850832e-09
the O 0 3.4470128973396186e-09
association O 0 1.1263470156563926e-09
between O 0 2.2243067387961446e-09
mutations O 0 2.7040076844286887e-09
in O 0 9.347473906018422e-10
exons O 0 8.300038700781442e-08
8 O 0 1.9851485433264315e-07
and O 0 8.911982263271057e-08
9 O 0 1.071250153472647e-06
and O 0 2.23275105781795e-06
DMS B-Disease 0 0.04358997941017151
; O 0 3.064435105670782e-08
( O 0 4.939169628848106e-10
2 O 0 2.993596126543707e-08
) O 0 8.427911701858193e-09
among O 0 2.003645693804401e-09
patients O 0 3.829384365161559e-09
with O 0 2.61694481196173e-07
DMS B-Disease 0 0.005158551502972841
, O 0 2.4336404003122425e-09
a O 0 1.9301896192480683e-10
higher O 0 9.102869152899373e-11
frequency O 0 2.8141680652460366e-10
of O 0 8.534408596494458e-11
exon O 0 7.727726369921584e-08
8 O 0 4.58971847194789e-08
mutations O 0 4.485225968409168e-09
among O 0 1.2347257660749733e-09
46 O 0 1.5527170660334377e-07
, O 0 3.697983856909559e-07
XY O 0 0.11661569774150848
patients O 0 6.9169465710672284e-09
with O 0 3.6598828412337525e-09
female O 0 8.423479869179573e-08
phenotype O 0 2.3955740857672936e-07
than O 0 1.4647358881347827e-09
among O 0 4.202532100094913e-09
46 O 0 1.249907654710114e-06
, O 0 4.276168965589022e-06
XY O 1 0.9337132573127747
patients O 0 4.0125957667669354e-08
with O 0 1.3307509760807079e-08
sexual O 0 7.685158465164932e-08
ambiguity O 0 3.189975075201801e-07
or O 0 2.3812380334220506e-07
male O 0 5.326899099600269e-07
phenotype O 0 2.902215101130423e-06
; O 0 5.1179359417119485e-08
and O 0 9.986141549234162e-07
( O 0 2.6002546782422087e-09
3 O 0 1.5551291809856593e-08
) O 0 4.58563603755735e-10
statistically O 0 1.9871347622935076e-10
significant O 0 1.0645540005072007e-10
evidence O 0 1.0871635147680081e-08
that O 0 8.566283682398534e-09
mutations O 0 3.032766704436085e-09
in O 0 1.286389994525905e-09
exons O 0 1.638879751908462e-07
8 O 0 6.725987589106808e-08
and O 0 2.7292273330203898e-08
9 O 0 1.0767364244657074e-07
preferentially O 0 1.0109289405590971e-08
affect O 0 2.522084485701015e-10
amino O 0 1.2905154722631096e-10
acids O 0 1.1593413729027446e-11
with O 0 3.0408380674584734e-11
different O 0 6.301618515197616e-12
functions O 0 6.923856626928071e-11
. O 0 8.535067763659754e-09
. O 0 1.1760136686689293e-07

The O 0 3.6336382436275017e-07
185delAG O 0 5.981350113870576e-05
BRCA1 O 0 4.2355484765721485e-05
mutation O 0 3.444156391196884e-07
originated O 0 4.2446014703045876e-08
before O 0 5.2113553472565854e-09
the O 0 1.2884108224753277e-09
dispersion O 0 3.738054203950014e-07
of O 0 1.1386810383484658e-09
Jews O 0 3.368108636436773e-08
in O 0 4.533182274002456e-09
the O 0 9.704057113424369e-09
diaspora O 0 1.0241421222190183e-07
and O 0 9.897098607325461e-08
is O 0 4.691886434926573e-09
not O 0 3.980180907081632e-10
limited O 0 5.582057593933598e-10
to O 0 6.3338743139240705e-09
Ashkenazim O 0 1.1984899174422026e-05
. O 0 1.7810430108511355e-07

The O 0 1.7449379186018632e-07
185delAG O 0 1.3583123291027732e-05
mutation O 0 3.2013730333346757e-07
in O 0 9.999219230394374e-08
BRCA1 O 0 1.077347496902803e-05
is O 0 5.045071205245222e-08
detected O 0 2.8284534892009106e-07
in O 0 1.0283050855264264e-08
Ashkenazi O 0 5.343116299627582e-06
Jews O 0 2.6938367980733346e-08
both O 0 8.934103234992108e-09
in O 0 4.801633508577652e-07
familial B-Disease 1 0.762893795967102
breast I-Disease 1 0.999956488609314
and I-Disease 1 0.9999675750732422
ovarian I-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999878406524658
and O 0 2.4388543806708185e-06
in O 0 8.287395658612695e-09
the O 0 1.036676522403468e-08
general O 0 1.0204136202673908e-08
population O 0 1.2607278776499697e-08
. O 0 6.975581641199824e-07

All O 0 6.443003286449311e-08
tested O 0 3.343548087286763e-06
Ashkenazi O 0 2.644147571118083e-05
mutation O 0 5.104083697915485e-07
carriers O 0 9.220870822446159e-08
share O 0 1.9908052095729545e-08
the O 0 6.984555711575524e-10
same O 0 2.415489364082646e-09
allelic O 0 2.635176997500821e-06
pattern O 0 2.4705161195015535e-05
at O 0 3.6723495213664137e-06
the O 0 3.182078103236563e-07
BRCA1 O 0 0.00019589367730077356
locus O 0 8.848700963426381e-05
. O 0 7.908124644018244e-06

Our O 0 1.1192209825594546e-07
previous O 0 7.672927608837199e-07
study O 0 1.4407303794428117e-08
showed O 0 6.726795618305914e-07
that O 0 2.625496930974691e-09
this O 0 2.5362090205760524e-10
Ashkenazi O 0 2.187324298574822e-06
mutation O 0 2.5839558048801337e-08
also O 0 1.2198741217162024e-07
occurs O 0 4.166265998861718e-09
in O 0 5.590122809095988e-10
Iraqi O 0 1.687838313557677e-08
Jews O 0 2.3340165355989484e-09
with O 0 1.3766955353489152e-09
a O 0 1.6519630108291494e-08
similar O 0 9.730750605285721e-08
allelic O 0 4.404912397149019e-05
pattern O 0 0.0004732837260235101
. O 0 2.929228685388807e-06

We O 0 4.582598478464206e-08
extended O 0 2.8853377465054564e-09
our O 0 1.1733216620513076e-09
analysis O 0 5.230093580443906e-10
to O 0 6.394781232321733e-11
other O 0 6.938265934008925e-11
non O 0 8.399919093626806e-10
- O 0 3.897027340826753e-07
Ashkenazi O 0 1.6854134798904852e-07
subsets O 0 1.3141740140554248e-08
354 O 0 1.0918417103766842e-07
of O 0 2.165721074698368e-10
Moroccan O 0 9.071126783055661e-07
origin O 0 2.95835111963072e-09
, O 0 1.6848720196804834e-09
200 O 0 9.75095670874282e-10
Yemenites O 0 1.1648826614418795e-07
and O 0 3.778617418959129e-09
150 O 0 7.327616291519234e-10
Iranian O 0 1.4611258869479116e-08
Jews O 0 2.8160984655301036e-08
. O 0 1.7074678737571958e-07

Heteroduplex O 0 0.00022788527712691575
analysis O 0 4.84238604769871e-08
complemented O 0 6.801676732948181e-08
by O 0 4.665781094814747e-10
direct O 0 4.552647842048785e-11
DNA O 0 3.225023093023083e-08
sequencing O 0 2.03379482144328e-08
of O 0 9.549196988700714e-10
abnormally O 0 3.8841525906718743e-07
migrating O 0 1.2128874571359916e-09
bands O 0 8.888398461692759e-09
were O 0 2.1402918548574235e-08
employed O 0 9.109830045872513e-08
. O 0 1.152848483343405e-07

Four O 0 8.637987036763661e-08
of O 0 2.211202110302679e-09
Moroccan O 0 3.3046699172700755e-06
origin O 0 2.053017134073798e-08
( O 0 2.8141036723106083e-10
1 O 0 2.4625798622501804e-10
. O 0 2.6681845621823186e-10
1 O 0 3.5835536760231435e-09
% O 0 9.556685443001811e-10
) O 0 1.3481481486721236e-09
and O 0 4.990468038812423e-09
none O 0 3.516251179114249e-10
of O 0 2.4529824352303997e-11
the O 0 3.544831761459477e-09
Yemenites O 0 5.58217379875714e-07
or O 0 1.741622135398302e-08
Iranians O 0 6.183235967682776e-08
was O 0 3.650438884506002e-07
a O 0 5.8955382797876155e-09
carrier O 0 5.656767143591424e-07
of O 0 6.645821670758778e-10
the O 0 7.335747653769431e-08
185delAG O 0 2.886388756451197e-05
mutation O 0 3.388732636722125e-07
. O 0 5.422459139481361e-07

BRCA1 O 0 0.0008544091251678765
allelic O 0 0.00011745998199330643
patterns O 0 8.302655623992905e-05
were O 0 5.722453693124407e-07
determined O 0 1.2506738755746483e-07
for O 0 5.344010789443132e-10
four O 0 1.044042363673725e-08
of O 0 4.977812606554721e-10
these O 0 5.98686877850696e-10
individuals O 0 6.108044625641185e-11
and O 0 9.146662316439347e-10
for O 0 7.509813604311688e-11
12 O 0 1.2416619954436214e-09
additional O 0 3.8477644681567114e-11
non O 0 1.3139176413545783e-09
- O 0 6.869322078273399e-06
Ashkenazi O 0 3.875740731018595e-06
185delAG O 0 1.6547908217035001e-06
mutation O 0 5.1235225839718623e-08
carriers O 0 6.954850562124193e-08
who O 0 4.4857424654765055e-06
had O 0 0.334138959646225
breast B-Disease 1 0.9987945556640625
/ I-Disease 1 0.999613344669342
ovarian I-Disease 1 0.999976634979248
cancer I-Disease 1 0.9998224377632141
. O 0 6.734461203450337e-05

Six O 0 1.3063563528703526e-06
non O 0 3.5946251841778576e-07
- O 0 0.0004412792040966451
Ashkenazi O 0 0.00023485171550419182
individuals O 0 3.890504807202433e-09
shared O 0 6.9418999437687035e-09
the O 0 4.632017436279057e-09
common O 0 3.9291130349283776e-08
Ashkenazi O 0 7.076426118146628e-05
haplotype O 0 0.0012809827458113432
, O 0 1.0443614684163549e-07
four O 0 5.732439589678506e-08
had O 0 6.032695637259167e-06
a O 0 2.097586104810034e-08
closely O 0 1.6694055204879987e-07
related O 0 2.903702522871754e-07
pattern O 0 1.2721195162157528e-05
, O 0 4.516975948831714e-08
and O 0 1.5436274480862267e-08
the O 0 1.2222423073637856e-08
rest O 0 1.0556003360306931e-07
( O 0 1.3918507457688634e-09
n O 0 7.729686331003904e-07
= O 0 1.2006770475636586e-06
6 O 0 1.6318273310389486e-07
) O 0 1.9132198048055216e-09
displayed O 0 4.4614317573632434e-08
a O 0 2.4356848982165502e-08
distinct O 0 3.182869789952747e-08
BRCA1 O 0 2.844397931767162e-05
allelic O 0 4.200272815069184e-05
pattern O 0 0.001500406302511692
. O 0 9.30907299334649e-06

We O 0 1.1777117236988488e-07
conclude O 0 1.1671289001924379e-07
that O 0 1.879166156015799e-09
the O 0 2.41332953621054e-09
185delAG O 0 5.495381628861651e-06
BRCA1 O 0 3.9945543903741054e-06
mutation O 0 4.891007066021302e-08
occurs O 0 5.700565797184254e-09
in O 0 4.524628172131173e-10
some O 0 3.716251958940653e-11
non O 0 1.9115931060298408e-09
- O 0 1.082423568732338e-05
Ashkenazi O 0 1.055449502018746e-05
populations O 0 5.147302140073862e-09
at O 0 3.580645397960325e-07
rates O 0 1.1503632180165368e-07
comparable O 0 4.92333285251334e-09
with O 0 3.9662011452890056e-09
that O 0 2.1091562274477837e-08
of O 0 1.4707807416414198e-08
Ashkenazim O 0 0.0003033786197192967
. O 0 9.035193215822801e-07

The O 0 2.3808564719729475e-07
majority O 0 2.243969277060387e-08
of O 0 1.0037637387938503e-09
Jewish O 0 6.299504207163409e-08
185delAG O 0 4.313025328883668e-06
mutation O 0 7.037208149540675e-08
carriers O 0 1.6825445925405802e-08
have O 0 9.166782333203116e-10
a O 0 1.4910293000269803e-09
common O 0 6.805216834493422e-09
allelic O 0 8.983814041130245e-06
pattern O 0 0.0004167027655057609
, O 0 6.494155257996681e-08
supporting O 0 2.928640663313331e-09
the O 0 1.005130201292559e-08
founder O 0 1.2148349242124823e-06
effect O 0 1.5264987052177048e-09
notion O 0 9.713237991704204e-10
, O 0 4.88672435849935e-09
but O 0 3.976919682457947e-09
dating O 0 8.814171081894528e-08
the O 0 2.787820641003691e-09
mutations O 0 1.0006064421475003e-08
origin O 0 5.925296364672761e-10
to O 0 2.834714685207018e-10
an O 0 1.7953782904811533e-09
earlier O 0 6.475366944869165e-07
date O 0 1.5814034526329124e-08
than O 0 9.088994001871242e-10
currently O 0 5.841809258555486e-09
estimated O 0 5.323618523789264e-08
. O 0 8.35630231676987e-08

However O 0 4.800168653673609e-07
, O 0 3.927560054961532e-09
the O 0 3.843678847426091e-11
different O 0 1.2227277350340682e-11
allelic O 0 1.4513510393499018e-07
pattern O 0 8.0108029578696e-06
at O 0 5.288286047289148e-06
the O 0 5.4104138058619355e-08
BRCA1 O 0 6.6267411966691725e-06
locus O 0 2.6857724151341245e-06
even O 0 1.0289372198712954e-07
in O 0 3.4962235329061286e-09
some O 0 8.916831856220497e-11
Jewish O 0 3.731414821572798e-08
mutation O 0 3.905986289964858e-08
carriers O 0 5.334657160460665e-08
, O 0 8.1743202429152e-08
might O 0 4.58439934902799e-08
suggest O 0 3.914143675842752e-09
that O 0 7.525131073826685e-10
the O 0 1.312960740129654e-09
mutation O 0 1.4973162709708276e-09
arose O 0 2.4225164096947083e-09
independently O 0 3.872174580976662e-09
. O 0 7.30828775274972e-09
. O 0 1.2491969414440973e-07

Crystal O 0 0.004807098302990198
structure O 0 1.1791620408985182e-06
of O 0 7.605017060541286e-08
the O 0 1.015138241200475e-05
hemochromatosis B-Disease 1 0.9999059438705444
protein O 0 4.321185315347975e-06
HFE O 0 4.50570514658466e-05
and O 0 1.0441762299251423e-07
characterization O 0 1.1078940787001557e-07
of O 0 2.1640363112584993e-10
its O 0 1.4536144510302051e-09
interaction O 0 5.168628303131584e-10
with O 0 3.7694199761517666e-08
transferrin O 0 1.309242634306429e-05
receptor O 0 7.418128689096193e-08
. O 0 1.3459782621794147e-07

HFE O 0 0.00975747313350439
is O 0 1.021394950839749e-06
an O 0 7.35724228206891e-08
MHC O 0 5.858991789864376e-05
- O 0 0.003717022715136409
related O 0 1.2717453046207083e-06
protein O 0 1.3496102013732525e-08
that O 0 2.314819669280155e-09
is O 0 8.021039943351127e-10
mutated O 0 8.679750251872065e-09
in O 0 6.203351166078619e-09
the O 0 4.8305919335689396e-06
iron B-Disease 1 0.998991072177887
- I-Disease 1 0.9998297691345215
overload I-Disease 1 0.9994423985481262
disease I-Disease 1 0.9760816693305969
hereditary B-Disease 1 0.9999583959579468
hemochromatosis I-Disease 1 0.999985933303833
. O 0 0.0019892193377017975

HFE O 0 0.0003017802082467824
binds O 0 1.6380905663027079e-06
to O 0 9.58778585413711e-08
transferrin O 0 4.935463221045211e-05
receptor O 0 3.416272136291809e-07
( O 0 3.3961877754506986e-09
TfR O 0 1.6208106217163731e-06
) O 0 1.7203493074546827e-09
and O 0 1.4622905109007434e-09
reduces O 0 8.575335441740606e-10
its O 0 5.3077937878232007e-11
affinity O 0 7.205723129288799e-09
for O 0 7.959519265909876e-09
iron O 0 0.00037956199957989156
- O 0 4.873864963883534e-05
loaded O 0 5.850091383763356e-06
transferrin O 0 2.9215705581009388e-05
, O 0 4.459857549932167e-08
implicating O 0 5.897102892049588e-05
HFE O 0 0.00023790255363564938
in O 0 4.669186353112309e-07
iron O 0 0.012849888764321804
metabolism O 0 1.7292944903601892e-05
. O 0 2.529405378481897e-07

The O 0 9.072961120182299e-07
2 O 0 4.722369794762926e-06
. O 0 9.037330528371967e-07

6 O 0 4.7322875616373494e-05
A O 0 2.039970422629267e-05
crystal O 0 0.006795252673327923
structure O 0 1.5325156255130423e-07
of O 0 7.728651496563543e-09
HFE O 0 5.8126955991610885e-05
reveals O 0 1.3209764802013524e-06
the O 0 1.7566876842067813e-09
locations O 0 7.569648374783355e-08
of O 0 2.5648505470599048e-06
hemochromatosis B-Disease 1 0.999994158744812
mutations O 0 5.712798156309873e-06
and O 0 2.2391174070435227e-07
a O 0 2.982812929985812e-07
patch O 0 0.4659901261329651
of O 0 1.9419756824845535e-07
histidines O 0 0.002651760121807456
that O 0 7.163382775843274e-08
could O 0 1.4670489711932078e-08
be O 0 3.6592179286643045e-10
involved O 0 6.490880055665116e-10
in O 0 1.5106271789022685e-08
pH O 0 2.0650875740102492e-05
- O 0 0.00025666411966085434
dependent O 0 2.3302455076645856e-08
interactions O 0 5.277795978031463e-09
. O 0 1.2405126881276374e-07

We O 0 3.294313160040474e-07
also O 0 1.2657732639809183e-08
demonstrate O 0 1.116619063878943e-08
that O 0 2.1637784897166057e-08
soluble O 0 8.802561524134944e-08
TfR O 0 8.24533708509989e-06
and O 0 1.6631395283184247e-07
HFE O 0 2.867759030777961e-05
bind O 0 1.9470047618597164e-07
tightly O 0 2.7674891498463694e-06
at O 0 2.5915699097822653e-07
the O 0 1.1580164605007326e-09
basic O 0 1.5599290748014027e-09
pH O 0 2.358000159574658e-07
of O 0 6.048158085469879e-10
the O 0 1.813976879816437e-08
cell O 0 0.00041115397471003234
surface O 0 1.8988059309776872e-05
, O 0 7.059404083520349e-08
but O 0 1.770733248918077e-08
not O 0 1.039549113457383e-09
at O 0 2.7833812055177987e-07
the O 0 2.156506617723153e-08
acidic O 0 3.8113878417789238e-06
pH O 0 9.440200869903492e-07
of O 0 1.7565737753244548e-09
intracellular O 0 2.9061950499453815e-06
vesicles O 0 3.875992206303636e-06
. O 0 5.957446091997554e-07

TfR O 0 0.007138602901250124
HFE O 0 0.002003491623327136
stoichiometry O 0 2.1905640096520074e-05
( O 0 5.4872259624971775e-08
2 O 0 1.0138973749462821e-07
1 O 0 2.393719178428455e-08
) O 0 3.1532354505259264e-09
differs O 0 4.778953233142147e-09
from O 0 2.4055766267849776e-09
TfR O 0 1.6160937548193033e-06
transferrin O 0 1.3127707916282816e-06
stoichiometry O 0 1.3442692292642278e-08
( O 0 3.900532952183511e-10
2 O 0 7.283782021971774e-09
2 O 0 1.8912558630290732e-08
) O 0 1.3380753172143045e-09
, O 0 8.207088342260249e-10
implying O 0 3.3780533925664713e-09
a O 0 2.4264769013515597e-11
different O 0 1.053491929109418e-12
mode O 0 4.7565529293081e-10
of O 0 3.5756574784384654e-11
binding O 0 2.4304860346546775e-09
for O 0 1.8983092875402008e-09
HFE O 0 6.092454896133859e-06
and O 0 8.463629086463698e-08
transferrin O 0 1.7207560176757397e-06
to O 0 3.1570026592930844e-09
TfR O 0 1.3984554243506864e-06
, O 0 1.8428477632781437e-09
consistent O 0 2.6672380970538256e-10
with O 0 3.40316969049681e-10
our O 0 8.688624264507894e-10
demonstration O 0 3.870920650683729e-08
that O 0 1.0768736125044143e-08
HFE O 0 9.19669764698483e-06
, O 0 2.1578607345418277e-07
transferrin O 0 2.5195609850925393e-05
, O 0 6.743933056441165e-08
and O 0 1.2148635164521693e-07
TfR O 0 3.3248256841034163e-06
form O 0 6.761843307501181e-10
a O 0 4.6383323848431246e-08
ternary O 0 8.604045547144779e-07
complex O 0 5.808491550851613e-06
. O 0 2.599741264930344e-06

Identification O 0 4.323104292325297e-07
of O 0 4.964789823702631e-08
three O 0 3.2148471973414416e-07
novel O 0 7.00649763984984e-07
mutations O 0 1.998914029854859e-07
and O 0 1.1259480459102633e-08
a O 0 9.434134362606983e-09
high O 0 1.762387711323754e-07
frequency O 0 1.553462958270302e-08
of O 0 2.2434878954591397e-10
the O 0 1.4128559655546269e-08
Arg778Leu O 0 1.4757518329133745e-05
mutation O 0 2.2878523964209307e-08
in O 0 2.8052106415543676e-08
Korean O 0 5.250260528555373e-06
patients O 0 1.6648495915205785e-08
with O 0 1.3918241847932222e-06
Wilson B-Disease 0 0.007649503648281097
disease I-Disease 0 8.285650983452797e-05
. O 0 4.873937200500222e-07

Four O 0 5.069398412160808e-07
mutations O 0 3.358151843713131e-06
- O 0 0.00045399967348203063
- O 0 0.0003016525006387383
R778L O 0 1.800202426238684e-06
, O 0 6.236509531021284e-09
A874V O 0 1.7608716262884627e-08
, O 0 1.2104399704782054e-09
L1083F O 0 1.9065437228960036e-08
, O 0 1.0626942659186511e-09
and O 0 7.459626694128474e-09
2304delC O 0 1.42996384511207e-06
- O 0 4.754325345857069e-05
- O 0 1.7465576092945412e-05
in O 0 5.512672540675112e-09
the O 0 1.3823639122279019e-08
copper O 0 4.928888301947154e-05
- O 0 6.881944045744603e-07
transporting O 0 1.2328250420523545e-08
enzyme O 0 9.925621213824343e-09
, O 0 2.2638564800558925e-08
P O 0 6.803385622333735e-05
- O 0 3.007749910466373e-05
type O 0 3.3699728874125867e-07
ATPase O 0 5.1513594371499494e-05
( O 0 4.335115821874069e-09
ATP7B O 0 2.4280918296426535e-05
) O 0 2.8972109156200077e-09
, O 0 1.6156163074043661e-09
were O 0 3.375625112767011e-09
identified O 0 5.828857041478841e-08
in O 0 4.4851255154299e-08
Korean O 0 4.9771429075917695e-06
Patients O 0 1.850883712961604e-08
with O 0 6.37306129647186e-07
Wilson B-Disease 0 0.002485277596861124
disease I-Disease 0 6.781188130844384e-05
. O 0 1.2657111483349581e-06

Arg778Leu O 0 0.0012144579086452723
, O 0 2.1429720220567106e-07
the O 0 3.909413237579429e-09
most O 0 7.051538242208721e-10
frequently O 0 1.424967450702752e-07
reported O 0 1.4985961342972587e-06
mutation O 0 1.0865660593495363e-09
of O 0 6.886504561043338e-11
this O 0 4.860100655257327e-10
enzyme O 0 2.1385085702263495e-08
, O 0 3.265030557031423e-08
was O 0 2.229520214314107e-05
found O 0 1.7653148631779914e-07
in O 0 2.52179210846748e-09
six O 0 2.312914304525293e-08
of O 0 1.133735549885273e-09
eight O 0 1.8321615868899244e-07
unrelated O 0 5.607584625977324e-06
patients O 0 5.221504117969289e-09
studied O 0 4.092585381698655e-09
, O 0 5.044392681341492e-10
an O 0 1.7060590440376444e-10
allele O 0 1.2145825678544497e-08
frequency O 0 1.879604205612395e-08
of O 0 5.733147290243323e-09
37 O 0 1.4921103002052405e-06
. O 0 4.559154831440537e-07

5 O 0 1.2007918485323898e-05
% O 0 1.5203849557110516e-07
, O 0 2.1407123185213095e-08
which O 0 2.7652078404827307e-09
is O 0 4.370823147858971e-10
considerably O 0 2.420354805465763e-09
higher O 0 6.778501093762657e-10
than O 0 1.1544917799533039e-10
those O 0 2.9381955202190113e-10
in O 0 9.292190350507212e-10
other O 0 3.798410030952937e-09
Asian O 0 1.0891980650740152e-07
populations O 0 2.3809693772136598e-08
. O 0 1.6795233648281283e-07

The O 0 5.993684482064054e-08
novel O 0 1.2495098289377893e-08
single O 0 6.701370014461361e-10
nucleotide O 0 1.1713859215944922e-08
deletion O 0 7.227418450383993e-07
, O 0 5.7649277351856654e-08
2304delC O 0 5.442069777927827e-06
, O 0 9.922672461470938e-08
was O 0 2.1853977159480564e-05
found O 0 6.08173422733671e-07
in O 0 1.1797606447316866e-08
one O 0 5.182236506584559e-08
patient O 0 6.973127142373414e-07
. O 0 6.092352009545721e-07

Since O 0 3.3810465538408607e-07
a O 0 1.1744687888892713e-08
mutation O 0 1.3481078475763297e-08
at O 0 4.406621201269445e-08
cDNA O 0 3.4609808352570326e-08
nucleotide O 0 5.1264159139918775e-08
2302 O 0 1.4150090464681853e-05
( O 0 1.8150176916975624e-09
2302insC O 0 6.438464197344729e-07
) O 0 2.8401658802579277e-09
had O 0 3.5212283933105937e-07
been O 0 5.338341679816949e-08
previously O 0 9.248488908042418e-08
described O 0 8.175924790521094e-07
, O 0 3.2887799150671526e-09
this O 0 1.5324491675627883e-10
region O 0 3.132636372527031e-10
of O 0 3.3775621188780747e-10
the O 0 8.747263535724414e-08
ATP7B O 0 0.0020000850781798363
gene O 0 2.537862258122914e-07
may O 0 1.5201602820980042e-07
be O 0 1.376200131630867e-08
susceptible O 0 2.9813796231792367e-07
to O 0 8.151181063453805e-09
gene O 0 3.255243825606158e-07
rearrangements O 0 0.00043931492837145925
causing O 0 0.0012015352258458734
Wilson B-Disease 0 0.013381230644881725
disease I-Disease 0 0.0008618904394097626
. O 0 3.115603021797142e-06

Disruption O 0 3.33790876538842e-06
of O 0 1.7860267709224331e-09
splicing O 0 5.530600333258917e-08
regulated O 0 2.804065957207058e-08
by O 0 1.228588075719017e-08
a O 0 8.496804326796337e-08
CUG O 0 0.0005186830530874431
- O 0 2.969711749756243e-05
binding O 0 4.3897765067413275e-07
protein O 0 7.314189360840828e-07
in O 0 8.74399393069325e-06
myotonic B-Disease 1 0.9998947381973267
dystrophy I-Disease 1 0.9998519420623779
. O 0 7.695404201513156e-05

Myotonic B-Disease 1 0.9992215633392334
dystrophy I-Disease 1 0.9997879862785339
( O 0 0.02010115049779415
DM B-Disease 1 0.9999661445617676
) O 0 0.00023786581004969776
is O 0 8.369188435608521e-07
caused O 0 2.6123490215468337e-07
by O 0 8.538254547829638e-10
a O 0 9.275938239738934e-09
CTG O 0 2.1535363430302823e-06
expansion O 0 5.193870222797159e-09
in O 0 8.032461362716958e-10
the O 0 3.111806812228224e-09
3 O 0 1.305617445268581e-07
untranslated O 0 3.8336361285473686e-06
region O 0 3.8922709499900066e-09
of O 0 5.768243660497774e-10
the O 0 5.194403911445988e-07
DM B-Disease 1 0.9998769760131836
gene O 0 1.5087043720996007e-06
. O 0 1.1042586720577674e-06

One O 0 8.056220224261779e-08
model O 0 6.027021299814805e-07
of O 0 2.3584790653785603e-07
DM B-Disease 1 0.9999336004257202
pathogenesis O 0 0.0007703769369982183
suggests O 0 6.956508400435268e-07
that O 0 1.2308561281315633e-08
RNAs O 0 2.4013249912968604e-06
from O 0 1.1989048642746525e-10
the O 0 1.6747521772164653e-11
expanded O 0 1.0736424249646603e-10
allele O 0 2.9512499111206125e-09
create O 0 7.569941201657215e-11
a O 0 2.7842921301868273e-09
gain O 0 3.2529476357012754e-07
- O 0 9.378926188219339e-05
of O 0 2.254987485628135e-08
- O 0 9.006558684632182e-05
function O 0 1.8051575789712615e-09
mutation O 0 6.695850540694437e-10
by O 0 2.674635235511147e-10
the O 0 7.533633161749265e-10
inappropriate O 0 2.658859976634176e-08
binding O 0 2.6877127190516603e-09
of O 0 9.778945014859985e-11
proteins O 0 4.829725508415095e-10
to O 0 3.7667211016945146e-10
the O 0 1.0023829766225845e-08
CUG O 0 0.00012937374413013458
repeats O 0 5.71030341234291e-06
. O 0 2.5427172545278154e-07

Data O 0 2.4093239971989533e-06
presented O 0 6.544440793732065e-07
here O 0 4.616866178253076e-08
indicate O 0 1.3236781448711099e-08
that O 0 4.557489663437053e-10
the O 0 1.43923484241526e-10
conserved O 0 1.2352582290375835e-09
heterogeneous O 0 3.1075086326382007e-07
nuclear O 0 0.0002538791159167886
ribonucleoprotein O 0 8.894590791896917e-06
, O 0 1.4732600028821707e-08
CUG O 0 7.956311492307577e-06
- O 0 2.0981997295166366e-06
binding O 0 1.7823387210569308e-08
protein O 0 9.23258802743021e-09
( O 0 4.323858771027034e-10
CUG O 0 1.3479360859491862e-05
- O 0 0.0001387825614074245
BP O 0 8.114665251923725e-05
) O 0 3.0094466918484386e-09
, O 0 3.635393097667361e-09
may O 0 7.133887702792663e-09
mediate O 0 6.178933631417749e-07
the O 0 1.2794510340086163e-08
trans O 0 1.2235109352332074e-06
- O 0 1.3177780601836275e-05
dominant O 0 1.9989903421446797e-07
effect O 0 2.181201441686653e-09
of O 0 5.258658439255548e-11
the O 0 3.955345384554221e-09
RNA O 0 9.150672894975287e-07
. O 0 1.631746471275619e-07

CUG O 0 0.07974378019571304
- O 0 0.1324266940355301
BP O 0 0.0036288921255618334
was O 0 2.035638681263663e-05
found O 0 9.573788162242636e-08
to O 0 5.729001162357861e-10
bind O 0 1.1360826945860936e-08
to O 0 3.836854167715842e-10
the O 0 6.550807452043728e-09
human O 0 2.0673878964316827e-07
cardiac O 0 0.006877648178488016
troponin O 0 0.015326368622481823
T O 0 0.02476968616247177
( O 0 6.030824728497919e-09
cTNT O 0 5.231200930211344e-07
) O 0 3.774648593690699e-09
pre O 0 3.8620569853264897e-07
- O 0 2.9437624107231386e-05
messenger O 0 2.912304580604541e-06
RNA O 0 3.683836879986302e-08
and O 0 6.256510864943721e-10
regulate O 0 7.319552602913504e-11
its O 0 6.130804891535391e-11
alternative O 0 2.762169937220449e-10
splicing O 0 2.398330991582043e-07
. O 0 2.0631888730804349e-07

Splicing O 0 1.4253766948968405e-06
of O 0 6.371098493218597e-08
cTNT O 0 6.981355545576662e-05
was O 0 3.744102286873385e-05
disrupted O 0 0.00021160392498131841
in O 0 6.78705964674009e-06
DM B-Disease 1 0.9999619722366333
striated O 1 0.9568715691566467
muscle O 0 0.005526392254978418
and O 0 3.0974339892964053e-07
in O 0 9.89047066468629e-09
normal O 0 2.2087121465119708e-08
cells O 0 2.7213106434942347e-08
expressing O 0 2.4513246987822868e-09
transcripts O 0 1.8219247976958286e-07
that O 0 8.1519310413114e-08
contain O 0 9.893889796330768e-08
CUG O 0 0.00025320317945443094
repeats O 0 1.8184015061706305e-05
. O 0 7.933806500659557e-07

Altered O 0 3.2291952720697736e-06
expression O 0 2.0348114304624687e-08
of O 0 1.2499954404887603e-09
genes O 0 1.7555228382093446e-08
regulated O 0 6.199071833634662e-08
posttranscriptionally O 0 2.3144353690440767e-05
by O 0 8.363573300584903e-08
CUG O 0 0.005444766953587532
- O 0 0.011048230342566967
BP O 0 0.0001478584745200351
therefore O 0 8.610512303164342e-09
may O 0 5.490458310219992e-09
contribute O 0 6.083836906478624e-11
to O 0 2.471230509115685e-08
DM B-Disease 1 0.9998795986175537
pathogenesis O 0 5.8524805353954434e-05
. O 0 5.940805891668788e-08
. O 0 1.8672520241125312e-07

Identification O 0 2.0455949822917319e-07
of O 0 1.4142768733904632e-08
a O 0 1.345352131920663e-07
novel O 0 4.2440271386112727e-07
nonsense O 0 4.727831310447073e-06
mutation O 0 3.755419086814982e-08
and O 0 1.257418524858167e-08
a O 0 2.3444213237411304e-09
missense O 0 2.865572001908845e-09
substitution O 0 1.0472063494137984e-10
in O 0 3.774315859850219e-10
the O 0 1.990785314376353e-09
vasopressin O 0 4.0900914655139786e-07
- O 0 0.0002038543316302821
neurophysin O 0 8.746219828026369e-05
II O 0 3.7491292459890246e-05
gene O 0 5.276849623925273e-09
in O 0 6.195543522657943e-10
two O 0 1.0233703662265725e-08
Spanish O 0 1.5577229532937054e-06
kindreds O 0 0.0005598048446699977
with O 0 1.5169224752753507e-05
familial B-Disease 1 0.9638281464576721
neurohypophyseal I-Disease 1 0.9993891716003418
diabetes I-Disease 1 0.9986042380332947
insipidus I-Disease 0 0.2486913502216339
. O 0 1.3447570381686091e-05

Familial B-Disease 1 0.9943845272064209
neurohypophyseal I-Disease 1 0.998647153377533
diabetes I-Disease 1 0.9997448325157166
insipidus I-Disease 1 0.9992332458496094
( O 0 0.0018264870159327984
FNDI B-Disease 1 0.9999504089355469
) O 0 4.219511174596846e-05
is O 0 4.375002617962309e-07
an O 0 1.4480938261840492e-06
autosomal B-Disease 1 0.9363620281219482
dominant I-Disease 1 0.9886893630027771
disease I-Disease 1 0.9682057499885559
caused O 0 0.0007560487138107419
by O 0 5.8278201322536916e-05
deficiency O 0 0.21629370748996735
in O 0 4.2850540893368816e-08
the O 0 5.229709358900436e-07
antidiuretic O 0 4.5615368435392156e-05
hormone O 0 1.5831363953111577e-07
arginine O 0 1.9250521177127666e-07
vasopressin O 0 8.027016917822039e-08
( O 0 1.4217924615422817e-09
AVP O 0 2.5770411866687937e-06
) O 0 1.799196208684961e-10
encoded O 0 1.5326150071270916e-11
by O 0 7.503714316570154e-11
the O 0 2.644171770427306e-09
AVP O 0 0.0006328871240839362
- O 0 0.0030533208046108484
neurophysin O 0 0.0015258160419762135
II O 0 0.0038449771236628294
( O 0 6.2141154444361746e-09
AVP O 0 0.00021170562831684947
- O 0 0.00928932148963213
NPII O 0 0.0006895533297210932
) O 0 1.8498733656002742e-09
gene O 0 2.157426903792725e-09
on O 0 1.0401713552710135e-06
chromosome O 0 0.00024157320149242878
20p13 O 0 2.8823234970332123e-05
. O 0 6.406473289644055e-07

In O 0 1.1490825357896028e-07
this O 0 3.10628012201164e-09
study O 0 5.2781383708122576e-09
, O 0 3.1302247460729404e-09
we O 0 1.471826133192522e-10
analyzed O 0 3.990368480089046e-09
two O 0 8.976822840622845e-09
families O 0 3.7234944016972804e-08
with O 0 7.745966001948545e-08
FNDI B-Disease 1 0.9389684796333313
using O 0 8.320410332940398e-11
direct O 0 4.424694985405431e-12
automated O 0 6.608737113111829e-09
fluorescent O 0 2.1630851776421878e-08
, O 0 1.2598377896466673e-09
solid O 0 1.1446219083666165e-08
phase O 0 1.17508278663081e-08
, O 0 1.6604344565962492e-09
single O 0 1.6034288341515435e-09
- O 0 3.82001189791481e-06
stranded O 0 9.58898915826012e-09
DNA O 0 2.77884870669709e-09
sequencing O 0 1.1520375764462187e-09
of O 0 1.914715747064477e-10
PCR O 0 1.1393743761800579e-06
- O 0 5.865319508302491e-06
amplified O 0 6.583560661965748e-06
AVP O 0 0.0005416384665295482
- O 0 0.00034173327730968595
NPII O 0 0.00014050489699002355
DNA O 0 7.0049873102107085e-06
. O 0 3.727353430349467e-07

In O 0 1.3517748698177456e-07
one O 0 4.879515902445064e-09
of O 0 1.1124987597810332e-09
the O 0 3.132316805931623e-08
families O 0 2.6051938561977295e-07
, O 0 6.126909113390866e-08
affected O 0 2.377020358323989e-09
individuals O 0 6.277556946487906e-11
presented O 0 9.28000876143642e-09
a O 0 2.603407622814302e-08
novel O 0 5.725347662632885e-08
nonsense O 0 3.1968457392395067e-07
mutation O 0 2.49546161512626e-09
in O 0 2.883093319638874e-09
exon O 0 2.2429580326388532e-07
3 O 0 1.62851527818475e-08
of O 0 1.4787990276765584e-10
the O 0 5.084559884238615e-09
gene O 0 7.139236757325307e-09
, O 0 1.908132540862084e-09
consisting O 0 1.187887982423419e-10
in O 0 1.6366261679223726e-09
a O 0 1.013054600207397e-07
G O 0 0.00017450588347855955
to O 0 2.0738523787144914e-08
T O 0 2.717682764341589e-05
transition O 0 1.534444571404947e-09
at O 0 1.6154938720092105e-08
nucleotide O 0 3.946889925998676e-09
2101 O 0 6.652569481957471e-06
, O 0 1.0703863573269246e-08
which O 0 1.2188056119910584e-09
produces O 0 2.3843524377120673e-10
a O 0 5.154254800743274e-10
stop O 0 5.3002722211203945e-09
signal O 0 6.697759857843266e-08
in O 0 1.0325654775655835e-09
codon O 0 4.9473936059030166e-09
82 O 0 6.29578025268529e-08
( O 0 8.934115669489984e-10
Glu O 0 4.33765990237589e-06
) O 0 5.489170007422217e-09
of O 0 6.983826850159858e-09
NPII O 0 0.00045181746827438474
. O 0 4.2844533254537964e-07

The O 0 7.302814424292592e-07
premature O 0 1.718593375699129e-05
termination O 0 2.502250424640806e-07
eliminates O 0 9.959228464140324e-08
part O 0 4.4934098109017384e-10
of O 0 4.3458017739972377e-10
the O 0 6.869040447554653e-08
C O 0 5.3103838581591845e-05
- O 0 1.0633298188622575e-05
terminal O 0 5.3177526382341966e-08
domain O 0 5.102647193666598e-10
of O 0 9.943522671918004e-10
NPII O 0 0.0003437578270677477
, O 0 2.303004009718279e-09
including O 0 4.0772479142914264e-11
a O 0 6.03877503557726e-10
cysteine O 0 5.8708069516910655e-09
residue O 0 1.314863506962638e-08
in O 0 1.0612818263089352e-10
position O 0 6.812931552246937e-09
85 O 0 7.716822736369977e-09
, O 0 4.614962190174765e-09
which O 0 1.2311566877087898e-08
could O 0 4.381985885260065e-09
be O 0 2.1073046085895442e-10
involved O 0 2.473392601842761e-10
in O 0 2.4501595197179427e-10
the O 0 2.6062529911996535e-09
correct O 0 7.00317741575418e-07
folding O 0 6.923139153514057e-06
of O 0 2.3843764740405504e-09
the O 0 1.6431897620350355e-07
prohormone O 0 0.00012671614240389317
. O 0 6.744139113834535e-07

In O 0 6.977398925300804e-08
the O 0 3.011211191505936e-08
second O 0 4.758717864206119e-07
family O 0 2.400715857220348e-06
, O 0 1.249833347927165e-09
a O 0 2.0858464955253453e-10
G279A O 0 9.824098201605125e-10
substitution O 0 4.9212627029060485e-11
at O 0 4.2940374811450965e-08
position O 0 1.8085495767650173e-08
- O 0 4.949981757818023e-06
1 O 0 1.3254914943416907e-09
of O 0 1.8354862768577007e-11
the O 0 1.8693985248674494e-10
signal O 0 1.1235821517630029e-07
peptide O 0 1.7035569399581618e-08
was O 0 6.395253535629308e-07
observed O 0 5.900578248230204e-09
in O 0 6.459361934219032e-10
all O 0 3.410109417067986e-10
affected O 0 3.060373954255624e-09
individuals O 0 3.718026442278699e-10
. O 0 6.555509202144094e-08

This O 0 4.6448661805698066e-08
missense O 0 8.228299520851579e-06
mutation O 0 1.1335737326589879e-06
, O 0 2.912660761467123e-07
which O 0 9.87102595217948e-08
replaces O 0 3.4046464861603454e-05
Ala O 0 4.036454265587963e-05
with O 0 4.309397354518296e-07
Thr O 0 0.005565913859754801
, O 0 9.595927252803449e-08
is O 0 3.5241221052473293e-09
frequent O 0 1.339822830459525e-08
among O 0 3.314690104616602e-07
FNDI B-Disease 1 0.9999879598617554
patients O 0 3.782103021876537e-07
and O 0 7.352304720598113e-08
is O 0 3.1644480369408257e-09
thought O 0 2.2969368629333076e-09
to O 0 3.296131978469674e-10
reduce O 0 1.1375457242834841e-09
the O 0 1.7392368101276645e-10
efficiency O 0 2.6362556582171237e-09
of O 0 9.618911916975392e-11
cleavage O 0 3.750012069758668e-07
by O 0 2.328360615422298e-09
signal O 0 4.908015398541465e-07
peptidases O 0 2.4106041109916987e-06
. O 0 6.9020544835041164e-09
. O 0 6.959481879675877e-08

Genetic O 0 8.168385647877585e-06
heterogeneity O 0 2.4013410438783467e-05
of O 0 3.7151421565795317e-06
Saethre B-Disease 1 0.9749062061309814
- I-Disease 1 0.9997965693473816
Chotzen I-Disease 1 0.9998155236244202
syndrome I-Disease 1 0.9998596906661987
, O 0 4.548653294023097e-07
due O 0 7.337902729886991e-08
to O 0 9.444594439855791e-09
TWIST O 0 2.4278742785099894e-05
and O 0 1.8343082501814933e-06
FGFR O 0 0.0032830138225108385
mutations O 0 2.817114136632881e-06
. O 0 4.890484888164792e-07

Thirty O 0 1.002689987217309e-05
- O 0 0.00023586736642755568
two O 0 5.097263624520565e-07
unrelated O 0 2.3711028916295618e-05
patients O 0 2.647574603997782e-08
with O 0 1.6422545545680123e-09
features O 0 1.3389100672611676e-07
of O 0 4.2089439489245706e-07
Saethre B-Disease 1 0.860174834728241
- I-Disease 1 0.999881386756897
Chotzen I-Disease 1 0.9998277425765991
syndrome I-Disease 1 0.9972184896469116
, O 0 1.5063351099797728e-07
a O 0 4.4303115487309697e-07
common O 0 9.384249096910935e-06
autosomal B-Disease 0 0.2549912929534912
dominant I-Disease 0 0.006647400092333555
condition I-Disease 0 0.002159419469535351
of O 0 1.0467879292264115e-06
craniosynostosis B-Disease 1 0.9613763093948364
and O 0 0.0011113674845546484
limb B-Disease 0 0.11614914983510971
anomalies I-Disease 0 0.0490117147564888
, O 0 1.8535357071414182e-07
were O 0 3.273548898619083e-08
screened O 0 5.04776629384196e-08
for O 0 7.260725354285569e-10
mutations O 0 6.9187411355642325e-09
in O 0 7.975414995087249e-09
TWIST O 0 4.279698623577133e-05
, O 0 6.541570769513783e-07
FGFR2 O 0 0.0012647139374166727
, O 0 1.5397098707126133e-07
and O 0 8.724666713533225e-07
FGFR3 O 0 0.0016217126976698637
. O 0 5.55523286038806e-07

Nine O 0 4.711631845566444e-06
novel O 0 1.0420518492537667e-06
and O 0 1.321986928815022e-07
three O 0 4.406999565276237e-08
recurrent O 0 1.9949424313381314e-05
TWIST O 0 0.00016751357179600745
mutations O 0 7.066327611937595e-07
were O 0 2.502097800061165e-07
found O 0 8.224770908782375e-07
in O 0 2.37199433428259e-08
12 O 0 5.206410946811957e-07
families O 0 2.813082176089665e-07
. O 0 4.0732209072302794e-07

Seven O 0 4.137477390031563e-06
families O 0 5.935935405432247e-07
were O 0 1.3978059598684922e-07
found O 0 4.330688696541074e-08
to O 0 6.161263166326592e-10
have O 0 7.45178807548541e-10
the O 0 2.4733228798368145e-09
FGFR3 O 0 4.9954192945733666e-05
P250R O 0 1.7460881451825117e-07
mutation O 0 1.930684767614821e-08
, O 0 1.1497463425769183e-08
and O 0 6.98150914857365e-09
one O 0 1.7865445789411183e-09
individual O 0 1.8129625578566788e-09
was O 0 1.828571294026915e-05
found O 0 1.3458320324843953e-07
to O 0 1.924653991736136e-09
have O 0 2.4249480201632423e-09
an O 0 1.9067073253609124e-08
FGFR2 O 0 0.0004575681814458221
VV269 O 0 2.8335309707472334e-06
- O 0 3.949686652049422e-05
270 O 0 1.1940200010940316e-06
deletion O 0 3.108047167188488e-06
. O 0 3.330984554850147e-07

To O 0 3.5098754125328924e-08
date O 0 6.852317113725803e-08
, O 0 8.664016171167077e-10
our O 0 1.2015718975355583e-10
detection O 0 1.8367357412785168e-08
rate O 0 7.614361585694951e-09
for O 0 1.442937297424507e-10
TWIST O 0 2.4068735910987016e-06
or O 0 1.8904719922829827e-07
FGFR O 0 0.00012103739572921768
mutations O 0 3.034174156368863e-08
is O 0 5.240031075715024e-09
68 O 0 2.1533587357680517e-07
% O 0 4.3383979742017686e-10
in O 0 1.6209963371593972e-09
our O 0 4.674924980463402e-08
Saethre B-Disease 0 0.01336386427283287
- I-Disease 1 0.9953314661979675
Chotzen I-Disease 1 0.9995182752609253
syndrome I-Disease 1 0.9985975623130798
patients O 0 3.525952507743568e-08
, O 0 2.882581950913732e-09
including O 0 5.492518662109092e-10
our O 0 2.18162599097127e-09
five O 0 7.005174751384402e-08
patients O 0 1.0195168265170196e-08
elsewhere O 0 4.191900604411103e-09
reported O 0 3.704355151512573e-07
with O 0 9.371045450734528e-08
TWIST O 0 0.00025747588369995356
mutations O 0 2.120318640663754e-06
. O 0 6.041212259333406e-07

More O 0 3.910681112273551e-09
than O 0 6.953478348670217e-10
35 O 0 7.777996025026823e-10
different O 0 5.984605866427017e-11
TWIST O 0 1.2262103155080695e-05
mutations O 0 1.7301850618878234e-07
are O 0 2.7629776244708637e-09
now O 0 2.031220702747305e-08
known O 0 8.090278669214968e-09
in O 0 4.612410453574967e-09
the O 0 5.248325862794445e-08
literature O 0 2.627873030291994e-08
. O 0 2.9105561338838015e-07

The O 0 3.2629824175955946e-08
most O 0 4.118597407565261e-10
common O 0 9.844318693552623e-10
phenotypic O 0 2.1987188458805207e-10
features O 0 1.0279563866788521e-07
, O 0 5.4813678929122034e-08
present O 0 7.655832634512194e-10
in O 0 3.1378810660953604e-10
more O 0 2.705098471611489e-11
than O 0 7.464658058342621e-11
a O 0 5.336730612981455e-09
third O 0 2.390286510944861e-07
of O 0 1.7633813298445489e-09
our O 0 3.327015463128191e-08
patients O 0 1.8484238584193236e-09
with O 0 7.523527578712219e-09
TWIST O 0 9.035408766067121e-06
mutations O 0 4.8551857645406926e-08
, O 0 7.432302773224819e-09
are O 0 4.689245103328687e-10
coronal B-Disease 0 4.958702629664913e-05
synostosis I-Disease 0 0.00037207649438641965
, O 0 1.0262109384484575e-07
brachycephaly B-Disease 0 3.419353743083775e-05
, O 0 1.853378392979721e-07
low B-Disease 0 4.284386886865832e-05
frontal I-Disease 1 0.7631217241287231
hairline I-Disease 1 0.9998606443405151
, O 0 6.52010976409656e-06
facial B-Disease 0 0.009129207581281662
asymmetry I-Disease 0 0.002987742191180587
, O 0 8.103830623440444e-05
ptosis B-Disease 0 0.2357322722673416
, O 0 3.34513947564119e-06
hypertelorism B-Disease 0 0.0005676593282260001
, O 0 1.9797866457338387e-07
broad B-Disease 0 1.2074232245140593e-06
great I-Disease 0 1.2038533895974979e-05
toes I-Disease 0 0.12532909214496613
, O 0 3.4874278753704857e-07
and O 0 6.041246365384723e-07
clinodactyly B-Disease 0 0.000219380744965747
. O 0 1.1276640634605428e-06

Significant O 0 1.2756063938468287e-07
intra O 0 2.4123008188325912e-05
- O 0 0.0020382963120937347
and O 0 1.2825878457078943e-06
interfamilial O 0 2.056058292509988e-05
phenotypic O 0 1.7180351363776936e-08
variability O 0 3.7010040614404716e-06
is O 0 8.287632802250755e-09
present O 0 3.8267536361935583e-10
for O 0 4.839352807373132e-10
either O 0 1.185220988020319e-08
TWIST O 0 7.862818165449426e-05
mutations O 0 4.903355375063256e-07
or O 0 9.952902928489493e-07
FGFR O 0 0.002014762256294489
mutations O 0 1.5311759398173308e-06
. O 0 1.1560340453797835e-06

The O 0 5.9694741594285e-08
overlap O 0 1.052542444313076e-07
in O 0 1.7882227254517602e-08
clinical O 0 4.187707247638173e-08
features O 0 8.259168282620521e-08
and O 0 6.638668992309249e-08
the O 0 7.040951377490501e-09
presence O 0 6.7437890827193314e-09
, O 0 3.1034017577979967e-09
in O 0 3.41942280046581e-10
the O 0 6.595763379912967e-10
same O 0 3.4351985700453724e-09
genes O 0 9.739510531403539e-09
, O 0 5.517216461470298e-09
of O 0 1.7675931551774937e-10
mutations O 0 2.1958825868750864e-09
for O 0 4.0180886395901894e-11
more O 0 3.814843926863709e-11
than O 0 2.988737868303559e-10
one O 0 2.3780373226145457e-08
craniosynostotic B-Disease 0 0.00025576588814146817
condition I-Disease 0 1.538842411719088e-06
- O 0 9.414074497726688e-07
such O 0 9.411370988088308e-11
as O 0 6.013904485513422e-09
Saethre B-Disease 0 9.071957720152568e-06
- I-Disease 0 0.00010583630501059815
Chotzen I-Disease 0 2.1288353309500962e-05
, I-Disease 0 2.7078229436483525e-08
Crouzon I-Disease 0 1.0099604878632817e-05
, I-Disease 0 8.349116598083128e-08
and I-Disease 0 2.6868742679653224e-06
Pfeiffer I-Disease 0 0.14315985143184662
syndromes I-Disease 0 0.0013359514996409416
- O 0 3.840061253868043e-06
support O 0 1.726430554072067e-09
the O 0 4.00863120475492e-09
hypothesis O 0 3.107727408746541e-08
that O 0 1.1362105034606884e-08
TWIST O 0 4.011045348306652e-06
and O 0 1.6871825891939807e-07
FGFRs O 0 1.823859520300175e-06
are O 0 7.296330206685298e-11
components O 0 2.7833311211367118e-09
of O 0 4.974981884786622e-11
the O 0 5.762766930317298e-10
same O 0 9.454628191463144e-10
molecular O 0 4.6204256420878664e-08
pathway O 0 2.487867023504009e-09
involved O 0 2.494598971836126e-10
in O 0 2.1347977552377273e-10
the O 0 2.582239755355431e-09
modulation O 0 1.2051604016960482e-06
of O 0 5.278071171233023e-07
craniofacial O 1 0.8456138968467712
and O 0 1.0917570762103423e-05
limb O 0 9.270074224332348e-05
development O 0 3.8718050987540664e-09
in O 0 6.26942719961221e-09
humans O 0 1.883849298778273e-09
. O 0 6.804671937032936e-09
. O 0 2.544502422097139e-07

Mutation O 0 4.664033440349158e-06
analysis O 0 7.355978937084728e-07
of O 0 1.5788920109116589e-06
UBE3A O 1 0.9817336797714233
in O 1 0.8916192650794983
Angelman B-Disease 1 0.9999569654464722
syndrome I-Disease 1 0.9999716281890869
patients O 0 0.0004842763300985098
. O 0 3.785147418966517e-05

Angelman B-Disease 1 0.9998205304145813
syndrome I-Disease 1 0.9999765157699585
( O 0 0.0012779806274920702
AS B-Disease 1 0.9498559236526489
) O 0 2.649388761710725e-06
is O 0 2.5096161948567897e-07
caused O 0 2.0851771864727198e-07
by O 0 1.5291805155470684e-08
chromosome O 0 0.0001050253922585398
15q11 O 0 1.0622341505950317e-05
- O 0 0.0003009401261806488
q13 O 0 7.648044970665069e-07
deletions O 0 8.243116411676965e-08
of O 0 3.7332208435714165e-09
maternal O 0 5.592340812654584e-07
origin O 0 1.5465390745816876e-08
, O 0 2.4455584224369886e-08
by O 0 3.817936189420834e-08
paternal O 0 3.09249953716062e-05
uniparental B-Disease 0 0.02668369561433792
disomy I-Disease 0 0.07729168981313705
( O 0 4.275396463526704e-07
UPD B-Disease 1 0.9993405938148499
) O 0 8.364243342384725e-08
15 O 0 5.612465159288149e-09
, O 0 4.817583665328584e-09
by O 0 3.166399764609196e-08
imprinting O 1 0.5358162522315979
defects O 1 0.9706903696060181
, O 0 1.724439329109373e-07
and O 0 2.3440646756967e-08
by O 0 7.768688803366786e-09
mutations O 0 2.0886991691781986e-08
in O 0 5.4094515533620324e-09
the O 0 1.1567416180469081e-07
UBE3A O 0 0.00011826152331195772
gene O 0 8.777394100434321e-07
. O 0 6.490416240012564e-07

UBE3A O 0 0.0002296102320542559
encodes O 0 1.4732452200405532e-06
a O 0 1.7632787319143972e-07
ubiquitin O 0 2.870473326765932e-05
- O 0 8.14667873783037e-05
protein O 0 6.611702474401682e-08
ligase O 0 2.223400770162698e-07
and O 0 2.7965455728917732e-08
shows O 0 6.268084007388097e-07
brain O 0 3.7282366974977776e-05
- O 0 8.467352927254979e-06
specific O 0 7.390713374633151e-09
imprinting O 0 0.0003500959719531238
. O 0 2.8443039354897337e-06

Here O 0 2.2445222214173555e-07
we O 0 4.549163268308121e-09
describe O 0 1.3349354510694411e-08
UBE3A O 0 6.4643254518159665e-06
coding O 0 4.6872173697920516e-05
- O 0 0.002148065948858857
region O 0 9.943095591324891e-08
mutations O 0 3.2814380546142274e-08
detected O 0 1.4623869049046334e-07
by O 0 1.1119857923347354e-08
SSCP O 0 8.855944543029182e-06
analysis O 0 6.914717243233781e-09
in O 0 1.3367291273880255e-08
13 O 0 6.889042651891941e-07
AS B-Disease 0 0.03203636035323143
individuals O 0 1.2107385316539876e-08
or O 0 4.538219684491196e-07
families O 0 9.998452696891036e-07
. O 0 1.0328200232834206e-06

Two O 0 1.0487710255802085e-07
identical O 0 2.7861824491992593e-06
de O 0 1.8426662791171111e-06
novo O 0 1.092699562832422e-06
5 O 0 9.445876969493838e-08
- O 0 7.648922291991767e-06
bp O 0 1.9718511339306133e-06
duplications O 0 2.973729174016171e-08
in O 0 1.734652643747836e-09
exon O 0 2.1017154949731776e-07
16 O 0 8.765919545794532e-08
were O 0 2.8360273063299246e-07
found O 0 2.698226126085501e-06
. O 0 3.28769090174319e-07

Among O 0 1.886982481380528e-08
the O 0 3.5827474320626607e-09
other O 0 7.101464416514602e-10
11 O 0 1.0861521460014956e-08
unique O 0 1.1141783051726861e-09
mutations O 0 1.642409053204119e-08
, O 0 5.8189009166653705e-09
8 O 0 1.5207975323505707e-08
were O 0 1.1186698678500306e-08
small O 0 3.0298354936064698e-09
deletions O 0 2.0370293896121439e-07
or O 0 1.5280528486982803e-07
insertions O 0 3.0726107524969848e-06
predicted O 0 4.9910577217815444e-05
to O 0 1.652631098636448e-08
cause O 0 1.1181924719494418e-07
frameshifts O 0 8.847283424984198e-06
, O 0 2.1241179481990002e-08
1 O 0 6.0300080484410046e-09
was O 0 1.6011350680855685e-06
a O 0 1.4963205785534228e-08
mutation O 0 1.438209107362809e-09
to O 0 3.7327779756068935e-10
a O 0 2.720048186688473e-09
stop O 0 6.267478092070178e-09
codon O 0 5.081474130363972e-10
, O 0 7.854804584539465e-10
1 O 0 1.357799539469795e-09
was O 0 2.3728863141059264e-07
a O 0 5.914189582512108e-09
missense O 0 1.5524476282280375e-07
mutation O 0 1.121447201768433e-08
, O 0 8.283713270884618e-09
and O 0 4.56471482834786e-08
1 O 0 2.8301254673124276e-08
was O 0 2.956368916784413e-05
predicted O 0 8.086321940936614e-06
to O 0 4.586110602389226e-09
cause O 0 4.210354731526422e-09
insertion O 0 4.1108219051011474e-09
of O 0 6.708979483072142e-10
an O 0 1.0205717160260974e-07
isoleucine O 0 0.0003173314325977117
in O 0 1.3345077931603555e-08
the O 0 1.2181740949301911e-08
hect O 0 2.0535555904643843e-06
domain O 0 4.949760601391517e-10
of O 0 4.318713095474713e-11
the O 0 2.0179591331270785e-09
UBE3A O 0 1.028416704684787e-06
protein O 0 5.204947584047659e-09
, O 0 1.0418496065867089e-09
which O 0 2.0912921394611317e-10
functions O 0 8.108231967784985e-12
in O 0 6.427605114822654e-10
E2 O 0 7.80221580498619e-06
binding O 0 2.1512645886900827e-08
and O 0 1.1357771612097167e-08
ubiquitin O 0 2.4845923007887905e-07
transfer O 0 9.628393193850115e-09
. O 0 5.2184400800570074e-08

Eight O 0 3.153276679768169e-07
of O 0 4.304687717393563e-09
the O 0 1.5647632523041466e-08
cases O 0 4.282562215962571e-08
were O 0 3.7439372135850135e-07
familial O 0 5.616326961899176e-05
, O 0 6.615259735553991e-07
and O 0 3.7049055379156925e-08
five O 0 1.95596339125359e-08
were O 0 1.0706623498890622e-07
sporadic O 0 1.95441043615574e-06
. O 0 6.598851882699819e-07

In O 0 5.222084382694447e-07
two O 0 4.0994402183969214e-07
familial O 0 0.00047003134386613965
cases O 0 5.658461077473476e-07
and O 0 4.358207661425695e-08
one O 0 2.194295856128292e-09
sporadic O 0 1.275562624414306e-07
case O 0 4.708716403456492e-07
, O 0 7.935299350947389e-08
mosaicism O 0 9.536038305668626e-06
for O 0 6.189700307857038e-09
UBE3A O 0 1.9726716345758177e-05
mutations O 0 9.457090044406868e-08
was O 0 6.18366539129056e-06
detected O 0 1.7836775612067868e-07
in O 0 3.200797182856263e-09
the O 0 3.0067631939800776e-08
mother O 0 8.485760190524161e-06
of O 0 2.846864077810096e-09
three O 0 2.751126658040448e-06
AS B-Disease 1 0.9542015194892883
sons O 0 0.0011441254755482078
, O 0 1.4699618411384563e-08
in O 0 1.7143190200741287e-09
the O 0 1.8300427839790245e-08
maternal O 0 5.603733370662667e-07
grandfather O 0 1.561329554533586e-06
of O 0 2.3138031768343836e-10
two O 0 1.7522378215062417e-08
AS B-Disease 0 0.0029202227015048265
first O 0 1.2684854766575882e-07
cousins O 0 0.00011301669292151928
, O 0 7.555657077773503e-08
and O 0 7.56133715640317e-08
in O 0 1.6067298602706614e-08
the O 0 3.963745243140693e-08
mother O 0 3.21274956149864e-06
of O 0 1.2637847435215122e-09
an O 0 4.4357059891808603e-07
AS B-Disease 1 0.7873795032501221
daughter O 0 0.1340969204902649
. O 0 1.9532851638359716e-06

The O 0 1.5668359054643588e-08
frequencies O 0 7.312613803378554e-08
with O 0 7.212958763602728e-08
which O 0 1.5669733954837284e-08
we O 0 8.994969213915738e-10
detected O 0 1.1908769081969695e-08
mutations O 0 3.5858784830367085e-09
were O 0 2.1125302396285406e-08
5 O 0 1.603304156105878e-08
( O 0 7.660594381064811e-10
14 O 0 4.641535866767299e-08
% O 0 1.1501800623037184e-09
) O 0 2.2916057940136625e-10
of O 0 2.9547277818897655e-11
35 O 0 1.074812905343947e-09
in O 0 2.6078778025961924e-10
sporadic O 0 3.530286107888969e-08
cases O 0 2.6127397134700914e-08
and O 0 1.1147852063686514e-07
8 O 0 2.72400399126127e-07
( O 0 6.981105693526501e-10
80 O 0 1.2601502064057968e-09
% O 0 4.2375594699883834e-10
) O 0 2.928214615227631e-10
of O 0 1.937821708652976e-10
10 O 0 4.0713874938091976e-08
in O 0 1.9810364904060407e-08
familial O 0 3.26976842188742e-05
cases O 0 4.0868084738576727e-07
. O 0 5.278543540043756e-07
. O 0 6.635661975451512e-07

The O 0 7.905530765128788e-06
hemochromatosis B-Disease 1 0.9987667798995972
845 O 0 0.0033574176486581564
G O 0 0.042165253311395645
- O 0 0.006443564314395189
- O 0 0.00027535887784324586
> O 0 8.724780897750861e-09
A O 0 2.585867520110696e-09
and O 0 2.607640325891225e-09
187 O 0 2.953182942633248e-08
C O 0 2.0820148165512364e-06
- O 0 0.0005756631144322455
- O 0 0.0003533410490490496
> O 0 2.6526798535542184e-08
G O 0 2.003552253881935e-05
mutations O 0 4.378738083232747e-08
: O 0 2.156793410534874e-09
prevalence O 0 2.4131426812346035e-07
in O 0 5.065152297589748e-09
non O 0 2.7270990798911043e-08
- O 0 0.000519702211022377
Caucasian O 0 5.2387284085853025e-05
populations O 0 1.6840365901771293e-07
. O 0 2.579662350399303e-07

Hemochromatosis B-Disease 1 0.8498860597610474
, O 0 0.0001541621604701504
the O 0 0.008240500465035439
inherited B-Disease 1 0.9999818801879883
disorder I-Disease 1 0.9999704360961914
of I-Disease 0 6.689653673674911e-06
iron I-Disease 1 0.980453372001648
metabolism I-Disease 0 0.0007129560108296573
, O 0 3.7778778505526134e-07
leads O 0 1.1841475497931242e-06
, O 0 3.5336992709744663e-07
if O 0 5.06043363657227e-07
untreated O 0 5.896844595554285e-05
, O 0 4.971365896722091e-08
to O 0 7.070777030548925e-08
progressive O 0 0.00013624403800349683
iron B-Disease 1 0.9365841746330261
overload I-Disease 0 0.03799029439687729
and O 0 6.799588845751714e-06
premature B-Disease 0 0.00010673916403902695
death I-Disease 0 1.933117709995713e-05
. O 0 7.842354534659535e-07

The O 0 2.4049641069723293e-05
hemochromatosis B-Disease 1 0.9990900754928589
gene O 0 1.3448557183437515e-05
, O 0 2.129987933585653e-06
HFE O 0 0.0010606545256450772
, O 0 1.1826330137409968e-06
recently O 0 5.423289621830918e-06
has O 0 3.2763665558377397e-07
been O 0 8.460320799485999e-08
identified O 0 1.277516474829099e-07
, O 0 1.4298021433489794e-08
and O 0 5.445891737565489e-09
characterization O 0 6.260300011717845e-08
of O 0 4.391647878687621e-10
this O 0 1.139126348803643e-09
gene O 0 1.606693089684086e-08
has O 0 2.1674925676506973e-07
shown O 0 8.827933584143466e-08
that O 0 6.835553456596699e-09
it O 0 1.4125184355506804e-09
contains O 0 1.0381813464466205e-10
two O 0 6.616204029086248e-09
mutations O 0 1.273779925980989e-08
that O 0 6.868016377836739e-09
result O 0 2.507183793909462e-09
in O 0 3.7266098540378323e-10
amino O 0 3.156296612960574e-10
acid O 0 1.3927688169435015e-10
substitutions O 0 8.566994336156597e-11
- O 0 1.6639258859640904e-08
cDNA O 0 2.731371351316625e-09
nucleotides O 0 2.729350745411807e-09
845 O 0 6.660127382929204e-07
G O 0 0.00011249671661062166
- O 0 9.309496090281755e-05
- O 0 8.865888958098367e-05
> O 0 5.256517887630707e-09
A O 0 2.1020959195539035e-08
( O 0 3.6669806080524836e-10
C282Y O 0 2.112034636070348e-08
) O 0 3.005750925932915e-10
and O 0 1.3570384815864145e-09
187 O 0 3.9678450747260285e-08
C O 0 3.178664428560296e-06
- O 0 0.0003590803244151175
- O 0 0.009841539897024632
> O 0 4.21203964151573e-07
G O 0 0.00027681796927936375
( O 0 1.8260747580711723e-08
H63D O 0 2.657140612427611e-05
) O 0 2.1903161950831418e-08
. O 0 2.933830423046402e-08

Although O 0 0.00034270648029632866
hemochromatosis B-Disease 1 0.9997010827064514
is O 0 1.3811747976433253e-06
common O 0 1.1418334366908311e-07
in O 0 5.523073909330378e-08
Caucasians O 0 4.909644530926016e-07
, O 0 1.9993558808550915e-08
affecting O 0 2.07159400744672e-09
> O 0 1.4479867971317617e-08
= O 0 4.408715028603183e-07
1 O 0 1.3796613629324384e-08
/ O 0 1.0628006208435181e-07
300 O 0 3.89356280550146e-09
individuals O 0 1.0514208427514493e-11
of O 0 2.1253710597024522e-11
northern O 0 1.5754807458634446e-09
European O 0 3.1890255769440046e-08
origin O 0 5.54970247534925e-09
, O 0 1.3000730270107397e-08
it O 0 1.4867362452264388e-08
has O 0 3.1387159538098786e-08
not O 0 1.1719708536972462e-09
been O 0 8.720123290117954e-09
recognized O 0 5.714115847155199e-10
in O 0 8.186514244279408e-10
other O 0 5.87775339511154e-09
populations O 0 2.9171021154184018e-08
. O 0 1.8488854891529627e-07

The O 0 1.0447519116496551e-07
present O 0 3.669885950685625e-09
study O 0 5.457139740094874e-10
used O 0 1.9855899147103173e-09
PCR O 0 8.426707722719584e-07
and O 0 3.9033427157164624e-08
restriction O 0 1.605602406584694e-08
- O 0 9.439381187803519e-07
enzyme O 0 2.5692403760047e-09
digestion O 0 1.2124132808821741e-09
to O 0 5.3984043797694614e-12
analyze O 0 2.0899075872660156e-11
the O 0 7.761450336596365e-12
frequency O 0 3.9392317185971137e-10
of O 0 1.5190211935522946e-11
the O 0 2.9186142391779413e-09
845 O 0 3.3066182822949486e-06
G O 0 0.00022893583809491247
- O 0 2.9026225092820823e-05
- O 0 9.863054401648697e-06
> O 0 8.064176548749913e-10
A O 0 1.057794296599468e-09
and O 0 2.4326749503700285e-09
187 O 0 2.545302635326152e-08
C O 0 1.1989721997451852e-06
- O 0 2.6089008315466344e-05
- O 0 2.318004953849595e-05
> O 0 4.574002954171874e-09
G O 0 6.142003030618071e-07
mutations O 0 2.2018884493490987e-09
in O 0 1.1388765486231023e-09
HLA O 0 3.4828414641197014e-07
- O 0 8.881943358574063e-07
typed O 0 5.4969259366544065e-08
samples O 0 7.541457236470706e-09
from O 0 9.335892059425532e-10
non O 0 1.641096036841816e-09
- O 0 3.002691300935112e-05
Caucasian O 0 4.361386345408391e-06
populations O 0 3.0803026795922506e-09
, O 0 7.986691308303762e-10
comprising O 0 1.071416635967104e-10
Australian O 0 1.6049479256707855e-07
Aboriginal O 0 2.6438200961820257e-08
, O 0 1.959722828459576e-09
Chinese O 0 4.9465962576045186e-11
, O 0 1.2446663699705596e-09
and O 0 3.410756477251198e-08
Pacific O 0 1.2975382333024754e-06
Islanders O 0 6.179947718010226e-07
. O 0 1.0304848530040545e-07

Results O 0 1.5046372027427424e-05
showed O 0 4.69967699245899e-06
that O 0 2.4629660533292963e-09
the O 0 2.5377198120679623e-09
845 O 0 2.186842539231293e-05
G O 0 0.004695066250860691
- O 0 0.005377075169235468
- O 0 0.0006374770309776068
> O 0 9.252384636226907e-09
A O 0 1.1175097291982183e-08
mutation O 0 7.285490877251277e-09
was O 0 1.9637670902739046e-06
present O 0 6.886928249905111e-10
in O 0 1.119862647058767e-09
these O 0 1.8656583222753653e-10
populations O 0 1.1501553875969961e-10
( O 0 4.4587432704301655e-12
allele O 0 9.037923881516363e-11
frequency O 0 1.8790764499954093e-09
0 O 0 2.720046965443146e-10
. O 0 1.8608994900581877e-10
32 O 0 5.41618305760494e-09
% O 0 3.4026373385565023e-10
) O 0 6.608456559753506e-10
, O 0 3.1663742738885503e-09
and O 0 2.7249932088579953e-08
, O 0 1.2450659170326617e-08
furthermore O 0 2.621143968539741e-09
, O 0 2.0590553706512082e-09
it O 0 3.242192070374017e-09
was O 0 2.441402557451511e-06
always O 0 1.5434508782163903e-08
seen O 0 9.55856727102855e-09
in O 0 1.0591181404118188e-10
conjunction O 0 1.136346461372284e-09
with O 0 1.752959910561458e-08
HLA O 0 2.9614518552989466e-06
haplotypes O 0 1.219426849274896e-06
common O 0 4.232973083162506e-09
in O 0 6.407045116674226e-09
Caucasians O 0 4.788801177824098e-08
, O 0 3.7244305417516443e-09
suggesting O 0 2.282534872222186e-08
that O 0 5.914889023017622e-09
845 O 0 6.910171123308828e-06
G O 0 0.0036075308453291655
- O 0 0.0015106379287317395
- O 0 0.0003712813195306808
> O 0 1.298333351940073e-08
A O 0 5.187557121644204e-07
may O 0 2.410060915281065e-07
have O 0 1.9877044454830184e-09
been O 0 2.086476325047215e-09
introduced O 0 4.69726535445858e-10
into O 0 1.1155727730471909e-10
these O 0 1.3921419572682225e-10
populations O 0 6.970196086975022e-10
by O 0 5.98698646214757e-09
Caucasian O 0 1.8107184587279335e-05
admixture O 0 6.827660399721935e-05
. O 0 2.837362899299478e-06

187 O 0 2.750372550508473e-05
C O 0 0.00016195450734812766
- O 0 0.0010850074468180537
- O 0 0.00589804258197546
> O 0 1.720916770864278e-06
G O 0 0.00023488665465265512
was O 0 1.7813193835536367e-06
present O 0 5.198803609829383e-10
at O 0 1.2181880393313804e-08
an O 0 1.1175810971097988e-10
allele O 0 5.609040787390995e-09
frequency O 0 9.245980869820869e-09
of O 0 6.03718941505349e-09
2 O 0 9.658631370257353e-07
. O 0 4.588379169945256e-07

68 O 0 0.00021355741773732007
% O 0 1.6823624093831313e-07
in O 0 3.795049607902001e-09
the O 0 1.8458026218581836e-09
two O 0 2.2922989728613175e-08
populations O 0 1.2598360576987488e-08
analyzed O 0 1.9160664521677973e-07
( O 0 6.819145248471159e-09
Australian O 0 7.461628683813615e-07
Aboriginal O 0 1.395488453681537e-07
and O 0 2.6542844366872487e-08
Chinese O 0 1.6445397266195982e-09
) O 0 3.326189323971107e-09
. O 0 4.391417718352386e-08

In O 0 5.850453987932269e-08
the O 0 7.191252038296625e-09
Australian O 0 5.22366825350673e-08
Aboriginal O 0 4.510172679772495e-09
samples O 0 1.4932036718207087e-09
, O 0 9.997760397340016e-10
187 O 0 8.926659411656601e-09
C O 0 7.725794830548693e-07
- O 0 7.213214121293277e-05
- O 0 0.0017843114910647273
> O 0 5.154338822421778e-08
G O 0 2.6878024073084816e-05
was O 0 3.695082796184579e-06
found O 0 9.629884090145424e-08
to O 0 1.97716998329156e-09
be O 0 2.6783528728202555e-09
associated O 0 2.1467669863994843e-09
with O 0 1.1973749991511795e-08
HLA O 0 2.0853015030297684e-06
haplotypes O 0 1.3975221690998296e-06
common O 0 3.849891783147541e-08
in O 0 2.934440423985052e-08
Caucasians O 0 2.6581960810290184e-07
, O 0 1.4478210630386457e-08
suggesting O 0 4.057154612269187e-08
that O 0 3.8828762427556285e-09
it O 0 5.286026727446824e-09
was O 0 3.727602120306983e-07
introduced O 0 7.601794749234614e-09
by O 0 2.1176849163140332e-09
recent O 0 1.409717924616416e-07
admixture O 0 9.52681148191914e-06
. O 0 8.165933991222118e-07

In O 0 7.953164526952605e-08
the O 0 3.3212126382409224e-09
Chinese O 0 2.0335912120916788e-10
samples O 0 6.034687749512102e-10
analyzed O 0 2.99912095158561e-09
, O 0 1.042388286798257e-09
187 O 0 2.188244963008401e-08
C O 0 1.3456540273182327e-06
- O 0 6.659092468908057e-05
- O 0 0.0006273057661019266
> O 0 8.160674269674928e-08
G O 0 7.348803774220869e-05
was O 0 1.7955071598407812e-05
present O 0 7.106739641216109e-09
in O 0 1.3957992983648637e-08
association O 0 7.851989058949016e-10
with O 0 5.177488993091117e-10
a O 0 3.089192679439634e-09
wide O 0 6.8553993592956886e-09
variety O 0 4.2285649981543827e-10
of O 0 2.4766084738558902e-09
HLA O 0 9.605926607036963e-06
haplotypes O 0 5.430219061963726e-06
, O 0 4.626616245673176e-08
showing O 0 2.0920786880651576e-07
this O 0 5.241198031136207e-10
mutation O 0 7.353265774057149e-10
to O 0 5.979519102083941e-10
be O 0 3.7061473889821173e-09
widespread O 0 5.258844471001112e-09
and O 0 9.457829719394795e-08
likely O 0 2.3086830225338417e-08
to O 0 6.95343838064133e-10
predate O 0 4.2874411576576676e-08
the O 0 1.8690633762918907e-10
more O 0 1.8579443539223917e-11
genetically O 0 1.1973995128755632e-09
restricted O 0 2.696147471947796e-10
845 O 0 1.289451483899029e-05
G O 0 0.036275818943977356
- O 0 0.005965959280729294
- O 0 0.0008674145792610943
> O 0 2.1034113117934794e-08
A O 0 1.3362912909542501e-07
mutation O 0 1.3599235160199896e-07
. O 0 2.738036926075438e-07

Genotype O 0 0.002688652602955699
- O 0 0.030833236873149872
phenotype O 0 0.0013118801871314645
correlations O 0 0.0004993462935090065
in O 0 7.623009150847793e-05
attenuated B-Disease 1 0.9966643452644348
adenomatous I-Disease 1 0.9996097683906555
polyposis I-Disease 1 0.9992399215698242
coli I-Disease 1 0.9992493987083435
. O 0 0.000359676982043311

Germ O 0 0.07582742720842361
- O 0 0.022213520482182503
line O 0 3.34196665789932e-05
mutations O 0 1.4334835896079312e-07
of O 0 2.310417634987516e-09
the O 0 1.9488959424052155e-07
tumor B-Disease 0 0.0006139082252047956
suppressor O 0 3.679110523080453e-05
APC O 0 3.932945764972828e-05
are O 0 7.173237559499057e-09
implicated O 0 2.0952500562998466e-05
in O 0 2.2949052436160855e-05
attenuated B-Disease 1 0.9949476718902588
adenomatous I-Disease 1 0.9999606609344482
polyposis I-Disease 1 0.9999010562896729
coli I-Disease 1 0.9999667406082153
( O 0 9.53514245338738e-05
AAPC B-Disease 1 0.9998704195022583
) O 0 5.148836521584599e-07
, O 0 4.713784562682122e-08
a O 0 1.6033369831802702e-07
variant O 0 0.0005445205024443567
of O 0 0.00032997148809954524
familial B-Disease 1 0.9999771118164062
adenomatous I-Disease 1 0.9998351335525513
polyposis I-Disease 1 0.9999244213104248
( O 0 2.0954519641236402e-05
FAP B-Disease 0 0.00026852250448428094
) O 0 7.787754725541163e-07
. O 0 9.906236755341524e-07

AAPC B-Disease 1 0.9978882670402527
is O 0 1.1745357824111125e-06
recognized O 0 4.7193684515889345e-09
by O 0 6.969836929826556e-10
the O 0 8.717923605239264e-10
occurrence O 0 2.0839040715259216e-08
of O 0 2.202930282635407e-09
< O 0 2.2908484709205368e-07
100 O 0 2.631459139479375e-08
colonic B-Disease 0 3.7849527871003374e-05
adenomas I-Disease 0 4.594971323967911e-05
and O 0 1.2813241134779219e-08
a O 0 2.007215549326702e-08
later O 0 1.7095147995860316e-05
onset O 0 0.0005812088493257761
of O 0 0.022072911262512207
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999924898147583
( O 0 9.741242479321954e-08
age O 0 2.2081988504396577e-07
> O 0 3.4406692606125944e-08
40 O 0 3.045259688860824e-08
years O 0 4.9249041467192e-07
) O 0 2.774507379399438e-08
. O 0 1.2839153384902602e-07

The O 0 7.1137129964427e-08
aim O 0 1.4833463524155377e-07
of O 0 3.515084334715368e-10
this O 0 1.648087222250183e-10
study O 0 2.0163574976361787e-10
was O 0 8.249423899542307e-08
to O 0 8.65483296141889e-10
assess O 0 5.7949334220097626e-09
genotype O 0 5.964899401078583e-07
- O 0 0.0002708745305426419
phenotype O 0 5.6665144256839994e-06
correlations O 0 6.879319698782638e-06
in O 0 6.842260972916847e-06
AAPC B-Disease 1 0.9998188614845276
families O 0 6.931596089998493e-06
. O 0 9.991495062422473e-07

By O 0 8.575180743264355e-08
protein O 0 3.446962466568948e-07
- O 0 1.1255366189288907e-05
truncation O 0 4.885482667305041e-06
test O 0 5.124021527080913e-07
( O 0 3.8442818373063403e-10
PTT O 0 4.151847576849832e-07
) O 0 6.019352793984467e-10
assay O 0 1.899614332501187e-08
, O 0 3.0651275961801616e-10
the O 0 6.653288336933016e-11
entire O 0 2.011415034530728e-09
coding O 0 2.3376410354103427e-06
region O 0 1.5662912078440172e-09
of O 0 8.319823302516127e-11
the O 0 3.0867308709048302e-09
APC B-Disease 0 5.381318146646663e-07
gene O 0 8.912708793218371e-09
was O 0 1.2035752661176957e-06
screened O 0 3.036756623941983e-08
in O 0 6.356506432325659e-09
affected O 0 8.008291252359356e-10
individuals O 0 1.2819291461685367e-10
from O 0 1.1125650623000638e-08
11 O 0 2.286656126671005e-05
AAPC B-Disease 1 0.9998879432678223
kindreds O 0 0.00010891850979533046
, O 0 1.7867090917889072e-08
and O 0 3.060537379084849e-09
their O 0 6.202886537742813e-10
phenotypic O 0 2.5776094592089294e-09
differences O 0 6.549885256390553e-07
were O 0 1.575657961438992e-06
examined O 0 3.075174754485488e-05
. O 0 1.2829793831770075e-06

Five O 0 6.356424364639679e-07
novel O 0 2.061223540295032e-06
germ O 0 0.0008081029518507421
- O 0 0.0017601479776203632
line O 0 2.7164076527697034e-05
APC B-Disease 0 1.1432523024268448e-05
mutations O 0 1.4618876775784884e-07
were O 0 1.1750047690384235e-07
identified O 0 1.6593214979820914e-07
in O 0 1.9006581197800188e-08
seven O 0 1.7876348010759102e-06
kindreds O 0 0.0001535684132250026
. O 0 6.801922722843301e-07

Mutations O 0 8.048530617088545e-06
were O 0 4.5624867084370635e-07
located O 0 3.236318235622093e-08
in O 0 1.6094097166075017e-09
three O 0 6.247769523959334e-10
different O 0 5.3445990688683054e-11
regions O 0 7.341896535173476e-11
of O 0 3.863739883591677e-10
the O 0 2.5839854700393516e-08
APC B-Disease 0 5.898493327549659e-06
gene O 0 1.2753601730253195e-08
( O 0 1.7011848874037838e-10
1 O 0 1.4633423361942732e-09
) O 0 3.8102063171230327e-10
at O 0 1.390763326725164e-08
the O 0 6.883619230180216e-10
5 O 0 3.838422468760427e-09
end O 0 1.2330508170066423e-08
spanning O 0 3.5279956733802464e-09
exons O 0 3.00971230160485e-08
4 O 0 5.8551091086656015e-08
and O 0 3.279854965398954e-08
5 O 0 3.2778597613969396e-08
, O 0 1.7500701332551216e-08
( O 0 7.421160908016589e-11
2 O 0 1.5890219140501927e-09
) O 0 4.104033432539289e-11
within O 0 1.958483071898276e-12
exon O 0 1.8292052317292473e-08
9 O 0 5.01244073802809e-07
, O 0 3.721492447539276e-08
and O 0 9.180018167853632e-08
( O 0 3.913828150459153e-10
3 O 0 6.169074140416342e-09
) O 0 4.090687510949209e-10
at O 0 8.176781030044822e-09
the O 0 1.4061637410023309e-09
3 O 0 8.460546041533235e-08
distal O 0 9.439954737899825e-06
end O 0 4.2041978076667874e-07
of O 0 5.738264308163821e-10
the O 0 1.3696195289014668e-08
gene O 0 2.1431722529996478e-07
. O 0 4.962195703228645e-07

Variability O 0 4.185043144389056e-05
in O 0 1.7116015271767537e-08
the O 0 1.9316046540041043e-09
number O 0 6.21726892191532e-09
of O 0 6.056620986782946e-05
colorectal B-Disease 1 0.9999994039535522
adenomas I-Disease 1 0.9999879598617554
was O 0 0.014686084352433681
most O 0 3.5798869646441744e-08
apparent O 0 2.5327843104605563e-05
in O 0 5.413975401324933e-08
individuals O 0 3.473867304926159e-10
with O 0 1.2921423930833953e-08
mutations O 0 7.777706656497685e-08
in O 0 1.2840324359331134e-08
region O 0 2.5281410742650223e-08
1 O 0 3.470374210223781e-08
, O 0 7.615497565893747e-08
and O 0 2.9924569844297366e-06
upper O 0 0.0013033552095293999
- O 1 0.9447062611579895
gastrointestinal O 0 0.0021785462740808725
manifestations O 0 9.768515383257181e-07
were O 0 2.7332495733389806e-07
more O 0 1.383912540120491e-08
severe O 0 2.8032159207214136e-06
in O 0 2.1036481001601715e-08
them O 0 4.1446934773148314e-08
. O 0 3.491161635338358e-07

In O 0 4.023885651349701e-07
individuals O 0 6.8749623771680035e-09
with O 0 1.2820183137307595e-08
mutations O 0 5.1204356310563526e-08
in O 0 1.5229428385055144e-08
either O 0 7.692473324993898e-09
region O 0 4.964682887020899e-09
2 O 0 4.214928850387878e-08
or O 0 5.546932513311731e-08
region O 0 1.0312394493894317e-08
3 O 0 1.663989301903257e-08
, O 0 2.827523326587311e-09
the O 0 6.151798515041662e-10
average O 0 1.1165723456940668e-08
number O 0 8.967453168917672e-11
of O 0 6.069794888929891e-09
adenomas B-Disease 0 2.5564513634890318e-05
tended O 0 3.4799253256778684e-08
to O 0 1.2456708997632404e-09
be O 0 3.3379083941298404e-09
lower O 0 3.414108817878514e-08
than O 0 3.6062197672492857e-10
those O 0 1.070593946828069e-09
in O 0 2.151998135246913e-09
individuals O 0 7.189790429684706e-11
with O 0 4.193996261392385e-09
mutations O 0 1.2975510443880012e-08
in O 0 6.181394063276002e-09
region O 0 3.1819880064176687e-09
1 O 0 6.621544201834695e-09
, O 0 4.152099819521027e-08
although O 0 1.3354855887826034e-08
age O 0 4.7085546128755595e-08
at O 0 1.8359744444751414e-06
diagnosis O 0 4.6927934818086214e-06
was O 0 1.0965623005176894e-05
similar O 0 3.898008742453385e-07
. O 0 1.463274315938179e-06

In O 0 1.6922438135225093e-06
all O 0 5.834540388605092e-07
AAPC B-Disease 1 0.998401939868927
kindreds O 0 0.00015242899826262146
, O 0 4.871882808288319e-08
a O 0 7.734211493470866e-09
predominance O 0 2.0999937078158837e-06
of O 0 1.3830660350322432e-07
right O 0 0.004249549936503172
- O 1 0.9997283816337585
sided O 1 0.9999819993972778
colorectal B-Disease 1 0.9999991655349731
adenomas I-Disease 1 0.9999822378158569
and O 0 0.016810642555356026
rectal B-Disease 1 0.999561607837677
polyp I-Disease 1 0.6337717175483704
sparing O 0 4.441802957444452e-06
was O 0 5.82767570449505e-05
observed O 0 4.3593468035396654e-07
. O 0 5.869969754712656e-07

No O 0 0.0001608130260137841
desmoid B-Disease 1 0.9223167300224304
tumors I-Disease 1 0.9998962879180908
were O 0 1.3254741134005599e-05
found O 0 1.6753350564613356e-06
in O 0 1.2886327560579502e-08
these O 0 2.3151786265884766e-08
kindreds O 0 8.600425644544885e-05
. O 0 9.099424573832948e-07

Our O 0 3.3975954494280813e-08
data O 0 1.0001031114370562e-07
suggest O 0 5.207403575013814e-08
that O 0 1.4476166043664307e-08
, O 0 6.478839509327372e-08
in O 0 4.102455477550393e-07
AAPC B-Disease 1 0.9999138116836548
families O 0 2.5253777380385145e-07
, O 0 1.8418286895638403e-09
the O 0 5.491178067806857e-10
location O 0 9.15878217710997e-09
of O 0 1.531135107590842e-09
the O 0 2.7682233394443756e-07
APC B-Disease 0 0.00014603137969970703
mutation O 0 5.361883950172341e-07
may O 0 5.055580913904123e-07
partially O 0 2.351091325181187e-06
predict O 0 2.7338954211586497e-08
specific O 0 1.3410027255300605e-10
phenotypic O 0 2.2708135372084826e-09
expression O 0 4.4082018035851434e-08
. O 0 1.034030333357805e-06

This O 0 4.7290214411077613e-08
should O 0 1.1009967160191536e-08
help O 0 2.8116049488602357e-09
in O 0 3.667714743027517e-10
the O 0 1.1575174152511636e-09
design O 0 4.723207425172404e-08
of O 0 1.042173680687597e-09
tailored O 0 5.897863388781843e-07
clinical O 0 3.0363861469595577e-07
- O 0 0.00019417927251197398
management O 0 1.2139507532538119e-07
protocols O 0 5.512728051826343e-08
in O 0 2.027109369251434e-09
this O 0 6.333941010572275e-11
subset O 0 3.6897118693701714e-10
of O 0 2.7438038507909823e-09
FAP B-Disease 0 5.54166308575077e-06
patients O 0 1.9950206819885352e-08
. O 0 7.252354716769105e-09
. O 0 1.8716876581947872e-07

Wilms B-Disease 0 0.06120629236102104
' I-Disease 0 2.094237061101012e-05
tumor I-Disease 0 6.223135278560221e-05
1 O 0 2.4104970464122744e-08
and O 0 1.3075089100311743e-07
Dax O 0 0.35081204771995544
- O 0 0.0002151925873477012
1 O 0 5.211335363242142e-09
modulate O 0 3.288630878728327e-08
the O 0 2.5956117255532263e-09
orphan O 0 4.960256205777114e-07
nuclear O 0 1.2074704045517137e-06
receptor O 0 1.1656223541933741e-08
SF O 0 0.0005429324810393155
- O 0 2.306228270754218e-05
1 O 0 1.0833301367085824e-08
in O 0 2.9287579028647315e-09
sex O 0 3.52863693819927e-08
- O 0 1.7393072937466059e-07
specific O 0 1.2365235224631732e-10
gene O 0 1.144377392847673e-08
expression O 0 1.422389939165214e-08
. O 0 1.8327610007418116e-07

Products O 0 9.327550287707709e-07
of O 0 8.265358175663096e-09
steroidogenic O 0 4.114478088013129e-06
factor O 0 5.1856080318657405e-08
1 O 0 7.533291324079983e-09
( O 0 2.2776498465049144e-09
SF O 0 0.005190158728510141
- O 0 0.00022260028345044702
1 O 0 3.7432048571872656e-08
) O 0 1.4878369647419731e-08
and O 0 1.2422759709806996e-06
Wilms B-Disease 0 0.003650916740298271
tumor I-Disease 0 9.061573655344546e-05
1 O 0 2.784814157053006e-08
( O 0 3.1125251265251563e-09
WT1 O 0 6.2386216086451896e-06
) O 0 9.800068534460138e-10
genes O 0 2.6842070233179527e-10
are O 0 1.5657699095616984e-11
essential O 0 1.6725303433884342e-11
for O 0 4.1707783060562775e-11
mammalian O 0 2.2558140244655078e-07
gonadogenesis O 0 7.684383490413893e-06
prior O 0 1.8622178243887788e-09
to O 0 2.8704005838875446e-10
sexual O 0 5.7487290483493325e-09
differentiation O 0 4.066932888235897e-07
. O 0 9.146074830823636e-07

In O 0 1.9040621168642247e-07
males O 0 6.80866548918857e-07
, O 0 4.197979990294698e-07
SF O 0 0.013489636592566967
- O 0 0.0001964383409358561
1 O 0 3.3746676564305744e-08
participates O 0 2.128091036723845e-09
in O 0 2.7326689799878068e-09
sexual O 0 6.32694430180436e-09
development O 0 9.182374305360952e-10
by O 0 7.176683136655981e-10
regulating O 0 2.7427051740858133e-09
expression O 0 2.2589240200598937e-10
of O 0 1.4812097381966538e-10
the O 0 1.0952829754273807e-08
polypeptide O 0 4.198186616122257e-06
hormone O 0 1.0217169688075955e-07
Mullerian O 0 2.1630210085277213e-06
inhibiting O 0 7.281533953573671e-07
substance O 0 1.443491441932565e-06
( O 0 1.3743402860200149e-08
MIS O 0 2.8725215088343248e-05
) O 0 1.2929268677908112e-07
. O 0 1.6530604796116677e-07

Here O 0 1.4392837783816503e-06
, O 0 4.7518064150153805e-08
we O 0 1.6235429667332824e-09
show O 0 1.4827827854446696e-08
that O 0 2.1615882417336252e-08
WT1 O 0 2.5182180252159014e-05
- O 0 0.00010957355698337778
KTS O 0 0.00023691992100793868
isoforms O 0 2.5542681858503613e-10
associate O 0 2.8575650734552482e-09
and O 0 1.865876342321826e-09
synergize O 0 4.2243053144375153e-07
with O 0 1.1703233582238681e-07
SF O 0 0.15632188320159912
- O 0 0.00021882381406612694
1 O 0 4.974303635663091e-09
to O 0 2.9853250427258615e-10
promote O 0 4.244234741435093e-09
MIS O 0 1.7782724171411246e-05
expression O 0 4.360884986454039e-08
. O 0 3.597743045702373e-07

In O 0 3.922419296031876e-07
contrast O 0 5.148208401806187e-07
, O 0 1.9555388064418366e-07
WT1 O 0 0.00018431244825478643
missense O 0 1.4430810551857576e-05
mutations O 0 1.9057131339650368e-06
, O 0 1.1895720319898828e-07
associated O 0 3.49054154469286e-08
with O 0 1.3919475350121502e-07
male B-Disease 0 2.4540577214793302e-05
pseudohermaphroditism I-Disease 1 0.9998952150344849
in O 0 6.540766480611637e-05
Denys B-Disease 1 0.9995439648628235
- I-Disease 1 0.999956488609314
Drash I-Disease 1 0.9998233914375305
syndrome I-Disease 1 0.9990890026092529
, O 0 3.365351517459203e-07
fail O 0 2.897328421624934e-08
to O 0 2.5620505716972275e-10
synergize O 0 2.2018114123056876e-06
with O 0 6.006181365592056e-07
SF O 1 0.6092311143875122
- O 0 0.0009229158749803901
1 O 0 1.5309116463413375e-07
. O 0 1.5351339754943183e-07

Additionally O 0 1.5832677036087262e-06
, O 0 1.3288440925407485e-07
the O 0 5.298950611631881e-08
X O 0 0.003415356855839491
- O 0 0.00840306282043457
linked O 0 2.445101381454151e-05
, O 0 1.4850527918497392e-08
candidate O 0 2.9488982367098515e-09
dosage O 0 1.5179466572590172e-07
- O 0 3.3268684092035983e-06
sensitive O 0 2.485834329490899e-07
sex O 0 1.8671735801945033e-07
- O 0 1.1540938430698588e-05
reversal O 0 9.206212325807428e-07
gene O 0 1.8504592302903689e-09
, O 0 1.0460834865000379e-08
Dax O 0 0.1714959442615509
- O 0 0.00028908063541166484
1 O 0 1.014560435663725e-08
, O 0 9.321782235005571e-10
antagonizes O 0 3.7945664388416844e-08
synergy O 0 2.188754244514257e-08
between O 0 3.1868726324546515e-08
SF O 0 0.0153665104880929
- O 0 0.0001586481521371752
1 O 0 1.2417147310372911e-08
and O 0 8.389775985051529e-08
WT1 O 0 2.5005831048474647e-05
, O 0 7.595446938069017e-09
most O 0 1.2539061455818512e-10
likely O 0 2.3120312331315063e-09
through O 0 8.542975354908222e-11
a O 0 1.442637259652102e-10
direct O 0 1.1100261335106332e-11
interaction O 0 2.0778335996229913e-10
with O 0 1.3648426033796568e-07
SF O 0 0.4226316511631012
- O 0 0.001008182647638023
1 O 0 2.0128634048433014e-07
. O 0 1.3787727937142336e-07

We O 0 1.949527295153075e-08
propose O 0 2.7151617842946507e-08
that O 0 7.260770207295764e-09
WT1 O 0 2.7678904643835267e-06
and O 0 7.882697872219069e-08
Dax O 0 0.25504064559936523
- O 0 0.0002004999842029065
1 O 0 1.1239096764370515e-08
functionally O 0 3.645546797770294e-08
oppose O 0 6.878959624145864e-10
each O 0 1.756123024776457e-11
other O 0 1.5062409652877307e-10
in O 0 8.091034509050132e-09
testis O 0 6.192812634253642e-06
development O 0 7.862839268568678e-10
by O 0 2.2657602460895987e-09
modulating O 0 2.31118474403047e-06
SF O 0 0.20808729529380798
- O 0 0.00031311216298490763
1 O 0 6.424485832212667e-08
- O 0 1.0705418389989063e-05
mediated O 0 1.628096833883319e-05
transactivation O 0 5.6343715186812915e-06
. O 0 2.7949722536391164e-08
. O 0 9.420939051096866e-08

A O 0 1.0257955409542774e-06
mouse O 0 6.28344714641571e-05
model O 0 1.050917762768222e-05
for O 0 9.072130524145905e-06
Prader B-Disease 1 0.9998949766159058
- I-Disease 1 0.9999788999557495
Willi I-Disease 1 0.999993085861206
syndrome I-Disease 1 0.9999128580093384
imprinting O 0 0.05474155396223068
- O 0 0.4171064794063568
centre O 0 0.0001518538047093898
mutations O 0 5.330056865204824e-06
. O 0 1.1434869975346373e-06

Imprinting O 0 5.1390139560680836e-05
in O 0 4.5869267495390886e-08
the O 0 1.3932537790140032e-08
15q11 O 0 1.2567038538691122e-06
- O 0 5.078177127870731e-05
q13 O 0 4.206319488275767e-07
region O 0 1.9024888331387046e-09
involves O 0 8.167081455567882e-10
an O 0 3.87771770249401e-09
imprinting O 0 5.9610560128930956e-05
centre O 0 6.129309895186452e-06
( O 0 3.389166725042969e-09
IC O 0 1.7035915789165301e-06
) O 0 2.4573025836360785e-09
, O 0 3.0218808011461817e-10
mapping O 0 1.356889001158379e-08
in O 0 1.05745534551005e-09
part O 0 5.563201566083364e-10
to O 0 2.1288858176315983e-10
the O 0 9.61867807625083e-10
promoter O 0 4.592039033468609e-07
and O 0 6.983746914102085e-09
first O 0 5.1499240427688164e-09
exon O 0 9.266707934330043e-07
of O 0 6.395229235067745e-08
SNRPN O 0 0.006786588113754988
. O 0 1.2050016948705888e-06

Deletion O 0 1.615873770788312e-05
of O 0 1.262450766148504e-08
this O 0 1.4843136497688647e-08
IC O 0 9.574328942107968e-06
abolishes O 0 1.8857393797588884e-06
local O 0 1.859091325329132e-09
paternally O 0 1.4774112742088619e-06
derived O 0 4.685927756931108e-10
gene O 0 8.831462228187092e-10
expression O 0 1.2059440113176834e-09
and O 0 1.3607460402909055e-07
results O 0 4.191106199868955e-06
in O 0 0.00041821657214313745
Prader B-Disease 1 0.9999841451644897
- I-Disease 1 0.9999960660934448
Willi I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999746084213257
( O 0 3.252917667850852e-05
PWS B-Disease 1 0.9998451471328735
) O 0 2.589531732155592e-06
. O 0 8.182211104212911e-07

We O 0 2.639981175889261e-07
have O 0 2.405406984706815e-09
created O 0 4.635037631484096e-10
two O 0 5.8151954362983815e-09
deletion O 0 1.1276780469415826e-06
mutations O 0 1.777067808461652e-07
in O 0 2.168563497662035e-07
mice O 0 5.027074439567514e-05
to O 0 7.249163758160648e-08
understand O 0 3.978265112891677e-07
PWS B-Disease 1 0.9998341798782349
and O 0 6.538252250720689e-08
the O 0 4.826026245297044e-09
mechanism O 0 1.814672501154746e-08
of O 0 8.700813403095253e-10
this O 0 6.2541154477457894e-09
IC O 0 2.936702367151156e-05
. O 0 2.1326030719137634e-07

Mice O 0 0.006562415044754744
harbouring O 0 0.003307212609797716
an O 0 7.984594958543312e-07
intragenic O 0 0.0005963497678749263
deletion O 0 1.00596853371826e-05
in O 0 1.0747625367457658e-07
Snrpn O 0 3.2221574656432495e-05
are O 0 1.7675401142724922e-09
phenotypically O 0 4.6658122698772786e-08
normal O 0 1.1592591775411165e-08
, O 0 2.1848585163297685e-08
suggesting O 0 3.5410431564741884e-07
that O 0 2.154907008389273e-08
mutations O 0 2.6557579246855312e-08
of O 0 4.914944895517692e-09
SNRPN O 0 0.00020325907098595053
are O 0 1.935099441796595e-10
not O 0 1.7696069609662857e-10
sufficient O 0 9.544311868614486e-11
to O 0 9.679046897304033e-09
induce O 0 3.74685942006181e-06
PWS B-Disease 1 0.9992882609367371
. O 0 3.6037872632732615e-06

Mice O 0 0.00021951676171738654
with O 0 4.070098214015161e-08
a O 0 4.105746498339613e-08
larger O 0 1.4385173052744449e-08
deletion O 0 2.0584052151662036e-07
involving O 0 4.403243991646377e-08
both O 0 7.306935945194937e-09
Snrpn O 0 3.4239801607327536e-06
and O 0 1.2184413478166789e-08
the O 0 3.3205871829977696e-08
putative O 0 0.001124879578128457
PWS O 1 0.9999728202819824
- O 0 0.057162992656230927
IC O 0 4.04241363867186e-05
lack O 0 2.415272648548239e-09
expression O 0 5.3375491526619356e-11
of O 0 1.715374647881518e-10
the O 0 2.9743192797582196e-08
imprinted O 0 0.00029675019322894514
genes O 0 1.790919696986748e-07
Zfp127 O 0 1.2127478839829564e-05
( O 0 7.052008976771162e-10
mouse O 0 1.1046125791835948e-06
homologue O 0 1.3409115808826755e-06
of O 0 1.1736267957473956e-08
ZNF127 O 0 0.0009765215800143778
) O 0 1.0219873836092574e-08
, O 0 1.1850151970804745e-08
Ndn O 0 4.13657789977151e-06
and O 0 3.490861288923952e-08
Ipw O 0 7.200956588349072e-06
, O 0 1.4747620014077256e-07
and O 0 4.015037902149743e-08
manifest O 0 1.2479264910325583e-07
several O 0 2.783028474340199e-09
phenotypes O 0 5.829446081406786e-07
common O 0 3.5720236724046117e-07
to O 0 1.7231768651981838e-05
PWS B-Disease 1 0.9999315738677979
infants O 0 0.0004010655975434929
. O 0 1.0178932825510856e-06

These O 0 1.2644509439496687e-08
data O 0 8.686875929697635e-08
demonstrate O 0 2.3788267355939752e-08
that O 0 3.221320543644879e-09
both O 0 1.7950622932527693e-10
the O 0 4.802205300080686e-10
position O 0 9.725477312372277e-09
of O 0 2.170042062710209e-10
the O 0 4.308005951969562e-09
IC O 0 3.09810388898768e-06
and O 0 9.525370714413839e-09
its O 0 5.721848550521713e-10
role O 0 3.5220909522237775e-10
in O 0 1.450744108177915e-10
the O 0 1.1105456138027492e-10
coordinate O 0 4.842491962975259e-10
expression O 0 1.86618512310055e-10
of O 0 5.211509349067889e-11
genes O 0 8.54874948608142e-10
is O 0 1.919300829378301e-10
conserved O 0 3.3508751329236475e-10
between O 0 3.064826614718186e-08
mouse O 0 0.0004497295885812491
and O 0 2.9180907290538016e-07
human O 0 1.8414047175951964e-08
, O 0 2.9527662093187246e-08
and O 0 5.5963162992611615e-08
indicate O 0 1.844501440473323e-08
that O 0 1.3497640782844655e-09
the O 0 3.16689363621947e-09
mouse O 0 9.373149623570498e-06
is O 0 9.799132616450379e-10
a O 0 4.31301883097035e-10
suitable O 0 4.294305355756478e-09
model O 0 1.0075068246351293e-07
system O 0 9.229369624108585e-08
in O 0 1.1971991398240789e-08
which O 0 8.870497225643703e-09
to O 0 5.05830488606307e-10
investigate O 0 2.3544501903671744e-09
the O 0 4.347517901237552e-10
molecular O 0 2.9343565799422322e-08
mechanisms O 0 3.1732361183145485e-09
of O 0 4.9137144353395e-10
imprinting O 0 1.9146254999213852e-05
in O 0 9.554520730148397e-09
this O 0 6.211600123151584e-10
region O 0 9.08817965328268e-10
of O 0 1.7062282142710217e-10
the O 0 1.4611761578464666e-08
genome O 0 4.943099725096545e-07
. O 0 1.9944652152048548e-08
. O 0 9.976358938956764e-08

Mutations O 0 1.796698484213266e-06
of O 0 3.914486956801966e-09
the O 0 1.1199507987669222e-08
ATM O 0 2.486873017915059e-05
gene O 0 2.1037990904915205e-07
detected O 0 1.3535643574869027e-06
in O 0 2.424889657959284e-07
Japanese O 0 0.01848630979657173
ataxia B-Disease 1 0.9999864101409912
- I-Disease 1 0.999985933303833
telangiectasia I-Disease 1 0.9999889135360718
patients O 0 3.4649158351385267e-06
: O 0 2.139078691953955e-09
possible O 0 4.315835688828429e-09
preponderance O 0 3.53725283730455e-07
of O 0 7.232349163999174e-10
the O 0 9.089865748990178e-09
two O 0 1.4881639742725383e-07
founder O 0 1.555593917146325e-05
mutations O 0 1.3331954562545434e-07
4612del165 O 0 2.3881833044470113e-07
and O 0 1.4830861516657023e-07
7883del5 O 0 4.656540113501251e-06
. O 0 4.5763749767502304e-07

The O 0 4.6767803496550187e-07
ATM O 0 0.006182380951941013
( O 0 6.00110206505633e-06
A O 1 0.9915848970413208
- O 1 0.9999576807022095
T O 1 0.9999866485595703
, O 0 1.410346044394828e-06
mutated O 0 3.736435871815047e-07
) O 0 9.21097065287313e-09
gene O 0 5.468197894487048e-09
on O 0 5.516913574865612e-07
human O 0 6.589494319086953e-07
chromosome O 0 0.0001265946339117363
11q22 O 0 3.13222044496797e-05
. O 0 1.150032289842784e-06

3 O 0 2.1257863409118727e-05
has O 0 1.5458881534868851e-06
recently O 0 1.5771945527376374e-06
been O 0 3.8424534665182364e-08
identified O 0 3.2108493641658242e-09
as O 0 3.118745262042921e-10
the O 0 1.3193571790637293e-09
gene O 0 3.8665355361899856e-09
responsible O 0 6.569601307404582e-09
for O 0 3.134955628425473e-10
the O 0 9.845303594602228e-08
human O 0 6.720859528286383e-05
recessive B-Disease 1 0.9981667995452881
disease I-Disease 1 0.9996415376663208
ataxia B-Disease 1 0.9999923706054688
- I-Disease 1 0.99998939037323
telangiectasia I-Disease 1 0.9999908208847046
( O 0 7.266589091159403e-05
A B-Disease 1 0.9998370409011841
- I-Disease 1 0.999961256980896
T I-Disease 1 0.9999783039093018
) O 0 1.9092058209935203e-06
. O 0 4.461270464162226e-07

In O 0 1.299814300637081e-07
order O 0 3.7117504625427955e-09
to O 0 5.528358881790041e-10
define O 0 2.3953437011670076e-09
the O 0 5.2210853418444e-09
types O 0 1.2342701438683434e-07
of O 0 5.254225357020914e-07
disease O 0 0.0008864718256518245
- O 0 0.0016138431383296847
causing O 0 1.8048178844765062e-06
ATM O 0 1.7791850041248836e-05
mutations O 0 4.879080961472937e-08
in O 0 1.9824879515795146e-08
Japanese O 0 0.00021742125682067126
A B-Disease 1 0.9999165534973145
- I-Disease 1 0.999990701675415
T I-Disease 1 0.9999973773956299
patients O 0 4.312924417604336e-08
as O 0 8.529237316423632e-10
well O 0 3.599485709493422e-10
as O 0 4.0313480331732876e-10
to O 0 2.909197882594583e-10
look O 0 4.6430539968334017e-10
for O 0 1.5265320257862314e-11
possible O 0 1.096963297975151e-09
mutational O 0 9.687626061349874e-07
hotspots O 0 1.8462881143932464e-06
, O 0 2.026700585133767e-08
reverse O 0 3.466231191850966e-06
- O 0 7.03089426679071e-06
transcribed O 0 1.2249921610418824e-07
RNA O 0 4.141714526895157e-08
derived O 0 2.4107979501586385e-10
from O 0 1.175083780280417e-10
ten O 0 5.022694482548218e-10
patients O 0 2.832325762813781e-10
belonging O 0 1.920217096440524e-09
to O 0 2.831769541078444e-10
eight O 0 1.2374802516035288e-08
unrelated O 0 7.469367915291514e-07
Japanese O 0 1.8285085388924927e-05
A B-Disease 1 0.9985567927360535
- I-Disease 1 0.9999778270721436
T I-Disease 1 0.9999963045120239
families O 0 4.721838138266321e-07
was O 0 4.503891886997735e-06
analyzed O 0 4.219264226890118e-08
for O 0 2.5493862576553283e-10
mutations O 0 2.468440341019118e-09
by O 0 3.1434699288013235e-10
the O 0 9.6489782830389e-10
restriction O 0 3.846924556683007e-09
endonuclease O 0 1.179078822133306e-06
fingerprinting O 0 9.448594369132479e-07
method O 0 1.1736965888076156e-07
. O 0 2.812701325183298e-07

As O 0 3.564468897820916e-07
has O 0 5.128323437020299e-07
been O 0 1.687047443965639e-07
reported O 0 1.0005245485444902e-06
by O 0 3.2814801986802422e-09
others O 0 1.2556809814157077e-08
, O 0 3.48019590923343e-09
mutations O 0 3.357267797099439e-09
that O 0 3.4803684378914568e-09
lead O 0 3.174920948367799e-08
to O 0 8.30579549582211e-10
exon O 0 2.3245330282861687e-07
skipping O 0 9.578351409800234e-07
or O 0 1.0963575647338075e-07
premature O 0 3.374706807335315e-07
protein O 0 1.3713806756854297e-09
truncation O 0 1.7492399706497963e-07
were O 0 5.901323874013542e-08
also O 0 1.1679412992293692e-08
predominant O 0 4.035042522332333e-09
in O 0 1.0778430370450565e-09
our O 0 8.057738476452414e-09
mutants O 0 2.9707614430662943e-06
. O 0 1.2627739920390013e-07

Six O 0 7.817909164486991e-08
different O 0 8.079695246188123e-10
mutations O 0 6.789765194525899e-08
were O 0 2.9232733567141622e-08
identified O 0 2.962112866100597e-08
on O 0 2.2777601316192886e-07
12 O 0 2.8279671937525563e-08
of O 0 3.644027302129871e-10
the O 0 8.24245205421903e-09
16 O 0 8.209570268036259e-08
alleles O 0 3.115704316769552e-08
examined O 0 4.013287707493873e-06
. O 0 5.973871566311573e-07

Four O 0 1.85830387522401e-07
were O 0 8.517281457898207e-08
deletions O 0 1.0685747611205443e-06
involving O 0 2.7089236027677543e-06
a O 0 1.3808693211103673e-06
loss O 0 1.3690765626961365e-05
of O 0 2.0689078228386393e-10
a O 0 3.8406047231376306e-09
single O 0 2.6894768634377897e-09
exon O 0 4.878578465650207e-07
exon O 0 6.593818966393883e-07
7 O 0 1.2644019875551749e-07
, O 0 1.2490571243972681e-08
exon O 0 1.3553764688367664e-07
16 O 0 4.560998689839835e-08
, O 0 1.0940447658924768e-08
exon O 0 2.5897489308590593e-07
33 O 0 6.691438869665944e-08
or O 0 3.009287752320233e-08
exon O 0 1.6295518889819505e-06
35 O 0 7.849747589716571e-07
. O 0 5.33507432010083e-07

The O 0 8.295590703255584e-08
others O 0 3.3357459017224755e-08
were O 0 1.886801381800751e-09
minute O 0 1.63567115407659e-09
deletions O 0 4.196334657535772e-08
, O 0 7.4064483435165585e-09
4649delA O 0 5.8521056445215436e-08
in O 0 1.3767638140649296e-09
exon O 0 1.9549010232822184e-07
33 O 0 7.892867870396003e-08
and O 0 2.1499641178479578e-08
7883del5 O 0 2.0911612352847442e-07
in O 0 9.664104183570998e-09
exon O 0 2.793589828797849e-06
55 O 0 6.921943622728577e-07
. O 0 2.3463286424885155e-07

The O 0 8.851571919876733e-08
mutations O 0 6.62068771362101e-07
4612del165 O 0 2.5231586278096074e-06
and O 0 1.9020149011339527e-07
7883del5 O 0 1.5852787100811838e-06
were O 0 1.3173490742701688e-07
found O 0 3.766782441516625e-08
in O 0 3.28641419633513e-10
more O 0 2.3673535354262754e-11
than O 0 1.5818785170651495e-10
two O 0 6.5182277353414975e-09
unrelated O 0 6.764674708392704e-06
families O 0 1.336451873612532e-07
; O 0 6.161783527858233e-09
44 O 0 2.2489054174457124e-08
% O 0 1.135313065780963e-09
( O 0 1.643425673325538e-10
7 O 0 1.0768058444909911e-08
of O 0 9.197430594909406e-10
16 O 0 8.813263008278227e-08
) O 0 4.013234744526528e-10
of O 0 1.1932215632226573e-11
the O 0 7.571923643645562e-10
mutant O 0 6.802895882174198e-07
alleles O 0 1.6987160122994283e-08
had O 0 4.1899608049789094e-07
one O 0 6.230573834642428e-10
of O 0 6.506271910122763e-11
the O 0 2.2896891049839496e-09
two O 0 3.300023649899231e-07
mutations O 0 2.1028874925832497e-06
. O 0 5.352350740395195e-07

The O 0 2.7886522957487614e-07
4612del165 O 0 6.056630354578374e-06
mutations O 0 3.1623082463738683e-07
in O 0 2.29324226275196e-09
three O 0 9.425603630930368e-10
different O 0 1.9077021906621638e-10
families O 0 2.0714171711233575e-08
were O 0 9.803699185795267e-09
all O 0 5.987597223588992e-11
ascribed O 0 3.211308996498019e-09
to O 0 2.1397794647270985e-10
the O 0 2.4432864620393957e-09
same O 0 2.716674885050452e-07
T O 0 0.0681619793176651
- O 0 0.0002978388802148402
- O 0 1.1481110959721263e-05
> O 0 2.339542171103659e-10
A O 0 6.584849332469389e-11
substitution O 0 5.2139154105290686e-11
at O 0 1.5284397747450384e-08
the O 0 1.67912850290719e-10
splice O 0 1.4413784583666711e-06
donor O 0 1.6454785978226028e-08
site O 0 1.4285582494721893e-07
in O 0 1.8257335199223235e-08
intron O 0 0.00041172205237671733
33 O 0 3.44763748216792e-06
. O 0 3.1896402674647106e-07

Microsatellite O 0 0.0003867963096126914
genotyping O 0 1.385448376822751e-05
around O 0 5.810496972458168e-08
the O 0 7.862903217414896e-09
ATM O 0 6.900788866914809e-05
locus O 0 4.958920180797577e-05
also O 0 8.774347293183382e-07
indicated O 0 9.338239124190295e-07
that O 0 5.999377439280806e-09
a O 0 1.79073484929404e-08
common O 0 2.0089933627787104e-07
haplotype O 0 0.0009350752807222307
was O 0 2.357014273002278e-05
shared O 0 9.747371798596305e-09
by O 0 6.771743166211763e-10
the O 0 8.624281844227255e-10
mutant O 0 1.7980801203520969e-07
alleles O 0 4.4129020437821964e-09
in O 0 1.2955867489949924e-09
both O 0 2.2128361365503224e-08
mutations O 0 8.440397323283833e-07
. O 0 8.199975241041102e-07

This O 0 2.8340454605313425e-07
suggests O 0 2.2429259161071968e-07
that O 0 4.294879119015604e-09
these O 0 1.7300588739388445e-10
two O 0 1.3140937227262839e-08
founder O 0 1.5483681636396796e-05
mutations O 0 1.2727132059353607e-07
may O 0 8.460833811341217e-09
be O 0 1.360689616536348e-10
predominant O 0 2.102014784455264e-09
among O 0 1.3864764891735604e-10
Japanese O 0 3.083842869955333e-08
ATM O 0 3.91691064578481e-05
mutant O 0 3.930420461983886e-06
alleles O 0 1.0216740520263556e-07
. O 0 2.9467639706126647e-07

W474C O 0 1.6268149920506403e-05
amino O 0 2.4697561684661196e-07
acid O 0 2.5131360104069245e-08
substitution O 0 1.1187034631987558e-09
affects O 0 5.860980589744713e-10
early O 0 1.7561707643665159e-10
processing O 0 6.279033404332779e-10
of O 0 7.113509000594709e-12
the O 0 7.827148651440297e-11
alpha O 0 5.10420178345683e-11
- O 0 3.6906002698344764e-09
subunit O 0 1.6055785173607617e-11
of O 0 9.957405559812837e-12
beta O 0 1.187519416134819e-09
- O 0 4.3243517211521976e-06
hexosaminidase O 0 5.235416210780386e-06
A O 0 6.505313621119058e-08
and O 0 5.728887231271074e-08
is O 0 5.890592458257515e-09
associated O 0 2.3614402877569773e-08
with O 0 8.375991455977783e-07
subacute O 0 0.012690084055066109
G B-Disease 0 0.36605069041252136
( I-Disease 0 5.344882225699621e-08
M2 I-Disease 0 0.005825215019285679
) I-Disease 0 5.37910182174528e-07
gangliosidosis I-Disease 0 5.8255809562979266e-05
. O 0 2.3369049984012236e-07

Mutations O 0 7.205463134596357e-06
in O 0 6.888222259249233e-08
the O 0 1.7342863145586307e-08
HEXA O 0 3.447913331910968e-05
gene O 0 1.0363463864848654e-08
, O 0 3.4486943856215646e-10
encoding O 0 2.0921450336053304e-11
the O 0 1.2735819343578925e-10
alpha O 0 2.434061563416634e-10
- O 0 9.966940162087212e-09
subunit O 0 3.087823052805305e-11
of O 0 1.1421041196113535e-10
beta O 0 1.4467491649128306e-09
- O 0 1.0375100828241557e-05
hexosaminidase O 0 2.2710346456733532e-06
A O 0 7.705854443429416e-08
( O 0 5.311077133640651e-10
Hex O 0 8.204543178180757e-07
A O 0 9.354616281598283e-08
) O 0 3.3787364017712207e-09
, O 0 3.9016118114076903e-10
that O 0 1.0862172966641381e-10
abolish O 0 3.758448663404579e-09
Hex O 0 7.663582834993576e-08
A O 0 3.104834611633578e-09
enzyme O 0 4.1230245884094074e-09
activity O 0 2.539576655635756e-07
cause O 0 0.00014581669529434294
Tay B-Disease 1 0.9999923706054688
- I-Disease 1 0.9999914169311523
Sachs I-Disease 1 0.9999947547912598
disease I-Disease 0 0.14055034518241882
( O 0 3.9328241996372526e-08
TSD B-Disease 0 0.00016635985230095685
) O 0 4.1012693685615886e-08
, O 0 2.4069962023531843e-08
the O 0 1.4283361338129907e-07
fatal O 0 0.2627095878124237
infantile B-Disease 0 0.0008617673302069306
form I-Disease 0 1.440933772300923e-08
of I-Disease 0 2.4378468310715107e-07
G I-Disease 0 0.173310786485672
( I-Disease 0 2.7382530021213825e-08
M2 I-Disease 0 0.0041246539913117886
) I-Disease 0 1.429726381729779e-07
gangliosidosis I-Disease 0 1.17471663543256e-05
, I-Disease 0 1.1070972583127059e-08
Type I-Disease 0 2.1825801610475537e-08
1 I-Disease 0 3.070455534270877e-08
. O 0 2.257389297710688e-07

Less O 0 2.3817610781406984e-05
severe O 0 0.0013678277609869838
, O 0 7.258243385876995e-06
subacute O 0 0.0050474777817726135
( O 0 7.764261340525991e-07
juvenile O 0 0.2449595183134079
- O 1 0.9779596328735352
onset O 0 0.19964158535003662
) O 0 1.2529530067695305e-05
and O 0 0.0002606129564810544
chronic O 0 0.006894516758620739
( O 0 3.345187016279283e-09
adult O 0 2.4080759430944454e-07
- O 0 0.03442305698990822
onset O 0 2.126021536241751e-05
) O 0 1.2019077288982771e-08
variants O 0 1.8992881933854733e-08
are O 0 1.3688509215015188e-09
characterized O 0 9.03259405049539e-08
by O 0 3.684973437501071e-09
a O 0 2.9119989974901728e-08
broad O 0 1.286565378677551e-07
spectrum O 0 7.854360433157126e-07
of O 0 1.245464886778791e-08
clinical O 0 6.949492785679467e-07
manifestations O 0 5.299082204146544e-07
and O 0 5.10966003730573e-07
are O 0 1.7721175638030218e-09
associated O 0 8.640586912633808e-09
with O 0 8.616459545862654e-09
residual O 0 8.382911573789897e-07
levels O 0 1.8351451469555968e-09
of O 0 1.7216515713069924e-10
Hex O 0 2.3907887225504965e-06
A O 0 2.4504657858415158e-08
enzyme O 0 2.326240000627422e-08
activity O 0 4.9108621169580147e-08
. O 0 1.2198567844734498e-07

We O 0 3.4971655793469836e-08
identified O 0 1.6518937329124128e-08
a O 0 2.5083139121306885e-08
1422 O 0 0.00026987894671037793
G O 0 0.010501351207494736
- O 0 0.0021338490769267082
- O 0 0.002265235874801874
> O 0 9.773624753961485e-08
C O 0 3.8877880115251173e-07
( O 0 3.152859570643152e-11
amino O 0 3.0476721840644316e-11
acid O 0 1.6759064969118498e-10
W474C O 0 1.3294945144792791e-09
) O 0 6.999512081051762e-12
substitution O 0 2.9458692429873423e-12
in O 0 1.7196815152442646e-11
the O 0 7.844634664078143e-11
first O 0 2.0290658042654286e-10
position O 0 7.663839007854278e-10
of O 0 1.0973248004697567e-10
exon O 0 1.806560732120488e-07
13 O 0 2.2003405319992453e-08
of O 0 2.8676441221620053e-09
HEXA O 0 2.6522140615270473e-05
of O 0 5.198565466990601e-10
a O 0 1.2725342557473596e-08
non O 0 1.8604366047725307e-08
- O 0 5.782244625152089e-05
Jewish O 0 1.3138591157257906e-06
proband O 0 0.0008056312799453735
who O 0 2.594198349470389e-07
manifested O 0 1.1947382461130474e-07
a O 0 5.0305711596365654e-08
subacute O 0 1.6760184735176153e-05
variant O 0 6.6907509790326e-06
of O 0 7.794560588081367e-07
G B-Disease 1 0.6122894287109375
( I-Disease 0 7.496000620221821e-08
M2 I-Disease 0 0.004734582733362913
) I-Disease 0 7.515814104408491e-07
gangliosidosis I-Disease 0 9.979965398088098e-05
. O 0 6.48615866793989e-07

On O 0 9.56212375058385e-07
the O 0 6.163054422358982e-08
second O 0 2.1669418401870644e-06
maternally O 0 0.0006428530323319137
inherited O 0 0.00021041888976469636
allele O 0 5.589306510955794e-07
, O 0 4.669889719366438e-08
we O 0 1.7978455391087778e-09
identified O 0 1.1585451709095196e-08
the O 0 4.4364838913679705e-08
common O 0 1.5457078916369937e-05
infantile O 1 0.9637715816497803
disease O 0 0.11141424626111984
- O 0 0.008604785427451134
causing O 0 1.216264263348421e-05
4 O 0 3.442744400672382e-07
- O 0 3.255769843235612e-05
bp O 0 3.101468109889538e-06
insertion O 0 6.345098313431663e-08
, O 0 3.23130961987772e-08
+ O 0 4.379260474252078e-07
TATC O 0 1.72042527992744e-05
1278 O 0 8.027719559322577e-06
, O 0 4.662020547385737e-09
in O 0 2.7725537421474655e-09
exon O 0 2.0822728856728645e-06
11 O 0 1.767542926245369e-06
. O 0 4.977419507667946e-07

Pulse O 0 0.0003547907981555909
- O 0 0.00021860651031602174
chase O 0 1.5881336366874166e-05
analysis O 0 2.000533516621772e-09
using O 0 2.1085437840184795e-09
proband O 0 5.063342541689053e-06
fibroblasts O 0 2.221323711637524e-07
revealed O 0 1.1832546533696586e-06
that O 0 1.001910332476541e-09
the O 0 5.956571347276451e-10
W474C O 0 4.26812825082834e-08
- O 0 8.848314081433273e-08
containing O 0 5.167159478070005e-10
alpha O 0 8.088927444527272e-11
- O 0 3.444869944857487e-09
subunit O 0 2.16792694907042e-11
precursor O 0 2.9771254905774924e-10
was O 0 4.523441887727131e-08
normally O 0 1.7869389301594651e-10
synthesized O 0 1.4120470348544245e-09
, O 0 5.705882433204579e-10
but O 0 1.630344054204258e-10
not O 0 1.9525610295278994e-11
phosphorylated O 0 5.745963704839596e-10
or O 0 2.8692197506785533e-09
secreted O 0 8.582147437152798e-09
, O 0 2.4062789538703555e-09
and O 0 2.1625314872153467e-09
the O 0 3.4715044172628495e-09
mature O 0 2.1983227682653705e-08
lysosomal O 0 7.759435334264708e-07
alpha O 0 1.1016789702722463e-09
- O 0 2.0335045292085852e-07
subunit O 0 1.1901519769708102e-09
was O 0 3.260951757511066e-07
not O 0 3.1457145777125106e-09
detected O 0 1.6490390919443598e-07
. O 0 7.069738217069244e-08

When O 0 3.1665030064687016e-07
the O 0 1.085700684910762e-08
W474C O 0 1.4416407623230043e-07
- O 0 2.607990552405681e-07
containing O 0 1.68568203839925e-09
alpha O 0 2.80913764472146e-10
- O 0 1.7701456300756035e-08
subunit O 0 2.5599355968353166e-10
was O 0 8.369276542907755e-07
transiently O 0 7.9852492262944e-07
co O 0 4.356065346655669e-06
- O 0 1.1407573765609413e-06
expressed O 0 6.452122169875452e-10
with O 0 1.0882724582605974e-10
the O 0 3.3654468101218526e-10
beta O 0 7.151126912852135e-11
- O 0 5.842845762771276e-09
subunit O 0 8.149582571281844e-12
to O 0 2.1228671598372273e-11
produce O 0 3.7500454130867666e-11
Hex O 0 8.784129335026591e-08
A O 0 7.711398097853817e-08
( O 0 1.3455151437469226e-09
alphabeta O 0 1.461354031562223e-06
) O 0 2.004070021044413e-09
in O 0 6.6961982625457495e-09
COS O 0 0.0007381618488579988
- O 0 2.7179883545613848e-05
7 O 0 7.801686763286853e-08
cells O 0 5.250595958017357e-09
, O 0 1.3011507149496282e-10
the O 0 1.0291791724403865e-10
mature O 0 2.3432755735797173e-10
alpha O 0 2.8375152921755742e-11
- O 0 3.087939504098358e-08
subunit O 0 9.973871728519157e-11
was O 0 1.3819045818763698e-07
present O 0 2.119639741504642e-10
, O 0 2.966893675182547e-10
but O 0 7.499521836873413e-11
its O 0 9.23284296239224e-11
level O 0 1.661517923245981e-09
was O 0 2.7441149086371297e-07
much O 0 1.2447707309348743e-09
lower O 0 1.2328721155085987e-08
than O 0 8.52276096918736e-11
that O 0 2.8646904293161413e-10
from O 0 1.0720927617891007e-11
normal O 0 2.16865483904094e-11
alpha O 0 7.374850730101912e-11
- O 0 3.385517999276999e-08
subunit O 0 2.9153859881780875e-10
transfections O 0 5.913357199460734e-07
, O 0 2.524471742759715e-10
although O 0 5.258999485890925e-11
higher O 0 1.4207372778241023e-10
than O 0 2.6983786732825976e-11
in O 0 3.6400399361369296e-10
those O 0 5.607647124428183e-10
cells O 0 2.050238734341292e-08
transfected O 0 2.8263127660466125e-07
with O 0 3.4166067197638483e-10
an O 0 4.688314736434052e-10
alpha O 0 1.198167121074789e-09
- O 0 7.362758651652257e-07
subunit O 0 5.1136592738032505e-09
associated O 0 4.295634781215085e-08
with O 0 5.20546223015117e-07
infantile O 0 0.04274431988596916
TSD B-Disease 0 0.003789080772548914
. O 0 1.3244352885521948e-06

Furthermore O 0 1.3302494608069537e-06
, O 0 1.0690682117342476e-08
the O 0 4.2565798108462616e-10
precursor O 0 2.6932600594165024e-09
level O 0 2.6883317794101913e-10
of O 0 1.2764095336237347e-11
the O 0 1.585935827108642e-10
W474C O 0 2.6193496260873417e-09
alpha O 0 6.364991866902869e-11
- O 0 1.884148481678949e-08
subunit O 0 2.0440400760879385e-10
was O 0 9.070910209629801e-07
found O 0 2.0056885929875534e-08
to O 0 2.7595279394887484e-09
accumulate O 0 1.7865360746327497e-07
in O 0 4.250300666974738e-10
comparison O 0 5.069915043343087e-10
to O 0 1.9095723266526754e-11
the O 0 2.990852010498202e-11
normal O 0 6.503678845470873e-11
alpha O 0 1.1321488885274178e-10
- O 0 3.9127645123926413e-08
subunit O 0 4.1992048727124143e-10
precursor O 0 6.120575601897826e-09
levels O 0 3.151251481980921e-09
. O 0 8.679353236118459e-09

We O 0 9.578354820405366e-08
conclude O 0 1.5826381627448427e-07
that O 0 1.2121034176360013e-09
the O 0 8.303091547645636e-09
1422 O 0 0.00012413618969731033
G O 0 0.0014815727481618524
- O 0 0.0009204302332364023
- O 0 0.0010483922669664025
> O 0 7.934588097668893e-08
C O 0 9.562305649524205e-07
mutation O 0 6.123074491881653e-09
is O 0 1.0824537932663247e-09
the O 0 3.4924378944367618e-09
cause O 0 2.8293321463479515e-08
of O 0 2.005748900302251e-09
Hex B-Disease 0 0.0028180049266666174
A I-Disease 0 0.005484884604811668
enzyme I-Disease 1 0.9999685287475586
deficiency I-Disease 1 0.9999212026596069
in O 0 9.832370473361607e-09
the O 0 3.185281514106464e-07
proband O 0 0.002277202671393752
. O 0 1.657741449889727e-06

The O 0 4.703743528011728e-08
resulting O 0 5.012593717879099e-08
W474C O 0 4.335407766120625e-08
substitution O 0 6.078376690865639e-10
clearly O 0 3.756443689439948e-08
interferes O 0 2.2545917133243165e-08
with O 0 1.3435526302618683e-10
alpha O 0 1.5868162339671699e-10
- O 0 1.7619466774476678e-08
subunit O 0 6.350428516377349e-11
processing O 0 4.175287227070612e-09
, O 0 2.158135004037831e-09
but O 0 4.732391145623183e-10
because O 0 1.539315029608357e-11
the O 0 3.707888596854447e-12
base O 0 1.666697058144706e-10
substitution O 0 4.521143182056875e-10
falls O 0 6.085324002924608e-06
at O 0 3.1424601587559664e-08
the O 0 2.9689034564128747e-10
first O 0 2.4812976673338483e-10
position O 0 9.90313275828214e-10
of O 0 1.3553486111206325e-10
exon O 0 7.148832281700379e-08
13 O 0 3.781727286877867e-08
, O 0 2.5074131659863497e-09
aberrant O 0 1.3489055561421992e-07
splicing O 0 1.2329824130574707e-06
may O 0 8.147702601490892e-08
also O 0 3.830874728549816e-09
contribute O 0 9.57074419716264e-11
to O 0 1.5137616715676927e-09
Hex B-Disease 0 0.0001706309849396348
A I-Disease 0 0.0005749248084612191
deficiency I-Disease 0 0.002632920863106847
in O 0 2.7860982410032875e-09
this O 0 5.847093031974282e-09
proband O 0 3.458494393271394e-05
. O 0 5.277305348272421e-08
. O 0 1.9269366191565496e-07

Two O 0 4.127323336433619e-07
frequent O 0 3.4415074878779706e-06
missense O 0 0.0002406233543297276
mutations O 0 0.0005354609456844628
in O 0 0.021650252863764763
Pendred B-Disease 1 0.9998891353607178
syndrome I-Disease 1 0.9998672008514404
. O 0 0.00026557265664450824

Pendred B-Disease 1 0.9996128678321838
syndrome I-Disease 1 0.9999521970748901
is O 0 0.02703039161860943
an O 1 0.9139075875282288
autosomal B-Disease 1 0.9999960660934448
recessive I-Disease 1 0.9999982118606567
disorder I-Disease 1 0.999998927116394
characterized O 1 0.9709229469299316
by O 0 6.632292934227735e-05
early O 0 0.02562824636697769
childhood O 1 0.9950643181800842
deafness B-Disease 1 0.9999890327453613
and O 1 0.9810406565666199
goiter B-Disease 1 0.9999305009841919
. O 0 0.00031042221235111356

A O 0 5.538072969102359e-07
century O 0 1.963679352456893e-07
after O 0 6.951681541522703e-08
its O 0 1.454701581415918e-09
recognition O 0 6.360723614484698e-10
as O 0 1.8495816433983236e-08
a O 0 2.769538878055755e-05
syndrome O 0 0.4817468822002411
by O 0 3.00590308199844e-08
Vaughan O 0 1.3468503311742097e-05
Pendred O 0 0.000288487586658448
, O 0 2.3772535939770023e-07
the O 0 1.1587637800403172e-06
disease O 0 5.6087585107889026e-05
gene O 0 3.778115740260546e-07
( O 0 3.4267781501284844e-08
PDS O 0 6.74671828164719e-05
) O 0 1.5307678680187564e-08
was O 0 1.704277337921667e-06
mapped O 0 3.159220113957417e-06
to O 0 1.180990309990193e-07
chromosome O 0 0.00010959592327708378
7q22 O 0 1.4836571608611848e-05
- O 0 0.00036483199801295996
q31 O 0 2.014154233620502e-05
. O 0 3.512401178795699e-07

1 O 0 2.492842668289086e-06
and O 0 6.854630214547797e-07
, O 0 1.1238351049769335e-07
recently O 0 1.3626774943986675e-06
, O 0 4.6633896744197045e-09
found O 0 1.6989483153651008e-09
to O 0 7.31958035848912e-11
encode O 0 1.0402948502630238e-09
a O 0 4.649918494692429e-08
putative O 0 2.941509046650026e-05
sulfate O 0 0.00011127915058750659
transporter O 0 0.004538530483841896
. O 0 1.0117797728526057e-06

We O 0 5.630696264802282e-08
performed O 0 1.181832587349163e-08
mutation O 0 3.933587677806827e-09
analysis O 0 9.486963437055351e-10
of O 0 4.350296789468189e-10
the O 0 1.0486769497219939e-07
PDS B-Disease 0 0.00011031455505872145
gene O 0 4.282186338855354e-08
in O 0 3.901146783391596e-08
patients O 0 9.680837464998149e-09
from O 0 2.0548573953504956e-09
14 O 0 1.1288083356930656e-07
Pendred B-Disease 0 1.70862658706028e-05
families O 0 8.314533062048213e-09
originating O 0 2.9893778563661044e-09
from O 0 9.248903865000102e-10
seven O 0 4.4976991020462265e-09
countries O 0 1.9656853922356277e-10
and O 0 7.566585580320861e-09
identified O 0 1.9856477351254398e-08
all O 0 8.357728953356514e-10
mutations O 0 1.5047757528918737e-07
. O 0 2.932119684828649e-07

The O 0 3.0498668479594926e-07
mutations O 0 2.3633738521766645e-07
include O 0 3.229895240153269e-10
three O 0 5.440075612206385e-10
single O 0 7.138611035628628e-09
base O 0 4.4617806338465016e-08
deletions O 0 3.116721245532972e-07
, O 0 1.2734787446788687e-08
one O 0 2.0625103847038417e-09
splice O 0 2.0995226805098355e-05
site O 0 4.111273938178783e-06
mutation O 0 3.4950186744708844e-08
and O 0 9.059787231535665e-08
10 O 0 7.380166522352738e-08
missense O 0 3.0695443911099574e-06
mutations O 0 1.782976482900267e-06
. O 0 1.1770856644943706e-06

One O 0 1.1606505267991452e-06
missense O 0 3.149284384562634e-05
mutation O 0 5.891493856324814e-06
( O 0 6.484452086397141e-08
L236P O 0 3.6740977975568967e-06
) O 0 1.5589073143473797e-07
was O 0 1.3935420611232985e-05
found O 0 7.082465458552178e-07
in O 0 4.9766950560581336e-09
a O 0 2.3611791633015855e-08
homozygous O 0 7.225600029414636e-08
state O 0 6.368748306506689e-10
in O 0 5.674819503198592e-10
two O 0 2.5957765714679226e-08
consanguineous O 0 1.7209929865202866e-05
families O 0 1.2953594819009595e-07
and O 0 1.3547942323555162e-08
in O 0 2.045932756544744e-09
a O 0 1.4195901343327932e-08
heterozygous O 0 1.5005561238012888e-08
state O 0 4.2399039834606356e-10
in O 0 5.794874580189457e-10
five O 0 1.3936889420307352e-09
additional O 0 2.665946075008918e-10
non O 0 2.1062538380078877e-08
- O 0 0.00011055823415517807
consanguineous O 0 2.2924074073671363e-05
families O 0 2.341388665172417e-07
. O 0 1.5025601385332266e-07

Another O 0 2.308900320713292e-06
missense O 0 3.286844366812147e-05
mutation O 0 6.544686129927868e-06
( O 0 1.072638866617126e-07
T416P O 0 9.188755029754248e-06
) O 0 2.567087165061821e-07
was O 0 3.14155658998061e-05
found O 0 3.597691602408304e-07
in O 0 6.383284123501198e-09
a O 0 2.066807702760798e-08
homozygous O 0 1.2435853591341584e-07
state O 0 1.7283711128968093e-09
in O 0 4.136320619352318e-09
one O 0 3.9777411586783273e-08
family O 0 2.3566406071040547e-06
and O 0 5.4866603704795125e-08
in O 0 2.2825075163268593e-09
a O 0 2.772803853190453e-08
heterozygous O 0 4.0929080569185317e-08
state O 0 1.9710175713782974e-09
in O 0 2.4426807243571602e-09
four O 0 6.940764052387749e-08
families O 0 2.148763513787344e-07
. O 0 1.6368554156542814e-07

Pendred B-Disease 0 0.0137777179479599
patients O 0 2.3575059913127916e-06
in O 0 2.605836968427866e-08
three O 0 3.982630047971725e-08
non O 0 1.4874103726469912e-07
- O 0 0.0007993234321475029
consanguineous O 0 3.774067590711638e-05
families O 0 9.587274263367362e-08
were O 0 3.759375033496326e-08
shown O 0 7.211181429767066e-09
to O 0 1.9687096397547066e-10
be O 0 3.608462972870541e-10
compound O 0 2.693841949508169e-08
heterozygotes O 0 7.473783369960074e-09
for O 0 2.975723556453147e-10
L236P O 0 2.0190464056213386e-07
and O 0 1.168427488096313e-07
T416P O 0 4.208484824630432e-06
. O 0 2.444272126922442e-07

In O 0 3.7009931475040503e-07
total O 0 3.614432131371359e-08
, O 0 2.1569260155729353e-08
one O 0 5.1710267179316816e-09
or O 0 8.572527576689026e-09
both O 0 2.2610319172500226e-10
of O 0 2.5824947735841874e-10
these O 0 5.374830580606726e-10
mutations O 0 5.913411094127241e-09
were O 0 3.9614324265357936e-08
found O 0 1.957785400463763e-07
in O 0 3.6158160909849357e-09
nine O 0 3.166152140465783e-08
of O 0 1.0057606969482435e-09
the O 0 3.2458689958048126e-08
14 O 0 3.663202789994102e-07
families O 0 2.392167175457871e-08
analyzed O 0 4.113193483590294e-07
. O 0 4.7021825366755365e-07

The O 0 2.996035064484204e-08
identification O 0 2.1686579643187542e-08
of O 0 2.73728040234289e-09
two O 0 4.8427370558101757e-08
frequent O 0 4.351097970811679e-07
PDS B-Disease 0 0.0001055629545589909
mutations O 0 2.463446691081117e-08
will O 0 1.057228957157541e-10
facilitate O 0 6.046736722442603e-11
the O 0 1.0629380042814773e-08
molecular O 0 6.289478187682107e-05
diagnosis O 0 0.0013674123911187053
of O 0 0.00046358551480807364
Pendred B-Disease 1 0.9999816417694092
syndrome I-Disease 1 0.9999783039093018
. O 0 4.1395316657144576e-05

Insertional O 0 0.0002708956890273839
mutation O 0 2.1951514383999893e-07
by O 0 2.2470862948154036e-09
transposable O 0 3.446282050845184e-07
element O 0 1.7121566386890663e-08
, O 0 5.516609391520433e-08
L1 O 0 0.003975376486778259
, O 0 3.830920292102746e-08
in O 0 1.0334979094750452e-08
the O 0 5.403095997280616e-07
DMD B-Disease 1 0.9997541308403015
gene O 0 7.830040971157359e-08
results O 0 6.874931273159746e-07
in O 0 1.4064428341953317e-06
X B-Disease 1 0.9858457446098328
- I-Disease 1 0.9996546506881714
linked I-Disease 1 0.9978163242340088
dilated I-Disease 1 0.9932752847671509
cardiomyopathy I-Disease 1 0.9998612403869629
. O 0 4.443601574166678e-05

X B-Disease 1 0.9910542368888855
- I-Disease 1 0.9992604851722717
linked I-Disease 1 0.9994890689849854
dilated I-Disease 1 0.9998080134391785
cardiomyopathy I-Disease 1 0.9999881982803345
( O 0 7.420600923069287e-06
XLDCM B-Disease 0 0.19232052564620972
) O 0 2.3400158966069284e-07
is O 0 3.792111957778843e-09
a O 0 2.510213903406111e-08
clinical O 0 1.879056412690261e-07
phenotype O 0 2.1246057713142363e-06
of O 0 2.4481860094738295e-08
dystrophinopathy B-Disease 0 0.002838017651811242
which O 0 5.938608182987082e-07
is O 0 5.341295050698136e-08
characterized O 0 6.740891080880829e-07
by O 0 3.466536924179309e-08
preferential O 0 4.064606287101924e-07
myocardial B-Disease 1 0.6535977125167847
involvement I-Disease 0 3.259702054947411e-07
without O 0 5.318132600962144e-10
any O 0 1.2470466326242047e-10
overt O 0 2.5031376083006762e-08
clinical O 0 6.993472538852075e-07
signs O 0 9.56663552642567e-06
of O 0 1.2096270438632928e-05
skeletal B-Disease 1 0.9999850988388062
myopathy I-Disease 1 0.999985933303833
. O 0 0.0006408215849660337

To O 0 9.422412716730832e-08
date O 0 1.990646438798649e-07
, O 0 3.751000399176974e-09
several O 0 5.642580847009526e-10
mutations O 0 6.825836607049496e-08
in O 0 2.3939289661711882e-08
the O 0 6.5350877775927074e-06
Duchenne B-Disease 1 0.9996119141578674
muscular I-Disease 1 0.9985857009887695
dystrophy I-Disease 1 0.9980356097221375
gene O 0 8.645082561997697e-05
, O 0 0.0016260389238595963
DMD O 1 0.9999923706054688
, O 0 3.194113560311962e-06
have O 0 3.5897944172802454e-08
been O 0 7.447986405395568e-08
identified O 0 1.4311450513559976e-07
in O 0 3.70462274190686e-08
patients O 0 1.773920921266381e-08
with O 0 2.2066998894842982e-07
XLDCM B-Disease 0 0.05989701673388481
, O 0 6.435585220287976e-08
but O 0 1.3101488782751858e-09
a O 0 2.947266042330199e-10
pathogenic O 0 1.1162692992172651e-09
correlation O 0 2.048177849545141e-09
of O 0 1.200154142733112e-10
these O 0 1.2992120712596034e-09
cardiospecific O 0 9.934466652339324e-05
mutations O 0 2.7167371285941044e-07
in O 0 3.0053186605982773e-07
DMD O 1 0.9994574189186096
with O 0 9.830479541506065e-08
the O 0 3.5290517530484067e-07
XLDCM B-Disease 0 0.13190053403377533
phenotype O 0 2.7473528461996466e-05
has O 0 6.313842391136859e-07
remained O 0 5.196945380703255e-07
to O 0 2.0188752891669992e-09
be O 0 5.353879117819815e-09
elucidated O 0 1.3386779755819589e-05
. O 0 6.144346684777702e-07

We O 0 1.452273295399209e-06
report O 0 4.1846175236059935e-07
here O 0 1.1256983123431041e-09
the O 0 5.0068050400087216e-11
identification O 0 5.536135438966028e-10
of O 0 8.27004992265401e-11
a O 0 4.919165075278897e-09
unique O 0 2.0870414285667493e-09
de O 0 7.75323840684905e-08
novo O 0 1.7055768353202438e-07
L1 O 0 2.8770591598004103e-05
insertion O 0 1.9110908411335004e-08
in O 0 4.88041607127343e-10
the O 0 1.945499761291103e-09
muscle O 0 4.346403272847965e-07
exon O 0 4.71719317829411e-07
1 O 0 1.020052096123436e-07
in O 0 1.063388026523171e-06
DMD O 1 0.9999481439590454
in O 0 1.6717075368433143e-07
three O 0 6.744936058566964e-07
XLDCM B-Disease 0 0.08719273656606674
patients O 0 2.659691666906383e-08
from O 0 6.98306412694194e-10
two O 0 1.8910393251303503e-08
unrelated O 0 4.361768787930487e-06
Japanese O 0 5.7205070334021e-06
families O 0 3.168599391756288e-07
. O 0 2.6613847126100154e-07

The O 0 2.414348365675778e-08
insertion O 0 7.016607810328424e-07
was O 0 1.8104880155078718e-06
a O 0 1.5109094420040492e-08
5 O 0 4.572697065441389e-08
- O 0 3.4961233268404612e-06
truncated O 0 5.460893603981276e-08
form O 0 4.11184725157554e-10
of O 0 2.0236007314267113e-10
human O 0 9.887881624592865e-10
L1 O 0 3.4888225854956545e-06
inversely O 0 8.373245918846806e-08
integrated O 0 6.44073994138239e-09
in O 0 1.6945600478379674e-09
the O 0 7.557931169799303e-09
5 O 0 1.1747436445830317e-07
- O 0 9.151737322099507e-05
untranslated O 0 5.779212642664788e-06
region O 0 4.219012250672449e-09
in O 0 3.896681033399574e-10
the O 0 2.011741218055363e-09
muscle O 0 1.6735148733459937e-07
exon O 0 2.2400315913273516e-07
1 O 0 4.941916742495778e-08
, O 0 3.555322081183476e-08
which O 0 3.1667141797697695e-08
affected O 0 1.2457725129255692e-10
the O 0 2.127830273090936e-10
transcription O 0 2.1552482465381217e-08
or O 0 1.641384983486205e-08
the O 0 7.738830021253307e-09
stability O 0 1.200824328861927e-07
of O 0 3.207046850306483e-10
the O 0 3.628218792073312e-08
muscle O 0 4.117919161217287e-07
form O 0 5.8032890992709696e-11
of O 0 3.976933227178847e-10
dystrophin O 0 5.2414531381828056e-08
transcripts O 0 1.3291837319684419e-07
but O 0 1.2163724250058294e-08
not O 0 3.7951053410978375e-10
that O 0 4.0803857515037123e-10
of O 0 1.7312275224501406e-10
the O 0 2.5068118247872917e-08
brain O 0 6.376897363224998e-05
or O 0 2.555630942424614e-07
Purkinje O 0 0.00331905041821301
cell O 0 0.00012204184895381331
form O 0 1.2868838439317187e-08
, O 0 4.5044450303066697e-07
probably O 0 4.2250141518707096e-07
due O 0 4.788597518512461e-09
to O 0 2.7840463268091753e-10
its O 0 7.732849915953466e-10
unique O 0 2.7758173537506536e-10
site O 0 3.763076961149636e-08
of O 0 7.689109904340796e-10
integration O 0 2.3620266631496634e-07
. O 0 5.028705913900922e-07

We O 0 2.0381038723371603e-07
speculate O 0 9.250394583659727e-08
that O 0 1.2746713684563815e-09
this O 0 1.1256542573057082e-11
insertion O 0 2.112049646285641e-09
of O 0 1.2554425554700543e-10
an O 0 4.85340523326272e-09
L1 O 0 0.00040513480780646205
sequence O 0 1.8383414612799243e-07
in O 0 1.3127860256645363e-05
DMD O 1 0.999983549118042
is O 0 2.6708704581324128e-08
responsible O 0 2.8197626456005764e-09
for O 0 1.4435097561715793e-10
some O 0 1.1300039896855463e-11
of O 0 1.0124852345416713e-10
the O 0 7.238397881081937e-09
population O 0 2.9423177783094445e-10
of O 0 2.0064681027776032e-09
Japanese O 0 8.552134204364847e-06
patients O 0 5.120393886670627e-09
with O 0 1.8554045411178777e-08
XLDCM B-Disease 0 0.0005179706495255232
. O 0 8.454610167518695e-08
. O 0 4.564314508570533e-07

Severe O 0 0.0010812695836648345
early O 0 7.41396943340078e-05
- O 1 0.9940546154975891
onset O 1 0.9919365644454956
obesity B-Disease 1 0.9999570846557617
, O 0 0.13047266006469727
adrenal B-Disease 1 0.9999310970306396
insufficiency I-Disease 1 0.9999316930770874
and O 0 0.00039245723746716976
red O 0 0.009493260644376278
hair O 1 0.9904008507728577
pigmentation O 0 0.02779145911335945
caused O 0 3.7507743400055915e-05
by O 0 1.9608162915574212e-07
POMC O 0 0.0008110412745736539
mutations O 0 5.473077635542722e-07
in O 0 6.406460784091905e-08
humans O 0 7.259610157461793e-08
. O 0 6.787757342863188e-07

Sequential O 0 1.4525364804285346e-06
cleavage O 0 6.742332334397361e-05
of O 0 3.845897378340624e-09
the O 0 1.719443920578101e-09
precursor O 0 7.918770528192454e-09
protein O 0 3.619852861902473e-09
pre O 0 8.142728802340571e-07
- O 0 0.0006821195711381733
pro O 0 0.00021807731536682695
- O 0 0.014692929573357105
opiomelanocortin O 0 0.0006605630042031407
( O 0 2.823659084327801e-09
POMC O 0 1.4765112155146198e-06
) O 0 6.685195175215597e-10
generates O 0 6.157171994480848e-11
the O 0 6.696399545980114e-10
melanocortin O 0 1.8948179558719858e-06
peptides O 0 5.023533731218777e-07
adrenocorticotrophin O 0 1.384699407935841e-05
( O 0 1.5497244598705606e-09
ACTH O 0 2.1870980049243371e-07
) O 0 1.3610952365183948e-09
, O 0 3.2085476497911714e-09
melanocyte O 0 2.534691475375439e-06
- O 0 6.617054168600589e-05
stimulating O 0 2.0154219271262264e-07
hormones O 0 1.7996166334910413e-08
( O 0 3.5752295568514114e-10
MSH O 0 1.7477559310918878e-07
) O 0 5.3735463995119304e-11
alpha O 0 2.932998288684985e-11
, O 0 2.7586620487962676e-11
beta O 0 1.0216623554104576e-11
and O 0 6.614998132592476e-11
gamma O 0 2.914650465424273e-11
as O 0 2.1236125705148545e-11
well O 0 2.5882926010800666e-11
as O 0 3.748171911732712e-11
the O 0 4.431937594695512e-10
opioid O 0 3.775716450604705e-08
- O 0 1.929669366518283e-07
receptor O 0 1.2911562929929232e-09
ligand O 0 4.2871692862433974e-09
beta O 0 7.775152965905363e-09
- O 0 2.5113373339991085e-05
endorphin O 0 7.306305633392185e-05
. O 0 1.1674685396201312e-07

While O 0 4.244755587023974e-07
a O 0 3.459225439428337e-08
few O 0 8.285767627569385e-09
cases O 0 6.124406315421993e-09
of O 0 5.235068911702001e-08
isolated O 0 0.014955315738916397
ACTH B-Disease 1 0.8010453581809998
deficiency I-Disease 0 0.08141296356916428
have O 0 6.759334780781501e-08
been O 0 1.2077894098183606e-06
reported O 0 0.0001150325988419354
( O 0 8.246918703491701e-09
OMIM O 0 0.0001625895092729479
201400 O 0 9.247460184269585e-06
) O 0 4.369211126231676e-08
, O 0 2.649994712555781e-08
an O 0 3.242676598347316e-07
inherited O 0 0.17685949802398682
POMC O 0 0.29353493452072144
defect O 0 0.0010103167733177543
has O 0 8.533604614058277e-07
not O 0 1.2666161453012137e-08
been O 0 1.4318003138669155e-07
described O 0 8.314709134538134e-07
so O 0 2.227942452748266e-08
far O 0 5.860114171696296e-08
. O 0 2.034536379369456e-07

Recent O 0 2.204669044658658e-06
studies O 0 4.3948197969712055e-08
in O 0 1.961626416857598e-09
animal O 0 1.144368599881318e-08
models O 0 1.4749582000206374e-08
elucidated O 0 1.0944667394596763e-07
a O 0 1.7892897163918065e-09
central O 0 1.6655594958780995e-10
role O 0 7.378621325049295e-11
of O 0 1.0319821386328698e-10
alpha O 0 1.7117084416540251e-09
- O 0 1.358042936772108e-05
MSH O 0 2.568196805441403e-06
in O 0 3.656420166642249e-10
the O 0 2.00479147172139e-10
regulation O 0 2.148319300232515e-09
of O 0 3.613835342086702e-10
food O 0 1.4598661168818694e-09
intake O 0 1.1505612435014356e-10
by O 0 6.209674701523893e-12
activation O 0 8.930822747998945e-11
of O 0 9.438912845771696e-11
the O 0 1.449191344704559e-08
brain O 0 5.168918050912907e-06
melanocortin O 0 4.959981652064016e-07
- O 0 5.197597147343913e-06
4 O 0 5.981977579949671e-08
- O 0 1.3395210771705024e-06
receptor O 0 1.2015776817975166e-08
( O 0 1.3283539823660817e-09
MC4 O 0 1.7610280337976292e-05
- O 0 0.0003112935519311577
R O 0 7.68412573961541e-05
; O 0 2.728740289281717e-10
refs O 0 4.882804560679688e-08
3 O 0 6.172216959754451e-09
- O 0 2.6424397674418287e-06
5 O 0 4.328318681245946e-08
) O 0 8.604089107855373e-10
and O 0 1.0371091763161644e-09
the O 0 9.420140223426188e-10
linkage O 0 1.2394784789648838e-06
of O 0 4.506305373297437e-08
human O 0 5.792962838313542e-06
obesity B-Disease 1 0.9840677976608276
to O 0 1.5957411392264476e-08
chromosome O 0 1.9458200313238194e-06
2 O 0 2.4438378432023455e-08
in O 0 1.4839364181895576e-09
close O 0 4.8061320256920226e-08
proximity O 0 3.308030960269548e-09
to O 0 6.356503101656585e-10
the O 0 1.4854437679900911e-08
POMC O 0 0.00011273082054685801
locus O 0 1.3101741842547199e-06
, O 0 2.549967526022101e-08
led O 0 7.4122001869625365e-09
to O 0 6.083978876247897e-10
the O 0 4.4400794152466005e-09
proposal O 0 3.969707407236456e-08
of O 0 1.909617047823886e-10
an O 0 2.007449140251083e-08
association O 0 7.930651690912782e-09
of O 0 3.787680391553749e-09
POMC O 0 0.0005931301275268197
with O 0 1.5367393189080758e-06
human O 0 2.378957469773013e-05
obesity B-Disease 1 0.9988859295845032
. O 0 3.166075657645706e-06

The O 0 3.007463078574801e-08
dual O 0 1.7812103791925438e-08
role O 0 4.208901227542583e-09
of O 0 4.46516462693225e-10
alpha O 0 1.1290533841190609e-08
- O 0 3.287305298727006e-05
MSH O 0 5.0788376029231586e-06
in O 0 3.220120836644469e-10
regulating O 0 6.467243185426241e-09
food O 0 1.6368227884200337e-09
intake O 0 2.0223285268627933e-09
and O 0 1.742159416728839e-09
influencing O 0 2.743737148591663e-08
hair O 0 0.004836723208427429
pigmentation O 0 1.6884339856915176e-05
predicts O 0 1.221816819452215e-05
that O 0 7.089720810427025e-09
the O 0 1.1282762280018233e-08
phenotype O 0 7.02706711308565e-06
associated O 0 9.575175852205575e-08
with O 0 4.263677766402907e-08
a O 0 5.068545760877896e-06
defect O 0 0.0002404742845101282
in O 0 4.1878351453306095e-08
POMC O 0 3.056897548958659e-05
function O 0 6.102204963553959e-09
would O 0 1.0279054407646981e-07
include O 0 1.6445349615423765e-07
obesity B-Disease 1 0.9997199177742004
, O 0 1.545634376043381e-07
alteration O 0 2.752664727267984e-07
in O 0 2.467223225721682e-07
pigmentation O 0 0.0028871449176222086
and O 0 0.0006727544241584837
ACTH B-Disease 0 0.4487041234970093
deficiency I-Disease 0 0.023587753996253014
. O 0 3.993904442722851e-07

The O 0 6.589080214780552e-08
observation O 0 9.451776463720307e-07
of O 0 1.359077739238046e-08
these O 0 4.024430211302388e-08
symptoms O 0 3.54576741301571e-07
in O 0 4.3704586616399865e-09
two O 0 7.390265466256096e-08
probands O 0 6.348095485009253e-05
prompted O 0 2.2760788809250698e-08
us O 0 5.334125141587265e-09
to O 0 5.201856306813468e-11
search O 0 7.897920650812296e-10
for O 0 1.928084775171257e-10
mutations O 0 2.0877064521585e-09
within O 0 4.305487910638561e-11
their O 0 1.675694072389433e-08
POMC O 0 0.00011322984209982678
genes O 0 1.4936978232071851e-07
. O 0 2.4992408498292207e-07

Patient O 0 9.963681804947555e-06
1 O 0 8.243704314736533e-07
was O 0 1.7611691873753443e-05
found O 0 1.822328101752646e-07
to O 0 9.512766130370665e-10
be O 0 4.4215689443127815e-10
a O 0 7.859165540580193e-10
compound O 0 2.5642238554723917e-08
heterozygote O 0 1.0404382244644239e-08
for O 0 3.634322010004354e-11
two O 0 1.253799286615731e-09
mutations O 0 3.7979099865026456e-09
in O 0 1.6198929975175247e-09
exon O 0 5.232193984738842e-07
3 O 0 2.7263143920208677e-07
( O 0 8.644324145379301e-10
G7013T O 0 1.9720062027772656e-07
, O 0 1.1417179734962701e-07
C7133delta O 0 9.856641554506496e-06
) O 0 3.875396004104914e-09
which O 0 2.222072081892179e-09
interfere O 0 9.999039374264385e-10
with O 0 7.001865753863967e-11
appropriate O 0 7.785424215034364e-12
synthesis O 0 1.3505185858520008e-09
of O 0 1.916437675220095e-09
ACTH O 0 7.377800557151204e-07
and O 0 1.1435830948869352e-08
alpha O 0 2.818575772778331e-08
- O 0 8.17009640741162e-05
MSH O 0 0.00011390537110855803
. O 0 2.1020102280999708e-07

Patient O 0 2.1483556338353083e-05
2 O 0 1.6476006976517965e-06
was O 0 1.73239720879792e-06
homozygous O 0 6.478073544258223e-08
for O 0 7.195872231413603e-10
a O 0 5.925096413506026e-09
mutation O 0 6.3421792262374765e-09
in O 0 1.0500635916343981e-08
exon O 0 1.5150179706324707e-06
2 O 0 8.545722494091024e-07
( O 0 3.4498475187660915e-09
C3804A O 0 2.314516791557253e-07
) O 0 6.003269437115932e-09
which O 0 2.388802400332679e-08
abolishes O 0 8.046857146837283e-06
POMC O 0 7.834295684006065e-05
translation O 0 1.5260285124440998e-07
. O 0 4.5032896878183237e-07

These O 0 6.451143974572915e-08
findings O 0 3.954095006974967e-08
represent O 0 1.727859383349184e-10
the O 0 3.365626388696086e-10
first O 0 2.6173272438256845e-09
examples O 0 1.6114123368993205e-09
of O 0 5.356718624227597e-09
a O 0 5.862860052729957e-05
genetic B-Disease 1 0.9997376799583435
defect I-Disease 1 0.9977483153343201
within O 0 7.352662367843266e-10
the O 0 1.0233454617036841e-07
POMC O 0 0.0004570840683300048
gene O 0 2.886781658162363e-08
and O 0 1.0045706488881478e-08
define O 0 8.01616550916151e-09
a O 0 6.497673865624165e-08
new O 0 2.2386087948689237e-05
monogenic B-Disease 1 0.9238229393959045
endocrine I-Disease 1 0.9808869361877441
disorder I-Disease 0 0.022378819063305855
resulting O 0 2.1798058469357784e-07
in O 0 4.110808404789168e-08
early O 0 1.969776531041134e-05
- O 1 0.9976748824119568
onset O 1 0.9649143218994141
obesity B-Disease 1 0.9999916553497314
, O 0 0.004350041504949331
adrenal B-Disease 1 0.9999529123306274
insufficiency I-Disease 1 0.9999619722366333
and O 0 4.267309486749582e-05
red O 0 0.00030530293588526547
hair O 0 0.18214164674282074
pigmentation O 0 8.699498721398413e-05
. O 0 2.546745747622481e-07
. O 0 5.301013175085245e-07

A O 0 6.944928372831782e-06
European O 0 4.982557129551424e-06
multicenter O 0 0.00010682163701858371
study O 0 1.7024338205828826e-07
of O 0 7.671003459108761e-07
phenylalanine B-Disease 1 0.9995218515396118
hydroxylase I-Disease 1 0.9997044205665588
deficiency I-Disease 1 0.9999699592590332
: O 0 2.724354075667179e-08
classification O 0 3.9844081811679644e-08
of O 0 1.3309280344486751e-09
105 O 0 2.1238572855963866e-07
mutations O 0 2.3697424467172823e-08
and O 0 2.5816637716502555e-09
a O 0 5.093050425841739e-10
general O 0 2.7465658219982814e-11
system O 0 5.099419553289408e-09
for O 0 1.5778595097160064e-09
genotype O 0 1.2421930932760006e-06
- O 0 2.8036492949468084e-05
based O 0 4.259946990714525e-07
prediction O 0 1.047328896675026e-05
of O 0 7.378881505815116e-09
metabolic O 0 0.0005093329818919301
phenotype O 0 1.946924749063328e-05
. O 0 8.114078582366346e-07

Phenylketonuria B-Disease 1 0.5641242265701294
( O 0 2.0483590560615994e-05
PKU B-Disease 0 0.004452820401638746
) O 0 1.2359220136204385e-06
and O 0 2.4162285626516677e-05
mild B-Disease 0 0.028851060196757317
hyperphenylalaninemia I-Disease 1 0.999974250793457
( O 0 1.887443067971617e-05
MHP B-Disease 1 0.9999407529830933
) O 0 6.824801630500588e-07
are O 0 2.6364077143625764e-08
allelic B-Disease 0 0.04157168045639992
disorders I-Disease 1 0.9946281313896179
caused O 0 3.26052941090893e-05
by O 0 4.7143956294348754e-08
mutations O 0 7.221231612675183e-08
in O 0 1.8365456933011615e-09
the O 0 3.7067131586354662e-09
gene O 0 2.5874772546785607e-08
encoding O 0 6.316444256526665e-08
phenylalanine O 0 6.862230748083675e-06
hydroxylase O 0 0.00021919676510151476
( O 0 4.188905577962032e-08
PAH O 0 8.10177607490914e-06
) O 0 5.75407419489693e-08
. O 0 2.3067734389314865e-07

Previous O 0 5.578530362981837e-06
studies O 0 1.1306157148283091e-06
have O 0 2.1649015025104745e-08
suggested O 0 1.716066932999638e-08
that O 0 4.2993844595606845e-10
the O 0 4.4282197353417985e-10
highly O 0 6.32759578067521e-09
variable O 0 3.580699967642431e-07
metabolic O 0 0.0014364846283569932
phenotypes O 0 5.3182793635642156e-05
of O 0 1.4495498362521175e-05
PAH B-Disease 1 0.8954979777336121
deficiency I-Disease 0 0.45957711338996887
correlate O 0 1.375682586512994e-06
with O 0 8.310758857987821e-06
PAH O 0 0.005926960613578558
genotypes O 0 0.00014172900409903377
. O 0 5.910565505473642e-06

We O 0 1.4498431255560718e-07
identified O 0 1.7410981456578156e-07
both O 0 6.4335696770001505e-09
causative O 0 6.4471828409296e-07
mutations O 0 6.882665957164136e-07
in O 0 2.2410485200907715e-07
686 O 0 0.003676344407722354
patients O 0 3.161385393468663e-07
from O 0 1.1586600123791868e-08
seven O 0 1.5044658141505352e-07
European O 0 6.074031375646882e-07
centers O 0 2.48917444878316e-07
. O 0 5.243463192527997e-07

On O 0 3.9527233752778557e-07
the O 0 2.7990734174920817e-09
basis O 0 3.102459400494695e-10
of O 0 1.1361508261975573e-10
the O 0 1.046324471509763e-09
phenotypic O 0 2.974094859276022e-10
characteristics O 0 1.8189338923946252e-09
of O 0 2.69896816007531e-09
297 O 0 1.1364723832230084e-05
functionally O 0 0.00019364805484656245
hemizygous O 0 0.0029957653023302555
patients O 0 1.309360175838492e-08
, O 0 2.411010724401308e-09
105 O 0 5.403171687845543e-09
of O 0 1.267724120124214e-10
the O 0 4.280828580505158e-09
mutations O 0 6.2809166756494506e-09
were O 0 1.1365870467017203e-09
assigned O 0 2.151180206189096e-10
to O 0 2.3411803051764934e-10
one O 0 9.498184183609482e-11
of O 0 5.3048381659648314e-11
four O 0 4.274309794993769e-09
arbitrary O 0 2.2274670641309058e-07
phenotype O 0 2.4316154849657323e-06
categories O 0 2.793278213175654e-07
. O 0 1.0100001190949115e-06

We O 0 2.0131091105213272e-07
proposed O 0 2.8465942492061913e-08
and O 0 2.550459043959563e-08
tested O 0 2.5675664261370912e-08
a O 0 9.594437466731165e-10
simple O 0 1.1697465218674097e-09
model O 0 6.892648674039492e-09
for O 0 1.7105686311857937e-10
correlation O 0 1.2074959698793464e-08
between O 0 1.6450080408958456e-08
genotype O 0 4.0340333384847327e-07
and O 0 1.6111611600422293e-08
phenotypic O 0 6.986504708095254e-09
outcome O 0 2.7822770221064275e-07
. O 0 7.050084604998119e-07

The O 0 1.114464183160635e-07
observed O 0 5.259459499029617e-07
phenotype O 0 1.6562416931265034e-06
matched O 0 4.544830517261289e-06
the O 0 2.3839282903281855e-07
predicted O 0 4.520480797509663e-05
phenotype O 0 1.4770985217182897e-06
in O 0 5.720632145767013e-08
79 O 0 2.5110336991929216e-06
% O 0 1.0996005217478455e-09
of O 0 1.95171684369555e-10
the O 0 1.9207822887779002e-08
cases O 0 4.3592219611809924e-08
, O 0 2.3275449123616454e-08
and O 0 3.022120154128061e-08
in O 0 1.2166827545456727e-09
only O 0 8.297272591217819e-11
5 O 0 1.3420218269999395e-09
of O 0 3.6322031493618567e-10
184 O 0 5.91081459333509e-07
patients O 0 2.2580248781878254e-09
was O 0 7.007914177847852e-07
the O 0 1.8312463767600207e-09
observed O 0 2.5436817097101994e-08
phenotype O 0 1.3589661840285316e-08
more O 0 1.5700165126308896e-11
than O 0 1.6552099968425438e-10
one O 0 2.4437105672348025e-09
category O 0 3.280036153796573e-08
away O 0 1.9431686837378948e-07
from O 0 2.414913602422075e-09
that O 0 2.4683899368938e-08
expected O 0 8.662570394335489e-08
. O 0 1.897974186704232e-07

Among O 0 4.3612178757257425e-08
the O 0 7.13229564297535e-09
seven O 0 3.4501322687674474e-08
contributing O 0 1.2397884496806455e-08
centers O 0 1.6604282393473113e-09
, O 0 1.8136128154822018e-09
the O 0 9.250633037360956e-10
proportion O 0 8.53884074558664e-10
of O 0 1.245540226513242e-09
patients O 0 1.6269280367353645e-09
for O 0 7.083513220429438e-10
whom O 0 1.2050456632550777e-08
the O 0 1.2830084772375017e-09
observed O 0 4.616866178253076e-08
phenotype O 0 7.126668322143814e-08
did O 0 3.524081693129233e-09
not O 0 1.4649083335260826e-10
match O 0 1.3678207011480481e-08
the O 0 7.64169971745332e-09
predicted O 0 4.480205916479463e-06
phenotype O 0 1.1445350622807382e-07
was O 0 1.0585586096567567e-06
4 O 0 5.232593025539245e-08
% O 0 3.5319143165679634e-09
- O 0 6.807090539950877e-05
23 O 0 1.3493601045411197e-06
% O 0 2.1615376155637023e-09
( O 0 1.068588662000991e-09
P O 0 9.924136975314468e-06
< O 0 7.556647751982837e-09
. O 0 7.158704740106714e-10
0001 O 0 1.0830800647454453e-06
) O 0 2.759801720486621e-09
, O 0 2.0021939661774013e-09
suggesting O 0 1.08633448903106e-08
that O 0 1.8356106634698222e-09
differences O 0 4.194060210238604e-09
in O 0 5.424240917539791e-11
methods O 0 3.7492103865943704e-10
used O 0 1.4241021695227118e-09
for O 0 1.443793418154371e-10
mutation O 0 1.7635967131113262e-09
detection O 0 1.4747141108273354e-07
or O 0 2.9499693710022257e-07
phenotype O 0 2.862487008314929e-06
classification O 0 2.6121674636669923e-06
may O 0 3.444064589075424e-07
account O 0 4.379888451921943e-09
for O 0 3.4076708121943966e-10
a O 0 6.150393527803999e-09
considerable O 0 3.544999016558137e-10
proportion O 0 5.41639677553718e-10
of O 0 4.359186345226362e-09
genotype O 0 1.3339587894733995e-05
- O 0 0.008228186517953873
phenotype O 0 3.935196582460776e-05
inconsistencies O 0 0.0001862266508396715
. O 0 3.5257687613921007e-06

Our O 0 7.029065329788864e-08
data O 0 2.992215115682484e-07
indicate O 0 2.0539303591249336e-07
that O 0 7.1973311754902625e-09
the O 0 7.91179886050486e-08
PAH O 0 1.8868257029680535e-05
- O 0 6.174403097247705e-05
mutation O 0 6.997683499321283e-08
genotype O 0 1.8045875549432822e-07
is O 0 7.922664191362117e-10
the O 0 4.0811795609663193e-10
main O 0 1.7040639122001267e-08
determinant O 0 3.3629088846964805e-08
of O 0 9.334454986742458e-09
metabolic O 0 0.0009363372228108346
phenotype O 0 4.117426215088926e-06
in O 0 3.214129051798409e-08
most O 0 6.267396912562617e-08
patients O 0 9.011734505293134e-07
with O 0 0.00020650138321798295
PAH B-Disease 1 0.9690324664115906
deficiency I-Disease 1 0.5737505555152893
. O 0 2.2669298687105766e-06

In O 0 1.5295354671707173e-07
the O 0 7.03491087605812e-09
present O 0 4.934021635705221e-09
study O 0 9.690772628800914e-10
, O 0 1.272562721865711e-09
the O 0 6.747092329284499e-10
classification O 0 4.709470857733322e-08
of O 0 3.7234857419576883e-09
105 O 0 4.222229563310975e-06
PAH O 0 4.008846008218825e-05
mutations O 0 1.4676707849048398e-07
may O 0 7.725924788815064e-09
allow O 0 3.932991085586757e-11
the O 0 4.606897530123888e-09
prediction O 0 2.7172916361450916e-06
of O 0 1.3841118529089869e-10
the O 0 4.665160258099377e-09
biochemical O 0 9.088080901165085e-07
phenotype O 0 9.204932638340324e-08
in O 0 2.1417609907814494e-09
> O 0 1.8417022351613355e-09
10 O 0 9.05191921418691e-10
, O 0 2.3733053300389884e-09
000 O 0 6.080316250489659e-09
genotypes O 0 1.3040444457601552e-07
, O 0 2.4887368610393423e-08
which O 0 5.674944603129006e-08
may O 0 7.78668418632833e-09
be O 0 5.4671284860363656e-11
useful O 0 4.646303133903906e-11
for O 0 5.0446976457285686e-11
the O 0 9.479895979325192e-09
management O 0 3.987556169704476e-07
of O 0 6.156241028065779e-08
hyperphenylalaninemia B-Disease 1 0.9997798800468445
in O 0 2.7025396320823347e-06
newborns O 0 2.011800643231254e-05
. O 0 3.980170220074797e-07

Somatic O 0 1.760344639478717e-05
instability O 0 4.7962523240130395e-05
of O 0 1.2066625032502998e-08
the O 0 3.434368522903242e-08
CTG O 0 2.4506336558260955e-05
repeat O 0 1.3015959439144353e-06
in O 0 1.1892676177183148e-08
mice O 0 9.513487952972355e-07
transgenic O 0 1.24757661978947e-07
for O 0 5.751613407767309e-09
the O 0 5.147523552295752e-05
myotonic B-Disease 1 0.9999948740005493
dystrophy I-Disease 1 0.9999960660934448
region O 0 5.208558832237031e-06
is O 0 5.315055418009251e-08
age O 0 3.113553859179774e-08
dependent O 0 2.7513082923036336e-09
but O 0 2.8665065876509743e-09
not O 0 1.6007815906160516e-10
correlated O 0 3.365949075018193e-09
to O 0 1.993139819855827e-10
the O 0 1.4059975406155445e-09
relative O 0 8.526773598305226e-08
intertissue O 0 2.830152652677498e-06
transcription O 0 3.2872012667439776e-08
levels O 0 8.184504629582534e-09
and O 0 6.7543474813192e-08
proliferative O 0 0.00018903396266978234
capacities O 0 1.3165168866180466e-06
. O 0 2.676182191407861e-07

A O 0 1.7065354768419638e-05
( O 0 1.5526016738931503e-07
CTG O 0 1.9196570065105334e-05
) O 0 2.6487667170727036e-08
nexpansion O 0 1.482001835029223e-06
in O 0 8.796829931156935e-10
the O 0 8.923407790462079e-09
3 O 0 6.412751076823042e-07
- O 0 0.001439231215044856
untranslated O 0 4.218972026137635e-05
region O 0 1.04152675817204e-07
( O 0 1.077057998344344e-09
UTR O 0 2.58237747630119e-07
) O 0 1.859100928758295e-10
of O 0 4.695399624665697e-11
the O 0 9.826636215848339e-08
DM O 1 0.9999489784240723
protein O 0 1.7810310737331747e-07
kinase O 0 1.234029355146049e-06
gene O 0 3.836214190755527e-08
( O 0 2.329115789123648e-09
DMPK O 0 3.864109385176562e-05
) O 0 5.981849682257234e-09
is O 0 1.2135145111002998e-09
responsible O 0 8.909343485186128e-09
for O 0 3.3154361744891503e-07
causing O 0 0.3780074119567871
myotonic B-Disease 1 0.9999839067459106
dystrophy I-Disease 1 0.9999895095825195
( O 0 9.121897164732218e-05
DM B-Disease 1 0.9999593496322632
) O 0 9.500127816863824e-06
. O 0 1.0972578365908703e-06

Major O 0 8.698432793607935e-06
instability O 0 0.00013058226613793522
, O 0 7.764278109334555e-08
with O 0 3.413703097976395e-09
very O 0 1.2661950377079734e-09
large O 0 6.435419419581478e-10
expansions O 0 3.844198204205895e-08
between O 0 3.826341554713508e-08
generations O 0 7.379166788723523e-08
and O 0 4.64869494010145e-08
high O 0 9.707392933933079e-08
levels O 0 1.2804335369764885e-10
of O 0 2.1114473017225244e-11
somatic O 0 9.135651168890035e-08
mosaicism O 0 3.898092472809367e-05
, O 0 7.605220986306449e-08
is O 0 8.82027162418808e-09
observed O 0 4.2693660162740343e-08
in O 0 5.71103839774878e-08
patients O 0 9.191230532223926e-08
. O 0 3.1826488111619256e-07

There O 0 3.7770601579723007e-07
is O 0 1.3931155784518978e-08
a O 0 1.4231843481482542e-09
good O 0 1.912738190057439e-09
correlation O 0 7.047857408792879e-09
between O 0 2.2241847474901988e-08
repeat O 0 1.8341856957704294e-06
size O 0 1.8014836768998066e-06
( O 0 1.1426930512925537e-09
at O 0 7.318892869534466e-08
least O 0 2.566251655622409e-10
in O 0 2.666731901967978e-08
leucocytes O 0 9.66959705692716e-05
) O 0 9.906102604873013e-09
, O 0 1.956683526316283e-08
clinical O 0 1.216762655076309e-07
severity O 0 1.4490387911791913e-06
and O 0 1.8542429813805938e-07
age O 0 7.898891851709777e-08
of O 0 1.3621114014483737e-08
onset O 0 2.3465809135814197e-05
. O 0 2.5321812699985458e-06

The O 0 2.159599262085976e-06
trinucleotide O 0 0.0004033510049339384
repeat O 0 2.733316614467185e-05
instability O 0 1.4610027392336633e-06
mechanisms O 0 8.49793835300261e-08
involved O 0 1.9118134275686316e-07
in O 0 2.362987061133026e-06
DM B-Disease 1 0.9999825954437256
and O 0 7.474665380868828e-06
other O 0 1.633973170100944e-07
human O 0 5.818114004796371e-05
genetic B-Disease 1 0.9999287128448486
diseases I-Disease 1 0.9999092817306519
are O 0 6.185855028206788e-08
unknown O 0 3.4512197544245282e-06
. O 0 1.32519846829382e-06

We O 0 5.661301116788309e-08
studied O 0 2.3756980382927395e-08
somatic O 0 3.072588299346535e-07
instability O 0 1.8308617200091248e-06
by O 0 9.213518836759249e-09
measuring O 0 1.948102180904243e-06
the O 0 6.190859380694747e-08
CTG O 0 0.0001721885782899335
repeat O 0 2.026971287705237e-06
length O 0 2.6955669341077737e-07
at O 0 2.8205178637108475e-07
several O 0 1.3301463264170366e-09
ages O 0 1.150606276922872e-08
in O 0 7.101546017906912e-10
various O 0 9.400051570462864e-11
tissues O 0 3.527257419477792e-08
of O 0 6.451605361057489e-10
transgenic O 0 1.809887180570513e-06
mice O 0 1.6126604123201105e-06
carrying O 0 5.169876260424644e-08
a O 0 9.047214888369126e-08
( O 0 2.280953870226199e-09
CTG O 0 5.763778972323053e-06
) O 0 4.602313197210606e-09
55expansion O 0 3.704256243963755e-07
surrounded O 0 1.8115710531674267e-07
by O 0 2.2324249115968087e-09
45 O 0 3.5881910775970027e-09
kb O 0 2.372581548115704e-06
of O 0 4.994836766414323e-10
the O 0 2.0123790633874705e-08
human O 0 1.0980617162203998e-06
DM B-Disease 1 0.9999376535415649
region O 0 2.4250834229633256e-08
, O 0 6.216814840698248e-10
using O 0 8.499324577471157e-10
small O 0 2.5249605073440762e-08
- O 0 0.00024619061150588095
pool O 0 4.528631961875362e-06
PCR O 0 8.816640729492065e-06
. O 0 3.2253896620204614e-07

These O 0 5.11789721713285e-07
mice O 0 7.934984751045704e-05
have O 0 2.291669431997434e-08
been O 0 2.024405709732946e-08
shown O 0 6.072354619135467e-09
to O 0 6.682504549715418e-10
reproduce O 0 4.528518005031401e-08
the O 0 2.2809016897440415e-09
intergenerational O 0 3.1141175895754714e-06
and O 0 7.040094374133332e-08
somatic O 0 6.650911643646396e-08
instability O 0 1.1014088840965996e-07
of O 0 1.334450466794479e-10
the O 0 7.790353251380111e-09
55 O 0 1.2884709121863125e-07
CTG O 0 2.1481218936969526e-05
repeat O 0 9.718357887322782e-07
suggesting O 0 1.3733227888224064e-07
that O 0 1.9693340291837558e-09
surrounding O 0 2.3594401987736546e-09
sequences O 0 4.8342254643785054e-09
and O 0 8.190297329235818e-09
the O 0 1.1420153711583225e-09
chromatin O 0 1.504755573478178e-07
environment O 0 6.030849419857987e-08
are O 0 5.787681098268216e-11
involved O 0 8.667636053338867e-10
in O 0 1.9918649840633407e-08
instability O 0 5.434946501736704e-07
mechanisms O 0 1.9991867361568438e-07
. O 0 5.350084393285215e-07

As O 0 1.1740123539993874e-07
observed O 0 2.5319542373836157e-07
in O 0 2.4884319049789383e-09
some O 0 1.638329576170161e-11
of O 0 9.221983593432626e-11
the O 0 8.72964189824188e-09
tissues O 0 1.2995507177038235e-06
of O 0 1.1937489716729033e-06
DM B-Disease 1 0.9999951124191284
patients O 0 4.743493491332629e-07
, O 0 4.506408401994122e-08
there O 0 1.4432847139644878e-09
is O 0 2.5602344688735457e-09
a O 0 8.694182263013772e-09
tendency O 0 1.9226407133032808e-08
for O 0 6.963153387218313e-10
repeat O 0 1.237535087739161e-07
length O 0 3.847975804660564e-08
and O 0 8.102261972453562e-09
somatic O 0 1.4175257412318842e-08
mosaicism O 0 1.466385356252431e-06
to O 0 1.2896056444944293e-09
increase O 0 2.471760851552318e-10
with O 0 3.977860263404409e-09
the O 0 4.034205858260975e-08
age O 0 2.1202644973072893e-08
of O 0 1.4909319612232963e-10
the O 0 3.658488978430796e-08
mouse O 0 0.0003825120802503079
. O 0 1.725633637761348e-06

Furthermore O 0 8.711615919310134e-06
, O 0 2.5169504169753054e-07
we O 0 5.6729505537589375e-09
observed O 0 3.2229001689643155e-09
no O 0 7.607433016865173e-10
correlation O 0 2.524078057675183e-09
between O 0 1.2676619753904106e-09
the O 0 1.3234048301669077e-09
somatic O 0 7.360695519764704e-08
mutation O 0 2.921206601058657e-07
rate O 0 6.089522912589018e-07
and O 0 6.363727038660727e-07
tissue O 0 0.0001060073118424043
proliferation O 0 2.2746504328097217e-05
capacity O 0 2.7233667765358405e-08
. O 0 9.274562984273871e-08

The O 0 2.4256292974200733e-08
somatic O 0 2.220040329348194e-07
mutation O 0 1.8846535567718092e-06
rates O 0 2.013617176999105e-06
in O 0 3.667149917063739e-09
different O 0 2.6850932588473597e-10
tissues O 0 1.4214751331564912e-07
were O 0 1.8216329067399784e-07
also O 0 1.2983409014566405e-08
not O 0 2.905105878081571e-10
correlated O 0 2.507790863859327e-09
to O 0 3.056627173592119e-10
the O 0 3.0279345697437066e-09
relative O 0 3.3306923796772026e-07
inter O 0 7.917020070635772e-07
- O 0 0.0008491315529681742
tissue O 0 6.289728389674565e-06
difference O 0 3.730615816266436e-09
in O 0 1.1623288442841329e-10
transcriptional O 0 4.516905072193822e-09
levels O 0 3.9430050891020585e-10
of O 0 1.1789243192783516e-11
the O 0 6.833829058194851e-10
three O 0 9.006028811597844e-09
genes O 0 1.3052559033610578e-08
( O 0 2.0922068522111203e-09
DMAHP O 0 0.00013773629325442016
, O 0 7.010895330950007e-08
DMPK O 0 0.00014280066534411162
and O 0 1.9637973025510291e-07
59 O 0 4.033167897432577e-07
) O 0 1.655321324456338e-09
surrounding O 0 5.017335436008352e-09
the O 0 1.615746647587457e-08
repeat O 0 1.7994609606830636e-06
. O 0 3.846867713264146e-08
. O 0 1.1778454478417189e-07

A O 0 1.1558936421351973e-05
novel O 0 6.881406079628505e-06
missense O 0 1.3103018318361137e-05
mutation O 0 3.4005047382379416e-06
in O 0 8.523974202034879e-07
patients O 0 9.711541082424446e-08
from O 0 8.153170583113933e-09
a O 0 6.113211270530883e-07
retinoblastoma B-Disease 0 0.0011764969676733017
pedigree O 0 0.0009808059548959136
showing O 0 2.6595844246912748e-05
only O 0 9.999864047927076e-09
mild O 0 4.913222824143304e-07
expression O 0 1.7896549797669081e-09
of O 0 4.619691740259668e-09
the O 0 1.1496309753056266e-06
tumor B-Disease 0 0.08977188915014267
phenotype O 0 2.3809774575056508e-05
. O 0 2.095074705721345e-06

We O 0 1.0213389600721712e-07
have O 0 1.0719385379331925e-09
used O 0 2.7525665080574413e-10
single O 0 6.114190265193997e-10
strand O 0 9.405791274730291e-07
conformation O 0 2.0045072801622155e-07
polymorphism O 0 1.1229459317974033e-07
analysis O 0 3.905336498633005e-09
to O 0 5.289221283177881e-10
study O 0 1.2533347970578035e-10
the O 0 1.0426707275357217e-09
27 O 0 1.6361461518954457e-08
exons O 0 1.411315420085657e-08
of O 0 4.4343559379989017e-10
the O 0 4.935850128617858e-08
RB1 O 0 0.00028850548551417887
gene O 0 1.9079150703760206e-08
in O 0 2.4145878185777292e-08
individuals O 0 7.839254245745053e-10
from O 0 4.234523398594092e-09
a O 0 3.9317819755524397e-07
family O 0 0.0010567262070253491
showing O 0 0.0017262593610212207
mild O 0 5.525061169464607e-06
expression O 0 2.176285596178218e-09
of O 0 7.215608111010852e-10
the O 0 2.5703306505420187e-07
retinoblastoma B-Disease 0 0.0009732869220897555
phenotype O 0 3.225237742299214e-05
. O 0 1.6930702031459077e-06

In O 0 3.928828391508432e-07
this O 0 2.355780814866648e-08
family O 0 7.09000596543774e-06
affected O 0 1.3765753870131903e-08
individuals O 0 4.107590656499127e-10
developed O 0 7.875722189965018e-07
unilateral B-Disease 0 0.011721499264240265
tumors I-Disease 1 0.9999966621398926
and O 0 9.848006811807863e-06
, O 0 9.560978497802353e-08
as O 0 1.3057382952652574e-09
a O 0 1.7256445161706324e-08
result O 0 4.771912642809184e-09
of O 0 6.817308384476917e-10
linkage O 0 2.342930656595854e-06
analysis O 0 2.8575662724961148e-08
, O 0 2.3919026759244844e-08
unaffected O 0 2.950340842744481e-07
mutation O 0 2.3580152941349297e-08
carriers O 0 2.6158012644827977e-08
were O 0 4.103836204194522e-08
also O 0 3.094991640750777e-08
identified O 0 1.5404685527187212e-08
within O 0 3.345063948057003e-10
the O 0 2.48917444878316e-07
pedigree O 0 0.000719524803571403
. O 0 2.070104073936818e-06

A O 0 2.1053706689144747e-07
single O 0 4.387522345439265e-09
band O 0 1.7015045372659188e-08
shift O 0 2.703770318746024e-09
using O 0 6.16905060368822e-09
SSCP O 0 6.751526962034404e-05
was O 0 2.144846121154842e-06
identified O 0 4.216424187575285e-08
in O 0 2.945997223946506e-09
exon O 0 6.939122272342502e-07
21 O 0 1.8687893543756218e-07
which O 0 7.791545186819349e-08
resulted O 0 8.586965094536936e-08
in O 0 2.898626005887195e-09
a O 0 9.028938485755589e-09
missense O 0 9.946167978114318e-08
mutation O 0 1.1193374005458168e-09
converting O 0 2.2383341846676785e-09
a O 0 1.0191050137109414e-07
cys O 0 0.0005939339753240347
- O 0 0.00014067006122786552
- O 0 5.235291973804124e-05
> O 0 3.208113108499333e-09
arg O 0 5.123835222775597e-08
at O 0 7.698505832820501e-09
nucleotide O 0 5.273043668374555e-10
position O 0 6.72901290243999e-09
28 O 0 5.705482752915714e-09
in O 0 8.724244104918455e-10
the O 0 3.970600559455306e-08
exon O 0 3.7360314308898523e-05
. O 0 1.0951648619084153e-06

The O 0 2.8022753895129426e-07
mutation O 0 1.6203808854697854e-06
destroyed O 0 1.7740037947078235e-05
an O 0 2.1064631994249794e-07
NdeI O 0 5.912306369282305e-05
restriction O 0 9.920780286165609e-08
enzyme O 0 7.905161680810124e-08
site O 0 1.4660832903246046e-06
. O 0 5.441880830403534e-07

Analysis O 0 2.8301155907684006e-07
of O 0 7.385104972001955e-09
all O 0 2.0518338139652315e-09
family O 0 3.4135427995352075e-07
members O 0 3.665805714536674e-10
demonstrated O 0 1.4114499791162416e-08
that O 0 6.061623980535558e-10
the O 0 1.7306637234426603e-09
missense O 0 3.533163237534609e-07
mutation O 0 6.323327284007974e-08
co O 0 2.9973216442158446e-05
- O 0 1.4486086911347229e-05
segregated O 0 2.09138647733198e-07
with O 0 7.654648470634129e-07
patients O 0 2.281986866137231e-07
with O 0 0.0009590969420969486
tumors B-Disease 1 0.9999973773956299
or O 0 1.730003896227572e-05
who O 0 2.2004849142831517e-06
, O 0 1.7608448033001878e-08
as O 0 1.4715852980629052e-09
a O 0 1.491160972477701e-08
result O 0 1.2379925529160118e-08
of O 0 5.973956329619057e-10
linkage O 0 1.7097308955271728e-06
analysis O 0 4.631003847066495e-08
had O 0 1.3156774002709426e-05
been O 0 5.767698780800856e-07
predicted O 0 3.118290976544813e-07
to O 0 1.0634886027371948e-10
carry O 0 1.2291405671049915e-09
the O 0 8.094337644592997e-09
predisposing O 0 2.3052743927109987e-06
mutation O 0 1.9868153344759776e-07
. O 0 5.414552788352012e-07

These O 0 8.121818773076939e-09
observations O 0 5.901031130406409e-08
point O 0 1.6813069692034333e-07
to O 0 2.978109536755369e-09
another O 0 3.458207942230729e-09
region O 0 9.121104982412476e-10
of O 0 1.766959495386189e-10
the O 0 3.2341645805900043e-08
RB1 O 0 8.190252992790192e-05
gene O 0 4.154474542161779e-09
where O 0 8.254944283692112e-09
mutations O 0 1.1419717393934548e-09
only O 0 3.563266348649563e-11
modify O 0 1.1193735938164195e-09
the O 0 8.783886396024343e-10
function O 0 3.0683858232016803e-10
of O 0 9.751694590720561e-11
the O 0 7.056896844659377e-09
gene O 0 2.437636936747367e-08
and O 0 8.000969842214545e-08
raise O 0 1.2535601445762268e-09
important O 0 1.7912376443218747e-11
questions O 0 1.0102518821497597e-09
for O 0 2.5402174808064615e-10
genetic O 0 7.86452645229474e-08
counseling O 0 6.914970640536922e-08
in O 0 2.404224730412352e-08
families O 0 1.1819206058305554e-08
with O 0 5.300939687202799e-09
these O 0 1.301680097043345e-09
distinctive O 0 1.3745295746048214e-07
phenotypes O 0 8.293058044728241e-07
. O 0 5.054770468859715e-08
. O 0 3.6061280184185307e-07

Maternal B-Disease 0 0.0026997083332389593
disomy I-Disease 1 0.5052351951599121
and O 0 0.045039840042591095
Prader B-Disease 1 0.9998791217803955
- I-Disease 1 0.9999772310256958
Willi I-Disease 1 0.9999901056289673
syndrome I-Disease 1 0.9999125003814697
consistent O 0 1.053230789693771e-06
with O 0 2.3729997167265537e-07
gamete O 0 2.213005609519314e-05
complementation O 0 0.014455065131187439
in O 0 3.9918624850088236e-08
a O 0 3.808088777645935e-08
case O 0 2.1054950138932327e-07
of O 0 4.316337509635559e-09
familial O 0 1.3482586837199051e-05
translocation O 0 0.00013722556468565017
( O 0 9.700134029344554e-09
3 O 0 6.526539664264419e-08
; O 0 7.884017882986427e-09
15 O 0 1.895379853067425e-08
) O 0 2.139470378637043e-09
( O 0 4.343479395596539e-11
p25 O 0 9.9742614168008e-09
; O 0 1.1880382233542264e-09
q11 O 0 3.1048717374915213e-08
. O 0 1.8026973247486922e-09
2 O 0 4.6323204827558584e-08
) O 0 8.986432931124e-09
. O 0 2.14794351194314e-08

Maternal B-Disease 0 0.006182053126394749
uniparental I-Disease 0 0.41203033924102783
disomy I-Disease 1 0.8889559507369995
( I-Disease 0 7.475849270122126e-05
UPD I-Disease 1 0.9991596937179565
) I-Disease 0 3.182105388077616e-07
for I-Disease 0 6.938352559160421e-09
chromosome I-Disease 0 1.0922162800852675e-05
15 I-Disease 0 7.492341325132656e-08
is O 0 4.907413586607845e-09
responsible O 0 1.6790013823708705e-09
for O 0 2.259695347506252e-10
an O 0 5.6088804711862394e-09
estimated O 0 2.3279977057200085e-08
30 O 0 6.549095488139756e-09
% O 0 1.6162873817116008e-10
of O 0 2.9413019242419125e-10
cases O 0 5.625929944130803e-08
of O 0 1.1891599569935352e-05
Prader B-Disease 1 0.9999889135360718
- I-Disease 1 0.9999967813491821
Willi I-Disease 1 0.9999982118606567
syndrome I-Disease 1 0.9999850988388062
( O 0 2.0187309928587638e-05
PWS B-Disease 1 0.9998893737792969
) O 0 4.010586508229608e-06
. O 0 5.081731728751038e-07

We O 0 1.781771743480931e-07
report O 0 4.7238380318503914e-08
on O 0 1.3115597496948794e-08
an O 0 9.224662145257412e-10
unusual O 0 4.81635265003888e-09
case O 0 3.790725244812165e-08
of O 0 7.629011311571787e-10
maternal B-Disease 0 9.424413178749091e-07
disomy I-Disease 0 2.4952330932137556e-05
15 I-Disease 0 4.704290645918263e-08
in O 0 4.4523110886984796e-07
PWS B-Disease 1 0.9999780654907227
that O 0 4.4492375650406757e-07
is O 0 1.0373386594153544e-09
most O 0 2.608990801178379e-11
consistent O 0 1.182524189680123e-09
with O 0 4.602584979807034e-09
adjacent O 0 3.552861471689539e-08
- O 0 4.966834239894524e-06
1 O 0 6.0798988066324e-09
segregation O 0 4.317509194606828e-08
of O 0 2.2895263462885396e-10
a O 0 7.889781983294597e-08
paternal O 0 1.376608543068869e-05
t O 0 0.002934803953394294
( O 0 6.094443838478014e-10
3 O 0 1.113337688707361e-08
; O 0 2.5965625205515153e-09
15 O 0 5.4732374188404265e-09
) O 0 9.455638494415552e-10
( O 0 2.6140466527491135e-11
p25 O 0 4.410655396469565e-09
; O 0 2.7695978843667035e-10
q11 O 0 5.872263120210164e-09
. O 0 5.354529597489943e-10
2 O 0 5.835049332603148e-09
) O 0 2.0471108141961736e-10
with O 0 1.7256887585581637e-10
simultaneous O 0 3.106755741555389e-08
maternal O 0 3.888395440299064e-06
meiotic O 0 0.0002378283825237304
nondisjunction O 0 3.909335646312684e-05
for O 0 1.4474531573327454e-09
chromosome O 0 7.070546871545957e-06
15 O 0 2.3723525544028234e-07
. O 0 5.518271564142196e-07

The O 0 1.8978687421622453e-06
patient O 0 1.015147972793784e-05
( O 0 8.464630241178384e-08
J O 0 0.0001068884739652276
. O 0 4.5959907879478124e-08
B O 0 2.5646403400969575e-07
. O 0 1.954813866333893e-09
) O 0 3.4698147133305213e-10
, O 0 2.456500003411577e-10
a O 0 2.246169250597063e-09
17 O 0 8.788452987573692e-08
- O 0 4.237544271745719e-05
year O 0 4.785304099641507e-07
- O 0 0.0003121842455584556
old O 0 0.001783603336662054
white O 0 7.900872151367366e-05
male O 0 7.200944907026496e-08
with O 0 1.1317505368424463e-06
PWS B-Disease 1 0.9999876022338867
, O 0 1.3278577171149664e-06
was O 0 1.3221436347521376e-05
found O 0 8.624553515801381e-08
to O 0 9.654242960621673e-10
have O 0 1.4332827147356397e-09
47 O 0 1.3570702783738398e-08
chromosomes O 0 7.866326967587156e-08
with O 0 5.254432888790461e-09
a O 0 1.8790206013363786e-07
supernumerary O 0 0.00010350521188229322
, O 0 6.4694722823333e-07
paternal O 0 1.6154734112205915e-05
der O 0 0.013251484371721745
( O 0 1.381343150974601e-09
15 O 0 7.800835533089412e-09
) O 0 2.395543485800289e-10
consisting O 0 1.8545808985748202e-11
of O 0 2.298978368786564e-10
the O 0 1.1732053195601111e-07
short O 0 2.0320661860750988e-05
arm O 0 0.011038689874112606
and O 0 9.273306744717047e-08
the O 0 8.111109650599246e-08
proximal O 0 0.0011728716781362891
long O 0 0.0006100548198446631
arm O 0 0.01150394044816494
of O 0 1.052222842190531e-08
chromosome O 0 1.0406513865746092e-05
15 O 0 9.893531682791945e-08
, O 0 6.030355592656633e-08
and O 0 7.329803111133515e-07
distal O 0 0.0027359866071492434
chromosome O 0 0.03652568906545639
arm O 0 0.4673216938972473
3p O 0 0.228346586227417
. O 0 4.750429070554674e-06

The O 0 2.1768173610325903e-06
t O 0 0.0006024026079103351
( O 0 9.370594966640056e-09
3 O 0 3.859523545202137e-08
; O 0 1.3166276957576883e-08
15 O 0 2.6640480044193282e-08
) O 0 8.979459842350934e-09
was O 0 4.951578489453823e-07
present O 0 2.936951792875675e-10
in O 0 2.8867458423675885e-10
the O 0 1.6895058685406639e-09
balanced O 0 4.8930505869293484e-08
state O 0 1.6678841641137865e-09
in O 0 3.28204952104727e-09
the O 0 8.671430862250418e-08
patients O 0 2.300445700598175e-08
father O 0 7.512317097280174e-07
and O 0 7.793685341539458e-08
a O 0 2.532036091906775e-07
sister O 0 0.00191167660523206
. O 0 2.3343218344962224e-06

Fluorescent O 0 2.6113305011676857e-06
in O 0 2.231855411594097e-08
situ O 0 2.2937729937666518e-08
hybridization O 0 2.3639730173385942e-08
analysis O 0 1.5340530623575432e-08
demonstrated O 0 2.7753472409131064e-07
that O 0 1.8401932422307254e-08
the O 0 3.9710556620775606e-07
PWS B-Disease 1 0.9998770952224731
critical O 0 1.5567205480238044e-07
region O 0 1.158096640807571e-08
resided O 0 2.496062556645029e-08
on O 0 6.403285368605793e-08
the O 0 1.4565320505255386e-08
derivative O 0 3.5915073226533423e-07
chromosome O 0 7.013208687567385e-06
3 O 0 2.483801040398248e-07
and O 0 7.398022461302389e-08
that O 0 2.0777800813220892e-08
there O 0 1.6402886826583085e-09
was O 0 1.352876552118687e-06
no O 0 8.885601587849123e-09
deletion O 0 8.579467447589195e-08
of O 0 4.419058896587558e-09
the O 0 1.0212371535089915e-06
PWS B-Disease 1 0.9999473094940186
region O 0 1.4094887923477017e-08
on O 0 4.3882028677444396e-08
the O 0 3.6201359687737522e-09
normal O 0 3.6923182289427814e-09
pair O 0 9.776291420848793e-08
of O 0 6.897629134527961e-10
15s O 0 3.00914422268761e-08
present O 0 6.821486930874698e-09
in O 0 9.924546162665138e-08
J O 0 0.002917172387242317
. O 0 1.3483850125339814e-06

B O 0 0.0015286095440387726
. O 0 2.4582994228694588e-05

Methylation O 0 2.222545163022005e-06
analysis O 0 5.354596765982933e-08
at O 0 5.3348809814224296e-08
exon O 0 6.524187767809053e-08
alpha O 0 1.8710939464483545e-09
of O 0 1.2246680058947135e-10
the O 0 3.861082120693027e-09
small O 0 5.148826787149119e-08
nuclear O 0 0.0002141589211532846
ribonucleoprotein O 0 1.597255868546199e-05
- O 0 1.9678574972203933e-05
associated O 0 6.604707181168123e-08
polypeptide O 0 4.821106358576799e-07
N O 0 2.0085073629161343e-05
( O 0 6.076664504917062e-09
SNRPN O 0 2.219667840108741e-05
) O 0 2.0459951510787278e-09
gene O 0 5.223695254130689e-09
showed O 0 2.1336843474273337e-06
a O 0 1.822616013669176e-08
pattern O 0 7.742930392851122e-06
characteristic O 0 2.5376147405609117e-08
of O 0 3.1832006475163155e-10
only O 0 4.0118647293141407e-10
the O 0 2.2368928043192682e-08
maternal O 0 1.9223236904508667e-06
chromosome O 0 1.1287386769254226e-05
15 O 0 1.583574231744933e-07
in O 0 3.5370405271351046e-07
J O 0 0.015529551543295383
. O 0 9.180890856441692e-07

B O 0 0.0015690760919824243
. O 0 1.4145422028377652e-05

Maternal B-Disease 0 0.0010742683662101626
disomy I-Disease 0 0.009015166200697422
was O 0 5.240331302047707e-05
confirmed O 0 2.564170813457167e-07
by O 0 2.1525767834873477e-09
polymerase O 0 2.504213171050651e-06
chain O 0 5.11052076035412e-06
reaction O 0 2.005186461317976e-09
analysis O 0 3.53991808088594e-10
of O 0 3.8227851439920357e-10
microsatellite O 0 8.141850230458658e-06
repeats O 0 7.415702043545025e-07
at O 0 1.1038821412512334e-07
the O 0 2.7334821073310422e-09
gamma O 0 1.0119456383961278e-08
- O 0 4.356788394943578e-06
aminobutyric O 0 2.5907470444508363e-06
acid O 0 1.557289186493449e-09
receptor O 0 3.2666222504751374e-10
beta3 O 0 1.6504016286944534e-07
subunit O 0 2.0057029370690316e-09
( O 0 2.2156942947049174e-09
GABRB3 O 0 1.2019937457807828e-05
) O 0 2.0753363472181263e-08
locus O 0 1.9535270894266432e-06
. O 0 3.4559022310531873e-07

A O 0 3.0833351047476754e-05
niece O 0 0.016206834465265274
( O 0 1.0486188983804823e-07
B O 0 3.1772717079547874e-07
. O 0 5.003335523667829e-09
B O 0 7.153170145102195e-08
. O 0 4.672869868826979e-10
) O 0 6.903759508514185e-11
with O 0 7.682660063679236e-10
45 O 0 2.899715356718957e-09
chromosomes O 0 3.4893435696403685e-08
and O 0 1.817071826337724e-09
the O 0 7.566177684381614e-10
derivative O 0 1.6804822422500365e-08
3 O 0 1.0359985758157109e-08
but O 0 2.3371884427803025e-09
without O 0 2.164288054329333e-10
the O 0 2.6545221132323604e-08
der O 0 0.0003480400482658297
( O 0 6.163331511821468e-10
15 O 0 4.6975365819434955e-09
) O 0 5.857359597349898e-10
demonstrated O 0 7.812554159158935e-09
a O 0 8.571971576998294e-09
phenotype O 0 8.079209834477297e-08
consistent O 0 8.492683889471664e-09
with O 0 2.023730161226922e-08
that O 0 1.7888783077069093e-07
reported O 0 2.136649072781438e-06
for O 0 8.631291792404738e-10
haploinsufficiency O 0 2.6858954242925392e-06
of O 0 1.7344706781941e-09
distal O 0 6.392105569830164e-05
3 O 0 8.366861948161386e-06
p O 0 0.0005951675702817738
. O 0 7.202201004474773e-07

Uniparental B-Disease 1 0.9962486624717712
disomy I-Disease 1 0.9980849027633667
associated O 0 2.5703609935590066e-05
with O 0 2.2067757754484774e-07
unbalanced O 0 0.0003314122441224754
segregation O 0 1.4260485841077752e-05
of O 0 2.0067599137973957e-08
non O 0 1.2181234865238366e-07
- O 0 0.0006285406998358667
Robertsonian O 0 0.00014541347627528012
translocations O 0 1.1629790606093593e-05
has O 0 3.2299528811563505e-06
been O 0 8.727312774681195e-07
reported O 0 2.4483493689331226e-05
previously O 0 5.601237944574677e-07
but O 0 3.980253282520607e-08
has O 0 3.90047745213451e-08
not O 0 1.2003996685550078e-09
, O 0 9.03704888699508e-10
to O 0 1.490050582919622e-10
our O 0 9.411334905840008e-11
knowledge O 0 1.6281719028565789e-10
, O 0 2.5801771830202824e-09
been O 0 8.161634923453676e-09
observed O 0 9.590489291610993e-09
in O 0 2.1093724544840597e-09
a O 0 7.103679422471032e-08
case O 0 1.4025090422364883e-06
of O 0 7.41290250516613e-07
PWS B-Disease 1 0.999813973903656
. O 0 8.683513442520052e-06

Furthermore O 0 2.7355390557204373e-06
, O 0 9.425809821550502e-08
our O 0 5.088168553157857e-09
findings O 0 2.3348903255282494e-08
are O 0 2.0726957650207822e-10
best O 0 4.0024483727307825e-10
interpreted O 0 1.5209157266937723e-09
as O 0 4.2303882619165734e-10
true O 0 2.3959069395118604e-08
gamete O 0 4.855866677644372e-07
complementation O 0 0.0015634424053132534
resulting O 0 4.919890557175677e-07
in O 0 4.410632641338452e-07
maternal B-Disease 0 0.0006201551295816898
UPD I-Disease 1 0.9996739625930786
15 I-Disease 0 1.8866565369535238e-05
and O 0 9.625035454519093e-05
PWS B-Disease 1 0.9994099140167236

Schwartz B-Disease 0 0.39370644092559814
- I-Disease 1 0.9976924657821655
Jampel I-Disease 1 0.9973031282424927
syndrome I-Disease 1 0.996283233165741
type I-Disease 0 3.556540605131886e-06
2 I-Disease 0 3.2401280805061106e-06
and O 0 1.7128353647422045e-05
Stuve B-Disease 1 0.6567244529724121
- I-Disease 1 0.9998372793197632
Wiedemann I-Disease 1 0.9999501705169678
syndrome I-Disease 1 0.9993436932563782
: O 0 6.016233733419085e-09
a O 0 5.490646604044969e-09
case O 0 7.082452668782935e-08
for O 0 4.375646955878665e-09
" O 0 3.121671170447371e-07
lumping O 0 8.423065082752146e-06
" O 0 2.8817240149692225e-07
. O 0 1.5621189675130154e-07

Recent O 0 1.6451135707029607e-06
studies O 0 1.044325586008199e-07
demonstrated O 0 1.2096701595964987e-07
the O 0 5.133761860065533e-09
existence O 0 1.2347570965687282e-08
of O 0 3.424069916491135e-10
a O 0 2.5257746116835733e-08
genetically O 0 5.232373467833895e-08
distinct O 0 2.757255090912736e-09
, O 0 3.8341365637961644e-08
usually O 0 6.223364046320512e-10
lethal O 0 2.046116165388412e-09
form O 0 6.20631532277649e-11
of O 0 1.162943630284019e-09
the O 0 1.5981922842911445e-06
Schwartz B-Disease 1 0.6908875107765198
- I-Disease 1 0.9996763467788696
Jampel I-Disease 1 0.9997943043708801
syndrome I-Disease 1 0.9995953440666199
( O 0 1.411069661116926e-07
SJS B-Disease 0 0.013107804581522942
) O 0 1.560882267881425e-08
of O 0 2.6023252885920556e-08
myotonia B-Disease 0 0.03747943043708801
and O 0 0.00010477571049705148
skeletal B-Disease 1 0.9965950846672058
dysplasia I-Disease 1 0.9851111769676208
, O 0 4.2538491129562317e-07
which O 0 6.847548661426117e-08
we O 0 9.280645585363345e-09
called O 0 5.199285055823566e-07
SJS B-Disease 0 0.011846944689750671
type I-Disease 0 1.7252355632990657e-07
2 I-Disease 0 2.1063948452137993e-07
. O 0 2.3744257759972243e-07

This O 0 9.167371899820864e-06
disorder O 0 0.00480219442397356
is O 0 8.190738753910409e-08
reminiscent O 0 5.52040501133888e-06
of O 0 1.0987018406183324e-08
another O 0 4.71439591365197e-07
rare O 0 2.09560835173761e-06
condition O 0 6.345803740259726e-06
, O 0 3.586919916642728e-08
the O 0 4.1847971488095936e-07
Stuve B-Disease 0 0.3833765387535095
- I-Disease 1 0.9999337196350098
Wiedemann I-Disease 1 0.9999818801879883
syndrome I-Disease 1 0.9998935461044312
( O 0 7.356820930226604e-08
SWS B-Disease 0 0.08439036458730698
) O 0 9.787561339180684e-08
, O 0 1.1024614110510811e-08
which O 0 7.963953940759438e-09
comprises O 0 2.1805111050099413e-09
campomelia B-Disease 0 3.717379877343774e-05
at O 0 3.266680778324371e-06
birth O 0 3.689525840400165e-07
with O 0 1.7282554836128838e-06
skeletal B-Disease 1 0.9946411848068237
dysplasia I-Disease 1 0.996032178401947
, O 0 4.21483491663821e-06
contractures B-Disease 0 0.0012673083692789078
, O 0 6.517633011071666e-08
and O 0 3.6534611780325577e-08
early B-Disease 0 2.7967917048954405e-07
death I-Disease 0 9.168866199615877e-06
. O 0 3.746841343854612e-07

To O 0 4.4872731308487346e-08
test O 0 2.378999219843081e-08
for O 0 2.5857180285804304e-10
possible O 0 4.282330934302081e-09
nosologic O 0 7.630664185853675e-06
identity O 0 3.281713816249976e-07
between O 0 4.4593650727620116e-07
these O 0 4.646726665669121e-07
disorders O 0 0.017338166013360023
, O 0 4.467563030630117e-08
we O 0 2.0001786893431017e-09
reviewed O 0 2.690538902783146e-09
the O 0 1.0800903504915027e-09
literature O 0 8.350781732779922e-10
and O 0 2.044454383565153e-09
obtained O 0 6.530195273413142e-10
a O 0 8.614911006787906e-10
follow O 0 4.201914816093222e-09
- O 0 1.0903057955147233e-05
up O 0 2.8281506914140664e-08
of O 0 7.912662886022659e-11
the O 0 1.165079477338793e-09
only O 0 1.3337303483851315e-10
two O 0 3.7376548078782434e-08
surviving O 0 1.1629035725491121e-05
patients O 0 6.633944948930548e-09
, O 0 1.8883783425849288e-09
one O 0 1.4452599117475984e-09
with O 0 1.9139130813528027e-07
SJS B-Disease 0 0.002466699108481407
type I-Disease 0 3.6980996043212144e-08
2 I-Disease 0 2.9721753946887475e-08
at O 0 3.6206077425049443e-07
age O 0 4.613360360394836e-09
10 O 0 2.995610870470955e-09
years O 0 2.512076946459274e-08
and O 0 3.6958833771194577e-09
another O 0 4.337191938930118e-09
with O 0 2.729696575443086e-07
SWS B-Disease 0 0.17668786644935608
at O 0 5.594816684606485e-05
age O 0 3.091711846536782e-07
7 O 0 5.094440211905749e-07
years O 0 6.425270271392947e-07
. O 0 4.7595344199180545e-07

Patients O 0 1.6771136870374903e-05
reported O 0 3.218653364456259e-05
as O 0 5.644197997867195e-09
having O 0 3.796919401111154e-08
either O 0 1.780178706667357e-07
neonatal O 1 0.549030601978302
SJS B-Disease 1 0.9345542788505554
or O 0 1.0545129043748602e-05
SWS B-Disease 0 0.03902476653456688
presented O 0 4.059655509536242e-07
a O 0 2.2841986080379684e-08
combination O 0 4.586288326891008e-08
of O 0 8.37528713049096e-09
a O 0 1.0393917364126537e-05
severe O 0 0.00011788907431764528
, O 0 5.057046337242355e-07
prenatal O 0 9.584944564267062e-06
- O 1 0.9689461588859558
onset O 1 0.7121267914772034
neuromuscular B-Disease 1 0.9999771118164062
disorder I-Disease 1 0.9936354160308838
( O 0 1.6046922155510401e-06
with O 0 0.0011833946919068694
congenital B-Disease 1 0.9999779462814331
joint I-Disease 0 0.46087387204170227
contractures I-Disease 1 0.9995138645172119
, O 0 0.005926836747676134
respiratory O 0 0.234564870595932
and O 0 5.035975846112706e-06
feeding O 0 3.386332173249684e-05
difficulties O 0 2.4594241949671414e-06
, O 0 2.2749242489794597e-08
tendency O 0 2.6618231174779794e-08
to O 0 1.1738846694697713e-07
hyperthermia B-Disease 0 0.31972843408584595
, O 0 1.2199556920222676e-07
and O 0 4.360768457445374e-08
frequent O 0 3.9074915747505656e-08
death O 0 8.018613698368426e-06
in O 0 3.7181794709795213e-07
infancy O 0 0.0002391216839896515
) O 0 1.7703304378002827e-09
with O 0 2.3492017220405614e-09
a O 0 5.359255439429944e-08
distinct O 0 7.533409984716855e-08
campomelic B-Disease 0 0.061296913772821426
- I-Disease 1 0.6463338732719421
metaphyseal I-Disease 0 0.442793071269989
skeletal I-Disease 1 0.9594390988349915
dysplasia I-Disease 1 0.9666051268577576
. O 0 9.164356924884487e-06

The O 0 5.728755780864958e-08
similarity O 0 9.427230196479286e-08
of O 0 3.90890608770178e-09
the O 0 4.305954348637897e-08
clinical O 0 2.5482083287897694e-07
and O 0 4.23549920469668e-07
radiographic O 0 3.557270247256383e-05
findings O 0 4.771760586663731e-07
is O 0 6.062621960012393e-09
so O 0 1.0286144158655475e-09
extensive O 0 2.0518808874214756e-09
that O 0 4.790381922248343e-07
these O 0 2.902957589867583e-07
disorders O 0 0.008413566276431084
appear O 0 4.767402828065315e-08
to O 0 2.2580421976670095e-09
be O 0 1.4567673733978381e-09
a O 0 7.106359500852477e-09
single O 0 7.182605088473792e-08
entity O 0 2.0294837668188848e-06
. O 0 5.693940693163313e-06

The O 0 3.372190704453715e-08
follow O 0 3.3359114581799076e-08
- O 0 4.4019270717399195e-06
up O 0 7.55744409275394e-08
observation O 0 7.135346180575652e-08
of O 0 1.3677495802610906e-09
an O 0 1.0787814197499301e-08
identical O 0 2.6339105261286022e-06
and O 0 7.182098471503195e-08
unique O 0 1.7469110602519322e-09
pattern O 0 1.589215207786765e-05
of O 0 2.8954289632565633e-07
progressive O 0 0.14895270764827728
bone B-Disease 1 0.9996267557144165
dysplasia I-Disease 1 0.8274476528167725
in O 0 3.805126169709183e-08
the O 0 5.6129501047053054e-08
two O 0 7.508702310587978e-06
patients O 0 1.9385598193366604e-07
( O 0 1.0080883905416727e-09
one O 0 5.347755571705193e-09
with O 0 5.028010150454065e-07
SJS B-Disease 0 0.0310356542468071
type I-Disease 0 9.168853409846633e-08
2 I-Disease 0 1.9596640754571126e-08
, O 0 7.139318913829129e-09
one O 0 4.395722896788357e-09
with O 0 4.3431671770122193e-07
SWS B-Disease 0 0.037568092346191406
) O 0 2.134352250493521e-08
surviving O 0 1.3826598888044828e-07
beyond O 0 2.69976254685389e-08
infancy O 0 6.955182243473246e-07
adds O 0 6.704211408248284e-09
to O 0 1.4739275078223812e-10
the O 0 1.1495746576883903e-09
evidence O 0 2.8166411425445403e-08
in O 0 3.1652207521659648e-09
favor O 0 3.1843254699737145e-09
of O 0 1.2566818696768678e-09
identity O 0 1.034661636367673e-06
. O 0 9.878114042294328e-07

The O 0 2.930129312517238e-07
hypothesis O 0 2.2484800865640864e-06
that O 0 2.823790907768853e-07
SWS B-Disease 0 0.03544196859002113
and O 0 1.0710728020058013e-05
SJS B-Disease 0 0.020652836188673973
type I-Disease 0 3.108729913492425e-07
2 I-Disease 0 6.973167643309353e-08
are O 0 3.2747507483499305e-10
the O 0 1.783277170375186e-08
same O 0 4.6346722228918225e-06
disorder O 0 0.000202371840714477
should O 0 1.537547089647262e-09
be O 0 3.921344915447378e-10
testable O 0 1.7868410084886932e-09
by O 0 1.6824691639882872e-10
molecular O 0 4.7039048212127454e-08
methods O 0 3.0495957759058e-08
. O 0 4.6457344637929054e-08
. O 0 3.4307160490243405e-07

A O 0 1.5889310134298285e-06
mouse O 0 7.384687341982499e-05
model O 0 7.401356469927123e-06
of O 0 5.912183951295447e-06
severe O 1 0.9548870325088501
von B-Disease 1 0.9999920129776001
Willebrand I-Disease 1 0.999976634979248
disease I-Disease 1 0.9999908208847046
: O 0 0.0024307023268193007
defects O 1 0.9981963038444519
in O 0 0.00014440849190577865
hemostasis O 1 0.9565610289573669
and O 0 0.003310533706098795
thrombosis B-Disease 1 0.8577772974967957
. O 0 2.522426439099945e-05

von B-Disease 1 0.9869613647460938
Willebrand I-Disease 1 0.9581362009048462
factor I-Disease 0 0.00020096047956030816
( I-Disease 0 5.457381575979525e-06
vWf I-Disease 0 0.0014187550405040383
) I-Disease 0 0.003979266155511141
deficiency I-Disease 1 0.9959190487861633
causes O 0 0.00789413508027792
severe O 1 0.9928075075149536
von B-Disease 1 0.9999948740005493
Willebrand I-Disease 1 0.9999755620956421
disease I-Disease 1 0.9999790191650391
in O 0 1.1600946891121566e-05
humans O 0 2.086932681777398e-06
. O 0 2.06233835342573e-06

We O 0 3.984157359582241e-08
generated O 0 4.211230031359037e-09
a O 0 5.548622894480104e-09
mouse O 0 2.6451220946910325e-06
model O 0 1.621175584887169e-07
for O 0 3.359509781475367e-09
this O 0 3.6431277550263985e-08
disease O 0 4.807810114471067e-07
by O 0 8.781302074378772e-11
using O 0 1.394135584753542e-09
gene O 0 5.9348035819084544e-08
targeting O 0 1.173178930002905e-06
. O 0 1.1291879218333634e-06

vWf B-Disease 0 0.0014633677201345563
- I-Disease 1 0.6640121936798096
deficient I-Disease 1 0.6852222084999084
mice O 0 0.0009567960514687002
appeared O 0 3.590545702536474e-06
normal O 0 4.775520778821374e-08
at O 0 4.69599899588502e-06
birth O 0 7.281978469109163e-07
; O 0 7.623778941479031e-09
they O 0 1.2871532728553348e-09
were O 0 1.2775269730980199e-08
viable O 0 6.062531809902794e-08
and O 0 9.999276073813235e-08
fertile O 0 3.0952069209888577e-06
. O 0 1.4798057463849545e-06

Neither O 0 2.0460003725020215e-05
vWf O 0 4.5575678086606786e-05
nor O 0 4.786628323927289e-06
vWf O 0 2.6615634851623327e-05
propolypeptide O 0 0.0005091603961773217
( O 0 3.1804398759049946e-07
von B-Disease 0 0.40372735261917114
Willebrand I-Disease 0 0.12623800337314606
antigen O 0 0.0010267019970342517
II O 0 0.1501002460718155
) O 0 7.46162243103754e-08
were O 0 2.786073061145089e-08
detectable O 0 6.505012972723989e-09
in O 0 1.935835047817136e-09
plasma O 0 6.263313025556272e-06
, O 0 1.6281789783079148e-07
platelets O 0 9.97440565697616e-06
, O 0 6.379342920581621e-08
or O 0 3.6385930712867776e-08
endothelial O 0 3.925602868548594e-06
cells O 0 3.883446453301076e-09
of O 0 3.590679142906339e-11
the O 0 1.676985839083045e-08
homozygous O 0 4.020631422463339e-06
mutant O 0 5.362258161767386e-05
mice O 0 7.787207141518593e-05
. O 0 8.103685331661836e-07

The O 0 1.0765018032543594e-06
mutant O 0 0.0005978805129416287
mice O 0 0.14231657981872559
exhibited O 0 0.01631629467010498
defects O 1 0.9670354723930359
in O 0 3.819964604190318e-06
hemostasis O 0 0.0009172736317850649
with O 0 1.341754227723868e-07
a O 0 4.4113014041613496e-07
highly O 0 1.8467918607711908e-06
prolonged O 0 0.00037806923501193523
bleeding O 0 0.07240463048219681
time O 0 1.927844692772851e-07
and O 0 4.6642284701192693e-07
spontaneous O 0 4.299007798636012e-07
bleeding O 0 0.01794583536684513
events O 0 5.71735974119747e-08
in O 0 3.927372649314975e-09
approximately O 0 2.662822184973379e-09
10 O 0 5.7523187990682345e-08
% O 0 4.35966818201905e-09
of O 0 2.1800090621582058e-08
neonates O 0 0.0001680036511970684
. O 0 2.380066916884971e-06

As O 0 8.699792886091018e-08
in O 0 2.9330641027058846e-08
the O 0 7.978005100994778e-08
human O 0 1.6855949525051983e-06
disease O 0 6.449030479416251e-06
, O 0 3.844056628565795e-09
the O 0 4.831699484952878e-09
factor O 0 9.235476383651076e-09
VIII O 0 7.5354600994614884e-06
level O 0 8.372460058581055e-09
in O 0 8.417562202822637e-10
these O 0 1.200846200255512e-09
mice O 0 8.606411938671954e-06
was O 0 4.1203329601557925e-06
reduced O 0 2.7844724304060264e-09
strongly O 0 2.8450890532383255e-09
as O 0 2.971004831042734e-10
a O 0 4.735337011396723e-09
result O 0 4.27273638692327e-09
of O 0 3.158759920296461e-10
the O 0 8.639136517274437e-09
lack O 0 5.041682182849172e-09
of O 0 8.10191747024902e-10
protection O 0 7.789386913259477e-09
provided O 0 2.3278501348755753e-09
by O 0 3.0952751473023454e-08
vWf O 0 4.043543242460146e-07
. O 0 2.1309561759608187e-07

Defective O 1 0.7005406022071838
thrombosis B-Disease 1 0.8947123289108276
in O 0 8.887739681995299e-07
mutant O 0 0.0001265313767362386
mice O 0 0.0012851640349254012
was O 0 0.00011112221545772627
also O 0 4.3418876316536625e-07
evident O 0 2.3611617905316962e-07
in O 0 3.4809792825996055e-09
an O 0 7.55494777848753e-09
in O 0 1.2265374493836134e-07
vivo O 0 1.7231341189472005e-05
model O 0 1.946382553796866e-06
of O 0 1.0009272273237002e-06
vascular B-Disease 1 0.9977951049804688
injury I-Disease 0 0.02164069376885891
. O 0 3.8061027680669213e-06

In O 0 9.284173074775026e-08
this O 0 1.4296213102227284e-09
model O 0 3.487407340685422e-08
, O 0 3.795237901726978e-09
the O 0 4.31106395026859e-09
exteriorized O 0 1.6773921743151732e-05
mesentery O 0 1.1521254236868117e-05
was O 0 2.8105234378017485e-05
superfused O 0 1.374732528347522e-05
with O 0 9.045420767961332e-08
ferric O 0 3.702071990119293e-05
chloride O 0 6.951229920559854e-07
and O 0 1.9145643292972636e-08
the O 0 4.3750376654827505e-09
accumulation O 0 2.591184511402389e-07
of O 0 7.270165802708561e-09
fluorescently O 0 0.00484753493219614
labeled O 0 0.00024498143466189504
platelets O 0 2.5167653802782297e-05
was O 0 2.6486309252504725e-06
observed O 0 8.383134186829011e-09
by O 0 4.002595588303848e-09
intravital O 0 4.072260253451532e-06
microscopy O 0 3.3021688068402e-06
. O 0 6.667131060567044e-07

We O 0 2.6257995955347724e-07
conclude O 0 3.2759288615125115e-07
that O 0 1.082371703375884e-08
these O 0 2.1742483369280308e-09
mice O 0 1.437167270523787e-06
very O 0 2.8468096768818896e-09
closely O 0 1.1105594239779748e-06
mimic O 0 0.00042453009518794715
severe O 0 0.0015043002786114812
human O 0 0.009018553420901299
von B-Disease 1 0.9999979734420776
Willebrand I-Disease 1 0.9999856948852539
disease I-Disease 1 0.9999903440475464
and O 0 5.392741513787769e-06
will O 0 6.631898230580191e-08
be O 0 3.72927111413901e-09
very O 0 1.936916321776394e-10
useful O 0 8.436234349984417e-11
for O 0 5.027916277766664e-11
investigating O 0 1.6041024508695045e-08
the O 0 9.561480496245167e-10
role O 0 5.580950146466535e-10
of O 0 3.6411301751471115e-10
vWf O 0 8.613404212098885e-09
in O 0 8.682113361579979e-10
normal O 0 3.324184927322449e-09
physiology O 0 8.065396741585573e-07
and O 0 1.939354916657976e-07
in O 0 6.297401569099748e-07
disease O 0 5.211067673371872e-06
models O 0 2.8625532877413207e-07
. O 0 5.353156851128915e-08
. O 0 5.367986659621238e-07

Oral O 0 0.0001289164792979136
contraceptives O 0 0.0006336532533168793
and O 0 1.976005705728312e-06
the O 0 6.707359716529027e-07
risk O 0 1.2085662092431448e-05
of O 0 6.6265006353205536e-06
hereditary B-Disease 1 0.9999470710754395
ovarian I-Disease 1 0.9999947547912598
cancer I-Disease 1 0.9999079704284668
. O 0 8.443154365522787e-05

Hereditary B-Disease 1 0.998416543006897
Ovarian I-Disease 1 0.9995661377906799
Cancer I-Disease 1 0.7398896813392639
Clinical O 0 1.259148120880127e-05
Study O 0 5.248961656434403e-07
Group O 0 1.101466295949649e-05
. O 0 1.4670847576780943e-06

BACKGROUND O 0 1.0943871529889293e-05
Women O 0 1.3720138269945892e-07
with O 0 7.433042981119797e-08
mutations O 0 1.303655352558053e-07
in O 0 1.1391921184156217e-08
either O 0 5.687381232633015e-09
the O 0 7.82233868790172e-08
BRCA1 O 0 7.349462248384953e-05
or O 0 2.7477443609313923e-07
the O 0 3.0274921414275013e-07
BRCA2 O 0 2.61757832049625e-05
gene O 0 7.84609710535733e-08
have O 0 6.056010803945355e-09
a O 0 3.399967951622784e-08
high O 0 7.821068720659241e-05
lifetime O 0 2.019970997935161e-05
risk O 0 8.8207116277772e-06
of O 0 0.00012759881792590022
ovarian B-Disease 1 0.9999911785125732
cancer I-Disease 1 0.9998849630355835
. O 0 5.3014573495602235e-05

Oral O 0 0.0001641059498069808
contraceptives O 0 0.008305568248033524
protect O 0 0.015480413101613522
against O 1 0.998231828212738
ovarian B-Disease 1 0.9999948740005493
cancer I-Disease 1 0.9999456405639648
in O 0 1.6955750936631375e-07
general O 0 5.335254904537123e-09
, O 0 1.5166530431542924e-07
but O 0 2.8607129110014284e-08
it O 0 1.5444726386704133e-08
is O 0 2.688999689581806e-09
not O 0 5.037719685851982e-10
known O 0 6.453476086853982e-10
whether O 0 2.829756873268252e-09
they O 0 6.617213443860237e-09
also O 0 4.232959227579158e-08
protect O 0 1.1037389668899777e-07
against O 0 2.7052628865931183e-06
hereditary B-Disease 0 0.0046253209002316
forms I-Disease 0 1.3133040965840337e-06
of I-Disease 0 0.014009019359946251
ovarian I-Disease 1 0.9999958276748657
cancer I-Disease 1 0.9999033212661743
. O 0 1.605903889867477e-05

METHODS O 0 1.0488409429854073e-07
We O 0 1.9440616227939245e-08
enrolled O 0 1.1066960681205273e-08
207 O 0 4.630810508388095e-06
women O 0 8.54167296893138e-07
with O 0 0.0009312721085734665
hereditary B-Disease 1 0.9999877214431763
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999850988388062
and O 0 7.680219482608663e-07
161 O 0 3.564078099316248e-07
of O 0 3.2306610719956552e-09
their O 0 3.084172206513358e-08
sisters O 0 3.1610960604666616e-07
as O 0 4.2502112940212555e-10
controls O 0 2.7748884079414893e-08
in O 0 4.937325659426506e-09
a O 0 5.994598240022242e-08
case O 0 2.3938437152537517e-06
- O 0 0.0004252997459843755
control O 0 1.0495468814042397e-06
study O 0 4.039734236016557e-08
. O 0 1.3741546922574344e-07

All O 0 2.64412776118661e-08
the O 0 4.9823679404426e-08
patients O 0 1.2401265792050253e-08
carried O 0 4.866914338208517e-08
a O 0 8.182225563757584e-09
pathogenic O 0 2.1742161848692376e-08
mutation O 0 5.182500206757368e-09
in O 0 4.281694110375156e-09
either O 0 2.6341057335343976e-08
BRCA1 O 0 2.5715329684317112e-05
( O 0 4.55194903992151e-09
179 O 0 3.311729415145237e-07
women O 0 9.172876502816507e-08
) O 0 2.4107546181539874e-08
or O 0 5.524353241526114e-07
BRCA2 O 0 0.0004065670946147293
( O 0 4.64869494010145e-08
28 O 0 5.389705393099575e-07
women O 0 1.9846316945404396e-07
) O 0 8.923514371872443e-08
. O 0 4.6069439463281014e-07

The O 0 1.5933542840684822e-07
control O 0 5.141706651556888e-07
women O 0 4.849161072684183e-08
were O 0 1.3873878934589357e-08
enrolled O 0 9.0731627766516e-10
regardless O 0 2.8190674794537074e-10
of O 0 9.968945807736773e-11
whether O 0 1.1858179327361995e-08
or O 0 2.5576442297392532e-08
not O 0 1.1759363482966023e-09
they O 0 2.133329513043236e-09
had O 0 3.69403238664745e-07
either O 0 5.089168642058439e-09
mutation O 0 2.8776121041573788e-08
. O 0 2.0413759216353355e-07

Lifetime O 0 2.6038875148515217e-05
histories O 0 1.0091634976561181e-06
of O 0 2.842937085745234e-08
oral O 0 9.87780254035897e-07
- O 0 2.2973445084062405e-05
contraceptive O 0 7.535028544225497e-06
use O 0 2.3721378195062925e-09
were O 0 2.2075159478163187e-08
obtained O 0 7.3176611437020256e-09
by O 0 1.7901166771139287e-08
interview O 0 3.8932368624955416e-05
or O 0 6.040750832880804e-08
by O 0 7.563061288351491e-10
written O 0 7.194678186550618e-10
questionnaire O 0 1.9011366703125532e-08
and O 0 1.0353115698080728e-07
were O 0 1.5217965199099126e-07
compared O 0 6.108414822847408e-07
between O 0 1.3488721606336185e-07
patients O 0 1.3601434645238442e-08
and O 0 1.5332517477872898e-08
control O 0 2.7812953362627013e-07
women O 0 1.0090045243771328e-08
, O 0 9.199013994987126e-09
after O 0 2.1091285873353627e-07
adjustment O 0 1.0126928629006215e-08
for O 0 3.858982300375402e-10
year O 0 8.23362178437037e-09
of O 0 9.87738335567201e-10
birth O 0 3.613698140725319e-07
and O 0 1.7250727069040295e-07
parity O 0 2.5863430437311763e-06
. O 0 4.6693111244167085e-07

RESULTS O 0 8.15445491753053e-06
The O 0 4.743818848851333e-08
adjusted O 0 1.5440093193319626e-05
odds O 0 0.0010713825467973948
ratio O 0 3.460912557784468e-05
for O 0 0.03954065218567848
ovarian B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999934434890747
associated O 0 6.780402600270463e-06
with O 0 2.6645304629369093e-08
any O 0 6.872913904665268e-10
past O 0 7.918725231093049e-09
use O 0 6.080614900483283e-10
of O 0 2.4511095375601144e-09
oral O 0 1.8317141439183615e-06
contraceptives O 0 6.570085679413751e-05
was O 0 5.504720684257336e-05
0 O 0 7.750517738713825e-08
. O 0 1.0768822278350854e-07

5 O 0 5.869594588148175e-06
( O 0 1.7412732589150437e-08
95 O 0 1.5100516748134396e-07
percent O 0 3.7698482628911734e-06
confidence O 0 1.5514583395770387e-08
interval O 0 6.358689130792072e-09
, O 0 7.846359117991142e-10
0 O 0 6.324139129043616e-11
. O 0 3.107361243315232e-11
3 O 0 2.0218106355773813e-10
to O 0 2.388649555928879e-10
0 O 0 3.205885001911213e-10
. O 0 5.175119222045055e-10
8 O 0 2.9800657941336794e-08
) O 0 9.105396436837054e-09
. O 0 6.944816277609789e-08

The O 0 2.2451697532233084e-06
risk O 0 1.0468944310559891e-05
decreased O 0 1.7756481440756033e-07
with O 0 1.6604282393473113e-09
increasing O 0 2.2748873618194665e-10
duration O 0 1.3212256844141734e-09
of O 0 1.4933566883090776e-10
use O 0 2.127279241648239e-09
( O 0 1.0070064782041754e-09
P O 0 3.1854106055106968e-06
for O 0 5.069895614440156e-10
trend O 0 1.9840767251366742e-08
, O 0 1.3562931888699836e-09
< O 0 7.894757625415139e-10
0 O 0 5.602833474949165e-11
. O 0 1.6914268596845972e-10
001 O 0 1.4857383767719057e-08
) O 0 2.5253385493861913e-10
; O 0 1.1700487800858639e-11
use O 0 3.312496327581571e-12
for O 0 5.527280716455252e-11
six O 0 3.6477427745040814e-09
or O 0 2.4381332508482956e-09
more O 0 1.5147630372247534e-10
years O 0 8.076528956735274e-08
was O 0 9.24468258745037e-06
associated O 0 5.109837442063281e-09
with O 0 9.487072238911765e-10
a O 0 2.075680782809286e-08
60 O 0 6.64747545897626e-08
percent O 0 3.047670361411292e-06
reduction O 0 4.642412676503227e-08
in O 0 5.804250235996733e-08
risk O 0 6.802727057220181e-07
. O 0 2.0219714258473687e-07

Oral O 0 1.612330561329145e-05
- O 0 8.115152741083875e-05
contraceptive O 0 6.094622585806064e-05
use O 0 1.2951086603152362e-07
protected O 0 0.00035258696880191565
against O 1 0.9969971179962158
ovarian B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9998871088027954
both O 0 6.485921133503325e-09
for O 0 6.525538442936352e-10
carriers O 0 5.2301953878952645e-09
of O 0 6.028199606156193e-10
the O 0 4.8213916414852065e-08
BRCA1 O 0 4.21706099587027e-05
mutation O 0 1.7442192756789154e-07
( O 0 2.6353004223267362e-09
odds O 0 1.4247815443013678e-06
ratio O 0 3.3859490766730005e-09
, O 0 6.533110163964295e-10
0 O 0 8.84082806962283e-11
. O 0 1.5855546042775615e-10
5 O 0 1.886017120256156e-09
; O 0 2.5484578336509855e-10
95 O 0 5.5493001305251255e-09
percent O 0 4.4526504439090786e-07
confidence O 0 6.549008446654625e-09
interval O 0 4.95502394670666e-09
, O 0 3.364278577944191e-10
0 O 0 2.59368429511575e-11
. O 0 9.891964851405088e-12
3 O 0 4.992129626346653e-11
to O 0 1.440009084197058e-10
0 O 0 2.863237424932663e-10
. O 0 3.1580130177566446e-10
9 O 0 1.669912741419921e-08
) O 0 3.986547758572101e-10
and O 0 3.6419151028255214e-10
for O 0 5.36693987862602e-11
carriers O 0 2.442134550140196e-10
of O 0 5.211886824896261e-11
the O 0 5.005093939303151e-08
BRCA2 O 0 6.40667758489144e-06
mutation O 0 2.6935595087707043e-08
( O 0 7.889624509260784e-10
odds O 0 3.3213285632882616e-07
ratio O 0 5.795018354071146e-10
, O 0 9.30801324905417e-10
0 O 0 1.4725448638230887e-10
. O 0 4.937669370597142e-11
4 O 0 1.4376606571886441e-09
; O 0 3.278250448879305e-10
95 O 0 9.469739659095922e-09
percent O 0 6.900496600792394e-07
confidence O 0 8.478441948511772e-09
interval O 0 2.4441815238418485e-09
, O 0 2.9592864270178154e-10
0 O 0 5.083798659821781e-11
. O 0 3.128455133838415e-11
2 O 0 2.1190454946307113e-10
to O 0 1.6199662444815743e-10
1 O 0 6.804823926565007e-10
. O 0 5.95828719696101e-10
1 O 0 6.430576515725761e-09
) O 0 1.4383855884148034e-08
. O 0 9.09840309759602e-08

CONCLUSIONS O 0 1.0215497241006233e-05
Oral O 0 7.39753841116908e-06
- O 0 0.0004022110078949481
contraceptive O 0 3.870293585350737e-05
use O 0 2.0288743129981412e-08
may O 0 4.136306586133287e-08
reduce O 0 3.6652199053577306e-09
the O 0 4.1440294751282636e-08
risk O 0 6.484751338575734e-06
of O 0 0.00011603524762904271
ovarian B-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999747276306152
in O 0 2.0316009852194838e-07
women O 0 2.2934797172524668e-08
with O 0 1.5897200000836165e-08
pathogenic O 0 1.3601570003629604e-07
mutations O 0 2.8598291734738268e-08
in O 0 4.734741043677104e-09
the O 0 2.7235546440351754e-07
BRCA1 O 0 0.001008589519187808
or O 0 2.144511199730914e-05
BRCA2 O 0 0.0018747510621324182
gene O 0 6.731198664056137e-05

A O 0 3.899022885889281e-06
Japanese O 0 2.709210639295634e-05
family O 0 5.223393236519769e-05
with O 0 5.190083356865216e-06
adrenoleukodystrophy B-Disease 1 0.9997571110725403
with O 0 4.926848617969881e-08
a O 0 1.757915235600649e-08
codon O 0 1.60227404677471e-08
291 O 0 9.084545240511943e-07
deletion O 0 1.7488056300862809e-06
: O 0 1.1182937909026691e-09
a O 0 1.1943664723901293e-08
clinical O 0 1.8866680306928174e-07
, O 0 3.1091096275304153e-07
biochemical O 0 5.093532308819704e-05
, O 0 1.386808094139269e-06
pathological O 0 3.736259168363176e-05
, O 0 4.6373949658118363e-07
and O 0 8.006157941053971e-07
genetic O 0 8.713360330148134e-06
report O 0 7.321012162719853e-06
. O 0 7.116887559277529e-07

We O 0 5.753129812546831e-07
report O 0 1.076198543614737e-07
a O 0 4.616679483149255e-09
Japanese O 0 1.2681881571552367e-06
family O 0 3.482060492387973e-05
with O 0 0.0010418299352750182
adrenoleukodystrophy B-Disease 1 0.9999862909317017
( O 0 5.351224899641238e-05
ALD B-Disease 1 0.999983549118042
) O 0 9.945048873305495e-08
with O 0 4.855590152175182e-09
a O 0 7.323036843587261e-09
three O 0 2.798370246637205e-08
base O 0 3.1192010396807746e-07
pair O 0 7.560244557680562e-05
deletion O 0 4.68822190669016e-06
( O 0 1.9519188487748806e-09
delGAG O 0 7.741268177596794e-07
291 O 0 5.447390094559523e-07
) O 0 1.6844744266109046e-08
in O 0 1.3947267341052338e-08
the O 0 1.6673067193551105e-06
ALD B-Disease 1 0.9998742341995239
gene O 0 7.306594397959998e-06
. O 0 1.0118685622728663e-06

A O 0 1.187094085253193e-06
variety O 0 2.1748673972865618e-08
of O 0 1.3419047206753021e-08
phenotypes O 0 1.1870918115164386e-06
were O 0 1.1928199228350422e-07
observed O 0 4.070874837225347e-08
within O 0 4.71732319873297e-10
this O 0 8.067164714020691e-09
family O 0 2.350249451410491e-05
. O 0 1.1820433201137348e-06

While O 0 1.0178573575103655e-06
the O 0 3.350923805101047e-07
proband O 0 0.00033099387655965984
( O 0 6.6527241493474776e-09
patient O 0 1.9941191808925396e-08
1 O 0 4.472388681620032e-08
) O 0 1.8718907313086675e-08
was O 0 2.8688330075965496e-06
classified O 0 1.6587171103310538e-07
as O 0 5.091197685658244e-09
having O 0 1.324880383180016e-08
a O 0 1.2927587000888252e-08
rare O 0 4.499503347688005e-08
intermediate O 0 1.8624035647007986e-08
type O 0 4.587842994396851e-09
of O 0 1.0743497202980734e-09
adult O 0 1.0979833859892096e-05
cerebral O 0 0.02183539606630802
and O 0 2.6006688131019473e-05
cerebello O 0 0.32258665561676025
- O 1 0.8095693588256836
brain O 0 0.003309517866000533
stem O 0 7.63342029586056e-07
forms O 0 3.229065459464664e-09
, O 0 5.428037397336993e-08
his O 0 4.426258783496451e-06
younger O 0 4.174145942670293e-06
brother O 0 6.441130972234532e-05
( O 0 1.6036244554484824e-09
patient O 0 2.6338744518739077e-08
2 O 0 6.653791615462978e-07
) O 0 7.799485501891468e-08
and O 0 4.237951998220524e-07
nephew O 0 0.00021984265185892582
( O 0 1.5477777948191829e-09
patient O 0 1.0734551025848305e-08
3 O 0 1.932029931595025e-07
) O 0 3.762660583106481e-08
had O 0 1.0529483006394003e-05
a O 0 1.4297892448666971e-05
childhood O 0 0.03064265288412571
ALD B-Disease 1 0.9999310970306396
type O 0 2.0550094632199034e-05
. O 0 2.2814001567894593e-06

Another O 0 2.1871512217330746e-05
nephew O 0 0.004780101589858532
( O 0 1.0385392812395366e-07
patient O 0 4.151316659317672e-07
4 O 0 8.907722417461628e-07
) O 0 6.703290811316265e-09
of O 0 3.9854530786698206e-10
patient O 0 8.70014105203154e-08
1 O 0 4.960094912576096e-08
was O 0 3.7741825508419424e-05
classified O 0 2.992426288983552e-07
as O 0 1.2731703691315488e-08
having O 0 4.379849016800108e-08
an O 0 2.903524531916446e-08
adolescent O 0 2.4307284547830932e-05
form O 0 6.449420908438697e-08
. O 0 1.1269104334132862e-06

The O 0 1.043001844891478e-07
tau O 0 1.9227273639899067e-07
level O 0 1.3727263770135778e-08
in O 0 4.210169990415125e-09
the O 0 4.841370326857941e-08
cerebrospinal O 0 0.007071608677506447
fluid O 0 0.001003673067316413
( O 0 6.840485298198473e-07
CSF O 1 0.6412652730941772
) O 0 5.186963036862835e-08
in O 0 4.363128969231411e-09
patient O 0 2.262000364794403e-08
1 O 0 1.0509772607747436e-08
was O 0 1.0202743396803271e-05
as O 0 6.080711045797216e-09
high O 0 3.78834812408968e-07
as O 0 1.6104967359709121e-09
that O 0 4.083073434912876e-09
of O 0 5.0449240340810775e-09
patients O 0 1.2756258627177886e-07
with O 0 0.0005379953654482961
Alzheimers B-Disease 1 0.9998821020126343
disease I-Disease 0 0.002807506127282977
( O 0 6.052823575686261e-09
AD B-Disease 0 1.033461194310803e-05
) O 0 1.0837748476433262e-07
. O 0 2.4397189690716914e-07

His O 0 3.5263616155134514e-05
brain O 0 0.0003019198193214834
magnetic O 0 1.0273982297803741e-05
resonance O 0 2.8451629987102933e-05
image O 0 0.00015466450713574886
( O 0 1.0245953774301597e-07
MRI O 0 0.0015831302152946591
) O 0 1.9147817056364147e-06
showed O 0 0.016400163993239403
abnormalities B-Disease 0 0.034459687769412994
in I-Disease 0 1.2414637318158839e-08
the I-Disease 0 2.830838141676395e-08
bilateral I-Disease 0 2.9257138521643355e-05
cerebellar I-Disease 0 0.2721405029296875
hemispheres I-Disease 0 0.00038783089257776737
and O 0 2.879883504647296e-05
brain O 0 0.005696849897503853
stem O 0 1.3517646038962994e-05
, O 0 7.256370793129463e-08
but O 0 1.7672105556698625e-08
not O 0 1.5687908749839607e-09
in O 0 3.4442591001493383e-09
the O 0 6.622404953304795e-07
cerebral O 0 0.01683390699326992
white O 0 0.00018636697495821863
matter O 0 5.218317777888615e-09
, O 0 2.363277573635969e-09
where O 0 2.8404205654197767e-09
marked O 0 5.2444832476794545e-08
reductions O 0 1.9186877864285634e-08
of O 0 8.723712308089659e-10
the O 0 8.733124445825524e-07
cerebral O 0 0.025251764804124832
blood O 0 3.2913310406001983e-06
flow O 0 3.0192680355867196e-08
and O 0 2.6536161712442663e-08
oxygen O 0 7.36471150730722e-08
metabolism O 0 1.758050132139033e-07
were O 0 1.753789291569774e-08
clearly O 0 4.392473229586358e-08
demonstrated O 0 5.582837747653002e-09
by O 0 9.869436379261742e-10
positron O 0 6.9639568209822755e-06
emission O 0 1.487996428295446e-07
tomography O 0 5.971085101919016e-06
( O 0 9.187774097085821e-09
PET O 0 2.597243337731925e-06
) O 0 4.1005499440416315e-08
. O 0 1.3221040262578754e-07

In O 0 1.3578983271145262e-06
patients O 0 2.3047702768508316e-07
2 O 0 7.410364588622542e-08
and O 0 5.3556789225694956e-08
3 O 0 1.2820262895729684e-07
, O 0 4.234959938287375e-09
the O 0 8.590532729613187e-09
autopsy O 0 0.0028896250296384096
findings O 0 1.9128251551592257e-06
showed O 0 0.00016639824025332928
massive O 0 3.9710856071906164e-05
demyelination B-Disease 1 0.9920532703399658
of I-Disease 0 3.6702935801713465e-08
the I-Disease 0 4.869105396210216e-06
cerebral I-Disease 0 0.08917960524559021
white I-Disease 0 3.369491241755895e-05
matter I-Disease 0 3.3727483028656025e-09
with O 0 2.9265077028384212e-09
sparing O 0 5.127527735737658e-09
of O 0 3.294730321901085e-10
the O 0 5.984853856944028e-08
U O 0 0.00010957167251035571
- O 0 0.003605018835514784
fibers O 0 8.148061897372827e-05
, O 0 2.798785203594889e-09
compatible O 0 2.4696568345916603e-08
with O 0 1.0116329995923934e-08
the O 0 3.393968484033394e-08
findings O 0 3.739690725979017e-07
of O 0 2.204367319791345e-07
childhood O 0 0.013998833484947681
ALD B-Disease 1 0.9998289346694946
. O 0 1.6252270143013448e-05

Oleic O 0 0.0016571751330047846
and O 0 7.211320280475775e-06
erucic O 0 0.0010241800919175148
acids O 0 9.096578992284776e-07
( O 0 3.323019726053644e-08
Lorenzos O 0 1.530460940557532e-05
Oil O 0 9.103990237235848e-07
) O 0 2.940147902918966e-09
were O 0 2.4736577231010415e-09
administered O 0 2.0084772733852674e-10
to O 0 6.406589703189525e-10
patients O 0 2.0351159646381234e-10
1 O 0 4.595451241762305e-10
and O 0 9.108836351856553e-09
4 O 0 2.714571323281234e-08
, O 0 1.4832006733911385e-09
but O 0 3.83278020432698e-10
sufficient O 0 5.777919462324199e-11
effectiveness O 0 3.1091489383072712e-09
was O 0 4.309323173856683e-07
not O 0 1.526868409484905e-09
obtained O 0 3.1565225100393945e-08
. O 0 1.1913476782865473e-07

The O 0 1.5448608792212326e-07
findings O 0 3.8514750144713616e-07
in O 0 2.0267082234681766e-08
this O 0 5.8588707219087155e-09
family O 0 2.0154229787294753e-06
suggest O 0 1.7764604010039875e-08
that O 0 9.395382249977047e-09
delGAG291 O 0 3.1755450891068904e-07
is O 0 9.634338882236193e-10
part O 0 3.413089533221836e-10
of O 0 1.0256717697387785e-09
the O 0 7.39590575449256e-08
cause O 0 2.0800429467726644e-07
of O 0 1.6987547368785272e-08
Japanese O 0 0.00043985151569359004
ALD B-Disease 1 0.9998983144760132
with O 0 3.5269857789899106e-07
phenotypic O 0 7.456699790964194e-08
variations O 0 9.248521450899716e-07
. O 0 2.6851116672332864e-06

Moreover O 0 2.8349991225695703e-06
, O 0 5.820324844307834e-08
although O 0 1.828942552961621e-09
the O 0 1.976107055767784e-09
scale O 0 3.690412597734394e-07
of O 0 6.398285790076841e-10
the O 0 6.229079474451282e-09
study O 0 1.6459832385962159e-09
is O 0 6.588772305526902e-10
limited O 0 9.989469251792116e-10
, O 0 1.2744069799452973e-08
there O 0 5.38166289310027e-10
is O 0 6.143250907975073e-10
a O 0 1.651351055897976e-09
possibility O 0 9.636844211513562e-09
that O 0 4.24576747093397e-08
PET O 0 9.992953664550441e-07
can O 0 1.3517967856202517e-09
detect O 0 1.480768361261653e-07
an O 0 5.633499711166223e-08
insidious B-Disease 0 0.002643305342644453
lesion I-Disease 1 0.8757508397102356
which O 0 8.845198635754059e-07
is O 0 1.742246524827351e-08
undetectable O 0 1.0169864594899991e-07
by O 0 8.375394267012837e-10
computed O 0 4.311279866442419e-08
tomogram O 0 9.157665772363544e-05
( O 0 3.784026869624313e-09
CT O 0 0.00018625504162628204
) O 0 3.298808337603987e-08
or O 0 2.459859516079632e-08
MRI O 0 2.889800725824898e-06
analysis O 0 5.6833826533875254e-08
, O 0 1.9009734231190123e-08
and O 0 1.0078812451297381e-08
that O 0 1.55619050978828e-09
the O 0 1.1468022087512963e-09
higher O 0 3.6062770547573564e-09
level O 0 4.716836921048184e-10
of O 0 1.5366580230491422e-10
tau O 0 7.836697957230854e-10
reflects O 0 5.7838407674370984e-11
the O 0 3.5905559775395446e-11
process O 0 3.623049082968066e-10
of O 0 7.01925240154111e-10
neuronal B-Disease 0 0.0034453209955245256
degeneration I-Disease 1 0.8835970759391785
in O 0 2.9996146622579545e-05
ALD B-Disease 1 0.9999004602432251
. O 0 3.4930726542370394e-05

Lorenzos O 0 0.0021119117736816406
Oil O 0 1.0045486305898521e-05
should O 0 5.39524203091446e-09
be O 0 1.6340426234329186e-10
given O 0 3.64694429169643e-12
in O 0 3.8865841101021203e-11
the O 0 7.342235708307498e-10
early O 0 1.99657002042386e-08
stage O 0 9.063163020073262e-07
. O 0 5.512023193432469e-08
. O 0 1.388679180536201e-07

Nonsense O 0 1.4016589375387412e-05
mutation O 0 8.168192948687647e-07
in O 0 6.895162840692137e-08
exon O 0 2.7418807349022245e-06
4 O 0 3.895727047620312e-07
of O 0 9.306734827241314e-10
human O 0 4.513545981410516e-09
complement O 0 5.220219367885193e-09
C9 O 0 2.3300082830246538e-05
gene O 0 4.5916095814391156e-08
is O 0 3.812927307222935e-09
the O 0 3.0533657824349802e-09
major O 0 1.5707646738860603e-08
cause O 0 3.779145885118851e-08
of O 0 1.605552579775349e-09
Japanese O 0 2.1563846530625597e-06
complement B-Disease 0 2.9810121304763015e-06
C9 I-Disease 1 0.7967855930328369
deficiency I-Disease 0 0.0049925255589187145
. O 0 2.0427528113486915e-07

Deficiency B-Disease 1 0.8493481278419495
of I-Disease 0 3.1602198635738432e-09
the I-Disease 0 3.86785625750008e-09
ninth I-Disease 0 2.8349401759442117e-07
component I-Disease 0 1.3017007027826821e-08
of I-Disease 0 3.098030165737953e-10
human I-Disease 0 6.638249061552415e-09
complement I-Disease 0 8.326562550564631e-09
( O 0 2.1443729014691826e-09
C9 O 0 8.30736735224491e-06
) O 0 2.76315148539652e-09
is O 0 1.2529691173490676e-10
the O 0 3.080894428464376e-10
most O 0 1.451591846723943e-09
common O 0 1.0531032330618473e-06
complement B-Disease 1 0.9739364385604858
deficiency I-Disease 1 0.9999635219573975
in O 0 3.950551885623099e-08
Japan O 0 3.072807999160432e-07
but O 0 7.132325663405936e-08
is O 0 8.212244217986608e-09
rare O 0 1.6738413322059387e-08
in O 0 1.4892330701954393e-09
other O 0 1.504903535121116e-09
countries O 0 1.7730473755861453e-09
. O 0 1.2359073764400819e-07

We O 0 4.2941771027926734e-08
studied O 0 3.661181358083354e-09
the O 0 2.875688576153834e-10
molecular O 0 3.5104850582001745e-08
basis O 0 5.5518412089838876e-09
of O 0 1.4123958180789487e-07
C9 B-Disease 1 0.8744324445724487
deficiency I-Disease 0 0.015189362689852715
in O 0 2.2167931934546914e-09
four O 0 1.9672325990427453e-08
Japanese O 0 3.1905517516861437e-06
C9 B-Disease 0 0.016803868114948273
- I-Disease 1 0.9019240736961365
deficient I-Disease 0 0.44640180468559265
patients O 0 5.203948489906907e-07
who O 0 9.63650927587878e-06
had O 0 0.09577614068984985
suffered O 1 0.6326072216033936
from O 0 9.561666229274124e-05
meningococcal B-Disease 1 0.999908447265625
meningitis I-Disease 1 0.999734103679657
. O 0 6.077842044760473e-06

Direct O 0 8.005454965598346e-09
sequencing O 0 1.0690747132002798e-07
of O 0 1.8554673353321505e-09
amplified O 0 1.2176778909633867e-06
C9 O 0 1.3422034498944413e-05
cDNA O 0 3.037011708784121e-07
and O 0 3.680507631997898e-08
DNA O 0 1.0409304422864807e-06
revealed O 0 1.2800816193703213e-06
a O 0 5.201405084420685e-09
nonsense O 0 1.2074548294549459e-07
substitution O 0 7.422297221282292e-10
( O 0 1.2453590936267744e-10
CGA O 0 5.660668875862029e-07
- O 0 0.0003463920729700476
- O 0 0.0010580528760328889
> O 0 5.693940252626817e-08
TGA O 0 2.905618657678133e-06
) O 0 2.1149712536860932e-10
at O 0 2.974157309321157e-10
codon O 0 9.58210073787047e-12
95 O 0 6.158158705193983e-11
in O 0 8.831609055182099e-11
exon O 0 2.114424901833445e-08
4 O 0 1.7317905331992733e-08
in O 0 5.789604906603074e-10
the O 0 3.3681839539667635e-09
four O 0 6.85973759573244e-07
C9 B-Disease 0 0.008534366264939308
- I-Disease 0 0.1372043341398239
deficient I-Disease 0 0.0019760089926421642
individuals O 0 4.211422766076112e-09
. O 0 2.0420125679265766e-07

An O 0 8.089263303645566e-08
allele O 0 3.5761038361670217e-06
- O 0 3.506267603370361e-06
specific O 0 1.4885230825711915e-09
polymerase O 0 3.015262564076693e-06
chain O 0 1.1055421055061743e-05
reaction O 0 1.2105376256954514e-08
system O 0 3.298424644526676e-08
designed O 0 3.43890832255056e-07
to O 0 1.0023671892511743e-09
detect O 0 3.004848281307204e-08
exclusively O 0 1.9954754515438822e-10
only O 0 2.957986980356431e-11
one O 0 9.679055473776899e-11
of O 0 7.187377776274317e-11
the O 0 2.5300208594813967e-09
normal O 0 5.40027667028653e-09
and O 0 2.0889780572019845e-08
mutant O 0 1.588932576623847e-07
alleles O 0 4.3930574733508365e-09
indicated O 0 4.58116495849481e-08
that O 0 5.861427454512125e-10
all O 0 1.1616965202299046e-11
the O 0 1.066818855477436e-09
four O 0 2.1332695609999064e-08
patients O 0 1.3099964446539047e-09
were O 0 1.1581534620219713e-09
homozygous O 0 6.595452184399164e-09
for O 0 3.5626685629397414e-11
the O 0 3.2449867792827547e-10
mutation O 0 1.4440529882975284e-09
in O 0 9.863940775289848e-10
exon O 0 2.4741504489611543e-07
4 O 0 4.84671943468129e-07
and O 0 9.174906523412574e-08
that O 0 1.0403569561390213e-08
the O 0 5.740368624884695e-09
parents O 0 3.21566062666534e-09
of O 0 4.124005581473966e-10
patient O 0 2.170338042617459e-08
2 O 0 3.987099361779656e-08
were O 0 1.7603083790618257e-07
heterozygous O 0 6.131749046289769e-07
. O 0 2.28695427040293e-07

The O 0 8.003686957636091e-08
common O 0 4.3247784020650215e-08
mutation O 0 3.4872677190378454e-08
at O 0 4.156354904694126e-08
codon O 0 6.80263068097986e-10
95 O 0 1.158677154222687e-09
in O 0 7.711699612222844e-10
exon O 0 4.776240416504152e-07
4 O 0 1.0143436384169036e-06
might O 0 1.876698974001556e-08
be O 0 2.2305807201306038e-10
responsible O 0 4.1962344710100297e-10
for O 0 1.2282518058182035e-10
most O 0 2.5961168770294307e-09
Japanese O 0 5.965048330835998e-05
C9 B-Disease 0 0.4684961438179016
deficiency I-Disease 0 0.0012367140734568238
. O 0 9.638131182043708e-09
. O 0 1.1158530810462253e-07

BRCA1 O 0 0.00029528632876463234
required O 0 3.1492159990875734e-08
for O 0 6.159714960318752e-09
transcription O 0 1.1883061006301432e-06
- O 0 0.0057457201182842255
coupled O 0 0.00022181340318638831
repair O 0 0.00028578127967193723
of O 0 3.879080523461198e-08
oxidative O 0 1.2019708265142981e-05
DNA O 0 0.0007594929193146527
damage O 0 0.0009743213886395097
. O 0 2.082789251289796e-06

The O 0 0.00011027647997252643
breast B-Disease 1 0.9984316229820251
and I-Disease 1 0.9980729818344116
ovarian I-Disease 1 0.9999899864196777
cancer I-Disease 1 0.9999154806137085
susceptibility O 0 0.00015800082474015653
gene O 0 1.535589262857684e-06
BRCA1 O 0 2.6733923732535914e-05
encodes O 0 2.0258330550859682e-06
a O 0 2.8550482966238633e-05
zinc O 0 0.33939170837402344
finger O 0 0.009788710623979568
protein O 0 2.9268830914475075e-08
of O 0 1.1276388711678464e-09
unknown O 0 1.8648245259100804e-07
function O 0 1.2818422767679749e-08
. O 0 2.2874603189393383e-07

Association O 0 1.1685806384775788e-06
of O 0 3.2208475886363885e-09
the O 0 3.880516175058801e-08
BRCA1 O 0 5.331500688043889e-06
protein O 0 6.9279582071146706e-09
with O 0 1.057638976398323e-09
the O 0 1.725868337132397e-08
DNA O 0 0.00015718096983619034
repair O 0 0.007399276364594698
protein O 0 1.6541865477393003e-07
Rad51 O 0 3.4916251934191678e-06
and O 0 3.337793597069094e-09
changes O 0 2.137526614043317e-11
in O 0 8.550832958365007e-11
the O 0 9.187905297691756e-11
phosphorylation O 0 5.489481647025229e-10
and O 0 4.771512074341899e-09
cellular O 0 4.6199144776437606e-07
localization O 0 1.0244718851026846e-08
of O 0 4.321449101341024e-11
the O 0 4.138086262539531e-10
protein O 0 1.963782692016025e-09
after O 0 7.354562825412359e-08
exposure O 0 1.181444986286806e-08
to O 0 9.533254186067097e-10
DNA O 0 2.837113424902782e-05
- O 0 0.005762718617916107
damaging O 0 3.9449430914828554e-05
agents O 0 3.001107984346163e-08
are O 0 4.719985166601326e-11
consistent O 0 6.089342918791374e-10
with O 0 1.4705023865246858e-09
a O 0 6.455387335790874e-09
role O 0 2.4540940390949117e-09
for O 0 2.814030120035227e-09
BRCA1 O 0 8.758874173508957e-06
in O 0 1.5346304849117587e-07
DNA O 0 0.0004499457136262208
repair O 0 0.03222137317061424
. O 0 1.5814175640116446e-06

Here O 0 1.6534971791770658e-06
, O 0 5.464196917159825e-08
it O 0 4.481822468704877e-09
is O 0 4.479956960956599e-10
shown O 0 3.314131635789863e-09
that O 0 2.717823521791729e-09
mouse O 0 1.5949233329592971e-06
embryonic O 0 3.862653841224528e-07
stem O 0 2.9947950679343194e-06
cells O 0 5.404142484621843e-07
deficient B-Disease 0 7.268723857123405e-05
in I-Disease 0 5.5002193022346546e-08
BRCA1 I-Disease 0 6.3689030866953544e-06
are O 0 2.578415925214017e-09
defective O 0 1.5345003703259863e-05
in O 0 1.0829499075271087e-08
the O 0 3.4781055813226658e-09
ability O 0 1.6595860241608307e-09
to O 0 1.9121318417525401e-10
carry O 0 1.4621287514060555e-09
out O 0 5.907470068677867e-09
transcription O 0 5.993547347316053e-08
- O 0 0.00010077760089188814
coupled O 0 9.090291314350907e-06
repair O 0 8.756860188441351e-05
of O 0 9.588002392035833e-09
oxidative O 0 3.5601040053734323e-06
DNA O 0 0.0015762082766741514
damage O 0 0.0019331281073391438
, O 0 1.4127043357348157e-07
and O 0 5.2481052392749916e-08
are O 0 6.102318095280168e-10
hypersensitive O 0 3.701102741615614e-06
to O 0 1.3209063176589098e-08
ionizing O 0 1.1017029777349308e-07
radiation O 0 3.470566980467993e-07
and O 0 3.861570263552494e-08
hydrogen O 0 1.5340260972607211e-07
peroxide O 0 8.77146958373487e-05
. O 0 7.892098210504628e-07

These O 0 6.13793886827807e-08
results O 0 3.9356686443170474e-07
suggest O 0 8.668288842272887e-08
that O 0 2.1248759196623723e-08
BRCA1 O 0 1.3533463061321527e-06
participates O 0 1.2174283803290109e-08
, O 0 1.156337514629513e-08
directly O 0 4.683776477776291e-09
or O 0 3.526154301880524e-08
indirectly O 0 1.5704239331171266e-07
, O 0 9.472394424392405e-09
in O 0 2.101220974992657e-09
transcription O 0 6.820279168096022e-07
- O 0 0.007218783255666494
coupled O 0 0.00010306682088412344
repair O 0 5.9565380070125684e-05
of O 0 8.234564141673673e-09
oxidative O 0 9.347291438643879e-07
DNA O 0 0.00022239916143007576
damage O 0 0.00039875003858469427
. O 0 4.673828613022124e-08
. O 0 2.0446374549010216e-07

Truncation O 0 6.608711555600166e-05
mutations O 0 5.340691132005304e-06
in O 0 5.5462557213559194e-08
the O 0 1.3276124199990136e-08
transactivation O 0 8.817549314699136e-06
region O 0 1.8405337698368385e-08
of O 0 1.7231440718745716e-09
PAX6 O 0 6.839749858045252e-06
result O 0 3.0779840898276234e-08
in O 0 6.518463990801138e-09
dominant O 0 5.890173611078353e-07
- O 0 0.00040213469765149057
negative O 0 4.0693069536246185e-07
mutants O 0 5.699563644157024e-06
. O 0 1.5845336065467563e-07

PAX6 O 0 0.0013560348888859153
is O 0 1.6300916172440338e-07
a O 0 1.787080528004026e-08
transcription O 0 9.774948495078206e-08
factor O 0 1.4144927007464503e-08
with O 0 9.686410562537162e-10
two O 0 1.1402637944968319e-08
DNA O 0 4.898112820228562e-05
- O 0 4.84400698042009e-05
binding O 0 1.1450437398252689e-07
domains O 0 5.730832342010217e-08
( O 0 1.721159992307264e-09
paired O 0 9.529642284178408e-07
box O 0 6.424702587537467e-05
and O 0 3.834319954876264e-07
homeobox O 0 4.190320339603204e-07
) O 0 7.468293206081e-10
and O 0 1.0661740379447338e-09
a O 0 8.620207658793788e-09
proline O 0 4.489332354751241e-07
- O 0 4.441311830305494e-06
serine O 0 4.156736395088956e-07
- O 0 2.6415315005579032e-05
threonine O 0 7.119411748135462e-06
( O 0 3.143255433712966e-09
PST O 0 0.00010562055831542239
) O 0 1.1337665029031996e-08
- O 0 1.3678126151717152e-06
rich O 0 6.298396471038359e-09
transactivation O 0 4.177731227628101e-07
domain O 0 1.4013745719410053e-08
. O 0 5.765367916410469e-08

PAX6 O 0 0.0014005543198436499
regulates O 0 2.8930189728271216e-05
eye O 0 7.965720578795299e-05
development O 0 1.195048184854386e-07
in O 0 4.2329673988206196e-08
animals O 0 2.386711983604073e-08
ranging O 0 4.232603956211278e-08
from O 0 2.8807516372353348e-09
jellyfish O 0 4.2515857501257415e-08
to O 0 1.9514340143800268e-10
Drosophila O 0 8.895059133706695e-10
to O 0 2.675754062764213e-09
humans O 0 5.309520378915522e-09
. O 0 4.582571833111615e-08

Heterozygous O 0 2.4799366656225175e-05
mutations O 0 6.265547654038528e-06
in O 0 1.1801954968859718e-07
the O 0 2.6454646473439425e-08
human O 0 3.4447143804072766e-08
PAX6 O 0 5.523417257791152e-06
gene O 0 8.919753469172065e-08
result O 0 1.9049480215471704e-08
in O 0 7.569844195920439e-10
various O 0 2.426774614594507e-10
phenotypes O 0 5.714796884603857e-07
, O 0 1.5638121908523317e-07
including O 0 8.118590244521329e-07
aniridia B-Disease 1 0.99997878074646
, O 0 0.00451777596026659
Peters B-Disease 1 0.9999839067459106
anomaly I-Disease 1 0.9999768733978271
, O 0 1.3103068340569735e-05
autosomal B-Disease 0 0.012551401741802692
dominant I-Disease 0 0.005801079794764519
keratitis I-Disease 1 0.9581941962242126
, O 0 1.2738604709738865e-05
and O 0 2.9262328098411672e-05
familial B-Disease 1 0.8381528258323669
foveal I-Disease 1 0.9985694885253906
dysplasia I-Disease 1 0.9978654980659485
. O 0 2.636387580423616e-05

It O 0 5.698959171240858e-07
is O 0 1.897079826562731e-08
believed O 0 2.2337973248909293e-08
that O 0 3.805354920061177e-10
the O 0 2.91862950474453e-10
mutated O 0 1.5092965099938738e-08
allele O 0 3.853616803439763e-08
of O 0 2.210873262242785e-09
PAX6 O 0 2.932348024842213e-06
produces O 0 8.450285804428859e-09
an O 0 3.7483738335453154e-10
inactive O 0 1.8558999670403864e-08
protein O 0 8.208473900594981e-08
and O 0 5.220015736995265e-06
aniridia B-Disease 1 0.9999396800994873
is O 0 2.5215131245204248e-06
caused O 0 3.9598116927663796e-06
due O 0 1.2588751374664753e-08
to O 0 1.4745896947943038e-08
genetic O 0 7.133990038710181e-06
haploinsufficiency O 0 0.0016369294608011842
. O 0 2.2325934878608678e-06

However O 0 3.97962367060245e-07
, O 0 9.673897238826612e-09
several O 0 3.923282809736861e-10
truncation O 0 2.7269800284557277e-06
mutations O 0 3.110120587734855e-07
have O 0 1.3349609417900865e-08
been O 0 7.011805536194515e-08
found O 0 7.361580145470725e-08
to O 0 2.3051882624969267e-09
occur O 0 5.164489391695781e-10
in O 0 2.8425597986547757e-10
the O 0 2.2924607989693868e-08
C O 0 9.764060814632103e-05
- O 0 4.089875073987059e-05
terminal O 0 4.5326572717385716e-07
half O 0 1.4803179793076993e-09
of O 0 4.885892801453906e-10
PAX6 O 0 1.8820815057551954e-06
in O 0 2.2019568390874156e-08
patients O 0 9.914117526932387e-09
with O 0 9.044316584549961e-08
Aniridia B-Disease 1 0.9987742304801941
resulting O 0 5.3156028911871545e-08
in O 0 1.3333621984301658e-09
mutant O 0 8.697006137481367e-08
proteins O 0 7.170662397193439e-10
that O 0 9.038583215215112e-10
retain O 0 4.776727347000076e-10
the O 0 2.0083632534806384e-09
DNA O 0 2.330104734937777e-06
- O 0 1.1688788617902901e-05
binding O 0 1.9931684747120926e-08
domains O 0 8.358084002679789e-09
but O 0 1.7514024008846718e-08
have O 0 9.212042684225707e-09
lost O 0 1.244108460696225e-07
most O 0 1.7799714827071433e-11
of O 0 7.087996856114387e-11
the O 0 1.0120922766532203e-08
transactivation O 0 3.4211632282676874e-06
domain O 0 3.820543881261074e-08
. O 0 2.1060493793356727e-07

It O 0 4.0765516473584285e-07
is O 0 1.1578316083671325e-08
not O 0 4.983655155221811e-10
clear O 0 6.182192535675313e-10
whether O 0 1.5728618407706563e-10
such O 0 2.573357672785992e-11
mutants O 0 5.39192114956677e-07
really O 0 4.59443931788428e-08
behave O 0 3.622594890728692e-09
as O 0 4.838874634316426e-09
loss O 0 8.50794640427921e-06
- O 0 1.867932041932363e-06
of O 0 1.915750447167852e-09
- O 0 3.904965524270665e-06
function O 0 6.80326683877297e-10
mutants O 0 1.105451801208801e-07
as O 0 3.6805618552904207e-09
predicted O 0 1.6706570704627666e-06
by O 0 4.829214717005925e-08
haploinsufficiency O 0 0.00014355016173794866
. O 0 4.3651334635796957e-07

Contrary O 0 9.481424285695539e-07
to O 0 1.2945500671435184e-08
this O 0 3.365055178949916e-10
theory O 0 1.7702290744381344e-09
, O 0 1.0878454803631143e-09
our O 0 4.6437803602472627e-10
data O 0 2.705205837116864e-08
showed O 0 8.044272021834331e-07
that O 0 1.0833955954581143e-09
these O 0 1.5149941023917535e-10
mutants O 0 1.3123585063112841e-07
are O 0 1.0628679880664293e-10
dominant O 0 7.914741928516378e-08
- O 0 8.515432273270562e-05
negative O 0 5.439600769818753e-09
in O 0 6.094303950376911e-10
transient O 0 9.33477473097355e-09
transfection O 0 2.843975835276069e-06
assays O 0 9.151259661166478e-08
when O 0 1.908097146952059e-08
they O 0 6.004480246346589e-10
are O 0 1.973981117453505e-10
coexpressed O 0 1.8760907778414548e-06
with O 0 3.2835227870009476e-08
wild O 0 1.2535293762994115e-06
- O 0 0.003349888836964965
type O 0 6.820781436545076e-06
PAX6 O 0 0.00013104654499329627
. O 0 9.651772643337608e-07

We O 0 4.179329096132278e-07
found O 0 2.711177558012423e-07
that O 0 3.5088230099233897e-09
the O 0 3.818167115809956e-09
dominant O 0 8.880139716893609e-07
- O 0 0.009763602167367935
negative O 0 1.024912066327488e-07
effects O 0 4.418749455226134e-08
result O 0 1.3519076969004118e-09
from O 0 6.02185246112441e-11
the O 0 3.9927627176750136e-11
enhanced O 0 3.186366948071395e-09
DNA O 0 2.51740175372106e-07
binding O 0 9.600299222256581e-09
ability O 0 7.859630168915999e-10
of O 0 6.070958319392972e-11
these O 0 1.347310263355439e-09
mutants O 0 1.7676053403192782e-06
. O 0 2.2799420662522607e-07

Kinetic O 0 5.1572978918557055e-06
studies O 0 1.2795929649200843e-07
of O 0 1.2278190686387802e-09
binding O 0 1.2857140063715633e-07
and O 0 4.224550878006994e-07
dissociation O 0 1.107971797864593e-06
revealed O 0 2.8437730748009926e-07
that O 0 7.135485952103338e-11
various O 0 1.3585929256598739e-12
truncation O 0 3.3148918276992845e-08
mutants O 0 3.0999282785160176e-07
have O 0 2.3448682995308445e-09
3 O 0 1.540427341240047e-08
- O 0 2.663772647792939e-05
5 O 0 9.762576524963151e-08
- O 0 6.9956267907400616e-06
fold O 0 7.090386588970432e-08
higher O 0 1.5168706568591261e-10
affinity O 0 2.6901578187299435e-10
to O 0 1.1873301820897186e-11
various O 0 2.452256279983356e-12
DNA O 0 2.320685723589122e-07
- O 0 5.892089802728151e-07
binding O 0 2.6082174198194252e-09
sites O 0 7.915252453472021e-09
when O 0 2.857168546199773e-08
compared O 0 1.1020094170532957e-08
with O 0 3.35616506808023e-10
the O 0 7.954162661860664e-09
wild O 0 8.695261612956529e-07
- O 0 0.001410102006047964
type O 0 3.704980372276623e-06
PAX6 O 0 0.00010716669203247875
. O 0 5.178333708499849e-07

These O 0 7.325512996203543e-08
results O 0 3.3245921571278814e-08
provide O 0 8.164802861587717e-11
a O 0 1.0071504741304693e-09
new O 0 3.256136027474099e-09
insight O 0 1.2111264879877126e-08
into O 0 1.3000270304708295e-10
the O 0 2.722439496061213e-10
role O 0 3.0778815607312993e-10
of O 0 4.223615623910604e-10
mutant O 0 2.663990017026663e-06
PAX6 O 0 1.9332410374772735e-05
in O 0 1.5739743730591726e-07
causing O 0 3.6320008803159e-05
aniridia B-Disease 1 0.9975430965423584
. O 0 2.387481856658269e-07
. O 0 4.2861901761170884e-07

Reversal O 0 0.002743710530921817
of O 0 0.0001240170531673357
severe O 1 0.9885045886039734
hypertrophic B-Disease 1 0.9997460246086121
cardiomyopathy I-Disease 1 0.9999701976776123
and O 0 2.7358120860299096e-05
excellent O 0 6.907561669322604e-07
neuropsychologic O 0 6.884147296659648e-05
outcome O 0 2.201291806613881e-07
in O 0 1.2649961078636807e-08
very B-Disease 0 5.111253642553493e-08
- I-Disease 0 0.022416671738028526
long I-Disease 0 0.00023123444407247007
- I-Disease 0 0.006069332826882601
chain I-Disease 0 0.0002722659264691174
acyl I-Disease 0 1.148155774899351e-07
- I-Disease 0 6.1696810007561e-06
coenzyme I-Disease 0 8.885724156471042e-08
A I-Disease 0 4.149794676777674e-06
dehydrogenase I-Disease 0 0.001478360267356038
deficiency I-Disease 0 0.0010970336152240634
. O 0 1.8952719926801365e-07

Very B-Disease 0 4.870345492236083e-06
- I-Disease 0 0.006923337001353502
long I-Disease 0 0.00023000485089141876
- I-Disease 0 0.0019083722727373242
chain I-Disease 0 0.0002648424415383488
acyl I-Disease 0 4.470035150916374e-07
- I-Disease 0 5.773241355200298e-06
coenzyme I-Disease 0 3.575362583774222e-08
A I-Disease 0 5.97152450154681e-07
dehydrogenase I-Disease 0 1.4091162483964581e-05
( I-Disease 0 8.189208244857582e-08
VLCAD I-Disease 0 0.033364180475473404
) I-Disease 0 2.1608957467833534e-05
deficiency I-Disease 0 0.004234807565808296
is O 0 2.420379097145542e-08
a O 0 3.212344836356351e-06
disorder O 0 0.0033346714917570353
of O 0 4.249850604765015e-08
fatty O 0 4.5002374804425926e-07
acid O 0 1.560834661518129e-08
beta O 0 5.127369084867439e-10
oxidation O 0 2.385704966911817e-09
that O 0 2.0298420722042465e-08
reportedly O 0 5.777360911451979e-06
has O 0 1.2484811406920926e-07
high O 0 8.182663577827043e-07
rates O 0 1.0418764873065811e-07
of O 0 5.260088808967112e-09
morbidity O 0 0.0005196935380809009
and O 0 1.983185484277783e-06
mortality O 0 1.1902763617399614e-05
. O 0 5.516498617907928e-07

We O 0 6.406705921335742e-08
describe O 0 7.506699262194161e-09
the O 0 1.2895319256855942e-09
outcome O 0 6.283205511437018e-09
of O 0 1.1996849347273297e-10
a O 0 5.848911133199408e-09
5 O 0 8.29842363714306e-08
- O 0 0.0005068728351034224
year O 0 7.044183689686179e-07
- O 0 0.0003093126288149506
old O 0 0.002402855549007654
girl O 0 0.012667985633015633
with O 0 0.006637813989073038
VLCAD B-Disease 1 0.9999974966049194
deficiency I-Disease 1 0.9999873638153076
who O 0 7.261340897457558e-07
was O 0 5.788406838291849e-07
first O 0 7.0356622750011866e-09
seen O 0 1.1165088409370583e-07
at O 0 1.8860204420434457e-07
5 O 0 1.6920028045319668e-08
months O 0 6.46782609692309e-08
of O 0 5.512346579195082e-09
age O 0 4.792081654159119e-06
with O 0 0.002110593719407916
severe O 1 0.8719913959503174
hypertrophic B-Disease 1 0.9999144077301025
cardiomyopathy I-Disease 1 0.9999933242797852
, O 1 0.5044069290161133
hepatomegaly B-Disease 1 0.9999762773513794
, O 0 0.07741831988096237
encephalopathy B-Disease 1 0.979570746421814
, O 0 1.6447245343442773e-06
and O 0 1.6840293028508313e-05
hypotonia B-Disease 0 0.04292561113834381
. O 0 4.890018317382783e-06

Biochemical O 0 0.0010573233012109995
studies O 0 0.0004658216785173863
indicated O 1 0.979296863079071
VLCAD B-Disease 1 0.9999836683273315
deficiency I-Disease 1 0.9999891519546509
caused O 0 5.121938738739118e-05
by O 0 2.3709539220817533e-08
a O 0 9.928503175160586e-08
stable O 0 1.7256713817914715e-06
yet O 0 2.452733660618378e-08
inactive O 0 5.126327806692643e-08
enzyme O 0 1.46260163091938e-07
. O 0 2.8159811904515664e-07

Molecular O 0 6.705398845952004e-05
genetic O 0 2.441750439174939e-05
analysis O 0 4.3176285657864355e-07
of O 0 8.893473335547242e-08
her O 0 0.00016645918367430568
VLCAD O 0 0.021248802542686462
gene O 0 1.2378695828374475e-06
revealed O 0 4.026999886264093e-05
a O 0 6.910645424795803e-07
T1372C O 0 2.0722152839880437e-05
( O 0 1.5918317330942955e-08
F458L O 0 6.430339567486953e-07
) O 0 2.075656801991954e-08
missense O 0 3.0303516496132943e-07
mutation O 0 4.247484497454934e-08
and O 0 1.293400515578469e-07
a O 0 1.8497952396501205e-06
1668 O 0 0.09592648595571518
ACAG O 0 0.01798771694302559
1669 O 0 7.267684122780338e-05
splice O 0 5.810651055071503e-05
site O 0 4.858751708525233e-06
mutation O 0 3.30140835558268e-07
. O 0 3.7447122736011806e-07

After O 0 1.0279470188834239e-05
initial O 0 3.522558813529031e-07
treatment O 0 2.097460622962899e-07
with O 0 5.443984107955657e-08
intravenous O 0 7.800375669830828e-07
glucose O 0 8.417242497671396e-06
and O 0 4.439878864559432e-07
carnitine O 0 2.6377867925475584e-06
, O 0 1.042635400239078e-08
the O 0 2.1763975066591e-09
patient O 0 3.284355898358626e-08
has O 0 5.325324892169192e-08
thrived O 0 7.195851026153832e-08
on O 0 6.873313651567514e-08
a O 0 9.404547540725616e-08
low O 0 6.75650608172873e-06
- O 0 0.00041079334914684296
fat O 0 9.605870587847676e-08
diet O 0 7.093221010556761e-10
supplemented O 0 1.2803798299376723e-10
with O 0 2.9100983844898565e-09
medium O 0 4.846118599743932e-07
- O 0 2.885095454985276e-05
chain O 0 1.2688627975876443e-05
triglyceride O 0 3.05009649537169e-07
oil O 0 7.111270861059893e-08
and O 0 1.1498560326117513e-08
carnitine O 0 1.8222618791696732e-07
and O 0 2.8509177241176076e-09
avoidance O 0 3.584013938962016e-07
of O 0 4.584379098560021e-09
fasting O 0 9.613602287572576e-07
. O 0 8.769096382366115e-08

Her O 0 0.00038197520188987255
ventricular O 0 0.0066379364579916
hypertrophy O 0 0.0006051957607269287
resolved O 0 1.6966133671303396e-06
significantly O 0 7.70582531117725e-08
over O 0 4.538574671641982e-08
1 O 0 3.619067712179458e-08
year O 0 6.71753923597862e-08
, O 0 2.0134196532239912e-08
and O 0 2.3162525053521676e-07
cognitively O 0 0.0002274563448736444
, O 0 4.985077453056874e-07
she O 0 6.9481279751926195e-06
is O 0 3.228997735860162e-09
in O 0 4.6332790382130895e-10
the O 0 4.537490383427212e-09
superior O 0 7.50985236663837e-07
range O 0 2.670407752702886e-07
for O 0 1.2623881495699152e-08
age O 0 4.6508677087331307e-07
. O 0 1.5218255100535316e-07

Clinical O 0 5.749790489062434e-06
recognition O 0 3.296894874438294e-06
of O 0 0.0003847992920782417
VLCAD B-Disease 1 0.9999911785125732
deficiency I-Disease 1 0.999988317489624
is O 0 2.5139181047961756e-07
important O 0 3.799214276511975e-09
because O 0 8.295097941868335e-09
it O 0 8.196783696234888e-09
is O 0 2.801957776910058e-09
one O 0 1.1188443505005807e-09
of O 0 1.398342691638632e-10
the O 0 1.3140360799468453e-08
few O 0 5.233131972204319e-08
directly O 0 9.527979614176729e-07
treatable O 0 0.04572102427482605
causes O 0 4.204733613732969e-06
of O 0 4.011063720099628e-05
cardiomyopathy B-Disease 1 0.9999916553497314
in O 0 2.495092758181272e-06
children O 0 7.703634992139996e-07
. O 0 1.193718901504326e-07
. O 0 7.4798322202696e-07

Cloning O 0 1.3913590919401031e-05
of O 0 2.295164591714638e-08
a O 0 7.707074445306716e-08
novel O 0 4.466625469490282e-08
member O 0 2.151561706575933e-10
of O 0 3.476903487342753e-10
the O 0 9.54594483459914e-08
low O 0 1.0740965080913156e-05
- O 0 0.0004380904429126531
density O 0 3.9806334939385124e-07
lipoprotein O 0 2.633779149618931e-05
receptor O 0 1.3321418634859583e-07
family O 0 6.457818926719483e-06
. O 0 4.3598291199486994e-07

A O 0 3.2194554933084873e-07
gene O 0 2.6343165870912344e-08
encoding O 0 2.9675870649725766e-08
a O 0 2.2018271295110026e-07
novel O 0 9.108645713240549e-07
transmembrane O 0 1.1215624908800237e-06
protein O 0 2.5826796701267085e-08
was O 0 4.902747718915634e-07
identified O 0 2.3787256608898133e-09
by O 0 1.2893001943847793e-10
DNA O 0 4.23300754448519e-08
sequence O 0 7.525848833012105e-10
analysis O 0 2.1983832809713277e-10
within O 0 1.6596349294850654e-11
the O 0 1.7615803926673834e-08
insulin B-Disease 0 0.0004094610922038555
- I-Disease 1 0.9877814054489136
dependent I-Disease 0 0.395230233669281
diabetes I-Disease 1 0.9999929666519165
mellitus I-Disease 1 0.9999755620956421
( O 0 6.706720228066843e-07
IDDM B-Disease 0 0.010549170896410942
) O 0 1.8188138994901237e-07
locus O 0 5.492332547873957e-06
IDDM4 O 0 0.0005077069508843124
on O 0 2.2154996258905157e-05
chromosome O 0 0.0009936372516676784
11q13 O 0 3.705367271322757e-05
. O 0 1.0750799219749752e-06

Based O 0 2.338675102464549e-07
on O 0 1.6809174496756896e-07
its O 0 3.749621768633915e-08
chromosomal O 0 3.6418608942767605e-05
position O 0 7.070587457747024e-07
, O 0 2.0297411751357686e-08
this O 0 3.009996418779082e-10
gene O 0 1.6421669579713694e-09
is O 0 1.5373300410459478e-09
a O 0 2.8085229697438763e-09
candidate O 0 2.237847462893683e-09
for O 0 4.659573282772556e-10
conferring O 0 2.6253514988638926e-06
susceptibility O 0 1.4547001228493173e-05
to O 0 4.241107490088325e-06
diabetes B-Disease 0 0.08769871294498444
. O 0 2.5108611225732602e-06

The O 0 1.1202802596699257e-07
gene O 0 1.9559976749405905e-07
, O 0 6.889536052767653e-08
termed O 0 1.7756087800080422e-06
low O 0 7.45877923691296e-06
- O 0 0.0002297103201271966
density O 0 6.90693013893906e-08
lipoprotein O 0 2.375765006945585e-06
receptor O 0 6.962373344521211e-09
related O 0 1.9238182602521192e-08
protein O 0 1.3546806343356366e-08
5 O 0 5.003060721264774e-08
( O 0 2.863954406961966e-09
LRP5 O 0 3.9408823795383796e-05
) O 0 3.047431196279149e-09
, O 0 1.5010498399803396e-10
encodes O 0 4.0493039477063064e-10
a O 0 1.617133094100609e-09
protein O 0 1.7207298919075242e-09
of O 0 5.053040208480297e-10
1615 O 0 1.422091031599848e-06
amino O 0 5.295388572079673e-10
acids O 0 1.4243831808480323e-11
that O 0 3.181220217807201e-11
contains O 0 6.8985303580682e-12
conserved O 0 1.644846342463424e-10
modules O 0 5.687915916041675e-08
which O 0 8.016517227815712e-09
are O 0 2.568498191912738e-11
characteristic O 0 5.232687616540943e-10
of O 0 2.367919194057322e-10
the O 0 1.0172328757107607e-07
low O 0 3.9591817767359316e-05
- O 0 0.059618595987558365
density O 0 5.0730141083477065e-06
lipoprotein O 0 0.001108042779378593
( O 0 2.4643396656642835e-08
LDL O 0 1.4233422007237095e-05
) O 0 7.285907877019326e-09
receptor O 0 3.7209527903314665e-08
family O 0 2.1900505089433864e-06
. O 0 3.3463538784417324e-07

These O 0 1.2446337294136356e-08
modules O 0 1.7592610390693153e-07
include O 0 6.880783720575323e-10
a O 0 7.212897501496229e-10
putative O 0 5.4595503229393216e-08
signal O 0 5.279097337052008e-08
peptide O 0 3.472385268210587e-09
for O 0 4.14687000016567e-11
protein O 0 6.505530558698069e-10
export O 0 2.2182142789262116e-09
, O 0 1.3300017753792304e-09
four O 0 2.3693717210448995e-08
epidermal O 0 4.0144768718164414e-05
growth O 0 1.6075244957391988e-07
factor O 0 5.377356337987749e-09
( O 0 2.6194232893850256e-10
EGF O 0 3.5920655250265554e-07
) O 0 2.076400384964927e-09
repeats O 0 4.3214555489612394e-08
with O 0 1.7117779194109062e-08
associated O 0 1.0369301151058608e-07
spacer O 0 1.2860374226875138e-05
domains O 0 5.780596268323279e-08
, O 0 3.365822465184465e-08
three O 0 9.202071282743418e-08
LDL O 0 7.073365122778341e-05
- O 0 0.0002522792783565819
receptor O 0 1.0866167343692723e-07
( O 0 4.7635646538424226e-09
LDLR O 0 3.69143599527888e-05
) O 0 8.085465630358613e-09
repeats O 0 1.9597320033426513e-07
, O 0 2.358459205709096e-09
a O 0 1.6914696310266208e-09
single O 0 1.2266283100359487e-08
transmembrane O 0 1.4849698004582024e-07
spanning O 0 7.106985577820524e-08
domain O 0 3.4195831943861776e-08
, O 0 3.4954183547597495e-08
and O 0 1.1744732297813698e-08
a O 0 2.3150372285840604e-08
cytoplasmic O 0 1.5834973510209238e-06
domain O 0 1.4030038641976716e-07
. O 0 4.7045597284522955e-07

The O 0 1.0401167926943344e-08
encoded O 0 2.0977420689405335e-08
protein O 0 6.497302251773363e-08
has O 0 1.5738805814180523e-08
a O 0 9.272661527504056e-10
unique O 0 3.411937399278031e-10
organization O 0 5.120713297834811e-10
of O 0 2.7824234027917782e-09
EGF O 0 1.9761548173846677e-05
and O 0 3.1059323646331904e-07
LDLR O 0 4.4675231038127095e-05
repeats O 0 1.0445451152918395e-06
; O 0 2.9385727184916277e-09
therefore O 0 1.580663822053907e-09
, O 0 6.346103020860028e-08
LRP5 O 0 0.0003163008950650692
likely O 0 6.172324873432444e-08
represents O 0 2.6022431431904636e-10
a O 0 4.6339593273714286e-10
new O 0 1.2553193151632058e-08
category O 0 3.973275042312707e-08
of O 0 2.7008117964300027e-09
the O 0 6.079710033191077e-07
LDLR O 0 0.12110984325408936
family O 0 3.734399797394872e-05
. O 0 1.073378257387958e-06

Both O 0 8.271781126722999e-08
human O 0 9.630490183099027e-08
and O 0 3.1380491805066413e-07
mouse O 0 0.00026642048032954335
LRP5 O 0 0.0016836693976074457
cDNAs O 0 9.992380910262e-06
have O 0 1.8916995969675554e-08
been O 0 3.237361312358189e-08
isolated O 0 2.7928149393119384e-07
and O 0 4.763909711158476e-09
the O 0 6.139841413066449e-10
encoded O 0 1.696319196220486e-09
mature O 0 3.5262532893653997e-09
proteins O 0 2.430948498055585e-10
are O 0 3.5921383922943306e-11
95 O 0 3.2438374208965115e-09
% O 0 1.4961286654013861e-09
identical O 0 1.3980687754155952e-06
, O 0 6.74675106893119e-08
indicating O 0 5.305321906234894e-07
a O 0 5.23137551056152e-08
high O 0 1.016493570205057e-06
degree O 0 5.330809571546524e-09
of O 0 4.351989602024986e-10
evolutionary O 0 8.064337464475102e-08
conservation O 0 8.948940255493198e-09
. O 0 7.81733877630586e-09
. O 0 9.132654810173335e-08

The O 0 6.906165594955382e-08
APC B-Disease 0 2.3711904759693425e-06
variants O 0 2.404633505648235e-07
I1307K O 0 2.7166852305526845e-06
and O 0 1.1008817324409392e-07
E1317Q O 0 8.353272846761683e-07
are O 0 1.1618091377840756e-08
associated O 0 4.967725089954911e-06
with O 1 0.8429755568504333
colorectal B-Disease 1 0.9999998807907104
tumors I-Disease 1 0.9999997615814209
, O 0 6.694499461445957e-05
but O 0 1.551959201151476e-07
not O 0 7.003742474864794e-09
always O 0 1.7915752437147603e-08
with O 0 1.6279159353871364e-08
a O 0 6.388145834534953e-07
family O 0 4.081731822225265e-05
history O 0 1.584320557412866e-06
. O 0 1.4926796438885503e-06

Classical O 0 0.14184853434562683
familial B-Disease 1 0.9994921684265137
adenomatous I-Disease 1 0.9989571571350098
polyposis I-Disease 1 0.999839186668396
( O 0 0.00014346340321935713
FAP B-Disease 0 0.0007850825786590576
) O 0 6.591757255591801e-07
is O 0 8.157732622748881e-08
a O 0 5.038907033849682e-07
high O 0 0.00352114369161427
- O 1 0.9869376420974731
penetrance O 1 0.6017307639122009
autosomal B-Disease 1 0.9156641364097595
dominant I-Disease 1 0.5520076155662537
disease I-Disease 0 0.02989095076918602
that O 0 7.96278811776574e-08
predisposes O 0 1.284273366763955e-06
to O 0 3.3751295092088185e-09
hundreds O 0 1.3074336280283205e-08
or O 0 6.936237895160957e-08
thousands O 0 1.532175133434066e-07
of O 0 0.0001888772239908576
colorectal B-Disease 1 0.9999995231628418
adenomas I-Disease 1 0.9999951124191284
and I-Disease 1 0.9057233929634094
carcinoma I-Disease 1 0.9999979734420776
and O 0 7.868826651247218e-05
that O 0 8.970251315076894e-07
results O 0 2.3181351593848376e-07
from O 0 8.292723840952476e-09
truncating O 0 1.4943118458177196e-06
mutations O 0 4.395037578319716e-08
in O 0 1.4958376759466319e-09
the O 0 2.150677858026029e-08
APC B-Disease 0 4.098112913197838e-05
gene O 0 1.2305121117606177e-06
. O 0 6.433394901250722e-07

A O 0 2.893316604968277e-06
variant O 0 1.480993796576513e-05
of O 0 1.980357069442107e-07
FAP B-Disease 0 0.0004533079918473959
is O 0 8.67251401359681e-06
attenuated B-Disease 1 0.5892659425735474
adenomatous I-Disease 1 0.9999029636383057
polyposis I-Disease 1 0.9998432397842407
coli I-Disease 1 0.9998860359191895
, O 0 5.721739853470353e-06
which O 0 4.363514847227634e-07
results O 0 3.8071885910540004e-07
from O 0 3.2846692477050965e-08
germ O 0 0.004570646211504936
- O 0 0.005221873987466097
line O 0 1.9027937014470808e-05
mutations O 0 1.2725027254134602e-08
in O 0 7.069691498884367e-10
the O 0 3.5942873122252195e-09
5 O 0 2.3428935236324833e-08
and O 0 2.0781605769570888e-08
3 O 0 9.514403487287382e-09
regions O 0 1.023349877060653e-10
of O 0 8.788406807846982e-11
the O 0 1.657982728886509e-08
APC B-Disease 0 7.416172138619004e-06
gene O 0 2.5717773155520263e-07
. O 0 5.247305239208799e-07

Attenuated B-Disease 1 0.9868301749229431
adenomatous I-Disease 1 0.9987230896949768
polyposis I-Disease 1 0.9991415739059448
coli I-Disease 1 0.9996654987335205
patients O 0 0.00013061986828688532
have O 0 6.85206828165974e-07
" O 0 6.447336886594712e-07
multiple O 0 8.016150241019204e-05
" O 1 0.9781413674354553
colorectal B-Disease 1 0.9999990463256836
adenomas I-Disease 1 0.9999850988388062
( O 0 1.6095124522053084e-07
typically O 0 4.444994150532011e-09
fewer O 0 1.702937929559667e-10
than O 0 2.353564565460431e-10
100 O 0 6.641946992402836e-09
) O 0 4.593131652796956e-09
without O 0 4.49777409761154e-10
the O 0 1.3079499261436922e-08
florid O 0 0.0002754568704403937
phenotype O 0 6.235160071810242e-06
of O 0 6.327523838223215e-09
classical O 0 1.1679255749186268e-06
FAP B-Disease 0 2.241262154711876e-05
. O 0 4.865448204327549e-07

Another O 0 6.27359213467571e-07
group O 0 9.103364959628379e-07
of O 0 9.906216291710734e-09
patients O 0 1.4195631337088344e-08
with O 0 3.0041093168620137e-08
multiple O 0 7.319685664697317e-06
adenomas B-Disease 0 0.09571172297000885
has O 0 2.67836776401964e-06
no O 0 3.86486398440411e-08
mutations O 0 2.1243044656671373e-08
in O 0 3.37530314808987e-09
the O 0 1.9746270396581167e-08
APC B-Disease 0 4.469047325983411e-06
gene O 0 6.276632547042027e-08
, O 0 1.2237001634218814e-08
and O 0 3.763821698754555e-09
their O 0 1.2475118715826738e-08
phenotype O 0 1.1626202649495099e-06
probably O 0 1.0168546538125156e-07
results O 0 5.444562578560408e-09
from O 0 2.8646413019473016e-10
variation O 0 4.6877626225239055e-09
at O 0 1.8687160263652913e-06
a O 0 1.709634886992717e-07
locus O 0 3.1818794923310634e-06
, O 0 5.109372480660568e-08
or O 0 1.5952998921875405e-08
loci O 0 8.976086540712913e-09
, O 0 1.0187237720060693e-08
elsewhere O 0 1.5287364707461393e-09
in O 0 1.2898222490065336e-09
the O 0 2.76154601408507e-08
genome O 0 2.645707581905299e-06
. O 0 8.02701435986819e-07

Recently O 0 0.00012333481572568417
, O 0 2.3403795523790905e-07
however O 0 1.569539875845294e-08
, O 0 6.360699189578156e-10
a O 0 9.008550017064465e-10
missense O 0 4.637960770992322e-08
variant O 0 2.872315576496476e-07
of O 0 2.685874278540723e-08
APC B-Disease 0 0.0002451389445923269
( O 0 1.2559707940340559e-08
I1307K O 0 2.5488816390861757e-07
) O 0 7.77009656616201e-09
was O 0 1.3294034033606295e-06
described O 0 6.355381287903583e-07
that O 0 4.7961479232583315e-09
confers O 0 2.0567405556448648e-08
an O 0 2.9957192282381584e-09
increased O 0 6.018497344939533e-08
risk O 0 1.6746624851293745e-06
of O 0 0.0026152280624955893
colorectal B-Disease 1 0.9999998807907104
tumors I-Disease 1 0.9999998807907104
, O 0 9.92786772258114e-06
including O 0 3.408331039622681e-08
multiple O 0 8.7230382632697e-06
adenomas B-Disease 0 0.16849537193775177
, O 0 1.0812883601829526e-06
in O 0 4.3422812723292736e-07
Ashkenazim O 0 0.000602179323323071
. O 0 4.994121809431817e-06

We O 0 5.420762931862555e-07
have O 0 4.587738189343327e-09
studied O 0 1.863042164984563e-09
a O 0 6.482739345337052e-10
set O 0 7.635638787917287e-09
of O 0 1.6354839704746382e-09
164 O 0 2.044181019300595e-05
patients O 0 2.7722961704057525e-08
with O 0 9.712593964650296e-07
multiple O 1 0.6702601909637451
colorectal B-Disease 1 0.9999995231628418
adenomas I-Disease 1 0.9999892711639404
and I-Disease 0 0.00769016845151782
/ I-Disease 0 0.00404364662244916
or I-Disease 0 0.0006298672524280846
carcinoma I-Disease 1 0.9999892711639404
and O 0 2.5886229195748456e-06
analyzed O 0 6.665414389317448e-07
codons O 0 1.4403352111003187e-07
1263 O 0 3.398055923753418e-05
- O 0 0.00017626328917685896
1377 O 0 7.590823224745691e-05
( O 0 8.183609900846989e-10
exon O 0 5.697188498743344e-08
15G O 0 1.1757445150806234e-07
) O 0 8.175981003333277e-10
of O 0 3.419362362699907e-11
the O 0 2.072586102741525e-09
APC B-Disease 0 3.853308498946717e-07
gene O 0 3.4632374745768857e-09
for O 0 2.0545594114906862e-09
germ O 0 0.0015793796628713608
- O 0 0.000111608904262539
line O 0 7.618528343300568e-06
variants O 0 4.57379627505361e-07
. O 0 4.084482156940794e-07

Three O 0 1.39793280595768e-06
patients O 0 9.356311636565806e-08
with O 0 5.027930516376955e-09
the O 0 9.65334567837317e-09
I1307K O 0 7.251776992234227e-07
allele O 0 2.658211428752111e-07
were O 0 1.5627864513589884e-07
detected O 0 1.8043637339815177e-07
, O 0 1.8822654546113426e-09
each O 0 2.9458872841114925e-11
of O 0 3.4502292134419577e-09
Ashkenazi O 0 0.0003236094780731946
descent O 0 0.0004640917759388685
. O 0 3.298071078461362e-06

Four O 0 5.6077878980431706e-06
patients O 0 9.171370152216696e-07
had O 0 1.375942360937188e-06
a O 0 1.7923721884471888e-07
germ O 0 0.006676076911389828
- O 0 0.0024846342857927084
line O 0 1.0767630556074437e-05
E1317Q O 0 4.934490220875887e-07
missense O 0 6.701017696286726e-08
variant O 0 1.36722007937351e-07
of O 0 2.2289965428967662e-08
APC O 0 1.8373180864728056e-05
that O 0 3.1475954642701254e-07
was O 0 6.499621576949721e-06
not O 0 1.8751489250234954e-09
present O 0 8.759209468856e-10
in O 0 3.4438385476676103e-09
controls O 0 1.7379691996666224e-07
; O 0 1.5460723812310562e-09
one O 0 6.454189960258816e-10
of O 0 3.4403704884944375e-10
these O 0 3.2589133613925014e-09
individuals O 0 8.716111721263076e-10
had O 0 4.231789034747635e-07
an O 0 6.968006172058949e-09
unusually O 0 1.6665183011355111e-07
large O 0 1.2016549977289515e-09
number O 0 3.9491315773076963e-10
of O 0 4.279997867229213e-08
metaplastic B-Disease 0 0.043687306344509125
polyps I-Disease 0 0.0003608608094509691
of I-Disease 0 3.864796038755003e-09
the I-Disease 0 3.9131532503233757e-07
colorectum I-Disease 0 0.0006069228402338922
. O 0 1.3935268725617789e-06

There O 0 1.7367233340337407e-07
is O 0 8.90835760714026e-09
increasing O 0 6.93091528614076e-10
evidence O 0 7.18792003695512e-09
that O 0 2.758859585227924e-09
there O 0 2.743729132781425e-10
exist O 0 9.83769288254166e-10
germ O 0 7.182223635027185e-05
- O 0 4.6198489144444466e-05
line O 0 6.464606485678814e-07
variants O 0 2.7784088363347337e-09
of O 0 1.7252083095442572e-10
the O 0 1.503722124596152e-08
APC B-Disease 0 1.7644205172473448e-06
gene O 0 2.9081578034606537e-08
that O 0 4.100628103742565e-08
predispose O 0 2.2154418743980386e-08
to O 0 1.8961264502959096e-10
the O 0 7.398933132840568e-10
development O 0 9.800441569396412e-10
of O 0 1.6476361608397383e-08
multiple O 0 0.2284875512123108
colorectal B-Disease 1 0.9999995231628418
adenomas I-Disease 1 0.9999942779541016
and I-Disease 1 0.9447147846221924
carcinoma I-Disease 1 0.9999977350234985
, O 0 3.822803591901902e-06
but O 0 2.775280094624577e-08
without O 0 2.926606734732218e-10
the O 0 4.0926093625159865e-09
florid O 0 1.4355030543811154e-05
phenotype O 0 4.4176039182275417e-07
of O 0 7.973099402924788e-10
classical O 0 9.530826616810373e-08
FAP B-Disease 0 6.669089316346799e-07
, O 0 3.660995062659822e-08
and O 0 7.292122461421968e-09
possibly O 0 4.0239984677725715e-09
with O 0 2.563879997197205e-09
importance O 0 9.064159911531533e-08
for O 0 0.027760963886976242
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999973773956299
risk O 0 2.4076723548205337e-06
in O 0 1.1996283966198007e-09
the O 0 1.0132121808226202e-09
general O 0 7.101451093838307e-10
population O 0 5.69041702647155e-10
. O 0 8.948940255493198e-09
. O 0 1.6544262848583458e-07

Genomic O 0 5.904480985918781e-06
structure O 0 7.298929176613456e-07
of O 0 8.16891230215333e-08
the O 0 9.559056707075797e-06
human O 0 0.05391549691557884
congenital B-Disease 1 0.9999748468399048
chloride I-Disease 1 0.9998767375946045
diarrhea I-Disease 1 0.9999897480010986
( O 0 1.0317368833057117e-05
CLD B-Disease 0 0.04583611711859703
) O 0 1.5861407121064985e-07
gene O 0 2.931115830051567e-07
. O 0 8.808883080746455e-07

Congenital B-Disease 1 0.9994520545005798
chloride I-Disease 1 0.9987316727638245
diarrhea I-Disease 1 0.9999200105667114
( O 0 0.0001849634718382731
CLD B-Disease 1 0.7891973853111267
) O 0 1.5585443179588765e-05
is O 0 1.4310483038570965e-06
caused O 0 1.474575014981383e-06
by O 0 7.867223317248317e-09
mutations O 0 3.130292114406075e-08
in O 0 1.0668581573725078e-08
a O 0 7.348575792320844e-08
gene O 0 7.183591321791027e-08
which O 0 2.4352761585078042e-08
encodes O 0 1.0776815884128155e-07
an O 0 1.3445508102449821e-06
intestinal O 0 0.08885114639997482
anion O 0 8.019254164537415e-05
transporter O 0 0.031409986317157745
. O 0 5.238842732069315e-06

We O 0 6.605160365324991e-07
report O 0 1.1866781335356791e-07
here O 0 2.2036152902416006e-09
the O 0 2.1920107395878574e-10
complete O 0 1.6590859797105395e-09
genomic O 0 1.0231088864998128e-08
organization O 0 2.1619778189929661e-10
of O 0 2.9048730088021557e-10
the O 0 1.4548494853272587e-08
human O 0 7.367296461779915e-08
CLD B-Disease 0 5.5040170991560444e-05
gene O 0 5.674133163324768e-08
which O 0 4.8036024935527166e-08
spans O 0 2.1613826106658962e-07
approximately O 0 5.737238684133672e-09
39kb O 0 2.9353835998335853e-05
, O 0 2.1765647062466087e-08
and O 0 2.649908736884754e-08
comprises O 0 3.9832435128062116e-09
21 O 0 1.2868267162957636e-07
exons O 0 3.9812362047086935e-06
. O 0 7.426254455822345e-07

All O 0 9.661104627411987e-08
exon O 0 1.5127142432902474e-05
/ O 0 9.582505299476907e-06
intron O 0 3.3332136808894575e-05
boundaries O 0 3.2338562050426845e-08
conform O 0 4.2315221548960835e-08
to O 0 2.3234982826636497e-09
the O 0 7.456699790964194e-08
GT O 0 0.0005282640922814608
/ O 0 7.18030787538737e-05
AG O 1 0.8204187750816345
rule O 0 1.2575212622323306e-06
. O 0 3.3357085271745746e-07

An O 0 4.766020822444261e-08
analysis O 0 1.5346971693475098e-08
of O 0 5.758328258664847e-10
the O 0 3.5095930606132697e-09
putative O 0 6.678802151327545e-07
promoter O 0 8.518741196894553e-07
region O 0 7.463152873476986e-10
sequence O 0 2.413029220882379e-10
shows O 0 9.771812692349613e-09
a O 0 2.2124604370787893e-08
putative O 0 1.0969304639729671e-05
TATA O 0 0.06072092428803444
box O 0 6.549567478941754e-05
and O 0 1.9284091479221388e-07
predicts O 0 5.972036660750746e-07
multiple O 0 1.9948447338435926e-09
transcription O 0 1.401583027416109e-08
factor O 0 1.8201971041520437e-09
binding O 0 2.8771769411406467e-09
sites O 0 9.5998267113373e-08
. O 0 3.358916274009971e-07

The O 0 6.89484735971746e-08
genomic O 0 1.059658643498551e-06
structure O 0 9.345891953671526e-07
was O 0 2.342479092476424e-06
determined O 0 1.5392409125070117e-08
using O 0 7.018194358998642e-10
DNA O 0 1.094921572075691e-06
from O 0 1.327047249866098e-09
several O 0 1.653663733724997e-10
sources O 0 3.855737673585935e-10
including O 0 1.2423839734765352e-10
multiple O 0 2.2376736907858685e-08
large O 0 1.2809617544462526e-07
- O 0 0.0013500063214451075
insert O 0 1.000897646008525e-05
libaries O 0 1.3683886209037155e-05
and O 0 1.5563546895691616e-08
genomic O 0 5.327803620502891e-08
DNA O 0 7.743698006379418e-06
from O 0 6.309520728109419e-08
Finnish O 0 0.00023417623015120625
CLD B-Disease 0 0.022765742614865303
patients O 0 1.2328820275797625e-07
and O 0 2.8502995519374963e-08
controls O 0 2.1166417809581617e-06
. O 0 4.436306539901125e-07

Exon O 0 5.278595199342817e-05
- O 0 1.555350718263071e-05
specific O 0 1.2707563890046458e-08
primers O 0 9.593686627340503e-06
developed O 0 7.260426286848087e-07
in O 0 1.581801711836306e-08
this O 0 4.822030552631418e-10
study O 0 2.5266103098608994e-10
will O 0 2.71997806222668e-11
facilitate O 0 9.389742455789829e-12
mutation O 0 5.834980276731017e-10
screening O 0 3.0299105446829344e-09
studies O 0 4.232076911137028e-09
of O 0 1.7057670831377436e-09
patients O 0 1.0699658936630385e-08
with O 0 1.035708550034542e-07
the O 0 6.9280531533877365e-06
disease O 0 0.0004213241918478161
. O 0 9.258369573217351e-07

Genomic O 0 7.331354936468415e-07
sequencing O 0 3.1901512898002693e-07
of O 0 4.234604222830285e-09
a O 0 6.847235312079647e-08
BAC O 0 4.662485935114091e-06
clone O 0 0.010042285546660423
H O 1 0.9998997449874878
_ O 0 1.6677854546287563e-06
RG364P16 O 0 3.054518060707778e-07
revealed O 0 5.461669161377358e-07
the O 0 4.954776033905262e-10
presence O 0 2.3282219208109467e-10
of O 0 1.0131034205995704e-10
another O 0 2.5506570189293143e-09
, O 0 7.708493843239239e-10
highly O 0 9.37788111055049e-11
homologous O 0 4.365393380112437e-09
gene O 0 1.6897186982944845e-09
3 O 0 1.4494311306734176e-09
of O 0 1.6017191739603476e-10
the O 0 6.240450289851651e-08
CLD B-Disease 0 9.012693772092462e-05
gene O 0 3.502833223478774e-08
, O 0 3.801468473341174e-09
with O 0 5.219001897316389e-10
a O 0 2.801332499302589e-09
similar O 0 6.937876051438252e-09
genomic O 0 6.056406220977806e-08
structure O 0 1.399018145775699e-07
, O 0 4.5583632868329005e-08
recently O 0 4.506559037054103e-07
identified O 0 3.11742240910462e-08
as O 0 3.55724871781149e-08
the O 0 0.0018179925391450524
Pendred B-Disease 1 0.999995231628418
syndrome I-Disease 1 0.9999946355819702
gene O 0 1.783377410902176e-05
( O 0 4.791797891812166e-08
PDS B-Disease 0 8.626356429886073e-05
) O 0 4.703420586338325e-08
. O 0 4.595710123567187e-08
. O 0 4.219232039304188e-07

The O 0 3.282546572336287e-07
APCI1307K O 0 0.0007585598505102098
allele O 0 7.768026989651844e-05
and O 0 0.0005561211728490889
cancer B-Disease 0 0.027410829439759254
risk O 0 1.1754792694773641e-06
in O 0 8.768457071539615e-09
a O 0 1.0038278475121842e-07
community O 0 1.635250690412704e-08
- O 0 1.4137896869215183e-05
based O 0 4.2139397748997e-08
study O 0 2.0029731206960832e-09
of O 0 3.575511220432759e-09
Ashkenazi O 0 3.4297456295462325e-05
Jews O 0 6.208283025443961e-07
. O 0 7.577477276754507e-07

Mutations O 0 0.00010080922220367938
in O 0 2.1458322407852393e-06
APC O 0 0.00022659223759546876
are O 0 1.9136486173465528e-07
classically O 0 0.002320242114365101
associated O 0 2.2409434677683748e-05
with O 0 0.0019629267044365406
familial B-Disease 1 0.9999797344207764
adenomatous I-Disease 1 0.9999287128448486
polyposis I-Disease 1 0.9999767541885376
( O 0 1.9690553017426282e-05
FAP B-Disease 0 0.00022599913063459098
) O 0 2.4553835942242586e-07
, O 0 3.557390826358642e-08
a O 0 1.333663419700315e-07
highly O 0 1.5143481505219825e-05
penetrant O 1 0.83204585313797
autosomal B-Disease 1 0.9999929666519165
dominant I-Disease 1 0.9998770952224731
disorder I-Disease 1 0.9999966621398926
characterized O 0 0.006296725012362003
by O 0 3.758504362849635e-06
multiple O 0 0.004185945261269808
intestinal O 1 0.9998691082000732
polyps B-Disease 1 0.9724568128585815
and O 0 7.783562068652827e-06
, O 0 1.017392037283571e-07
without O 0 5.7895639393734655e-09
surgical O 0 2.3286031591851497e-06
intervention O 0 9.28628054452929e-08
, O 0 2.7001731961462383e-09
the O 0 3.813305227140518e-09
development O 0 2.6386774720776884e-07
of O 0 0.005485322326421738
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999933242797852
( O 0 2.0392114947753726e-06
CRC B-Disease 0 0.0002291293058078736
) O 0 2.2517087927553803e-07
. O 0 2.7923300649490557e-07

APC B-Disease 0 0.001307163736782968
is O 0 1.394250034536526e-06
a O 0 1.3039519217272755e-05
tumour O 1 0.9999468326568604
- O 0 0.026980821043252945
suppressor O 0 4.535304105957039e-05
gene O 0 5.433444627556128e-08
, O 0 1.836196261706391e-08
and O 0 1.0531584493378432e-08
somatic O 0 7.649124427189236e-07
loss O 0 0.0043747578747570515
occurs O 0 8.917556897358736e-07
in O 0 6.280108209466562e-06
tumours B-Disease 1 0.9999352693557739
. O 0 2.247741213068366e-05

The O 0 1.0732256896517356e-06
germline O 0 0.00030020365375094116
T O 0 0.04317741468548775
- O 0 0.00013686045713257045
to O 0 8.553178076908807e-08
- O 0 3.622291478677653e-05
A O 0 3.259773393438081e-07
transversion O 0 3.831545200227993e-06
responsible O 0 9.150116775380468e-10
for O 0 2.6826292923165518e-11
the O 0 8.517045402278711e-10
APC O 0 8.172138166173681e-08
I1307K O 0 1.4856215146963336e-09
allele O 0 2.34604391469162e-10
converts O 0 2.1324213228535172e-10
the O 0 9.907497044991942e-10
wild O 0 7.03899374343564e-08
- O 0 2.146433871530462e-06
type O 0 3.269079673628994e-09
sequence O 0 7.540274515882572e-10
to O 0 4.063348324478966e-09
a O 0 2.660915242813644e-06
homopolymer O 1 0.9012242555618286
tract O 0 0.3554651141166687
( O 0 2.3811016092167847e-07
A8 O 1 0.8979942798614502
) O 0 1.1814363887197032e-07
that O 0 4.7062918895335315e-08
is O 0 8.02068029770453e-08
genetically O 0 6.676938028249424e-06
unstable O 0 0.014433098025619984
and O 0 3.080191845583613e-06
prone O 0 0.00011000152881024405
to O 0 7.462359619125891e-09
somatic O 0 4.7643030143262877e-07
mutation O 0 1.019343699226738e-06
. O 0 8.548103096472914e-07

The O 0 1.0602534672443653e-07
I1307K O 0 2.69720976575627e-06
allele O 0 2.970713012473425e-06
was O 0 2.5835530323092826e-05
found O 0 9.590728495822987e-07
in O 0 6.71724436074328e-08
6 O 0 2.2510139388032258e-06
. O 0 2.995441263919929e-07

1 O 0 8.120193797367392e-07
% O 0 1.76768608639577e-08
of O 0 1.2310105157453677e-09
unselected O 0 5.034189143771073e-06
Ashkenazi O 0 1.6181562386918813e-05
Jews O 0 1.4531111958149268e-07
and O 0 1.0751336532166533e-07
higher O 0 4.046427903858785e-08
proportions O 0 9.981250315149737e-08
of O 0 5.780218081952171e-09
Ashkenazim O 0 8.483116835122928e-05
with O 0 2.392789156147046e-06
family O 0 0.00028261172701604664
or O 0 9.57023416958691e-07
personal O 0 4.6485183702316135e-06
histories O 0 1.1046588497265475e-06
of O 0 1.3857170699793642e-07
CRC B-Disease 0 0.0008201258606277406
( O 0 1.0619005230694256e-08
ref O 0 3.730377648025751e-05
. O 0 1.4829468319987882e-08
2 O 0 1.317711024739765e-07
) O 0 3.857948271956957e-08
. O 0 1.8026885584276897e-07

To O 0 1.325123033524278e-08
evaluate O 0 7.087327613675143e-09
the O 0 4.611528658937658e-10
role O 0 1.5090252381000369e-09
of O 0 1.5422610966098205e-09
I1307K O 0 1.1325137165840715e-06
in O 0 4.895599090559699e-07
cancer B-Disease 0 3.466058478807099e-05
, O 0 8.22367152153447e-09
we O 0 2.689040767833717e-09
genotyped O 0 6.067795084163663e-07
5 O 0 3.010416804727356e-09
, O 0 2.2281367861864965e-09
081 O 0 2.6579729706099897e-07
Ashkenazi O 0 6.275494683904981e-07
volunteers O 0 1.5932100083659861e-09
in O 0 1.4923438040881365e-09
a O 0 2.727603565233494e-08
community O 0 3.1914044740233294e-08
survey O 0 1.2338269925749046e-06
. O 0 1.637857991454439e-07

Risk O 0 1.6844551282702014e-05
of O 0 1.8195599693626718e-07
developing O 0 6.53956230962649e-05
colorectal B-Disease 1 0.9999691247940063
, I-Disease 0 0.0002697027812246233
breast I-Disease 0 0.02202470973134041
and I-Disease 0 1.5472966197194182e-06
other I-Disease 0 1.2643995717098733e-07
cancers I-Disease 0 0.001371082616969943
were O 0 2.3205551258342894e-07
compared O 0 3.032149891168956e-07
between O 0 4.13990584036128e-08
genotyped O 0 7.136495696613565e-05
I1307K O 0 6.940227308405156e-07
carriers O 0 3.516972668649032e-08
and O 0 1.97869880480539e-08
non O 0 3.014433369585845e-09
- O 0 1.757444624672644e-05
carriers O 0 1.3971071410878722e-08
and O 0 2.615844874043205e-09
their O 0 6.524592532919371e-10
first O 0 1.6144772629900217e-08
- O 0 7.149355224100873e-05
degree O 0 1.2856429520979873e-07
relatives O 0 6.082012760089128e-07
. O 0 1.2623019074453623e-07

Sperm O 0 2.252079502795823e-05
DNA O 0 1.2830604646296706e-05
analysis O 0 2.2220525863758667e-07
in O 0 3.7601353142235894e-08
a O 0 1.1504788517413544e-06
Friedreich B-Disease 0 0.08107578754425049
ataxia I-Disease 1 0.656871497631073
premutation O 0 0.0198849868029356
carrier O 0 4.1867595427902415e-05
suggests O 0 1.3633439266413916e-07
both O 0 2.0125008326488114e-09
meiotic O 0 1.045962289936142e-05
and O 0 3.810108495372333e-08
mitotic O 0 5.597507879429031e-06
expansion O 0 5.004463687896532e-08
in O 0 3.5933276354427335e-09
the O 0 1.961807072348165e-08
FRDA B-Disease 0 0.00022283427824731916
gene O 0 2.0985831383768527e-07
. O 0 2.508295438019559e-07

Friedreich B-Disease 1 0.9790284037590027
ataxia I-Disease 1 0.9974710941314697
is O 0 0.00011060716497013345
usually O 0 6.426007985282922e-06
caused O 0 8.085343097263831e-07
by O 0 1.2408309935096895e-09
an O 0 3.2671971794684396e-09
expansion O 0 2.2812507438629837e-08
of O 0 1.665827142893761e-09
a O 0 1.8086328168465116e-07
GAA O 0 2.1484702301677316e-05
trinucleotide O 0 9.11789175006561e-06
repeat O 0 9.763508046489733e-08
in O 0 2.0819919122061492e-09
intron O 0 4.327871010900708e-06
1 O 0 5.05797936867225e-09
of O 0 4.14905582113434e-10
the O 0 8.598585310437556e-08
FRDA B-Disease 0 0.0009286192944273353
gene O 0 5.237326377027784e-07
. O 0 4.958619683748111e-07

Occasionally O 0 5.32548392584431e-06
, O 0 6.349856107590313e-08
a O 0 1.897719315024915e-09
fully O 0 1.2483418743158836e-09
expanded O 0 2.9446586835568667e-10
allele O 0 1.9614259372247034e-07
has O 0 1.872391237611737e-07
been O 0 1.1401032651292553e-07
found O 0 9.99980969140779e-08
to O 0 5.0058073242098544e-09
arise O 0 3.746853494135394e-09
from O 0 1.3774723028880942e-10
a O 0 8.827053754600911e-09
premutation O 0 4.011726105090929e-06
of O 0 4.0104491949577437e-10
100 O 0 6.1014833185879525e-09
or O 0 1.2501248036755896e-08
less O 0 8.756924962938228e-09
triplet O 0 0.00024158103042282164
repeats O 0 5.877913281437941e-05
. O 0 1.506187004451931e-06

We O 0 2.9316024097170157e-07
have O 0 1.342186273234347e-08
examined O 0 8.189770284161568e-08
the O 0 8.453348243619985e-09
sperm O 0 1.3023397968936479e-06
DNA O 0 9.392265383212361e-07
of O 0 3.5109855023307546e-09
a O 0 5.661797217726416e-07
premutation O 0 0.0015372539637610316
carrier O 0 5.7689267123350874e-05
. O 0 1.1009947229467798e-06

This O 0 3.5767268258268814e-08
mans O 0 3.0507208066410385e-06
leucocyte O 0 5.243381019681692e-05
DNA O 0 2.6446696210769005e-05
showed O 0 2.445410245854873e-06
one O 0 6.192377721703224e-10
normal O 0 1.018742645797488e-09
allele O 0 1.9829643704838418e-08
and O 0 4.407258114014212e-09
one O 0 8.71117511458408e-10
allele O 0 9.475123796676144e-09
of O 0 9.712305959475032e-11
approximately O 0 4.745153714402761e-10
100 O 0 5.7197566682987144e-09
repeats O 0 2.2805779735790566e-06
. O 0 5.135174774295592e-07

His O 0 6.660065992036834e-06
sperm O 0 2.7821766707347706e-05
showed O 0 2.716094513743883e-06
an O 0 5.155297300163397e-10
expanded O 0 1.9155714792162826e-09
allele O 0 8.72568435283938e-08
in O 0 5.610752751294967e-09
a O 0 2.4098993023358162e-08
tight O 0 4.623771928891074e-06
range O 0 3.414264782009013e-08
centering O 0 3.1392488608616986e-08
on O 0 2.391189184436371e-07
a O 0 1.440516061990138e-08
size O 0 1.490855794372692e-07
of O 0 1.4345901133694383e-09
approximately O 0 7.01853286599885e-09
320 O 0 3.40015702704477e-07
trinucleotide O 0 4.474328670767136e-05
repeats O 0 9.131448678090237e-06
. O 0 4.897270855508395e-07

His O 0 1.701254404906649e-05
affected O 0 1.4375073078554124e-06
son O 0 0.00010158768418477848
has O 0 1.3077259097826754e-07
repeat O 0 3.052791157642787e-07
sizes O 0 1.7396830642724126e-08
of O 0 1.8289112446723266e-09
1040 O 0 1.584301753609907e-05
and O 0 9.743524742589216e-07
540 O 0 2.9998951504239812e-05
. O 0 1.3206125686338055e-06

These O 0 1.5140598108587255e-08
data O 0 5.291769511472921e-08
suggest O 0 8.423283404113135e-09
that O 0 1.1439840186255879e-09
expansion O 0 6.853438261344991e-09
occurs O 0 1.3333087967026813e-09
in O 0 1.6836311511614355e-10
two O 0 8.368963300142696e-09
stages O 0 3.3330817927890166e-07
, O 0 3.556364980283888e-09
the O 0 1.485941092393972e-10
first O 0 5.010963310958516e-10
during O 0 2.8846829369655325e-09
meiosis O 0 3.7238196970434956e-09
followed O 0 4.830547961631737e-09
by O 0 2.425372402914405e-10
a O 0 2.8423283726652926e-09
second O 0 1.7627694148814044e-07
mitotic O 0 0.00013129593571648002
expansion O 0 3.1150620998232625e-06
. O 0 5.618433078780072e-07

We O 0 4.5541312942987133e-07
also O 0 4.904131856164895e-08
show O 0 5.975294925519847e-08
that O 0 4.587455693094711e-10
in O 0 7.203902058217082e-11
all O 0 9.76935806557e-12
informative O 0 1.2744677313492048e-08
carrier O 0 2.6282473299943376e-06
father O 0 4.841249960918503e-07
to O 0 2.7986837292104383e-09
affected O 0 7.678470081984301e-10
child O 0 4.087524629881045e-08
transmissions O 0 1.0140380481971079e-06
, O 0 5.9139186880941e-09
with O 0 2.3353881051235703e-09
the O 0 2.7293767246305833e-09
notable O 0 1.3761967121439511e-09
exception O 0 1.7991755307811275e-10
of O 0 9.123310440450894e-11
the O 0 1.0513341308637791e-08
premutation O 0 5.1015045755775645e-05
carrier O 0 5.407870276030735e-07
, O 0 4.996190128281341e-10
the O 0 1.7114823447350602e-10
expansion O 0 5.535737201967095e-09
size O 0 2.5889292487590865e-07
decreases O 0 4.3490235412946276e-08
. O 0 3.872588028031032e-09
. O 0 1.819702220018371e-07

The O 0 1.3849984270564164e-07
R496H O 0 3.0136986879369942e-06
mutation O 0 3.143515527881391e-07
of O 0 1.653939740720034e-08
arylsulfatase O 0 0.0002635821292642504
A O 0 1.3979914683659445e-06
does O 0 5.10130959696653e-08
not O 0 1.5537570163814962e-07
cause O 0 1.8832122805179097e-05
metachromatic B-Disease 1 0.999322772026062
leukodystrophy I-Disease 1 0.999254047870636
. O 0 4.876849925494753e-05

Deficiency B-Disease 1 0.9777681231498718
of I-Disease 0 1.4510482060359209e-06
arylsulfatase I-Disease 0 0.014064916409552097
A I-Disease 0 4.3568947148742154e-05
( O 0 1.1793251815106487e-06
ARSA O 0 0.046290323138237
) O 0 7.050885386661321e-08
enzyme O 0 3.8906625832169084e-07
activity O 0 4.276083473087056e-06
causes O 0 0.00011471538164187223
metachromatic B-Disease 1 0.9998610019683838
leukodystrophy I-Disease 1 0.9998862743377686
( O 0 1.538979086035397e-05
MLD B-Disease 1 0.9994854927062988
) O 0 1.3994867913424969e-06
. O 0 9.093491257772257e-07

A O 0 3.309068006274174e-07
number O 0 2.328218728919751e-09
of O 0 2.045867475430896e-08
ARSA O 0 0.01206667535007
gene O 0 1.7265423934986757e-07
mutations O 0 1.2728212084311963e-07
responsible O 0 4.3174512853738634e-08
for O 0 1.7788023853881896e-07
MLD B-Disease 1 0.999901294708252
have O 0 7.265594348382365e-08
been O 0 2.0521427757103083e-07
identified O 0 8.544769229956728e-07
. O 0 2.570580761585006e-07

Recently O 0 2.548700649640523e-05
, O 0 4.836709166511355e-08
the O 0 2.458760750556621e-09
R496H O 0 1.9479371360375808e-07
mutation O 0 1.195747678650605e-08
of O 0 1.15860920857358e-08
ARSA O 0 0.0801830142736435
was O 0 6.579568889719667e-06
proposed O 0 3.808638737723413e-09
to O 0 7.855389116961931e-10
be O 0 1.265328397614951e-09
a O 0 5.3956672019239704e-08
cause O 0 2.3787457337220985e-07
of O 0 1.9027407915928052e-07
MLD B-Disease 1 0.9999114274978638
( O 0 3.100386081200668e-08
Draghia O 0 1.1835913028335199e-05
et O 0 7.498733339161845e-06
al O 0 1.5442448784597218e-05
. O 0 2.6741735936752775e-08
, O 0 4.146749432720753e-08
1997 O 0 5.894270316275652e-07
) O 0 1.933625526362448e-08
. O 0 5.7295537203572167e-08

We O 0 2.324320149682535e-07
have O 0 4.551697685428735e-09
investigated O 0 3.7317278156479006e-08
the O 0 6.301135613284714e-09
R496H O 0 5.44603949492739e-07
mutation O 0 3.330431397330358e-08
and O 0 5.408113423754912e-08
found O 0 1.4677044646305148e-07
this O 0 7.031700777204719e-10
mutation O 0 5.154946247643011e-09
at O 0 1.3873277282527852e-07
a O 0 6.184602163727959e-09
relatively O 0 5.9662963458606555e-09
high O 0 6.358109061466166e-08
frequency O 0 4.3208125077853765e-08
in O 0 3.2760769652639965e-09
an O 0 5.025581728546058e-09
African O 0 1.2405998006670416e-08
American O 0 5.215713727579896e-08
population O 0 3.4173691654260097e-10
( O 0 1.0170182057622768e-10
f O 0 1.4362558431457728e-07
= O 0 3.248742785899594e-08
0 O 0 1.442697766806944e-10
. O 0 2.487424433095242e-10
09 O 0 1.419709327876717e-08
, O 0 1.8977202032033347e-08
n O 0 1.244244231202174e-06
= O 0 9.865244692264241e-07
61 O 0 8.277620366925476e-08
subjects O 0 2.3724558317894662e-08
) O 0 1.4154210248307209e-08
. O 0 1.2650315284190583e-07

The O 0 5.336194135452388e-07
ARSA O 0 0.0014032364124432206
enzyme O 0 2.9153954983485164e-07
activity O 0 1.2613945443717967e-07
in O 0 3.4285612127149534e-09
subjects O 0 7.039393956631557e-09
with O 0 1.3229662698677203e-08
and O 0 4.59166251687293e-08
without O 0 8.478874269357561e-10
the O 0 2.520234243519326e-09
R496H O 0 2.802205756324838e-07
mutation O 0 9.74634950523523e-09
was O 0 2.1225400814728346e-06
determined O 0 1.6487246057295124e-07
and O 0 2.8709674637639182e-08
found O 0 2.8391438533503788e-08
to O 0 1.0672788208765382e-09
be O 0 2.645483387908598e-09
normal O 0 1.6746204423156996e-08
. O 0 2.0265407840724947e-07

It O 0 1.0800763448060025e-06
is O 0 3.5701155809420015e-08
therefore O 0 1.2541556682066357e-09
concluded O 0 2.4878684001805595e-08
that O 0 7.78788256106111e-10
the O 0 1.3826058076205072e-09
R496H O 0 2.922836870311585e-07
mutation O 0 1.7353418257926023e-08
of O 0 2.0654047361290395e-08
ARSA O 0 0.022350266575813293
does O 0 3.4788354419390544e-09
not O 0 1.0038973125015005e-10
negatively O 0 1.0474959788453475e-10
influence O 0 3.746856644393226e-11
the O 0 2.3568030860232625e-10
activity O 0 1.2782655822718425e-08
of O 0 6.49884945858048e-09
ARSA O 0 0.07311397045850754
and O 0 1.8451019911935873e-07
is O 0 6.182738765403428e-09
not O 0 1.9080923507885927e-09
a O 0 8.66015881229032e-08
cause O 0 9.370998554913967e-07
of O 0 4.411673216964118e-06
MLD B-Disease 1 0.9992683529853821

Down O 0 0.0019456354202702641
- O 0 5.4673360864399e-05
regulation O 0 5.884453102567022e-08
of O 0 5.790282031625793e-09
transmembrane O 0 6.042946552042849e-07
carbonic O 0 5.217693797021639e-07
anhydrases O 0 6.675756594631821e-05
in O 0 7.765372060930531e-07
renal B-Disease 1 0.8232502341270447
cell I-Disease 1 0.924005389213562
carcinoma I-Disease 1 0.999992847442627
cell O 0 0.021504370495676994
lines O 0 5.980865353194531e-06
by O 0 1.3056410352874082e-07
wild O 0 1.5232588339131325e-05
- O 1 0.5327687859535217
type O 0 0.0005113263032399118
von B-Disease 1 0.9978145360946655
Hippel I-Disease 1 0.9899416565895081
- I-Disease 1 0.9329378604888916
Lindau I-Disease 1 0.8077227473258972
transgenes O 0 0.0007925844402052462
. O 0 5.579642220254755e-06

To O 0 7.399433599175609e-08
discover O 0 3.931493210984627e-07
genes O 0 7.678268687527634e-09
involved O 0 4.114361829010704e-08
in O 0 1.1825269439214026e-06
von B-Disease 1 0.9955175518989563
Hippel I-Disease 1 0.9954491257667542
- I-Disease 1 0.9993950128555298
Lindau I-Disease 1 0.9861002564430237
( O 0 4.08377729854692e-07
VHL B-Disease 0 0.0001459345076000318
) O 0 5.3347690709415474e-08
- O 0 1.6302223230013624e-05
mediated O 0 0.00016379203589167446
carcinogenesis O 0 0.005197722464799881
, O 0 1.072426201176313e-07
we O 0 7.716219663223e-09
used O 0 8.220881682063919e-07
renal B-Disease 1 0.5270171761512756
cell I-Disease 1 0.8619992733001709
carcinoma I-Disease 1 0.9999891519546509
cell O 0 0.024429429322481155
lines O 0 4.882638677372597e-05
stably O 0 0.00025978239136748016
transfected O 0 0.00026945347781293094
with O 0 3.40077974669839e-07
wild O 0 2.682077138160821e-05
- O 0 0.38805490732192993
type O 0 0.0003661290684249252
VHL O 0 0.016041982918977737
- O 0 0.003517331089824438
expressing O 0 1.4874163980493904e-06
transgenes O 0 1.559860356792342e-05
. O 0 4.2203831185361196e-07

Large O 0 1.1794780903073843e-06
- O 0 3.22147534461692e-05
scale O 0 1.843613745222683e-06
RNA O 0 2.475677831625944e-07
differential O 0 2.9643624444020134e-08
display O 0 2.70874256358411e-08
technology O 0 7.43907051514725e-08
applied O 0 3.2194147348008073e-10
to O 0 7.123451134516401e-11
these O 0 1.1385978965217092e-10
cell O 0 2.599339495645836e-06
lines O 0 2.4758358563303773e-07
identified O 0 2.2452409709217136e-08
several O 0 2.352563421847975e-10
differentially O 0 7.076632613234324e-08
expressed O 0 3.000717452295021e-09
genes O 0 2.155313039153839e-09
, O 0 1.6889453169355306e-09
including O 0 1.0382902870809119e-10
an O 0 8.881971269580902e-10
alpha O 0 2.393850229154282e-09
carbonic O 0 5.6104529910783185e-09
anhydrase O 0 4.115075924460143e-08
gene O 0 6.109215799909862e-09
, O 0 4.2356568030754715e-08
termed O 0 8.325728231284302e-06
CA12 O 0 0.0008911569020710886
. O 0 9.942297083398444e-07

The O 0 5.5956761002562416e-08
deduced O 0 2.2463852644705185e-07
protein O 0 6.679424124911293e-09
sequence O 0 8.030841769368635e-09
was O 0 1.4779483308302588e-06
classified O 0 4.772151740439767e-08
as O 0 2.460055270603334e-09
a O 0 5.866108665486536e-08
one O 0 1.8097561849117483e-07
- O 0 0.033748526126146317
pass O 0 3.535944642862887e-06
transmembrane O 0 7.629449100932106e-06
CA O 0 8.013980732357595e-07
possessing O 0 3.1329143723723973e-08
an O 0 6.899001370186397e-09
apparently O 0 3.251388989156112e-06
intact O 0 1.5239866968386195e-07
catalytic O 0 6.779539152290681e-09
domain O 0 8.800387640839347e-10
in O 0 3.349814314823618e-10
the O 0 1.8809087620752507e-09
extracellular O 0 1.1714438414855977e-06
CA O 0 1.7434489564038813e-05
module O 0 6.394330557668582e-05
. O 0 4.63703202058241e-07

Reintroduced O 0 4.222521965857595e-05
wild O 0 1.5144390999921598e-05
- O 0 0.001537249656394124
type O 0 4.17676574215875e-06
VHL B-Disease 0 4.474498928175308e-05
strongly O 0 9.476916318362782e-08
inhibited O 0 5.576944417384766e-08
the O 0 4.827404587182116e-10
overexpression O 0 5.103995803779071e-08
of O 0 5.421968429786261e-10
the O 0 2.997509795932274e-08
CA12 O 0 9.699397924123332e-05
gene O 0 9.5607921579699e-09
in O 0 1.6732084606729813e-09
the O 0 5.7013842535980075e-08
parental O 0 1.3938425581727643e-05
renal B-Disease 1 0.9602929353713989
cell I-Disease 1 0.8531838655471802
carcinoma I-Disease 1 0.999980092048645
cell O 0 0.07626363635063171
lines O 0 0.00035922310780733824
. O 0 1.0329478755011223e-05

Similar O 0 6.925476441210776e-07
results O 0 1.3452254279400222e-06
were O 0 1.0241792836040986e-07
obtained O 0 2.0536750966471118e-08
with O 0 1.790045587313216e-07
CA9 O 0 0.000193980144103989
, O 0 4.527134223053508e-09
encoding O 0 4.758207161614791e-09
another O 0 4.0716597027312673e-07
transmembrane O 0 1.4719261343998369e-05
CA O 0 4.6844090206832334e-07
with O 0 6.169450728066295e-09
an O 0 4.630518191106603e-08
intact O 0 3.7631923532899236e-06
catalytic O 0 1.8394516132502758e-07
domain O 0 1.806691756200962e-07
. O 0 6.791383384552319e-07

Although O 0 1.4168666950808984e-07
both O 0 5.319434226436215e-09
domains O 0 7.300750670680145e-09
of O 0 4.0513353782856143e-10
the O 0 9.055463934259933e-09
VHL B-Disease 0 1.1471994184830692e-05
protein O 0 3.1636755437602915e-09
contribute O 0 1.3780312828337582e-11
to O 0 3.5264451081484793e-11
regulation O 0 1.1904494057191073e-09
of O 0 9.5454633086689e-10
CA12 O 0 3.571907291188836e-05
expression O 0 8.949619378917362e-10
, O 0 1.0236588243728306e-09
the O 0 7.301178550633836e-10
elongin O 0 6.289916996138345e-07
binding O 0 4.02663946630355e-09
domain O 0 2.5920215307451144e-08
alone O 0 4.4359595108289795e-07
could O 0 7.754743513999074e-09
effectively O 0 3.110141122419918e-08
regulate O 0 5.263764180085673e-08
CA9 O 0 2.1547282813116908e-05
expression O 0 2.3077056710008037e-08
. O 0 1.2768039425736788e-07

We O 0 7.059672384457372e-07
mapped O 0 4.478964547161013e-05
CA12 O 0 0.0018837577663362026
and O 0 2.1248085886327317e-06
CA9 O 0 4.3863685277756304e-05
loci O 0 2.549558963949039e-08
to O 0 9.834695724464382e-09
chromosome O 0 4.093941697647097e-06
bands O 0 2.1812864758885553e-07
15q22 O 0 2.158308461730485e-06
and O 0 1.8600077567043627e-07
17q21 O 0 5.768948085460579e-06
. O 0 5.443712893793418e-07

2 O 0 2.728134859353304e-06
respectively O 0 6.355471668939572e-07
, O 0 4.889393778739759e-08
regions O 0 5.754312581984777e-09
prone O 0 9.446375770494342e-06
to O 0 6.0713465366291075e-09
amplification O 0 3.8851926547067706e-06
in O 0 9.285320068386227e-09
some O 0 2.4125517139594876e-09
human O 0 1.4977646287661628e-06
cancers B-Disease 0 0.0019585485570132732
. O 0 1.0322114576410968e-06

Additional O 0 2.166905055389634e-08
experiments O 0 1.1142924449814018e-06
are O 0 8.144867558179669e-10
needed O 0 3.591194563945521e-10
to O 0 6.75155625851076e-11
define O 0 2.2215668193936722e-10
the O 0 5.13703080073924e-10
role O 0 3.129269732227158e-09
of O 0 1.3528885567382076e-08
CA O 0 3.6156466194370296e-06
IX O 0 4.272040314390324e-06
and O 0 1.0718612202254008e-06
CA O 0 1.1943582194362534e-06
XII O 0 8.307283110298158e-07
enzymes O 0 2.898830508968331e-09
in O 0 5.567447614041043e-10
the O 0 1.3516576746752662e-09
regulation O 0 8.362628811653394e-09
of O 0 6.937092011938262e-10
pH O 0 5.437408958641754e-07
in O 0 2.8044908062518914e-10
the O 0 4.090898175768132e-10
extracellular O 0 2.856689107488819e-08
microenvironment O 0 5.216853082856687e-07
and O 0 9.693494007478876e-09
its O 0 3.350665744861203e-09
potential O 0 1.0941992201196626e-08
impact O 0 1.92747648952718e-08
on O 0 1.8181726773036644e-05
cancer B-Disease 0 0.000832454941701144
cell O 0 0.00032102217664942145
growth O 0 1.3557231568483985e-06
. O 0 2.406037538094097e-07

A O 0 1.350161795699023e-07
gene O 0 1.1921791553959338e-08
encoding O 0 1.113233683014414e-08
a O 0 5.991260820792377e-08
transmembrane O 0 2.596034960333782e-07
protein O 0 6.489881521076768e-09
is O 0 9.416798452122066e-10
mutated O 0 3.8713196204298583e-08
in O 0 3.0097703529463615e-07
patients O 0 4.699968485510908e-06
with O 0 0.4717281460762024
diabetes B-Disease 1 0.9999973773956299
mellitus I-Disease 1 0.9999954700469971
and O 1 0.7007320523262024
optic B-Disease 1 0.9999862909317017
atrophy I-Disease 1 0.999788224697113
( O 0 0.007004600949585438
Wolfram B-Disease 1 0.9999563694000244
syndrome I-Disease 1 0.9999834299087524
) O 0 1.937862907652743e-05
. O 0 4.620937488652999e-06

Wolfram B-Disease 1 0.9982592463493347
syndrome I-Disease 1 0.9998384714126587
( O 0 0.00033041532151401043
WFS B-Disease 1 0.9247193336486816
; O 0 0.00011355280730640516
OMIM O 0 0.4502446949481964
222300 O 0 0.0030897182878106833
) O 0 1.8005939637077972e-06
is O 0 4.581776806844573e-07
an O 0 9.521733772999141e-06
autosomal B-Disease 1 0.999043881893158
recessive I-Disease 1 0.9999504089355469
neurodegenerative I-Disease 1 0.9999864101409912
disorder I-Disease 1 0.9512364268302917
defined O 0 1.4280392690579902e-07
by O 0 2.0027722769100365e-07
young O 0 1.3742061355515034e-06
- O 0 0.004487080965191126
onset O 0 0.0001133484547608532
non O 0 5.035976187173219e-07
- O 0 0.07551310956478119
immune O 0 0.00015910051297396421
insulin B-Disease 0 0.0002543404116295278
- I-Disease 1 0.9727448225021362
dependent I-Disease 0 0.17286215722560883
diabetes I-Disease 1 0.9999901056289673
mellitus I-Disease 1 0.999964714050293
and O 0 0.000413160101743415
progressive O 0 0.036583010107278824
optic B-Disease 1 0.9997938275337219
atrophy I-Disease 1 0.6430598497390747
. O 0 2.7571795726544224e-05

Linkage O 0 3.81506652047392e-05
to O 0 2.13325790809904e-07
markers O 0 2.9165041269152425e-05
on O 0 1.7451424355385825e-05
chromosome O 0 0.03618714585900307
4p O 1 0.9850876927375793
was O 0 0.0005217648576945066
confirmed O 0 3.1350177778222132e-06
in O 0 1.5510590145595415e-08
five O 0 8.747847601853209e-08
families O 0 3.8488789755319885e-07
. O 0 6.26609391929378e-07

On O 0 1.26880124184936e-07
the O 0 9.521061716810664e-10
basis O 0 1.0132391592421186e-09
of O 0 4.901193229045475e-09
meiotic O 0 0.007600749842822552
recombinants O 1 0.5172258615493774
and O 0 0.0018892904045060277
disease O 0 0.0007771197706460953
- O 0 0.0029389383271336555
associated O 0 6.536070031870622e-07
haplotypes O 0 3.131748826490366e-06
, O 0 4.005514853133718e-08
the O 0 2.515409214254305e-08
WFS B-Disease 0 6.606663373531774e-05
gene O 0 1.6625332222020006e-08
was O 0 4.212911619561055e-07
localized O 0 1.0441319808762728e-08
to O 0 1.415112693692322e-09
a O 0 5.333639663263057e-08
BAC O 0 1.2892126051156083e-06
/ O 0 1.529358996776864e-06
P1 O 0 0.0004107365384697914
contig O 0 5.016764248466643e-07
of O 0 1.6087726636970778e-11
less O 0 4.2747860806713334e-11
than O 0 1.1354923251660765e-10
250 O 0 9.079417218060826e-09
kb O 0 6.037815546733327e-05
. O 0 5.82674488214252e-07

Mutations O 0 2.13723487831885e-05
in O 0 2.2532768184646557e-07
a O 0 4.504268815708201e-07
novel O 0 1.3427876410787576e-06
gene O 0 7.108138220246474e-07
( O 0 2.7533991087125287e-08
WFS1 O 0 3.518880475894548e-05
) O 0 5.200033181829156e-10
encoding O 0 2.3645566060714884e-10
a O 0 8.397793571646162e-09
putative O 0 1.0715893949964084e-06
transmembrane O 0 1.7915587591232907e-07
protein O 0 2.967778023332812e-09
were O 0 1.2173680730143133e-08
found O 0 3.621166655420893e-08
in O 0 1.4499786926691627e-09
all O 0 3.544708415681441e-10
affected O 0 1.3406300514162695e-09
individuals O 0 6.074723363225232e-11
in O 0 3.3421321266047244e-09
six O 0 1.0171490885113599e-06
WFS B-Disease 0 0.006235961802303791
families O 0 1.625180203745913e-07
, O 0 1.2498077239797567e-08
and O 0 1.1705104441261938e-08
these O 0 4.477992143758769e-10
mutations O 0 1.7792409323647007e-08
were O 0 8.610877699766206e-08
associated O 0 4.9829949944069085e-08
with O 0 7.562534420912925e-08
the O 0 9.060691809281707e-06
disease O 0 0.0006904976908117533
phenotype O 0 1.202390376420226e-05
. O 0 1.021736807160778e-06

WFS1 O 0 0.003005277132615447
appears O 0 3.292577503088978e-06
to O 0 4.089378613514327e-09
function O 0 1.8350819752654957e-09
in O 0 2.24641887314192e-08
survival O 0 1.4748457942914683e-05
of O 0 9.465802364161391e-09
islet O 0 0.001191511983051896
beta O 0 3.374345780571275e-08
- O 0 1.4304493561212439e-05
cells O 0 5.292436000559064e-08
and O 0 1.3429313661106335e-08
neurons O 0 1.0729213073545907e-07
. O 0 1.0287523721785874e-08
. O 0 1.5486503457395884e-07

Stable O 0 3.1426241093868157e-06
interaction O 0 1.2501200963299652e-08
between O 0 2.633071005675447e-08
the O 0 4.205803705303879e-09
products O 0 2.9715973681732066e-08
of O 0 1.6866363861112177e-10
the O 0 5.1284889224234576e-08
BRCA1 O 0 8.44934766064398e-05
and O 0 6.82263544149464e-06
BRCA2 O 0 0.00019850043463520706
tumor B-Disease 0 4.46561498392839e-05
suppressor O 0 6.079768581912504e-07
genes O 0 2.784971808722503e-09
in O 0 1.840557373178342e-09
mitotic O 0 4.7081739467103034e-05
and O 0 6.0788755718022e-07
meiotic O 0 0.0005266271764412522
cells O 0 4.741928478324553e-06
. O 0 4.415481100750185e-07

BRCA1 O 0 0.007860246114432812
and O 0 2.9492111934814602e-05
BRCA2 O 0 5.469223469845019e-05
account O 0 3.130166703613213e-08
for O 0 7.161573001290833e-10
most O 0 8.106431081955634e-10
cases O 0 3.876556409210252e-09
of O 0 1.6221870513533077e-09
familial O 0 6.179339834488928e-05
, O 0 6.764918794033292e-07
early O 0 1.2186339972686255e-06
onset O 0 0.00023921518004499376
breast B-Disease 0 0.007957668974995613
and I-Disease 0 0.0006307725561782718
/ I-Disease 0 0.24484378099441528
or I-Disease 1 0.9630751609802246
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999603033065796
and O 0 2.283950806258872e-07
encode O 0 1.8192679362982744e-08
products O 0 1.0437182140776713e-07
that O 0 1.6998040752724819e-09
each O 0 7.841956944920625e-11
interact O 0 1.7839557608922973e-10
with O 0 3.661790870523873e-08
hRAD51 O 0 7.362797623500228e-05
. O 0 1.2380654652588419e-06

Results O 0 1.868247295533365e-06
presented O 0 6.94208779350447e-07
here O 0 4.866635450184731e-08
show O 0 3.225195825962146e-07
that O 0 6.263990570687383e-08
BRCA1 O 0 7.89535897638416e-06
and O 0 1.5106868431757903e-06
BRCA2 O 0 3.079168891417794e-05
coexist O 0 3.094283101745532e-06
in O 0 6.730733748128159e-09
a O 0 3.1597632954571964e-08
biochemical O 0 2.2800604710937478e-06
complex O 0 3.7440267419697193e-07
and O 0 3.289660526206717e-07
colocalize O 0 4.216534216539003e-05
in O 0 2.7091557441849545e-08
subnuclear O 0 1.112013342208229e-05
foci O 0 1.2461144933695323e-06
in O 0 3.690542316192591e-10
somatic O 0 4.498170724787087e-09
cells O 0 1.540797711641062e-08
and O 0 6.93657886685628e-09
on O 0 9.941805956259486e-08
the O 0 7.100465992948557e-09
axial O 0 4.315384671826905e-08
elements O 0 2.7923865442147644e-09
of O 0 4.179398604975404e-09
developing O 0 1.9019859109903337e-07
synaptonemal O 0 5.79309489694424e-05
complexes O 0 2.382660568400752e-06
. O 0 5.710351160814753e-07

Like O 0 3.839735654764809e-06
BRCA1 O 0 0.0001281712466152385
and O 0 2.790929556795163e-06
RAD51 O 0 0.0018137762090191245
, O 0 4.3095863588860084e-07
BRCA2 O 0 2.1848725282325177e-06
relocates O 0 4.7581369244653615e-07
to O 0 3.679560123259762e-08
PCNA O 0 0.00034851153031922877
+ O 0 2.089592356924186e-07
replication O 0 5.916719558740624e-08
sites O 0 8.394414052759203e-09
following O 0 5.758902243968578e-09
exposure O 0 2.241860208584967e-08
of O 0 2.391224995790253e-10
S O 0 6.1986206674191635e-06
phase O 0 1.748505340515294e-08
cells O 0 1.0816453510642532e-08
to O 0 1.284631956366411e-09
hydroxyurea O 0 7.954224656714359e-07
or O 0 1.138682037549188e-07
UV O 0 7.554822786914883e-06
irradiation O 0 7.424866339533764e-07
. O 0 2.0443663117930555e-07

Thus O 0 8.058492539930739e-07
, O 0 4.007002019079664e-07
BRCA1 O 0 1.1290336260572076e-05
and O 0 2.653713124800561e-07
BRCA2 O 0 8.725365319151024e-07
participate O 0 2.694697520677636e-10
, O 0 1.5791068008752518e-08
together O 0 4.3192304843842066e-08
, O 0 9.992942473502353e-09
in O 0 1.9706378751038756e-09
a O 0 4.433413280935383e-08
pathway O 0 4.607567802850099e-07
( O 0 9.75209513143227e-09
s O 0 0.00043941650073975325
) O 0 9.348476659454263e-09
associated O 0 9.768211794991544e-10
with O 0 1.1959837287189856e-10
the O 0 1.22671831026544e-10
activation O 0 1.9828727548798497e-09
of O 0 1.5246596207774132e-09
double O 0 2.0709549062303267e-05
- O 0 0.026727113872766495
strand O 0 0.0014112720964476466
break O 0 4.241141868988052e-05
repair O 0 0.0018967268988490105
and O 0 4.4733610593539197e-07
/ O 0 2.530771041620028e-07
or O 0 1.5622314109009494e-08
homologous O 0 1.9287419661395688e-07
recombination O 0 7.96245876699686e-06
. O 0 1.4355891835293733e-06

Dysfunction O 0 0.015598380006849766
of O 0 7.71494370610526e-08
this O 0 2.1045993392476703e-08
pathway O 0 6.921712838448002e-07
may O 0 2.026546752631475e-07
be O 0 2.3224251688436226e-10
a O 0 3.912529189520342e-10
general O 0 2.4855936753276353e-10
phenomenon O 0 7.174991623060123e-08
in O 0 2.802700960202742e-09
the O 0 2.3839321627860954e-08
majority O 0 2.89747070780777e-09
of O 0 1.0761380675461396e-09
cases O 0 3.813387294826498e-08
of O 0 2.362607744998968e-07
hereditary B-Disease 1 0.7660980224609375
breast I-Disease 1 0.6233037114143372
and I-Disease 0 0.0019399324664846063
/ I-Disease 0 0.11164917796850204
or I-Disease 1 0.901900589466095
ovarian I-Disease 1 0.9999954700469971
cancer I-Disease 1 0.9999310970306396
. O 0 1.9219680780224735e-06
. O 0 3.0115356821625028e-06

A O 0 6.589440090465359e-06
novel O 0 1.8231500007459545e-06
Arg362Ser O 0 9.80814547801856e-06
mutation O 0 4.287760191346024e-08
in O 0 3.030430573147669e-09
the O 0 7.983344652018332e-09
sterol O 0 3.487094727461226e-05
27 O 0 3.7886545669607585e-06
- O 0 0.002665980253368616
hydroxylase O 0 4.863066351390444e-05
gene O 0 6.093519289152027e-08
( O 0 2.9609028562305184e-09
CYP27 O 0 2.786305412882939e-05
) O 0 4.9088928477658555e-09
: O 0 4.6013606119776895e-11
its O 0 6.073637148773514e-10
effects O 0 4.207047599180669e-09
on O 0 2.2330389981561893e-08
pre O 0 1.8638343135535251e-07
- O 0 1.4458333907896304e-07
mRNA O 0 1.0064855893165969e-10
splicing O 0 4.698468281105761e-09
and O 0 3.1343889705937045e-09
enzyme O 0 2.6137501052403422e-09
activity O 0 1.5512540585405077e-08
. O 0 5.5147470590100056e-08

A O 0 3.4486272397771245e-06
novel O 0 1.6662036159686977e-06
C O 0 5.1108763727825135e-06
to O 0 2.458568459928756e-09
A O 0 2.3675376326082187e-08
mutation O 0 5.7756670557296275e-09
in O 0 2.131348875167305e-09
the O 0 9.17773856912163e-09
sterol O 0 2.3018974388833158e-05
27 O 0 5.248233264865121e-06
- O 0 0.00015989619714673609
hydroxylase O 0 2.099754783557728e-05
gene O 0 4.643067796905598e-08
( O 0 4.732619185432441e-09
CYP27 O 0 4.579420419759117e-05
) O 0 6.685350939505952e-09
was O 0 1.0565007357854483e-07
identified O 0 1.012860462168419e-09
by O 0 4.604688158549308e-11
sequencing O 0 1.2313257968799007e-08
amplified O 0 1.8570385691418778e-06
CYP27 O 0 3.7894958950346336e-05
gene O 0 1.5161896627091664e-08
products O 0 6.09355410574608e-08
from O 0 9.045619808745187e-10
a O 0 1.7913841077188408e-08
patient O 0 4.986123371963913e-07
with O 0 0.00010144500265596434
cerebrotendinous B-Disease 1 0.9999654293060303
xanthomatosis I-Disease 1 0.9999309778213501
( O 0 1.1456569382062298e-06
CTX B-Disease 0 0.07390549033880234
) O 0 3.456159731740627e-07
. O 0 2.468056266025087e-07

The O 0 3.856094465959359e-08
mutation O 0 7.501750332039592e-08
changed O 0 6.745926839357708e-08
the O 0 2.5272379744478712e-09
adrenodoxin O 0 1.195690515487513e-06
cofactor O 0 5.801004121508413e-09
binding O 0 6.794037776813866e-09
residue O 0 8.305074317149774e-08
362Arg O 0 4.7057174157316695e-08
to O 0 2.2483037653842075e-09
362Ser O 0 8.918007097236114e-07
( O 0 3.8092326515304364e-10
CGT O 0 1.263490645442289e-07
362Arg O 0 7.629600418113114e-08
to O 0 3.463799025382741e-09
AGT O 0 3.4895545013569063e-06
362Ser O 0 5.193058768782066e-06
) O 0 9.39140498701363e-09
, O 0 3.2891689372149813e-09
and O 0 1.0037988218414284e-08
was O 0 8.248509288932837e-07
responsible O 0 2.4548912236355136e-08
for O 0 8.703377574192928e-08
deficiency O 0 3.204549284419045e-05
in O 0 4.056222024928502e-10
the O 0 3.936604819898548e-09
sterol O 0 2.6119084850506624e-06
27 O 0 4.490013054692099e-07
- O 0 2.5636412829044275e-05
hydroxylase O 0 1.916254177558585e-06
activity O 0 5.165585292843389e-09
, O 0 9.01331120850557e-10
as O 0 1.7973576793561818e-10
confirmed O 0 6.719304668223458e-09
by O 0 4.76375952573882e-11
expression O 0 1.9540327689249182e-11
of O 0 4.788328067384384e-11
mutant O 0 1.5398752495343615e-08
cDNA O 0 2.0557640922902465e-08
into O 0 1.845564234770336e-08
COS O 0 0.00029805561644025147
- O 0 5.783843789686216e-06
1 O 0 1.8144543645348676e-08
cells O 0 4.966247857396411e-08
. O 0 8.828961028939375e-08

Quantitative O 0 2.309142473677639e-06
analysis O 0 1.4242353927329532e-06
showed O 0 1.587246333656367e-05
that O 0 1.0281716811277875e-08
the O 0 2.3741251187203716e-09
expression O 0 1.3477780003157136e-09
of O 0 1.1486870343802025e-09
CYP27 O 0 1.1011103197233751e-05
gene O 0 1.2203268395793998e-09
mRNA O 0 5.008670145301153e-10
in O 0 1.464478871504582e-09
the O 0 1.0410476036781802e-08
patient O 0 1.4577416607153282e-07
represented O 0 2.9650975008621572e-08
52 O 0 1.2285339607842616e-06
. O 0 3.61604577392427e-07

5 O 0 4.784282282344066e-06
% O 0 2.0273965617434442e-08
of O 0 2.4998811354315364e-10
the O 0 1.0264703531603914e-09
normal O 0 1.2464369092413108e-08
level O 0 5.329053465175093e-08
. O 0 2.366387121810476e-07

As O 0 2.3569766582909324e-08
the O 0 1.7052498302305708e-09
mutation O 0 1.0362633418026235e-08
occurred O 0 2.8152125963742947e-08
at O 0 9.49178247111604e-09
the O 0 1.8131277035315918e-10
penultimate O 0 3.166164219692291e-08
nucleotide O 0 4.3629855284166297e-10
of O 0 2.635178186771725e-10
exon O 0 1.947491341525165e-07
6 O 0 2.694854970286542e-07
( O 0 7.907778876159455e-10
- O 0 4.652083021028375e-07
2 O 0 2.5160749039798702e-09
position O 0 9.365266340211065e-10
of O 0 2.0948293100175874e-10
exon O 0 1.0894099489178188e-07
6 O 0 8.837486120683025e-08
- O 0 1.3937241419625934e-05
intron O 0 3.5216806281823665e-05
6 O 0 1.0847779208233987e-07
splice O 0 1.1675875612127129e-05
site O 0 1.8484548718333826e-06
) O 0 2.3615789324082925e-09
of O 0 8.037147336548145e-11
the O 0 3.3624971695900285e-09
gene O 0 2.07374952765349e-08
, O 0 1.4543999782290484e-08
we O 0 9.780982690443807e-10
hypothesized O 0 4.8536459296144585e-09
that O 0 1.747794353690324e-09
the O 0 1.6420644399772755e-08
mutation O 0 2.864683210646035e-07
may O 0 3.0750214818908717e-07
partially O 0 2.540264176786877e-07
affect O 0 4.264134878528836e-11
the O 0 1.9577221788136256e-11
normal O 0 2.6364438410197977e-11
splicing O 0 8.819240338020506e-10
efficiency O 0 2.1549060313930113e-09
in O 0 6.141317454577688e-10
exon O 0 1.2160712969944143e-07
6 O 0 1.9903957593214727e-07
and O 0 1.727271303764155e-08
cause O 0 4.1488579238802004e-10
alternative O 0 2.2472553332097966e-11
splicing O 0 4.090972183234953e-08
elsewhere O 0 1.3915063767910851e-08
, O 0 5.793739710213686e-09
which O 0 7.495482456931768e-09
resulted O 0 1.5544914688803146e-08
in O 0 5.717466056154308e-09
decreased O 0 1.344006932413322e-07
transcript O 0 2.680008265087963e-06
in O 0 1.3772267770661983e-08
the O 0 8.542433249658643e-08
patient O 0 9.87139969765849e-07
. O 0 1.5207039041342796e-06

Transfection O 0 0.0001429017138434574
of O 0 2.370332907730699e-07
constructed O 0 6.949863745830953e-05
minigenes O 0 0.0025371231604367495
, O 0 2.712253319714364e-07
with O 0 1.6342811548497593e-08
or O 0 1.613190647731244e-08
without O 0 1.119078510414262e-10
the O 0 1.2570557927915615e-09
mutation O 0 9.873978079610879e-09
, O 0 2.6937687636063856e-09
into O 0 7.359288289876531e-09
COS O 0 0.000390305562177673
- O 0 5.508262802322861e-06
1 O 0 3.574126994365656e-09
cells O 0 1.7628266624214461e-09
confirmed O 0 1.3806827681150935e-08
that O 0 4.674831632911491e-10
the O 0 1.0443346187827274e-09
mutant O 0 1.2254365628905362e-06
minigene O 0 3.4939192119054496e-05
was O 0 2.4967612262116745e-06
responsible O 0 6.476090219642572e-10
for O 0 8.697121148260045e-12
a O 0 2.0710912151944427e-10
mRNA O 0 4.997696145814245e-10
species O 0 7.14863168660429e-11
alternatively O 0 6.498985793967904e-09
spliced O 0 1.526362211734522e-05
at O 0 1.2103988638045848e-06
an O 0 2.245509556075831e-09
activated O 0 6.1805003781501e-08
cryptic O 0 3.2166690289159305e-07
5 O 0 3.697583128570159e-09
splice O 0 3.0645396691397764e-06
site O 0 8.187159892258933e-07
88 O 0 7.99081334434959e-08
bp O 0 1.2420035773175186e-06
upstream O 0 1.0832722274756179e-08
from O 0 1.2268235038970232e-10
the O 0 1.5296222621863365e-10
3 O 0 4.106057716057876e-09
end O 0 8.349368307847271e-09
of O 0 1.2959279205304597e-09
exon O 0 6.878610747662606e-06
6 O 0 4.127655756747117e-06
. O 0 5.530504836315231e-07

Our O 0 5.158863558563098e-08
data O 0 1.0701397457069106e-07
suggest O 0 2.524469167042298e-08
that O 0 1.699745788563689e-09
the O 0 7.783417466100673e-09
C O 0 7.53892891225405e-07
to O 0 4.682541576706001e-10
A O 0 4.512375362253351e-09
mutation O 0 6.110144612492263e-10
at O 0 1.5965234467785194e-08
the O 0 1.2319777142888455e-10
penultimate O 0 3.064446829625922e-08
nucleotide O 0 5.228397714773791e-10
of O 0 7.391297990322343e-11
exon O 0 7.467232165936366e-08
6 O 0 6.08052772577139e-08
of O 0 3.80564496582636e-10
the O 0 2.0070279660444612e-08
CYP27 O 0 7.951020234031603e-05
gene O 0 6.683362308024243e-09
not O 0 8.325145572918302e-10
only O 0 7.993564143937704e-10
causes O 0 1.3040967417055072e-07
the O 0 3.2441846542496933e-06
deficiency B-Disease 0 0.0008480185060761869
in I-Disease 0 9.568850156682629e-10
the I-Disease 0 4.4624086648070715e-09
sterol I-Disease 0 2.8984202344872756e-06
27 I-Disease 0 6.11101938829961e-07
- I-Disease 0 3.481349995126948e-05
hydroxylase I-Disease 0 3.977153482992435e-06
activity I-Disease 0 1.0337167566376593e-08
, O 0 1.0459773047699628e-09
but O 0 3.0965194852683453e-09
also O 0 2.613517224858697e-08
partially O 0 4.433375409007567e-07
leads O 0 4.908237372092117e-09
to O 0 1.7423180953546336e-10
alternative O 0 8.203813323115483e-11
pre O 0 3.564774075925925e-08
- O 0 5.3668458122047014e-08
mRNA O 0 8.76741179656193e-11
splicing O 0 2.4410691246146143e-09
of O 0 5.438889963405025e-11
the O 0 1.5383302409688326e-09
gene O 0 1.8067882479044783e-07
. O 0 3.9501759374616086e-07

To O 0 2.304565072108744e-08
our O 0 2.3167101570464865e-09
knowledge O 0 1.023752527196109e-09
, O 0 3.5048568491902188e-09
this O 0 7.601105855847834e-11
is O 0 2.496745588054239e-10
the O 0 4.101875505924113e-10
first O 0 1.3086711270204887e-08
report O 0 3.93648633689736e-08
regarding O 0 3.7159278432064013e-10
effects O 0 1.5428849309273573e-09
on O 0 2.2494887730317714e-08
pre O 0 1.6690663073859469e-07
- O 0 6.902386218143874e-08
mRNA O 0 3.1361142849295476e-11
splicing O 0 6.55720422404471e-10
of O 0 2.995779319059366e-11
a O 0 1.3978100898981438e-09
mutation O 0 8.488275082818575e-10
at O 0 6.174621347554421e-08
the O 0 4.989450186343447e-09
- O 0 4.599022213369608e-05
2 O 0 1.180692521529636e-08
position O 0 2.0874315609376026e-09
of O 0 5.903994654277156e-11
a O 0 6.872064695073732e-09
5 O 0 2.0430247715808036e-08
splice O 0 3.9202288462547585e-05
site O 0 1.0485671737114899e-05
. O 0 5.723851472794195e-07

ATM O 0 0.0007459749467670918
germline O 0 0.000129219755763188
mutations O 0 1.3978733477415517e-05
in O 0 3.226818762414041e-06
classical O 0 0.03333037719130516
ataxia B-Disease 1 0.9999895095825195
- I-Disease 1 0.9999856948852539
telangiectasia I-Disease 1 0.9999856948852539
patients O 0 3.789062247960828e-05
in O 0 8.373820747920036e-08
the O 0 1.5466341096725955e-07
Dutch O 0 3.939927773899399e-05
population O 0 3.0511198900740055e-08
. O 0 4.942906457472418e-07

Germline O 0 0.00017252677935175598
mutations O 0 1.5725741832284257e-05
in O 0 7.977274663062417e-08
the O 0 2.888312700122242e-08
ATM O 0 0.00020525589934550226
gene O 0 2.0058307370618422e-07
are O 0 2.9928334810414015e-10
responsible O 0 6.484004000384402e-09
for O 0 8.097445203247844e-08
the O 0 0.0555385984480381
autosomal B-Disease 1 0.9999982118606567
recessive I-Disease 1 0.9999991655349731
disorder I-Disease 1 0.9999997615814209
ataxia B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999924898147583
telangiectasia I-Disease 1 0.9999912977218628
( O 0 0.002355784410610795
A B-Disease 1 0.9999650716781616
- I-Disease 1 0.9999831914901733
T I-Disease 1 0.999980092048645
) O 0 1.4193201423040591e-06
. O 0 5.545239218918141e-07

In O 0 2.0208879902838817e-07
our O 0 9.011079882270678e-09
study O 0 2.405498911173254e-09
, O 0 1.5524135310585052e-09
we O 0 4.747761073176093e-10
have O 0 1.326803528156617e-10
determined O 0 5.67591362798936e-10
the O 0 1.8081994235252807e-10
ATM O 0 3.65676305591478e-06
mutation O 0 2.762129192035445e-09
spectrum O 0 1.2490951384336313e-08
in O 0 3.227741407485496e-09
19 O 0 6.172113131697188e-08
classical O 0 7.300057518477843e-07
A B-Disease 1 0.9998798370361328
- I-Disease 1 0.999993085861206
T I-Disease 1 0.9999978542327881
patients O 0 5.152727311497074e-08
, O 0 1.733366006284598e-09
including O 0 1.6179343975686322e-10
some O 0 3.1810196837733784e-11
immigrant O 0 4.643413120675177e-08
populations O 0 3.040974583257139e-09
, O 0 2.5702602268751207e-09
as O 0 6.030844712512362e-10
well O 0 5.999443164483864e-10
as O 0 5.204865982655349e-10
12 O 0 2.6097597416452345e-09
of O 0 8.003313012316937e-10
Dutch O 0 1.2955845249962294e-06
ethnic O 0 7.937491552922893e-09
origin O 0 3.8190869133813976e-08
. O 0 1.5533807129486377e-07

Both O 0 1.220055168005274e-08
the O 0 4.136833542389695e-09
protein O 0 1.4121583014059524e-08
truncation O 0 2.883953129639849e-06
test O 0 9.079210485651856e-07
( O 0 7.342614294358896e-10
PTT O 0 6.975760697969235e-07
) O 0 8.721449118453961e-10
and O 0 3.7298100719063143e-10
the O 0 1.9051785149493128e-10
restriction O 0 5.508184575120367e-09
endonuclease O 0 3.2443208510812838e-06
fingerprinting O 0 9.083766599360388e-06
( O 0 3.0075919532635e-10
REF O 0 1.988871417779592e-06
) O 0 4.018211111067593e-11
method O 0 5.343977343974515e-11
were O 0 1.712684882804183e-09
used O 0 1.2252954206815048e-08
and O 0 1.516765202325132e-08
compared O 0 5.572018402233425e-09
for O 0 5.317356364248349e-12
their O 0 4.311239906740205e-11
detection O 0 5.011233650265012e-09
efficiency O 0 1.458646869956226e-09
, O 0 2.445047497801056e-10
identifying O 0 3.967858486220166e-09
76 O 0 1.3790871378205338e-07
% O 0 7.724654249585683e-10
and O 0 9.043037429989909e-09
60 O 0 4.448335921836133e-09
% O 0 6.889946946309067e-11
of O 0 3.179145835474628e-11
the O 0 7.237209942445588e-09
mutations O 0 1.0239780579013313e-07
, O 0 3.1375847697745485e-08
respectively O 0 2.0923900478919677e-07
. O 0 1.4875368492539565e-07

Most O 0 6.134123964329774e-07
patients O 0 6.685302196274279e-07
were O 0 1.197737589109238e-07
found O 0 2.1722395615597634e-07
to O 0 3.196861664278572e-09
be O 0 5.053215623718188e-09
compound O 0 1.4916748796167667e-06
heterozygote O 0 5.125783445691923e-06
. O 0 5.38896017587831e-07

Seventeen O 0 1.1573997653613333e-06
mutations O 0 7.45755926345737e-07
were O 0 3.5096615391694286e-08
distinct O 0 4.663184949293964e-09
, O 0 2.3690464701076053e-08
of O 0 1.6126853186193557e-09
which O 0 3.312705132429983e-08
10 O 0 6.076571690272203e-09
were O 0 3.201537523978004e-08
not O 0 9.832482383842489e-09
reported O 0 7.579943940072553e-06
previously O 0 1.418803208252939e-06
. O 0 2.3429210216363572e-07

Mutations O 0 3.366818782524206e-05
are O 0 2.991604119984004e-08
small O 0 2.7027198257201235e-08
deletions O 0 2.0312652395659825e-06
or O 0 1.068636947820778e-06
point O 0 2.52193399319367e-06
mutations O 0 2.02409751182131e-07
frequently O 0 1.6981984174435638e-07
affecting O 0 1.9512757631900968e-08
splice O 0 6.988776294747368e-05
sites O 0 6.210667834238848e-06
. O 0 2.525977834011428e-06

Moreover O 0 6.681709692202276e-06
, O 0 1.1512916842093546e-07
a O 0 1.1476785033437409e-07
16 O 0 9.416929742656066e-07
. O 0 5.740929509556736e-07

7 O 0 2.1363013729569502e-05
- O 0 0.0003103961644228548
kb O 0 0.0003345623263157904
genomic O 0 1.1645066706478246e-06
deletion O 0 6.193635613271908e-07
of O 0 1.3389791497786518e-09
the O 0 1.2929263881744646e-08
3 O 0 1.2475396715672105e-07
end O 0 1.1729781590474886e-07
of O 0 1.8612227037362317e-10
the O 0 3.2784959191900498e-09
gene O 0 9.568800862780336e-09
, O 0 4.655045238166622e-09
most O 0 3.895313793744748e-10
likely O 0 1.0485025292439332e-08
a O 0 2.245680974510833e-09
result O 0 1.0608330880401695e-09
of O 0 5.005420730674892e-11
recombination O 0 5.1702802039699236e-08
between O 0 1.1867320459657549e-08
two O 0 1.2648609271082023e-08
LINE O 0 6.4383989410998765e-06
elements O 0 1.2423472917078016e-08
, O 0 3.947268112369784e-08
was O 0 2.707069370444515e-06
identified O 0 8.645929483463988e-07
. O 0 3.0453995236712217e-07

The O 0 8.282200525400185e-08
most O 0 3.257484060270599e-09
frequently O 0 1.3307362678460777e-07
found O 0 7.102527632696365e-08
mutation O 0 7.016230707534987e-09
, O 0 7.608278451698425e-09
identified O 0 2.4592777592147286e-08
in O 0 1.7375433314370525e-09
three O 0 2.2596889692749755e-08
unrelated O 0 2.2200003513717093e-05
Turkish O 0 2.2008829546393827e-05
A B-Disease 1 0.9997619986534119
- I-Disease 1 0.9999850988388062
T I-Disease 1 0.9999964237213135
individuals O 0 9.469757422664316e-09
, O 0 3.103054524444815e-08
was O 0 1.0450828995089978e-05
previously O 0 3.703676725308469e-07
described O 0 3.542005799772596e-07
to O 0 6.007516151207426e-10
be O 0 5.114495493785398e-10
a O 0 2.5529361735721068e-08
Turkish O 0 1.2274447726667859e-05
A B-Disease 1 0.9977545142173767
- I-Disease 1 0.9998623132705688
T I-Disease 1 0.9999692440032959
founder O 0 7.908063707873225e-05
mutation O 0 1.466000583150162e-07
. O 0 1.1060656390782242e-07

The O 0 2.3163579498941544e-08
presence O 0 3.7244305417516443e-09
of O 0 1.3480916383201702e-09
a O 0 2.9252813504854203e-08
founder O 0 2.731818767642835e-06
mutation O 0 6.503784621969544e-09
among O 0 1.499670526650121e-10
relatively O 0 8.805021711744132e-10
small O 0 1.1049533510387732e-09
ethnic O 0 3.7642433614593074e-10
population O 0 1.202254962251459e-10
groups O 0 8.658643246839404e-11
in O 0 1.1889336182235866e-09
Western O 0 2.4167304601974138e-08
Europe O 0 2.4263840714411344e-07
could O 0 3.072470633469493e-08
indicate O 0 2.881147320721311e-09
a O 0 1.2254543158007891e-08
high O 0 5.510803475772263e-07
carrier O 0 1.8036686810773972e-07
frequency O 0 5.348145748484967e-08
in O 0 1.4669669923250694e-09
such O 0 3.2665972704570834e-10
communities O 0 1.0949257500669773e-08
. O 0 2.3592978948272503e-07

In O 0 9.741194162415923e-07
patients O 0 7.172405958044692e-08
of O 0 7.739253682359504e-10
Dutch O 0 2.2931129706194042e-07
ethnic O 0 2.285260647383325e-09
origin O 0 1.3808935328540883e-08
, O 0 4.976745060503163e-08
however O 0 2.037825552747563e-08
, O 0 1.0601095112861003e-08
no O 0 5.881207520985754e-09
significant O 0 7.267361712415266e-10
founder O 0 1.2348723430477548e-06
effect O 0 5.598352448288324e-09
could O 0 6.868932977965869e-09
be O 0 2.200297277710206e-09
identified O 0 1.6618000131529698e-07
. O 0 1.3307236201853812e-07

The O 0 3.3706672297739715e-07
observed O 0 4.837733058593585e-07
genetic O 0 4.5356671307672514e-07
heterogeneity O 0 5.28091050000512e-07
including O 0 2.0929171729022755e-09
the O 0 1.4095130396185596e-08
relative O 0 1.8662798595414642e-07
high O 0 2.6068119041156024e-07
percentage O 0 2.7107581956897775e-08
of O 0 2.963347622841894e-10
splice O 0 0.00037889243685640395
- O 0 0.03265654668211937
site O 0 2.2906351659912616e-05
mutations O 0 2.164526193837446e-07
had O 0 7.391815870505525e-07
no O 0 4.164645517334975e-09
reflection O 0 1.6877346187271769e-09
on O 0 2.504045824025525e-07
the O 0 2.1891139567742357e-07
phenotype O 0 2.018176564888563e-05
. O 0 8.862228924044757e-07

All O 0 1.2322624343141797e-07
patients O 0 4.0997844052981236e-07
manifested O 0 3.465014231096575e-07
classical O 0 3.0183698527253e-06
A B-Disease 1 0.9974798560142517
- I-Disease 1 0.9998961687088013
T I-Disease 1 0.9999704360961914
and O 0 3.1116189802560257e-07
increased O 0 4.895988947595242e-09
cellular O 0 3.8195498746063095e-06
radioresistant O 0 1.473293832532363e-05
DNA O 0 9.85240149020683e-07
synthesis O 0 5.160945306670328e-07
. O 0 1.01951275155443e-06

Determination O 0 1.6601887864453602e-06
of O 0 3.5490803629301126e-09
the O 0 3.464922349039057e-09
genomic O 0 8.682437169227342e-08
structure O 0 2.2553058087737554e-08
of O 0 1.03136876816734e-09
the O 0 6.479729108832544e-08
COL4A4 O 0 0.00027315414627082646
gene O 0 5.20750305099682e-08
and O 0 6.019644871457785e-08
of O 0 2.5821575988516088e-08
novel O 0 2.3167893232312053e-05
mutations O 0 0.0001198360332637094
causing O 0 0.009503942914307117
autosomal B-Disease 1 0.9993301630020142
recessive I-Disease 1 0.9998703002929688
Alport I-Disease 1 0.9998883008956909
syndrome I-Disease 1 0.9998447895050049
. O 0 0.0008060267427936196

Autosomal B-Disease 1 0.9981520771980286
recessive I-Disease 1 0.9996262788772583
Alport I-Disease 1 0.9998873472213745
syndrome I-Disease 1 0.9999253749847412
is O 0 4.255085877957754e-05
a O 0 2.020206011366099e-05
progressive O 0 0.2718116044998169
hematuric B-Disease 1 0.9993172883987427
glomerulonephritis I-Disease 1 0.9999362230300903
characterized O 0 0.00704784644767642
by O 0 9.195838174491655e-06
glomerular B-Disease 1 0.9658243060112
basement I-Disease 1 0.9779250621795654
membrane I-Disease 0 0.3604799807071686
abnormalities I-Disease 1 0.9618348479270935
and O 0 3.838611519313417e-06
associated O 0 2.864552186565561e-07
with O 0 7.092550902143557e-08
mutations O 0 1.1823787104958683e-07
in O 0 9.582882931624681e-09
either O 0 2.9192823713941607e-09
the O 0 3.26592761723532e-08
COL4A3 O 0 0.0004724789469037205
or O 0 3.382555391340247e-08
the O 0 2.3790626357822475e-08
COL4A4 O 0 0.00018480411381460726
gene O 0 1.730073861949677e-08
, O 0 1.375317637553053e-09
which O 0 8.484807301201158e-11
encode O 0 7.368607807256566e-11
the O 0 5.755629750581193e-09
alpha3 O 0 3.099295645370148e-05
and O 0 1.9568260256619396e-07
alpha4 O 0 4.860710760112852e-05
type O 0 3.974067794842995e-07
IV O 0 0.007082089316099882
collagen O 0 5.7547287724446505e-05
chains O 0 2.7971647796221077e-05
, O 0 4.1149505136672815e-08
respectively O 0 1.2928923354138533e-07
. O 0 3.231519656310411e-07

To O 0 5.636122324403914e-08
date O 0 2.0523951604900503e-07
, O 0 4.108235529542981e-09
mutation O 0 6.901182403318273e-10
screening O 0 3.1082342255572826e-10
in O 0 4.595328562118084e-10
the O 0 1.1818568346200209e-09
two O 0 1.5704442191122325e-08
genes O 0 1.0559789132003061e-07
has O 0 3.5987690694128105e-07
been O 0 4.42085735130604e-07
hampered O 0 3.637820918811485e-05
by O 0 3.2509541725289637e-09
the O 0 4.191741176384767e-09
lack O 0 1.2090486389837451e-09
of O 0 3.333713860520504e-10
genomic O 0 9.252440946738716e-08
structure O 0 2.7450090200886734e-08
information O 0 4.661640318204263e-08
. O 0 6.616540417780925e-07

We O 0 4.7541314529553347e-07
report O 0 1.496127168820749e-07
here O 0 9.35717836547667e-10
the O 0 1.1074509365105456e-10
complete O 0 1.4649957913448475e-09
characterization O 0 1.891028666989314e-08
of O 0 7.861800793707019e-11
the O 0 1.2906686830405079e-09
48 O 0 3.925470615229187e-09
exons O 0 5.9246443306903984e-09
of O 0 3.2129368610078757e-10
the O 0 2.4432273093566437e-08
COL4A4 O 0 0.00030457493267022073
gene O 0 7.863173223654485e-09
, O 0 2.6043098788619545e-09
a O 0 4.2582526393886155e-10
comprehensive O 0 4.07813727232309e-10
gene O 0 9.265965772442541e-09
screen O 0 3.2574660053796833e-06
, O 0 2.6886061377240367e-08
and O 0 1.546010430786282e-09
the O 0 2.1323276477858144e-10
subsequent O 0 6.509353056571854e-10
detection O 0 3.811444049262036e-09
of O 0 2.618159578027246e-10
10 O 0 1.536882265895656e-08
novel O 0 3.899093670156617e-08
mutations O 0 3.4089421063754344e-08
in O 0 2.0254253385587617e-08
eight O 0 2.8264626962481998e-05
patients O 0 2.267596391902771e-05
diagnosed O 0 0.22355981171131134
with O 0 0.003284256439656019
autosomal B-Disease 1 0.9999184608459473
recessive I-Disease 1 0.9999505281448364
Alport I-Disease 1 0.9999630451202393
syndrome I-Disease 1 0.999893307685852
. O 0 0.00016779970610514283

Furthermore O 0 2.393373506492935e-06
, O 0 5.5858546232911976e-08
we O 0 3.2215847767247396e-09
identified O 0 2.0141022183395307e-09
a O 0 2.1773181868578462e-10
glycine O 0 1.3014127553390153e-08
to O 0 1.893582096679225e-10
alanine O 0 2.129938669881426e-09
substitution O 0 5.3397387206333136e-11
in O 0 2.2093631091291144e-10
the O 0 1.162347107452888e-09
collagenous O 0 2.2216636352823116e-06
domain O 0 5.45018385977869e-09
that O 0 7.085476205759278e-09
is O 0 4.446639056965296e-09
apparently O 0 8.268561373370176e-07
silent O 0 2.900403615058167e-07
in O 0 4.802571673678813e-10
the O 0 1.898048607174019e-09
heterozygous O 0 5.10125097719083e-08
carriers O 0 1.4352585786525651e-08
, O 0 4.718441637407977e-09
in O 0 4.321716762234473e-09
11 O 0 6.623471904276812e-07
. O 0 4.7186554752443044e-07

5 O 0 2.9970578907523304e-06
% O 0 8.365883097383175e-09
of O 0 2.600496762372728e-10
all O 0 1.9496593228751635e-10
control O 0 6.230472138213372e-08
individuals O 0 8.351497826630805e-10
, O 0 9.972569436911272e-09
and O 0 2.2998754900527274e-08
in O 0 1.3791239261706778e-09
one O 0 1.1761785989605755e-09
control O 0 1.0603987021795547e-08
individual O 0 1.828393964009578e-10
homozygous O 0 2.7909381472568384e-09
for O 0 2.8161264986614754e-11
this O 0 3.8522879330926685e-11
glycine O 0 3.292949202204909e-08
substitution O 0 6.4834972945959635e-09
. O 0 9.308997306334277e-08

There O 0 5.853177071912796e-07
has O 0 2.1230653146631084e-07
been O 0 4.076779802630881e-08
no O 0 2.27277641151602e-09
previous O 0 1.0321309140692847e-08
finding O 0 9.204257356287826e-10
of O 0 5.841521710792108e-12
a O 0 3.4921895930573044e-10
glycine O 0 1.0984419596127282e-08
substitution O 0 7.93082877148521e-10
that O 0 3.2799238880443227e-08
is O 0 7.293917025918972e-09
not O 0 9.566770708957506e-10
associated O 0 1.3946409582743513e-09
with O 0 5.306682870909185e-10
any O 0 8.998057854370245e-10
obvious O 0 1.0163407893060139e-07
phenotype O 0 3.466035423116409e-07
in O 0 4.1299134778682856e-08
homozygous O 0 2.810963223964791e-06
individuals O 0 2.592446790572467e-08
. O 0 5.769271638200735e-07

Founder O 0 0.0008373500313609838
BRCA1 O 0 0.00274671264924109
and O 0 1.5044793144625146e-05
BRCA2 O 0 0.00010041577479569241
mutations O 0 5.938584877185349e-07
in O 0 3.9577852817274106e-07
French O 0 0.0006328331073746085
Canadian O 0 0.13697248697280884
breast B-Disease 1 0.9997860789299011
and I-Disease 1 0.9993295669555664
ovarian I-Disease 1 0.9999957084655762
cancer I-Disease 1 0.9999483823776245
families O 0 2.6650021027307957e-05
. O 0 2.549812961660791e-06

We O 0 1.9581553090119996e-07
have O 0 6.976224931065644e-09
identified O 0 1.6670293589982066e-08
four O 0 6.777457706164114e-09
mutations O 0 6.337161462255381e-09
in O 0 1.621290102171713e-09
each O 0 3.277694227143968e-10
of O 0 1.794588300185751e-08
the O 0 0.00014107640890870243
breast B-Disease 1 0.9038487672805786
cancer I-Disease 0 0.0036970884539186954
- O 0 0.0001432042772648856
susceptibility O 0 5.863770411451696e-07
genes O 0 1.4192842456850485e-08
, O 0 9.065664130503137e-08
BRCA1 O 0 6.611591743421741e-06
and O 0 2.0944933112332365e-06
BRCA2 O 0 1.6293643056997098e-05
, O 0 1.1683338385637398e-07
in O 0 2.6591337132231274e-08
French O 0 0.00015747200814075768
Canadian O 0 0.018845010548830032
breast B-Disease 1 0.998383641242981
cancer I-Disease 1 0.7782853841781616
and O 0 0.06784164905548096
breast B-Disease 1 0.9998767375946045
/ I-Disease 1 0.9999395608901978
ovarian I-Disease 1 0.9999982118606567
cancer I-Disease 1 0.9999821186065674
families O 0 3.831830326816998e-06
from O 0 1.5015788790151419e-07
Quebec O 0 1.986700590350665e-05
. O 0 7.760080734442454e-06

To O 0 1.826542188609892e-07
identify O 0 7.318222401409002e-07
founder O 0 4.631825504475273e-05
effects O 0 1.3545432011596859e-06
, O 0 2.253731778978363e-08
we O 0 8.256357264535552e-10
examined O 0 1.8525295075733084e-08
independently O 0 2.4139557019964286e-09
ascertained O 0 6.863585326755128e-07
French O 0 1.110067023546435e-05
Canadian O 0 0.00013765477342531085
cancer B-Disease 0 0.002589251846075058
families O 0 1.136045835181676e-08
for O 0 1.662125714840812e-10
the O 0 9.47036671306023e-10
distribution O 0 2.656845854431822e-09
of O 0 8.364295367435659e-11
these O 0 3.5354780214547077e-10
eight O 0 9.989248894726188e-08
mutations O 0 5.047111812928051e-07
. O 0 2.491292718787008e-07

Mutations O 0 1.9596698621171527e-05
were O 0 1.1756563935705344e-06
found O 0 6.121220508248371e-07
in O 0 1.87890876190977e-08
41 O 0 5.977165074000368e-08
of O 0 7.695467374446707e-09
97 O 0 2.421232466076617e-06
families O 0 3.884756267780176e-07
. O 0 5.068122277407383e-07

Six O 0 9.794936772777874e-08
of O 0 3.5015024213436163e-09
eight O 0 7.089737863452683e-08
mutations O 0 4.7151150539548325e-08
were O 0 3.0125896444133105e-08
observed O 0 3.6629575816959914e-08
at O 0 3.3224503681594797e-07
least O 0 1.385562553579689e-09
twice O 0 4.196166685233038e-07
. O 0 7.091143174875469e-07

The O 0 6.398547611752292e-07
BRCA1 O 0 8.921779954107478e-05
C4446T O 0 9.564573701936752e-06
mutation O 0 9.060777301783673e-07
was O 0 2.5396882392669795e-06
the O 0 3.662703917939325e-09
most O 0 1.3874957849324687e-09
common O 0 4.017022092739353e-08
mutation O 0 1.032397065614532e-07
found O 0 2.508245188437286e-06
, O 0 1.0761020519112208e-07
followed O 0 4.597630010039211e-08
by O 0 3.928354086468744e-09
the O 0 9.933352629332148e-08
BRCA2 O 0 9.420391143066809e-05
8765delAG O 0 2.3502854674006812e-05
mutation O 0 5.748884746026306e-07
. O 0 3.096908471889037e-07

Together O 0 1.4703481383548933e-06
, O 0 2.7477959463340085e-08
these O 0 3.787086477746726e-10
mutations O 0 6.547697051217938e-09
were O 0 5.523115831351788e-08
found O 0 3.664820553694881e-07
in O 0 8.608870949444736e-09
28 O 0 4.0698033387798205e-08
of O 0 2.722586378567371e-09
41 O 0 7.507446184717992e-07
families O 0 3.1937915423441154e-08
identified O 0 3.135233583861918e-08
to O 0 1.6367478483658715e-09
have O 0 3.6838700978591987e-09
a O 0 9.582776527850001e-08
mutation O 0 3.9284313402276894e-07
. O 0 6.986493303884345e-07

The O 0 5.46778210264165e-07
odds O 0 2.0856672563240863e-05
of O 0 1.4173925366733897e-09
detection O 0 8.671761975165282e-08
of O 0 2.642441265798823e-10
any O 0 9.346826784772944e-11
of O 0 8.319744199125623e-11
the O 0 4.491577776377653e-09
four O 0 4.228521106597327e-07
BRCA1 O 0 2.464371755195316e-05
mutations O 0 1.5961437327405292e-07
was O 0 1.8066526536131278e-05
18 O 0 4.3187941400901764e-07
. O 0 3.216662776139856e-07

7x O 0 0.001869373838417232
greater O 0 1.5197284142232093e-07
if O 0 2.0172903347770443e-08
one O 0 3.9410352759006173e-10
or O 0 1.7191127410498552e-09
more O 0 1.9292840935936084e-10
cases O 0 2.4298157086377614e-07
of O 0 0.0030387737788259983
ovarian B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999890327453613
were O 0 8.200037700589746e-05
also O 0 7.780553232805687e-07
present O 0 1.0090392521533431e-08
in O 0 1.3501972873086743e-08
the O 0 1.3999057557612105e-07
family O 0 5.1409257139312103e-05
. O 0 1.2131412177041057e-06

The O 0 1.292357438842373e-07
odds O 0 3.575224127416732e-06
of O 0 3.3971836455037874e-10
detection O 0 1.2620057532330975e-07
of O 0 1.8222978681592394e-10
any O 0 5.913732004092509e-11
of O 0 2.2641218067054325e-10
the O 0 7.048354788707911e-09
four O 0 3.5134598874719813e-07
BRCA2 O 0 1.3142590432835277e-05
mutations O 0 5.661063440243197e-08
was O 0 6.688237590424251e-06
5 O 0 4.3684443085112434e-07
. O 0 3.8427540971497365e-07

3x O 0 8.290851837955415e-05
greater O 0 2.1425670126973273e-08
if O 0 9.924542077044407e-09
there O 0 3.560170491745396e-10
were O 0 2.6813891107480003e-09
at O 0 2.805167831354538e-08
least O 0 3.816459301364539e-11
five O 0 1.5665543307008534e-09
cases O 0 1.479209466026532e-08
of O 0 1.763682121236343e-06
breast B-Disease 1 0.9482795596122742
cancer I-Disease 0 0.001291383057832718
in O 0 4.460130043071331e-08
the O 0 3.2490598300682905e-07
family O 0 0.00013777700951322913
. O 0 1.1598405080803786e-06

Interestingly O 0 8.337471626873594e-06
, O 0 3.92284498218487e-08
the O 0 9.309823467695821e-10
presence O 0 6.260055807061349e-10
of O 0 2.149655564664954e-09
a O 0 1.4973767065384891e-05
breast B-Disease 1 0.5090689659118652
cancer I-Disease 0 0.0004773551190737635
case O 0 4.3227251467214955e-07
< O 0 5.990941076561285e-08
36 O 0 9.701799363881491e-09
years O 0 1.4048000984701048e-08
of O 0 1.7955494868715505e-09
age O 0 9.441625792305786e-08
was O 0 1.539474965284171e-06
strongly O 0 1.1203781014046399e-08
predictive O 0 2.0128474886860204e-08
of O 0 2.0592388905171788e-10
the O 0 2.2859756310111834e-09
presence O 0 9.000460932107046e-10
of O 0 4.597509178916326e-11
any O 0 2.4066207360284864e-11
of O 0 8.66179766800812e-11
the O 0 4.631540484467678e-09
eight O 0 1.196800099023676e-07
mutations O 0 8.202792400879844e-08
screened O 0 3.7085860071783827e-07
. O 0 1.5670548236812465e-07

Carriers O 0 1.4181836149873561e-06
of O 0 2.0506873976700035e-09
the O 0 2.3109023583600674e-09
same O 0 8.279496199747882e-09
mutation O 0 5.707422801037865e-08
, O 0 2.461042036827621e-08
from O 0 2.0879563356057673e-10
different O 0 1.0090035751364468e-10
families O 0 1.6110782041778293e-08
, O 0 5.539486647165859e-09
shared O 0 5.3166036018126306e-09
similar O 0 3.467740583573686e-08
haplotypes O 0 1.0076698345073964e-05
, O 0 3.6940178915756405e-08
indicating O 0 4.166331635246934e-08
that O 0 9.028986447390253e-10
the O 0 2.7428240234605994e-10
mutant O 0 7.631681597786155e-08
alleles O 0 4.230132244487095e-09
were O 0 3.9254349104567154e-08
likely O 0 1.538683314095124e-08
to O 0 6.026210641607577e-10
be O 0 1.3268776077879352e-09
identical O 0 1.3118054198457685e-07
by O 0 7.18661752330263e-09
descent O 0 1.6439624914710294e-06
for O 0 1.057064102916172e-09
a O 0 1.8288110581465844e-08
mutation O 0 8.069473089733492e-09
in O 0 3.5541136700345533e-09
the O 0 1.7709190558434784e-08
founder O 0 1.579597665113397e-05
population O 0 7.894340292580182e-09
. O 0 2.095287356951303e-07

The O 0 1.1437925273583005e-08
identification O 0 2.1247339887509042e-08
of O 0 9.689501645482324e-09
common O 0 7.002409461165371e-07
BRCA1 O 0 0.00035748674417845905
and O 0 9.133853382081725e-06
BRCA2 O 0 3.8175923691596836e-05
mutations O 0 5.803940084092574e-08
will O 0 1.5974144229602416e-10
facilitate O 0 1.0938266264970409e-10
carrier O 0 1.808794962698812e-07
detection O 0 1.3993610536999768e-07
in O 0 2.174274271737886e-08
French O 0 4.200461626169272e-05
Canadian O 0 0.02292112447321415
breast B-Disease 1 0.9960651993751526
cancer I-Disease 0 0.44268283247947693
and O 0 0.02246018312871456
breast B-Disease 1 0.9998502731323242
/ I-Disease 1 0.9999266862869263
ovarian I-Disease 1 0.9999939203262329
cancer I-Disease 1 0.999953031539917
families O 0 2.7422509447205812e-05
. O 0 2.894268845921033e-06

Are O 0 2.3453711150978052e-07
Dp71 O 0 9.685358236311004e-05
and O 0 4.464190226372011e-07
Dp140 O 0 7.652315616724081e-06
brain O 0 2.137817682523746e-05
dystrophin O 0 1.887764113917001e-07
isoforms O 0 7.956316494528437e-09
related O 0 1.3332564208212716e-07
to O 0 9.040677895200133e-08
cognitive B-Disease 0 9.275566844735295e-05
impairment I-Disease 0 0.11102260649204254
in O 0 0.0012486836640164256
Duchenne B-Disease 1 0.9997983574867249
muscular I-Disease 1 0.9998113512992859
dystrophy I-Disease 1 0.9993708729743958
? O 0 0.0014483622508123517

Molecular O 0 1.9173608961864375e-05
study O 0 5.915354108765314e-07
and O 0 6.72664214107499e-07
neuropsychological O 0 1.5078713886396145e-06
analysis O 0 3.5328171499315886e-09
were O 0 3.1334268513205643e-09
performed O 0 4.970602263121293e-10
concurrently O 0 2.319309855280949e-09
on O 0 2.275726274092449e-06
49 O 0 1.1739819456124678e-05
patients O 0 2.5897119826368e-07
with O 0 0.00020388892153277993
Duchenne B-Disease 1 0.9999414682388306
muscular I-Disease 1 0.9999680519104004
dystrophy I-Disease 1 0.9999599456787109
( O 0 9.168325050268322e-05
DMD B-Disease 1 0.9999854564666748
) O 0 1.7888133641008608e-07
in O 0 3.231918066504136e-09
order O 0 8.079418245543479e-10
to O 0 1.3979993829238424e-09
find O 0 2.9073354834707743e-09
a O 0 1.0762161162247708e-09
molecular O 0 2.825853506749354e-08
explanation O 0 6.142242825468713e-10
for O 0 2.888078387552895e-10
the O 0 2.8734328694213218e-08
cognitive B-Disease 0 1.1154461390106007e-05
impairment I-Disease 0 3.464518886175938e-05
observed O 0 9.182242166616561e-08
in O 0 5.99135248080529e-08
most O 0 1.986736833714531e-06
DMD B-Disease 1 0.9999465942382812
patients O 0 3.1270333238353487e-06
. O 0 1.378199840473826e-06

Complete O 0 1.0972864572522667e-07
analysis O 0 1.7020985509930142e-08
of O 0 1.9430819175880742e-09
the O 0 1.0865520927438865e-08
dystrophin O 0 5.072667477179493e-07
gene O 0 5.498236532730516e-08
was O 0 3.2393124911322957e-06
performed O 0 1.4511358337188085e-08
to O 0 4.1489450763876334e-10
define O 0 6.554640719080851e-10
the O 0 6.403498842288968e-10
localization O 0 1.433997098843065e-08
of O 0 4.796786301497491e-10
deletions O 0 1.251440977512175e-07
and O 0 7.548570124527032e-08
duplications O 0 2.81820547343159e-07
in O 0 9.625491514952955e-09
relation O 0 8.335827139660523e-09
to O 0 8.545553709105036e-10
the O 0 6.97887303502398e-09
different O 0 7.454637795945018e-08
DMD B-Disease 1 0.9997264742851257
promoters O 0 2.0133897123741917e-05
. O 0 4.0467679696121195e-07

Qualitative O 0 5.763893682342314e-07
analysis O 0 9.381489718407465e-08
of O 0 1.4696330818964043e-09
the O 0 2.0668315059424458e-08
Dp71 O 0 9.553606105328072e-06
transcript O 0 5.231373506831005e-06
and O 0 4.980153889277972e-08
testing O 0 2.4308801638284194e-09
for O 0 2.55327321785348e-11
the O 0 2.6405504519044776e-11
specific O 0 3.93059673350904e-12
first O 0 5.621118570608985e-10
exon O 0 8.100658277498951e-08
of O 0 3.2498321811402775e-09
Dp140 O 0 1.8334077367399004e-07
were O 0 2.0568425185274464e-08
also O 0 4.695690947187359e-09
carried O 0 9.707504489142593e-08
out O 0 1.1857912340929033e-07
. O 0 1.8176071137077088e-07

Neuropsychological O 0 0.00038796477019786835
analysis O 0 7.420484280373785e-07
assessed O 0 1.533335762360366e-06
verbal O 0 4.083489102413296e-07
and O 0 1.9886444135863712e-07
visuospatial O 0 2.045990413535037e-06
intelligence O 0 1.4402846773009514e-06
, O 0 4.267192466045344e-08
verbal O 0 2.907504494942259e-07
memory O 0 0.00026371158310212195
, O 0 1.1931327037473238e-07
and O 0 8.549817920311398e-08
reading O 0 3.9506582538706425e-07
skills O 0 3.332865503580251e-07
. O 0 2.926722117990721e-07

Comparison O 0 5.57918838239857e-07
of O 0 6.227998561314507e-09
molecular O 0 1.6709119563529384e-06
and O 0 5.577262527367566e-07
psychometric O 0 8.533134860044811e-06
findings O 0 2.992003942381416e-07
demonstrated O 0 2.448742293381656e-07
that O 0 6.345676428765046e-09
deletions O 0 9.384944377188731e-08
and O 0 3.9487890290956784e-08
duplications O 0 8.775688797868497e-08
that O 0 1.2859097786588336e-08
were O 0 2.1909304592782064e-08
localized O 0 2.5423720018125096e-08
in O 0 1.046610442756446e-08
the O 0 4.023155852905802e-08
distal O 0 3.454977195360698e-05
part O 0 2.2004117639085052e-08
of O 0 1.119760173473594e-09
the O 0 6.77604861110126e-09
gene O 0 2.3657907632923525e-08
seemed O 0 5.267992975177549e-08
to O 0 4.010755338956784e-10
be O 0 1.1305569813657712e-09
preferentially O 0 6.777460725970741e-08
associated O 0 6.598424562298533e-08
with O 0 3.884789805397304e-07
cognitive B-Disease 0 6.0465852584457025e-05
impairment I-Disease 0 0.0004525714321061969
. O 0 1.445047814740974e-06

Two O 0 1.6721284623599786e-07
altered O 0 4.5746564865112305e-06
Dp71 O 0 3.188308619428426e-05
transcripts O 0 2.429037976980908e-06
and O 0 4.604466496971327e-08
two O 0 2.0328243532929946e-09
deleted O 0 1.6575336658775086e-08
Dp140 O 0 2.051228342736522e-08
DNA O 0 7.832849746591819e-08
sequences O 0 1.218766687571815e-08
were O 0 7.232949172930603e-08
found O 0 2.627091930662573e-07
in O 0 1.588228926152624e-08
four O 0 9.123111794906436e-07
patients O 0 1.5793905561167776e-07
with O 0 1.9036613593925722e-05
severe O 0 0.3064647316932678
cerebral B-Disease 1 0.9889366626739502
dysfunction I-Disease 0 0.29840531945228577
. O 0 2.1275875042192638e-05

These O 0 5.927924817683561e-08
findings O 0 1.502464215263899e-07
suggest O 0 2.5689136151640923e-08
that O 0 2.5496585398521177e-10
some O 0 3.3378905108655266e-12
sequences O 0 4.0813663559902125e-10
located O 0 3.5187019964411093e-09
in O 0 1.0994517518625457e-09
the O 0 4.257815877650728e-09
distal O 0 4.2158721953455824e-06
part O 0 5.4854965014783374e-09
of O 0 4.1052330979063356e-10
the O 0 5.496849642128154e-09
gene O 0 2.12530952836687e-08
and O 0 1.6681562442499853e-07
, O 0 1.1344283734615601e-08
in O 0 1.0362904978578058e-09
particular O 0 2.5189211827481017e-10
, O 0 3.756019495426699e-09
some O 0 8.268429274593814e-10
DMD B-Disease 1 0.9290146827697754
isoforms O 0 2.165623014249718e-09
expressed O 0 1.8977230897831987e-09
in O 0 4.773268891256066e-09
the O 0 8.668592386129603e-07
brain O 0 0.04303165525197983
may O 0 4.7554783577652415e-07
be O 0 5.803184599528777e-09
related O 0 8.9765999078395e-09
to O 0 1.346205591445937e-09
the O 0 7.227129827924728e-08
cognitive B-Disease 0 0.00011973914661211893
impairment I-Disease 0 0.0015185188967734575
associated O 0 1.3096944257995347e-06
with O 0 1.764191620168276e-05
DMD B-Disease 1 0.9999535083770752
. O 0 2.368894001847366e-06
. O 0 1.1805190069935634e-06

I1307K O 0 9.046446211868897e-05
APC O 0 0.00011270619870629162
and O 0 7.957577849992958e-07
hMLH1 O 0 1.7607962945476174e-05
mutations O 0 3.570109470274474e-07
in O 0 1.7861298218235788e-08
a O 0 1.6195838270505192e-07
non O 0 1.8880594154779828e-07
- O 0 0.0002369181311223656
Jewish O 0 3.675439984363038e-06
family O 0 1.0204300451732706e-05
with O 0 8.797968575890991e-07
hereditary B-Disease 0 0.4291839599609375
non I-Disease 0 0.0016797067364677787
- I-Disease 1 0.9999017715454102
polyposis I-Disease 1 0.9998728036880493
colorectal I-Disease 1 0.9999960660934448
cancer I-Disease 1 0.999927282333374
. O 0 0.0001447578688384965

We O 0 6.168817634488732e-08
describe O 0 2.2813814837263635e-08
a O 0 1.4709546469759971e-08
French O 0 1.019308569993882e-06
Canadian O 0 6.7151186158298515e-06
hereditary B-Disease 1 0.697543740272522
non I-Disease 0 0.027111535891890526
- I-Disease 1 0.9999711513519287
polyposis I-Disease 1 0.9999619722366333
colorectal I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999936819076538
( O 0 5.341548239812255e-05
HNPCC B-Disease 1 0.6099480390548706
) O 0 1.6603045196461608e-06
kindred O 0 3.2869789720280096e-05
which O 0 3.5048458357778145e-07
carries O 0 1.237806941389863e-06
a O 0 4.799362329777068e-08
novel O 0 1.9894507374829118e-07
truncating O 0 1.8735966023086803e-06
mutation O 0 2.084683927705555e-07
in O 0 1.1368732089067635e-07
hMLH1 O 0 3.9978047425393015e-05
. O 0 6.632429290220898e-07

Interestingly O 0 6.012094672769308e-06
, O 0 3.9939269669275745e-08
the O 0 3.6881797615961887e-09
I1307K O 0 6.414629183382203e-07
APC O 0 3.31212845594564e-06
polymorphism O 0 4.127530246478273e-06
, O 0 1.9950137186697248e-07
associated O 0 1.2652131786694554e-08
with O 0 2.25858909352894e-09
an O 0 1.4584697005659564e-08
increased O 0 1.9499871939387958e-07
risk O 0 6.501612006104551e-06
of O 0 0.001479991478845477
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999958276748657
, O 0 4.703923696069978e-05
is O 0 1.2073189736838685e-07
also O 0 7.384883105032714e-08
present O 0 2.9020279512792513e-09
in O 0 1.0615947232395229e-08
this O 0 8.095943471175815e-09
family O 0 1.051243543770397e-05
. O 0 5.635605475617922e-07

The O 0 5.59919897114014e-08
I1307K O 0 4.050871211802587e-06
polymorphism O 0 3.635548864622251e-06
has O 0 9.173296433573341e-08
previously O 0 6.895781012872249e-08
only O 0 4.0235126341769956e-10
been O 0 2.9434598758371067e-08
identified O 0 3.451975416624009e-08
in O 0 9.490044305948686e-09
individuals O 0 5.72864089498637e-10
of O 0 3.3429545798213667e-09
self O 0 1.73677944985684e-05
- O 0 0.08536282181739807
reported O 0 0.00036763492971658707
Ashkenazi O 0 1.1940053809667006e-05
Jewish O 0 5.557945996770286e-07
origins O 0 2.7196040264243493e-06
. O 0 6.346429586301383e-07

In O 0 2.0775152620444715e-07
addition O 0 1.4888986932248827e-08
, O 0 2.4235342621636846e-08
in O 0 5.618795650974562e-09
this O 0 4.808944797929371e-09
family O 0 5.4213764997257385e-06
, O 0 3.387449254432795e-08
there O 0 7.881698071976473e-10
appears O 0 2.771936635781458e-08
to O 0 1.447698849688095e-09
be O 0 6.852131750889612e-09
no O 0 2.6839475086859466e-09
relationship O 0 7.094793641471142e-09
between O 0 2.374138663441272e-09
the O 0 3.5643101803373156e-09
I1307K O 0 2.3229110013289755e-07
polymorphism O 0 1.0984926035462195e-07
and O 0 6.160479237848904e-09
the O 0 2.842024615645755e-09
presence O 0 2.7965652016348486e-09
or O 0 2.8043974253932902e-08
absence O 0 1.4912973966829668e-08
of O 0 3.6433917216527334e-08
cancer B-Disease 0 6.5566913690418e-05
. O 0 2.5991703012095968e-08
. O 0 2.8099827886762796e-07

Identification O 0 3.5450779023449286e-07
of O 0 2.4678486809648348e-08
a O 0 2.8634158866225334e-07
novel O 0 1.6861628182596178e-07
mutation O 0 1.224489309947785e-08
of O 0 7.616042241309628e-10
the O 0 3.899778278082522e-08
CPO O 0 4.514065585681237e-05
gene O 0 1.7488854808789256e-08
in O 0 2.0016213131412997e-09
a O 0 8.984449095805758e-08
Japanese O 0 5.7209355873055756e-05
hereditary B-Disease 0 0.1157342940568924
coproporphyria I-Disease 0 0.020187096670269966
family O 0 8.963907021097839e-05
. O 0 1.8877403817896266e-06

Hereditary B-Disease 1 0.985630214214325
coproporphyria I-Disease 1 0.9611225128173828
( O 0 3.1124171073315665e-05
HCP B-Disease 1 0.7852211594581604
) O 0 2.645513177412795e-06
is O 0 2.0761288510584563e-07
an O 0 1.0908379408647306e-06
autosomal B-Disease 1 0.6884706020355225
dominant I-Disease 1 0.950253427028656
disease I-Disease 1 0.5427910685539246
characterized O 0 0.00010703840962378308
by O 0 1.4854799701424781e-06
a O 0 0.001291628577746451
deficiency B-Disease 0 0.1598394811153412
of I-Disease 0 1.7336876823037528e-08
coproporphyrinogen I-Disease 0 0.00975875835865736
oxidase I-Disease 0 1.0460650628374424e-05
( O 0 2.2150741685322828e-08
CPO O 0 0.0004199952236376703
) O 0 5.52277867882367e-08
caused O 0 9.615729545942031e-09
by O 0 1.5576805123540538e-10
a O 0 6.753365866529748e-09
mutation O 0 7.4408559314065315e-09
in O 0 2.2863548831963953e-09
the O 0 2.8263816176377077e-08
CPO O 0 0.00025740396813489497
gene O 0 5.65209688829782e-07
. O 0 3.836668156509404e-07

Only O 0 3.7424769061544794e-08
11 O 0 1.8249158983962843e-07
mutations O 0 4.988976698427905e-08
of O 0 5.528981161795343e-10
the O 0 6.5410188376802125e-09
gene O 0 6.762210347233122e-08
have O 0 6.233978666614348e-08
been O 0 9.112816314882366e-07
reported O 0 0.0002168994687963277
in O 0 6.953948172849778e-07
HCP B-Disease 1 0.6813229322433472
patients O 0 9.609497055862448e-07
. O 0 4.754861890887696e-07

We O 0 2.8692164733001846e-07
report O 0 7.398558921067888e-08
another O 0 4.755022153801747e-09
mutation O 0 1.0606839850879624e-08
in O 0 5.254873869375842e-09
a O 0 6.066625957146243e-08
Japanese O 0 1.265498485736316e-05
family O 0 3.7494297430384904e-05
. O 0 5.441974622044654e-07

Polymerase O 0 0.0001162608532467857
chain O 0 0.00022256336524151266
reaction O 0 3.9724420730635757e-07
- O 0 3.523493796819821e-05
single O 0 1.371551974216345e-07
strand O 0 1.3011495866521727e-05
conformational O 0 3.984755636565751e-09
polymorphism O 0 8.377974580753289e-08
and O 0 1.1975844760314658e-09
direct O 0 1.468757407363519e-11
sequence O 0 5.034204164644507e-10
analyses O 0 4.223416727455742e-09
demonstrated O 0 1.4968458472708335e-08
a O 0 6.249440964722908e-09
C O 0 3.7491074067474983e-07
to O 0 1.0668209649011828e-09
T O 0 4.391380343804485e-07
substitution O 0 1.385925835900581e-11
in O 0 1.3996501180280063e-10
exon O 0 1.6976276384639277e-08
1 O 0 5.785211754094632e-10
of O 0 3.3614291905514904e-11
the O 0 1.2856957720686069e-09
CPO O 0 1.121226659961394e-06
gene O 0 5.195235353028238e-10
at O 0 3.2145386352766536e-09
nucleotide O 0 1.8306552107549834e-10
position O 0 2.1657315940615263e-08
85 O 0 5.043182760289255e-09
, O 0 4.839123768363152e-09
which O 0 1.5386245166837398e-08
lies O 0 2.846659867827839e-07
in O 0 6.34429342394327e-10
the O 0 3.692233629948305e-09
putative O 0 1.2886496278952109e-06
presequence O 0 1.5848419252506574e-06
for O 0 3.3996774145839126e-11
targeting O 0 6.261204887891836e-09
to O 0 2.948819410875103e-09
mitochondria O 0 2.7977731065220723e-07
. O 0 1.2460832010674494e-07

This O 0 3.000037906986108e-08
mutation O 0 1.4270776560465492e-08
changes O 0 1.6516778222896988e-10
the O 0 1.453245024318761e-10
codon O 0 2.8849897470983876e-10
for O 0 3.066523771022567e-11
glutamine O 0 1.882854316903604e-09
to O 0 8.964819858681139e-11
a O 0 1.8598680373571597e-09
termination O 0 3.28326592580197e-08
codon O 0 8.71727467988137e-10
at O 0 2.6306311795565307e-08
amino O 0 2.2146240397091788e-10
acid O 0 9.092167019275621e-10
position O 0 9.471744277789185e-09
29 O 0 3.2176936315408966e-07
. O 0 1.1650449494027271e-07

MaeI O 0 0.000122003213618882
restriction O 0 4.032375500173657e-07
analysis O 0 8.175380372676955e-08
showed O 0 9.558367537465529e-07
two O 0 5.087955390337129e-09
other O 0 2.002354504426762e-09
carriers O 0 1.913428882005519e-08
in O 0 4.91222706955341e-09
the O 0 7.062824636250298e-08
family O 0 5.969269841443747e-05
. O 0 1.1155674428664497e-06

The O 0 2.788476422210806e-06
C O 0 0.0027100658044219017
- O 0 0.45930391550064087
T O 0 0.30424076318740845
mutation O 0 2.0951016210801754e-07
is O 0 5.273972369934654e-09
located O 0 3.3768614571272337e-09
within O 0 8.950484797765057e-11
a O 0 1.0693803176309302e-08
recently O 0 2.4506019258296874e-07
proposed O 0 3.407833459867504e-10
putative O 0 4.344594017879899e-09
alternative O 0 2.7016435963367336e-11
translation O 0 1.4668515013749328e-10
initiation O 0 5.149931592285384e-10
codon O 0 8.802775397498408e-09
( O 0 1.1963630086597732e-09
TIC O 0 2.4673017833265476e-05
- O 0 3.7388894270407036e-05
1 O 0 1.2116810665929734e-08
) O 0 1.5458188062922318e-09
, O 0 4.079623028285795e-10
supporting O 0 2.2475834526858307e-09
that O 0 6.880291181232678e-08
TIC O 0 0.00015985323989298195
- O 0 2.94563560601091e-05
1 O 0 1.3690788946973953e-08
is O 0 1.6981028805318488e-09
the O 0 2.213092598069011e-09
real O 0 2.1518928861041786e-07
TIC O 0 3.853635644190945e-05
rather O 0 1.3960328448803239e-09
than O 0 4.4746473193413294e-09
TIC O 0 0.00032428125268779695
- O 0 2.5093024305533618e-05
2 O 0 8.723154110157338e-08
. O 0 8.129475759233173e-09
. O 0 4.6403766162939064e-08

Human B-Disease 0 6.302592510110117e-07
complement I-Disease 0 3.989430297224317e-06
factor I-Disease 0 0.0005338896880857646
H I-Disease 1 0.9999717473983765
deficiency I-Disease 1 0.99628746509552
associated O 0 0.0003316809015814215
with O 0 0.4216853976249695
hemolytic B-Disease 1 0.9999501705169678
uremic I-Disease 1 0.9999312162399292
syndrome I-Disease 1 0.9997456669807434
. O 0 9.31449540075846e-05

This O 0 4.397469055561487e-08
study O 0 3.66245256344655e-09
reports O 0 9.174027759684122e-09
on O 0 1.2021834550068888e-07
six O 0 1.6980719408365985e-07
cases O 0 1.119983252806378e-07
of O 0 2.5309161628683796e-06
deficiency B-Disease 0 0.010416529141366482
in I-Disease 0 1.2190194409456012e-09
the I-Disease 0 1.2807712668205795e-09
human I-Disease 0 3.608339183003295e-10
complement I-Disease 0 1.0951919926505127e-10
regulatory I-Disease 0 1.0843803188720358e-08
protein I-Disease 0 1.3645088614566703e-08
Factor I-Disease 0 6.67107471485906e-08
H I-Disease 1 0.9975419044494629
( O 0 2.182259706273726e-08
FH O 0 2.0566150851664133e-05
) O 0 2.5764002042905076e-09
in O 0 1.6280569947735302e-10
the O 0 1.9169593690193665e-10
context O 0 4.403617193116105e-10
of O 0 1.6310174544287293e-08
an O 0 0.004021670203655958
acute B-Disease 1 0.999014139175415
renal I-Disease 1 0.9999909400939941
disease I-Disease 1 0.9998438358306885
. O 0 1.0999640835507307e-05

Five O 0 1.6133544988861104e-07
of O 0 4.075122017610511e-09
the O 0 1.2772297885987882e-08
cases O 0 1.4758867905584339e-08
were O 0 3.50616211619581e-08
observed O 0 5.29001340510149e-08
in O 0 1.4666263759011144e-08
children O 0 9.833780012513671e-08
presenting O 0 3.9412152545992285e-06
with O 0 0.22286120057106018
idiopathic O 1 0.9999850988388062
hemolytic B-Disease 1 0.9999908208847046
uremic I-Disease 1 0.9999909400939941
syndrome I-Disease 1 0.9999630451202393
( O 0 8.09188568382524e-05
HUS B-Disease 1 0.9990191459655762
) O 0 9.571608643454965e-06
. O 0 3.7252393667586148e-06

Two O 0 1.0920979320871993e-07
of O 0 4.965175381954623e-09
the O 0 9.507295573030206e-08
children O 0 4.1021149854714167e-07
exhibited O 0 2.659501888047089e-06
a O 0 3.006966608154471e-06
homozygous O 0 0.02825656346976757
deficiency O 0 0.3613795340061188
characterized O 0 5.400628424467868e-07
by O 0 8.18795431456465e-09
the O 0 3.871982290348797e-09
absence O 0 2.7406970026788713e-09
of O 0 5.468035399469606e-11
the O 0 7.347937813761973e-10
150 O 0 3.707102180783295e-09
- O 0 3.18022603096324e-06
kD O 0 2.26750003662346e-07
form O 0 1.6113645140425348e-11
of O 0 1.4068927967070266e-10
Factor O 0 1.9404385653842837e-08
H O 1 0.825218915939331
and O 0 5.181126194742092e-09
the O 0 1.8279128211062812e-10
presence O 0 3.0680114004866255e-10
, O 0 2.467224757829456e-10
upon O 0 1.908743163525628e-10
immunoblotting O 0 1.8104465198121034e-06
, O 0 4.080159821118201e-10
of O 0 1.4805988032828843e-11
the O 0 1.301272978260215e-09
42 O 0 4.258979657834061e-08
- O 0 2.115620645781746e-06
kD O 0 9.357432873002836e-07
Factor O 0 1.3126259190698875e-08
H O 0 0.3259967565536499
- O 0 1.5755904314573854e-06
like O 0 1.1175944614194577e-09
protein O 0 9.070048601067526e-10
1 O 0 9.741141226982108e-10
( O 0 1.8894043274375605e-10
FHL O 0 2.235500886627051e-07
- O 0 2.280808530485956e-06
1 O 0 2.5615389809274802e-09
) O 0 1.5403466002705812e-10
and O 0 2.684218847193165e-09
other O 0 1.0948005169097996e-08
FH O 0 0.00024235433374997228
- O 0 2.4639348339405842e-05
related O 0 1.6165255090072606e-07
protein O 0 3.546152527178492e-08
( O 0 2.313557123656551e-09
FHR O 0 1.2633568076125812e-05
) O 0 2.5345174847757335e-09
bands O 0 4.4353669181873556e-08
. O 0 1.1828298340788024e-07

Southern O 0 7.901821845734958e-06
blot O 0 0.00028932245913892984
and O 0 1.7500309468232444e-07
PCR O 0 7.429285915350192e-07
analysis O 0 4.919578078244058e-09
of O 0 6.410684760815855e-10
DNA O 0 1.3791451465294813e-06
of O 0 4.208949189177247e-09
one O 0 6.9021105275624e-08
patient O 0 2.059037456092483e-07
with O 0 6.0913980632903986e-06
homozygous O 0 0.062042780220508575
deficiency O 0 0.12820398807525635
ruled O 0 2.0208744899719022e-07
out O 0 3.0520266314226774e-09
the O 0 8.375314330955064e-10
presence O 0 7.009993696627248e-10
of O 0 1.3879847271525136e-10
a O 0 1.0219387114318579e-08
large O 0 6.431986943056245e-09
deletion O 0 4.469906755844022e-08
of O 0 4.129822872567246e-10
the O 0 6.905441551907643e-08
FH O 0 6.901671440573409e-05
gene O 0 2.4125010877895647e-09
as O 0 9.249062626892623e-10
the O 0 3.11387466922497e-08
underlying O 0 5.928521204623394e-05
defect O 0 2.8756327083101496e-05
for O 0 3.077902022141643e-08
the O 0 6.566164665855467e-05
deficiency O 0 0.07272659987211227
. O 0 1.277938508792431e-06

The O 0 6.415216091681941e-08
other O 0 4.475245063417788e-09
four O 0 3.205411402973368e-08
children O 0 6.150771270085897e-08
presented O 0 2.782133776690898e-07
with O 0 8.531833373126574e-06
heterozygous O 0 0.04410979896783829
deficiency O 0 0.4003622233867645
and O 0 8.570536635943427e-08
exhibited O 0 1.6351111753465375e-07
a O 0 1.4929453229228784e-08
normal O 0 4.7845556849779314e-08
immunoblotting O 0 2.3188227714854293e-05
pattern O 0 1.7522966118121985e-06
of O 0 1.198848353922699e-09
proteins O 0 1.510171210306055e-09
of O 0 1.162515639308026e-09
the O 0 3.16906334774103e-06
FH O 0 0.04905049875378609
family O 0 6.308218144113198e-05
. O 0 3.6730605756929435e-07

Factor B-Disease 0 0.09333217144012451
H I-Disease 1 0.9999157190322876
deficiency I-Disease 1 0.9663663506507874
is O 0 3.307502538518747e-08
the O 0 1.8848098193302576e-08
only O 0 3.7992381862750335e-07
complement B-Disease 1 0.99216228723526
deficiency I-Disease 1 0.9999663829803467
associated O 0 2.8929193831572775e-06
with O 0 2.6593153961584903e-05
HUS B-Disease 1 0.998201847076416
. O 0 3.657495471998118e-05

These O 0 1.7162108179036295e-08
observations O 0 1.4033759043741156e-07
suggest O 0 2.0308100090460357e-08
a O 0 1.9212944568636203e-09
role O 0 5.430934368888529e-09
for O 0 2.144881250387698e-08
FH O 0 0.0003646303666755557
and O 0 1.6449835982257355e-07
/ O 0 9.254132464775466e-07
or O 0 2.2207072447599785e-07
FH O 0 1.9387223801459186e-05
receptors O 0 1.2285926942467995e-08
in O 0 4.196636815834154e-09
the O 0 5.05408586093381e-08
pathogenesis O 0 0.00011633237591013312
of O 0 3.422794861762668e-06
idiopathic O 1 0.9967531561851501
HUS B-Disease 1 0.9985439777374268
. O 0 1.5494939589189016e-06
. O 0 1.8088414890371496e-06

Further O 0 9.961109270761881e-08
evidence O 0 5.245443546186834e-08
for O 0 3.1356492402601077e-10
a O 0 4.836918865436246e-09
major O 0 5.3346136397181e-09
ancient O 0 8.260190611508733e-07
mutation O 0 9.093479457078502e-05
underlying O 1 0.9396079182624817
myotonic B-Disease 1 0.9999881982803345
dystrophy I-Disease 1 0.9999904632568359
from O 0 5.270161182124866e-06
linkage O 0 0.002028251765295863
disequilibrium O 0 0.08383657783269882
studies O 0 1.650596743729693e-07
in O 0 4.25766177869491e-09
the O 0 1.4179475371633998e-08
Japanese O 0 1.8769371763482923e-06
population O 0 5.442610362393907e-09
. O 0 1.5616585358202428e-07

The O 0 0.013173784129321575
myotonic B-Disease 1 0.9997281432151794
dystrophy I-Disease 1 0.9999312162399292
( O 0 0.0020337405148893595
DM B-Disease 1 0.9999589920043945
) O 0 1.0400917744846083e-05
mutation O 0 6.553946718668158e-07
is O 0 1.1014551404286976e-07
an O 0 7.629694209754234e-07
unstable O 0 0.2247721254825592
( O 0 2.1748300937929343e-08
CTG O 0 3.276166899013333e-05
) O 0 1.4121906311004295e-08
n O 0 3.371403352048219e-07
repeat O 0 1.196293482053079e-07
, O 0 5.602475816601782e-09
present O 0 6.575640587591636e-10
at O 0 4.7434209449193077e-08
a O 0 9.285316404650246e-10
copy O 0 8.921944072426413e-09
number O 0 1.6465185118108572e-11
of O 0 1.9775575621494568e-10
5 O 0 2.650788211155941e-08
- O 0 9.400147973792627e-06
37 O 0 1.4293031647127918e-08
repeats O 0 2.963469292183163e-08
on O 0 2.1272724026744072e-08
normal O 0 5.352160936666905e-10
chromosomes O 0 1.5100768635534223e-08
but O 0 6.433222843327258e-10
amplified O 0 3.878087184716605e-09
to O 0 1.0349666262898793e-10
50 O 0 2.459481784899964e-10
- O 0 2.4938123033280135e-07
3000 O 0 5.760553278832958e-08
copies O 0 2.701498402757352e-08
on O 0 5.342052099877037e-05
DM B-Disease 1 0.9999082088470459
chromosomes O 0 0.00014421749801840633
. O 0 1.2996536042919615e-06

Previous O 0 2.342202151339734e-06
findings O 0 5.065643335910863e-07
in O 0 6.07710717304144e-08
Caucasian O 0 1.7411775843356736e-05
populations O 0 2.88768458034383e-08
of O 0 5.9098139715274556e-09
a O 0 9.451379446545616e-05
DM B-Disease 1 0.9999880790710449
founder O 0 0.008769798092544079
chromosome O 0 1.2251631233084481e-05
raise O 0 1.844086305879955e-08
a O 0 1.1297125901421623e-08
question O 0 5.57692025893175e-09
about O 0 1.1114530407141388e-09
the O 0 1.0576751696689257e-09
molecular O 0 1.9669687389978208e-07
events O 0 1.0138331063558326e-08
involved O 0 3.3331368776146064e-09
in O 0 4.248955076668892e-10
the O 0 3.031546347287417e-09
expansion O 0 1.1505584751603237e-07
mutation O 0 1.0393537053232649e-07
. O 0 4.3905470192839857e-07

To O 0 4.592573077388806e-08
investigate O 0 5.32435997513403e-08
whether O 0 1.1174671854519147e-08
a O 0 1.9158793662654716e-08
founder O 0 3.6077212826057803e-06
chromosome O 0 1.529704832137213e-06
for O 0 1.5080555693103292e-09
the O 0 1.119447802011564e-06
DM B-Disease 1 0.9999810457229614
mutation O 0 8.660423134188022e-08
exists O 0 8.313085775313311e-10
in O 0 2.6100371863790883e-10
the O 0 1.0866365585116e-09
Japanese O 0 1.863907215238214e-07
population O 0 4.038582246401745e-10
, O 0 3.804260906292711e-09
we O 0 1.465789489785152e-09
genotyped O 0 9.50718458625488e-07
families O 0 6.842907351867211e-10
using O 0 9.531690992048425e-10
polymorphic O 0 2.0472850792430108e-07
markers O 0 9.85931619652547e-05
near O 0 2.5726023523020558e-05
the O 0 2.9033813575551903e-07
( O 0 1.5979340517446872e-08
CTG O 0 9.187072464555968e-06
) O 0 1.2264738558087629e-08
n O 0 4.3055604237451917e-07
repeat O 0 3.8727677065253374e-07
region O 0 1.048310505069594e-08
and O 0 5.3106980146822025e-08
constructed O 0 1.7150421626865864e-05
haplotypes O 0 6.60618461552076e-05
. O 0 9.870872190731461e-07

Six O 0 1.0838162012305474e-07
different O 0 1.90938842514754e-09
haplotypes O 0 1.1929651009268127e-05
were O 0 1.132518036683905e-06
found O 0 2.577621444288525e-06
and O 0 2.9654822810698533e-06
DM B-Disease 1 0.9999312162399292
alleles O 0 1.6648282041842322e-07
were O 0 2.173248816461637e-07
always O 0 1.2048782593865326e-07
haplotype O 0 1.5564128261758015e-05
A O 0 4.221923063596478e-06
. O 0 1.9443232304183766e-06

To O 0 2.91683512898544e-08
find O 0 2.105245577865844e-08
an O 0 9.893410535255498e-10
origin O 0 2.2077213390758743e-09
of O 0 1.302017826887436e-09
the O 0 5.257463087104952e-08
( O 0 3.1386186982729214e-09
CTG O 0 3.0485571187455207e-06
) O 0 3.136392479063943e-09
n O 0 1.7410184227628633e-07
repeat O 0 7.00398530284474e-08
mutation O 0 4.3976600139217226e-09
and O 0 8.781512406130787e-09
to O 0 2.88129964332029e-10
investigate O 0 2.5595119357291196e-09
the O 0 3.829039030289749e-10
mechanism O 0 3.1423443846989585e-09
of O 0 8.804479367796603e-11
the O 0 1.565816365456385e-09
expansion O 0 4.3562358165161186e-09
mutation O 0 1.1485511430819884e-09
in O 0 3.512892754464758e-10
the O 0 8.83422446307236e-10
Japanese O 0 5.366855759803002e-08
population O 0 3.8077780512013604e-11
we O 0 9.982208115655311e-11
have O 0 2.537088074350269e-11
studied O 0 8.560117892297825e-11
90 O 0 7.112810895826271e-10
Japanese O 0 1.8238353050037404e-06
DM B-Disease 1 0.9999326467514038
families O 0 5.552730719671217e-09
comprising O 0 9.508026310722784e-11
190 O 0 1.0927601046262225e-08
affected O 0 3.503076995148291e-10
and O 0 2.0925738919430614e-09
130 O 0 1.6868856533847065e-08
unaffected O 0 3.2633690238981217e-07
members O 0 1.785372849560929e-09
. O 0 8.04286344191496e-08

The O 0 6.796216780458053e-07
results O 0 1.0805873671415611e-06
suggest O 0 3.7896409565973954e-08
that O 0 2.546496125077624e-09
a O 0 3.365910661301541e-09
few O 0 4.064665937164591e-09
common O 0 7.853745209729368e-09
ancestral O 0 1.0682558695407351e-06
mutations O 0 4.294398081583495e-08
in O 0 5.2375228598577905e-09
both O 0 1.3724069880538536e-08
Caucasian O 0 1.4300675502454396e-05
and O 0 2.2999681448254705e-07
Japanese O 0 3.740864258361398e-07
populations O 0 9.320235694332268e-10
have O 0 7.605082674722041e-10
originated O 0 8.195106815378495e-10
by O 0 1.2920671477179013e-10
expansion O 0 4.677810361286561e-10
of O 0 6.78169256862482e-11
an O 0 1.6330713448198253e-09
ancestral O 0 3.5674588616529945e-06
n O 0 4.6357772589544766e-06
= O 0 3.7332944202717044e-07
5 O 0 3.0476692280956286e-09
repeat O 0 7.99652699612352e-09
to O 0 1.8429355819193916e-09
n O 0 4.811158191841969e-07
= O 0 3.5087316518911393e-07
19 O 0 6.897359128288372e-08
- O 0 1.3426361874735449e-05
37 O 0 4.6897326910766424e-08
copies O 0 4.519509388956067e-08
. O 0 5.324633889358665e-08

These O 0 3.8819432113257335e-09
data O 0 3.1566536051741423e-09
support O 0 2.0360906016758662e-10
multistep O 0 1.1609119887623365e-08
models O 0 3.130805836804029e-08
of O 0 5.834902006007781e-10
triplet O 0 4.546805575955659e-05
repeat O 0 1.16217017875897e-06
expansion O 0 4.88161262524045e-08
that O 0 1.0073354594908324e-08
have O 0 1.7769813398516021e-09
been O 0 1.2472709531863302e-09
proposed O 0 4.691884103458221e-10
for O 0 1.0159949548338432e-09
both O 0 1.9509060678046808e-07
DM B-Disease 1 0.9999734163284302
and O 0 3.3259297197218984e-05
Friedreichs B-Disease 0 0.0008886131690815091
ataxia I-Disease 0 0.0009514998528175056
. O 0 9.288972790955086e-08
. O 0 4.627463283668476e-07

The O 0 1.0408829353991678e-08
molecular O 0 2.502947609173134e-07
basis O 0 4.27630979515925e-08
of O 0 5.4391402954934165e-05
C6 B-Disease 1 0.9999946355819702
deficiency I-Disease 1 0.9999890327453613
in O 0 1.820791872830796e-08
the O 0 9.694066882559582e-09
western O 0 2.7007314429283724e-07
Cape O 0 5.544718078454025e-06
, O 0 3.3377062891304377e-08
South O 0 2.3040516339278838e-07
Africa O 0 5.735446961807611e-08
. O 0 2.7192820439836396e-08

Deficiency B-Disease 1 0.8070508241653442
of I-Disease 0 5.996951824016605e-09
the I-Disease 0 1.7871283120030057e-08
sixth I-Disease 0 6.816871405135316e-07
component I-Disease 0 1.7723010614645318e-08
of I-Disease 0 3.6439021244838443e-10
human I-Disease 0 3.2284803719306865e-09
complement I-Disease 0 5.9903673133021584e-09
( O 0 2.0059132133098956e-09
C6 O 0 0.0006617755861952901
) O 0 1.7479550251664477e-08
has O 0 1.0518038351392534e-07
been O 0 2.666697014319652e-07
reported O 0 2.4210962692450266e-06
in O 0 5.432112537562261e-10
a O 0 2.0360566566068883e-09
number O 0 1.362239904212359e-10
of O 0 8.726440681172676e-10
families O 0 1.4403786607886104e-08
from O 0 3.582683871794501e-10
the O 0 1.0597409616508457e-09
western O 0 7.092793907759187e-08
Cape O 0 1.1630594372036285e-06
, O 0 6.0226748033187505e-09
South O 0 8.145868690689895e-08
Africa O 0 8.370610515839871e-08
. O 0 3.658628244807005e-08

Meningococcal B-Disease 1 0.9906533360481262
disease I-Disease 1 0.8222771883010864
is O 0 5.46857245353749e-06
endemic O 0 7.283947343239561e-05
in O 0 3.91820123013531e-08
the O 0 2.351835206582109e-07
Cape O 0 9.740276254888158e-06
and O 0 6.051738665746598e-09
almost O 0 9.494561387102252e-11
all O 0 3.28632468460377e-11
pedigrees O 0 4.5825109395991603e-07
of O 0 2.9458975703278156e-08
total O 0 0.0009809400653466582
C6 B-Disease 1 0.9999982118606567
deficiency I-Disease 1 0.9999961853027344
( O 0 2.1543981176819216e-07
C6Q0 O 0 0.001415702048689127
) O 0 1.0775002223795127e-08
have O 0 2.86996937326478e-09
been O 0 6.293702625725928e-08
ascertained O 0 2.646000325512432e-07
because O 0 1.1516228859420607e-08
of O 0 6.797423424131921e-08
recurrent O 0 0.15181325376033783
disease O 0 0.005508385598659515
. O 0 2.2481692667497555e-06

We O 0 1.1876677064037722e-07
have O 0 2.357235961980564e-09
sequenced O 0 3.1399778332996675e-09
the O 0 7.588289441251561e-10
expressed O 0 7.096400689299287e-10
exons O 0 1.938337312878957e-08
of O 0 5.003867320496624e-10
the O 0 3.170122653273211e-08
C6 O 0 0.00031658748048357666
gene O 0 3.542898419084395e-09
from O 0 6.76266875831999e-10
selected O 0 1.803628496555021e-10
cases O 0 2.5812845194650436e-09
and O 0 7.698714910020499e-08
have O 0 2.4386599406511777e-08
found O 0 7.037758820160889e-08
three O 0 2.6181280077253177e-07
molecular O 0 0.010770718567073345
defects O 1 0.8860674500465393
leading O 0 1.9602007341745775e-06
to O 0 1.7833494325714128e-07
total O 0 4.765684479934862e-06
deficiency O 0 0.004246768541634083
879delG O 0 1.9851192973874277e-06
, O 0 6.63944135226302e-08
which O 0 2.175838353934978e-08
is O 0 1.699752227857232e-09
the O 0 3.383237690002261e-09
common O 0 1.3572001478223683e-07
defect O 0 9.826738278206903e-06
in O 0 1.5885794901748795e-09
the O 0 2.6205903225218208e-08
Cape O 0 1.484836843701487e-06
and O 0 1.334227839322466e-08
hitherto O 0 1.1439217217912301e-07
unreported O 0 3.56021487846192e-08
, O 0 1.3754095640194919e-09
and O 0 1.0386061788381085e-08
1195delC O 0 3.7486282167265017e-07
and O 0 4.906667072646087e-08
1936delG O 0 1.5272020164047717e-06
, O 0 6.28725738138769e-09
which O 0 1.0649429782461084e-08
have O 0 6.878214886540945e-09
been O 0 5.716509221542765e-08
previously O 0 2.735466466674552e-07
reported O 0 4.814500243810471e-06
in O 0 8.994424760544462e-09
African O 0 7.844137428492104e-08
- O 0 9.94838192127645e-05
Americans O 0 1.415544517158196e-07
. O 0 7.412754854385639e-08

We O 0 2.953972568775498e-07
also O 0 4.724657642896091e-08
show O 0 3.304148066263224e-08
that O 0 8.452473720943487e-10
the O 0 3.091025879697895e-09
879delG O 0 4.8447227527503856e-06
and O 0 1.5865657587710302e-06
1195delC O 0 0.002901080995798111
defects O 0 0.23231777548789978
are O 0 1.1519342146826261e-09
associated O 0 5.632798227850344e-09
with O 0 3.7141600017776e-08
characteristic O 0 5.4661322792526335e-06
C6 O 1 0.7437052130699158
/ O 0 0.00020127571769990027
C7 O 0 0.04511081054806709
region O 0 1.081759180010522e-07
DNA O 0 8.880590030457824e-06
marker O 0 6.878005660837516e-05
haplotypes O 0 2.6152183636440895e-05
, O 0 5.096660515846452e-08
although O 0 2.5768769340572817e-09
small O 0 2.1522730264678103e-09
variations O 0 9.38841360209608e-09
were O 0 1.1524429766041067e-07
observed O 0 7.893964948380017e-07
. O 0 4.3906226210310706e-07

The O 0 1.2357039622656885e-06
1936delG O 0 0.0005950121558271348
defect O 0 0.00026876432821154594
was O 0 2.0855281945841853e-06
observed O 0 1.495869739187583e-08
only O 0 4.973437772726186e-10
once O 0 1.6123969714954e-08
in O 0 1.0371843384149315e-09
the O 0 3.609746812571757e-08
Cape O 0 4.552369773591636e-06
, O 0 1.1335631988629302e-08
but O 0 2.1419979123749044e-09
its O 0 3.374479362605598e-09
associated O 0 3.357160593964181e-08
haplotype O 0 3.0139142381813144e-06
could O 0 4.1845535037055015e-08
be O 0 2.959784639600116e-09
deduced O 0 2.6900175953414873e-07
. O 0 2.032077759395179e-07

The O 0 7.574645621843956e-08
data O 0 2.1324078147699765e-07
from O 0 5.3512247966125415e-09
the O 0 1.6807259584084022e-08
haplotypes O 0 2.861526127162506e-06
indicate O 0 5.470902308957193e-08
that O 0 2.8814550745437373e-09
these O 0 1.8267522217119136e-10
three O 0 8.272916574014744e-08
molecular O 0 0.011252790689468384
defects O 1 0.5455595254898071
account O 0 1.7967664689422236e-08
for O 0 1.274674410467469e-08
the O 0 2.2296826500678435e-06
defects O 0 0.14982827007770538
in O 0 2.7192235130257814e-09
all O 0 9.026881325757685e-11
the O 0 4.063022807088146e-09
38 O 0 1.0716102849528397e-07
unrelated O 0 9.590906302037183e-06
C6Q0 O 0 0.0011251351097598672
individuals O 0 6.84507450721128e-10
we O 0 1.0513897530373129e-09
have O 0 3.5582695123714814e-10
studied O 0 9.079395568711845e-10
from O 0 6.260736373775444e-10
the O 0 7.025339243682538e-08
Cape O 0 1.700148277450353e-05
. O 0 3.787300499880075e-07

We O 0 6.126254561422684e-07
have O 0 1.3605819582096501e-08
also O 0 2.5118600532891833e-09
observed O 0 3.431079864668618e-09
the O 0 8.975521659237984e-09
879delG O 0 2.0725197828141972e-05
defect O 0 9.16016233531991e-06
in O 0 2.664940712548969e-09
two O 0 3.4499160506129556e-07
Dutch O 0 0.06805284321308136
C6 B-Disease 1 0.9999828338623047
- I-Disease 1 0.9997145533561707
deficient I-Disease 1 0.9999027252197266
kindreds O 0 4.247853212291375e-05
, O 0 1.631957324832456e-08
but O 0 2.7906241761854744e-09
the O 0 3.6970118078016867e-09
879delG O 0 3.9034053770592436e-05
defect O 0 4.984229690307984e-06
in O 0 4.203493997323449e-09
the O 0 7.972255389177008e-08
Cape O 0 1.6812422472867183e-05
probably O 0 2.4301448320329655e-07
did O 0 5.247782208783747e-09
not O 0 1.8599982665179482e-10
come O 0 1.1927214771390027e-10
from O 0 7.24206319913101e-11
The O 0 1.0583957044119074e-09
Netherlands O 0 2.620066084091377e-07
. O 0 5.330118124646788e-09
. O 0 9.235585451961015e-08

Complement B-Disease 0 0.04312707111239433
C7 I-Disease 1 0.999788224697113
deficiency I-Disease 1 0.9999102354049683
: O 0 4.097188934792939e-07
seven O 0 6.54708713909713e-08
further O 0 4.977609080469847e-08
molecular O 0 0.006160881370306015
defects O 1 0.9647023677825928
and O 0 2.6264558528055204e-07
their O 0 1.1644861785953253e-07
associated O 0 1.3508408756024437e-06
marker O 0 0.00014941835252102464
haplotypes O 0 0.0001978726650122553
. O 0 2.106650981659186e-06

Seven O 0 1.3853721725354262e-07
further O 0 5.7195492786377145e-09
molecular O 0 8.208910458051832e-07
bases O 0 2.502179086150136e-06
of O 0 0.00022869149688631296
C7 B-Disease 1 0.9999876022338867
deficiency I-Disease 1 0.9999701976776123
are O 0 1.1878364603035152e-07
described O 0 5.767876064055599e-05
. O 0 4.6756304072914645e-06

All O 0 4.4728727388587686e-09
these O 0 6.661253215689555e-10
new O 0 1.5006163422981444e-08
molecular O 0 2.0853231035289355e-05
defects O 0 0.0017766740638762712
involve O 0 1.561759943591312e-09
single O 0 1.3074710203397899e-08
- O 0 8.328094736498315e-06
nucleotide O 0 2.8051998057776473e-08
events O 0 8.374296811552995e-09
, O 0 2.5877617826353116e-09
deletions O 0 1.576034591721509e-08
and O 0 1.3187942293768629e-08
substitutions O 0 3.4261555814651956e-09
, O 0 1.6740832053940835e-09
some O 0 2.402340479323861e-12
of O 0 1.01194663759685e-10
which O 0 1.103753266562535e-08
alter O 0 4.246131624086047e-08
splice O 0 3.5834302707371535e-06
sites O 0 2.310599995780649e-07
, O 0 2.208210858611892e-08
and O 0 2.7313049599797523e-08
others O 0 1.8873064888680346e-08
codons O 0 9.429927416704231e-08
. O 0 1.5900890559805703e-07

They O 0 8.70095391292125e-08
are O 0 1.9893532654524648e-10
distributed O 0 2.4523241770602056e-10
along O 0 9.9486441307306e-10
the O 0 1.9250441241069893e-08
C7 O 0 0.000762205570936203
gene O 0 3.5593526348520754e-08
, O 0 1.3933388665066104e-08
but O 0 3.817291205354678e-10
predominantly O 0 5.442945139738642e-12
towards O 0 3.501834378027979e-10
the O 0 7.203277530010155e-09
3 O 0 1.4804859915784618e-07
end O 0 1.4994882349128602e-06
. O 0 1.5617763438058319e-07

All O 0 6.30252046107671e-08
were O 0 3.907000518665882e-07
found O 0 6.039840627636295e-07
in O 0 7.084773656629295e-09
compound O 0 2.842481535481056e-06
heterozygous O 0 8.185231763491174e-07
individuals O 0 1.2615745781374699e-08
. O 0 4.739920882457227e-07

The O 0 2.755721880021156e-06
C6 O 1 0.5540380477905273
/ O 0 0.001541724894195795
C7 O 0 0.3403206169605255
marker O 0 0.0008619725704193115
haplotypes O 0 0.00031610223231837153
associated O 0 6.401368182196165e-07
with O 0 1.775077578258788e-07
most O 0 1.4837526123301359e-06
C7 B-Disease 1 0.9996317625045776
defects I-Disease 1 0.9983755350112915
are O 0 4.4446910152373675e-08
tabulated O 0 0.00019015479483641684
. O 0 2.03342295890252e-07
. O 0 5.963761964267178e-07

A O 0 1.0211173503194004e-05
genome O 0 1.5001710380602162e-05
- O 0 2.6042152967420407e-05
wide O 0 7.734671925163639e-08
search O 0 2.17192823726009e-08
for O 0 9.627143526813597e-09
chromosomal O 0 6.928727816557512e-05
loci O 0 2.0561776636895956e-06
linked O 0 0.0013824733905494213
to O 0 1.776235308170726e-06
mental O 0 0.00015242131485138088
health O 0 5.391011086430808e-07
wellness O 0 1.2436733413778711e-05
in O 0 1.204353310413353e-07
relatives O 0 1.1422008583394927e-06
at O 0 4.1946364945033565e-05
high O 0 0.00043751910561695695
risk O 0 1.1389071005396545e-05
for O 0 1.8779828678816557e-06
bipolar B-Disease 1 0.9998860359191895
affective I-Disease 1 0.9965903759002686
disorder I-Disease 0 0.2861213684082031
among O 0 2.8552509689916405e-08
the O 0 9.149758994908552e-08
Old O 0 0.00014000591181684285
Order O 0 4.0677784340914513e-07
Amish O 0 0.0001253834052477032
. O 0 6.746120106981834e-07

Bipolar B-Disease 1 0.9985503554344177
affective I-Disease 1 0.9984583854675293
disorder I-Disease 1 0.9990899562835693
( O 0 0.0007782617467455566
BPAD B-Disease 1 0.99993896484375
; O 0 0.018216075375676155
manic B-Disease 1 0.9998342990875244
- I-Disease 1 0.9999713897705078
depressive I-Disease 1 0.9999781847000122
illness I-Disease 1 0.9705309867858887
) O 0 8.294244935314055e-07
is O 0 4.693965394153565e-08
characterized O 0 7.82005486144044e-07
by O 0 6.535033403309853e-09
episodes O 0 3.56138400547934e-07
of O 0 1.3121220376888232e-07
mania B-Disease 0 0.4960959553718567
and O 0 4.689590241468977e-06
/ O 0 1.1056475159421097e-05
or O 0 1.4770380403206218e-06
hypomania B-Disease 0 0.001891688210889697
interspersed O 0 4.3092759369756095e-06
with O 0 1.6697795501841028e-07
periods O 0 1.1798915267036136e-07
of O 0 1.6917744005695567e-07
depression B-Disease 0 0.00012099135346943513
. O 0 1.4159780903355568e-06

Compelling O 0 4.68012643750626e-07
evidence O 0 2.654958279890707e-07
supports O 0 6.536269125945182e-08
a O 0 1.5621449023228706e-08
significant O 0 4.1991807253616287e-10
genetic O 0 2.3550215999534885e-08
component O 0 1.6722522033774112e-08
in O 0 5.154670468243694e-09
the O 0 3.1367171970941854e-08
susceptibility O 0 3.2509797165403143e-06
to O 0 1.0617631573950348e-07
develop O 0 1.13266169137205e-05
BPAD B-Disease 1 0.9995027780532837
. O 0 6.501134976133471e-06

To O 0 6.51954792374454e-08
date O 0 3.2991547982419434e-07
, O 0 3.069295928526117e-08
however O 0 2.710167423813914e-09
, O 0 3.0784406135353493e-09
linkage O 0 7.264429768838454e-07
studies O 0 7.499372678410055e-09
have O 0 1.6202019725852779e-09
attempted O 0 3.3207396654688637e-07
only O 0 1.0118384602408881e-10
to O 0 2.887472760892962e-10
identify O 0 2.1485456969116967e-08
chromosomal O 0 3.4426826459821314e-05
loci O 0 2.0635586395201244e-07
that O 0 1.1676160056595108e-06
cause O 0 3.285302625499753e-07
or O 0 5.301710714888941e-08
increase O 0 2.000995147355411e-09
the O 0 3.930589542733287e-08
risk O 0 4.4426994350033056e-07
of O 0 2.0408982948083576e-08
developing O 0 5.789395800093189e-06
BPAD B-Disease 1 0.9995342493057251
. O 0 3.5413036130194087e-06

To O 0 1.4527260816521448e-07
determine O 0 7.910923471854403e-08
whether O 0 5.513145495683602e-09
there O 0 1.382684966522163e-09
could O 0 9.331624362118873e-09
be O 0 1.6157641891112462e-09
protective O 0 1.093646631034062e-07
alleles O 0 1.2997754872401401e-08
that O 0 2.7858021667270805e-08
prevent O 0 1.449523665542074e-07
or O 0 1.635313218173451e-08
reduce O 0 7.013180258752527e-09
the O 0 1.3272731358426881e-08
risk O 0 3.6767890065902975e-08
of O 0 1.2987115827201023e-09
developing O 0 5.668988478646497e-07
BPAD B-Disease 1 0.999871015548706
, O 0 1.856431097735367e-08
similar O 0 1.975251517905008e-09
to O 0 1.0525214033663133e-09
what O 0 1.2691013795418371e-09
is O 0 1.0028566865827315e-09
observed O 0 5.103350186885791e-09
in O 0 2.87631145567957e-08
other O 0 4.6553232095902786e-06
genetic B-Disease 1 0.99998939037323
disorders I-Disease 1 0.9999934434890747
, O 0 3.829601610050304e-06
we O 0 1.9943728091220692e-07
used O 0 3.22588971357618e-06
mental O 0 0.001968148397281766
health O 0 9.664316849011811e-07
wellness O 0 2.639889862621203e-05
( O 0 6.360144411132751e-09
absence O 0 6.709814481808962e-09
of O 0 9.330308081700878e-09
any O 0 6.056660026843019e-07
psychiatric B-Disease 0 0.1276930719614029
disorder I-Disease 0 0.008934919722378254
) O 0 1.2167575391686114e-08
as O 0 1.277443484326568e-09
the O 0 2.0243517084850282e-08
phenotype O 0 8.936064546105627e-07
in O 0 8.61116955519492e-09
our O 0 2.6685842868801046e-08
genome O 0 1.3650134178533335e-06
- O 0 2.5932982680387795e-05
wide O 0 4.81896442749985e-08
linkage O 0 1.5333532701333752e-06
scan O 0 1.080807919606741e-06
of O 0 2.640174190382538e-10
several O 0 7.268831092588357e-10
large O 0 9.013229274046353e-09
multigeneration O 0 1.135175898525631e-05
Old O 0 6.618138741032453e-06
Order O 0 4.359244520912853e-09
Amish O 0 3.5313751141075045e-06
pedigrees O 0 6.636794864789408e-07
exhibiting O 0 2.0958584201480335e-08
an O 0 7.220719577816226e-09
extremely O 0 1.0751538184194942e-06
high O 0 3.702630056068301e-05
incidence O 0 0.00012723520922008902
of O 0 8.172057732735993e-07
BPAD B-Disease 1 0.9998443126678467
. O 0 1.0205321814282797e-05

We O 0 4.5007479343439627e-07
have O 0 7.715635064187154e-08
found O 0 7.718990957528149e-08
strong O 0 1.0968566055424844e-09
evidence O 0 2.969165135979779e-09
for O 0 1.1046241005230328e-10
a O 0 5.559576798930266e-09
locus O 0 4.0139590851140383e-07
on O 0 1.738832906994503e-05
chromosome O 0 0.010745290666818619
4p O 1 0.5636070370674133
at O 0 6.49337789582205e-06
D4S2949 O 0 5.468439780997869e-07
( O 0 2.628005590921134e-10
maximum O 0 1.173908192875217e-09
GENEHUNTER O 0 9.76464434643276e-06
- O 0 1.0369621122663375e-05
PLUS O 0 9.199347950072934e-09
nonparametric O 0 1.7018940923207992e-08
linkage O 0 7.512030464340569e-08
score O 0 4.132062692008276e-09
= O 0 4.144330389976858e-08
4 O 0 2.5129143210733673e-09
. O 0 6.425840415325013e-10
05 O 0 1.0410957429485279e-07
, O 0 1.808867011732218e-08
P O 0 1.9274897567811422e-05
= O 0 3.190369923800063e-08
5 O 0 5.200668229399241e-10
. O 0 1.948124161987863e-10
22 O 0 2.9401703294240633e-09
x O 0 6.451353442571417e-07
10 O 0 2.0715358317602295e-08
( O 0 5.288958715432557e-10
- O 0 4.231415914546233e-06
4 O 0 1.2158845663634565e-07
) O 0 3.7945571129682776e-09
; O 0 7.559455839079021e-10
SIBPAL O 0 6.717538667544432e-07
Pempirical O 0 1.3989421177029726e-07
value O 0 2.761385287097795e-10
< O 0 2.398873322206896e-09
3 O 0 2.503422802391242e-09
x O 0 1.7402029470758862e-06
10 O 0 1.4708397166884879e-08
( O 0 1.1562398816167274e-09
- O 0 1.8534648916102014e-05
5 O 0 1.2235956603490195e-07
) O 0 4.479164594783924e-09
) O 0 7.750111108428825e-10
and O 0 3.153740602002131e-09
suggestive O 0 3.0026999553456335e-08
evidence O 0 7.501346210858628e-09
for O 0 1.5242053452713122e-10
a O 0 7.337199736667799e-09
locus O 0 1.027665689434798e-06
on O 0 0.0002713982539717108
chromosome O 0 0.07591476291418076
4q O 0 0.03362603858113289
at O 0 3.0551900636055507e-06
D4S397 O 0 2.0096985053896788e-07
( O 0 1.03098272974389e-10
maximum O 0 1.548805417250776e-09
GENEHUNTER O 0 3.980692781624384e-05
- O 0 5.057392627350055e-06
PLUS O 0 9.940986700485155e-09
nonparametric O 0 1.850901476529998e-08
linkage O 0 5.915478240581251e-08
score O 0 2.849477098720854e-09
= O 0 2.8020556541719088e-08
3 O 0 2.301603352350412e-09
. O 0 8.599905232387073e-10
29 O 0 3.9737752643986823e-08
, O 0 6.993264189958381e-09
P O 0 1.0652288437995594e-05
= O 0 3.859663166849714e-08
2 O 0 1.5081677018358164e-09
. O 0 7.797232304262991e-10
57 O 0 2.40786839356133e-08
x O 0 2.66671759163728e-06
10 O 0 3.5650394636377314e-08
( O 0 4.740277614878607e-10
- O 0 4.632029686035821e-06
3 O 0 9.067081663260979e-08
) O 0 4.5967158968096555e-09
; O 0 5.960935633986253e-10
SIBPAL O 0 5.837584922119277e-07
Pempirical O 0 9.60022887852574e-08
value O 0 8.529298795023621e-11
< O 0 3.802032022548474e-10
1 O 0 4.91121310286502e-10
x O 0 1.2826942565880017e-06
10 O 0 2.3770397206135385e-08
( O 0 5.800381841503111e-10
- O 0 7.09497680873028e-06
3 O 0 1.7703253263334773e-07
) O 0 3.1175930725879653e-09
) O 0 1.1717004033684475e-09
that O 0 3.803121817469446e-09
are O 0 8.224074754537014e-10
linked O 0 8.714523573871702e-06
to O 0 4.622470441972837e-07
mental O 0 0.00015170415281318128
health O 0 2.923285649103491e-07
wellness O 0 2.1956149794277735e-05
. O 0 8.214752824642346e-07

These O 0 6.449052136758837e-08
findings O 0 2.3612788879745494e-07
are O 0 9.384918397969955e-10
consistent O 0 3.131490844410223e-09
with O 0 5.564456895257308e-09
the O 0 2.021677580898995e-08
hypothesis O 0 5.132697111775997e-08
that O 0 6.872415969638723e-10
certain O 0 7.142144514693527e-11
alleles O 0 9.125651345698316e-09
could O 0 9.130147304858838e-08
prevent O 0 2.0594725924638624e-08
or O 0 1.1848231729061354e-08
modify O 0 1.3787301966772247e-08
the O 0 2.2377719233190874e-08
clinical O 0 7.699185289311572e-08
manifestations O 0 3.756659339160251e-07
of O 0 2.3921086267364444e-07
BPAD B-Disease 1 0.9999771118164062
and O 0 9.754579650689266e-07
perhaps O 0 2.4512745611104947e-08
other O 0 2.2904023566638898e-08
related O 0 9.278990182792768e-05
affective B-Disease 1 0.7649033665657043
disorders I-Disease 1 0.8726589679718018
. O 0 2.4253382434835657e-05

Segregation O 0 0.007351683918386698
distortion O 1 0.5574576258659363
in O 0 0.014936263673007488
myotonic B-Disease 1 0.9992769360542297
dystrophy I-Disease 1 0.9994580149650574
. O 0 0.0022364926990121603

Myotonic B-Disease 1 0.9992132186889648
dystrophy I-Disease 1 0.9998533725738525
( O 0 0.01921781711280346
DM B-Disease 1 0.9999442100524902
) O 0 0.0001092999373213388
is O 0 1.3006579138163943e-06
an O 0 1.573666736476298e-06
autosomal B-Disease 0 0.3715967833995819
dominant I-Disease 1 0.7653102874755859
disease I-Disease 0 0.255997896194458
which O 0 3.0442952265730128e-06
, O 0 8.71771561605783e-08
in O 0 1.9812471663271936e-09
the O 0 2.0313175141950524e-08
typical O 0 5.650437060467084e-07
pedigree O 0 2.907561975007411e-05
, O 0 1.244913860887209e-08
shows O 0 5.15423836944251e-09
a O 0 3.642361745548328e-09
three O 0 1.3242639873567441e-08
generation O 0 1.6371676281323744e-07
anticipation O 0 1.681483325910449e-07
cascade O 0 5.6112730817403644e-05
. O 0 4.4309282998256094e-07

This O 0 1.8002558022089943e-07
results O 0 6.059484348952537e-06
in O 0 1.9310115021653473e-05
infertility B-Disease 1 0.9987693428993225
and O 1 0.9951661825180054
congenital B-Disease 1 0.999991774559021
myotonic I-Disease 1 0.9999945163726807
dystrophy I-Disease 1 0.9999947547912598
( O 0 1.1147293662361335e-05
CDM B-Disease 0 0.0004966770065948367
) O 0 5.5300095169741326e-08
with O 0 9.750309892808673e-09
the O 0 7.094309495414564e-08
disappearance O 0 0.00034004170447587967
of O 0 1.57494002905878e-06
DM B-Disease 1 0.9999855756759644
in O 0 4.2736189698189264e-07
that O 0 1.0293017567164497e-06
pedigree O 0 0.00047566951252520084
. O 0 9.624812946640304e-07

The O 0 7.525292389232163e-09
concept O 0 6.924695483689902e-09
of O 0 2.1737756039641454e-09
segregation O 0 2.9069547053950373e-06
distortion O 0 7.275783718796447e-05
, O 0 2.5173385154175776e-08
where O 0 2.2444390790354873e-09
there O 0 1.5122861296568146e-10
is O 0 2.631351248005842e-10
preferential O 0 2.1558463347837176e-10
transmission O 0 2.793709938941902e-07
of O 0 4.759872357373851e-11
the O 0 4.5097059420129426e-10
larger O 0 8.264108841693485e-10
allele O 0 1.7492524762019457e-08
at O 0 3.182940133683587e-07
the O 0 7.626907176927489e-07
DM B-Disease 1 0.9999842643737793
locus O 0 0.00011690607061609626
, O 0 4.225094869525492e-07
has O 0 6.356823689657176e-08
been O 0 1.8622115405264594e-08
put O 0 5.288477211706777e-09
forward O 0 3.1833158331551203e-10
to O 0 4.901742345353455e-10
explain O 0 1.1184906334449352e-08
partially O 0 2.2770043983655341e-07
the O 0 9.207440143654821e-09
maintenance O 0 5.935906983722816e-07
of O 0 1.6846807682213694e-07
DM B-Disease 1 0.9999682903289795
in O 0 6.160069432326054e-08
the O 0 3.0811442286449164e-08
population O 0 8.470958157147379e-09
. O 0 2.4430835310340626e-07

In O 0 3.084467152802972e-07
a O 0 1.3115352714976325e-07
survey O 0 6.548486339852388e-07
of O 0 3.741962828485157e-08
DM B-Disease 1 0.9999606609344482
in O 0 7.945401847564426e-08
Northern O 0 4.06933757801653e-08
Ireland O 0 1.509527578491543e-07
, O 0 2.7722432349719384e-08
59 O 0 1.2346704636456707e-07
pedigrees O 0 9.754636494108126e-07
were O 0 2.2991260095750476e-07
ascertained O 0 2.4468238279951038e-06
. O 0 3.034848816696467e-07

Sibships O 0 0.00028470056713558733
where O 0 1.0281819129431824e-07
the O 0 9.42362632372351e-10
status O 0 1.2093062662366094e-10
of O 0 9.243891069266041e-11
all O 0 3.089307629156046e-11
the O 0 6.441129296597126e-10
members O 0 5.843355799228789e-10
had O 0 1.4101484566708677e-06
been O 0 9.652557508843529e-08
identified O 0 2.2507592234433105e-08
were O 0 1.746272282332484e-08
examined O 0 3.0035533171712814e-08
to O 0 1.5199146108368922e-10
determine O 0 6.531515328589421e-10
the O 0 1.1013426837180873e-09
transmission O 0 1.7889003629534272e-06
of O 0 1.0740832667721634e-09
the O 0 9.682813697509118e-07
DM B-Disease 1 0.9999872446060181
expansion O 0 4.932080628350377e-07
from O 0 6.941092589585196e-09
affected O 0 5.496941235527686e-10
parents O 0 4.11707959391272e-11
to O 0 4.979699985696584e-11
their O 0 4.254057550667767e-09
offspring O 0 5.523241384253197e-07
. O 0 3.7260667795635527e-07

Where O 0 1.8099977694419067e-07
the O 0 1.5493736071903186e-08
transmitting O 0 5.119965862832032e-05
parent O 0 3.0015430638741236e-06
was O 0 2.0068950107088313e-05
male O 0 3.979157270350697e-07
, O 0 7.599638252031582e-08
58 O 0 1.1620815030255471e-06
. O 0 2.6710495149018243e-07

3 O 0 4.255969543009996e-06
% O 0 1.627611645460547e-08
of O 0 1.8488918729353543e-10
the O 0 3.737082199251063e-09
offspring O 0 9.683242296887329e-08
were O 0 1.94929739905092e-07
affected O 0 4.912939388646009e-09
, O 0 1.4412525395357534e-08
and O 0 2.4913251905900324e-08
in O 0 2.6882460701926902e-09
the O 0 4.260797492605661e-09
case O 0 8.061354606070381e-08
of O 0 1.6773712974149646e-10
a O 0 4.778144813144536e-08
female O 0 5.247895842330763e-07
transmitting O 0 0.00011297832679701969
parent O 0 7.438388820446562e-07
, O 0 8.09705866799959e-08
68 O 0 3.8699727156199515e-06
. O 0 3.786383047099662e-07

7 O 0 4.0637336496729404e-05
% O 0 5.165637730897288e-07
were O 0 4.83518704186281e-07
affected O 0 1.1366812913138347e-07
. O 0 1.934781010959341e-07

Studies O 0 2.0260209510070126e-07
on O 0 2.9065728313071304e-07
meiotic O 0 0.00013104004028718919
drive O 0 4.381268081488088e-05
in O 0 2.062847670458723e-06
DM B-Disease 1 0.9999608993530273
have O 0 7.509022736940096e-08
shown O 0 7.18368475816078e-09
increased O 0 1.4591861052792865e-10
transmission O 0 8.769297465960335e-08
of O 0 7.087212761103245e-11
the O 0 7.610030938742796e-10
larger O 0 6.100782101725599e-10
allele O 0 1.557013895592263e-08
at O 0 2.513848471608071e-07
the O 0 1.7268602903186547e-07
DM B-Disease 1 0.9999511241912842
locus O 0 5.583081019722158e-06
in O 0 2.042164481963482e-07
non O 0 1.069538257070235e-06
- O 1 0.517614483833313
DM O 1 0.999948263168335
heterozygotes O 0 3.2211062261922052e-06
for O 0 1.0732606803287581e-08
CTGn O 0 0.00010343496251152828
. O 0 6.396863909685635e-07

This O 0 1.1638806363123422e-08
study O 0 1.3123998554576133e-09
provides O 0 8.746866425601851e-11
further O 0 2.379368924110281e-10
evidence O 0 8.43402236938573e-09
that O 0 8.69021921090507e-09
the O 0 3.024799468676065e-07
DM B-Disease 1 0.9999500513076782
expansion O 0 1.536469653729e-07
tends O 0 5.0685567742903004e-08
to O 0 3.7900418914382783e-10
be O 0 2.3644315394477644e-09
transmitted O 0 4.589823561218509e-07
preferentially O 0 2.943983190561994e-07
. O 0 2.4333454007319233e-07

Diagnosis O 0 0.02477896399796009
of O 0 0.00010629610187606886
hemochromatosis B-Disease 1 0.9984025359153748
. O 0 0.0005117942346259952

If O 0 0.00029014534084126353
untreated O 0 0.39775779843330383
, O 0 0.0023232949897646904
hemochromatosis B-Disease 1 0.9999666213989258
can O 0 0.00036273562000133097
cause O 0 0.0005594221875071526
serious O 0 0.0031237213406711817
illness O 0 0.0006507160142064095
and O 0 3.824467000868026e-07
early B-Disease 0 4.14778696722351e-07
death I-Disease 0 6.0924143326701596e-05
, O 0 1.1639210129033017e-07
but O 0 2.9985051241965266e-07
the O 0 4.572013494907878e-06
disease O 0 0.00011877901124535128
is O 0 1.1040985903321143e-08
still O 0 1.1120413745402402e-07
substantially O 0 2.23001563881553e-07
under O 0 4.219876075239881e-07
- O 1 0.7238821983337402
diagnosed O 0 0.0584307424724102
. O 0 1.5305072338378523e-06

The O 0 1.7610371116916212e-07
cornerstone O 0 3.1608656172466e-06
of O 0 2.195652326619779e-09
screening O 0 1.4014654325933407e-08
and O 0 1.1048443937511365e-08
case O 0 5.8657922963334386e-09
detection O 0 3.056665320855245e-08
is O 0 4.2351677720375847e-10
the O 0 3.6152555948909537e-10
measurement O 0 5.57336079509696e-08
of O 0 2.571657553573914e-09
serum O 0 1.393122943227354e-06
transferrin O 0 4.1254662619394367e-07
saturation O 0 3.357333611120339e-08
and O 0 1.0091161684044891e-08
the O 0 1.3948970867261323e-08
serum O 0 2.295592821610626e-06
ferritin O 0 1.8212246004623012e-06
level O 0 1.5927064112020162e-08
. O 0 4.2485702067551756e-08

Once O 0 6.869381195429014e-06
the O 0 5.819946977680956e-07
diagnosis O 0 3.499163722153753e-05
is O 0 1.4989949193022767e-07
suspected O 0 2.8235206627869047e-05
, O 0 8.49547490133773e-08
physicians O 0 6.859712797790962e-10
must O 0 5.5751382677105e-11
use O 0 2.2828111623240943e-10
serum O 0 7.870503964113595e-07
ferritin O 0 2.2275148694461677e-06
levels O 0 2.733914872266041e-09
and O 0 2.5328475317110133e-07
hepatic O 0 0.004245204385370016
iron O 0 0.0015359210083261132
stores O 0 6.654083790635923e-07
on O 0 0.00016597039939370006
liver O 0 0.0019350232323631644
biopsy O 0 0.0005972314393147826
specimens O 0 9.400780953683352e-08
to O 0 6.408719332995361e-09
assess O 0 9.73438485374345e-09
patients O 0 1.7744378189021859e-09
for O 0 1.3475151550146336e-10
the O 0 1.8400028167775417e-09
presence O 0 1.7596763157712303e-08
of O 0 1.3382781105519825e-07
iron B-Disease 0 0.33539047837257385
overload I-Disease 0 0.0011214867699891329
. O 0 3.870021032525983e-07

Liver O 1 0.8427883386611938
biopsy O 0 0.35619983077049255
is O 0 1.8297621409146814e-06
also O 0 7.178262961815562e-08
used O 0 5.19810239296703e-09
to O 0 2.3104602953072373e-10
establish O 0 5.818764914344854e-10
the O 0 1.5354018056967789e-09
presence O 0 4.067783887506948e-09
or O 0 6.1920168548113e-08
absence O 0 5.5281432764786587e-08
of O 0 1.0233338088028177e-07
cirrhosis B-Disease 0 0.01739213429391384
, O 0 1.4451771335188823e-07
which O 0 1.057940508530919e-07
can O 0 4.1929886229752356e-09
affect O 0 1.2407677552062069e-08
prognosis O 0 3.887030834448524e-05
and O 0 7.233845167320396e-07
management O 0 1.7708618997858139e-06
. O 0 2.8124438244958583e-07

A O 0 1.4662426792710903e-06
DNA O 0 2.0606514226528816e-05
- O 0 0.0001769766677170992
based O 0 1.0037148712171984e-07
test O 0 4.876054671143493e-09
for O 0 5.055457094615967e-11
the O 0 1.4921018864910707e-09
HFE O 0 1.0614691063892678e-06
gene O 0 4.795596697526605e-10
is O 0 1.332006727139401e-10
commercially O 0 2.1044779252576973e-09
available O 0 4.994589186679832e-10
, O 0 1.006136729486684e-09
but O 0 2.1065489630434087e-10
its O 0 1.4040243967450294e-10
place O 0 6.211769321140537e-09
in O 0 2.1060237997971853e-09
the O 0 4.112094487140894e-08
diagnosis O 0 8.588292985223234e-06
of O 0 1.7717926539262407e-06
hemochromatosis B-Disease 1 0.999994158744812
is O 0 1.3565651215685648e-06
still O 0 1.3461939829539915e-07
being O 0 1.5061152680573286e-07
evaluated O 0 2.911805552230362e-07
. O 0 2.894501278660755e-07

Currently O 0 6.147476483420178e-07
, O 0 1.4139478032859643e-08
the O 0 4.924870511402446e-10
most O 0 2.929241224580714e-11
useful O 0 4.6469945946814306e-11
role O 0 1.7690772458056614e-10
for O 0 7.758226699960957e-11
this O 0 2.9566460391095006e-10
test O 0 8.047877031458484e-09
is O 0 1.4151901872594408e-10
in O 0 4.2113226100815027e-11
the O 0 5.081706722087631e-10
detection O 0 3.391755853954237e-07
of O 0 1.5150483534398518e-07
hemochromatosis B-Disease 1 0.9999914169311523
in O 0 1.5624287641458068e-07
the O 0 3.789799762898838e-08
family O 0 2.1776875200885115e-06
members O 0 1.8528140133255988e-10
of O 0 1.5806970177223434e-09
patients O 0 3.377402579829436e-09
with O 0 9.778469589605265e-09
a O 0 9.670558256402728e-07
proven O 0 4.444262958713807e-05
case O 0 1.6964679616648937e-07
of O 0 9.447062687684138e-09
the O 0 3.679409928736277e-06
disease O 0 0.00017792197468224913
. O 0 7.034470286271244e-07

It O 0 2.6416961418362916e-07
is O 0 2.1471775468739907e-08
crucial O 0 4.271988984783093e-08
to O 0 1.1828427659565932e-06
diagnose O 1 0.5862928032875061
hemochromatosis B-Disease 1 0.9999555349349976
before O 0 0.4452335238456726
hepatic B-Disease 1 0.99973064661026
cirrhosis I-Disease 1 0.9540128111839294
develops O 0 0.0002337403711862862
because O 0 1.7244918808501097e-06
phlebotomy O 0 0.0008830887963995337
therapy O 0 2.5398419893463142e-05
can O 0 6.630911002503126e-07
avert O 0 0.025783054530620575
serious O 1 0.8295186161994934
chronic O 1 0.9967769980430603
disease O 0 0.0069390651769936085
and O 0 2.5491663109278306e-06
can O 0 4.3372772040584096e-08
even O 0 3.803268810997906e-08
lead O 0 2.4441041546197084e-07
to O 0 7.2443087084650415e-09
normal O 0 4.4421824441087665e-08
life O 0 4.6629742200821056e-07
expectancy O 0 5.366803748074744e-07
. O 0 1.1397137456015116e-08
. O 0 2.8337399271549657e-07

Prevalence O 0 0.0002004397683776915
of O 0 4.429784983273066e-09
the O 0 1.637220137240547e-08
I1307K O 0 5.2714608500537e-07
APC B-Disease 0 1.0047336900242954e-06
gene O 0 4.224997951496334e-08
variant O 0 5.99755480834574e-07
in O 0 7.98832555659601e-09
Israeli O 0 4.12877034250414e-06
Jews O 0 1.8059575168649644e-08
of O 0 1.3411075028280095e-10
differing O 0 9.053318095197938e-10
ethnic O 0 1.5347694226619524e-09
origin O 0 3.2409943173661304e-08
and O 0 3.0210483146220213e-06
risk O 0 1.7479222151450813e-05
for O 0 0.0002652709954418242
colorectal B-Disease 1 0.9999979734420776
cancer I-Disease 1 0.9999641180038452
. O 0 4.746479316963814e-05

BACKGROUND O 0 9.577077435096726e-06
& O 0 2.907561975007411e-05
AIMS O 0 3.4577749374875566e-07
Israeli O 0 6.775695169380924e-07
Jews O 0 7.938312762689748e-08
of O 0 2.3898492074181377e-09
European O 0 1.2341007504801382e-07
birth O 0 4.0427605085824325e-07
, O 0 3.94082846355559e-08
i O 0 1.1605449401486112e-07
. O 0 1.0459473287482979e-09
e O 0 6.13570083629611e-09
. O 0 6.354829995558475e-10
, O 0 3.956688310324807e-09
Ashkenazim O 0 5.647345346915245e-07
, O 0 7.432586102140704e-09
have O 0 8.962657283007047e-09
the O 0 2.1708822259824956e-06
highest O 1 0.9795998930931091
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999971389770508
incidence O 0 0.0008458198863081634
of O 0 1.3604931625721406e-09
any O 0 8.98862317910698e-10
Israeli O 0 3.06175866171543e-06
ethnic O 0 5.5086285755123754e-08
group O 0 3.703546099131927e-06
. O 0 4.48969615263195e-07

The O 0 2.8114595806982834e-07
I1307K O 0 1.0606074283714406e-05
APC B-Disease 0 6.949745511519723e-06
gene O 0 3.3558805512257095e-07
variant O 0 1.479559523431817e-05
was O 0 0.0006128988461568952
found O 0 3.0002436233189655e-06
in O 0 1.0576802367268101e-07
6 O 0 5.670882273989264e-06
. O 0 1.1342832522132085e-06

1 O 0 1.7663433027337305e-06
% O 0 1.810081862174684e-08
of O 0 4.946721365861606e-10
American O 0 6.056914259033874e-08
Jews O 0 7.565664361663949e-08
, O 0 3.8381021028044415e-08
28 O 0 6.122703410937902e-08
% O 0 1.7675999552935195e-10
of O 0 1.107552938250933e-09
their O 0 3.57635180989746e-05
familial O 1 0.9999749660491943
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999960660934448
cases O 0 2.1656733224517666e-06
, O 0 3.10120555013782e-07
but O 0 5.918977308283502e-08
not O 0 4.540607445591149e-09
in O 0 6.8206542636062295e-09
non O 0 6.019450182748187e-08
- O 0 0.000146733334986493
Jews O 0 8.070736612353357e-07
. O 0 8.468988426102442e-07

We O 0 6.295827859048586e-08
assessed O 0 1.5610063996973622e-07
the O 0 1.2769277191182482e-08
I1307K O 0 1.9985207018180517e-06
prevalence O 0 4.2868264245043974e-06
in O 0 4.138609011050676e-09
Israeli O 0 7.212697141767421e-07
Jews O 0 6.279479602966376e-09
of O 0 1.4641680923244138e-10
differing O 0 5.020491800067362e-10
ethnic O 0 1.0669695127418777e-09
origin O 0 2.10734274475044e-08
and O 0 3.93219761463115e-06
risk O 0 2.2332355001708493e-05
for O 0 0.00027561894967220724
colorectal B-Disease 1 0.9999980926513672
cancer I-Disease 1 0.9999419450759888
. O 0 2.861978100554552e-05

METHODS O 0 2.752811667505739e-07
DNA O 0 4.464643097890075e-06
samples O 0 8.384465388644458e-08
from O 0 4.331818015401723e-09
500 O 0 3.608742105143392e-08
unrelated O 0 1.797336039999209e-07
Jews O 0 1.2284147032914916e-08
of O 0 2.5371245104821583e-09
European O 0 1.0760507507256989e-07
or O 0 6.301847577105946e-08
non O 0 1.0583881326908795e-08
- O 0 1.1632274436124135e-05
European O 0 1.049695512733706e-07
origin O 0 4.888896398824727e-09
, O 0 8.129118711508454e-09
with O 0 7.566398174674305e-09
or O 0 3.425275352242352e-08
without O 0 5.363197663754704e-10
a O 0 7.435209337103288e-09
personal O 0 8.035201972234063e-06
and O 0 6.072176347515779e-06
/ O 0 1.0276814464305062e-05
or O 0 3.6871341535515967e-07
family O 0 5.577858246397227e-07
history O 0 9.774534959205994e-09
of O 0 1.9190904865240554e-08
neoplasia B-Disease 0 0.00360689009539783
, O 0 1.6662195889693976e-07
were O 0 4.31554134650014e-08
examined O 0 6.38547845710491e-08
for O 0 1.0358355839734656e-10
the O 0 1.694769991011924e-09
I1307K O 0 8.011354424297679e-08
variant O 0 2.2889960149541366e-08
by O 0 3.7319733414697964e-10
the O 0 1.3361167727765633e-09
allele O 0 5.3490435192316e-08
- O 0 6.887236168040545e-07
specific O 0 1.546258121543076e-09
oligonucleotide O 0 0.0006964075146242976
( O 0 6.009481268165473e-08
ASO O 0 0.0021307445131242275
) O 0 1.5935504027453362e-09
method O 0 4.679883147673536e-09
. O 0 1.813967145380957e-07

RESULTS O 0 2.019705243583303e-05
In O 0 4.869086822623103e-08
persons O 0 3.809874193905216e-09
at O 0 1.8618229660205543e-06
average O 0 4.450902906683041e-06
risk O 0 2.2684896975988522e-05
for O 0 0.0006826079334132373
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999897480010986
, O 0 4.440757038537413e-06
I1307K O 0 5.967122888250742e-06
was O 0 1.8982156689162366e-05
found O 0 5.164977778804314e-07
in O 0 3.937162418310436e-08
5 O 0 7.275259008565627e-07
. O 0 5.020957019041816e-07

0 O 0 1.6765944792496157e-06
% O 0 9.242137721798827e-09
of O 0 2.55977433694099e-10
120 O 0 3.6720775309362352e-09
European O 0 2.326683734565904e-08
and O 0 6.073781122495348e-08
1 O 0 3.439422613382703e-08
. O 0 1.3490702599483484e-07

6 O 0 6.392036993929651e-06
% O 0 1.9784534899258688e-08
of O 0 1.4145782323282674e-09
188 O 0 4.7876504538635345e-08
non O 0 2.0999399552579234e-08
- O 0 6.898710125824437e-05
European O 0 2.309450195525642e-07
Jews O 0 1.337265160827883e-07
( O 0 4.031088796097038e-09
P O 0 1.982459070859477e-05
= O 0 1.3054579994786764e-07
0 O 0 2.057477077599401e-09
. O 0 1.1402045974051589e-09
08 O 0 8.926625660876653e-09
) O 0 3.0886861956958e-09
. O 0 2.828021195000474e-08

It O 0 3.833142727671657e-07
occurred O 0 2.5006620489875786e-06
in O 0 6.5401977167312e-08
15 O 0 1.3932994136212073e-07
. O 0 5.001868430554168e-07

4 O 0 6.359925919241505e-06
% O 0 4.64842848657554e-08
of O 0 8.714166610523932e-10
52 O 0 1.4808559001266985e-07
Ashkenazi O 0 5.2441861043917015e-05
Israelis O 0 8.361779327969998e-05
with O 0 1.9187675206921995e-05
familial O 1 0.9307224750518799
cancer B-Disease 0 0.4422743022441864
( O 0 2.2008445910159935e-07
P O 0 0.0009337420924566686
= O 0 1.049481852533063e-06
0 O 0 5.755037335575253e-09
. O 0 4.913576656662144e-09
02 O 0 1.2152926274211495e-06
) O 0 1.5243862838687505e-09
and O 0 5.4038000740774805e-09
was O 0 1.1730917321983725e-06
not O 0 2.0744210793566253e-09
detected O 0 2.1266842509248818e-08
in O 0 2.1039920916621213e-09
51 O 0 8.214519198190828e-08
non O 0 5.2421404994618115e-09
- O 0 9.146091542788781e-06
European O 0 1.33719893824491e-07
Jews O 0 3.641675760945873e-08
at O 0 7.389077836705837e-06
increased O 0 6.578092097697663e-07
cancer B-Disease 0 7.021897181402892e-05
risk O 0 5.334260322342743e-07
. O 0 1.02756828823658e-07

Colorectal B-Disease 1 0.8920385837554932
neoplasia I-Disease 0 0.2886444926261902
occurred O 0 0.00024031201610341668
personally O 0 5.150150536792353e-05
or O 0 1.1321844795020297e-06
in O 0 1.1099855257157287e-08
the O 0 1.3074311411287454e-08
families O 0 2.191858250455425e-08
of O 0 5.495169874691896e-10
13 O 0 1.2639903346212122e-08
of O 0 3.5432007328140003e-10
20 O 0 6.029030608090125e-09
Ashkenazi O 0 7.228741765175073e-07
I1307K O 0 2.9181160243751947e-07
carriers O 0 6.073872071965525e-09
, O 0 3.671951409600638e-09
8 O 0 1.151089179529663e-08
of O 0 3.726306374574051e-09
whom O 0 1.1644628727935924e-07
also O 0 3.2222752111010777e-07
had O 0 3.931095307052601e-06
a O 0 1.6391173573993e-07
personal O 0 9.157945169135928e-05
or O 0 9.422801667824388e-06
family O 0 9.38293305807747e-06
history O 0 6.940526020571269e-08
of O 0 6.770908811404297e-08
noncolonic O 0 0.029023585841059685
neoplasia B-Disease 0 0.012565520592033863
. O 0 1.5372303323601955e-06

CONCLUSIONS O 0 2.9109160095686093e-06
The O 0 2.53753711376703e-08
I1307K O 0 2.0984759885323e-06
APC O 0 1.3504799426300451e-05
variant O 0 3.551195914042182e-05
may O 0 3.0206888368411455e-07
represent O 0 6.757198967033418e-11
a O 0 1.7614528502463145e-08
susceptibility O 0 4.210313022667833e-07
gene O 0 1.0284898621648608e-07
for O 0 9.365431878904928e-07
colorectal B-Disease 1 0.9999908208847046
, I-Disease 0 6.483996912720613e-06
or I-Disease 0 2.0278032764053933e-07
other I-Disease 0 3.827647887533203e-08
, I-Disease 0 1.9122269350191345e-06
cancers I-Disease 0 0.00012595861335285008
in O 0 3.5012234889109095e-08
Ashkenazi O 0 6.783710705349222e-05
Jews O 0 6.040451694389048e-07
, O 0 1.9424906838594325e-07
and O 0 1.934150049009986e-07
partially O 0 2.0551444777083816e-06
explains O 0 8.59240429917918e-08
the O 0 4.284030463708177e-09
higher O 0 1.0586546750346315e-06
incidence O 0 0.005574815906584263
of O 0 0.005343702156096697
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999847412109375
in O 0 4.5233127821120434e-07
European O 0 1.7579070572537603e-06
Israelis O 0 5.4242584155872464e-05
. O 0 1.2354483942544903e-06

Systematic O 0 4.873110128755798e-07
analysis O 0 1.4918812496489409e-07
of O 0 5.9481759961954594e-08
coproporphyrinogen O 0 0.0013116654008626938
oxidase O 0 2.8418306101229973e-05
gene O 0 4.7987501602619886e-05
defects O 1 0.8865670561790466
in O 0 2.387910626566736e-06
hereditary B-Disease 0 0.14072564244270325
coproporphyria I-Disease 0 0.005450290162116289
and O 0 1.775290343175584e-06
mutation O 0 2.5596850150577666e-07
update O 0 5.877352577954298e-06
. O 0 2.7508015136845643e-06

Hereditary B-Disease 1 0.9530099630355835
coproporphyria I-Disease 1 0.7473182082176208
( O 0 8.909421012504026e-06
HC B-Disease 1 0.8513888120651245
) O 0 1.5078088836162351e-05
is O 0 1.881291836980381e-06
an O 0 6.645295798080042e-05
acute O 1 0.9679180383682251
hepatic B-Disease 1 0.9998445510864258
porphyria I-Disease 1 0.9981036186218262
with O 0 0.00030269395210780203
autosomal O 1 0.8806197047233582
dominant O 0 0.1323901265859604
inheritance O 1 0.6088058352470398
caused O 0 0.0004938021884299815
by O 0 1.9729260714029806e-07
deficient B-Disease 0 0.00012177111057098955
activity I-Disease 0 3.5895070027436304e-08
of I-Disease 0 1.3250926578223243e-08
coproporphyrinogen I-Disease 0 0.001409341348335147
III I-Disease 0 0.010058064945042133
oxidase I-Disease 0 1.3908503433412989e-06
( O 0 6.9423768955800824e-09
CPO O 0 4.2711042624432594e-05
) O 0 4.2476468564700554e-08
. O 0 4.899522565438019e-08

Clinical O 0 2.8741220376105048e-05
manifestations O 0 2.7803411285276525e-05
of O 0 4.5825109395991603e-07
the O 0 4.3133331928402185e-05
disease O 0 0.009651620872318745
are O 0 2.14713242741027e-08
characterized O 0 1.2264033102837857e-05
by O 0 4.855703991779592e-06
acute O 0 0.0005133718950673938
attacks O 0 0.006398028694093227
of O 0 4.929780698148534e-05
neurological B-Disease 1 0.9979085922241211
dysfunction I-Disease 0 0.23612751066684723
often O 0 1.2469479315768695e-06
precipitated O 0 1.9564786271075718e-05
by O 0 8.520498084862993e-08
drugs O 0 7.6913174495985e-08
, O 0 1.0701168839943875e-08
fasting O 0 9.689597391115967e-08
, O 0 6.580476963335968e-08
cyclical O 0 2.7041411158279516e-05
hormonal O 0 2.943908839370124e-06
changes O 0 1.6651164003178565e-08
, O 0 1.4379789945451193e-06
or O 0 2.4782770196907222e-05
infectious B-Disease 0 0.0011595969554036856
diseases I-Disease 0 0.00045857945224270225
. O 0 3.6425099096959457e-06

Skin O 1 0.9974588751792908
photosensitivity O 1 0.9583900570869446
may O 0 0.00010251136700389907
also O 0 2.383050912158069e-07
be O 0 9.730078964764743e-09
present O 0 1.3652819319531773e-08
. O 0 2.4225690253842913e-07

The O 0 7.382094935337591e-08
seven O 0 2.408024712963197e-08
exons O 0 2.3336554022534983e-07
, O 0 4.863116576103721e-09
the O 0 2.344680671839683e-09
exon O 0 9.026890666063991e-07
/ O 0 7.686637673032237e-07
intron O 0 1.0094877325173002e-05
boundaries O 0 5.517332368754069e-09
and O 0 9.298612546615459e-09
part O 0 2.5845642293020887e-10
of O 0 7.251522160522939e-10
3 O 0 1.293493756548969e-08
noncoding O 0 1.5704381794989786e-08
sequence O 0 2.9978614035641726e-10
of O 0 8.782927163331067e-11
the O 0 4.722465973827639e-09
CPO O 0 3.0436624456342543e-06
gene O 0 9.131218003943786e-10
were O 0 2.9100595266839946e-09
systematically O 0 1.8674727186862583e-07
analyzed O 0 6.145878916896663e-09
by O 0 2.5156032812390094e-10
an O 0 2.3243273972184397e-09
exon O 0 3.848064409339713e-07
- O 0 7.652562999282964e-06
by O 0 1.134941296498937e-08
- O 0 3.961651600548066e-06
exon O 0 8.771837656240677e-07
denaturing O 0 1.2078979125362821e-05
gradient O 0 3.910126179107465e-05
gel O 0 0.00589847331866622
electrophoresis O 0 0.008584924973547459
( O 0 1.9037420528889015e-08
DGGE O 0 5.021526158088818e-05
) O 0 2.3580275509971216e-09
strategy O 0 1.3214607186284866e-08
followed O 0 9.313767534990802e-10
by O 0 1.672345421865895e-11
direct O 0 1.963045828320964e-12
sequencing O 0 5.406604497437684e-09
in O 0 3.709287543784967e-09
seven O 0 4.552663668278001e-08
unrelated O 0 3.455543719610432e-06
heterozygous O 0 1.6664657778164838e-06
HC B-Disease 0 0.18671433627605438
patients O 0 7.050966388533197e-08
from O 0 2.4947775401074068e-08
France O 0 1.211906123899098e-06
, O 0 8.748865809593553e-08
Holland O 0 1.2552013686217833e-05
, O 0 5.842291272983857e-08
and O 0 1.7525695739095681e-07
Czech O 0 3.165607722621644e-06
Republic O 0 1.477484516954064e-07
. O 0 3.795605891809828e-07

Seven O 0 3.7912932384642772e-06
novel O 0 3.6875949263048824e-06
mutations O 0 7.970610909069364e-07
and O 0 2.2311660075047257e-08
two O 0 6.222441673031653e-09
new O 0 4.292874677958025e-08
polymorphisms O 0 1.3169463954909588e-06
were O 0 1.1407290685383487e-06
detected O 0 9.230668183590751e-06
. O 0 4.743973249787814e-07

Among O 0 5.646677792014998e-08
these O 0 1.1257670351483284e-09
mutations O 0 1.328950105516924e-08
two O 0 1.6367206256973077e-08
are O 0 4.028114286569462e-09
missense O 0 3.840760882667382e-07
( O 0 3.399000192416679e-09
G197W O 0 2.6850148060475476e-07
, O 0 3.576310803055094e-08
W427R O 0 1.4963924854782817e-07
) O 0 3.6346512466423064e-09
, O 0 1.771918167747799e-09
two O 0 3.0334204037529844e-09
are O 0 1.6623612486554862e-09
nonsense O 0 1.1597012417041697e-06
( O 0 3.882822119383178e-10
Q306X O 0 5.1024482417005856e-08
, O 0 1.6331467733721183e-08
Q385X O 0 2.1597588784061372e-07
) O 0 3.0802673745000675e-09
, O 0 5.492267196594014e-10
two O 0 6.050535072965602e-10
are O 0 1.9953878827028149e-10
small O 0 3.812759885590822e-09
deletions O 0 2.057251151654782e-07
( O 0 2.719295899566987e-09
662de14bp O 0 1.563266494031268e-07
; O 0 2.6529112240325503e-09
1168del3bp O 0 3.230231584439025e-07
removing O 0 2.547059674284924e-09
a O 0 7.439801552600045e-10
glycine O 0 4.3769514235236784e-08
at O 0 7.98825254832991e-08
position O 0 5.913083800379582e-09
390 O 0 1.3408204324605322e-07
) O 0 6.0799565382296805e-09
, O 0 3.931082570574063e-09
and O 0 1.477891808931986e-09
one O 0 4.0984188265369426e-10
is O 0 4.2879194639411367e-10
a O 0 1.0786903592574504e-09
splicing O 0 4.0622697383696504e-07
mutation O 0 1.2523173609224614e-07
( O 0 8.757405356440984e-10
IVS1 O 0 4.72791225547553e-06
- O 0 1.2528167644632049e-05
15c O 0 1.5736142700006894e-07
- O 0 2.3835287720430642e-05
- O 0 0.0003631937725003809
> O 0 1.4315246232854406e-07
g O 0 5.780811079603154e-06
) O 0 2.584259917171039e-09
which O 0 8.38121128055036e-10
creates O 0 2.363212958655936e-10
a O 0 2.7172933347863193e-10
new O 0 3.041113805224427e-09
acceptor O 0 1.2683470274055253e-08
splice O 0 2.7904245143872686e-05
site O 0 2.6645499019650742e-05
. O 0 1.0111161827808246e-06

The O 0 9.459720899940294e-07
pathological O 0 1.2888638593722135e-05
significance O 0 1.3072266824565304e-08
of O 0 6.281968278898376e-10
the O 0 1.1020703460928871e-08
point O 0 7.785912430335884e-07
mutations O 0 1.8223101250214313e-08
G197W O 0 8.065845236160385e-08
, O 0 8.983930932515705e-09
W427R O 0 1.7464462587213347e-07
, O 0 3.5916007945502315e-09
and O 0 2.432415380226871e-09
the O 0 1.8174426408279487e-09
in O 0 1.5457487734238384e-08
- O 0 0.00079211441334337
frame O 0 0.001866989186964929
deletion O 0 7.97278516984079e-07
390delGly O 0 7.752290684948093e-07
were O 0 2.248862429610199e-08
assessed O 0 7.422669145995542e-09
by O 0 6.469617896964763e-11
their O 0 5.896544363892531e-11
respective O 0 1.5180892654065303e-10
expression O 0 6.598229185250659e-10
in O 0 6.567781318800314e-10
a O 0 1.3222744010832344e-09
prokaryotic O 0 3.221467981262549e-09
system O 0 1.4451972951690095e-08
using O 0 3.333282982964647e-09
site O 0 1.3959237321614637e-06
- O 0 1.9827804862870835e-05
directed O 0 1.834005729506316e-07
mutagenesis O 0 2.1230603124422487e-06
. O 0 8.135823037491718e-08

These O 0 2.966789125480318e-08
mutations O 0 3.951223277454119e-07
resulted O 0 3.544868150129332e-07
in O 0 1.0004995942836103e-08
the O 0 1.9471007917104544e-08
absence O 0 6.788405215729654e-08
or O 0 1.7711757394067718e-08
a O 0 3.006522319992655e-08
dramatic O 0 4.144742149492231e-07
decrease O 0 1.764862922470911e-08
of O 0 1.5091087268714887e-09
CPO O 0 9.024183236761019e-05
activity O 0 1.37499370111982e-07
. O 0 8.91847733441864e-08

The O 0 6.169864974481243e-08
two O 0 4.7442895834137744e-08
polymorphisms O 0 1.6870326362550259e-06
were O 0 1.1363973584366249e-07
localized O 0 1.6183194873065077e-07
in O 0 8.672920159824571e-08
noncoding O 0 1.2980791552763549e-06
part O 0 3.4276523841469952e-09
of O 0 3.7736966329582344e-10
the O 0 1.911367064622027e-09
gene O 0 3.098516332400436e-09
1 O 0 1.8942767354701573e-09
) O 0 9.056012606478703e-10
a O 0 1.0123317295551715e-08
C O 0 4.620593699655728e-06
/ O 0 8.266889608421479e-07
G O 0 5.979860816296423e-06
polymorphism O 0 3.932156644737006e-08
in O 0 7.494621034886961e-10
the O 0 5.365226041220694e-09
promotor O 0 7.3946325755969156e-06
region O 0 3.891543531864272e-09
, O 0 1.5883371284886039e-09
142 O 0 1.2233152268947833e-08
bp O 0 8.752467692829669e-07
upstream O 0 2.9991666927742244e-09
from O 0 1.2871273491477098e-11
the O 0 3.678801620971006e-12
transcriptional O 0 1.6694269577843812e-10
initiation O 0 7.738250595856755e-10
site O 0 1.0708625097777258e-07
( O 0 3.203427800801961e-10
- O 0 4.5748483898933046e-06
142C O 0 1.163747356258682e-06
/ O 0 7.212738069029001e-07
G O 0 3.6907673347741365e-05
) O 0 9.032344872039744e-10
, O 0 4.2020090185168613e-10
and O 0 3.3111366981586343e-09
2 O 0 1.0531143068703841e-08
) O 0 4.3178915998254297e-10
a O 0 2.6058355473423944e-09
6 O 0 7.485884623292804e-08
bp O 0 9.182274425256765e-07
deletion O 0 2.7216014331088445e-08
polymorphism O 0 3.2788104675773866e-08
in O 0 6.696131427119667e-10
the O 0 1.3581181734778625e-09
3 O 0 3.284932148517328e-08
noncoding O 0 7.609138208408694e-08
part O 0 1.5140178000194737e-10
of O 0 6.321654311136626e-11
the O 0 5.23509591232596e-09
CPO O 0 7.963006282807328e-06
gene O 0 3.76765685317082e-09
, O 0 6.4742415872842685e-09
574 O 0 3.0980839937910787e-07
bp O 0 1.4310566029962501e-06
downstream O 0 7.0723653600168745e-09
of O 0 3.232950712694915e-11
the O 0 1.7227791415663773e-09
last O 0 8.182650645949252e-08
base O 0 1.3875089965864618e-09
of O 0 4.943973702653537e-11
the O 0 5.989838625097832e-10
normal O 0 2.1193578003675384e-09
termination O 0 1.9074203549962476e-08
codon O 0 2.7456308338003055e-09
( O 0 3.575345575157485e-10
+ O 0 1.9066241918608284e-07
574 O 0 1.3602663102574297e-06
delATTCTT O 0 3.3137209811684443e-06
) O 0 1.3174642710112039e-08
. O 0 4.853185942010896e-08

Five O 0 3.988973730884027e-06
intragenic O 0 0.00047293200623244047
dimorphisms O 0 0.0002750343701336533
are O 0 1.8059848727602912e-08
now O 0 1.8529076939444167e-08
well O 0 4.264716579882588e-09
characterized O 0 3.097342755609134e-07
and O 0 2.8530896756251423e-08
the O 0 9.010737045400674e-09
high O 0 7.238565444822598e-07
degree O 0 1.5993542046288667e-09
of O 0 2.3897478440559894e-10
allelic O 0 9.420576816410176e-07
heterogeneity O 0 8.078829523583408e-06
in O 0 3.86926075179872e-07
HC B-Disease 0 0.17702661454677582
is O 0 1.0746128964456148e-07
demonstrated O 0 1.7059102219718625e-07
with O 0 5.423977711416228e-09
seven O 0 4.035666023582962e-09
new O 0 1.3446505020553445e-09
different O 0 9.723872401723455e-11
mutations O 0 3.42563910571414e-09
making O 0 6.5352789846429e-10
a O 0 1.5275122278168851e-09
total O 0 4.377773699104637e-10
of O 0 2.915196972708145e-10
nineteen O 0 7.722849204583326e-08
CPO O 0 0.00919528678059578
gene B-Disease 0 2.436298382235691e-05
defects I-Disease 0 0.17915134131908417
reported O 0 3.380967200428131e-06
so O 0 7.363781584501794e-09
far O 0 9.518396737462353e-09
. O 0 1.2694481910102695e-08
. O 0 2.405509746949974e-07

Coincidence O 0 1.4886480812492664e-06
of O 0 2.250419939286985e-08
two O 0 1.1822862688859459e-07
novel O 0 3.7447156842063123e-07
arylsulfatase O 0 8.663347216497641e-06
A O 0 7.568435478333413e-08
alleles O 0 1.5035960032605544e-08
and O 0 2.325179870865668e-08
mutation O 0 1.4600115783025558e-08
459 O 0 9.376227012580785e-07
+ O 0 2.4895066985664016e-07
1G O 0 6.0466632021416444e-06
> O 0 1.5733403913031907e-08
A O 0 1.0769147351652464e-08
within O 0 1.9246934601646615e-10
a O 0 1.6876009567567962e-07
family O 0 0.0003136837331112474
with O 0 0.0027292713057249784
metachromatic B-Disease 1 0.9999815225601196
leukodystrophy I-Disease 1 0.9998993873596191
: O 0 5.077446463275237e-09
molecular O 0 1.6200173647007432e-08
basis O 0 7.273712743227634e-10
of O 0 1.443449915150552e-09
phenotypic O 0 4.1172192766225635e-08
heterogeneity O 0 9.323884114564862e-06
. O 0 4.710976099886466e-06

In O 0 6.217271675268421e-07
a O 0 3.2363061563955853e-07
family O 0 1.4347297110361978e-06
with O 0 2.216934014143135e-08
three O 0 2.919179280524986e-07
siblings O 0 8.627696843177546e-06
, O 0 9.286825530807619e-09
one O 0 3.7303718447567746e-10
developed O 0 2.107218044500314e-08
classical O 0 3.365656198184297e-07
late O 0 0.0029592528007924557
infantile O 1 0.9973113536834717
metachromatic B-Disease 1 0.9999716281890869
leukodystrophy I-Disease 1 0.9999539852142334
( O 0 3.412589876461425e-06
MLD B-Disease 1 0.9998756647109985
) O 0 1.3792479194307816e-06
, O 0 3.726773911694181e-07
fatal O 0 0.0003241959202568978
at O 0 1.0332916644983925e-05
age O 0 1.7089421078253508e-07
5 O 0 7.577681060411123e-08
years O 0 1.2109097724533058e-07
, O 0 3.234652012906736e-08
with O 0 8.868755685398355e-07
deficient O 0 0.027421407401561737
arylsulfatase O 0 0.0007277915719896555
A O 0 4.265973984729499e-06
( O 0 3.266463366458083e-08
ARSA O 0 0.00041060594958253205
) O 0 1.803299287672644e-09
activity O 0 1.7278569686141054e-09
and O 0 5.080372122989729e-09
increased O 0 8.325704570211201e-09
galactosylsulfatide O 0 0.00016561879601795226
( O 0 4.65413307892959e-08
GS O 1 0.9996744394302368
) O 0 1.8364281118010695e-07
excretion O 0 3.9778555560587847e-07
. O 0 1.4949006299502798e-07

The O 0 4.107767281880115e-08
two O 0 1.3798456599545261e-08
other O 0 8.677913498900125e-09
siblings O 0 2.3131672151066596e-06
, O 0 4.220334659521541e-08
apparently O 0 7.52114829083439e-07
healthy O 0 1.2090446865897775e-08
at O 0 3.2215746159636183e-07
12 O 0 1.7335485935632278e-08
( O 0 6.180927991650265e-11
1 O 0 4.680701937154197e-10
/ O 0 3.8033920901625606e-08
2 O 0 1.8137797042072634e-08
) O 0 3.9795430839539847e-10
and O 0 1.5611553161321012e-09
15 O 0 2.738476334585016e-09
years O 0 1.794543713629082e-08
, O 0 5.762681887233612e-09
respectively O 0 7.283101233213074e-09
, O 0 1.5111278894863744e-09
and O 0 4.217516114124464e-09
their O 0 3.9499021831090886e-09
father O 0 6.8334838942973875e-06
, O 0 3.01332541141619e-08
apparently O 0 1.2688353763223859e-06
healthy O 0 2.948189470330931e-09
as O 0 2.4129553910512413e-10
well O 0 1.4242923507268301e-09
, O 0 1.0835781161233626e-08
presented O 0 3.033908342331415e-07
ARSA O 0 0.039679352194070816
and O 0 5.052051164966542e-06
GS O 1 0.9995144605636597
values O 0 1.0980586218067856e-08
within O 0 2.178230859573027e-11
the O 0 9.280500257169422e-10
range O 0 1.9789600003150554e-07
of O 0 6.989252483435848e-07
MLD B-Disease 1 0.9996567964553833
patients O 0 6.76169349844713e-07
. O 0 2.190295731452352e-07

Mutation O 0 5.992038722979487e-07
screening O 0 5.124832114233868e-08
and O 0 8.483942437464975e-09
sequence O 0 1.8021953929192591e-09
analysis O 0 4.0862442318712056e-09
disclosed O 0 9.658152748670545e-07
the O 0 4.505563921952671e-09
involvement O 0 3.7559349408411435e-08
of O 0 2.3854943020928943e-10
three O 0 6.069343694292684e-09
different O 0 1.903901036826028e-09
ARSA O 0 0.0032895237673074007
mutations O 0 1.1189281501344794e-08
being O 0 2.934075205018871e-09
the O 0 7.547324987200454e-10
molecular O 0 8.909245252652909e-08
basis O 0 2.7721891449061786e-09
of O 0 2.540297572295458e-08
intrafamilial O 0 0.0001234675437444821
phenotypic O 0 9.258620536911621e-08
heterogeneity O 0 1.761394196364563e-05
. O 0 4.133233687753091e-06

The O 0 6.639605771852075e-07
late O 0 9.569546818966046e-05
infantile O 1 0.6744670271873474
patient O 0 0.0015632847789674997
inherited O 0 0.277969092130661
from O 0 7.93609217453195e-07
his O 0 4.079280188307166e-05
mother O 0 9.885421604849398e-05
the O 0 1.6081033393788857e-08
frequent O 0 4.535848674436238e-08
0 O 0 2.0474679729431955e-08
- O 0 6.118213605077472e-06
type O 0 2.228167694795502e-08
mutation O 0 3.775332491073868e-09
459 O 0 1.7127780438386253e-07
+ O 0 7.653444811239751e-08
1G O 0 1.2446976143110078e-06
> O 0 7.364806986487338e-09
A O 0 5.3826227031095186e-08
, O 0 7.325764528332002e-08
and O 0 6.115793382832635e-08
from O 0 1.5116819795935044e-08
his O 0 3.455095793469809e-06
father O 0 2.3247355329658603e-06
a O 0 3.858080788177176e-08
novel O 0 9.328246619588754e-08
, O 0 4.710492440551661e-09
single O 0 8.491712222280512e-09
basepair O 0 6.129941084509483e-06
microdeletion O 0 4.798758368451672e-07
of O 0 2.3507142413170534e-11
guanine O 0 1.4792764790882984e-09
at O 0 5.279023884696699e-09
nucleotide O 0 4.687241705880751e-10
7 O 0 1.0836607167163947e-08
in O 0 1.556715978345835e-09
exon O 0 5.094391326565528e-07
1 O 0 4.915650464454302e-08
( O 0 2.192195758254911e-09
7delG O 0 1.977900637939456e-06
) O 0 3.433333617408607e-08
. O 0 4.80343764763802e-08

The O 0 1.339417110557406e-07
two O 0 2.624998103328835e-07
clinically O 0 8.81016458151862e-05
unaffected O 0 2.0508903617155738e-05
siblings O 0 4.5499914449464995e-06
carried O 0 2.508754732843954e-07
the O 0 7.753826913869943e-09
maternal O 0 1.8445020089075115e-07
mutation O 0 1.2120739967258487e-08
459 O 0 3.1894091989670414e-07
+ O 0 1.4193497577252856e-07
1G O 0 2.882561830119812e-06
> O 0 1.5727344759852713e-08
A O 0 2.598550885579698e-08
and O 0 1.4071792975300923e-07
, O 0 4.2718566461985574e-09
on O 0 2.884761407528913e-08
their O 0 1.67649238935752e-09
paternal O 0 1.2896462919798068e-07
allele O 0 6.722037682038717e-08
, O 0 3.386007030314886e-09
a O 0 1.2621321765493576e-09
novel O 0 1.5129562047633272e-09
cytosine O 0 3.2839533314898972e-09
to O 0 4.7623786858519424e-11
thymidine O 0 3.3144542666008192e-09
transition O 0 2.97424807005342e-10
at O 0 5.622911913860662e-09
nucleotide O 0 4.915129969695897e-10
2435 O 0 1.9677079876601056e-07
in O 0 5.663163826774564e-10
exon O 0 7.816134939275798e-08
8 O 0 9.231676045828863e-08
, O 0 6.956665465907008e-09
resulting O 0 1.0551323148533243e-09
in O 0 2.1952648032730337e-11
substitution O 0 7.844620092400945e-11
of O 0 3.3580091485241326e-10
alanine O 0 7.79876188516937e-07
464 O 0 2.5505621579213766e-06
by O 0 1.9814868323919654e-07
valine O 0 1.662313297856599e-05
( O 0 9.012352641946109e-09
A464V O 0 4.356205351996323e-07
) O 0 1.5986138635071256e-08
. O 0 5.499012445397966e-08

The O 0 1.1962796975240053e-07
fathers O 0 3.803349102327047e-07
genotype O 0 7.396286036964739e-07
thus O 0 2.1122078308621894e-08
was O 0 6.881628905830439e-06
7delG O 0 5.128977500135079e-05
/ O 0 1.1786182767536957e-05
A464V O 0 8.727048225409817e-06
. O 0 2.1254072635201737e-07

Mutation O 0 1.3313890121935401e-05
A464V O 0 3.0572824471164495e-05
was O 0 3.0378561859834008e-05
not O 0 1.693817530679098e-08
found O 0 1.0323812915657982e-07
in O 0 1.4491692290619085e-08
18 O 0 1.7633910829317756e-06
unrelated O 0 0.002855846891179681
MLD B-Disease 1 0.9999542236328125
patients O 0 1.1105153419066482e-07
and O 0 1.935263860275427e-08
50 O 0 2.1549933393316678e-08
controls O 0 1.2750326732202666e-06
. O 0 6.553233902195643e-07

A464V O 0 7.70891856518574e-05
, O 0 4.5084806288286927e-07
although O 0 7.844373151044692e-09
clearly O 0 3.7646781692046716e-08
modifying O 0 9.801625537875225e-07
ARSA O 0 0.044182706624269485
and O 0 1.7415977708878927e-05
GS O 1 0.9999110698699951
levels O 0 3.182457533057459e-07
, O 0 3.006717363973621e-08
apparently O 0 9.705261163617251e-07
bears O 0 1.6390487189710257e-07
little O 0 1.5004094633397358e-09
significance O 0 5.464180774517047e-10
for O 0 5.891792054235623e-10
clinical O 0 2.0454189453289473e-08
manifestation O 0 3.875893526128493e-07
of O 0 3.7444979739120754e-07
MLD B-Disease 1 0.9998791217803955
, O 0 3.4620180144884216e-07
mimicking O 0 1.8303554725207505e-06
the O 0 1.08107442997607e-07
frequent O 0 5.143618182046339e-06
ARSA O 0 0.2988872826099396
pseudodeficiency O 0 0.00040853748214431107
allele O 0 5.040838459535735e-06
. O 0 1.246217948391859e-06

Our O 0 1.2733711685086746e-07
results O 0 2.3832006945667672e-07
demonstrate O 0 2.0455280136388865e-08
that O 0 5.862022867120231e-09
in O 0 5.699965499594839e-10
certain O 0 1.9149129504292262e-10
genetic O 0 1.6769894273238606e-06
conditions O 0 0.000329350441461429
MLD B-Disease 1 0.9999294281005859
- O 0 0.09456156939268112
like O 0 1.4107899914961308e-06
ARSA O 0 0.12254976481199265
and O 0 4.208143309369916e-06
GS O 1 0.9966263771057129
values O 0 8.145368823875287e-09
need O 0 7.033051918625688e-11
not O 0 7.584350508738069e-11
be O 0 1.16336454358823e-10
paralleled O 0 1.8805945956046344e-07
by O 0 3.0003644724274636e-07
clinical O 0 4.930241630063392e-05
disease O 0 0.00025570247089490294
, O 0 5.289105331485189e-08
a O 0 2.7927022472340468e-08
finding O 0 1.5865718694385578e-07
with O 0 6.144446160760708e-07
serious O 0 5.714388862543274e-06
diagnostic O 0 2.014746769418707e-06
and O 0 3.775115374082816e-06
prognostic O 0 0.00013555801706388593
implications O 0 2.5352451302751433e-06
. O 0 8.520381697962875e-07

Moreover O 0 1.2514773288785364e-06
, O 0 2.393837839065327e-08
further O 0 3.966685646616952e-09
ARSA O 0 9.116452565649524e-05
alleles O 0 6.048174583384025e-08
functionally O 0 2.410998547475174e-07
similar O 0 8.275927498857527e-09
to O 0 1.3183591107690518e-08
A464V O 0 3.7484494441741845e-07
might O 0 1.5182152424131345e-08
exist O 0 1.4150174088012335e-10
which O 0 8.143691054840474e-09
, O 0 3.61769947332391e-09
together O 0 3.5874656578727127e-09
with O 0 1.6876709807434054e-08
0 O 0 5.8709666461709276e-08
- O 0 0.0001311610685661435
type O 0 1.1182333992110216e-06
mutations O 0 8.188550282284268e-07
, O 0 5.716366899832792e-07
may O 0 8.640802207082743e-07
cause O 0 2.3419380568157067e-07
pathological O 0 6.080811363062821e-05
ARSA O 0 0.3963026702404022
and O 0 2.8242799089639448e-05
GS O 1 0.9999752044677734
levels O 0 1.8724161066074885e-07
, O 0 1.5945332165756554e-08
but O 0 5.355094589987175e-09
not O 0 2.025134726579836e-09
clinical O 0 2.5792829205784074e-08
outbreak O 0 2.642589969070741e-08
of O 0 3.21477156006722e-09
the O 0 9.360081094200723e-06
disease O 0 0.00014126136375125498
. O 0 5.692962901093779e-08
. O 0 4.5580941332445946e-07

Human O 0 0.002329437294974923
MLH1 O 1 0.9938741326332092
deficiency O 1 0.9960417747497559
predisposes O 0 0.0007566750864498317
to O 0 5.314960617397446e-06
hematological B-Disease 1 0.685576856136322
malignancy I-Disease 1 0.9906988739967346
and O 0 0.0016814474947750568
neurofibromatosis B-Disease 1 0.8462369441986084
type I-Disease 0 1.9204771888325922e-05
1 I-Disease 0 2.025427193075302e-06
. O 0 3.784978162002517e-06

Heterozygous O 0 5.2848416089545935e-05
germ O 0 0.05118028447031975
- O 0 0.023345092311501503
line O 0 0.00019146616978105158
mutations O 0 7.817295681888936e-07
in O 0 1.0806822992037723e-08
the O 0 5.954737147817468e-08
DNA O 0 0.0006637191399931908
mismatch O 0 0.30627211928367615
repair O 0 0.005932860542088747
genes O 0 2.40502345150162e-07
lead O 0 6.473233952419832e-06
to O 0 4.620787876774557e-06
hereditary B-Disease 1 0.9994749426841736
nonpolyposis I-Disease 1 0.9998769760131836
colorectal I-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999173879623413
. O 0 0.00028449163073673844

The O 0 7.903584628365934e-05
disease O 0 0.020318375900387764
susceptibility O 0 6.508388469228521e-05
of O 0 9.451427729345596e-08
individuals O 0 5.870473884783678e-08
who O 0 6.216915267032164e-07
constitutionally O 0 1.1059480584663106e-06
lack O 0 1.9113388205482806e-08
both O 0 2.9880895535683294e-09
wild O 0 6.553358957717137e-07
- O 0 0.0020851902663707733
type O 0 6.926176752131141e-07
alleles O 0 6.136991004268566e-08
is O 0 6.545788977518896e-08
unknown O 0 1.5983050616341643e-06
. O 0 7.244256039484753e-07

We O 0 1.646933185384114e-07
have O 0 5.130208702297523e-09
identified O 0 3.841000406623607e-09
three O 0 2.9486617592056064e-09
offspring O 0 5.272426051305956e-08
in O 0 1.1608300987120401e-08
a O 0 1.6341025911970064e-05
hereditary B-Disease 1 0.9999349117279053
nonpolyposis I-Disease 1 0.9999890327453613
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999977350234985
family O 0 0.25087887048721313
who O 0 0.00010185957216890529
developed O 0 5.835138290422037e-05
hematological B-Disease 0 0.1444309949874878
malignancy I-Disease 0 0.2775508463382721
at O 0 7.542822004324989e-06
a O 0 2.5231935651959247e-08
very O 0 4.046117219047574e-09
early O 0 1.5307422529531323e-07
age O 0 1.4086805322222062e-07
, O 0 1.0340145628617847e-08
and O 0 1.758595935541507e-08
at O 0 1.1710334035797132e-07
least O 0 2.6763178478939054e-11
two O 0 9.504894649126072e-10
of O 0 5.802052172043659e-10
them O 0 1.7944540298131528e-09
displayed O 0 2.443563971610274e-06
signs O 0 9.762146646608016e-07
of O 0 4.5348194532834896e-08
neurofibromatosis B-Disease 0 0.04630378633737564
type I-Disease 0 4.251849645697803e-07
1 I-Disease 0 2.954502349439281e-07
( O 0 4.15612468884774e-08
NF1 B-Disease 0 5.6455275625921786e-05
) O 0 3.8430101767517044e-08
. O 0 1.2903350921078527e-07

DNA O 0 2.242477421532385e-06
sequence O 0 7.373805743782214e-08
analysis O 0 2.4486624283781566e-08
and O 0 9.768608144611335e-09
allele O 0 5.251259338479031e-08
- O 0 6.332850261969725e-07
specific O 0 3.7527231322442844e-10
amplification O 0 8.936141284721089e-07
in O 0 7.087895603774541e-09
two O 0 1.765070578585437e-07
siblings O 0 9.180048436974175e-06
revealed O 0 7.301335244846996e-06
a O 0 2.1044191100827447e-07
homozygous O 0 9.824752851272933e-06
MLH1 O 0 0.0026145046576857567
mutation O 0 3.929667968805006e-07
( O 0 4.1290606489496895e-09
C676T O 0 1.7659879176790128e-06
- O 0 0.005953566171228886
- O 0 0.017175903543829918
> O 0 6.376350256687147e-07
Arg226Stop O 0 2.022669832513202e-05
) O 0 2.3699955775668968e-08
. O 0 1.2669283933064435e-07

Thus O 0 9.126758300226356e-07
, O 0 3.500662515421027e-08
a O 0 2.514123664809631e-08
homozygous O 0 3.106340500380611e-06
germ O 0 0.019371753558516502
- O 0 0.004324798937886953
line O 0 0.00011822194937849417
MLH1 O 0 0.00046060478780418634
mutation O 0 2.625714330406481e-07
and O 0 1.4771463838769705e-06
consequent O 0 0.00045595018309541047
mismatch O 1 0.9985724687576294
repair O 1 0.9998480081558228
deficiency O 0 0.3880294859409332
results O 0 1.64177393457976e-07
in O 0 2.424560818781174e-08
a O 0 5.964688511994609e-07
mutator O 0 0.01605980284512043
phenotype O 0 0.00010426859080325812
characterized O 0 0.00010061196371680126
by O 0 4.7557670768583193e-05
leukemia B-Disease 1 0.9981531500816345
and O 0 0.0012461671140044928
/ O 0 0.1690930873155594
or O 1 0.6221103668212891
lymphoma B-Disease 1 0.999998927116394
associated O 0 4.184001954854466e-05
with O 0 2.0166624381090514e-05
neurofibromatosis B-Disease 1 0.6041896939277649
type I-Disease 0 9.269961083191447e-07
1 I-Disease 0 6.305538136075484e-08
. O 0 4.336333958576688e-08
. O 0 3.9513815863756463e-07

Missense O 0 0.00017509993631392717
mutations O 0 1.7459216905990615e-05
in O 0 4.561146482728873e-08
the O 0 4.321857094424786e-09
most O 0 9.179274562676198e-10
ancient O 0 1.589259213119476e-08
residues O 0 3.964455785876453e-08
of O 0 1.9808643614283028e-10
the O 0 1.166416296882744e-08
PAX6 O 0 2.7674152534018504e-06
paired O 0 4.23073544197905e-07
domain O 0 2.0946595569171222e-08
underlie O 0 3.8866795648573316e-07
a O 0 4.372020256937503e-08
spectrum O 0 1.7155193745566066e-06
of O 0 1.7429866829843377e-06
human O 0 0.024282753467559814
congenital B-Disease 1 0.9999632835388184
eye I-Disease 1 0.9810402989387512
malformations I-Disease 1 0.9990907907485962
. O 0 6.39267309452407e-05

Mutations O 0 6.7309233600099105e-06
of O 0 1.84198061248253e-08
the O 0 1.0831424646084997e-07
human O 0 6.586038807654404e-07
PAX6 O 0 0.0002826742420438677
gene O 0 8.132148650474846e-05
underlie O 0 0.152696430683136
aniridia B-Disease 1 0.999982476234436
( O 0 0.0001585468417033553
congenital B-Disease 1 0.99968421459198
absence I-Disease 0 5.510724463420047e-07
of I-Disease 0 1.3115297292642936e-08
the I-Disease 0 1.5861330666666618e-06
iris I-Disease 1 0.6559614539146423
) O 0 6.086619919187797e-07
, O 0 4.1608679168803064e-08
a O 0 3.2313781161974475e-07
rare O 0 1.925889591802843e-05
dominant O 0 0.0033106000628322363
malformation B-Disease 1 0.997954249382019
of I-Disease 0 1.2231056700784393e-07
the I-Disease 0 4.698955763160484e-06
eye I-Disease 0 0.0009519245941191912
. O 0 4.462846391106723e-06

The O 0 2.1762907920219732e-08
spectrum O 0 2.314602909336827e-07
of O 0 1.386382741941361e-08
PAX6 O 0 6.671747541986406e-05
mutations O 0 5.872338078916073e-06
in O 0 1.3809133633913007e-05
aniridia B-Disease 1 0.9999666213989258
patients O 0 7.51086929540179e-07
is O 0 2.463041326450366e-09
highly O 0 1.857719533759905e-09
biased O 0 1.2682377246164833e-06
, O 0 3.5395974151697374e-08
with O 0 5.187596485711765e-08
92 O 0 1.8465347011442645e-06
% O 0 4.873681458406054e-10
of O 0 1.6765812349550657e-10
all O 0 1.7167043342425359e-09
reported O 0 2.78061688732123e-05
mutations O 0 9.896056418767785e-09
leading O 0 8.490582814602021e-08
to O 0 8.522672345634419e-09
premature O 0 4.6734541570003785e-07
truncation O 0 8.375929638759771e-08
of O 0 2.7212040953905614e-10
the O 0 1.3800192988355775e-08
protein O 0 3.1833128133484934e-08
( O 0 2.2559919210518586e-10
nonsense O 0 5.217733445306294e-08
, O 0 2.2451444869897585e-10
splicing O 0 1.5366595107479952e-08
, O 0 3.998299913376968e-09
insertions O 0 3.996052555521601e-08
and O 0 1.3962172751291746e-08
deletions O 0 6.272934172102396e-08
) O 0 3.582986574102165e-09
and O 0 8.090602854338158e-09
just O 0 8.95269636203011e-09
2 O 0 1.860716913881788e-08
% O 0 2.865313541988712e-10
leading O 0 3.008826743311488e-09
to O 0 1.148466825112715e-11
substitution O 0 9.644699969224568e-12
of O 0 3.2232227303863326e-11
one O 0 1.6362891042120964e-09
amino O 0 5.164154659453857e-10
acid O 0 1.2012195682586935e-09
by O 0 4.0918421428948193e-10
another O 0 2.169858070999453e-08
( O 0 2.9604112494752144e-09
missense O 0 7.627729132764216e-07
) O 0 2.9396222345212664e-08
. O 0 2.2425581391871674e-07

The O 0 4.113882923206802e-08
extraordinary O 0 3.8716297723340176e-08
conservation O 0 2.1668626892790144e-09
of O 0 4.5570869994238095e-11
the O 0 1.4823211547110304e-09
PAX6 O 0 5.582168682849442e-07
protein O 0 3.155985250913318e-09
at O 0 1.2668141202709648e-08
the O 0 2.385412423144828e-10
amino O 0 4.236201944785023e-10
acid O 0 6.725802137452774e-10
level O 0 2.752519601134651e-10
amongst O 0 4.069589665256501e-10
vertebrates O 0 1.032302563430676e-07
predicts O 0 4.4995044845563825e-06
that O 0 3.1095360952804185e-08
pathological O 0 1.0993841897288803e-05
missense O 0 9.638021083446802e-07
mutations O 0 1.0939346140048656e-07
should O 0 5.7777818085469335e-09
in O 0 6.079875713993488e-09
fact O 0 5.993064267073578e-09
be O 0 4.1863397193253604e-09
common O 0 4.309460788221031e-09
even O 0 1.7020530762579256e-08
though O 0 6.732762347638754e-09
they O 0 1.1182447190449807e-09
are O 0 1.1475082689615945e-10
hardly O 0 8.828703990104714e-09
ever O 0 1.7394011564419998e-08
seen O 0 8.112886575872835e-07
in O 0 1.1548759175639134e-06
aniridia B-Disease 1 0.9998981952667236
patients O 0 7.223986813187366e-07
. O 0 2.1861721677396417e-07

This O 0 9.836031011900559e-08
indicates O 0 6.07319122991612e-07
that O 0 1.8639884302729115e-08
there O 0 5.968706084935604e-10
is O 0 8.669041595688043e-10
a O 0 3.2866351862281817e-09
heavy O 0 1.2939502084918786e-05
ascertainment O 0 0.00010791673412313685
bias O 0 4.858474312641192e-06
in O 0 1.8499335396882088e-09
the O 0 6.263161100861225e-10
selection O 0 3.0288399566202884e-10
of O 0 2.4534998477321324e-09
patients O 0 5.179427109425205e-09
for O 0 1.1399783339527403e-09
PAX6 O 0 2.001030452447594e-06
mutation O 0 7.650100108946845e-09
analysis O 0 1.9887436142340675e-09
and O 0 1.628714052515079e-08
that O 0 1.53975481254065e-08
the O 0 4.0247062571552306e-08
missing O 0 1.5427380276378244e-05
PAX6 O 0 3.449578071013093e-05
missense O 0 8.289703146147076e-06
mutations O 0 1.7512741123937303e-06
frequently O 0 1.3206616813477012e-06
may O 0 6.844740028100205e-07
underlie O 0 2.4028233838180313e-06
phenotypes O 0 2.1363821360864677e-06
distinct O 0 5.5567170420545153e-08
from O 0 6.406913257706037e-07
textbook O 0 0.0013025399530306458
aniridia B-Disease 1 0.9996368885040283
. O 0 2.794602551148273e-05

Here O 0 2.933836924512434e-07
we O 0 1.0302898978409303e-08
present O 0 7.294636561461232e-10
four O 0 1.2183855702119217e-08
novel O 0 2.109848793452329e-07
PAX6 O 0 1.7083071725210175e-05
missense O 0 2.5700342121126596e-06
mutations O 0 3.6285098303778796e-07
, O 0 4.101472939055384e-08
two O 0 1.629423280746778e-07
in O 0 5.665654043696122e-07
association O 0 4.9115080003048206e-08
with O 0 4.482320292709119e-08
atypical O 0 1.0466648745932616e-05
phenotypes O 0 7.280474528670311e-05
ectopia B-Disease 0 0.0079802256077528
pupillae I-Disease 0 0.0003834140079561621
( O 0 1.8496159048808636e-09
displaced B-Disease 0 4.969789912934175e-09
pupils I-Disease 0 9.150802782187384e-09
) O 0 3.4650307156880444e-07
and O 0 0.0007561423699371517
congenital B-Disease 1 0.9999603033065796
nystagmus I-Disease 0 0.0016464744694530964
( O 0 2.818724809117157e-09
searching B-Disease 0 1.2152713679824956e-07
gaze I-Disease 0 8.216365131374914e-06
) O 0 8.235160997571711e-09
, O 0 4.9968593707205855e-09
and O 0 1.5430387634296494e-08
two O 0 3.864981934498246e-08
in O 0 1.318983322562417e-07
association O 0 1.955678952114681e-09
with O 0 9.200185058233501e-10
more O 0 7.806726376458073e-10
recognizable O 0 1.1448768418631516e-05
aniridia B-Disease 1 0.9998134970664978
phenotypes O 0 3.795521115534939e-05
. O 0 7.074526706674078e-07

Strikingly O 0 5.7582863519201055e-05
, O 0 7.426240955510366e-08
all O 0 2.416105648883615e-10
four O 0 1.634542989847887e-08
mutations O 0 3.0540487472308087e-08
are O 0 6.585037376494185e-11
located O 0 5.417409298935638e-10
within O 0 3.1663827809724765e-11
the O 0 5.564180671768781e-09
PAX6 O 0 3.0115497793303803e-06
paired O 0 2.8613033009605715e-07
domain O 0 5.271578729093562e-09
and O 0 1.4751663890422151e-08
affect O 0 1.4269835313385215e-10
amino O 0 1.083345496644128e-10
acids O 0 1.2858447639985116e-10
which O 0 1.1282906831056039e-09
are O 0 9.76185104972771e-12
highly O 0 4.732686811892428e-11
conserved O 0 3.6803848857402954e-10
in O 0 6.611634018049983e-10
all O 0 5.212125522846556e-11
known O 0 3.647972368625574e-09
paired O 0 6.258461837660434e-08
domain O 0 6.995038326351732e-09
proteins O 0 1.0119726390200867e-08
. O 0 1.4158510452944029e-07

Our O 0 1.081604494856947e-07
results O 0 4.01300894736778e-08
support O 0 1.2047255415481573e-09
the O 0 4.231552441780195e-09
hypothesis O 0 5.072802977679203e-08
that O 0 1.3305929691398433e-09
the O 0 7.938546486840892e-10
under O 0 3.1286431223520594e-09
- O 0 2.398976164386113e-07
representation O 0 2.677190760747017e-11
of O 0 7.412846447785171e-10
missense O 0 1.0053249752672855e-06
mutations O 0 2.2471051863703906e-07
is O 0 3.2407839967163454e-08
caused O 0 1.2111593150621047e-07
by O 0 1.5771140837728126e-08
ascertainment O 0 0.00033683027140796185
bias O 0 0.00012562648043967783
and O 0 3.1920686183184444e-07
suggest O 0 2.234530249722866e-08
that O 0 1.4776663226356845e-09
a O 0 5.2816631068708375e-09
substantial O 0 2.4868280767975648e-09
burden O 0 5.253904760138539e-07
of O 0 1.3847231805641513e-08
PAX6 B-Disease 0 0.0022340475115925074
- I-Disease 1 0.6057607531547546
related I-Disease 0 0.0018915209220722318
disease I-Disease 0 7.559696678072214e-05
remains O 0 3.6465974062593887e-07
to O 0 2.589129355357045e-09
be O 0 1.655243231368786e-08
uncovered O 0 9.326947474619374e-05
. O 0 8.222514225053601e-08
. O 0 2.489209975919948e-07

The O 0 3.826444299193099e-07
chromosomal O 0 0.00017285531794186682
order O 0 9.542301171450163e-09
of O 0 8.28747070968916e-10
genes O 0 1.0638405711915766e-08
controlling O 0 5.80143861839133e-08
the O 0 5.861620522296107e-09
major O 0 1.4254943003777498e-08
histocompatibility O 0 3.0855401291773887e-06
complex O 0 1.0854442678009946e-07
, O 0 1.0933797511825105e-07
properdin O 0 7.958450623846147e-06
factor O 0 4.413670140479553e-08
B O 0 5.883206881662773e-07
, O 0 1.4316827900984208e-07
and O 0 1.7503709386801347e-05
deficiency B-Disease 0 3.773441130761057e-05
of I-Disease 0 3.040374202400997e-11
the I-Disease 0 1.0581635567774583e-09
second I-Disease 0 2.9726971106924793e-08
component I-Disease 0 2.9243649724008947e-09
of I-Disease 0 2.50595377782048e-10
complement I-Disease 0 2.6200307701174097e-08
. O 0 3.9768542592355516e-07

The O 0 6.713901257171528e-08
relationship O 0 6.035556054939661e-08
of O 0 1.8915137511843483e-10
the O 0 8.127113981792888e-10
genes O 0 3.702445461328807e-09
coding O 0 3.39695907314308e-06
for O 0 4.491543581508495e-09
HLA O 0 5.361843022910762e-07
to O 0 3.6430197747350235e-10
those O 0 1.5633058736419514e-10
coding O 0 1.4758705901840585e-07
for O 0 7.310793637138602e-10
properdin O 0 5.097476332593942e-06
Factor O 0 1.0226329116846955e-08
B O 0 9.816988466582188e-08
allotypes O 0 3.121372174064163e-06
and O 0 1.653003778301354e-07
for O 0 1.7403444019237213e-07
deficiency B-Disease 0 1.0885209121624939e-05
of I-Disease 0 1.7955784428758115e-11
the I-Disease 0 1.052469222884156e-09
second I-Disease 0 2.3744071597775473e-08
component I-Disease 0 7.540446600451389e-10
of I-Disease 0 9.75204847430966e-11
complement I-Disease 0 4.452834989621124e-09
( O 0 1.5389818308619851e-09
C2 O 0 0.00046552534331567585
) O 0 8.634556181164044e-09
was O 0 1.0516449719943921e-06
studied O 0 5.589166018893366e-09
in O 0 6.523601214780683e-09
families O 0 3.257324010519369e-08
of O 0 8.10416267427172e-09
patients O 0 1.1962796975240053e-07
with O 0 7.53270114728366e-06
connective O 1 0.9701406359672546
tissue O 1 0.9986855387687683
disorders O 1 0.9111035466194153
. O 0 1.9518585759215057e-05

Patients O 0 2.6125883323402377e-06
were O 0 8.848954990980928e-08
selected O 0 1.1866612137367838e-09
because O 0 1.8131423029643656e-09
they O 0 5.31527266645071e-10
were O 0 8.176717969377023e-09
heterozygous O 0 2.819823308186642e-08
or O 0 7.371232868536026e-08
homozygous O 0 1.26177110360004e-05
for O 0 0.0001077094639185816
C2 B-Disease 1 0.9999842643737793
deficiency I-Disease 1 0.9999274015426636
. O 0 1.1631675988610368e-05

12 O 0 3.6911237657477614e-06
families O 0 6.693353071796082e-08
with O 0 7.690756476108618e-09
15 O 0 1.0106648851149203e-08
matings O 0 5.972508915874641e-06
informative O 0 2.0724071418953827e-06
for O 0 0.00023829507699701935
C2 B-Disease 1 0.9999910593032837
deficiency I-Disease 1 0.9999701976776123
were O 0 2.5809420094446978e-06
found O 0 6.353300250339089e-06
. O 0 8.994596782940789e-07

Of O 0 5.933264546342798e-08
57 O 0 5.031291152590711e-07
informative O 0 1.1342578432049777e-07
meioses O 0 1.3877017408958636e-05
, O 0 1.5150528609453318e-09
two O 0 8.241944904341381e-10
crossovers O 0 8.959806052644126e-08
were O 0 5.615338238840195e-08
noted O 0 1.2458592379971378e-08
between O 0 3.654443858636114e-08
the O 0 0.0004060300998389721
C2 B-Disease 1 0.9999971389770508
deficiency I-Disease 1 0.9999493360519409
gene O 0 1.1246966913347478e-08
and O 0 1.9331979572712044e-08
the O 0 6.067841695767129e-08
HLA O 0 9.743673581397161e-05
- O 0 0.0034634070470929146
B O 0 1.056468022397894e-06
gene O 0 4.3138848049295575e-09
, O 0 1.0180005727278285e-09
with O 0 2.226716866449152e-10
a O 0 1.209939148871797e-09
recombinant O 0 7.188578177164118e-09
fraction O 0 3.1101732300697904e-10
of O 0 3.893612932071022e-10
0 O 0 3.787790703313476e-08
. O 0 7.029186122053943e-08

035 O 0 0.029729679226875305
. O 0 0.0001415007864125073

A O 0 5.455330665427027e-06
lod O 0 0.0001289017527597025
score O 0 2.4911210871891853e-08
of O 0 1.7230946669499758e-09
13 O 0 4.9021490866607564e-08
was O 0 4.4349275185595616e-07
calculated O 0 6.378756634006777e-09
for O 0 1.970806018380955e-10
linkage O 0 4.4908887502970174e-05
between O 0 0.013961775228381157
C2 B-Disease 1 0.999997615814209
deficiency I-Disease 1 0.9999843835830688
and O 0 1.96064570445742e-06
HLA O 0 6.670163566013798e-05
- O 0 0.0005174154648557305
B O 0 3.267074930590752e-07
at O 0 1.9307952570102316e-08
a O 0 1.9626358871427385e-10
maximum O 0 1.8368040421989917e-10
likelihood O 0 4.932917962996441e-10
value O 0 1.3195671985655189e-11
of O 0 4.501356752617536e-12
the O 0 1.2062700838200158e-10
recombinant O 0 2.2649133679664146e-09
fraction O 0 2.5088564559183624e-10
of O 0 5.252616674944477e-10
0 O 0 1.9089634761826346e-08
. O 0 6.70031496952106e-08

04 O 0 0.0037308589089661837
. O 0 3.557742093107663e-05

18 O 0 1.1784575690398924e-05
families O 0 1.9440156506789208e-07
with O 0 4.436456091383434e-09
21 O 0 3.663892078620279e-09
informative O 0 4.291570654402221e-09
matings O 0 2.2717402714533819e-07
for O 0 1.9028686959465801e-10
both O 0 1.1541092526101693e-09
properdin O 0 1.1964375516981818e-06
Factor O 0 2.510279539791327e-09
B O 0 3.461575204255496e-08
allotype O 0 5.698719860447454e-07
and O 0 1.0630033386860305e-07
HLA O 0 8.050648830248974e-06
- O 0 0.00027353648329153657
B O 0 4.3136199678883713e-07
were O 0 2.987031066936652e-08
found O 0 2.8075399427507364e-07
. O 0 1.0108426096167022e-07

Of O 0 8.607725021647639e-08
72 O 0 1.4716949863213813e-06
informative O 0 2.524994897612487e-07
meioses O 0 8.667965448694304e-05
, O 0 3.580412766268637e-08
three O 0 3.404361237357989e-08
recombinants O 0 8.89023722265847e-05
were O 0 3.1798060717846965e-07
found O 0 1.9941919049415446e-07
, O 0 8.203583368171508e-10
giving O 0 2.8754897768434873e-11
a O 0 1.8539098034509038e-10
recombinant O 0 1.5588701440805153e-09
fraction O 0 5.735824037955695e-10
of O 0 1.0872999167688135e-09
0 O 0 4.498756922544089e-08
. O 0 1.349919642734676e-07

042 O 0 0.005536692216992378
. O 0 4.0081235056277364e-05

A O 0 6.4135178945434745e-06
lod O 0 4.952908057020977e-05
score O 0 8.470230739021645e-09
of O 0 1.5257700658466433e-10
16 O 0 4.282388221810152e-09
between O 0 1.0596242994154181e-08
HLA O 0 7.563711733382661e-06
- O 0 0.0003370646445546299
B O 0 3.775680852413643e-07
and O 0 1.4029764905387765e-08
Factor O 0 5.012753767630329e-09
B O 0 9.002220480169854e-08
allotypes O 0 1.6947471976891393e-06
was O 0 5.044181534685777e-07
calculated O 0 5.3262358967742784e-09
at O 0 6.18942852526061e-09
a O 0 3.455812580543949e-10
maximum O 0 2.0652372867413504e-10
likelihood O 0 3.4279054594854586e-10
value O 0 4.333995662353374e-11
of O 0 1.348535172418508e-11
the O 0 2.7585267403651414e-10
recombinant O 0 2.2667414611987624e-09
fraction O 0 2.1149509921158938e-10
of O 0 1.0051930399157527e-09
0 O 0 5.274618786188512e-08
. O 0 9.057436756165771e-08

04 O 0 0.004614872392266989
. O 0 2.5419187295483425e-05

A O 0 4.917911269330943e-07
crossover O 0 2.2079914288042346e-06
was O 0 1.0801199096022174e-05
shown O 0 2.2354425865955818e-08
to O 0 5.282859150135266e-10
have O 0 1.2117866710070757e-09
occurred O 0 4.602594305680441e-09
between O 0 2.48637610500424e-10
genes O 0 6.911295841183218e-11
for O 0 1.2286500983282878e-10
Factor O 0 5.575385708667113e-10
B O 0 9.203541928570758e-09
and O 0 1.2989130659946113e-08
HLA O 0 1.941010623340844e-06
- O 0 0.0011572676012292504
D O 0 0.0002360919170314446
, O 0 1.5176788714654776e-09
in O 0 1.819744910314114e-10
which O 0 1.6087936316466767e-08
HLA O 0 2.714851461860235e-06
- O 0 0.0037701567634940147
D O 0 0.0004150934692006558
segregared O 0 1.1844659866255824e-06
with O 0 1.4693844363478092e-08
HLA O 0 2.5565041141817346e-06
- O 0 2.9612223443109542e-05
A O 0 4.4103759933022957e-07
and O 0 7.787168101458519e-07
B O 0 3.682130454762955e-06
. O 0 1.252956423059004e-07

These O 0 4.6350510984893845e-08
studies O 0 5.678041503642817e-08
suggest O 0 4.76428230200554e-09
that O 0 3.3825520162622524e-10
the O 0 4.713291909541617e-11
genes O 0 3.634794965012844e-10
for O 0 7.139832614022623e-10
Factor O 0 1.9799031747425033e-08
B O 0 1.3232675883045886e-05
and O 0 0.008451515808701515
C2 B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9999839067459106
are O 0 5.496563759699313e-10
located O 0 4.664606478854694e-10
outside O 0 4.667062847296677e-10
those O 0 2.679409472072791e-10
for O 0 1.9822337105068755e-09
HLA O 0 1.1649665339064086e-06
, O 0 5.447284401327579e-09
that O 0 4.0213721241855183e-10
the O 0 1.1884591921695886e-10
order O 0 9.60347634748615e-11
of O 0 1.096506704878486e-10
genese O 0 2.4990836209326517e-06
is O 0 6.79008582693541e-09
HLA O 0 1.5623825788679824e-07
- O 0 3.72127669834299e-06
A O 0 1.4329258135603595e-07
, O 0 5.910932898700594e-08
- O 0 2.524375668144785e-05
B O 0 4.494168308610824e-07
, O 0 1.0967170283038286e-08
- O 0 9.491471246292349e-06
D O 0 1.019601222651545e-05
, O 0 1.7885766201430897e-09
Factor O 0 6.582692169132542e-10
B O 0 1.454887552654327e-07
allotype O 0 0.0001457467587897554
, O 0 0.0004884558147750795
C2 B-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9999703168869019
, O 0 3.257919045651647e-09
that O 0 1.2648886105193213e-10
the O 0 4.3893094020530654e-11
genes O 0 2.2452739667500055e-09
coding O 0 7.423392526106909e-05
for O 0 5.174874604563229e-05
C2 B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9999817609786987
and O 0 7.082547170966791e-08
Factor O 0 5.132753333469964e-09
B O 0 5.722825946463672e-08
allotypes O 0 1.1864812421436e-07
are O 0 7.67772997956051e-12
approximately O 0 1.9303466811115833e-11
3 O 0 8.271697993222915e-09
- O 0 2.343624146305956e-05
- O 0 2.451844557072036e-05
5 O 0 1.14185700894609e-08
centimorgans O 0 2.421984390821308e-07
from O 0 6.022209120271071e-11
the O 0 4.2555975410252245e-10
HLA O 0 2.548441671024193e-07
- O 0 1.7523901760796434e-06
A O 0 4.950794618707732e-08
and O 0 3.455539498986582e-08
HLA O 0 1.2283535397727974e-06
- O 0 0.00011724735668394715
B O 0 1.4009394533331943e-07
loci O 0 1.0707369435536407e-09
, O 0 1.4043571860966608e-09
and O 0 3.415174809617838e-09
that O 0 3.3072362626285212e-09
the O 0 8.26928481245659e-09
apparent O 0 1.8610239749250468e-06
lack O 0 8.131239015440883e-10
of O 0 1.7413147312961286e-10
recombinants O 0 5.514925760508049e-07
between O 0 9.687537438907157e-10
the O 0 2.2247776954031906e-09
Factor O 0 4.422414878746395e-09
B O 0 1.404315668196432e-07
gene O 0 1.7352863324049395e-07
and O 0 0.01831028237938881
C2 B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9999759197235107
gene O 0 7.705443039185411e-08
suggests O 0 1.3089032968593983e-08
that O 0 6.477041125663163e-10
these O 0 3.0521047494902476e-11
two O 0 1.1503890284814133e-08
genes O 0 8.821957919735723e-08
lie O 0 4.7881717364361975e-06
in O 0 3.479226906577537e-09
close O 0 2.5043371465471864e-07
proximity O 0 2.515965746852089e-08
to O 0 2.6326880675497932e-09
one O 0 5.6043782947767795e-09
another O 0 1.0038259290467977e-07
. O 0 1.0088891713166959e-06

Distribution O 0 1.4848126284050522e-07
of O 0 2.398289034033496e-08
emerin O 0 0.00014577677939087152
and O 0 1.711904246803897e-06
lamins O 0 5.6145327107515186e-05
in O 0 2.5018300320311937e-08
the O 0 1.7071486979602923e-07
heart O 0 8.130079368129373e-05
and O 0 1.1196629401410974e-07
implications O 0 3.380723612167458e-08
for O 0 2.6501917105292705e-08
Emery B-Disease 0 0.06278179585933685
- I-Disease 1 0.9799119830131531
Dreifuss I-Disease 1 0.99657142162323
muscular I-Disease 1 0.9995648264884949
dystrophy I-Disease 1 0.9983672499656677
. O 0 2.3752963898004964e-05

Emerin O 0 0.0014074930222705007
is O 0 1.0569361563739221e-07
a O 0 1.221044687582662e-08
nuclear O 0 1.0801072676258627e-06
membrane O 0 6.861393586632403e-08
protein O 0 1.1441372294029861e-08
which O 0 1.5303825762202905e-08
is O 0 4.303521983217706e-09
missing O 0 1.8124281098153006e-07
or O 0 5.159473559501748e-08
defective O 0 2.6526789952185936e-05
in O 0 5.435978209789027e-07
Emery B-Disease 1 0.5879127979278564
- I-Disease 1 0.9991512298583984
Dreifuss I-Disease 1 0.9998119473457336
muscular I-Disease 1 0.9999438524246216
dystrophy I-Disease 1 0.9999388456344604
( O 0 2.7994919946650043e-05
EDMD B-Disease 1 0.9999086856842041
) O 0 2.005487658607308e-06
. O 0 8.088335334832664e-07

It O 0 4.786600698025723e-07
is O 0 1.4561848615812778e-08
one O 0 4.2332456984262024e-10
member O 0 6.24574073015971e-11
of O 0 1.0494138197314484e-10
a O 0 6.372556526912376e-08
family O 0 2.357467792535317e-06
of O 0 1.484016465269633e-08
lamina O 0 0.0013975751353427768
- O 0 0.0006517574656754732
associated O 0 3.795195979705568e-08
proteins O 0 3.9057593270719337e-10
which O 0 3.4882503552324806e-09
includes O 0 1.6043955053390846e-09
LAP1 O 0 4.971060116076842e-05
, O 0 6.092090387710414e-08
LAP2 O 0 2.178057184210047e-05
and O 0 1.1373253983038012e-07
lamin O 0 1.5951825844240375e-05
B O 0 1.90608022876404e-06
receptor O 0 1.6426571392003098e-07
( O 0 4.674015485761629e-08
LBR O 0 1.4984624613134656e-05
) O 0 4.4019671463502164e-08
. O 0 1.558847770866123e-07

A O 0 1.7712334283714881e-06
panel O 0 5.945373686699895e-07
of O 0 3.92125754089534e-09
16 O 0 1.0101949499130569e-07
monoclonal O 0 1.7224292037099076e-07
antibodies O 0 5.203591157965093e-08
( O 0 1.173646291263708e-09
mAbs O 0 9.281907153990687e-08
) O 0 4.940839737344049e-09
has O 0 1.7017123710161286e-08
been O 0 1.7062918189481024e-08
mapped O 0 1.1321137804998216e-07
to O 0 4.73999728356489e-10
six O 0 1.3890387451365172e-10
specific O 0 2.48406048335148e-12
sites O 0 3.8753053543949534e-10
throughout O 0 2.337079141323528e-11
the O 0 5.811189307536324e-10
emerin O 0 2.431735310892691e-07
molecule O 0 7.344757024796422e-10
using O 0 9.528673405867494e-10
phage O 0 5.976925621098417e-08
- O 0 1.537854927846638e-06
displayed O 0 2.5900051880967112e-08
peptide O 0 2.4591453318123513e-09
libraries O 0 1.4109020896047042e-10
and O 0 1.2747375599531097e-08
has O 0 1.026253571012603e-08
been O 0 2.215757577417321e-09
used O 0 2.601657500544974e-10
to O 0 1.7003835839357606e-10
localize O 0 4.636209496311494e-07
emerin O 0 3.6821260437136516e-05
in O 0 8.275375051880474e-09
human O 0 7.552487346629277e-08
and O 0 7.082180673023686e-06
rabbit O 0 0.21732673048973083
heart O 0 0.00115224439650774
. O 0 1.5274947600119049e-06

Several O 0 1.1497841256868924e-07
mAbs O 0 1.96915630112926e-06
against O 0 7.02914633166074e-08
different O 0 6.647976613649575e-10
emerin O 0 2.3309838070417754e-05
epitopes O 0 4.3704212657758035e-06
did O 0 2.9930536271649544e-08
not O 0 4.302567468972285e-10
recognize O 0 1.8924346534276992e-09
intercalated O 0 3.240623698275158e-07
discs O 0 9.415926615474746e-05
in O 0 2.2564071500141836e-08
the O 0 2.3525666392743005e-07
heart O 0 9.452019003219903e-05
, O 0 3.631853573438093e-08
though O 0 2.948099542265936e-09
they O 0 5.972544125931734e-10
recognized O 0 9.059017980206363e-10
cardiomyocyte O 0 1.0189178283326328e-06
nuclei O 0 2.223417183699894e-08
strongly O 0 1.99747667295469e-08
, O 0 2.0372492581799406e-09
both O 0 1.9345350321664512e-10
at O 0 1.8123381551049533e-07
the O 0 1.659517145924383e-08
rim O 0 6.389625195879489e-05
and O 0 8.102404081000714e-08
in O 0 2.312318869712726e-08
intranuclear O 0 1.8760709281195886e-05
spots O 0 2.440705770823115e-07
or O 0 3.095936662589338e-08
channels O 0 7.420902079502412e-07
. O 0 4.009536098692479e-07

A O 0 3.1504382604907732e-06
polyclonal O 0 4.093246388947591e-05
rabbit O 0 0.00045979302376508713
antiserum O 0 2.6091323888977058e-05
against O 0 1.1576919860090129e-05
emerin O 0 0.0008181642624549568
did O 0 1.6732579410927428e-07
recognize O 0 2.120170483621564e-09
both O 0 5.628059684958941e-10
nuclear O 0 6.58244687201659e-07
membrane O 0 1.6709895689359655e-08
and O 0 1.5047206147755787e-08
intercalated O 0 1.775140248128082e-07
discs O 0 5.383076768339379e-06
but O 0 4.022586264085248e-09
, O 0 3.5305991463729924e-10
after O 0 2.2386243969663155e-09
affinity O 0 1.6096551869182463e-09
purification O 0 2.148594901996148e-08
against O 0 1.0693904428649148e-08
a O 0 4.16320800056269e-09
pure O 0 8.355282687944054e-08
- O 0 0.00014625853509642184
emerin O 0 4.887743216386298e-06
band O 0 8.215440772119109e-09
on O 0 3.2856966925010056e-08
a O 0 8.220927050217597e-09
western O 0 3.118748637120916e-08
blot O 0 0.0005082572461105883
, O 0 1.3594852532605728e-07
it O 0 5.2415632723068484e-08
stained O 0 0.00035235309042036533
only O 0 2.92614876773456e-10
the O 0 3.0689140118056457e-09
nuclear O 0 8.355730642506387e-06
membrane O 0 3.6610933307201776e-07
. O 0 8.97143408451484e-08

These O 0 6.125343077201251e-08
results O 0 1.1921011378035473e-07
would O 0 6.661764917481605e-09
not O 0 5.005346692676937e-10
be O 0 7.58467177952582e-10
expected O 0 7.404089341633835e-09
if O 0 1.1968560587050092e-09
immunostaining O 0 2.57892452282249e-07
at O 0 7.483372144179157e-08
intercalated O 0 2.1651725035098934e-07
discs O 0 1.8290456864633597e-05
were O 0 2.9029539660996306e-08
due O 0 2.005672294913552e-09
to O 0 1.4978181195335338e-10
a O 0 1.4046547258672604e-09
product O 0 6.072550906566221e-09
of O 0 1.6803651525787444e-10
the O 0 7.544651126067947e-09
emerin O 0 3.961639777116943e-06
gene O 0 9.769707709494924e-09
and O 0 3.7192855018020055e-08
, O 0 1.1671930089107718e-08
therefore O 0 4.92868579282657e-10
, O 0 1.2606068411358251e-09
cast O 0 7.835980198045434e-10
some O 0 1.0860386374933473e-11
doubt O 0 4.913648932181047e-10
upon O 0 5.3671445759961856e-11
the O 0 8.421467967423268e-09
hypothesis O 0 9.972170573746553e-07
that O 0 2.719251369853737e-06
cardiac B-Disease 1 0.6542650461196899
defects I-Disease 1 0.9943404197692871
in O 0 5.98137266933918e-05
EDMD B-Disease 1 0.9999924898147583
are O 0 4.6756875349274196e-07
caused O 0 1.644730787120352e-06
by O 0 8.490789404902443e-09
absence O 0 1.2429397955315835e-08
of O 0 5.934811753149916e-09
emerin O 0 0.00024755296180956066
from O 0 5.5149786959418634e-08
intercalated O 0 1.4458485566137824e-05
discs O 0 0.0005091298371553421
. O 0 6.316142844298156e-07

Although O 0 9.957326483345241e-07
emerin O 0 0.00012896419502794743
was O 0 3.369148316778592e-06
abundant O 0 1.7175854072348784e-09
in O 0 5.609979147891409e-10
the O 0 6.446279621208362e-10
membranes O 0 1.322488856203563e-07
of O 0 2.260765574746415e-09
cardiomyocyte O 0 9.705329830467235e-06
nuclei O 0 3.7580704770334705e-08
, O 0 6.7870433717587275e-09
it O 0 6.76055700310485e-09
was O 0 4.523150437307777e-06
absent O 0 1.965586271523989e-08
from O 0 5.313448570021251e-10
many O 0 4.852576673819442e-11
non O 0 4.203782655309851e-09
- O 0 6.485675112344325e-05
myocyte O 0 7.920258940430358e-05
cells O 0 1.1422472567801378e-07
in O 0 6.766827098658723e-09
the O 0 2.998814068178035e-07
heart O 0 0.0005348001141101122
. O 0 1.2587247510964517e-06

This O 0 9.171263748442016e-09
distribution O 0 1.5977633438524208e-08
of O 0 8.288139063949984e-09
emerin O 0 5.58381543669384e-05
was O 0 2.6201589662377955e-06
similar O 0 4.154838695313856e-09
to O 0 1.0409378914388867e-09
that O 0 1.4214589505456843e-09
of O 0 4.4257711384609877e-10
lamin O 0 5.074078671896132e-06
A O 0 1.4475716625383939e-07
, O 0 1.1801702726188523e-08
a O 0 2.7697380389213322e-08
candidate O 0 1.8086083741764014e-08
gene O 0 8.351263680594911e-09
for O 0 8.328036038562914e-10
an O 0 1.236056021980403e-07
autosomal O 0 0.0009968788363039494
form O 0 1.6077483167009632e-07
of O 0 4.005517894256627e-06
EDMD B-Disease 1 0.999903678894043
. O 0 2.5132780137937516e-05

In O 0 1.9542673612704675e-07
contrast O 0 6.30043473393016e-07
, O 0 4.1820601381914457e-07
lamin O 0 0.0003881075535900891
B1 O 0 0.05410100519657135
was O 0 1.2871761100541335e-05
absent O 0 1.0316392717868439e-07
from O 0 1.1985693548766108e-09
cardiomyocyte O 0 6.126114726612286e-07
nuclei O 0 6.645903027902023e-08
, O 0 2.779189500756729e-08
showing O 0 8.302031915263797e-07
that O 0 4.22222683482687e-07
lamin O 0 0.0005467479350045323
B1 O 0 0.025919046252965927
is O 0 3.039472451504821e-09
not O 0 1.3044630653435973e-10
essential O 0 8.048770851198928e-12
for O 0 1.0452522528070496e-11
localization O 0 1.1550722156528082e-08
of O 0 4.1818365437151783e-10
emerin O 0 1.8541398958404898e-06
to O 0 6.006771191557903e-10
the O 0 1.7281411857084095e-08
nuclear O 0 0.0005652799736708403
lamina O 0 0.00012381438864395022
. O 0 3.770222463117534e-07

Lamin O 0 0.2096637338399887
B1 O 1 0.9648323059082031
is O 0 7.865004363338812e-07
also O 0 6.203921287806224e-08
almost O 0 3.733776399172939e-09
completely O 0 6.372593475134636e-07
absent O 0 4.902860268884979e-07
from O 0 3.114456958996925e-08
skeletal O 0 0.010067544877529144
muscle O 0 7.037846080493182e-05
nuclei O 0 7.572833965241443e-06
. O 0 1.669045445851225e-06

In O 0 1.9592138414736837e-05
EDMD B-Disease 1 0.9980161190032959
, O 0 7.038926241875743e-08
the O 0 6.382890882505876e-10
additional O 0 6.368246902033192e-11
absence O 0 4.612621395949645e-09
of O 0 2.0892889196488795e-08
lamin O 0 0.028351444751024246
B1 O 1 0.7995895743370056
from O 0 2.9420522196232923e-07
heart O 0 4.2464602302061394e-05
and O 0 8.44286091705726e-07
skeletal O 0 0.018869493156671524
muscle O 0 1.0532797205087263e-05
nuclei O 0 1.143466306530172e-06
which O 0 2.714598110742372e-07
already O 0 2.257858540133384e-07
lack O 0 2.96716837766553e-08
emerin O 0 0.0002351250732317567
may O 0 2.7413154413125085e-08
offer O 0 2.7326921975268093e-11
an O 0 6.89464041414567e-11
alternative O 0 2.1807886052549463e-10
explanation O 0 7.99315280630708e-10
of O 0 3.908054158063834e-10
why O 0 1.1262981658433091e-08
these O 0 4.5852602270635145e-10
tissues O 0 9.306618409254952e-08
are O 0 1.839780827683768e-10
particularly O 0 4.7580797080115644e-09
affected O 0 1.4299350592494875e-09
. O 0 3.6138647629968546e-09
. O 0 1.2055426168444683e-07

Genetic O 0 4.626634563464904e-06
mapping O 0 5.5846894611022435e-06
of O 0 5.40341140720102e-08
the O 0 6.246833663681173e-07
copper B-Disease 0 0.010596418753266335
toxicosis I-Disease 0 0.00038833366124890745
locus O 0 1.2497574743974837e-06
in O 0 3.364512934922459e-08
Bedlington O 0 0.00014534998626913875
terriers O 0 6.817303074058145e-05
to O 0 2.0451066617965807e-08
dog O 0 2.3936059733387083e-05
chromosome O 0 1.8488079149392433e-05
10 O 0 1.0553265639146048e-07
, O 0 1.5187366031454985e-08
in O 0 2.8775009042192323e-09
a O 0 1.1077292327854593e-07
region O 0 1.538813023671537e-07
syntenic O 0 2.1540090529015288e-05
to O 0 4.430613209649437e-09
human O 0 3.228001688171389e-08
chromosome O 0 1.6473179130116478e-05
region O 0 1.130137547988852e-07
2p13 O 0 4.727425221062731e-06
- O 0 0.00031519492040388286
p16 O 0 5.6580906857561786e-06
. O 0 9.018993551990206e-08

Abnormal O 1 0.9473353624343872
hepatic B-Disease 1 0.9988590478897095
copper I-Disease 1 0.9114082455635071
accumulation I-Disease 0 0.0002193753025494516
is O 0 5.800077573780982e-08
recognized O 0 1.7627703741140976e-08
as O 0 3.156715990826342e-07
an O 0 0.000863643188495189
inherited B-Disease 1 0.9999980926513672
disorder I-Disease 1 0.9999852180480957
in O 0 1.4797886933592963e-06
man O 0 0.0003544096543919295
, O 0 2.2189480830547836e-07
mouse O 0 0.000358759134542197
, O 0 2.077746103168465e-06
rat O 0 0.0007826321525499225
and O 0 1.766673449310474e-06
dog O 0 0.0004375099379103631
. O 0 2.8813387871196028e-06

The O 0 1.2604208450284204e-06
major O 0 1.2946187553097843e-06
cause O 0 4.225750217301538e-06
of O 0 1.4144234228297137e-06
hepatic B-Disease 1 0.9949488639831543
copper I-Disease 1 0.9232029318809509
accumulation I-Disease 0 5.1107464969391e-05
in O 0 1.7202984281539102e-07
man O 0 7.35474968678318e-05
is O 0 2.2834841573171616e-08
a O 0 7.298554294266069e-08
dysfunctional O 0 0.0010147764114663005
ATP7B O 0 0.0044016651809215546
gene O 0 2.064961790892994e-06
, O 0 8.84232395037543e-06
causing O 0 0.0030659299809485674
Wilson B-Disease 0 0.10955949127674103
disease I-Disease 0 0.02251254953444004
( O 0 2.3093002710083965e-07
WD B-Disease 0 0.15301541984081268
) O 0 3.870766818181437e-07
. O 0 3.0231615255615907e-07

Mutations O 0 5.569876066147117e-06
in O 0 6.499731597386926e-08
the O 0 3.076681309721607e-08
ATP7B O 0 0.0002495849330443889
genes O 0 3.869717701832087e-08
have O 0 9.212604901165378e-09
also O 0 1.4483955368405077e-08
been O 0 2.6056431678966874e-08
demonstrated O 0 9.227943564837915e-08
in O 0 1.0480246892541345e-08
mouse O 0 0.00012210682325530797
and O 0 5.654260348819662e-06
rat O 0 0.008960825391113758
. O 0 1.1604303153944784e-06

The O 0 1.5221025932987686e-06
ATP7B O 0 0.0005451664328575134
gene O 0 1.0713533811212983e-06
has O 0 5.429776592791313e-07
been O 0 6.338409264117217e-08
excluded O 0 1.0076044887341595e-08
in O 0 6.433075738776495e-10
the O 0 1.8766981302320573e-09
much O 0 7.725011741399612e-09
rarer O 0 3.0554465411114506e-06
human O 0 4.030993750347989e-06
copper B-Disease 1 0.9601404666900635
overload I-Disease 1 0.524640679359436
disease O 0 3.607815597206354e-05
non B-Disease 0 5.4324083009760216e-08
- I-Disease 0 0.004993737675249577
Indian I-Disease 0 3.441370063228533e-05
childhood I-Disease 0 0.0009061097516678274
cirrhosis I-Disease 0 0.006728270556777716
, O 0 1.5286154564364551e-07
indicating O 0 2.4589553504483774e-06
genetic O 0 2.7533367301657563e-06
heterogeneity O 0 4.644068030756898e-05
. O 0 1.0286845281370915e-05

By O 0 8.837164955366461e-08
investigating O 0 1.4404316743821255e-06
the O 0 5.776429361503688e-07
common O 0 1.5248750969476532e-05
autosomal O 1 0.7883028388023376
recessive O 1 0.9945434331893921
copper B-Disease 1 0.9997398257255554
toxicosis I-Disease 1 0.942753255367279
( O 0 3.7193640878285805e-07
CT B-Disease 0 0.0017895899945870042
) O 0 2.5620531474146446e-08
in O 0 1.9118127525530326e-08
Bedlington O 0 0.0002120361168636009
terriers O 0 0.0032907419372349977
, O 0 1.306270007717103e-07
we O 0 1.9714461174658027e-09
have O 0 7.147162861542711e-10
identified O 0 2.4467794457194714e-09
a O 0 1.6343457698297925e-09
new O 0 2.8349123937232434e-08
locus O 0 2.833220378306578e-06
involved O 0 3.887061268414982e-07
in O 0 2.0410854631336406e-05
progressive O 1 0.9665297269821167
liver B-Disease 1 0.9999809265136719
disease I-Disease 1 0.9997393488883972
. O 0 2.3129923647502437e-05

We O 0 1.8133029300315684e-07
examined O 0 1.85471520808278e-07
whether O 0 5.536687552876174e-09
the O 0 4.620874705096867e-08
WD B-Disease 0 0.016826657578349113
gene O 0 1.6037712384786573e-06
ATP7B O 0 0.0012875414686277509
was O 0 3.8341193430824205e-05
also O 0 4.0518958854818266e-08
causative O 0 1.3455927927452649e-08
for O 0 2.1250083914736706e-09
CT B-Disease 0 2.2067422833060846e-05
by O 0 9.229061959104001e-10
investigating O 0 3.1239398623483794e-08
the O 0 1.939483773583106e-08
chromosomal O 0 0.0035017956979572773
co O 0 0.0007293566013686359
- O 0 1.2889130630355794e-05
localization O 0 3.080818657963391e-07
of O 0 4.071261106020074e-09
ATP7B O 0 5.8470413932809606e-05
and O 0 2.298436996284181e-08
C04107 O 0 9.122692823382295e-09
, O 0 4.214311538630611e-11
using O 0 1.0735128931627091e-11
fluorescence O 0 5.295421434681202e-09
in O 0 9.855590787921642e-10
situ O 0 2.324705405953864e-08
hybridization O 0 1.290569002776465e-07
( O 0 2.809192878316935e-09
FISH O 0 2.988635685596819e-07
) O 0 2.565138679244683e-08
. O 0 5.8522061863186536e-08

C04107 O 0 0.0001779976737452671
is O 0 1.8199000351160066e-07
an O 0 3.7663514973473866e-08
anonymous O 0 6.839272259639984e-07
microsatellite O 0 0.0006712652975693345
marker O 0 5.189720104681328e-05
closely O 0 2.448934310450568e-06
linked O 0 1.731191878207028e-05
to O 0 4.878271511188359e-07
CT B-Disease 0 0.005051241256296635
. O 0 1.5042979839563486e-06

However O 0 2.5339109015476424e-06
, O 0 2.521626072393701e-07
BAC O 0 2.2132489903015085e-06
clones O 0 5.576934654527577e-06
containing O 0 4.167111740116525e-07
ATP7B O 0 0.00014081192784942687
and O 0 1.3087888817153726e-07
C04107 O 0 8.295274511738171e-08
mapped O 0 1.4836675177321013e-07
to O 0 5.209583320286981e-10
the O 0 5.598405738993506e-09
canine O 0 9.361410775454715e-06
chromosome O 0 3.369243859197013e-05
regions O 0 1.0787237769704916e-08
CFA22q11 O 0 1.0618989108479582e-05
and O 0 1.881330007336146e-07
CFA10q26 O 0 1.984129448828753e-05
, O 0 2.0843929249281246e-08
respectively O 0 7.930122336574641e-09
, O 0 1.5642790396341866e-09
demonstrating O 0 1.689416606609484e-08
that O 0 2.095691087333762e-07
WD B-Disease 0 0.0012289867736399174
cannot O 0 7.616453245873345e-09
be O 0 1.6467328889380184e-10
homologous O 0 6.269128327573981e-09
to O 0 1.5840599942862355e-08
CT B-Disease 0 0.00018929621728602797
. O 0 5.33852528405987e-07

The O 0 2.802269989388151e-07
copper O 0 9.122402116190642e-05
transport O 0 1.9669106166020356e-07
genes O 0 4.779694151579861e-08
CTR1 O 0 8.250770770246163e-05
and O 0 4.5610508436766395e-07
CTR2 O 0 7.364574412349612e-05
were O 0 6.517620931845158e-08
also O 0 9.644015364074221e-09
excluded O 0 1.415965789064444e-09
as O 0 1.0677059236741115e-10
candidate O 0 8.975940823940931e-11
genes O 0 2.983202018747022e-10
for O 0 1.655488635066149e-09
CT B-Disease 0 0.0001788104564184323
since O 0 3.294029937706e-08
they O 0 7.404692969892324e-10
both O 0 1.9243226456744367e-10
mapped O 0 1.3381863084305223e-07
to O 0 7.493539122549464e-09
canine O 0 3.8154958019731566e-05
chromosome O 0 0.0009534618002362549
region O 0 2.661092821654165e-06
CFA11q22 O 0 0.000511064485181123
. O 0 1.1034395583919832e-06

2 O 0 2.1727588318753988e-05
- O 0 0.002202405594289303
22 O 0 7.5929960985376965e-06
. O 0 7.919919653431862e-07

5 O 0 7.77210298110731e-05
. O 0 7.326054856093833e-06

A O 0 6.194474622134294e-07
transcribed O 0 4.060991329879471e-07
sequence O 0 3.253505553857394e-08
identified O 0 2.1072868605642725e-07
from O 0 1.7164915044887152e-09
the O 0 3.489967204117761e-09
C04107 O 0 6.343972813738219e-07
- O 0 1.4138287042442244e-05
containing O 0 2.0015541224438493e-07
BAC O 0 3.9428553577636194e-07
was O 0 1.776847057044506e-06
found O 0 1.716721520494957e-08
to O 0 2.58665533436897e-10
be O 0 5.931277691217929e-10
homologous O 0 7.988203876152511e-09
to O 0 1.4572981710259114e-09
a O 0 7.828006687304878e-09
gene O 0 6.0320788364265354e-09
expressed O 0 1.2084400147216456e-09
from O 0 2.3470106413903125e-10
human O 0 4.224189886770091e-09
chromosome O 0 5.114226041769143e-06
2p13 O 0 7.140464504118427e-07
- O 0 4.83068433823064e-05
p16 O 0 1.7259908702271787e-07
, O 0 4.850185142402097e-09
a O 0 7.82338016591666e-09
region O 0 2.8240361160669636e-09
devoid O 0 1.5427502830789308e-08
of O 0 4.076968276867099e-11
any O 0 8.661467376658294e-11
positional O 0 6.380852113352375e-08
candidate O 0 5.8804921820865275e-08
genes O 0 2.061011770138066e-07
. O 0 6.874053610772535e-07

Molecular O 0 3.3617404824326513e-06
analysis O 0 5.564098515264959e-08
of O 0 1.0820512263975957e-09
the O 0 8.513135085763679e-09
APC B-Disease 0 1.2432052471922361e-06
gene O 0 1.7911856886598798e-08
in O 0 1.2444367314401461e-08
205 O 0 4.2759222651511664e-07
families O 0 2.8640871008178692e-08
: O 0 2.4919785679422546e-10
extended O 0 1.6684218451246124e-09
genotype O 0 1.8726034340943443e-06
- O 0 0.0002331351861357689
phenotype O 0 2.1077864857943496e-06
correlations O 0 1.0587373253656551e-06
in O 0 7.044204863859704e-08
FAP B-Disease 0 7.902506240498042e-07
and O 0 5.255167323525711e-08
evidence O 0 7.3455175275682905e-09
for O 0 9.872255096743388e-11
the O 0 6.827549081656059e-10
role O 0 1.7158990894827753e-09
of O 0 5.905957389806815e-10
APC B-Disease 0 3.644991011242382e-07
amino O 0 1.8183545780203758e-09
acid O 0 8.193250522481321e-09
changes O 0 1.1030397928379898e-08
in O 0 0.00019197069923393428
colorectal B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999675750732422
predisposition O 0 0.06686463952064514
. O 0 8.368793714907952e-06

BACKGROUND O 0 7.90721969678998e-06
/ O 0 1.895739114843309e-05
AIMS O 0 1.0446985925227636e-06
The O 0 1.2021668993611456e-08
development O 0 1.2033235918806895e-07
of O 0 0.00028405041666701436
colorectal B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.999976634979248
and O 0 9.717059583636e-07
a O 0 6.737440116921789e-08
variable O 0 1.6276806036330527e-07
range O 0 1.7068458646463114e-07
of O 0 3.072986487495655e-08
extracolonic O 0 0.009201828390359879
manifestations O 0 6.713307811878622e-05
in O 0 7.360853487625718e-05
familial B-Disease 1 0.9999784231185913
adenomatous I-Disease 1 0.9998987913131714
polyposis I-Disease 1 0.9999716281890869
( O 0 5.60916760150576e-06
FAP B-Disease 0 8.919066021917388e-05
) O 0 9.969662784214961e-08
is O 0 3.0104398973662683e-09
the O 0 4.147949983490662e-09
result O 0 7.823141245921761e-09
of O 0 2.830738143888567e-10
the O 0 4.8109011885344444e-08
dominant O 0 1.2097817489120644e-05
inheritance O 0 0.0008778231567703187
of O 0 0.0005892337649129331
adenomatous B-Disease 1 0.9999657869338989
polyposis I-Disease 1 0.9999232292175293
coli I-Disease 1 0.9999325275421143
( O 0 3.0646751270069217e-07
APC B-Disease 0 3.379763074917719e-05
) O 0 8.785402627609074e-08
gene O 0 2.432621499792731e-07
mutations O 0 8.991569302452262e-07
. O 0 9.888142358249752e-07

In O 0 1.807894705052604e-07
this O 0 5.008452763632931e-09
study O 0 1.7392675077942954e-09
, O 0 4.1661449290408825e-10
direct O 0 2.8729954179573802e-11
mutation O 0 7.381946720563803e-10
analysis O 0 1.2035910046392928e-09
of O 0 2.381284891495028e-10
the O 0 1.4682889570849511e-08
APC B-Disease 0 2.9211332730483264e-06
gene O 0 1.5284456367226085e-08
was O 0 9.545824468659703e-07
performed O 0 2.897227568965377e-09
to O 0 1.706651348021282e-10
determine O 0 8.857258926298073e-09
genotype O 0 4.529913155693066e-07
- O 0 5.1774019084405154e-05
phenotype O 0 1.8908380639004463e-07
correlations O 0 7.610807983837731e-08
for O 0 1.8051059536006164e-09
nine O 0 5.572211989601783e-07
extracolonic O 0 0.00017448491416871548
manifestations O 0 2.8819465569540625e-07
and O 0 1.049222753124468e-08
to O 0 2.6490770688170073e-10
investigate O 0 5.338735675763928e-09
the O 0 1.771023683261319e-08
incidence O 0 1.2877262633992359e-05
of O 0 7.70164909624782e-09
APC B-Disease 0 1.3603658771899063e-05
mutations O 0 6.524100371052555e-08
in O 0 2.1539660721714426e-08
non O 0 1.1322287036819034e-06
- O 1 0.9249868988990784
FAP O 1 0.9915299415588379
colorectal B-Disease 1 0.9999939203262329
cancer I-Disease 1 0.9998582601547241
. O 0 6.584989023394883e-05

METHODS O 0 2.66145832483744e-07
The O 0 3.495111755569269e-08
APC B-Disease 0 3.515904154482996e-06
gene O 0 6.632657090221983e-08
was O 0 1.8887091073338524e-06
analysed O 0 8.266007966994948e-08
in O 0 6.109798444953185e-09
190 O 0 8.582723864947184e-08
unrelated O 0 1.0767872709038784e-06
FAP B-Disease 0 6.912609364917444e-07
and O 0 7.885735442414443e-08
15 O 0 4.743674253404606e-08
non O 0 3.9711389376861916e-07
- O 1 0.9793713092803955
FAP O 1 0.9983332753181458
colorectal B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999855756759644
patients O 0 5.2318743115620236e-08
using O 0 2.2354413875547152e-09
denaturing O 0 2.1791793187730946e-05
gradient O 0 5.265824438538402e-05
gel O 0 0.0024322716053575277
electrophoresis O 0 0.0014707182999700308
, O 0 3.6478699172448614e-08
the O 0 1.8543174773455462e-09
protein O 0 5.293603777545286e-09
truncation O 0 3.8717115558029036e-07
test O 0 1.2251369696514303e-07
, O 0 2.1371699965300195e-09
and O 0 6.782200356880708e-10
direct O 0 2.9490540565113577e-10
sequencing O 0 5.306885668687755e-07
. O 0 1.0482784773557796e-06

RESULTS O 0 1.83068223122973e-05
Chain O 0 1.6291716747218743e-05
terminating O 0 5.293304070619342e-07
signals O 0 6.201590849741478e-07
were O 0 9.729414074399756e-08
only O 0 6.276291153461955e-10
identified O 0 5.2952429996366845e-08
in O 0 3.190126562913065e-08
patients O 0 7.76046960027088e-09
belonging O 0 3.3129637699857994e-08
to O 0 2.586039826724118e-09
the O 0 3.6889979071474954e-08
FAP B-Disease 0 4.921157142234733e-06
group O 0 1.7322585108558997e-06
( O 0 2.992036174376267e-09
105 O 0 3.089300832925801e-07
patients O 0 2.5177804729992204e-08
) O 0 1.0835490726890384e-08
. O 0 1.3316248725914193e-07

Amino O 0 3.323305861613335e-07
acid O 0 9.336541495486017e-08
changes O 0 3.1637883979307446e-10
were O 0 4.804589615048371e-09
identified O 0 2.5274033532696194e-08
in O 0 5.503385303029518e-09
four O 0 1.928743955659229e-07
patients O 0 9.711722981364801e-09
, O 0 2.28694796433615e-09
three O 0 1.8058669004616945e-09
of O 0 2.248758290690489e-09
whom O 0 9.761385655338017e-08
belonged O 0 1.7408390817763575e-07
to O 0 1.1449510228800364e-09
the O 0 2.0086583507605837e-09
non O 0 1.1901775565092976e-08
- O 0 5.658009831677191e-05
FAP O 0 1.9421327124291565e-06
group O 0 6.518772806884954e-06
of O 0 0.0002132302470272407
colorectal B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999735355377197
patients O 0 5.934627097303746e-06
. O 0 1.4326828932098579e-06

Genotype O 0 0.0034436220303177834
- O 0 0.03911870718002319
phenotype O 0 0.00010985916014760733
correlations O 0 2.4195165678975172e-05
identified O 0 3.5658260912896367e-06
significant O 0 2.239650598312437e-08
differences O 0 9.673454997027875e-07
in O 0 2.6503283123702204e-08
the O 0 2.435466583960988e-08
nature O 0 1.772777835640227e-08
of O 0 1.3089449524272823e-09
certain O 0 3.2138700589712244e-09
extracolonic O 0 7.019072654657066e-05
manifestations O 0 4.716936814475048e-07
in O 0 3.609616427979745e-08
FAP B-Disease 0 1.5339031733674346e-06
patients O 0 4.263065456200366e-09
belonging O 0 1.3119100472636092e-08
to O 0 9.450157323342978e-10
three O 0 1.7757930237394248e-08
mutation O 0 2.391629436715448e-07
subgroups O 0 9.961943305825116e-07
. O 0 1.232578028975695e-06

CONCLUSIONS O 0 1.7004913388518617e-06
Extended O 0 2.5561868710610725e-07
genotype O 0 3.0790866730967537e-05
- O 0 0.0017576052341610193
phenotype O 0 6.2124390751705505e-06
correlations O 0 2.1734465462941444e-06
made O 0 1.7945170327493543e-07
in O 0 2.1367879909917065e-08
this O 0 1.7906895966035563e-09
study O 0 6.299825550115656e-09
may O 0 4.1754166346663624e-08
have O 0 3.621916100371436e-10
the O 0 7.247428768231146e-10
potential O 0 1.1482401696127909e-09
to O 0 1.5083338744670272e-10
determine O 0 3.6364591893267573e-10
the O 0 9.46115408240189e-11
most O 0 5.459008245445318e-12
appropriate O 0 9.276048679174309e-12
surveillance O 0 1.0263929794973592e-07
and O 0 2.7623835663348473e-08
prophylactic O 0 2.1083664591969864e-07
treatment O 0 4.3896925205899606e-08
regimens O 0 4.2129837396487346e-08
for O 0 4.971000833187134e-10
those O 0 3.809794257847443e-09
patients O 0 4.146447185604529e-09
with O 0 3.994772512783129e-08
mutations O 0 5.743991096096579e-07
associated O 0 2.0252637966677867e-07
with O 0 4.476186461488396e-07
life O 0 3.188174741808325e-05
threatening O 0 0.006781576666980982
conditions O 0 4.785392957273871e-05
. O 0 2.320299472557963e-06

This O 0 1.0232244562757842e-07
study O 0 7.301628190958809e-09
also O 0 9.15955133962143e-09
provided O 0 8.415828034458173e-10
evidence O 0 7.289577830249527e-09
for O 0 9.964425951025646e-10
the O 0 3.9504914894905596e-08
pathological O 0 9.527457223157398e-06
nature O 0 1.2436536245274965e-08
of O 0 3.667288139830305e-10
amino O 0 1.329182652831662e-09
acid O 0 9.43931266483844e-10
changes O 0 4.3224215873216565e-11
in O 0 3.2907876423848847e-09
APC O 0 4.5407150537357666e-06
associated O 0 8.221287650655995e-09
with O 0 5.834123184556006e-10
both O 0 3.3889147044163792e-09
FAP B-Disease 0 6.122832019173075e-07
and O 0 1.7568149246471876e-07
non O 0 8.419607411269681e-07
- O 1 0.9654725790023804
FAP O 1 0.9948705434799194
colorectal B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999786615371704
patients O 0 1.26111694953579e-06
. O 0 5.8507104938598786e-08
. O 0 6.657238600382698e-07

Inherited B-Disease 1 0.9982609152793884
colorectal I-Disease 1 0.9998836517333984
polyposis I-Disease 1 0.9994520545005798
and O 1 0.9556427597999573
cancer B-Disease 1 0.9523699879646301
risk O 0 6.869289336464135e-06
of O 0 3.646650537092455e-09
the O 0 1.7784851991109463e-07
APC O 0 9.741146641317755e-05
I1307K O 0 1.1484680726425722e-05
polymorphism O 0 4.639651706384029e-06
. O 0 1.0863924444493023e-06

Germ O 0 0.014207985252141953
- O 0 0.0014886296121403575
line O 0 5.72622684558155e-06
and O 0 8.96655638626953e-09
somatic O 0 1.0748380852021455e-08
truncating O 0 1.463638568566239e-06
mutations O 0 1.2195997101116518e-07
of O 0 2.2316160031010668e-09
the O 0 3.9789249228761037e-08
APC B-Disease 0 6.3714664975123014e-06
gene O 0 3.738395903951641e-08
are O 0 2.5667512559834904e-10
thought O 0 5.866966912293492e-09
to O 0 1.7474842683995462e-09
initiate O 0 2.396413492533611e-06
colorectal B-Disease 1 0.9999868869781494
tumor I-Disease 1 0.928928792476654
formation O 0 0.00018501780868973583
in O 0 0.00430260831490159
familial B-Disease 1 0.9999881982803345
adenomatous I-Disease 1 0.9999637603759766
polyposis I-Disease 1 0.9999940395355225
syndrome I-Disease 1 0.9999772310256958
and O 0 0.00022520858328789473
sporadic O 0 0.09279730916023254
colorectal O 1 0.9999805688858032
carcinogenesis O 1 0.9791916012763977
, O 0 1.385998257319443e-05
respectively O 0 4.433930826053256e-06
. O 0 1.2180809108031099e-06

Recently O 0 2.2432850528275594e-05
, O 0 6.44440447672423e-08
an O 0 1.4825961791586906e-08
isoleucine O 0 0.0004893253208138049
- O 0 0.0028739734552800655
- O 0 0.0035553574562072754
> O 0 9.147735369197108e-08
lysine O 0 4.2385582332826743e-07
polymorphism O 0 2.76701346280106e-08
at O 0 1.779563341131052e-08
codon O 0 1.8747197128021753e-09
1307 O 0 7.468708645319566e-06
( O 0 7.786248867880374e-10
I1307K O 0 1.7508281047184937e-08
) O 0 3.1925703747326395e-10
of O 0 4.13762635265158e-11
the O 0 5.033303995816141e-09
APC B-Disease 0 1.4343111160997069e-06
gene O 0 1.635709345748637e-08
has O 0 5.6143207416425867e-08
been O 0 1.1603717986474749e-08
identified O 0 5.500835342786559e-09
in O 0 1.3403436138759162e-09
6 O 0 1.95774063627141e-07
% O 0 4.971590694680117e-09
- O 0 7.51214538468048e-05
7 O 0 1.0204612408415414e-06
% O 0 3.923701641372901e-10
of O 0 5.763203803077488e-11
the O 0 1.0911689329873298e-08
Ashkenazi O 0 1.0184264283452649e-05
Jewish O 0 3.1063828487276623e-07
population O 0 5.551872739317787e-09
. O 0 1.518352092944042e-07

To O 0 1.7403145591288194e-07
assess O 0 2.184175684760703e-07
the O 0 3.5274592136147476e-08
risk O 0 7.777973820566331e-08
of O 0 7.099037330204894e-11
this O 0 3.3968533541539614e-10
common O 0 2.6640920580689453e-09
APC B-Disease 0 9.277027288590034e-07
allelic O 0 1.9427959614404244e-06
variant O 0 6.362397834891453e-05
in O 0 0.00017671327805146575
colorectal O 1 0.9999939203262329
carcinogenesis O 1 0.8475447297096252
, O 0 9.961601108443574e-07
we O 0 1.364758706046132e-08
have O 0 1.0134866279543076e-09
analyzed O 0 2.1609356526397505e-09
a O 0 1.9639925241676792e-09
large O 0 2.6099937766588255e-09
cohort O 0 2.8885661862432244e-08
of O 0 4.134898534680076e-10
unselected O 0 1.314419250775245e-06
Ashkenazi O 0 8.724353392608464e-06
Jewish O 0 2.1326538046650967e-07
subjects O 0 6.447490363825636e-08
with O 0 3.3775211250031134e-07
adenomatous B-Disease 0 0.04685239493846893
polyps I-Disease 0 0.12053927034139633
and O 0 4.013172656414099e-06
. O 0 7.939324859762564e-06
or O 1 0.9322274923324585
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999939203262329
, I-Disease 0 5.211279017203196e-07
for O 0 1.429954155085511e-09
the O 0 1.0773712233458355e-07
APC O 0 6.799066613893956e-05
I1307K O 0 7.314005415537395e-06
polymorphism O 0 4.607581558957463e-06
. O 0 4.238315796101233e-07

The O 0 5.273833636465497e-08
APC O 0 2.6392965537525015e-06
I1307K O 0 9.127045359491603e-07
allele O 0 7.075552161950327e-07
was O 0 2.271104222018039e-06
identified O 0 4.6938669839846625e-08
in O 0 1.1571272828803103e-08
48 O 0 7.642460531087636e-08
( O 0 2.882646621404916e-10
10 O 0 3.997466524463533e-10
. O 0 8.222820202519188e-10
1 O 0 6.461350121611531e-09
% O 0 1.048984121787555e-09
) O 0 5.345855980110059e-10
of O 0 6.370266536492863e-10
476 O 0 2.7776433853432536e-05
patients O 0 1.429081493142803e-07
. O 0 2.486227685949416e-07

Compared O 0 5.6499161473766435e-06
with O 0 5.350163423401e-09
the O 0 7.89935228340255e-10
frequency O 0 2.856144298846175e-08
in O 0 1.792982873283222e-09
two O 0 2.030344337100587e-09
separate O 0 6.360981519293318e-09
population O 0 1.1399755445173909e-10
control O 0 4.683463838972557e-09
groups O 0 6.106599947930391e-11
, O 0 6.650957007359182e-10
the O 0 8.645841265142451e-10
APC O 0 6.330374731078336e-07
I1307K O 0 1.8537053847467178e-07
allele O 0 2.331384507670009e-07
is O 0 2.0570622538684802e-08
associated O 0 5.029081595608886e-09
with O 0 6.981256017724036e-09
an O 0 9.362702257931232e-08
estimated O 0 2.787719211028161e-07
relative O 0 2.5116679580605705e-07
risk O 0 1.715137543101264e-08
of O 0 1.2095330292893891e-09
1 O 0 2.5856425622805546e-07
. O 0 6.510737762255303e-07

5 O 0 2.2113601517048664e-05
- O 0 0.0007842472987249494
1 O 0 1.6186603488677065e-06
. O 0 1.1289477015452576e-06

7 O 0 8.626076305517927e-05
for O 0 2.1146435756236315e-05
colorectal B-Disease 1 0.9999066591262817
neoplasia I-Disease 1 0.9007310271263123
( O 0 2.827018761308864e-07
both O 0 2.9906115628364205e-07
P O 0 0.08273526281118393
= O 0 3.993217251263559e-05
. O 0 9.093268005244681e-08
01 O 0 1.2424972737790085e-05
) O 0 1.2795540271781647e-07
. O 0 2.451043599194236e-07

Furthermore O 0 6.226858658919809e-06
, O 0 3.660590550680354e-07
compared O 0 3.742359524494532e-07
with O 0 1.73498779787451e-08
noncarriers O 0 7.251111674122512e-05
, O 0 9.581058435514933e-08
APC O 0 1.3646593970406684e-06
I1307K O 0 3.161032680054632e-07
carriers O 0 1.2562822782058447e-08
had O 0 3.247398439043536e-08
increased O 0 7.935242740675363e-11
numbers O 0 2.286937132722766e-11
of O 0 2.2978965397157936e-09
adenomas B-Disease 0 0.07924478501081467
and O 0 0.015693724155426025
colorectal B-Disease 1 0.9999971389770508
cancers I-Disease 0 0.485807865858078
per O 0 2.533838028284663e-07
patient O 0 5.513668384082848e-07
( O 0 1.2560618323220751e-08
P O 0 0.0011126869358122349
= O 0 2.6110565158887766e-06
. O 0 2.2667771659712344e-08
03 O 0 6.179099045766634e-07
) O 0 1.6622659915199733e-09
, O 0 4.2936645905378157e-10
as O 0 8.818445973446387e-11
well O 0 5.896659827087092e-10
as O 0 5.349395371112564e-10
a O 0 2.6234458161411567e-08
younger O 0 6.919323709553282e-07
age O 0 1.8462267803442955e-07
at O 0 7.560106041637482e-06
diagnosis O 0 2.2963282390264794e-05
. O 0 8.013399792616838e-07

We O 0 1.5533304065229459e-07
conclude O 0 1.0084315960057211e-07
that O 0 1.1985809011960669e-09
the O 0 8.543353802181741e-10
APC O 0 5.264457740850048e-07
I1307K O 0 1.7517307071557298e-07
variant O 0 2.670562935236376e-07
leads O 0 1.204945050403694e-07
to O 0 4.965907152154614e-08
increased O 0 6.93311562827148e-07
adenoma B-Disease 1 0.9998999834060669
formation O 0 2.1275447181778873e-07
and O 0 1.2936935078755596e-08
directly O 0 2.792491793357499e-10
contributes O 0 2.7541632863226084e-10
to O 0 2.7350141595938737e-10
3 O 0 1.807084082372512e-08
% O 0 1.934037818784873e-09
- O 0 5.583890470006736e-06
4 O 0 2.505092027149658e-07
% O 0 2.52451975990553e-10
of O 0 1.1285097162305746e-10
all O 0 1.1895035179065871e-08
Ashkenazi O 0 0.022626817226409912
Jewish O 1 0.5510070323944092
colorectal B-Disease 1 0.9999954700469971
cancer I-Disease 1 0.9999051094055176
. O 0 4.658955003833398e-05

The O 0 5.202688271310763e-07
estimated O 0 6.21395201960695e-07
relative O 0 4.522467520473583e-07
risk O 0 5.6174908280581803e-08
for O 0 1.3706327184337397e-09
carriers O 0 1.3495244388650462e-07
may O 0 2.1081909551412537e-08
justify O 0 2.3547375160859474e-09
specific O 0 1.808871108455179e-11
clinical O 0 5.144895065534172e-10
screening O 0 1.4626469480027993e-10
for O 0 3.2059445376209084e-11
the O 0 2.3802040893805554e-10
360 O 0 1.1446240399948238e-08
, O 0 7.832050563649773e-10
000 O 0 4.1650882742771955e-10
Americans O 0 1.332908783346909e-10
expected O 0 1.1282433876047548e-09
to O 0 4.819603049988075e-10
harbor O 0 5.353565484256251e-07
this O 0 3.9077710511925545e-10
allele O 0 3.373187240640618e-08
, O 0 7.130759094309269e-09
and O 0 7.016471403886726e-09
genetic O 0 3.736735010306802e-08
testing O 0 1.0455149634935879e-08
in O 0 3.216812372031086e-10
the O 0 5.562713623064042e-10
setting O 0 2.642756413706593e-08
of O 0 7.851737926500846e-09
long O 0 1.0031165402324405e-05
- O 0 0.0006353931967169046
term O 0 3.0519296956299513e-07
- O 0 1.1547015674295835e-05
outcome O 0 4.352649796146579e-08
studies O 0 5.705591554772127e-09
may O 0 5.8248303957952885e-09
impact O 0 3.415533411654792e-09
significantly O 0 2.854374940852722e-07
on O 1 0.9538290500640869
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999927282333374
prevention O 0 3.1293391657527536e-05
in O 0 1.0998507882220565e-08
this O 0 2.1651438419922897e-09
population O 0 5.1963477964989124e-09
. O 0 2.3253956271673815e-07

Localization O 0 1.4046498108655214e-05
of O 0 5.5877091398315315e-08
human O 0 3.416070057937759e-07
BRCA1 O 0 3.261157689848915e-05
and O 0 3.331149684981938e-07
its O 0 4.954686687597132e-07
loss O 0 6.648527778452262e-05
in O 0 3.1815829970582854e-08
high O 0 2.3961043552844785e-05
- O 0 0.006916088983416557
grade O 0 1.827969072110136e-06
, O 0 6.372362548745514e-08
non B-Disease 0 3.5695441624739033e-07
- I-Disease 1 0.9627463221549988
inherited I-Disease 1 0.9878872632980347
breast I-Disease 1 0.9771600365638733
carcinomas I-Disease 1 0.9998489618301392
. O 0 2.0147304894635454e-05

Although O 0 2.381351436042678e-07
the O 0 1.0251599569244263e-08
link O 0 7.492504892070428e-07
between O 0 6.940287278212054e-08
the O 0 5.777371256954211e-07
BRCA1 O 0 0.07125478982925415
tumour B-Disease 1 0.9999721050262451
- O 0 0.0038072564639151096
suppressor O 0 6.157632742542773e-05
gene O 0 2.1338021269912133e-06
and O 0 4.364645792520605e-05
hereditary B-Disease 1 0.9989312291145325
breast I-Disease 1 0.9999572038650513
and I-Disease 1 0.9999566078186035
ovarian I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999874830245972
is O 0 2.1442517095238145e-07
established O 0 1.748131772671968e-08
, O 0 1.866649768089701e-08
the O 0 3.3923874820374067e-09
role O 0 2.983802360745358e-08
, O 0 1.920196268656582e-08
if O 0 6.455249113024308e-10
any O 0 3.200482587284448e-11
, O 0 1.6974712746531395e-09
of O 0 1.2023726458920692e-09
BRCA1 O 0 1.902800977404695e-05
in O 0 8.955415609079864e-08
non B-Disease 0 7.504525569856924e-07
- I-Disease 1 0.6701145172119141
familial I-Disease 1 0.5127917528152466
cancers I-Disease 0 0.47485873103141785
is O 0 1.7862974743820814e-07
unclear O 0 7.861824542487739e-07
. O 0 6.62816091789864e-07

BRCA1 O 0 0.00680455332621932
mutations O 0 2.760257302725222e-05
are O 0 3.421755678800764e-08
rare O 0 2.018867348851927e-07
in O 0 5.310353401455359e-08
sporadic B-Disease 0 7.535426993854344e-05
cancers I-Disease 0 0.36420807242393494
, O 0 1.99983810489357e-06
but O 0 1.3973756267660065e-06
loss O 0 2.6734433049568906e-05
of O 0 2.482417293947492e-08
BRCA1 O 0 0.0001254562521353364
resulting O 0 1.6649964607040602e-07
from O 0 3.354732935889615e-09
reduced O 0 3.913755097784133e-09
expression O 0 1.2076658562065745e-09
or O 0 6.418812148467623e-09
incorrect O 0 1.136833063242193e-07
subcellular O 0 1.413150414464326e-07
localization O 0 4.7415215931323473e-07
is O 0 4.6494723626722134e-09
postulated O 0 6.855791934157196e-09
to O 0 2.6242841233425906e-10
be O 0 2.917171504357441e-10
important O 0 1.7996697188049637e-10
in O 0 1.094449686434018e-08
non B-Disease 0 1.982571689040924e-07
- I-Disease 1 0.5681996941566467
familial I-Disease 1 0.9628050923347473
breast I-Disease 1 0.9997914433479309
and I-Disease 1 0.9967888593673706
ovarian I-Disease 1 0.99998939037323
cancers I-Disease 1 0.9999405145645142
. O 0 9.45426436373964e-05

Epigenetic O 0 0.01851564086973667
loss O 0 0.17723055183887482
, O 0 2.149982265109429e-06
however O 0 1.274896135328163e-07
, O 0 2.6235058570023284e-08
has O 0 1.0191746113719091e-08
not O 0 2.9191921102622587e-10
received O 0 5.5163689588466625e-11
general O 0 6.442821970376045e-11
acceptance O 0 1.759307188820003e-08
due O 0 2.4271749055060354e-08
to O 0 9.99312854688128e-10
controversy O 0 2.495851969541718e-09
regarding O 0 4.010707391199908e-11
the O 0 1.264562898839472e-10
subcellular O 0 3.965439177022745e-08
localization O 0 3.312313268111211e-08
of O 0 9.815069867968873e-10
BRCA1 O 0 2.2639073904429097e-06
proteins O 0 9.343128937189249e-09
, O 0 8.667938367068473e-09
reports O 0 6.13247141956208e-09
of O 0 4.4295039858255336e-10
which O 0 6.685876741130414e-08
have O 0 1.399325988415967e-08
ranged O 0 1.4419295268908172e-07
from O 0 1.4017313698655443e-10
exclusively O 0 4.392217423099254e-10
nuclear O 0 2.4009725620999234e-06
, O 0 5.308241624035759e-10
to O 0 2.0175346115980375e-10
conditionally O 0 7.026706043689046e-07
nuclear O 0 3.985472176282201e-06
, O 0 2.501817919497995e-10
to O 0 6.055358298118207e-11
the O 0 4.858629498727396e-09
ER O 0 2.871956212402438e-06
/ O 0 1.5087258020685113e-07
golgi O 0 5.9004851209465414e-06
, O 0 1.3539049881217124e-09
to O 0 2.3237677060361506e-10
cytoplasmic O 0 7.116997124967384e-08
invaginations O 0 1.5901269989626599e-07
into O 0 2.212297844916833e-10
the O 0 2.153168088270263e-09
nucleus O 0 9.291525060461936e-08
. O 0 1.220337395579918e-07

In O 0 1.7297941212746082e-07
an O 0 1.281439043765431e-08
attempt O 0 6.780588819310651e-07
to O 0 1.3581915148108692e-08
resolve O 0 1.2308765917623532e-07
this O 0 5.001929981318654e-10
issue O 0 3.589869734810236e-08
, O 0 4.6862789204737965e-09
we O 0 7.400329793405547e-10
have O 0 1.3399781284562096e-09
comprehensively O 0 4.869375061389292e-06
characterized O 0 7.27021017610241e-07
19 O 0 2.331291000245983e-07
anti O 0 1.6935766325332224e-05
- O 0 0.06229995936155319
BRCA1 O 0 0.00013967815903015435
antibodies O 0 2.673444896572619e-07
. O 0 2.643536163304816e-07

These O 0 5.55056001161347e-09
reagents O 0 3.187389552294917e-08
detect O 0 3.7856500512134517e-07
a O 0 8.43215630652594e-09
220 O 0 8.403100082432502e-08
- O 0 4.340877421782352e-05
kD O 0 1.7238226064364426e-06
protein O 0 1.350176082048904e-09
localized O 0 1.0420304619174203e-09
in O 0 2.171926111182998e-10
discrete O 0 3.908609969016652e-08
nuclear O 0 3.164173540426418e-05
foci O 0 1.6634488702038652e-06
in O 0 1.105628033570838e-09
all O 0 3.6572433970150087e-10
epithelial O 0 2.388949496889836e-06
cell O 0 0.00012006318138446659
lines O 0 1.9655358300951775e-06
, O 0 3.7740530700602903e-08
including O 0 7.585366224027723e-10
those O 0 2.281554278837916e-09
derived O 0 7.81484921219544e-09
from O 0 2.823219915626396e-07
breast B-Disease 0 0.010272596031427383
malignancies I-Disease 0 0.005780106410384178
. O 0 2.2305291622615186e-06

Immunohistochemical O 0 0.0007179630920290947
staining O 0 0.00015882706793490797
of O 0 2.6680760356612154e-07
human O 0 8.467578481941018e-06
breast O 0 0.013017427176237106
specimens O 0 2.3254251573234797e-06
also O 0 8.848176662468177e-07
revealed O 0 0.00018500405712984502
BRCA1 O 0 0.0002809474535752088
nuclear O 0 0.002095365198329091
foci O 0 0.0002647560613695532
in O 0 8.464256779916468e-07
benign O 0 0.15013699233531952
breast O 0 0.103402279317379
, O 0 1.2657350453082472e-05
invasive B-Disease 0 0.02897225134074688
lobular I-Disease 1 0.99957674741745
cancers I-Disease 1 0.9590640068054199
and O 0 3.7779569538543e-05
low B-Disease 0 0.00026908557629212737
- I-Disease 1 0.7701210379600525
grade I-Disease 0 0.002159317722544074
ductal I-Disease 1 0.8544291853904724
carcinomas I-Disease 1 0.999829888343811
. O 0 0.00012332634651102126

Conversely O 0 3.956879663746804e-05
, O 0 6.629039717154228e-07
BRCA1 O 0 3.383624971320387e-06
expression O 0 2.174419400091665e-08
was O 0 1.1770288438128773e-05
reduced O 0 4.751462157059905e-08
or O 0 1.0378442283354161e-07
undetectable O 0 7.449775694112759e-07
in O 0 8.441711218942771e-10
the O 0 3.276214410874445e-09
majority O 0 1.5958712129560126e-09
of O 0 1.8292950487719395e-09
high O 0 6.258476787479594e-06
- O 0 0.0006043202010914683
grade O 0 1.7267167322643218e-06
, O 0 3.248607072237064e-07
ductal B-Disease 0 0.01616392284631729
carcinomas I-Disease 1 0.9999775886535645
, O 0 3.0838600650895387e-06
suggesting O 0 1.0412044275653898e-06
that O 0 4.702828348968069e-08
absence O 0 1.9046137111899952e-08
of O 0 1.1305230529501387e-08
BRCA1 O 0 8.301404886879027e-05
may O 0 1.2847665686877008e-07
contribute O 0 2.5731024949626757e-11
to O 0 2.494989215229282e-10
the O 0 5.761385590830059e-09
pathogenesis O 0 7.320358577089792e-07
of O 0 1.6159143467753267e-10
a O 0 9.712093351765816e-09
significant O 0 9.714237192426367e-10
percentage O 0 4.807332842915457e-08
of O 0 3.97098531834672e-09
sporadic B-Disease 0 0.0008140962454490364
breast I-Disease 1 0.8765749335289001
cancers I-Disease 0 0.040492843836545944
. O 0 2.2039657210370933e-07
. O 0 6.17852094819682e-07

